cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
UCEC	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	17.97	3.88e-39	1.34e-31	0.87	0.83	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-16.38	3.84e-35	8.13e-29	-0.86	-0.8	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-16.38	3.84e-35	8.13e-29	-0.86	-0.8	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	16.35	4.49e-35	8.13e-29	0.86	0.8	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	16.35	4.49e-35	8.13e-29	0.86	0.8	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	16.35	4.49e-35	8.13e-29	0.86	0.8	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	16.35	4.49e-35	8.13e-29	0.86	0.8	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	16.35	4.49e-35	8.13e-29	0.86	0.8	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	16.35	4.49e-35	8.13e-29	0.86	0.8	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-16.24	8.74e-35	1.41e-28	-0.86	-0.8	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	16.23	9.4e-35	1.41e-28	0.86	0.8	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	16.23	9.4e-35	1.41e-28	0.86	0.8	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	16.03	2.96e-34	4.07e-28	0.84	0.8	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	15.8	1.19e-33	1.51e-27	0.85	0.79	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-15.62	3.38e-33	3.83e-27	-0.85	-0.79	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-15.62	3.38e-33	3.83e-27	-0.85	-0.79	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	15.11	7.23e-32	4.42e-26	0.83	0.78	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-15.11	7.32e-32	4.42e-26	-0.94	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-15.11	7.32e-32	4.42e-26	-0.94	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-15.11	7.32e-32	4.42e-26	-0.94	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-15.11	7.32e-32	4.42e-26	-0.94	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-15.11	7.32e-32	4.42e-26	-0.94	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-15.11	7.32e-32	4.42e-26	-0.94	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-15.08	8.59e-32	4.72e-26	-0.91	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-15.01	1.35e-31	6.74e-26	-0.94	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-14.91	2.45e-31	1.08e-25	-0.94	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-14.91	2.45e-31	1.08e-25	-0.94	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-14.91	2.45e-31	1.08e-25	-0.94	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-14.91	2.45e-31	1.08e-25	-0.94	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-14.91	2.45e-31	1.08e-25	-0.94	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-14.91	2.45e-31	1.08e-25	-0.94	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-14.91	2.45e-31	1.08e-25	-0.94	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-14.84	3.71e-31	1.6e-25	-0.83	-0.77	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-14.82	4.06e-31	1.7e-25	-0.83	-0.77	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	14.78	5.42e-31	2.17e-25	0.91	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	14.78	5.42e-31	2.17e-25	0.91	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	14.78	5.42e-31	2.17e-25	0.91	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-14.77	5.55e-31	2.17e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-14.77	5.55e-31	2.17e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-14.59	1.67e-30	5.85e-25	-0.9	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	14.58	1.7e-30	5.85e-25	0.91	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-14.58	1.73e-30	5.85e-25	-0.92	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-14.58	1.73e-30	5.85e-25	-0.92	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-14.58	1.73e-30	5.85e-25	-0.92	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-14.58	1.73e-30	5.85e-25	-0.92	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-14.58	1.73e-30	5.85e-25	-0.92	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-14.53	2.43e-30	8.09e-25	-0.84	-0.77	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-14.51	2.67e-30	8.09e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-14.51	2.67e-30	8.09e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-14.51	2.67e-30	8.09e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-14.51	2.73e-30	8.09e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-14.51	2.73e-30	8.09e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-14.51	2.73e-30	8.09e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-14.51	2.73e-30	8.09e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-14.51	2.73e-30	8.09e-25	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-14.49	3.07e-30	8.09e-25	-0.93	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-14.49	3.07e-30	8.09e-25	-0.93	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-14.49	3.07e-30	8.09e-25	-0.93	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-14.49	3.07e-30	8.09e-25	-0.93	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-14.49	3.07e-30	8.09e-25	-0.93	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	14.48	3.19e-30	8.09e-25	0.83	0.76	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	14.43	4.48e-30	1.03e-24	0.84	0.76	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-14.42	4.61e-30	1.03e-24	-0.91	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-14.42	4.61e-30	1.03e-24	-0.91	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-14.33	7.94e-30	1.69e-24	-0.93	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	14.3	9.67e-30	1.99e-24	0.81	0.76	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	14.28	1.08e-29	2.19e-24	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	14.17	2.06e-29	4.11e-24	0.9	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	14.13	2.6e-29	5.05e-24	0.9	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	14.09	3.42e-29	6.39e-24	0.91	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	14.09	3.42e-29	6.39e-24	0.91	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	14.08	3.62e-29	6.73e-24	0.81	0.76	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	14.05	4.34e-29	7.58e-24	0.84	0.75	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-13.9	1.07e-28	1.84e-23	-0.91	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	13.87	1.33e-28	2.26e-23	0.83	0.75	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	13.64	5.41e-28	8.31e-23	0.82	0.75	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	13.63	5.72e-28	8.64e-23	0.81	0.74	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	13.63	5.72e-28	8.64e-23	0.81	0.74	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	13.63	5.72e-28	8.64e-23	0.81	0.74	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	13.55	8.95e-28	1.33e-22	0.88	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	13.53	1.05e-27	1.53e-22	0.8	0.74	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	13.48	1.37e-27	1.82e-22	0.89	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-13.36	2.89e-27	3.74e-22	-0.87	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	13.35	3.04e-27	3.91e-22	0.8	0.74	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
UCEC	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	13.32	3.67e-27	4.68e-22	1.07	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
UCEC	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	13.29	4.45e-27	5.61e-22	0.82	0.74	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	13.26	5.38e-27	6.76e-22	0.89	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
UCEC	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	13.26	5.43e-27	6.8e-22	0.99	0.74	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	13.17	9.1e-27	1.12e-21	0.79	0.73	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	13.12	1.25e-26	1.53e-21	0.81	0.73	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-13.11	1.33e-26	1.62e-21	-0.87	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	13.08	1.66e-26	1.9e-21	0.81	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	12.86	6.37e-26	6.4e-21	0.81	0.73	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	12.86	6.37e-26	6.4e-21	0.81	0.73	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	12.85	6.7e-26	6.71e-21	0.84	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-12.82	8.1e-26	8.03e-21	-0.81	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	12.72	1.48e-25	1.46e-20	0.79	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-12.62	2.71e-25	2.61e-20	-0.85	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
UCEC	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	12.61	2.88e-25	2.76e-20	0.94	0.72	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
UCEC	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	12.61	2.94e-25	2.81e-20	0.8	0.72	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-12.55	4.24e-25	4e-20	-0.86	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	12.53	4.79e-25	4.5e-20	0.87	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-12.51	5.2e-25	4.87e-20	-0.85	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	12.5	5.73e-25	5.36e-20	0.87	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	12.49	5.88e-25	5.48e-20	0.8	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	12.47	6.77e-25	6.23e-20	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	12.47	6.77e-25	6.23e-20	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	12.47	6.77e-25	6.23e-20	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
UCEC	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-12.47	6.81e-25	6.25e-20	-0.93	-0.71	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	12.44	7.96e-25	7.27e-20	0.87	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-12.37	1.26e-24	1.12e-19	-0.86	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-12.36	1.35e-24	1.19e-19	-0.78	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	12.36	1.37e-24	1.2e-19	0.78	0.71	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-12.33	1.57e-24	1.35e-19	-0.83	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-12.33	1.57e-24	1.35e-19	-0.83	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	12.31	1.86e-24	1.59e-19	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-12.28	2.19e-24	1.85e-19	-0.83	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	12.28	2.2e-24	1.85e-19	0.79	0.71	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	12.28	2.2e-24	1.85e-19	0.79	0.71	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	12.28	2.2e-24	1.85e-19	0.79	0.71	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	12.25	2.63e-24	2.16e-19	0.78	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	12.25	2.63e-24	2.16e-19	0.78	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	12.25	2.63e-24	2.16e-19	0.78	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	12.25	2.63e-24	2.16e-19	0.78	0.71	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	12.25	2.63e-24	2.16e-19	0.78	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	12.25	2.63e-24	2.16e-19	0.78	0.71	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	12.25	2.63e-24	2.16e-19	0.78	0.71	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-12.24	2.72e-24	2.21e-19	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-12.24	2.72e-24	2.21e-19	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	12.24	2.76e-24	2.24e-19	0.79	0.71	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-12.21	3.31e-24	2.68e-19	-0.83	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-12.2	3.54e-24	2.81e-19	-0.81	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-12.2	3.54e-24	2.81e-19	-0.81	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-12.2	3.54e-24	2.81e-19	-0.81	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-12.2	3.54e-24	2.81e-19	-0.81	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-12.2	3.54e-24	2.81e-19	-0.81	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	12.2	3.54e-24	2.81e-19	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	12.2	3.54e-24	2.81e-19	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	12.2	3.54e-24	2.81e-19	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	12.2	3.66e-24	2.87e-19	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	12.2	3.66e-24	2.87e-19	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	12.2	3.66e-24	2.87e-19	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	12.19	3.84e-24	3e-19	0.79	0.71	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
UCEC	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	12.18	4.13e-24	3.22e-19	0.94	0.71	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	12.17	4.17e-24	3.24e-19	0.94	0.71	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	12.15	4.98e-24	3.85e-19	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	12.14	5.3e-24	4.08e-19	0.8	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-12.11	6.29e-24	4.78e-19	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-12.1	6.52e-24	4.91e-19	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-12.1	6.52e-24	4.91e-19	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-12.1	6.52e-24	4.91e-19	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-12.1	6.52e-24	4.91e-19	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-12.1	6.72e-24	4.95e-19	-0.82	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-12.1	6.72e-24	4.95e-19	-0.82	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	12.09	7.24e-24	5.33e-19	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	12.08	7.51e-24	5.51e-19	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	12.08	7.68e-24	5.62e-19	0.77	0.7	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	12.07	8.17e-24	5.96e-19	0.79	0.7	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-12.05	8.83e-24	6.4e-19	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-12.05	8.83e-24	6.4e-19	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
UCEC	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-12.04	9.77e-24	7.02e-19	-0.92	-0.7	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
UCEC	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-12.04	9.77e-24	7.02e-19	-0.92	-0.7	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-12.03	1.01e-23	7.24e-19	-0.91	-0.7	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
UCEC	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	12.03	1.03e-23	7.39e-19	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-12.02	1.07e-23	7.64e-19	-0.9	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	11.99	1.26e-23	8.86e-19	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-11.94	1.76e-23	1.22e-18	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-11.9	2.27e-23	1.57e-18	-0.82	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	11.89	2.46e-23	1.7e-18	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	11.79	4.49e-23	3.08e-18	0.78	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
UCEC	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-11.77	4.95e-23	3.38e-18	-0.9	-0.69	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-11.75	5.56e-23	3.75e-18	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-11.75	5.56e-23	3.75e-18	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-11.75	5.56e-23	3.75e-18	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	11.75	5.76e-23	3.85e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	11.75	5.76e-23	3.85e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	11.75	5.76e-23	3.85e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	11.75	5.76e-23	3.85e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	11.75	5.8e-23	3.86e-18	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	11.75	5.8e-23	3.86e-18	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	11.74	5.92e-23	3.92e-18	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-11.74	5.94e-23	3.93e-18	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	11.73	6.24e-23	4.1e-18	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
UCEC	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-11.73	6.53e-23	4.27e-18	-0.9	-0.69	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	11.7	7.9e-23	5.1e-18	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	11.7	7.9e-23	5.1e-18	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
UCEC	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-11.69	8.2e-23	5.28e-18	-0.9	-0.69	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
UCEC	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	11.69	8.26e-23	5.29e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	11.69	8.26e-23	5.29e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	11.67	9.09e-23	5.72e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	11.67	9.09e-23	5.72e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	11.67	9.09e-23	5.72e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	11.67	9.09e-23	5.72e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	11.67	9.09e-23	5.72e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	11.67	9.09e-23	5.72e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	11.67	9.09e-23	5.72e-18	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	11.66	9.82e-23	6.17e-18	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	11.62	1.22e-22	7.63e-18	0.79	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	11.62	1.25e-22	7.8e-18	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	11.58	1.62e-22	1e-17	0.79	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	11.58	1.62e-22	1e-17	0.79	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-11.57	1.71e-22	1.05e-17	-0.78	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	11.56	1.82e-22	1.12e-17	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-11.55	1.91e-22	1.16e-17	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-11.55	1.91e-22	1.16e-17	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-11.55	1.91e-22	1.16e-17	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-11.55	1.95e-22	1.18e-17	-0.79	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	11.51	2.43e-22	1.45e-17	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-11.51	2.5e-22	1.49e-17	-0.79	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-11.5	2.63e-22	1.56e-17	-0.78	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-11.5	2.63e-22	1.56e-17	-0.78	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	11.39	5.17e-22	3.03e-17	0.79	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	11.39	5.17e-22	3.03e-17	0.79	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	11.39	5.17e-22	3.03e-17	0.79	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-11.39	5.17e-22	3.03e-17	-0.79	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-11.39	5.3e-22	3.1e-17	-0.77	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
UCEC	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-11.34	6.83e-22	3.97e-17	-0.94	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
UCEC	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	11.34	6.98e-22	4.05e-17	0.73	0.68	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	11.33	7.47e-22	4.31e-17	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	11.33	7.56e-22	4.36e-17	0.8	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-11.31	8.61e-22	4.95e-17	-0.79	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	11.3	8.8e-22	5.03e-17	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	11.3	8.89e-22	5.03e-17	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	11.3	8.89e-22	5.03e-17	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	11.3	8.89e-22	5.03e-17	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
UCEC	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	11.3	8.89e-22	5.03e-17	0.75	0.68	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	11.3	8.89e-22	5.03e-17	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	11.3	9.16e-22	5.13e-17	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	11.27	1.09e-21	6.1e-17	0.87	0.68	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	11.27	1.11e-21	6.21e-17	0.77	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
UCEC	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	11.24	1.34e-21	7.28e-17	0.87	0.68	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	11.23	1.38e-21	7.51e-17	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	11.23	1.41e-21	7.63e-17	0.73	0.68	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	11.23	1.41e-21	7.63e-17	0.73	0.68	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	11.21	1.51e-21	8.18e-17	0.87	0.68	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	11.21	1.6e-21	8.57e-17	0.87	0.68	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	11.21	1.6e-21	8.57e-17	0.87	0.68	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	11.2	1.62e-21	8.65e-17	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	11.2	1.62e-21	8.65e-17	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-11.19	1.72e-21	9.14e-17	-0.76	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	11.19	1.8e-21	9.52e-17	0.72	0.68	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	11.17	1.95e-21	1.02e-16	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	11.17	1.95e-21	1.02e-16	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	11.17	1.95e-21	1.02e-16	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	11.17	1.96e-21	1.03e-16	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	11.17	1.96e-21	1.03e-16	0.75	0.68	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	11.15	2.27e-21	1.13e-16	0.87	0.67	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-11.15	2.29e-21	1.14e-16	-0.87	-0.67	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	11.14	2.44e-21	1.21e-16	0.86	0.67	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
UCEC	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-11.14	2.46e-21	1.21e-16	-0.87	-0.67	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	11.13	2.51e-21	1.24e-16	0.7	0.67	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	11.13	2.56e-21	1.26e-16	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	11.13	2.61e-21	1.28e-16	0.77	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	11.13	2.61e-21	1.28e-16	0.77	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	11.12	2.65e-21	1.3e-16	0.77	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	11.11	2.8e-21	1.32e-16	0.87	0.67	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-11.11	2.82e-21	1.32e-16	-0.76	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	11.1	3.02e-21	1.41e-16	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
UCEC	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-11.1	3.06e-21	1.43e-16	-0.87	-0.67	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-11.1	3.06e-21	1.43e-16	-0.87	-0.67	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	11.09	3.23e-21	1.5e-16	0.78	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
UCEC	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	11.09	3.35e-21	1.56e-16	0.83	0.67	Shingles;	chr7:38346957	chr7:38343894~38350022:-
UCEC	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	11.07	3.62e-21	1.68e-16	0.87	0.67	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	11.06	3.86e-21	1.78e-16	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	11.06	3.95e-21	1.82e-16	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	11.05	4.26e-21	1.95e-16	0.86	0.67	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	11.05	4.26e-21	1.95e-16	0.86	0.67	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	11.03	4.72e-21	2.15e-16	0.72	0.67	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	11.03	4.81e-21	2.19e-16	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-11	5.67e-21	2.57e-16	-0.73	-0.67	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	10.94	7.95e-21	3.58e-16	0.85	0.67	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	10.94	7.95e-21	3.58e-16	0.85	0.67	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	10.94	7.95e-21	3.58e-16	0.85	0.67	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	10.92	9.16e-21	4.11e-16	0.85	0.67	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	10.91	9.71e-21	4.34e-16	0.85	0.67	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	10.89	1.11e-20	4.96e-16	0.83	0.67	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	10.89	1.13e-20	5.01e-16	0.76	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	10.89	1.13e-20	5.01e-16	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	10.89	1.13e-20	5.01e-16	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	10.89	1.13e-20	5.01e-16	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	10.87	1.24e-20	5.44e-16	0.84	0.67	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	10.87	1.24e-20	5.44e-16	0.84	0.67	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	10.87	1.24e-20	5.44e-16	0.84	0.67	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	10.87	1.24e-20	5.44e-16	0.84	0.67	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
UCEC	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-10.86	1.29e-20	5.65e-16	-0.86	-0.66	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-10.86	1.35e-20	5.9e-16	-0.75	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	10.84	1.53e-20	6.64e-16	0.86	0.66	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	10.82	1.72e-20	7.45e-16	0.78	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	10.81	1.83e-20	7.89e-16	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	10.78	2.2e-20	9.4e-16	0.85	0.66	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	10.77	2.25e-20	9.59e-16	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	10.77	2.25e-20	9.59e-16	0.86	0.66	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	10.76	2.37e-20	1.01e-15	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	10.76	2.37e-20	1.01e-15	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	10.76	2.39e-20	1.01e-15	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	10.76	2.39e-20	1.01e-15	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	10.76	2.39e-20	1.01e-15	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	10.76	2.39e-20	1.01e-15	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	10.76	2.51e-20	1.06e-15	0.73	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-10.75	2.55e-20	1.07e-15	-0.74	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	10.75	2.59e-20	1.09e-15	0.85	0.66	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	10.75	2.64e-20	1.11e-15	0.77	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	10.74	2.79e-20	1.17e-15	0.82	0.66	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	10.73	2.88e-20	1.2e-15	0.77	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
UCEC	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	10.72	3.21e-20	1.34e-15	0.95	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
UCEC	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	10.69	3.66e-20	1.52e-15	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	10.69	3.66e-20	1.52e-15	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	10.69	3.66e-20	1.52e-15	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	10.69	3.85e-20	1.59e-15	0.85	0.66	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
UCEC	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	10.67	4.17e-20	1.72e-15	0.82	0.66	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	10.67	4.27e-20	1.76e-15	0.73	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	10.67	4.32e-20	1.77e-15	0.82	0.66	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
UCEC	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	10.67	4.32e-20	1.77e-15	0.82	0.66	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	10.66	4.55e-20	1.86e-15	0.75	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	10.66	4.55e-20	1.86e-15	0.75	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	10.65	4.84e-20	1.98e-15	0.74	0.66	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	10.63	5.39e-20	2.19e-15	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	10.58	7.14e-20	2.87e-15	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	10.55	8.67e-20	3.47e-15	0.73	0.65	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
UCEC	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	10.53	9.67e-20	3.85e-15	0.82	0.65	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
UCEC	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	10.53	9.7e-20	3.86e-15	0.72	0.65	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	10.53	1e-19	3.96e-15	0.73	0.65	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	10.51	1.12e-19	4.42e-15	0.72	0.65	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	10.51	1.12e-19	4.42e-15	0.72	0.65	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	10.51	1.12e-19	4.42e-15	0.72	0.65	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	10.51	1.13e-19	4.43e-15	0.69	0.65	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-10.45	1.58e-19	6.15e-15	-0.84	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-10.43	1.81e-19	7.02e-15	-0.68	-0.65	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	10.43	1.87e-19	7.24e-15	0.72	0.65	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-10.42	1.9e-19	7.36e-15	-0.82	-0.65	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
UCEC	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-10.41	2.09e-19	8.03e-15	-0.68	-0.65	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-10.41	2.09e-19	8.03e-15	-0.68	-0.65	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	10.39	2.4e-19	9.15e-15	0.8	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-10.38	2.46e-19	9.34e-15	-0.84	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
UCEC	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	10.38	2.52e-19	9.52e-15	0.75	0.65	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
UCEC	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	10.37	2.58e-19	9.73e-15	0.81	0.65	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
UCEC	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	10.36	2.79e-19	1.05e-14	0.7	0.65	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
UCEC	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	10.34	3.08e-19	1.15e-14	0.8	0.65	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
UCEC	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	10.34	3.2e-19	1.19e-14	0.82	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	10.33	3.29e-19	1.23e-14	0.72	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-10.33	3.3e-19	1.23e-14	-0.68	-0.65	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
UCEC	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	10.33	3.45e-19	1.28e-14	0.82	0.65	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
UCEC	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-10.32	3.63e-19	1.34e-14	-0.83	-0.65	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	10.31	3.81e-19	1.4e-14	0.82	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	10.31	3.81e-19	1.4e-14	0.82	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-10.31	3.81e-19	1.4e-14	-0.82	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-10.31	3.81e-19	1.4e-14	-0.82	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-10.31	3.81e-19	1.4e-14	-0.82	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
UCEC	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-10.31	3.84e-19	1.4e-14	-0.82	-0.65	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
UCEC	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	10.3	3.93e-19	1.43e-14	0.82	0.65	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	10.3	3.96e-19	1.44e-14	0.72	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	10.3	4.1e-19	1.49e-14	0.73	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
UCEC	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	10.29	4.24e-19	1.54e-14	0.75	0.64	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-10.27	4.7e-19	1.7e-14	-0.75	-0.64	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
UCEC	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	10.24	5.88e-19	2.12e-14	0.81	0.64	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	10.24	5.88e-19	2.12e-14	0.81	0.64	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
UCEC	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-10.23	6.05e-19	2.17e-14	-0.75	-0.64	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
UCEC	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	10.23	6.17e-19	2.22e-14	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	10.23	6.3e-19	2.26e-14	0.75	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-10.21	6.87e-19	2.45e-14	-0.84	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	10.19	7.9e-19	2.8e-14	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	10.19	7.9e-19	2.8e-14	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-10.18	8.29e-19	2.93e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-10.18	8.29e-19	2.93e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-10.18	8.29e-19	2.93e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	10.17	8.99e-19	3.17e-14	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-10.16	9.19e-19	3.21e-14	-0.67	-0.64	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-10.16	9.19e-19	3.21e-14	-0.67	-0.64	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-10.16	9.19e-19	3.21e-14	-0.67	-0.64	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-10.16	9.19e-19	3.21e-14	-0.67	-0.64	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-10.15	9.76e-19	3.39e-14	-0.67	-0.64	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	10.15	9.91e-19	3.43e-14	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	10.15	9.91e-19	3.43e-14	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	10.15	9.91e-19	3.43e-14	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	10.15	9.94e-19	3.44e-14	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
UCEC	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	10.14	1.05e-18	3.61e-14	0.8	0.64	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
UCEC	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-10.14	1.08e-18	3.72e-14	-0.81	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-10.14	1.08e-18	3.72e-14	-0.81	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
UCEC	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	10.14	1.09e-18	3.75e-14	0.8	0.64	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
UCEC	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	10.12	1.17e-18	3.98e-14	0.74	0.64	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
UCEC	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	10.12	1.17e-18	3.98e-14	0.74	0.64	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	10.12	1.17e-18	3.98e-14	0.74	0.64	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	10.12	1.17e-18	3.98e-14	0.74	0.64	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	10.12	1.17e-18	3.98e-14	0.74	0.64	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	10.12	1.17e-18	3.98e-14	0.74	0.64	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
UCEC	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	10.12	1.17e-18	3.98e-14	0.74	0.64	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	10.12	1.2e-18	4.06e-14	0.74	0.64	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	10.12	1.2e-18	4.06e-14	0.74	0.64	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
UCEC	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	10.12	1.2e-18	4.06e-14	0.74	0.64	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	10.12	1.2e-18	4.06e-14	0.74	0.64	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	10.12	1.2e-18	4.06e-14	0.74	0.64	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	10.12	1.2e-18	4.06e-14	0.74	0.64	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
UCEC	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	10.11	1.26e-18	4.22e-14	0.66	0.64	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	10.11	1.26e-18	4.22e-14	0.66	0.64	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	10.11	1.26e-18	4.22e-14	0.66	0.64	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
UCEC	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	10.11	1.26e-18	4.23e-14	0.74	0.64	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
UCEC	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-10.11	1.27e-18	4.27e-14	-0.71	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	10.1	1.33e-18	4.43e-14	0.82	0.64	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	10.1	1.33e-18	4.43e-14	0.82	0.64	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	10.1	1.36e-18	4.51e-14	0.81	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	10.09	1.48e-18	4.92e-14	0.69	0.64	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-10.08	1.54e-18	5.1e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-10.08	1.55e-18	5.1e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-10.08	1.55e-18	5.1e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-10.08	1.55e-18	5.1e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-10.08	1.55e-18	5.1e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-10.08	1.55e-18	5.1e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-10.08	1.55e-18	5.1e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-10.08	1.55e-18	5.1e-14	-0.81	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	10.07	1.62e-18	5.33e-14	0.81	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-10.06	1.7e-18	5.55e-14	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-10.06	1.73e-18	5.66e-14	-0.66	-0.64	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-10.06	1.77e-18	5.77e-14	-0.67	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	10.05	1.8e-18	5.86e-14	0.81	0.64	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	10.05	1.83e-18	5.97e-14	0.71	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
UCEC	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	10.01	2.34e-18	7.55e-14	0.79	0.63	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	10.01	2.34e-18	7.55e-14	0.79	0.63	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	10.01	2.34e-18	7.55e-14	0.79	0.63	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	10.01	2.36e-18	7.59e-14	0.79	0.63	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
UCEC	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-10.01	2.37e-18	7.59e-14	-0.8	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-10.01	2.37e-18	7.59e-14	-0.8	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-10.01	2.37e-18	7.59e-14	-0.8	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	10	2.44e-18	7.82e-14	0.71	0.63	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-10	2.54e-18	8.1e-14	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-9.97	3.03e-18	9.61e-14	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-9.96	3.07e-18	9.69e-14	-0.71	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	9.94	3.45e-18	1.08e-13	0.8	0.63	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	9.94	3.46e-18	1.09e-13	0.68	0.63	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	9.94	3.48e-18	1.09e-13	0.8	0.63	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	9.93	3.77e-18	1.17e-13	0.71	0.63	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-9.93	3.82e-18	1.18e-13	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-9.93	3.82e-18	1.18e-13	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-9.93	3.82e-18	1.18e-13	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-9.93	3.82e-18	1.18e-13	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-9.93	3.82e-18	1.18e-13	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	9.92	3.94e-18	1.22e-13	0.79	0.63	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
UCEC	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	9.92	3.97e-18	1.22e-13	0.77	0.63	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	9.92	4.06e-18	1.25e-13	0.79	0.63	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	9.92	4.06e-18	1.25e-13	0.79	0.63	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	9.92	4.06e-18	1.25e-13	0.79	0.63	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	9.92	4.06e-18	1.25e-13	0.79	0.63	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
UCEC	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	9.91	4.16e-18	1.28e-13	0.74	0.63	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
UCEC	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	9.91	4.19e-18	1.28e-13	0.77	0.63	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
UCEC	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	9.91	4.22e-18	1.29e-13	0.74	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
UCEC	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	9.91	4.22e-18	1.29e-13	0.74	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
UCEC	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-9.91	4.29e-18	1.31e-13	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-9.91	4.29e-18	1.31e-13	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-9.91	4.29e-18	1.31e-13	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	9.9	4.5e-18	1.36e-13	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
UCEC	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	9.9	4.55e-18	1.37e-13	0.7	0.63	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
UCEC	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-9.89	4.71e-18	1.42e-13	-0.78	-0.63	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	9.87	5.39e-18	1.63e-13	0.78	0.63	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	9.87	5.47e-18	1.65e-13	0.78	0.63	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
UCEC	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-9.86	5.68e-18	1.71e-13	-0.66	-0.63	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
UCEC	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	9.86	5.8e-18	1.74e-13	0.75	0.63	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
UCEC	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	9.85	5.95e-18	1.78e-13	0.64	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
UCEC	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	9.85	5.95e-18	1.78e-13	0.64	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
UCEC	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	9.85	6.2e-18	1.85e-13	0.7	0.63	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
UCEC	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	9.84	6.45e-18	1.93e-13	0.74	0.63	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	9.84	6.51e-18	1.94e-13	0.74	0.63	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
UCEC	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	9.82	7.17e-18	2.13e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	9.82	7.17e-18	2.13e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	9.82	7.17e-18	2.13e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	9.82	7.17e-18	2.13e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	9.82	7.17e-18	2.13e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	9.82	7.17e-18	2.13e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	9.82	7.36e-18	2.18e-13	0.68	0.63	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	9.82	7.48e-18	2.21e-13	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
UCEC	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-9.81	8.02e-18	2.37e-13	-0.8	-0.63	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
UCEC	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	9.79	8.61e-18	2.51e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	9.79	8.61e-18	2.51e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	9.79	8.61e-18	2.51e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	9.79	8.61e-18	2.51e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	9.79	8.61e-18	2.51e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	9.79	8.61e-18	2.51e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	9.79	8.61e-18	2.51e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	9.79	8.61e-18	2.51e-13	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	9.77	9.76e-18	2.84e-13	0.69	0.62	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	9.77	1e-17	2.92e-13	0.78	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
UCEC	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	9.76	1.08e-17	3.15e-13	0.63	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
UCEC	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	9.75	1.09e-17	3.16e-13	0.69	0.62	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	9.75	1.09e-17	3.16e-13	0.69	0.62	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	9.75	1.09e-17	3.16e-13	0.69	0.62	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-9.75	1.09e-17	3.16e-13	-0.84	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
UCEC	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	9.73	1.24e-17	3.57e-13	0.77	0.62	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
UCEC	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	9.72	1.33e-17	3.83e-13	0.79	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	9.7	1.5e-17	4.29e-13	0.79	0.62	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	9.7	1.5e-17	4.29e-13	0.79	0.62	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
UCEC	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	9.69	1.65e-17	4.7e-13	0.77	0.62	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
UCEC	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-9.67	1.84e-17	5.23e-13	-0.68	-0.62	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	9.65	2.04e-17	5.79e-13	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	9.65	2.08e-17	5.91e-13	0.79	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
UCEC	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	9.63	2.26e-17	6.4e-13	0.74	0.62	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
UCEC	cis	rs858239	0.601	rs6966776	ENSG00000230658.1	KLHL7-AS1	9.63	2.26e-17	6.4e-13	0.71	0.62	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23101228~23105703:-
UCEC	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	9.63	2.31e-17	6.55e-13	0.74	0.62	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	9.63	2.31e-17	6.55e-13	0.74	0.62	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
UCEC	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	9.62	2.37e-17	6.7e-13	0.71	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
UCEC	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	9.58	3.01e-17	8.39e-13	0.79	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
UCEC	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	9.58	3.1e-17	8.64e-13	0.73	0.62	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
UCEC	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	9.58	3.19e-17	8.86e-13	0.69	0.62	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	9.57	3.28e-17	9.1e-13	0.77	0.62	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	9.57	3.36e-17	9.3e-13	0.78	0.62	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	9.55	3.7e-17	1.02e-12	0.68	0.62	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
UCEC	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	9.53	4.18e-17	1.15e-12	0.73	0.62	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
UCEC	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	9.52	4.54e-17	1.25e-12	0.63	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
UCEC	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	9.5	4.89e-17	1.34e-12	0.67	0.61	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	9.5	4.89e-17	1.34e-12	0.67	0.61	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	9.5	4.89e-17	1.34e-12	0.67	0.61	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	9.5	5.03e-17	1.38e-12	0.67	0.61	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	9.5	5.03e-17	1.38e-12	0.67	0.61	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	9.46	6.3e-17	1.71e-12	0.68	0.61	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
UCEC	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	9.46	6.46e-17	1.75e-12	0.68	0.61	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
UCEC	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-9.46	6.54e-17	1.77e-12	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	9.44	7.29e-17	1.97e-12	0.7	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	9.44	7.31e-17	1.98e-12	0.8	0.61	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	9.43	7.61e-17	2.06e-12	0.79	0.61	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
UCEC	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-9.43	7.66e-17	2.07e-12	-0.74	-0.61	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
UCEC	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	9.42	7.99e-17	2.15e-12	0.67	0.61	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
UCEC	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	9.42	8.15e-17	2.19e-12	0.67	0.61	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
UCEC	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	9.42	8.16e-17	2.19e-12	0.67	0.61	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	9.42	8.16e-17	2.19e-12	0.67	0.61	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-9.41	8.36e-17	2.24e-12	-0.68	-0.61	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-9.41	8.36e-17	2.24e-12	-0.68	-0.61	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	9.38	1.04e-16	2.77e-12	0.71	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
UCEC	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	9.37	1.08e-16	2.89e-12	0.9	0.61	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
UCEC	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	9.35	1.2e-16	3.18e-12	0.79	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
UCEC	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	9.35	1.26e-16	3.34e-12	0.76	0.61	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	9.35	1.26e-16	3.34e-12	0.76	0.61	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	9.34	1.28e-16	3.41e-12	0.75	0.61	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
UCEC	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-9.34	1.29e-16	3.41e-12	-0.74	-0.61	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	9.32	1.45e-16	3.82e-12	0.7	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
UCEC	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	9.31	1.56e-16	4.11e-12	0.74	0.61	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
UCEC	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	9.31	1.56e-16	4.11e-12	0.67	0.61	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
UCEC	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-9.3	1.62e-16	4.23e-12	-0.74	-0.61	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
UCEC	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	9.28	1.81e-16	4.72e-12	0.9	0.61	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
UCEC	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	9.28	1.85e-16	4.82e-12	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
UCEC	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	9.28	1.91e-16	4.98e-12	0.68	0.61	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	9.27	1.94e-16	5.02e-12	0.72	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
UCEC	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	9.27	1.94e-16	5.02e-12	0.72	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
UCEC	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	9.26	2.08e-16	5.39e-12	0.67	0.6	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	9.26	2.08e-16	5.39e-12	0.67	0.6	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
UCEC	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	9.26	2.09e-16	5.42e-12	0.85	0.6	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
UCEC	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	9.26	2.1e-16	5.43e-12	0.67	0.6	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
UCEC	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	9.25	2.17e-16	5.6e-12	0.72	0.6	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	9.23	2.55e-16	6.53e-12	0.64	0.6	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-9.23	2.56e-16	6.57e-12	-0.67	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
UCEC	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	9.22	2.64e-16	6.75e-12	0.72	0.6	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
UCEC	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	9.21	2.75e-16	7.01e-12	0.78	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	9.2	2.96e-16	7.5e-12	0.68	0.6	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
UCEC	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	9.2	3.05e-16	7.72e-12	0.67	0.6	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
UCEC	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	9.2	3.07e-16	7.76e-12	0.85	0.6	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
UCEC	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	9.19	3.22e-16	8.13e-12	0.68	0.6	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	9.19	3.22e-16	8.13e-12	0.68	0.6	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
UCEC	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	9.18	3.36e-16	8.48e-12	0.75	0.6	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
UCEC	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	9.18	3.47e-16	8.74e-12	0.68	0.6	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
UCEC	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-9.17	3.54e-16	8.92e-12	-0.8	-0.6	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
UCEC	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	9.16	3.78e-16	9.51e-12	0.73	0.6	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
UCEC	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	9.16	3.87e-16	9.73e-12	0.87	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
UCEC	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	9.14	4.17e-16	1.04e-11	0.73	0.6	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	9.14	4.17e-16	1.04e-11	0.73	0.6	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
UCEC	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	9.14	4.21e-16	1.05e-11	0.64	0.6	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	9.14	4.28e-16	1.07e-11	0.64	0.6	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	9.14	4.31e-16	1.08e-11	0.75	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
UCEC	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	9.14	4.37e-16	1.09e-11	0.79	0.6	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	9.13	4.43e-16	1.1e-11	0.65	0.6	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
UCEC	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	9.12	4.7e-16	1.17e-11	0.67	0.6	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	9.12	4.79e-16	1.19e-11	0.67	0.6	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-9.12	4.79e-16	1.19e-11	-0.67	-0.6	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
UCEC	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	9.11	4.99e-16	1.24e-11	0.63	0.6	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	9.1	5.43e-16	1.34e-11	0.62	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
UCEC	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	9.09	5.7e-16	1.41e-11	0.72	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
UCEC	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	9.09	5.78e-16	1.42e-11	0.66	0.6	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	9.09	5.78e-16	1.42e-11	0.66	0.6	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-9.08	6.23e-16	1.52e-11	-0.63	-0.6	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	9.08	6.26e-16	1.52e-11	0.76	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
UCEC	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	9.07	6.39e-16	1.55e-11	0.91	0.6	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
UCEC	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	9.07	6.39e-16	1.55e-11	0.91	0.6	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
UCEC	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-9.06	6.88e-16	1.66e-11	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-9.06	6.88e-16	1.66e-11	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-9.06	7.03e-16	1.69e-11	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-9.06	7.03e-16	1.69e-11	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
UCEC	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	9.06	7.06e-16	1.7e-11	0.66	0.6	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-9.04	7.54e-16	1.8e-11	-0.76	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
UCEC	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-9.03	8.03e-16	1.91e-11	-0.66	-0.59	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	9.03	8.03e-16	1.91e-11	0.66	0.59	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	9.03	8.26e-16	1.96e-11	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
UCEC	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	9.02	8.84e-16	2.09e-11	0.75	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
UCEC	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	9.01	9.02e-16	2.13e-11	0.77	0.59	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
UCEC	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	9	9.82e-16	2.32e-11	0.72	0.59	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
UCEC	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	9	9.99e-16	2.35e-11	0.74	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
UCEC	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-8.98	1.07e-15	2.52e-11	-0.62	-0.59	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
UCEC	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-8.98	1.12e-15	2.61e-11	-0.73	-0.59	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
UCEC	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	8.98	1.12e-15	2.62e-11	0.67	0.59	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
UCEC	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-8.98	1.13e-15	2.64e-11	-0.69	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
UCEC	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	8.97	1.14e-15	2.66e-11	0.66	0.59	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
UCEC	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	8.97	1.14e-15	2.66e-11	0.66	0.59	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
UCEC	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	8.97	1.15e-15	2.68e-11	0.73	0.59	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
UCEC	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-8.97	1.17e-15	2.72e-11	-0.82	-0.59	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
UCEC	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	8.97	1.17e-15	2.73e-11	0.66	0.59	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-8.96	1.27e-15	2.94e-11	-0.65	-0.59	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-8.95	1.3e-15	2.99e-11	-0.66	-0.59	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	8.95	1.35e-15	3.1e-11	0.74	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
UCEC	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	8.94	1.37e-15	3.15e-11	0.63	0.59	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
UCEC	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	8.94	1.37e-15	3.15e-11	0.66	0.59	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	8.93	1.45e-15	3.31e-11	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
UCEC	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	8.93	1.46e-15	3.33e-11	0.66	0.59	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	8.92	1.57e-15	3.58e-11	0.64	0.59	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	8.91	1.63e-15	3.71e-11	0.69	0.59	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
UCEC	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-8.91	1.67e-15	3.78e-11	-0.79	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
UCEC	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	8.91	1.7e-15	3.84e-11	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
UCEC	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	8.9	1.78e-15	4.02e-11	0.78	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-8.89	1.89e-15	4.26e-11	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	8.88	1.93e-15	4.34e-11	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	8.88	1.93e-15	4.34e-11	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	8.88	1.93e-15	4.34e-11	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	8.88	2e-15	4.46e-11	0.67	0.59	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	8.88	2.03e-15	4.5e-11	0.61	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
UCEC	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	8.88	2.03e-15	4.5e-11	0.61	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
UCEC	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-8.87	2.15e-15	4.73e-11	-0.65	-0.59	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
UCEC	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	8.86	2.21e-15	4.85e-11	0.77	0.59	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
UCEC	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-8.86	2.28e-15	5e-11	-0.81	-0.59	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-8.86	2.28e-15	5e-11	-0.81	-0.59	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
UCEC	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	8.85	2.38e-15	5.2e-11	0.54	0.59	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
UCEC	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-8.85	2.42e-15	5.28e-11	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
UCEC	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	8.84	2.53e-15	5.5e-11	0.85	0.59	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
UCEC	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	8.83	2.61e-15	5.64e-11	0.65	0.59	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	8.83	2.61e-15	5.64e-11	0.65	0.59	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-8.83	2.62e-15	5.65e-11	-0.67	-0.59	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	8.83	2.71e-15	5.83e-11	0.78	0.59	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
UCEC	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-8.82	2.74e-15	5.89e-11	-0.67	-0.59	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
UCEC	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	8.82	2.75e-15	5.91e-11	0.65	0.59	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	8.81	2.98e-15	6.37e-11	0.78	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
UCEC	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	8.81	3.01e-15	6.44e-11	0.64	0.59	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	8.79	3.29e-15	7.02e-11	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
UCEC	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	8.79	3.36e-15	7.15e-11	0.69	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
UCEC	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-8.79	3.39e-15	7.22e-11	-0.66	-0.58	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
UCEC	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	8.78	3.57e-15	7.58e-11	0.85	0.58	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
UCEC	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	8.78	3.64e-15	7.74e-11	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	8.77	3.75e-15	7.95e-11	0.66	0.58	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
UCEC	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-8.77	3.78e-15	8.01e-11	-0.82	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
UCEC	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	8.77	3.86e-15	8.13e-11	0.71	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
UCEC	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	8.77	3.86e-15	8.13e-11	0.71	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
UCEC	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-8.77	3.88e-15	8.18e-11	-0.7	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
UCEC	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-8.75	4.21e-15	8.84e-11	-0.78	-0.58	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-8.75	4.21e-15	8.84e-11	-0.78	-0.58	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-8.75	4.29e-15	9.01e-11	-0.65	-0.58	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	8.74	4.45e-15	9.32e-11	0.76	0.58	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
UCEC	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	8.74	4.61e-15	9.63e-11	0.64	0.58	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
UCEC	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	8.73	4.65e-15	9.69e-11	0.78	0.58	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
UCEC	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-8.73	4.79e-15	9.95e-11	-0.62	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
UCEC	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	8.73	4.87e-15	1.01e-10	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	8.71	5.37e-15	1.1e-10	0.75	0.58	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
UCEC	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-8.71	5.4e-15	1.1e-10	-0.7	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	8.7	5.53e-15	1.13e-10	0.76	0.58	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
UCEC	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	8.7	5.56e-15	1.13e-10	0.66	0.58	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
UCEC	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	8.69	5.9e-15	1.2e-10	0.64	0.58	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
UCEC	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-8.69	6.14e-15	1.24e-10	-0.79	-0.58	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-8.69	6.14e-15	1.24e-10	-0.79	-0.58	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
UCEC	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-8.69	6.15e-15	1.24e-10	-0.62	-0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
UCEC	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-8.68	6.3e-15	1.27e-10	-0.62	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
UCEC	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	8.68	6.31e-15	1.27e-10	0.65	0.58	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
UCEC	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-8.68	6.38e-15	1.28e-10	-0.78	-0.58	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
UCEC	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	8.68	6.44e-15	1.29e-10	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	8.68	6.44e-15	1.29e-10	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	8.68	6.44e-15	1.29e-10	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	8.68	6.52e-15	1.3e-10	0.76	0.58	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	8.68	6.52e-15	1.3e-10	0.76	0.58	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	8.68	6.52e-15	1.3e-10	0.76	0.58	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
UCEC	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	8.68	6.53e-15	1.31e-10	0.66	0.58	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	8.68	6.56e-15	1.31e-10	0.65	0.58	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
UCEC	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-8.67	6.83e-15	1.36e-10	-0.66	-0.58	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
UCEC	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	8.67	6.89e-15	1.37e-10	0.78	0.58	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
UCEC	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	8.66	7.2e-15	1.43e-10	0.66	0.58	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-8.66	7.3e-15	1.45e-10	-0.65	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
UCEC	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-8.65	7.56e-15	1.5e-10	-0.62	-0.58	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
UCEC	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	8.65	7.79e-15	1.54e-10	0.65	0.58	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
UCEC	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	8.64	7.85e-15	1.55e-10	0.66	0.58	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
UCEC	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	8.64	7.9e-15	1.56e-10	0.65	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	8.64	7.9e-15	1.56e-10	0.65	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
UCEC	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	8.63	8.39e-15	1.65e-10	0.67	0.58	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
UCEC	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	8.63	8.48e-15	1.67e-10	0.62	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
UCEC	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-8.62	8.83e-15	1.73e-10	-0.63	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
UCEC	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-8.59	1.06e-14	2.05e-10	-0.8	-0.58	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-8.59	1.09e-14	2.11e-10	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
UCEC	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	8.59	1.1e-14	2.12e-10	0.81	0.58	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
UCEC	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-8.59	1.1e-14	2.12e-10	-0.62	-0.58	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-8.59	1.11e-14	2.15e-10	-0.62	-0.58	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-8.58	1.15e-14	2.2e-10	-0.62	-0.58	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-8.58	1.15e-14	2.2e-10	-0.62	-0.58	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-8.58	1.15e-14	2.2e-10	-0.62	-0.58	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-8.58	1.15e-14	2.2e-10	-0.62	-0.58	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-8.58	1.15e-14	2.2e-10	-0.62	-0.58	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-8.58	1.15e-14	2.2e-10	-0.62	-0.58	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
UCEC	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	8.58	1.15e-14	2.21e-10	0.65	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
UCEC	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-8.57	1.18e-14	2.27e-10	-0.62	-0.57	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
UCEC	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	8.57	1.23e-14	2.36e-10	0.65	0.57	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	8.56	1.26e-14	2.41e-10	0.64	0.57	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
UCEC	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-8.56	1.27e-14	2.42e-10	-0.87	-0.57	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
UCEC	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	8.55	1.33e-14	2.53e-10	0.65	0.57	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
UCEC	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-8.54	1.44e-14	2.73e-10	-0.6	-0.57	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
UCEC	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	8.53	1.49e-14	2.8e-10	0.75	0.57	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	8.53	1.49e-14	2.8e-10	0.75	0.57	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	8.53	1.49e-14	2.8e-10	0.75	0.57	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
UCEC	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-8.53	1.5e-14	2.81e-10	-0.83	-0.57	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
UCEC	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	8.52	1.59e-14	2.98e-10	0.63	0.57	Depression;	chr6:28323463	chr6:28176188~28176674:+
UCEC	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	8.51	1.68e-14	3.14e-10	0.63	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
UCEC	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-8.51	1.72e-14	3.21e-10	-0.82	-0.57	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-8.51	1.72e-14	3.21e-10	-0.82	-0.57	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-8.51	1.72e-14	3.21e-10	-0.82	-0.57	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-8.51	1.76e-14	3.28e-10	-0.79	-0.57	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
UCEC	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	8.5	1.79e-14	3.33e-10	0.64	0.57	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	8.5	1.84e-14	3.42e-10	0.63	0.57	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-8.48	2.01e-14	3.73e-10	-0.7	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
UCEC	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	8.48	2.02e-14	3.73e-10	0.64	0.57	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
UCEC	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	8.48	2.06e-14	3.81e-10	0.83	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
UCEC	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	8.47	2.13e-14	3.92e-10	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
UCEC	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	8.47	2.18e-14	4.01e-10	0.64	0.57	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	8.47	2.18e-14	4.01e-10	0.64	0.57	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
UCEC	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-8.46	2.28e-14	4.17e-10	-0.6	-0.57	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
UCEC	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-8.46	2.33e-14	4.25e-10	-0.6	-0.57	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
UCEC	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-8.46	2.33e-14	4.25e-10	-0.6	-0.57	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
UCEC	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-8.46	2.33e-14	4.25e-10	-0.6	-0.57	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
UCEC	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-8.45	2.38e-14	4.33e-10	-0.61	-0.57	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-8.45	2.38e-14	4.33e-10	-0.61	-0.57	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
UCEC	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	8.45	2.42e-14	4.4e-10	0.66	0.57	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	8.45	2.42e-14	4.4e-10	0.66	0.57	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	8.45	2.42e-14	4.4e-10	0.66	0.57	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	8.45	2.42e-14	4.4e-10	0.66	0.57	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	8.45	2.42e-14	4.4e-10	0.66	0.57	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	8.45	2.43e-14	4.41e-10	0.64	0.57	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-8.45	2.46e-14	4.46e-10	-0.66	-0.57	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	8.44	2.55e-14	4.62e-10	0.64	0.57	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
UCEC	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-8.44	2.56e-14	4.62e-10	-0.66	-0.57	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	8.44	2.61e-14	4.72e-10	0.7	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
UCEC	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	8.44	2.62e-14	4.73e-10	0.62	0.57	Depression;	chr6:28327262	chr6:28176188~28176674:+
UCEC	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-8.44	2.63e-14	4.74e-10	-0.53	-0.57	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
UCEC	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	8.43	2.74e-14	4.92e-10	0.85	0.57	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
UCEC	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	8.43	2.74e-14	4.92e-10	0.85	0.57	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
UCEC	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	8.43	2.79e-14	4.99e-10	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	8.42	2.82e-14	5.03e-10	0.62	0.57	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
UCEC	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	8.42	2.83e-14	5.05e-10	0.63	0.57	Depression;	chr6:28301886	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	8.42	2.83e-14	5.05e-10	0.63	0.57	Depression;	chr6:28303421	chr6:28176188~28176674:+
UCEC	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	8.42	2.83e-14	5.05e-10	0.63	0.57	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	8.42	2.87e-14	5.09e-10	0.64	0.57	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
UCEC	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-8.42	2.96e-14	5.24e-10	-0.69	-0.57	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
UCEC	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-8.42	2.96e-14	5.24e-10	-0.69	-0.57	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
UCEC	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	8.41	2.99e-14	5.29e-10	0.66	0.57	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	8.41	3.04e-14	5.37e-10	0.69	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
UCEC	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	8.41	3.04e-14	5.37e-10	0.69	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
UCEC	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	8.41	3.14e-14	5.54e-10	0.62	0.57	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	8.4	3.2e-14	5.63e-10	0.75	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	8.4	3.29e-14	5.77e-10	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
UCEC	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	8.39	3.44e-14	6.02e-10	0.81	0.57	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
UCEC	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	8.39	3.44e-14	6.02e-10	0.81	0.57	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
UCEC	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	8.39	3.49e-14	6.1e-10	0.65	0.57	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
UCEC	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	8.38	3.58e-14	6.25e-10	0.7	0.57	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
UCEC	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	8.38	3.71e-14	6.47e-10	0.7	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
UCEC	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	8.38	3.71e-14	6.47e-10	0.7	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
UCEC	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-8.37	3.78e-14	6.55e-10	-0.61	-0.57	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
UCEC	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	8.37	3.88e-14	6.71e-10	0.66	0.57	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	8.37	3.88e-14	6.71e-10	0.66	0.57	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
UCEC	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-8.37	3.9e-14	6.74e-10	-0.66	-0.57	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
UCEC	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	8.36	4.09e-14	7.01e-10	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
UCEC	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	8.36	4.11e-14	7.03e-10	0.63	0.57	Depression;	chr6:28317705	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.965	rs1654774	ENSG00000216901.1	AL022393.7	8.36	4.13e-14	7.07e-10	0.65	0.56	Pubertal anthropometrics;	chr6:28128502	chr6:28176188~28176674:+
UCEC	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-8.36	4.13e-14	7.07e-10	-0.72	-0.56	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
UCEC	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	8.36	4.13e-14	7.07e-10	0.71	0.56	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	8.35	4.26e-14	7.25e-10	0.63	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
UCEC	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	8.35	4.28e-14	7.29e-10	0.74	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
UCEC	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	8.35	4.29e-14	7.29e-10	0.63	0.56	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	8.35	4.29e-14	7.29e-10	0.63	0.56	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	8.35	4.29e-14	7.29e-10	0.63	0.56	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
UCEC	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	8.35	4.42e-14	7.49e-10	0.73	0.56	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	8.34	4.48e-14	7.58e-10	0.76	0.56	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
UCEC	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	8.33	4.75e-14	7.96e-10	0.65	0.56	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	8.33	4.75e-14	7.96e-10	0.65	0.56	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	8.33	4.75e-14	7.96e-10	0.65	0.56	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	8.33	4.75e-14	7.96e-10	0.65	0.56	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	8.33	4.75e-14	7.96e-10	0.65	0.56	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	8.33	4.75e-14	7.96e-10	0.65	0.56	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	8.33	4.75e-14	7.96e-10	0.65	0.56	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
UCEC	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	8.33	4.76e-14	7.97e-10	0.69	0.56	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
UCEC	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-8.33	4.8e-14	8.04e-10	-0.6	-0.56	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
UCEC	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	8.33	4.82e-14	8.04e-10	0.63	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	8.33	4.82e-14	8.04e-10	0.73	0.56	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	8.33	4.98e-14	8.24e-10	0.73	0.56	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	8.33	4.98e-14	8.24e-10	0.73	0.56	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	8.33	4.98e-14	8.24e-10	0.73	0.56	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	8.33	4.98e-14	8.24e-10	0.73	0.56	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	8.33	4.98e-14	8.24e-10	0.73	0.56	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
UCEC	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	8.33	4.98e-14	8.24e-10	0.63	0.56	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-8.33	4.99e-14	8.24e-10	-0.76	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	8.32	5.02e-14	8.26e-10	0.73	0.56	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	8.32	5.02e-14	8.26e-10	0.73	0.56	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	8.32	5.02e-14	8.26e-10	0.73	0.56	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	8.32	5.02e-14	8.26e-10	0.73	0.56	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	8.32	5.02e-14	8.26e-10	0.73	0.56	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
UCEC	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	8.32	5.04e-14	8.3e-10	0.83	0.56	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
UCEC	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	8.32	5.13e-14	8.44e-10	0.73	0.56	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	8.32	5.19e-14	8.53e-10	0.73	0.56	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
UCEC	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	8.32	5.27e-14	8.65e-10	0.65	0.56	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	8.3	5.63e-14	9.21e-10	0.73	0.56	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	8.3	5.66e-14	9.22e-10	0.74	0.56	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	8.3	5.66e-14	9.22e-10	0.74	0.56	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	8.3	5.66e-14	9.22e-10	0.74	0.56	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	8.3	5.69e-14	9.22e-10	0.77	0.56	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
UCEC	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-8.3	5.71e-14	9.22e-10	-0.62	-0.56	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
UCEC	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-8.3	5.71e-14	9.22e-10	-0.67	-0.56	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
UCEC	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	8.3	5.84e-14	9.38e-10	0.66	0.56	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
UCEC	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	8.29	5.99e-14	9.57e-10	0.82	0.56	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
UCEC	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-8.29	6.02e-14	9.62e-10	-0.75	-0.56	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
UCEC	cis	rs1150668	0.805	rs2859348	ENSG00000216901.1	AL022393.7	8.29	6.16e-14	9.8e-10	0.65	0.56	Pubertal anthropometrics;	chr6:28391393	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.965	rs1150690	ENSG00000216901.1	AL022393.7	8.28	6.4e-14	1.02e-09	0.65	0.56	Pubertal anthropometrics;	chr6:28197520	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	8.28	6.51e-14	1.03e-09	0.66	0.56	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	8.28	6.61e-14	1.05e-09	0.74	0.56	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
UCEC	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-8.27	6.81e-14	1.08e-09	-0.6	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
UCEC	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-8.27	6.82e-14	1.08e-09	-0.78	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
UCEC	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-8.27	6.86e-14	1.08e-09	-0.65	-0.56	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-8.27	6.86e-14	1.08e-09	-0.65	-0.56	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-8.27	6.86e-14	1.08e-09	-0.65	-0.56	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-8.27	6.86e-14	1.08e-09	-0.65	-0.56	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	8.27	7.01e-14	1.1e-09	0.62	0.56	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	8.26	7.12e-14	1.12e-09	0.77	0.56	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	8.26	7.17e-14	1.12e-09	0.7	0.56	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
UCEC	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-8.26	7.19e-14	1.13e-09	-0.76	-0.56	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
UCEC	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-8.25	7.5e-14	1.17e-09	-0.65	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
UCEC	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-8.25	7.66e-14	1.19e-09	-0.65	-0.56	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-8.25	7.66e-14	1.19e-09	-0.65	-0.56	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-8.25	7.66e-14	1.19e-09	-0.65	-0.56	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-8.25	7.66e-14	1.19e-09	-0.65	-0.56	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-8.25	7.66e-14	1.19e-09	-0.65	-0.56	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-8.25	7.66e-14	1.19e-09	-0.65	-0.56	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-8.25	7.66e-14	1.19e-09	-0.65	-0.56	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	8.25	7.7e-14	1.19e-09	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
UCEC	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-8.25	7.81e-14	1.21e-09	-0.52	-0.56	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
UCEC	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-8.25	7.82e-14	1.21e-09	-0.52	-0.56	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	8.25	7.94e-14	1.23e-09	0.65	0.56	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	8.24	7.98e-14	1.23e-09	0.65	0.56	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	8.24	7.98e-14	1.23e-09	0.65	0.56	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-8.24	7.98e-14	1.23e-09	-0.65	-0.56	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-8.24	7.98e-14	1.23e-09	-0.65	-0.56	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-8.24	7.98e-14	1.23e-09	-0.65	-0.56	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-8.24	7.98e-14	1.23e-09	-0.65	-0.56	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-8.24	7.98e-14	1.23e-09	-0.65	-0.56	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-8.24	7.98e-14	1.23e-09	-0.65	-0.56	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-8.24	7.98e-14	1.23e-09	-0.65	-0.56	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-8.24	7.98e-14	1.23e-09	-0.65	-0.56	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-8.24	7.98e-14	1.23e-09	-0.65	-0.56	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
UCEC	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-8.24	8.08e-14	1.24e-09	-0.61	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
UCEC	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-8.24	8.36e-14	1.28e-09	-0.66	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
UCEC	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	8.24	8.38e-14	1.28e-09	0.65	0.56	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	8.24	8.38e-14	1.28e-09	0.65	0.56	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	8.24	8.38e-14	1.28e-09	0.65	0.56	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	8.24	8.38e-14	1.28e-09	0.65	0.56	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	8.24	8.38e-14	1.28e-09	0.65	0.56	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	8.23	8.64e-14	1.31e-09	0.76	0.56	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
UCEC	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	8.23	8.69e-14	1.31e-09	0.62	0.56	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
UCEC	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	8.23	8.69e-14	1.31e-09	0.62	0.56	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
UCEC	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	8.23	8.69e-14	1.31e-09	0.62	0.56	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	8.21	9.85e-14	1.48e-09	0.65	0.56	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	8.2	1.05e-13	1.56e-09	0.73	0.56	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
UCEC	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	8.2	1.05e-13	1.57e-09	0.7	0.56	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
UCEC	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	8.19	1.07e-13	1.59e-09	0.61	0.56	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	8.19	1.07e-13	1.6e-09	0.68	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
UCEC	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-8.19	1.08e-13	1.61e-09	-0.61	-0.56	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-8.19	1.08e-13	1.61e-09	-0.63	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
UCEC	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	8.18	1.13e-13	1.68e-09	0.68	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
UCEC	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-8.18	1.14e-13	1.69e-09	-0.65	-0.56	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	8.18	1.15e-13	1.7e-09	0.71	0.56	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
UCEC	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	8.18	1.18e-13	1.75e-09	0.65	0.56	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	8.18	1.18e-13	1.75e-09	0.65	0.56	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
UCEC	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-8.17	1.22e-13	1.81e-09	-0.59	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
UCEC	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	8.17	1.24e-13	1.83e-09	0.64	0.56	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
UCEC	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-8.17	1.25e-13	1.85e-09	-0.61	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
UCEC	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	8.16	1.26e-13	1.86e-09	0.65	0.56	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	8.16	1.26e-13	1.86e-09	0.65	0.56	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
UCEC	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-8.16	1.27e-13	1.86e-09	-0.59	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
UCEC	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-8.16	1.27e-13	1.86e-09	-0.59	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
UCEC	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-8.16	1.27e-13	1.86e-09	-0.59	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
UCEC	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-8.16	1.27e-13	1.86e-09	-0.59	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
UCEC	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-8.16	1.27e-13	1.86e-09	-0.59	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
UCEC	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	8.16	1.29e-13	1.89e-09	0.64	0.56	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
UCEC	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	8.16	1.29e-13	1.89e-09	0.59	0.56	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
UCEC	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-8.15	1.36e-13	1.98e-09	-0.64	-0.56	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
UCEC	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	8.15	1.38e-13	2e-09	0.79	0.56	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
UCEC	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	8.14	1.44e-13	2.1e-09	0.78	0.55	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
UCEC	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	8.14	1.44e-13	2.1e-09	0.78	0.55	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
UCEC	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	8.13	1.49e-13	2.16e-09	0.71	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
UCEC	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	8.13	1.5e-13	2.16e-09	0.64	0.55	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	8.13	1.5e-13	2.16e-09	0.64	0.55	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-8.13	1.5e-13	2.16e-09	-0.64	-0.55	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-8.13	1.5e-13	2.16e-09	-0.64	-0.55	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-8.13	1.5e-13	2.16e-09	-0.64	-0.55	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-8.13	1.5e-13	2.16e-09	-0.64	-0.55	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
UCEC	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-8.13	1.5e-13	2.16e-09	-0.64	-0.55	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	8.13	1.56e-13	2.25e-09	0.71	0.55	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	8.13	1.56e-13	2.25e-09	0.71	0.55	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
UCEC	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	8.13	1.57e-13	2.26e-09	0.64	0.55	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
UCEC	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	8.13	1.58e-13	2.27e-09	0.78	0.55	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
UCEC	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-8.12	1.6e-13	2.31e-09	-0.65	-0.55	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	8.12	1.61e-13	2.32e-09	0.66	0.55	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
UCEC	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-8.12	1.65e-13	2.37e-09	-0.58	-0.55	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
UCEC	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	8.11	1.68e-13	2.42e-09	0.67	0.55	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	8.11	1.68e-13	2.42e-09	0.67	0.55	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	8.11	1.69e-13	2.42e-09	0.71	0.55	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
UCEC	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	8.11	1.7e-13	2.43e-09	0.61	0.55	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	8.11	1.7e-13	2.43e-09	0.64	0.55	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	8.11	1.73e-13	2.48e-09	0.64	0.55	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-8.11	1.74e-13	2.49e-09	-0.64	-0.55	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
UCEC	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	8.1	1.77e-13	2.53e-09	0.58	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
UCEC	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	8.1	1.78e-13	2.54e-09	0.71	0.55	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	8.1	1.78e-13	2.54e-09	0.71	0.55	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
UCEC	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-8.1	1.82e-13	2.59e-09	-0.64	-0.55	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	8.1	1.82e-13	2.59e-09	0.65	0.55	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
UCEC	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	8.1	1.83e-13	2.61e-09	0.62	0.55	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
UCEC	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-8.1	1.84e-13	2.62e-09	-0.64	-0.55	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
UCEC	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	8.09	1.89e-13	2.68e-09	0.7	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	8.09	1.89e-13	2.68e-09	0.7	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
UCEC	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	8.09	1.89e-13	2.68e-09	0.7	0.55	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	8.09	1.89e-13	2.68e-09	0.7	0.55	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	8.09	1.89e-13	2.68e-09	0.7	0.55	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	8.09	1.89e-13	2.68e-09	0.7	0.55	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	8.09	1.89e-13	2.68e-09	0.7	0.55	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	8.09	1.89e-13	2.68e-09	0.7	0.55	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	8.09	1.89e-13	2.68e-09	0.7	0.55	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
UCEC	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	8.09	1.9e-13	2.69e-09	0.6	0.55	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	8.09	1.91e-13	2.7e-09	0.66	0.55	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
UCEC	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	8.09	1.91e-13	2.71e-09	0.6	0.55	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	8.09	1.92e-13	2.71e-09	0.63	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
UCEC	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	8.08	1.99e-13	2.8e-09	0.72	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
UCEC	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	8.08	1.99e-13	2.81e-09	0.74	0.55	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	8.08	2.05e-13	2.89e-09	0.77	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	8.08	2.07e-13	2.91e-09	0.71	0.55	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	8.08	2.08e-13	2.92e-09	0.74	0.55	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	8.08	2.08e-13	2.92e-09	0.74	0.55	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	8.08	2.08e-13	2.92e-09	0.74	0.55	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
UCEC	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	8.07	2.16e-13	3e-09	0.58	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
UCEC	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	8.07	2.16e-13	3e-09	0.58	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
UCEC	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	8.07	2.16e-13	3e-09	0.82	0.55	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
UCEC	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	8.07	2.16e-13	3.01e-09	0.77	0.55	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
UCEC	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-8.07	2.18e-13	3.04e-09	-0.68	-0.55	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
UCEC	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	8.07	2.21e-13	3.07e-09	0.6	0.55	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
UCEC	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	8.06	2.22e-13	3.09e-09	0.66	0.55	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.796	rs5760106	ENSG00000272787.1	KB-226F1.2	8.06	2.28e-13	3.15e-09	0.65	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23969211~23969873:+
UCEC	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	8.06	2.3e-13	3.17e-09	0.64	0.55	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	8.06	2.3e-13	3.17e-09	0.71	0.55	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
UCEC	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-8.06	2.35e-13	3.23e-09	-0.67	-0.55	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
UCEC	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	8.05	2.36e-13	3.24e-09	0.77	0.55	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
UCEC	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	8.05	2.36e-13	3.24e-09	0.77	0.55	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
UCEC	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	8.05	2.41e-13	3.29e-09	0.75	0.55	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
UCEC	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	8.05	2.41e-13	3.31e-09	0.7	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
UCEC	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	8.04	2.53e-13	3.47e-09	0.83	0.55	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
UCEC	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	8.04	2.56e-13	3.5e-09	0.73	0.55	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	8.04	2.56e-13	3.5e-09	0.73	0.55	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
UCEC	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	8.03	2.72e-13	3.68e-09	0.58	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
UCEC	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	8.03	2.75e-13	3.72e-09	0.75	0.55	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
UCEC	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	8.02	2.94e-13	3.95e-09	0.58	0.55	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-8.02	2.94e-13	3.95e-09	-0.58	-0.55	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-8.02	2.94e-13	3.95e-09	-0.58	-0.55	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-8.02	2.94e-13	3.95e-09	-0.58	-0.55	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
UCEC	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	8.02	2.95e-13	3.96e-09	0.68	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
UCEC	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-8.02	2.95e-13	3.96e-09	-0.64	-0.55	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
UCEC	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	8.01	3.12e-13	4.16e-09	0.56	0.55	Breast cancer;	chr11:750849	chr11:779617~780755:+
UCEC	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-8	3.16e-13	4.17e-09	-0.66	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
UCEC	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	8	3.21e-13	4.19e-09	0.7	0.55	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	7.99	3.32e-13	4.32e-09	0.6	0.55	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
UCEC	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-7.99	3.35e-13	4.36e-09	-0.5	-0.55	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
UCEC	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	7.99	3.38e-13	4.4e-09	0.66	0.55	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-7.99	3.4e-13	4.42e-09	-0.64	-0.55	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	7.98	3.52e-13	4.56e-09	0.76	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
UCEC	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	7.98	3.53e-13	4.57e-09	0.58	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
UCEC	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	7.98	3.59e-13	4.64e-09	0.61	0.55	Depression;	chr6:28314871	chr6:28176188~28176674:+
UCEC	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	7.97	3.82e-13	4.92e-09	0.83	0.55	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
UCEC	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-7.96	3.96e-13	5.08e-09	-0.58	-0.55	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
UCEC	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	7.96	4.01e-13	5.15e-09	0.67	0.55	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
UCEC	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-7.96	4.01e-13	5.15e-09	-0.69	-0.55	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
UCEC	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	7.96	4.07e-13	5.22e-09	1.09	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
UCEC	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	7.96	4.07e-13	5.22e-09	0.69	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	7.96	4.09e-13	5.23e-09	0.69	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	7.96	4.09e-13	5.23e-09	0.69	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	7.96	4.09e-13	5.23e-09	0.69	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	7.96	4.09e-13	5.23e-09	0.69	0.55	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	7.96	4.09e-13	5.23e-09	0.69	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	7.96	4.09e-13	5.23e-09	0.69	0.55	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	7.96	4.09e-13	5.23e-09	0.69	0.55	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
UCEC	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-7.96	4.12e-13	5.26e-09	-0.63	-0.55	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	7.95	4.32e-13	5.5e-09	0.72	0.55	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	7.94	4.49e-13	5.72e-09	0.66	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	7.93	4.68e-13	5.93e-09	0.58	0.54	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
UCEC	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-7.93	4.73e-13	5.98e-09	-0.65	-0.54	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
UCEC	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	7.93	4.75e-13	6e-09	0.59	0.54	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	7.93	4.82e-13	6.09e-09	0.72	0.54	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
UCEC	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-7.93	4.86e-13	6.13e-09	-0.62	-0.54	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	7.93	4.9e-13	6.18e-09	0.62	0.54	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
UCEC	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-7.92	5.05e-13	6.37e-09	-0.69	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
UCEC	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	7.92	5.08e-13	6.4e-09	0.64	0.54	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
UCEC	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-7.92	5.14e-13	6.47e-09	-1	-0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
UCEC	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	7.92	5.16e-13	6.49e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
UCEC	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-7.91	5.27e-13	6.63e-09	-0.63	-0.54	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	7.91	5.33e-13	6.69e-09	0.7	0.54	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
UCEC	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	7.91	5.42e-13	6.78e-09	0.68	0.54	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	7.91	5.42e-13	6.78e-09	0.68	0.54	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	7.91	5.42e-13	6.78e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	7.91	5.42e-13	6.78e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	7.91	5.42e-13	6.78e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	7.91	5.42e-13	6.78e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	7.91	5.43e-13	6.79e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	7.91	5.43e-13	6.79e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	7.91	5.43e-13	6.79e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	7.91	5.43e-13	6.79e-09	0.69	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
UCEC	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	7.91	5.5e-13	6.87e-09	0.77	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	7.91	5.5e-13	6.87e-09	0.77	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-7.9	5.65e-13	7.03e-09	-0.7	-0.54	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	7.9	5.68e-13	7.08e-09	0.7	0.54	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
UCEC	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	7.9	5.72e-13	7.12e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
UCEC	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	7.9	5.81e-13	7.23e-09	0.72	0.54	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
UCEC	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-7.89	6.13e-13	7.61e-09	-0.63	-0.54	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
UCEC	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	7.89	6.15e-13	7.63e-09	1.01	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
UCEC	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	7.88	6.32e-13	7.83e-09	0.68	0.54	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-7.88	6.4e-13	7.92e-09	-0.68	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
UCEC	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	7.88	6.52e-13	8.06e-09	0.58	0.54	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
UCEC	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	7.87	6.55e-13	8.08e-09	0.68	0.54	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
UCEC	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	7.87	6.61e-13	8.15e-09	0.66	0.54	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	7.86	7.03e-13	8.65e-09	0.59	0.54	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	7.86	7.25e-13	8.9e-09	0.71	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
UCEC	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	7.85	7.5e-13	9.19e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	7.85	7.5e-13	9.19e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	7.85	7.5e-13	9.19e-09	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	7.84	7.83e-13	9.59e-09	0.68	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
UCEC	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-7.84	7.89e-13	9.65e-09	-0.64	-0.54	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
UCEC	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-7.84	7.89e-13	9.65e-09	-0.64	-0.54	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
UCEC	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	7.84	8.1e-13	9.89e-09	0.69	0.54	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	7.83	8.23e-13	1e-08	0.57	0.54	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
UCEC	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.83	8.47e-13	1.03e-08	0.59	0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
UCEC	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	7.83	8.52e-13	1.04e-08	0.6	0.54	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.796	rs1150694	ENSG00000216901.1	AL022393.7	7.83	8.61e-13	1.05e-08	0.61	0.54	Pubertal anthropometrics;	chr6:28207375	chr6:28176188~28176674:+
UCEC	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	7.82	8.97e-13	1.09e-08	0.75	0.54	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
UCEC	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	7.81	9.16e-13	1.11e-08	0.56	0.54	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	7.81	9.31e-13	1.13e-08	0.66	0.54	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	7.81	9.35e-13	1.13e-08	0.61	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
UCEC	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-7.81	9.39e-13	1.14e-08	-0.58	-0.54	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
UCEC	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-7.81	9.48e-13	1.15e-08	-0.62	-0.54	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
UCEC	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	7.8	9.88e-13	1.17e-08	0.59	0.54	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
UCEC	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	7.8	9.9e-13	1.17e-08	0.97	0.54	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	7.8	9.97e-13	1.17e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
UCEC	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	7.8	1.02e-12	1.2e-08	0.59	0.54	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
UCEC	cis	rs1150668	1	rs1150668	ENSG00000216901.1	AL022393.7	7.8	1.02e-12	1.2e-08	0.63	0.54	Pubertal anthropometrics;	chr6:28162011	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	7.79	1.04e-12	1.22e-08	0.63	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	7.79	1.05e-12	1.24e-08	0.69	0.54	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
UCEC	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-7.79	1.07e-12	1.26e-08	-0.57	-0.54	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
UCEC	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	7.79	1.07e-12	1.26e-08	0.48	0.54	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
UCEC	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-7.79	1.08e-12	1.27e-08	-0.63	-0.54	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	7.78	1.08e-12	1.27e-08	0.69	0.54	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	7.78	1.09e-12	1.27e-08	0.69	0.54	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
UCEC	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-7.78	1.09e-12	1.28e-08	-0.64	-0.54	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
UCEC	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	7.78	1.1e-12	1.28e-08	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
UCEC	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-7.78	1.11e-12	1.3e-08	-0.75	-0.54	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
UCEC	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	7.78	1.15e-12	1.34e-08	0.61	0.54	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
UCEC	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	7.77	1.15e-12	1.34e-08	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
UCEC	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	7.76	1.25e-12	1.44e-08	1.01	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
UCEC	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	7.76	1.25e-12	1.44e-08	0.68	0.54	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	7.76	1.25e-12	1.44e-08	0.68	0.54	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	7.76	1.25e-12	1.44e-08	0.68	0.54	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	7.76	1.25e-12	1.44e-08	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	7.76	1.25e-12	1.44e-08	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	7.76	1.25e-12	1.44e-08	0.68	0.54	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	7.76	1.25e-12	1.44e-08	0.68	0.54	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	7.76	1.26e-12	1.46e-08	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	7.76	1.26e-12	1.46e-08	0.68	0.54	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	7.76	1.26e-12	1.46e-08	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	7.76	1.26e-12	1.46e-08	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
UCEC	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-7.76	1.28e-12	1.47e-08	-0.59	-0.54	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
UCEC	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	7.75	1.31e-12	1.51e-08	0.68	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	7.75	1.33e-12	1.53e-08	0.66	0.54	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	7.75	1.33e-12	1.53e-08	0.66	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	7.75	1.33e-12	1.53e-08	0.66	0.54	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
UCEC	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-7.75	1.34e-12	1.53e-08	-0.65	-0.54	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
UCEC	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-7.75	1.34e-12	1.54e-08	-0.65	-0.54	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
UCEC	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-7.74	1.4e-12	1.6e-08	-0.63	-0.54	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-7.74	1.4e-12	1.6e-08	-0.63	-0.54	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-7.74	1.4e-12	1.6e-08	-0.63	-0.54	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
UCEC	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	1.66e-08	-0.66	-0.54	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	7.73	1.46e-12	1.66e-08	0.75	0.54	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	7.73	1.46e-12	1.66e-08	0.61	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
UCEC	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	7.73	1.46e-12	1.67e-08	0.62	0.54	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
UCEC	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	7.73	1.49e-12	1.7e-08	0.82	0.53	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
UCEC	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	7.73	1.5e-12	1.71e-08	0.66	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
UCEC	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	7.73	1.5e-12	1.71e-08	0.61	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
UCEC	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	7.72	1.52e-12	1.73e-08	0.62	0.53	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
UCEC	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	7.72	1.55e-12	1.76e-08	0.61	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	7.72	1.55e-12	1.76e-08	0.61	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	7.71	1.62e-12	1.83e-08	0.61	0.53	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
UCEC	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	7.71	1.63e-12	1.85e-08	0.67	0.53	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
UCEC	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-7.71	1.64e-12	1.86e-08	-0.64	-0.53	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-7.71	1.66e-12	1.87e-08	-0.65	-0.53	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-7.71	1.68e-12	1.9e-08	-0.64	-0.53	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
UCEC	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-7.71	1.68e-12	1.9e-08	-0.64	-0.53	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
UCEC	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-7.71	1.68e-12	1.9e-08	-0.64	-0.53	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-7.71	1.69e-12	1.9e-08	-0.57	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
UCEC	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	7.71	1.7e-12	1.91e-08	0.85	0.53	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
UCEC	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-7.7	1.72e-12	1.93e-08	-0.65	-0.53	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	7.7	1.72e-12	1.93e-08	0.65	0.53	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-7.7	1.72e-12	1.93e-08	-0.65	-0.53	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	7.7	1.76e-12	1.98e-08	0.61	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
UCEC	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	7.7	1.78e-12	2e-08	0.56	0.53	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
UCEC	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	7.7	1.79e-12	2e-08	0.66	0.53	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
UCEC	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-7.69	1.8e-12	2.02e-08	-0.65	-0.53	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
UCEC	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	7.69	1.82e-12	2.04e-08	0.66	0.53	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
UCEC	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-7.69	1.87e-12	2.08e-08	-0.65	-0.53	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
UCEC	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-7.69	1.87e-12	2.08e-08	-0.62	-0.53	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-7.69	1.87e-12	2.08e-08	-0.62	-0.53	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-7.69	1.87e-12	2.08e-08	-0.62	-0.53	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-7.69	1.87e-12	2.08e-08	-0.62	-0.53	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-7.69	1.87e-12	2.08e-08	-0.62	-0.53	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
UCEC	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-7.69	1.87e-12	2.08e-08	-0.65	-0.53	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
UCEC	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	7.69	1.87e-12	2.08e-08	0.67	0.53	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
UCEC	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	7.69	1.88e-12	2.09e-08	0.85	0.53	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
UCEC	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	7.69	1.88e-12	2.09e-08	0.85	0.53	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
UCEC	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	7.68	1.9e-12	2.12e-08	0.58	0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
UCEC	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-7.68	1.93e-12	2.14e-08	-0.67	-0.53	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
UCEC	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	7.68	1.97e-12	2.19e-08	0.63	0.53	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
UCEC	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-7.67	2.04e-12	2.26e-08	-0.64	-0.53	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
UCEC	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.06e-12	2.28e-08	-0.63	-0.53	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.1e-12	2.31e-08	-0.63	-0.53	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.1e-12	2.31e-08	-0.63	-0.53	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.1e-12	2.31e-08	-0.63	-0.53	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
UCEC	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.1e-12	2.31e-08	-0.63	-0.53	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.1e-12	2.31e-08	-0.63	-0.53	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.1e-12	2.31e-08	-0.63	-0.53	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.1e-12	2.31e-08	-0.63	-0.53	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.1e-12	2.31e-08	-0.63	-0.53	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-7.67	2.1e-12	2.31e-08	-0.63	-0.53	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
UCEC	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	7.66	2.15e-12	2.37e-08	0.56	0.53	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
UCEC	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	7.66	2.16e-12	2.37e-08	0.56	0.53	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
UCEC	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-7.66	2.24e-12	2.46e-08	-0.5	-0.53	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
UCEC	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-7.66	2.24e-12	2.46e-08	-0.5	-0.53	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
UCEC	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-7.66	2.24e-12	2.46e-08	-0.5	-0.53	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-7.64	2.4e-12	2.62e-08	-0.53	-0.53	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
UCEC	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	7.64	2.47e-12	2.69e-08	0.56	0.53	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
UCEC	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	7.64	2.49e-12	2.71e-08	0.56	0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
UCEC	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-7.64	2.5e-12	2.72e-08	-0.63	-0.53	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-7.64	2.5e-12	2.72e-08	-0.63	-0.53	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
UCEC	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	7.63	2.64e-12	2.86e-08	0.71	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
UCEC	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-7.62	2.69e-12	2.91e-08	-0.56	-0.53	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	7.62	2.69e-12	2.92e-08	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
UCEC	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-7.62	2.7e-12	2.93e-08	-0.64	-0.53	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
UCEC	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-7.62	2.7e-12	2.93e-08	-0.59	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
UCEC	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-7.62	2.71e-12	2.93e-08	-0.61	-0.53	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
UCEC	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-7.62	2.71e-12	2.93e-08	-0.61	-0.53	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
UCEC	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-7.62	2.71e-12	2.93e-08	-0.61	-0.53	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
UCEC	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	7.62	2.71e-12	2.93e-08	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
UCEC	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-7.62	2.72e-12	2.94e-08	-0.66	-0.53	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
UCEC	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	7.62	2.74e-12	2.97e-08	0.59	0.53	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
UCEC	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-7.62	2.77e-12	2.99e-08	-0.63	-0.53	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
UCEC	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-7.62	2.77e-12	2.99e-08	-0.63	-0.53	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	7.61	2.82e-12	3.03e-08	0.58	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
UCEC	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	7.61	2.85e-12	3.06e-08	0.61	0.53	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
UCEC	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	7.61	2.93e-12	3.15e-08	0.57	0.53	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
UCEC	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-7.61	2.94e-12	3.16e-08	-0.56	-0.53	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
UCEC	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-7.61	2.94e-12	3.16e-08	-0.62	-0.53	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-7.61	2.94e-12	3.16e-08	-0.62	-0.53	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
UCEC	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	7.61	2.95e-12	3.16e-08	0.72	0.53	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	7.61	2.96e-12	3.17e-08	0.68	0.53	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
UCEC	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-7.6	2.98e-12	3.19e-08	-0.56	-0.53	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
UCEC	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	7.6	3.02e-12	3.23e-08	0.65	0.53	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
UCEC	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	7.6	3.07e-12	3.28e-08	0.51	0.53	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
UCEC	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-7.6	3.1e-12	3.31e-08	-0.64	-0.53	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	7.59	3.14e-12	3.35e-08	0.56	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
UCEC	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	7.59	3.14e-12	3.35e-08	0.62	0.53	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
UCEC	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-7.59	3.23e-12	3.44e-08	-0.62	-0.53	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-7.59	3.23e-12	3.44e-08	-0.62	-0.53	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-7.59	3.23e-12	3.44e-08	-0.62	-0.53	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
UCEC	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	7.59	3.23e-12	3.44e-08	0.61	0.53	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
UCEC	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-7.59	3.29e-12	3.5e-08	-0.64	-0.53	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-7.58	3.33e-12	3.54e-08	-0.64	-0.53	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	7.58	3.4e-12	3.6e-08	0.58	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
UCEC	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-7.58	3.41e-12	3.61e-08	-0.64	-0.53	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	7.58	3.44e-12	3.64e-08	0.57	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
UCEC	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	7.58	3.47e-12	3.67e-08	0.68	0.53	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
UCEC	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	7.58	3.48e-12	3.68e-08	0.62	0.53	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
UCEC	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	7.57	3.55e-12	3.74e-08	0.64	0.53	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	7.57	3.61e-12	3.8e-08	0.62	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	7.57	3.63e-12	3.83e-08	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
UCEC	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	7.57	3.65e-12	3.84e-08	0.62	0.53	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	7.56	3.71e-12	3.9e-08	0.68	0.53	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	7.56	3.71e-12	3.9e-08	0.68	0.53	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
UCEC	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-7.56	3.75e-12	3.94e-08	-0.76	-0.53	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
UCEC	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	7.56	3.81e-12	4e-08	0.69	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
UCEC	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-7.56	3.81e-12	4e-08	-0.66	-0.53	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
UCEC	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-7.55	4.01e-12	4.21e-08	-0.64	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
UCEC	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-7.55	4.01e-12	4.21e-08	-0.88	-0.53	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
UCEC	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-7.55	4.13e-12	4.32e-08	-0.56	-0.53	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
UCEC	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	7.54	4.16e-12	4.35e-08	0.68	0.53	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
UCEC	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	7.54	4.2e-12	4.38e-08	0.56	0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
UCEC	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	7.54	4.2e-12	4.38e-08	0.56	0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
UCEC	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-7.54	4.25e-12	4.44e-08	-0.72	-0.53	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
UCEC	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-7.54	4.25e-12	4.44e-08	-0.72	-0.53	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
UCEC	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-7.54	4.27e-12	4.46e-08	-0.58	-0.53	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
UCEC	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-7.54	4.29e-12	4.47e-08	-0.7	-0.53	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
UCEC	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-7.54	4.34e-12	4.53e-08	-0.67	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
UCEC	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-7.54	4.37e-12	4.55e-08	-0.56	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
UCEC	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-7.53	4.4e-12	4.58e-08	-0.56	-0.53	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-7.53	4.4e-12	4.58e-08	-0.56	-0.53	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-7.53	4.4e-12	4.58e-08	-0.56	-0.53	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-7.53	4.41e-12	4.59e-08	-0.56	-0.53	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
UCEC	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-7.53	4.52e-12	4.68e-08	-0.62	-0.52	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-7.53	4.52e-12	4.68e-08	-0.62	-0.52	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
UCEC	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	7.53	4.54e-12	4.71e-08	0.55	0.52	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
UCEC	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-7.53	4.57e-12	4.73e-08	-0.61	-0.52	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
UCEC	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-7.53	4.59e-12	4.75e-08	-0.71	-0.52	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
UCEC	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	7.53	4.59e-12	4.75e-08	0.5	0.52	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
UCEC	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-7.52	4.64e-12	4.79e-08	-0.64	-0.52	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
UCEC	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-7.52	4.64e-12	4.79e-08	-0.64	-0.52	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
UCEC	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	7.52	4.7e-12	4.85e-08	0.61	0.52	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
UCEC	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	7.52	4.71e-12	4.87e-08	0.5	0.52	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
UCEC	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	7.52	4.79e-12	4.94e-08	0.68	0.52	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
UCEC	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	7.52	4.8e-12	4.94e-08	0.69	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
UCEC	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	7.52	4.83e-12	4.97e-08	0.54	0.52	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
UCEC	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	7.52	4.84e-12	4.98e-08	0.5	0.52	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
UCEC	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	7.52	4.89e-12	5.03e-08	0.61	0.52	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	7.52	4.89e-12	5.03e-08	0.61	0.52	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	7.52	4.89e-12	5.03e-08	0.61	0.52	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
UCEC	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	7.51	4.98e-12	5.06e-08	0.67	0.52	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	7.51	4.98e-12	5.06e-08	0.67	0.52	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	7.51	4.98e-12	5.06e-08	0.67	0.52	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	7.51	4.98e-12	5.06e-08	0.67	0.52	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	7.51	4.98e-12	5.06e-08	0.67	0.52	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	7.51	4.98e-12	5.06e-08	0.67	0.52	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
UCEC	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	7.51	5.17e-12	5.26e-08	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
UCEC	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-7.5	5.21e-12	5.28e-08	-0.6	-0.52	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-7.5	5.21e-12	5.28e-08	-0.6	-0.52	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-7.5	5.21e-12	5.28e-08	-0.6	-0.52	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-7.5	5.21e-12	5.28e-08	-0.6	-0.52	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
UCEC	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-7.5	5.21e-12	5.28e-08	-0.6	-0.52	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-7.5	5.21e-12	5.28e-08	-0.6	-0.52	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
UCEC	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-7.5	5.32e-12	5.37e-08	-0.62	-0.52	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
UCEC	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-7.5	5.35e-12	5.39e-08	-0.64	-0.52	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
UCEC	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-7.49	5.5e-12	5.54e-08	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
UCEC	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	7.49	5.57e-12	5.6e-08	0.73	0.52	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
UCEC	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-7.49	5.62e-12	5.65e-08	-0.58	-0.52	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
UCEC	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-7.49	5.75e-12	5.78e-08	-0.62	-0.52	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
UCEC	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	7.48	5.88e-12	5.9e-08	0.97	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
UCEC	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	7.48	6.08e-12	6.1e-08	0.62	0.52	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
UCEC	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	7.47	6.22e-12	6.24e-08	0.67	0.52	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
UCEC	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-7.47	6.3e-12	6.32e-08	-0.65	-0.52	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
UCEC	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	7.47	6.34e-12	6.34e-08	0.67	0.52	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	7.47	6.34e-12	6.34e-08	0.67	0.52	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	7.47	6.34e-12	6.34e-08	0.67	0.52	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	7.47	6.34e-12	6.34e-08	0.67	0.52	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	7.47	6.34e-12	6.34e-08	0.67	0.52	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	7.47	6.34e-12	6.34e-08	0.67	0.52	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	7.47	6.36e-12	6.35e-08	0.67	0.52	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	7.47	6.36e-12	6.35e-08	0.67	0.52	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
UCEC	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-7.47	6.39e-12	6.38e-08	-0.6	-0.52	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
UCEC	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-7.47	6.44e-12	6.43e-08	-0.84	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
UCEC	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-7.47	6.45e-12	6.43e-08	-0.69	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
UCEC	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	7.46	6.46e-12	6.43e-08	0.55	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
UCEC	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	7.46	6.46e-12	6.43e-08	0.55	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
UCEC	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	7.46	6.59e-12	6.56e-08	0.62	0.52	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
UCEC	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-7.46	6.63e-12	6.6e-08	-0.75	-0.52	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
UCEC	cis	rs2739330	0.828	rs5760108	ENSG00000272787.1	KB-226F1.2	-7.46	6.78e-12	6.75e-08	-0.59	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23969211~23969873:+
UCEC	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	7.46	6.78e-12	6.75e-08	0.76	0.52	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
UCEC	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-7.45	6.83e-12	6.79e-08	-0.6	-0.52	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
UCEC	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	7.45	6.84e-12	6.79e-08	0.67	0.52	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-7.45	6.91e-12	6.85e-08	-0.58	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
UCEC	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	7.45	6.97e-12	6.91e-08	0.65	0.52	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
UCEC	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	7.45	7.08e-12	6.99e-08	0.5	0.52	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	7.45	7.08e-12	6.99e-08	0.5	0.52	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
UCEC	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	7.45	7.08e-12	6.99e-08	0.93	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	7.45	7.08e-12	6.99e-08	0.93	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	7.45	7.08e-12	6.99e-08	0.93	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	7.45	7.08e-12	6.99e-08	0.93	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
UCEC	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	7.45	7.12e-12	7.02e-08	0.67	0.52	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	7.45	7.17e-12	7.07e-08	0.61	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
UCEC	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	7.44	7.24e-12	7.13e-08	0.83	0.52	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
UCEC	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	7.44	7.35e-12	7.24e-08	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
UCEC	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	7.44	7.39e-12	7.27e-08	0.62	0.52	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
UCEC	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-7.44	7.44e-12	7.32e-08	-0.67	-0.52	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-7.44	7.44e-12	7.32e-08	-0.67	-0.52	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
UCEC	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-7.44	7.54e-12	7.41e-08	-0.86	-0.52	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
UCEC	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	7.43	7.8e-12	7.65e-08	0.46	0.52	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
UCEC	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-7.43	7.86e-12	7.71e-08	-0.55	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
UCEC	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	7.43	7.98e-12	7.79e-08	0.58	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
UCEC	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-7.43	8.03e-12	7.82e-08	-0.47	-0.52	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
UCEC	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-7.43	8.03e-12	7.82e-08	-0.47	-0.52	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
UCEC	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-7.43	8.03e-12	7.82e-08	-0.47	-0.52	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-7.43	8.03e-12	7.82e-08	-0.47	-0.52	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-7.43	8.03e-12	7.82e-08	-0.47	-0.52	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-7.43	8.03e-12	7.82e-08	-0.47	-0.52	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-7.43	8.03e-12	7.82e-08	-0.47	-0.52	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
UCEC	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	7.42	8.07e-12	7.85e-08	0.59	0.52	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
UCEC	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	7.42	8.17e-12	7.93e-08	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
UCEC	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-7.42	8.33e-12	8.09e-08	-0.47	-0.52	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
UCEC	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-7.42	8.34e-12	8.09e-08	-0.63	-0.52	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
UCEC	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	7.42	8.37e-12	8.11e-08	0.67	0.52	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
UCEC	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-7.42	8.44e-12	8.16e-08	-0.69	-0.52	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
UCEC	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-7.41	8.59e-12	8.28e-08	-0.92	-0.52	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
UCEC	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-7.41	8.75e-12	8.38e-08	-0.6	-0.52	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
UCEC	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	7.41	8.77e-12	8.39e-08	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
UCEC	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-7.41	8.78e-12	8.4e-08	-0.63	-0.52	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
UCEC	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	7.41	8.98e-12	8.56e-08	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	7.41	8.98e-12	8.56e-08	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	7.41	8.98e-12	8.56e-08	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	7.41	8.98e-12	8.56e-08	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
UCEC	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-7.4	9.32e-12	8.86e-08	-0.63	-0.52	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-7.4	9.32e-12	8.86e-08	-0.63	-0.52	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-7.4	9.32e-12	8.86e-08	-0.63	-0.52	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-7.4	9.32e-12	8.86e-08	-0.63	-0.52	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-7.4	9.32e-12	8.86e-08	-0.63	-0.52	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
UCEC	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	7.39	9.54e-12	9.02e-08	0.53	0.52	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
UCEC	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	7.39	9.7e-12	9.07e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
UCEC	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	7.39	9.73e-12	9.09e-08	0.55	0.52	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
UCEC	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-7.39	9.75e-12	9.11e-08	-0.9	-0.52	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-7.39	9.76e-12	9.11e-08	-0.7	-0.52	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
UCEC	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-7.39	9.79e-12	9.12e-08	-0.47	-0.52	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
UCEC	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-7.39	9.79e-12	9.12e-08	-0.47	-0.52	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-7.39	9.79e-12	9.12e-08	-0.47	-0.52	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
UCEC	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-7.39	1e-11	9.32e-08	-0.55	-0.52	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
UCEC	cis	rs858239	0.704	rs199656	ENSG00000230658.1	KLHL7-AS1	-7.39	1e-11	9.33e-08	-0.58	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.676	rs199359	ENSG00000230658.1	KLHL7-AS1	-7.38	1.01e-11	9.36e-08	-0.58	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23298895	chr7:23101228~23105703:-
UCEC	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	7.38	1.02e-11	9.45e-08	0.61	0.52	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
UCEC	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	7.38	1.02e-11	9.45e-08	0.61	0.52	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	7.38	1.02e-11	9.45e-08	0.61	0.52	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	7.38	1.02e-11	9.45e-08	0.61	0.52	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
UCEC	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	7.38	1.02e-11	9.49e-08	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
UCEC	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-7.38	1.02e-11	9.49e-08	-0.51	-0.52	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
UCEC	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-7.38	1.03e-11	9.58e-08	-0.73	-0.52	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
UCEC	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-7.38	1.04e-11	9.6e-08	-0.54	-0.52	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
UCEC	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	7.38	1.04e-11	9.6e-08	0.61	0.52	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
UCEC	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-7.38	1.05e-11	9.77e-08	-0.87	-0.52	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
UCEC	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-7.37	1.06e-11	9.85e-08	-0.55	-0.52	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
UCEC	cis	rs2739330	0.828	rs5760098	ENSG00000272787.1	KB-226F1.2	-7.37	1.07e-11	9.88e-08	-0.6	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23969211~23969873:+
UCEC	cis	rs2739330	0.828	rs5760102	ENSG00000272787.1	KB-226F1.2	-7.37	1.07e-11	9.88e-08	-0.6	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23969211~23969873:+
UCEC	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.37	1.08e-11	9.96e-08	-0.66	-0.52	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
UCEC	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-7.37	1.08e-11	9.99e-08	-0.46	-0.52	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
UCEC	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	7.37	1.09e-11	1e-07	0.63	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
UCEC	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	7.37	1.09e-11	1.01e-07	0.57	0.52	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
UCEC	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	7.37	1.12e-11	1.03e-07	0.61	0.52	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
UCEC	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-7.37	1.12e-11	1.03e-07	-0.47	-0.52	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
UCEC	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-7.36	1.13e-11	1.04e-07	-0.6	-0.52	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
UCEC	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-7.36	1.15e-11	1.05e-07	-0.73	-0.52	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
UCEC	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-7.36	1.15e-11	1.05e-07	-0.6	-0.52	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
UCEC	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-7.36	1.16e-11	1.06e-07	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
UCEC	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-7.36	1.17e-11	1.07e-07	-0.47	-0.52	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
UCEC	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-7.36	1.17e-11	1.07e-07	-0.47	-0.52	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-7.36	1.17e-11	1.07e-07	-0.47	-0.52	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
UCEC	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-7.36	1.17e-11	1.07e-07	-0.47	-0.52	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-7.36	1.17e-11	1.07e-07	-0.47	-0.52	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-7.36	1.17e-11	1.07e-07	-0.47	-0.52	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-7.36	1.17e-11	1.07e-07	-0.47	-0.52	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
UCEC	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-7.36	1.18e-11	1.07e-07	-0.91	-0.52	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-7.36	1.18e-11	1.07e-07	-0.91	-0.52	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-7.36	1.18e-11	1.07e-07	-0.91	-0.52	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
UCEC	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-7.36	1.18e-11	1.07e-07	-0.91	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-7.36	1.18e-11	1.07e-07	-0.91	-0.52	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
UCEC	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	7.36	1.18e-11	1.08e-07	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	7.36	1.18e-11	1.08e-07	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
UCEC	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	7.35	1.19e-11	1.08e-07	0.74	0.52	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
UCEC	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-7.35	1.19e-11	1.09e-07	-0.73	-0.52	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
UCEC	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-7.35	1.19e-11	1.09e-07	-0.73	-0.52	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	7.35	1.2e-11	1.09e-07	0.65	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
UCEC	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-7.35	1.22e-11	1.11e-07	-0.64	-0.52	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
UCEC	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-7.35	1.22e-11	1.11e-07	-0.47	-0.52	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-7.35	1.22e-11	1.11e-07	-0.47	-0.52	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
UCEC	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-7.35	1.22e-11	1.11e-07	-0.47	-0.52	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-7.35	1.22e-11	1.11e-07	-0.47	-0.52	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-7.35	1.22e-11	1.11e-07	-0.47	-0.52	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-7.35	1.22e-11	1.11e-07	-0.47	-0.52	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-7.35	1.22e-11	1.11e-07	-0.47	-0.52	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
UCEC	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-7.35	1.22e-11	1.11e-07	-0.62	-0.52	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	7.34	1.25e-11	1.13e-07	0.56	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
UCEC	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	7.34	1.25e-11	1.13e-07	0.66	0.52	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
UCEC	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-7.34	1.26e-11	1.14e-07	-0.55	-0.52	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-7.34	1.26e-11	1.14e-07	-0.55	-0.52	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-7.34	1.26e-11	1.14e-07	-0.55	-0.52	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-7.34	1.26e-11	1.14e-07	-0.55	-0.52	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-7.34	1.26e-11	1.14e-07	-0.55	-0.52	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-7.34	1.26e-11	1.14e-07	-0.55	-0.52	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
UCEC	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-7.34	1.3e-11	1.17e-07	-0.63	-0.52	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
UCEC	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	7.34	1.3e-11	1.17e-07	0.62	0.52	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
UCEC	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-7.34	1.3e-11	1.17e-07	-0.63	-0.52	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
UCEC	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	7.34	1.31e-11	1.18e-07	0.56	0.52	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	7.34	1.31e-11	1.18e-07	0.56	0.52	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
UCEC	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	7.34	1.32e-11	1.19e-07	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
UCEC	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	7.33	1.33e-11	1.19e-07	0.8	0.52	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
UCEC	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-7.33	1.36e-11	1.22e-07	-0.57	-0.51	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
UCEC	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-7.33	1.36e-11	1.22e-07	-0.57	-0.51	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-7.33	1.36e-11	1.22e-07	-0.57	-0.51	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-7.33	1.36e-11	1.22e-07	-0.57	-0.51	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
UCEC	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	7.33	1.37e-11	1.23e-07	0.55	0.51	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
UCEC	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-7.33	1.38e-11	1.24e-07	-0.62	-0.51	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
UCEC	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-7.33	1.38e-11	1.24e-07	-0.68	-0.51	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-7.33	1.38e-11	1.24e-07	-0.68	-0.51	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
UCEC	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	7.32	1.41e-11	1.26e-07	0.58	0.51	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
UCEC	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	7.32	1.41e-11	1.26e-07	0.81	0.51	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
UCEC	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-7.32	1.45e-11	1.29e-07	-0.47	-0.51	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
UCEC	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-7.32	1.45e-11	1.29e-07	-0.47	-0.51	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
UCEC	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-7.32	1.45e-11	1.29e-07	-0.47	-0.51	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
UCEC	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-7.32	1.45e-11	1.29e-07	-0.47	-0.51	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
UCEC	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	7.31	1.51e-11	1.34e-07	0.55	0.51	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-7.31	1.51e-11	1.34e-07	-0.54	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
UCEC	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	7.31	1.54e-11	1.37e-07	0.64	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	7.31	1.54e-11	1.37e-07	0.64	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	7.31	1.54e-11	1.37e-07	0.64	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
UCEC	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-7.3	1.58e-11	1.4e-07	-0.64	-0.51	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
UCEC	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-7.3	1.6e-11	1.42e-07	-0.69	-0.51	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
UCEC	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	7.3	1.61e-11	1.42e-07	0.65	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
UCEC	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	7.3	1.61e-11	1.42e-07	0.64	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
UCEC	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	7.3	1.63e-11	1.44e-07	0.63	0.51	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-7.3	1.63e-11	1.44e-07	-0.63	-0.51	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
UCEC	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-7.3	1.63e-11	1.44e-07	-0.63	-0.51	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
UCEC	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	7.29	1.66e-11	1.46e-07	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	7.29	1.66e-11	1.46e-07	0.64	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	7.29	1.66e-11	1.46e-07	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	7.29	1.66e-11	1.46e-07	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
UCEC	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	7.29	1.66e-11	1.46e-07	0.75	0.51	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
UCEC	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	7.29	1.66e-11	1.46e-07	0.58	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
UCEC	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	7.29	1.67e-11	1.47e-07	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
UCEC	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	7.29	1.68e-11	1.48e-07	0.58	0.51	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	7.29	1.71e-11	1.5e-07	0.57	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
UCEC	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	7.29	1.72e-11	1.51e-07	0.64	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	7.29	1.73e-11	1.52e-07	0.57	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
UCEC	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	7.28	1.79e-11	1.56e-07	0.63	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
UCEC	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	7.28	1.81e-11	1.58e-07	0.6	0.51	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
UCEC	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	7.28	1.81e-11	1.58e-07	1.03	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
UCEC	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	7.28	1.83e-11	1.59e-07	0.66	0.51	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
UCEC	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-7.28	1.83e-11	1.6e-07	-0.64	-0.51	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
UCEC	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-7.28	1.83e-11	1.6e-07	-0.71	-0.51	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
UCEC	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-7.27	1.86e-11	1.62e-07	-0.66	-0.51	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
UCEC	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-7.27	1.91e-11	1.66e-07	-0.54	-0.51	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-7.27	1.91e-11	1.66e-07	-0.54	-0.51	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-7.27	1.91e-11	1.66e-07	-0.54	-0.51	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
UCEC	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-7.27	1.91e-11	1.66e-07	-0.54	-0.51	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-7.27	1.91e-11	1.66e-07	-0.54	-0.51	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-7.27	1.91e-11	1.66e-07	-0.54	-0.51	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
UCEC	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-7.27	1.92e-11	1.66e-07	-0.62	-0.51	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-7.27	1.92e-11	1.66e-07	-0.62	-0.51	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-7.27	1.92e-11	1.66e-07	-0.62	-0.51	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-7.27	1.92e-11	1.66e-07	-0.62	-0.51	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
UCEC	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	7.27	1.92e-11	1.66e-07	0.68	0.51	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
UCEC	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-7.27	1.93e-11	1.67e-07	-0.67	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
UCEC	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-7.26	1.97e-11	1.7e-07	-0.53	-0.51	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.828	rs4820572	ENSG00000272787.1	KB-226F1.2	-7.26	2e-11	1.73e-07	-0.61	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23969211~23969873:+
UCEC	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	7.26	2.01e-11	1.74e-07	0.57	0.51	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	7.26	2.04e-11	1.77e-07	0.54	0.51	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
UCEC	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-7.25	2.07e-11	1.78e-07	-0.54	-0.51	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
UCEC	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-7.25	2.08e-11	1.78e-07	-0.64	-0.51	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-7.25	2.08e-11	1.78e-07	-0.64	-0.51	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
UCEC	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-7.25	2.08e-11	1.79e-07	-0.61	-0.51	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
UCEC	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-7.25	2.08e-11	1.79e-07	-0.46	-0.51	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
UCEC	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	7.25	2.13e-11	1.82e-07	0.64	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
UCEC	cis	rs9322193	0.923	rs958953	ENSG00000231760.4	RP11-350J20.5	7.25	2.14e-11	1.84e-07	0.65	0.51	Lung cancer;	chr6:149840735	chr6:149796151~149826294:-
UCEC	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	7.25	2.15e-11	1.84e-07	0.54	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
UCEC	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-7.25	2.15e-11	1.85e-07	-0.56	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
UCEC	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	7.24	2.17e-11	1.86e-07	0.64	0.51	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
UCEC	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	7.24	2.19e-11	1.88e-07	0.65	0.51	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
UCEC	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	7.24	2.22e-11	1.9e-07	0.61	0.51	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-7.24	2.23e-11	1.91e-07	-0.58	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
UCEC	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	7.24	2.25e-11	1.92e-07	0.53	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
UCEC	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	7.24	2.27e-11	1.94e-07	0.54	0.51	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-7.23	2.31e-11	1.97e-07	-0.66	-0.51	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
UCEC	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	7.23	2.38e-11	2.03e-07	0.66	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
UCEC	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-7.23	2.4e-11	2.05e-07	-0.71	-0.51	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
UCEC	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-7.22	2.48e-11	2.11e-07	-0.62	-0.51	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	7.22	2.48e-11	2.11e-07	0.8	0.51	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
UCEC	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	7.22	2.5e-11	2.12e-07	0.53	0.51	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
UCEC	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-7.21	2.55e-11	2.16e-07	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
UCEC	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-7.21	2.57e-11	2.18e-07	-0.71	-0.51	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
UCEC	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-7.21	2.57e-11	2.18e-07	-0.71	-0.51	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
UCEC	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-7.21	2.57e-11	2.18e-07	-0.71	-0.51	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-7.21	2.57e-11	2.18e-07	-0.63	-0.51	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
UCEC	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-7.21	2.58e-11	2.19e-07	-0.72	-0.51	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
UCEC	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	7.21	2.59e-11	2.19e-07	0.56	0.51	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
UCEC	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	7.21	2.59e-11	2.19e-07	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
UCEC	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	7.21	2.61e-11	2.2e-07	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
UCEC	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	7.21	2.61e-11	2.2e-07	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	7.21	2.61e-11	2.2e-07	0.63	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	7.21	2.61e-11	2.2e-07	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	7.21	2.61e-11	2.2e-07	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	7.21	2.61e-11	2.2e-07	0.63	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
UCEC	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	7.21	2.61e-11	2.2e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	7.21	2.61e-11	2.2e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	7.21	2.61e-11	2.2e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	7.21	2.61e-11	2.2e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	7.21	2.61e-11	2.2e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	7.21	2.61e-11	2.2e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
UCEC	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-7.21	2.64e-11	2.22e-07	-0.85	-0.51	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
UCEC	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-7.21	2.66e-11	2.24e-07	-0.62	-0.51	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
UCEC	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-7.21	2.67e-11	2.25e-07	-0.6	-0.51	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
UCEC	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	7.2	2.71e-11	2.28e-07	0.64	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
UCEC	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	7.2	2.71e-11	2.28e-07	0.64	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
UCEC	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	7.2	2.73e-11	2.29e-07	0.53	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
UCEC	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-7.2	2.77e-11	2.33e-07	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
UCEC	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-7.2	2.79e-11	2.34e-07	-0.62	-0.51	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
UCEC	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	7.2	2.8e-11	2.35e-07	0.43	0.51	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
UCEC	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-7.2	2.8e-11	2.35e-07	-0.55	-0.51	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	7.2	2.8e-11	2.35e-07	0.57	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
UCEC	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	7.2	2.81e-11	2.35e-07	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	7.2	2.81e-11	2.35e-07	0.63	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
UCEC	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	7.19	2.87e-11	2.4e-07	0.66	0.51	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
UCEC	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	7.19	2.97e-11	2.48e-07	0.58	0.51	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	7.19	2.97e-11	2.48e-07	0.55	0.51	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
UCEC	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-7.19	2.98e-11	2.48e-07	-0.59	-0.51	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-7.19	2.98e-11	2.48e-07	-0.59	-0.51	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
UCEC	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-7.19	2.98e-11	2.48e-07	-0.59	-0.51	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
UCEC	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-7.19	2.99e-11	2.49e-07	-0.46	-0.51	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
UCEC	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	7.19	2.99e-11	2.49e-07	0.58	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
UCEC	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	7.18	3e-11	2.5e-07	0.64	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
UCEC	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	7.18	3.01e-11	2.5e-07	0.98	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	7.18	3.01e-11	2.5e-07	0.98	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
UCEC	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	7.18	3.01e-11	2.5e-07	0.57	0.51	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
UCEC	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	7.18	3.02e-11	2.51e-07	0.59	0.51	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
UCEC	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	7.18	3.08e-11	2.55e-07	0.91	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	7.18	3.08e-11	2.55e-07	0.91	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	7.18	3.08e-11	2.55e-07	0.91	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	7.18	3.08e-11	2.55e-07	0.91	0.51	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	7.18	3.08e-11	2.55e-07	0.91	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
UCEC	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	7.18	3.09e-11	2.55e-07	0.65	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	7.18	3.09e-11	2.55e-07	0.65	0.51	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	7.18	3.09e-11	2.55e-07	0.65	0.51	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	7.18	3.09e-11	2.55e-07	0.65	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	7.18	3.09e-11	2.55e-07	0.65	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	7.18	3.09e-11	2.55e-07	0.65	0.51	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	7.18	3.09e-11	2.55e-07	0.65	0.51	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
UCEC	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-7.18	3.1e-11	2.56e-07	-0.72	-0.51	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
UCEC	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	7.18	3.12e-11	2.58e-07	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
UCEC	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	7.18	3.13e-11	2.58e-07	0.57	0.51	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	7.18	3.15e-11	2.6e-07	0.55	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
UCEC	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-7.17	3.18e-11	2.61e-07	-0.53	-0.51	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-7.17	3.18e-11	2.61e-07	-0.53	-0.51	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-7.17	3.18e-11	2.61e-07	-0.53	-0.51	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-7.17	3.18e-11	2.61e-07	-0.53	-0.51	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-7.17	3.18e-11	2.61e-07	-0.53	-0.51	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
UCEC	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-7.17	3.19e-11	2.62e-07	-0.71	-0.51	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
UCEC	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-7.17	3.19e-11	2.62e-07	-0.71	-0.51	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
UCEC	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	7.17	3.26e-11	2.67e-07	0.62	0.51	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
UCEC	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-7.17	3.27e-11	2.68e-07	-0.45	-0.51	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
UCEC	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	7.17	3.27e-11	2.68e-07	0.62	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	7.17	3.27e-11	2.68e-07	0.62	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	7.17	3.27e-11	2.68e-07	0.62	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	7.17	3.27e-11	2.68e-07	0.62	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	7.17	3.27e-11	2.68e-07	0.62	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	7.17	3.27e-11	2.68e-07	0.62	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	7.17	3.27e-11	2.68e-07	0.62	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
UCEC	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	7.17	3.29e-11	2.69e-07	0.52	0.51	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.828	rs5751770	ENSG00000272787.1	KB-226F1.2	-7.17	3.3e-11	2.7e-07	-0.57	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23969211~23969873:+
UCEC	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-7.17	3.31e-11	2.7e-07	-0.6	-0.51	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
UCEC	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-7.17	3.31e-11	2.7e-07	-0.6	-0.51	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
UCEC	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-7.17	3.32e-11	2.7e-07	-0.54	-0.51	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-7.17	3.32e-11	2.7e-07	-0.54	-0.51	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
UCEC	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-7.17	3.32e-11	2.7e-07	-0.54	-0.51	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-7.17	3.32e-11	2.7e-07	-0.54	-0.51	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-7.17	3.32e-11	2.7e-07	-0.54	-0.51	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-7.17	3.32e-11	2.7e-07	-0.54	-0.51	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-7.17	3.32e-11	2.7e-07	-0.54	-0.51	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-7.17	3.32e-11	2.7e-07	-0.54	-0.51	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-7.17	3.32e-11	2.7e-07	-0.54	-0.51	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-7.17	3.33e-11	2.71e-07	-0.54	-0.51	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-7.17	3.33e-11	2.71e-07	-0.54	-0.51	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-7.17	3.33e-11	2.71e-07	-0.54	-0.51	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-7.17	3.33e-11	2.71e-07	-0.54	-0.51	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-7.17	3.33e-11	2.71e-07	-0.54	-0.51	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
UCEC	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	7.16	3.34e-11	2.72e-07	0.63	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
UCEC	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-7.16	3.35e-11	2.73e-07	-0.61	-0.51	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-7.16	3.35e-11	2.73e-07	-0.61	-0.51	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-7.16	3.36e-11	2.74e-07	-0.64	-0.51	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
UCEC	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	7.16	3.37e-11	2.74e-07	0.62	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
UCEC	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	7.16	3.39e-11	2.76e-07	0.57	0.51	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
UCEC	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-7.16	3.45e-11	2.8e-07	-0.45	-0.51	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-7.16	3.45e-11	2.8e-07	-0.45	-0.51	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-7.16	3.45e-11	2.8e-07	-0.45	-0.51	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-7.16	3.45e-11	2.8e-07	-0.45	-0.51	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-7.16	3.45e-11	2.8e-07	-0.45	-0.51	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-7.16	3.45e-11	2.8e-07	-0.45	-0.51	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
UCEC	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	7.16	3.5e-11	2.83e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	7.16	3.5e-11	2.83e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	7.16	3.5e-11	2.83e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	7.16	3.5e-11	2.83e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	7.16	3.5e-11	2.83e-07	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
UCEC	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-7.16	3.51e-11	2.83e-07	-0.61	-0.51	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-7.16	3.51e-11	2.83e-07	-0.61	-0.51	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-7.16	3.51e-11	2.83e-07	-0.61	-0.51	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-7.16	3.51e-11	2.83e-07	-0.61	-0.51	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-7.16	3.51e-11	2.83e-07	-0.61	-0.51	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
UCEC	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	7.15	3.54e-11	2.86e-07	0.64	0.51	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
UCEC	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-7.15	3.54e-11	2.86e-07	-0.61	-0.51	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
UCEC	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	7.15	3.54e-11	2.86e-07	0.65	0.51	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
UCEC	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	7.15	3.62e-11	2.92e-07	0.75	0.51	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
UCEC	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	7.15	3.63e-11	2.92e-07	0.57	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
UCEC	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	7.15	3.71e-11	2.98e-07	1.03	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
UCEC	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	7.15	3.71e-11	2.98e-07	0.58	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
UCEC	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-7.14	3.73e-11	2.99e-07	-0.62	-0.51	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
UCEC	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	7.14	3.77e-11	3.02e-07	0.65	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
UCEC	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	7.14	3.82e-11	3.06e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	7.14	3.89e-11	3.11e-07	0.64	0.5	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	7.14	3.89e-11	3.11e-07	0.64	0.5	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	7.14	3.89e-11	3.11e-07	0.64	0.5	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs2275045	ENSG00000231760.4	RP11-350J20.5	7.14	3.89e-11	3.11e-07	0.64	0.5	Lung cancer;	chr6:149842775	chr6:149796151~149826294:-
UCEC	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-7.13	3.93e-11	3.13e-07	-0.53	-0.5	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-7.13	3.93e-11	3.13e-07	-0.53	-0.5	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-7.13	3.93e-11	3.13e-07	-0.53	-0.5	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-7.13	3.93e-11	3.13e-07	-0.53	-0.5	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-7.13	3.93e-11	3.13e-07	-0.53	-0.5	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
UCEC	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	7.13	4.04e-11	3.22e-07	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
UCEC	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	7.13	4.05e-11	3.22e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	7.13	4.05e-11	3.22e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	7.13	4.05e-11	3.22e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	7.13	4.05e-11	3.22e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	7.13	4.05e-11	3.22e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	7.13	4.05e-11	3.22e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
UCEC	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	7.13	4.06e-11	3.23e-07	0.69	0.5	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
UCEC	cis	rs2739330	0.828	rs2877178	ENSG00000272787.1	KB-226F1.2	-7.13	4.1e-11	3.25e-07	-0.57	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23969211~23969873:+
UCEC	cis	rs2739330	0.828	rs2154593	ENSG00000272787.1	KB-226F1.2	-7.13	4.1e-11	3.25e-07	-0.57	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23969211~23969873:+
UCEC	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	7.13	4.1e-11	3.25e-07	0.72	0.5	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
UCEC	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-7.12	4.21e-11	3.33e-07	-0.53	-0.5	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-7.12	4.21e-11	3.33e-07	-0.53	-0.5	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-7.12	4.21e-11	3.33e-07	-0.53	-0.5	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
UCEC	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	7.12	4.25e-11	3.36e-07	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	7.12	4.25e-11	3.36e-07	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	7.12	4.25e-11	3.36e-07	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	7.12	4.25e-11	3.36e-07	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	7.12	4.25e-11	3.36e-07	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
UCEC	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	7.12	4.25e-11	3.36e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	7.12	4.25e-11	3.36e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	7.12	4.25e-11	3.36e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
UCEC	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	7.12	4.27e-11	3.37e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
UCEC	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	7.12	4.27e-11	3.37e-07	0.86	0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
UCEC	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-7.12	4.27e-11	3.37e-07	-0.63	-0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.753	rs4822452	ENSG00000272787.1	KB-226F1.2	-7.12	4.28e-11	3.37e-07	-0.58	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23969211~23969873:+
UCEC	cis	rs2739330	0.828	rs5760107	ENSG00000272787.1	KB-226F1.2	-7.12	4.29e-11	3.38e-07	-0.59	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23969211~23969873:+
UCEC	cis	rs2739330	0.789	rs5760109	ENSG00000272787.1	KB-226F1.2	-7.12	4.29e-11	3.38e-07	-0.59	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23969211~23969873:+
UCEC	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	7.12	4.32e-11	3.4e-07	0.56	0.5	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	7.11	4.41e-11	3.47e-07	0.57	0.5	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
UCEC	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-7.11	4.49e-11	3.53e-07	-0.6	-0.5	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
UCEC	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	7.11	4.52e-11	3.55e-07	0.52	0.5	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
UCEC	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	7.11	4.54e-11	3.56e-07	0.61	0.5	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
UCEC	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	7.11	4.56e-11	3.57e-07	0.55	0.5	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
UCEC	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-7.1	4.63e-11	3.6e-07	-0.51	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
UCEC	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	7.1	4.63e-11	3.6e-07	0.63	0.5	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	7.1	4.67e-11	3.63e-07	0.53	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
UCEC	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-7.1	4.68e-11	3.64e-07	-0.47	-0.5	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
UCEC	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-7.1	4.73e-11	3.67e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
UCEC	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	7.1	4.78e-11	3.7e-07	0.52	0.5	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
UCEC	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-7.1	4.78e-11	3.7e-07	-0.61	-0.5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
UCEC	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-7.1	4.78e-11	3.71e-07	-0.89	-0.5	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
UCEC	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	7.1	4.82e-11	3.73e-07	0.61	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	7.1	4.82e-11	3.73e-07	0.61	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	7.1	4.82e-11	3.73e-07	0.61	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	7.1	4.82e-11	3.73e-07	0.61	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
UCEC	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	7.09	4.88e-11	3.77e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
UCEC	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-7.09	4.9e-11	3.78e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
UCEC	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	7.09	4.93e-11	3.8e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	7.09	4.95e-11	3.82e-07	0.54	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
UCEC	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	7.09	4.95e-11	3.82e-07	0.64	0.5	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
UCEC	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	7.09	4.96e-11	3.83e-07	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
UCEC	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-7.09	4.98e-11	3.84e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
UCEC	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	7.09	4.99e-11	3.84e-07	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
UCEC	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	7.09	5e-11	3.85e-07	0.87	0.5	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
UCEC	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	7.09	5.03e-11	3.87e-07	0.45	0.5	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
UCEC	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	7.09	5.06e-11	3.89e-07	0.64	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
UCEC	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	7.09	5.12e-11	3.93e-07	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	7.09	5.12e-11	3.93e-07	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	7.08	5.26e-11	4.04e-07	0.63	0.5	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	7.08	5.33e-11	4.09e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
UCEC	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-7.08	5.34e-11	4.09e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-7.08	5.34e-11	4.09e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	7.07	5.48e-11	4.18e-07	0.58	0.5	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	7.07	5.48e-11	4.18e-07	0.58	0.5	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	7.07	5.48e-11	4.18e-07	0.58	0.5	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
UCEC	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-7.07	5.48e-11	4.18e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
UCEC	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	7.07	5.52e-11	4.21e-07	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	7.07	5.52e-11	4.21e-07	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	7.07	5.52e-11	4.21e-07	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	7.07	5.52e-11	4.21e-07	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
UCEC	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-7.07	5.64e-11	4.29e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
UCEC	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	7.07	5.67e-11	4.32e-07	0.56	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
UCEC	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-7.07	5.68e-11	4.32e-07	-0.71	-0.5	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
UCEC	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	7.07	5.69e-11	4.33e-07	0.69	0.5	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
UCEC	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-7.07	5.69e-11	4.33e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
UCEC	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	7.07	5.72e-11	4.35e-07	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
UCEC	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-7.06	5.74e-11	4.36e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
UCEC	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	7.06	5.81e-11	4.41e-07	0.55	0.5	Depression;	chr6:28273214	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	7.06	5.81e-11	4.41e-07	0.55	0.5	Depression;	chr6:28273215	chr6:28176188~28176674:+
UCEC	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-7.06	5.83e-11	4.42e-07	-0.52	-0.5	Breast cancer;	chr11:743813	chr11:779617~780755:+
UCEC	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-7.06	5.83e-11	4.42e-07	-0.55	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
UCEC	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	7.06	5.86e-11	4.44e-07	0.61	0.5	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
UCEC	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-7.06	5.87e-11	4.45e-07	-0.54	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
UCEC	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-7.06	5.9e-11	4.47e-07	-0.59	-0.5	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	7.06	5.94e-11	4.49e-07	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
UCEC	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-7.06	5.94e-11	4.49e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-7.06	5.94e-11	4.49e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
UCEC	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-7.06	5.98e-11	4.51e-07	-0.91	-0.5	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
UCEC	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	7.06	5.99e-11	4.52e-07	0.72	0.5	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
UCEC	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	7.05	6.06e-11	4.57e-07	0.65	0.5	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	7.05	6.06e-11	4.57e-07	0.65	0.5	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	7.05	6.06e-11	4.57e-07	0.65	0.5	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
UCEC	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-7.05	6.12e-11	4.61e-07	-0.59	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
UCEC	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-7.05	6.15e-11	4.64e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
UCEC	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	7.05	6.19e-11	4.66e-07	0.87	0.5	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	7.05	6.28e-11	4.71e-07	0.64	0.5	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
UCEC	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	7.05	6.28e-11	4.71e-07	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
UCEC	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	7.05	6.29e-11	4.71e-07	0.65	0.5	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	7.05	6.29e-11	4.71e-07	0.65	0.5	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	7.05	6.29e-11	4.71e-07	0.65	0.5	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	7.05	6.33e-11	4.73e-07	0.65	0.5	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
UCEC	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-7.05	6.35e-11	4.74e-07	-0.52	-0.5	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-7.05	6.35e-11	4.74e-07	-0.52	-0.5	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
UCEC	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	7.04	6.42e-11	4.79e-07	0.58	0.5	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	7.04	6.42e-11	4.79e-07	0.58	0.5	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
UCEC	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-7.04	6.43e-11	4.79e-07	-0.53	-0.5	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-7.04	6.43e-11	4.79e-07	-0.53	-0.5	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
UCEC	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-7.04	6.45e-11	4.8e-07	-0.46	-0.5	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
UCEC	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-7.04	6.48e-11	4.82e-07	-0.62	-0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
UCEC	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	7.04	6.6e-11	4.91e-07	0.51	0.5	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
UCEC	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	7.03	6.85e-11	5.09e-07	0.45	0.5	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
UCEC	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-7.03	6.92e-11	5.14e-07	-1.08	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	7.03	7.11e-11	5.27e-07	0.62	0.5	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
UCEC	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-7.02	7.14e-11	5.29e-07	-0.68	-0.5	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
UCEC	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	7.02	7.39e-11	5.46e-07	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
UCEC	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-7.02	7.41e-11	5.48e-07	-0.7	-0.5	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
UCEC	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	7.02	7.41e-11	5.48e-07	0.59	0.5	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
UCEC	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-7.02	7.44e-11	5.49e-07	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-7.02	7.44e-11	5.49e-07	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-7.02	7.44e-11	5.49e-07	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	7.01	7.51e-11	5.53e-07	0.56	0.5	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
UCEC	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-7.01	7.54e-11	5.56e-07	-0.7	-0.5	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
UCEC	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-7.01	7.54e-11	5.56e-07	-0.7	-0.5	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
UCEC	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-7.01	7.56e-11	5.57e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
UCEC	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	7.01	7.6e-11	5.59e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	7.01	7.6e-11	5.59e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	7.01	7.6e-11	5.59e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	7.01	7.6e-11	5.59e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	7.01	7.6e-11	5.59e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
UCEC	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	7.01	7.61e-11	5.59e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
UCEC	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	7.01	7.66e-11	5.62e-07	0.6	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
UCEC	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	7.01	7.69e-11	5.64e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	7.01	7.69e-11	5.64e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	7.01	7.69e-11	5.64e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	7.01	7.69e-11	5.64e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	7.01	7.69e-11	5.64e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
UCEC	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	7.01	7.78e-11	5.7e-07	0.6	0.5	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
UCEC	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	7.01	7.81e-11	5.7e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
UCEC	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-7.01	7.88e-11	5.74e-07	-0.6	-0.5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-7.01	7.88e-11	5.74e-07	-0.6	-0.5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-7.01	7.88e-11	5.74e-07	-0.6	-0.5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
UCEC	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	7	7.94e-11	5.78e-07	0.61	0.5	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
UCEC	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-7	7.97e-11	5.8e-07	-0.64	-0.5	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-7	7.97e-11	5.8e-07	-0.64	-0.5	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
UCEC	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	7	8.02e-11	5.83e-07	0.56	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
UCEC	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	7	8.03e-11	5.84e-07	0.51	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
UCEC	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-7	8.04e-11	5.84e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-7	8.05e-11	5.84e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
UCEC	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	7	8.06e-11	5.85e-07	0.66	0.5	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
UCEC	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	7	8.08e-11	5.86e-07	0.65	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
UCEC	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	7	8.14e-11	5.9e-07	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	7	8.14e-11	5.9e-07	0.63	0.5	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	7	8.14e-11	5.9e-07	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
UCEC	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-7	8.15e-11	5.91e-07	-0.88	-0.5	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
UCEC	cis	rs2739330	0.828	rs4822454	ENSG00000272787.1	KB-226F1.2	-7	8.23e-11	5.95e-07	-0.59	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23969211~23969873:+
UCEC	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-7	8.24e-11	5.96e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
UCEC	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-6.99	8.5e-11	6.13e-07	-0.53	-0.5	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
UCEC	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-6.99	8.52e-11	6.13e-07	-0.88	-0.5	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-6.99	8.52e-11	6.13e-07	-0.88	-0.5	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
UCEC	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-6.99	8.52e-11	6.13e-07	-0.88	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-6.99	8.52e-11	6.13e-07	-0.88	-0.5	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
UCEC	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	6.99	8.52e-11	6.13e-07	0.64	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	6.99	8.62e-11	6.2e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
UCEC	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	6.99	8.74e-11	6.29e-07	0.58	0.5	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
UCEC	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	6.98	8.83e-11	6.34e-07	0.56	0.5	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
UCEC	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	6.98	8.99e-11	6.44e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-6.98	9.03e-11	6.46e-07	-0.62	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
UCEC	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-6.98	9.04e-11	6.46e-07	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-6.98	9.04e-11	6.46e-07	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
UCEC	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-6.98	9.05e-11	6.47e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
UCEC	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	6.98	9.21e-11	6.58e-07	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
UCEC	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-6.97	9.32e-11	6.65e-07	-0.52	-0.5	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
UCEC	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-6.97	9.35e-11	6.67e-07	-0.62	-0.5	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
UCEC	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-6.97	9.48e-11	6.76e-07	-0.49	-0.5	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
UCEC	cis	rs858239	0.704	rs466240	ENSG00000230658.1	KLHL7-AS1	-6.97	9.52e-11	6.79e-07	-0.57	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23299155	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	6.97	9.59e-11	6.83e-07	0.6	0.5	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
UCEC	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-6.97	9.63e-11	6.85e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
UCEC	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	6.97	9.7e-11	6.89e-07	0.59	0.5	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
UCEC	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	6.97	9.7e-11	6.9e-07	0.89	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
UCEC	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-6.97	9.73e-11	6.91e-07	-0.52	-0.5	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	6.97	9.78e-11	6.95e-07	0.52	0.5	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
UCEC	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-6.97	9.79e-11	6.95e-07	-0.61	-0.5	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
UCEC	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	6.96	9.83e-11	6.98e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	6.96	9.83e-11	6.98e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	6.96	9.83e-11	6.98e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	6.96	9.83e-11	6.98e-07	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
UCEC	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-6.96	9.92e-11	7.02e-07	-0.61	-0.5	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-6.96	9.92e-11	7.02e-07	-0.61	-0.5	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
UCEC	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-6.96	9.97e-11	7.04e-07	-0.61	-0.5	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
UCEC	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-6.96	1e-10	7.06e-07	-0.52	-0.5	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-6.96	1e-10	7.07e-07	-0.53	-0.5	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
UCEC	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-6.96	1.02e-10	7.17e-07	-0.6	-0.5	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-6.96	1.02e-10	7.17e-07	-0.6	-0.5	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
UCEC	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-6.96	1.03e-10	7.21e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-6.96	1.03e-10	7.21e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-6.96	1.03e-10	7.21e-07	-0.45	-0.5	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
UCEC	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-6.96	1.03e-10	7.27e-07	-0.87	-0.5	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
UCEC	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	6.95	1.04e-10	7.29e-07	0.68	0.5	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
UCEC	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-6.95	1.06e-10	7.42e-07	-0.87	-0.49	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-6.95	1.06e-10	7.42e-07	-0.87	-0.49	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
UCEC	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-6.95	1.06e-10	7.42e-07	-0.87	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-6.95	1.06e-10	7.42e-07	-0.87	-0.49	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
UCEC	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	6.95	1.07e-10	7.51e-07	0.58	0.49	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
UCEC	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-6.95	1.08e-10	7.58e-07	-0.59	-0.49	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
UCEC	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-6.95	1.09e-10	7.62e-07	-0.61	-0.49	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
UCEC	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-6.94	1.12e-10	7.83e-07	-0.62	-0.49	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
UCEC	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	6.94	1.13e-10	7.94e-07	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
UCEC	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-6.94	1.14e-10	7.94e-07	-0.6	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
UCEC	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	6.94	1.14e-10	7.94e-07	0.6	0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
UCEC	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	6.94	1.14e-10	7.96e-07	0.62	0.49	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
UCEC	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-6.94	1.15e-10	8.02e-07	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
UCEC	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-6.93	1.16e-10	8.11e-07	-0.61	-0.49	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
UCEC	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-6.93	1.17e-10	8.12e-07	-0.59	-0.49	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
UCEC	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-6.93	1.17e-10	8.15e-07	-0.56	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
UCEC	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	6.93	1.17e-10	8.16e-07	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
UCEC	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	6.93	1.2e-10	8.28e-07	0.58	0.49	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
UCEC	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	6.93	1.2e-10	8.3e-07	0.6	0.49	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
UCEC	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	6.93	1.2e-10	8.32e-07	0.57	0.49	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	6.92	1.22e-10	8.44e-07	0.59	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
UCEC	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-6.92	1.23e-10	8.51e-07	-0.72	-0.49	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
UCEC	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	6.92	1.24e-10	8.58e-07	0.44	0.49	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	6.92	1.27e-10	8.77e-07	0.57	0.49	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
UCEC	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-6.91	1.3e-10	8.91e-07	-0.6	-0.49	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-6.91	1.3e-10	8.91e-07	-0.6	-0.49	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-6.91	1.3e-10	8.91e-07	-0.6	-0.49	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
UCEC	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-6.91	1.31e-10	8.98e-07	-0.44	-0.49	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
UCEC	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	6.91	1.33e-10	9.14e-07	0.85	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
UCEC	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-6.91	1.33e-10	9.14e-07	-0.6	-0.49	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
UCEC	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-6.91	1.34e-10	9.16e-07	-0.6	-0.49	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-6.91	1.34e-10	9.16e-07	-0.6	-0.49	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-6.91	1.34e-10	9.16e-07	-0.6	-0.49	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-6.91	1.34e-10	9.16e-07	-0.6	-0.49	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-6.91	1.34e-10	9.16e-07	-0.6	-0.49	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
UCEC	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	6.91	1.35e-10	9.22e-07	0.7	0.49	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
UCEC	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	6.9	1.36e-10	9.27e-07	0.86	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
UCEC	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	6.9	1.37e-10	9.37e-07	0.53	0.49	Myopia;	chr6:28302807	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	6.9	1.39e-10	9.46e-07	0.58	0.49	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	6.9	1.39e-10	9.46e-07	0.58	0.49	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	6.9	1.39e-10	9.46e-07	0.58	0.49	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	6.9	1.39e-10	9.46e-07	0.58	0.49	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
UCEC	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-6.9	1.39e-10	9.46e-07	-0.61	-0.49	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
UCEC	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	6.89	1.43e-10	9.71e-07	0.61	0.49	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
UCEC	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-6.89	1.43e-10	9.72e-07	-0.59	-0.49	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-6.89	1.43e-10	9.72e-07	-0.59	-0.49	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-6.89	1.43e-10	9.72e-07	-0.59	-0.49	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
UCEC	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	6.89	1.45e-10	9.83e-07	0.6	0.49	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
UCEC	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	6.89	1.45e-10	9.83e-07	0.6	0.49	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
UCEC	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-6.89	1.47e-10	9.96e-07	-0.6	-0.49	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
UCEC	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	6.89	1.49e-10	1.01e-06	0.98	0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	6.89	1.49e-10	1.01e-06	0.56	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-6.88	1.51e-10	1.02e-06	-0.53	-0.49	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
UCEC	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	6.88	1.53e-10	1.03e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
UCEC	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-6.88	1.54e-10	1.04e-06	-0.52	-0.49	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
UCEC	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-6.88	1.55e-10	1.04e-06	-0.83	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
UCEC	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-6.88	1.57e-10	1.05e-06	-0.45	-0.49	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
UCEC	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-6.88	1.57e-10	1.06e-06	-0.86	-0.49	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	6.88	1.58e-10	1.06e-06	0.64	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
UCEC	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	6.88	1.58e-10	1.06e-06	0.58	0.49	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
UCEC	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-6.87	1.59e-10	1.07e-06	-0.45	-0.49	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
UCEC	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-6.87	1.62e-10	1.09e-06	-0.83	-0.49	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	6.87	1.67e-10	1.12e-06	0.63	0.49	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-6.86	1.69e-10	1.13e-06	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-6.86	1.7e-10	1.14e-06	-0.62	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
UCEC	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	6.86	1.73e-10	1.16e-06	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
UCEC	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-6.86	1.74e-10	1.17e-06	-0.45	-0.49	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
UCEC	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	6.86	1.76e-10	1.18e-06	0.52	0.49	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
UCEC	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-6.85	1.78e-10	1.18e-06	-0.52	-0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
UCEC	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-6.85	1.81e-10	1.2e-06	-0.61	-0.49	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
UCEC	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	6.85	1.81e-10	1.2e-06	0.54	0.49	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
UCEC	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	6.85	1.84e-10	1.22e-06	0.85	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	6.85	1.84e-10	1.22e-06	0.85	0.49	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	6.85	1.84e-10	1.22e-06	0.85	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	6.85	1.84e-10	1.22e-06	0.85	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
UCEC	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-6.85	1.85e-10	1.22e-06	-0.59	-0.49	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-6.85	1.85e-10	1.22e-06	-0.59	-0.49	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-6.85	1.85e-10	1.22e-06	-0.59	-0.49	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
UCEC	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-6.85	1.85e-10	1.23e-06	-0.59	-0.49	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
UCEC	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	6.85	1.86e-10	1.23e-06	0.58	0.49	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
UCEC	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	6.84	1.88e-10	1.24e-06	0.53	0.49	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	6.84	1.88e-10	1.24e-06	0.72	0.49	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
UCEC	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-6.84	1.89e-10	1.25e-06	-0.67	-0.49	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
UCEC	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	6.84	1.95e-10	1.28e-06	0.82	0.49	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-6.84	1.96e-10	1.28e-06	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
UCEC	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-6.83	2e-10	1.31e-06	-0.59	-0.49	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
UCEC	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-6.83	2e-10	1.31e-06	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
UCEC	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-6.83	2.05e-10	1.34e-06	-0.82	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
UCEC	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	6.83	2.05e-10	1.34e-06	0.58	0.49	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
UCEC	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	6.83	2.05e-10	1.34e-06	0.58	0.49	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
UCEC	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	6.83	2.05e-10	1.34e-06	0.58	0.49	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
UCEC	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	6.83	2.05e-10	1.34e-06	0.58	0.49	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
UCEC	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	6.83	2.05e-10	1.34e-06	0.58	0.49	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
UCEC	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	6.83	2.05e-10	1.34e-06	0.58	0.49	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
UCEC	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-6.83	2.05e-10	1.34e-06	-0.57	-0.49	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
UCEC	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-6.83	2.06e-10	1.34e-06	-0.66	-0.49	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
UCEC	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	6.83	2.06e-10	1.34e-06	0.66	0.49	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
UCEC	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-6.83	2.07e-10	1.35e-06	-0.44	-0.49	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
UCEC	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	6.82	2.1e-10	1.37e-06	0.74	0.49	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
UCEC	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	6.82	2.11e-10	1.37e-06	0.56	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
UCEC	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	6.82	2.14e-10	1.39e-06	0.55	0.49	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
UCEC	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	6.82	2.15e-10	1.39e-06	0.78	0.49	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	6.82	2.15e-10	1.39e-06	0.78	0.49	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	6.82	2.15e-10	1.39e-06	0.78	0.49	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	6.82	2.15e-10	1.39e-06	0.78	0.49	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	6.82	2.15e-10	1.39e-06	0.78	0.49	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	6.82	2.15e-10	1.39e-06	0.78	0.49	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	6.82	2.15e-10	1.39e-06	0.78	0.49	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	6.82	2.15e-10	1.39e-06	0.78	0.49	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	6.82	2.15e-10	1.39e-06	0.78	0.49	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
UCEC	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-6.82	2.15e-10	1.39e-06	-0.44	-0.49	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
UCEC	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	6.82	2.16e-10	1.39e-06	0.74	0.49	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
UCEC	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	6.81	2.2e-10	1.42e-06	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	6.81	2.2e-10	1.42e-06	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	6.81	2.2e-10	1.42e-06	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	6.81	2.2e-10	1.42e-06	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	6.81	2.2e-10	1.42e-06	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	6.81	2.2e-10	1.42e-06	0.61	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	6.81	2.2e-10	1.42e-06	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	6.81	2.2e-10	1.42e-06	0.61	0.49	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
UCEC	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-6.81	2.25e-10	1.44e-06	-0.44	-0.49	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
UCEC	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	6.81	2.26e-10	1.45e-06	0.62	0.49	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
UCEC	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	6.8	2.31e-10	1.48e-06	0.53	0.49	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
UCEC	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	6.8	2.32e-10	1.49e-06	0.6	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.828	rs2186366	ENSG00000272787.1	KB-226F1.2	6.8	2.36e-10	1.51e-06	0.57	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23969211~23969873:+
UCEC	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	6.8	2.38e-10	1.52e-06	0.53	0.49	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
UCEC	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	6.79	2.45e-10	1.56e-06	0.61	0.49	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
UCEC	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-6.79	2.45e-10	1.56e-06	-0.76	-0.49	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-6.79	2.45e-10	1.56e-06	-0.76	-0.49	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-6.79	2.45e-10	1.56e-06	-0.76	-0.49	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
UCEC	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-6.79	2.45e-10	1.56e-06	-0.76	-0.49	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
UCEC	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-6.79	2.45e-10	1.57e-06	-0.52	-0.49	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
UCEC	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	6.79	2.48e-10	1.58e-06	0.57	0.49	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
UCEC	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	6.79	2.48e-10	1.58e-06	0.57	0.49	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
UCEC	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-6.79	2.49e-10	1.59e-06	-0.58	-0.49	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
UCEC	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	6.79	2.5e-10	1.59e-06	0.58	0.49	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
UCEC	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	6.79	2.51e-10	1.6e-06	0.49	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
UCEC	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	6.79	2.52e-10	1.6e-06	0.66	0.49	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
UCEC	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-6.79	2.52e-10	1.6e-06	-0.44	-0.49	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
UCEC	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	6.79	2.54e-10	1.61e-06	0.78	0.49	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
UCEC	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-6.79	2.55e-10	1.61e-06	-0.63	-0.49	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.734	rs2000467	ENSG00000272787.1	KB-226F1.2	6.78	2.58e-10	1.63e-06	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23969211~23969873:+
UCEC	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-6.78	2.63e-10	1.66e-06	-0.95	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
UCEC	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	6.78	2.64e-10	1.67e-06	0.62	0.49	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	6.78	2.64e-10	1.67e-06	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
UCEC	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	6.78	2.68e-10	1.69e-06	0.6	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
UCEC	cis	rs7267979	1	rs2482943	ENSG00000276952.1	RP5-965G21.6	-6.77	2.7e-10	1.7e-06	-0.67	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25284915~25285588:-
UCEC	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	6.77	2.74e-10	1.72e-06	0.61	0.49	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	6.77	2.74e-10	1.72e-06	0.61	0.49	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	6.77	2.74e-10	1.72e-06	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
UCEC	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-6.77	2.78e-10	1.74e-06	-0.58	-0.48	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-6.77	2.78e-10	1.74e-06	-0.58	-0.48	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-6.77	2.78e-10	1.74e-06	-0.58	-0.48	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-6.77	2.78e-10	1.74e-06	-0.58	-0.48	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-6.77	2.78e-10	1.74e-06	-0.58	-0.48	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
UCEC	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	6.77	2.78e-10	1.75e-06	0.52	0.48	Depression;	chr6:28240757	chr6:28176188~28176674:+
UCEC	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-6.77	2.79e-10	1.75e-06	-0.44	-0.48	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
UCEC	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-6.77	2.8e-10	1.75e-06	-0.5	-0.48	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
UCEC	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	6.77	2.83e-10	1.77e-06	0.61	0.48	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	6.77	2.83e-10	1.77e-06	0.61	0.48	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
UCEC	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	6.77	2.84e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	6.76	2.86e-10	1.78e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
UCEC	cis	rs10256972	0.552	rs6953538	ENSG00000229043.2	AC091729.9	-6.76	2.87e-10	1.78e-06	-0.58	-0.48	Endometriosis;Longevity;	chr7:1157338	chr7:1160374~1165267:+
UCEC	cis	rs2739330	0.828	rs2330635	ENSG00000272787.1	KB-226F1.2	-6.76	2.87e-10	1.78e-06	-0.58	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23969211~23969873:+
UCEC	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	6.76	2.9e-10	1.8e-06	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
UCEC	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	6.76	2.91e-10	1.81e-06	0.61	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
UCEC	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-6.75	3.01e-10	1.86e-06	-0.62	-0.48	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
UCEC	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-6.75	3.11e-10	1.92e-06	-0.82	-0.48	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
UCEC	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	6.75	3.11e-10	1.92e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
UCEC	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-6.75	3.12e-10	1.93e-06	-0.6	-0.48	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
UCEC	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-6.75	3.13e-10	1.94e-06	-0.64	-0.48	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-6.74	3.22e-10	1.99e-06	-0.55	-0.48	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-6.74	3.23e-10	1.99e-06	-0.63	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
UCEC	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	6.74	3.29e-10	2.03e-06	0.61	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
UCEC	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	6.74	3.29e-10	2.03e-06	0.72	0.48	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
UCEC	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-6.74	3.31e-10	2.04e-06	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-6.74	3.31e-10	2.04e-06	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-6.74	3.31e-10	2.04e-06	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
UCEC	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-6.73	3.35e-10	2.06e-06	-0.64	-0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
UCEC	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	6.73	3.39e-10	2.09e-06	0.55	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
UCEC	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-6.73	3.5e-10	2.15e-06	-0.62	-0.48	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	6.72	3.57e-10	2.19e-06	0.58	0.48	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
UCEC	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-6.72	3.6e-10	2.21e-06	-0.44	-0.48	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
UCEC	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-6.72	3.61e-10	2.21e-06	-0.58	-0.48	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-6.72	3.61e-10	2.21e-06	-0.58	-0.48	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
UCEC	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	6.72	3.63e-10	2.23e-06	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
UCEC	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-6.72	3.66e-10	2.24e-06	-0.6	-0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
UCEC	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-6.72	3.67e-10	2.25e-06	-0.42	-0.48	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
UCEC	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-6.72	3.68e-10	2.25e-06	-0.59	-0.48	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
UCEC	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-6.71	3.75e-10	2.29e-06	-0.57	-0.48	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
UCEC	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-6.71	3.76e-10	2.29e-06	-0.43	-0.48	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
UCEC	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	6.71	3.79e-10	2.31e-06	0.6	0.48	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	6.71	3.79e-10	2.31e-06	0.62	0.48	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
UCEC	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-6.71	3.79e-10	2.31e-06	-0.57	-0.48	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
UCEC	cis	rs7267979	1	rs2258719	ENSG00000276952.1	RP5-965G21.6	6.71	3.8e-10	2.31e-06	0.66	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs1888998	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2500433	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2482948	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2482919	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6037086	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2482923	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2482927	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2482931	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2482940	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2027003	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2027004	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.934	rs2500399	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2500404	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2500405	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2482941	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.903	rs2500423	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2500418	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2500424	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2500448	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.873	rs6083853	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2387885	ENSG00000276952.1	RP5-965G21.6	-6.71	3.81e-10	2.31e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs1888999	ENSG00000276952.1	RP5-965G21.6	6.71	3.81e-10	2.31e-06	0.65	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2424713	ENSG00000276952.1	RP5-965G21.6	6.71	3.81e-10	2.31e-06	0.65	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25284915~25285588:-
UCEC	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-6.71	3.82e-10	2.31e-06	-0.55	-0.48	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-6.71	3.82e-10	2.31e-06	-0.55	-0.48	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-6.71	3.82e-10	2.31e-06	-0.55	-0.48	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
UCEC	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	6.71	3.87e-10	2.34e-06	0.76	0.48	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
UCEC	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	6.71	3.88e-10	2.34e-06	0.59	0.48	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
UCEC	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	6.7	3.91e-10	2.36e-06	0.6	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
UCEC	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-6.7	4e-10	2.42e-06	-0.77	-0.48	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	6.7	4.09e-10	2.46e-06	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
UCEC	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-6.7	4.1e-10	2.47e-06	-0.75	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
UCEC	cis	rs7267979	0.934	rs2482913	ENSG00000276952.1	RP5-965G21.6	-6.69	4.18e-10	2.52e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25284915~25285588:-
UCEC	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	6.69	4.19e-10	2.52e-06	0.6	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
UCEC	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-6.69	4.21e-10	2.53e-06	-0.51	-0.48	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
UCEC	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-6.69	4.22e-10	2.54e-06	-0.61	-0.48	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
UCEC	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	6.69	4.25e-10	2.55e-06	0.84	0.48	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
UCEC	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-6.69	4.26e-10	2.55e-06	-0.54	-0.48	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
UCEC	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-6.68	4.34e-10	2.6e-06	-0.43	-0.48	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
UCEC	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	6.68	4.37e-10	2.62e-06	0.55	0.48	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-6.68	4.37e-10	2.62e-06	-0.55	-0.48	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
UCEC	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	6.68	4.4e-10	2.63e-06	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	6.68	4.4e-10	2.63e-06	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	6.68	4.4e-10	2.63e-06	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	6.68	4.41e-10	2.64e-06	0.83	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
UCEC	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-6.68	4.44e-10	2.66e-06	-0.43	-0.48	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
UCEC	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	6.68	4.46e-10	2.67e-06	0.55	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
UCEC	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-6.68	4.47e-10	2.67e-06	-0.56	-0.48	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
UCEC	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-6.68	4.49e-10	2.68e-06	-0.74	-0.48	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
UCEC	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	6.68	4.51e-10	2.69e-06	0.6	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
UCEC	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	6.68	4.52e-10	2.7e-06	0.58	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
UCEC	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-6.68	4.53e-10	2.7e-06	-0.6	-0.48	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
UCEC	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	6.67	4.58e-10	2.73e-06	0.61	0.48	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
UCEC	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	6.67	4.64e-10	2.76e-06	0.66	0.48	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
UCEC	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-6.67	4.65e-10	2.77e-06	-0.84	-0.48	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
UCEC	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-6.67	4.69e-10	2.78e-06	-0.57	-0.48	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
UCEC	cis	rs7267979	0.933	rs2424708	ENSG00000276952.1	RP5-965G21.6	6.66	4.86e-10	2.87e-06	0.65	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs884613	ENSG00000276952.1	RP5-965G21.6	-6.66	4.86e-10	2.87e-06	-0.65	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25284915~25285588:-
UCEC	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	6.66	4.88e-10	2.88e-06	0.51	0.48	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
UCEC	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	6.66	5e-10	2.94e-06	0.52	0.48	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
UCEC	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	6.66	5.07e-10	2.98e-06	0.8	0.48	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
UCEC	cis	rs8005677	1	rs1043209	ENSG00000257285.4	RP11-298I3.1	-6.65	5.11e-10	3e-06	-0.45	-0.48	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	6.65	5.11e-10	3e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	6.65	5.11e-10	3e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	6.65	5.11e-10	3e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
UCEC	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	6.65	5.13e-10	3.01e-06	0.6	0.48	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
UCEC	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-6.65	5.14e-10	3.02e-06	-0.63	-0.48	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
UCEC	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	6.65	5.14e-10	3.02e-06	0.52	0.48	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
UCEC	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	6.65	5.17e-10	3.03e-06	0.63	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
UCEC	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-6.65	5.2e-10	3.05e-06	-0.59	-0.48	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-6.65	5.2e-10	3.05e-06	-0.59	-0.48	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-6.65	5.2e-10	3.05e-06	-0.59	-0.48	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-6.65	5.2e-10	3.05e-06	-0.59	-0.48	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-6.65	5.2e-10	3.05e-06	-0.59	-0.48	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-6.65	5.2e-10	3.05e-06	-0.59	-0.48	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-6.65	5.2e-10	3.05e-06	-0.59	-0.48	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-6.65	5.29e-10	3.09e-06	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
UCEC	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	6.65	5.32e-10	3.1e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	6.65	5.32e-10	3.1e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	6.65	5.32e-10	3.1e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	6.65	5.32e-10	3.1e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	6.65	5.32e-10	3.1e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	6.65	5.32e-10	3.1e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	6.65	5.32e-10	3.1e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	6.65	5.32e-10	3.1e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	6.65	5.32e-10	3.1e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
UCEC	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-6.64	5.36e-10	3.12e-06	-0.59	-0.48	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-6.64	5.36e-10	3.12e-06	-0.59	-0.48	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
UCEC	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-6.64	5.52e-10	3.21e-06	-0.61	-0.48	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-6.64	5.52e-10	3.21e-06	-0.61	-0.48	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
UCEC	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-6.64	5.56e-10	3.23e-06	-0.61	-0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
UCEC	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	6.64	5.59e-10	3.25e-06	0.59	0.48	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
UCEC	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-6.64	5.6e-10	3.25e-06	-0.53	-0.48	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
UCEC	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	6.63	5.64e-10	3.27e-06	0.75	0.48	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
UCEC	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	6.63	5.68e-10	3.29e-06	0.65	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	6.63	5.68e-10	3.29e-06	0.65	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
UCEC	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	6.63	5.77e-10	3.34e-06	0.55	0.48	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
UCEC	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	6.63	5.77e-10	3.34e-06	0.56	0.48	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
UCEC	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	6.63	5.87e-10	3.4e-06	0.78	0.48	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
UCEC	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	6.63	5.94e-10	3.43e-06	0.61	0.48	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
UCEC	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	6.62	5.99e-10	3.46e-06	0.5	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
UCEC	cis	rs8005677	0.828	rs2295680	ENSG00000279656.1	RP11-298I3.6	-6.62	6.01e-10	3.48e-06	-0.56	-0.48	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:23023083~23024217:-
UCEC	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	6.62	6.04e-10	3.49e-06	0.53	0.48	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
UCEC	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-6.62	6.05e-10	3.5e-06	-0.55	-0.48	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	6.62	6.07e-10	3.5e-06	0.57	0.48	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
UCEC	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	6.62	6.14e-10	3.53e-06	0.6	0.48	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	6.62	6.14e-10	3.53e-06	0.6	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	6.61	6.33e-10	3.63e-06	0.62	0.48	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
UCEC	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	6.61	6.4e-10	3.65e-06	0.59	0.48	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	6.61	6.4e-10	3.65e-06	0.59	0.48	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	6.61	6.4e-10	3.65e-06	0.59	0.48	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
UCEC	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-6.61	6.43e-10	3.67e-06	-0.59	-0.48	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
UCEC	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	6.61	6.47e-10	3.69e-06	0.53	0.48	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	6.61	6.49e-10	3.7e-06	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
UCEC	cis	rs7267979	0.866	rs2424698	ENSG00000276952.1	RP5-965G21.6	6.61	6.52e-10	3.72e-06	0.64	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25284915~25285588:-
UCEC	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	6.61	6.52e-10	3.72e-06	0.54	0.48	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
UCEC	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-6.61	6.54e-10	3.73e-06	-0.5	-0.48	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
UCEC	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	6.6	6.67e-10	3.8e-06	0.7	0.48	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
UCEC	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	6.6	6.71e-10	3.82e-06	0.55	0.48	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
UCEC	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-6.6	6.88e-10	3.91e-06	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-6.6	6.88e-10	3.91e-06	-0.53	-0.48	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
UCEC	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	6.6	6.9e-10	3.91e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	6.6	6.9e-10	3.91e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	6.6	6.9e-10	3.91e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
UCEC	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	6.6	6.9e-10	3.91e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	6.6	6.9e-10	3.91e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
UCEC	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	6.6	6.91e-10	3.91e-06	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
UCEC	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-6.6	6.91e-10	3.91e-06	-0.55	-0.48	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
UCEC	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-6.6	6.91e-10	3.91e-06	-0.55	-0.48	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-6.6	6.91e-10	3.91e-06	-0.55	-0.48	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
UCEC	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	6.59	7.01e-10	3.97e-06	0.54	0.48	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
UCEC	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-6.59	7.05e-10	3.99e-06	-0.63	-0.48	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
UCEC	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	6.59	7.07e-10	4e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.962	rs11157931	ENSG00000257285.4	RP11-298I3.1	6.59	7.07e-10	4e-06	0.45	0.48	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:22929609~22955562:+
UCEC	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-6.59	7.1e-10	4.01e-06	-0.59	-0.48	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
UCEC	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-6.58	7.41e-10	4.17e-06	-0.61	-0.47	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
UCEC	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	6.58	7.44e-10	4.19e-06	0.55	0.47	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
UCEC	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-6.58	7.44e-10	4.19e-06	-0.73	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
UCEC	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-6.58	7.44e-10	4.19e-06	-0.73	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-6.58	7.54e-10	4.25e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
UCEC	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-6.58	7.58e-10	4.26e-06	-1.01	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
UCEC	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-6.57	7.71e-10	4.33e-06	-0.58	-0.47	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
UCEC	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	6.57	7.76e-10	4.36e-06	0.58	0.47	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
UCEC	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	6.57	7.81e-10	4.39e-06	0.54	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
UCEC	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-6.57	7.86e-10	4.4e-06	-0.56	-0.47	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
UCEC	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-6.57	7.87e-10	4.41e-06	-0.59	-0.47	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-6.57	7.87e-10	4.41e-06	-0.59	-0.47	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-6.57	7.87e-10	4.41e-06	-0.59	-0.47	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
UCEC	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	6.57	7.88e-10	4.41e-06	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
UCEC	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-6.57	7.91e-10	4.43e-06	-0.6	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
UCEC	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-6.57	7.94e-10	4.43e-06	-0.58	-0.47	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-6.57	7.98e-10	4.46e-06	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
UCEC	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-6.56	8.19e-10	4.56e-06	-0.6	-0.47	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
UCEC	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-6.56	8.24e-10	4.58e-06	-0.59	-0.47	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-6.56	8.24e-10	4.58e-06	-0.59	-0.47	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-6.56	8.24e-10	4.58e-06	-0.59	-0.47	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
UCEC	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-6.56	8.29e-10	4.61e-06	-0.62	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
UCEC	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-6.56	8.53e-10	4.73e-06	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-6.55	8.64e-10	4.78e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-6.55	8.64e-10	4.78e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-6.55	8.64e-10	4.78e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-6.55	8.64e-10	4.78e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-6.55	8.64e-10	4.78e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-6.55	8.64e-10	4.78e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	6.55	8.64e-10	4.78e-06	0.52	0.47	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-6.55	8.7e-10	4.81e-06	-0.61	-0.47	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
UCEC	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-6.55	8.73e-10	4.82e-06	-0.43	-0.47	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-6.55	8.78e-10	4.84e-06	-0.58	-0.47	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-6.55	8.78e-10	4.84e-06	-0.58	-0.47	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
UCEC	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	6.55	8.85e-10	4.88e-06	0.55	0.47	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	6.55	8.85e-10	4.88e-06	0.55	0.47	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
UCEC	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-6.55	8.91e-10	4.9e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
UCEC	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	6.55	8.93e-10	4.91e-06	0.91	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
UCEC	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-6.55	8.93e-10	4.91e-06	-0.43	-0.47	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-6.55	8.93e-10	4.91e-06	-0.43	-0.47	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
UCEC	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-6.55	8.97e-10	4.93e-06	-0.83	-0.47	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-6.54	9.1e-10	5e-06	-0.61	-0.47	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-6.54	9.13e-10	5.01e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-6.54	9.13e-10	5.01e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-6.54	9.13e-10	5.01e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-6.54	9.13e-10	5.01e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-6.54	9.13e-10	5.01e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-6.54	9.13e-10	5.01e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-6.54	9.13e-10	5.01e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	6.54	9.25e-10	5.06e-06	0.57	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	6.54	9.33e-10	5.11e-06	0.63	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
UCEC	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-6.54	9.46e-10	5.17e-06	-0.43	-0.47	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
UCEC	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	6.54	9.46e-10	5.17e-06	0.56	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
UCEC	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-6.53	9.52e-10	5.2e-06	-0.59	-0.47	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
UCEC	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-6.53	9.6e-10	5.24e-06	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
UCEC	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	6.53	9.6e-10	5.24e-06	0.58	0.47	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
UCEC	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	6.53	9.62e-10	5.25e-06	0.51	0.47	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
UCEC	cis	rs7267979	1	rs6138572	ENSG00000276952.1	RP5-965G21.6	6.53	9.63e-10	5.25e-06	0.63	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6138575	ENSG00000276952.1	RP5-965G21.6	6.53	9.63e-10	5.25e-06	0.63	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs11087521	ENSG00000276952.1	RP5-965G21.6	6.53	9.63e-10	5.25e-06	0.63	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25284915~25285588:-
UCEC	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	6.53	9.65e-10	5.26e-06	0.51	0.47	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
UCEC	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	6.53	9.77e-10	5.33e-06	0.58	0.47	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
UCEC	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-6.53	9.79e-10	5.33e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-6.53	9.84e-10	5.36e-06	-0.62	-0.47	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	6.53	9.88e-10	5.38e-06	0.62	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
UCEC	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-6.52	1e-09	5.43e-06	-0.58	-0.47	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-6.52	1e-09	5.43e-06	-0.58	-0.47	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-6.52	1e-09	5.43e-06	-0.58	-0.47	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
UCEC	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	6.52	1e-09	5.43e-06	0.55	0.47	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
UCEC	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	6.52	1.01e-09	5.48e-06	0.54	0.47	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	6.52	1.01e-09	5.48e-06	0.54	0.47	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	6.52	1.01e-09	5.48e-06	0.54	0.47	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
UCEC	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	6.52	1.01e-09	5.48e-06	0.54	0.47	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
UCEC	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-6.52	1.02e-09	5.52e-06	-0.55	-0.47	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-6.52	1.02e-09	5.52e-06	-0.55	-0.47	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-6.52	1.02e-09	5.52e-06	-0.55	-0.47	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
UCEC	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-6.52	1.02e-09	5.52e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
UCEC	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	6.52	1.02e-09	5.53e-06	0.54	0.47	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
UCEC	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-6.52	1.03e-09	5.55e-06	-0.57	-0.47	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-6.52	1.03e-09	5.55e-06	-0.57	-0.47	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-6.52	1.03e-09	5.55e-06	-0.57	-0.47	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-6.52	1.03e-09	5.55e-06	-0.57	-0.47	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-6.52	1.03e-09	5.55e-06	-0.6	-0.47	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
UCEC	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-6.52	1.04e-09	5.61e-06	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-6.52	1.04e-09	5.61e-06	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-6.52	1.04e-09	5.61e-06	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	6.51	1.06e-09	5.7e-06	0.51	0.47	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
UCEC	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	6.51	1.1e-09	5.93e-06	0.56	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
UCEC	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	6.51	1.1e-09	5.94e-06	0.63	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	6.5	1.12e-09	6.01e-06	0.57	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
UCEC	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	6.5	1.12e-09	6.01e-06	0.51	0.47	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
UCEC	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-6.5	1.13e-09	6.05e-06	-0.58	-0.47	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	6.5	1.14e-09	6.1e-06	0.53	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
UCEC	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	6.5	1.14e-09	6.13e-06	0.58	0.47	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	6.5	1.14e-09	6.13e-06	0.58	0.47	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	6.5	1.14e-09	6.13e-06	0.58	0.47	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	6.5	1.14e-09	6.13e-06	0.58	0.47	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	6.5	1.14e-09	6.13e-06	0.58	0.47	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	6.5	1.14e-09	6.13e-06	0.58	0.47	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-6.5	1.15e-09	6.16e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
UCEC	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	6.5	1.15e-09	6.17e-06	0.83	0.47	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
UCEC	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	6.5	1.16e-09	6.22e-06	0.52	0.47	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
UCEC	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	6.49	1.17e-09	6.27e-06	0.49	0.47	Depression;	chr6:28363475	chr6:28176188~28176674:+
UCEC	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-6.49	1.2e-09	6.42e-06	-0.58	-0.47	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
UCEC	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-6.49	1.21e-09	6.47e-06	-0.59	-0.47	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
UCEC	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-6.49	1.22e-09	6.51e-06	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
UCEC	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	6.48	1.23e-09	6.56e-06	0.58	0.47	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
UCEC	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-6.48	1.25e-09	6.65e-06	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-6.48	1.26e-09	6.68e-06	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
UCEC	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	6.48	1.26e-09	6.68e-06	0.58	0.47	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	6.48	1.26e-09	6.68e-06	0.58	0.47	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	6.48	1.26e-09	6.68e-06	0.58	0.47	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	6.48	1.26e-09	6.68e-06	0.58	0.47	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
UCEC	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	6.48	1.27e-09	6.73e-06	0.44	0.47	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	6.48	1.27e-09	6.73e-06	0.44	0.47	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
UCEC	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	6.48	1.27e-09	6.76e-06	0.58	0.47	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	6.48	1.27e-09	6.76e-06	0.58	0.47	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
UCEC	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-6.48	1.27e-09	6.76e-06	-0.58	-0.47	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
UCEC	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	6.47	1.31e-09	6.9e-06	0.77	0.47	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
UCEC	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-6.47	1.31e-09	6.9e-06	-0.59	-0.47	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
UCEC	cis	rs2739330	0.796	rs2154594	ENSG00000272787.1	KB-226F1.2	6.47	1.31e-09	6.92e-06	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23969211~23969873:+
UCEC	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-6.47	1.31e-09	6.93e-06	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
UCEC	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-6.47	1.31e-09	6.94e-06	-0.8	-0.47	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
UCEC	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-6.47	1.32e-09	6.99e-06	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
UCEC	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-6.47	1.32e-09	7e-06	-0.58	-0.47	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
UCEC	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-6.47	1.33e-09	7.03e-06	-0.58	-0.47	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-6.47	1.33e-09	7.03e-06	-0.58	-0.47	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
UCEC	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	6.47	1.34e-09	7.07e-06	0.59	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
UCEC	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-6.47	1.35e-09	7.12e-06	-0.59	-0.47	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
UCEC	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	6.47	1.36e-09	7.14e-06	0.55	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	6.47	1.36e-09	7.14e-06	0.55	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	6.47	1.36e-09	7.14e-06	0.55	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	6.47	1.36e-09	7.14e-06	0.55	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
UCEC	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	6.47	1.36e-09	7.14e-06	0.55	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
UCEC	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-6.46	1.37e-09	7.19e-06	-0.59	-0.47	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
UCEC	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	6.46	1.38e-09	7.28e-06	0.53	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
UCEC	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-6.46	1.39e-09	7.28e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-6.46	1.39e-09	7.28e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-6.46	1.39e-09	7.28e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-6.46	1.39e-09	7.29e-06	-0.56	-0.47	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
UCEC	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	6.46	1.4e-09	7.33e-06	0.59	0.47	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
UCEC	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	6.46	1.4e-09	7.36e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
UCEC	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-6.46	1.42e-09	7.42e-06	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
UCEC	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	6.46	1.42e-09	7.45e-06	0.59	0.47	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
UCEC	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	6.46	1.42e-09	7.45e-06	0.52	0.47	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	6.46	1.42e-09	7.45e-06	0.52	0.47	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	6.45	1.44e-09	7.54e-06	0.51	0.47	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	6.45	1.45e-09	7.6e-06	0.68	0.47	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	6.45	1.45e-09	7.6e-06	0.68	0.47	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	6.45	1.45e-09	7.6e-06	0.68	0.47	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
UCEC	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	6.45	1.46e-09	7.62e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
UCEC	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	6.45	1.46e-09	7.63e-06	0.55	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
UCEC	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	6.45	1.46e-09	7.64e-06	0.62	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
UCEC	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-6.45	1.47e-09	7.65e-06	-0.5	-0.47	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
UCEC	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	6.45	1.47e-09	7.66e-06	0.43	0.47	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
UCEC	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-6.45	1.47e-09	7.67e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
UCEC	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	6.45	1.48e-09	7.67e-06	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
UCEC	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
UCEC	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
UCEC	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
UCEC	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
UCEC	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-6.45	1.48e-09	7.67e-06	-0.55	-0.47	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
UCEC	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-6.45	1.48e-09	7.69e-06	-0.57	-0.47	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-6.45	1.48e-09	7.69e-06	-0.57	-0.47	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
UCEC	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	6.45	1.48e-09	7.71e-06	0.69	0.47	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	6.45	1.48e-09	7.71e-06	0.69	0.47	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
UCEC	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	6.45	1.49e-09	7.75e-06	0.51	0.47	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
UCEC	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-6.45	1.5e-09	7.79e-06	-0.47	-0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
UCEC	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	6.44	1.52e-09	7.9e-06	0.64	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	6.44	1.52e-09	7.9e-06	0.64	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
UCEC	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	6.44	1.54e-09	7.96e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	6.44	1.54e-09	7.96e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	6.44	1.54e-09	7.96e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	6.44	1.54e-09	7.96e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	6.44	1.54e-09	7.96e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	6.44	1.54e-09	7.96e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	6.44	1.54e-09	7.96e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
UCEC	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	6.44	1.55e-09	8.02e-06	0.55	0.47	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	6.44	1.58e-09	8.17e-06	0.68	0.47	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	6.44	1.58e-09	8.17e-06	0.68	0.47	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
UCEC	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-6.44	1.58e-09	8.18e-06	-0.77	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
UCEC	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	6.44	1.58e-09	8.19e-06	0.67	0.47	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
UCEC	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-6.43	1.6e-09	8.23e-06	-0.58	-0.47	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
UCEC	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-6.43	1.6e-09	8.23e-06	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-6.43	1.6e-09	8.23e-06	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-6.43	1.6e-09	8.23e-06	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	6.43	1.6e-09	8.23e-06	0.59	0.47	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	6.43	1.62e-09	8.33e-06	0.61	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
UCEC	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	6.43	1.63e-09	8.4e-06	0.66	0.47	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
UCEC	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	6.43	1.63e-09	8.4e-06	0.66	0.47	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
UCEC	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	6.43	1.64e-09	8.41e-06	0.67	0.47	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	6.43	1.64e-09	8.41e-06	0.67	0.47	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
UCEC	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-6.43	1.66e-09	8.54e-06	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-6.43	1.67e-09	8.56e-06	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-6.42	1.7e-09	8.69e-06	-0.61	-0.47	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-6.42	1.7e-09	8.69e-06	-0.61	-0.47	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-6.42	1.7e-09	8.69e-06	-0.61	-0.47	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
UCEC	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	6.42	1.71e-09	8.73e-06	0.59	0.47	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
UCEC	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-6.42	1.72e-09	8.75e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-6.42	1.72e-09	8.75e-06	-0.51	-0.47	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
UCEC	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	6.42	1.73e-09	8.8e-06	0.66	0.47	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
UCEC	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	6.42	1.73e-09	8.8e-06	0.72	0.47	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	6.42	1.73e-09	8.8e-06	0.72	0.47	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	6.42	1.73e-09	8.8e-06	0.72	0.47	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	6.42	1.73e-09	8.8e-06	0.72	0.47	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	6.42	1.73e-09	8.8e-06	0.72	0.47	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	6.42	1.73e-09	8.8e-06	0.72	0.47	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	6.42	1.73e-09	8.8e-06	0.72	0.47	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	6.42	1.73e-09	8.8e-06	0.72	0.47	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
UCEC	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	6.42	1.73e-09	8.81e-06	0.5	0.47	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
UCEC	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-6.42	1.73e-09	8.82e-06	-0.54	-0.47	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-6.42	1.73e-09	8.82e-06	-0.54	-0.47	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
UCEC	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	6.42	1.73e-09	8.82e-06	0.58	0.47	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
UCEC	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-6.42	1.74e-09	8.83e-06	-0.5	-0.47	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	6.42	1.74e-09	8.83e-06	0.5	0.47	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
UCEC	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	6.42	1.74e-09	8.83e-06	0.51	0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
UCEC	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	6.42	1.74e-09	8.85e-06	0.59	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
UCEC	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	6.42	1.75e-09	8.86e-06	0.51	0.47	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
UCEC	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	6.42	1.75e-09	8.86e-06	0.54	0.47	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
UCEC	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	6.42	1.75e-09	8.86e-06	0.58	0.47	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	6.42	1.75e-09	8.86e-06	0.58	0.47	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	6.42	1.75e-09	8.86e-06	0.58	0.47	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	6.42	1.76e-09	8.93e-06	0.67	0.47	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-6.42	1.76e-09	8.94e-06	-0.61	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
UCEC	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-6.41	1.78e-09	9.01e-06	-0.95	-0.47	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
UCEC	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	6.41	1.78e-09	9.02e-06	0.63	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
UCEC	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	6.41	1.81e-09	9.17e-06	0.58	0.46	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
UCEC	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-6.41	1.82e-09	9.2e-06	-0.57	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
UCEC	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-6.41	1.82e-09	9.21e-06	-0.58	-0.46	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-6.41	1.82e-09	9.21e-06	-0.58	-0.46	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-6.41	1.82e-09	9.21e-06	-0.58	-0.46	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
UCEC	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-6.41	1.82e-09	9.21e-06	-0.55	-0.46	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-6.41	1.82e-09	9.21e-06	-0.55	-0.46	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
UCEC	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-6.41	1.84e-09	9.27e-06	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-6.41	1.85e-09	9.31e-06	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-6.41	1.85e-09	9.31e-06	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-6.41	1.85e-09	9.31e-06	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
UCEC	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-6.41	1.85e-09	9.31e-06	-0.42	-0.46	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-6.41	1.85e-09	9.31e-06	-0.43	-0.46	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
UCEC	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-6.41	1.85e-09	9.32e-06	-0.54	-0.46	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
UCEC	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-6.4	1.86e-09	9.39e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
UCEC	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-6.4	1.87e-09	9.39e-06	-0.41	-0.46	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
UCEC	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	6.4	1.87e-09	9.43e-06	0.59	0.46	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	6.4	1.88e-09	9.45e-06	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
UCEC	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	6.4	1.88e-09	9.46e-06	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
UCEC	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	6.4	1.88e-09	9.47e-06	0.5	0.46	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
UCEC	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	6.4	1.89e-09	9.51e-06	0.53	0.46	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	6.4	1.89e-09	9.51e-06	0.53	0.46	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
UCEC	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	6.4	1.9e-09	9.53e-06	0.51	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
UCEC	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	6.4	1.91e-09	9.59e-06	0.55	0.46	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	6.4	1.92e-09	9.62e-06	0.57	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-6.4	1.93e-09	9.67e-06	-0.59	-0.46	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-6.4	1.93e-09	9.67e-06	-0.59	-0.46	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-6.4	1.93e-09	9.67e-06	-0.59	-0.46	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-6.4	1.93e-09	9.67e-06	-0.59	-0.46	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
UCEC	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-6.4	1.94e-09	9.73e-06	-0.57	-0.46	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-6.4	1.94e-09	9.73e-06	-0.57	-0.46	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-6.4	1.94e-09	9.73e-06	-0.57	-0.46	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-6.4	1.94e-09	9.73e-06	-0.57	-0.46	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
UCEC	cis	rs875971	0.867	rs13227219	ENSG00000226824.5	RP4-756H11.3	-6.39	1.96e-09	9.82e-06	-0.58	-0.46	Aortic root size;	chr7:66379075	chr7:66654538~66669855:+
UCEC	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	6.39	1.97e-09	9.86e-06	0.5	0.46	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
UCEC	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	6.39	1.98e-09	9.92e-06	0.76	0.46	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	6.39	1.98e-09	9.92e-06	0.76	0.46	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	6.39	1.98e-09	9.92e-06	0.76	0.46	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
UCEC	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-6.39	1.99e-09	9.94e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-6.39	1.99e-09	9.96e-06	-0.59	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
UCEC	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-6.39	2.01e-09	1.01e-05	-0.6	-0.46	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
UCEC	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-6.39	2.02e-09	1.01e-05	-0.47	-0.46	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
UCEC	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	6.39	2.02e-09	1.01e-05	0.59	0.46	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
UCEC	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	6.39	2.02e-09	1.01e-05	0.59	0.46	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	6.39	2.02e-09	1.01e-05	0.59	0.46	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	6.39	2.02e-09	1.01e-05	0.59	0.46	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	6.39	2.02e-09	1.01e-05	0.58	0.46	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
UCEC	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-6.39	2.04e-09	1.02e-05	-0.85	-0.46	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
UCEC	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	6.38	2.06e-09	1.03e-05	0.76	0.46	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
UCEC	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	6.38	2.07e-09	1.03e-05	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	6.38	2.07e-09	1.03e-05	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
UCEC	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-6.38	2.07e-09	1.03e-05	-0.49	-0.46	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
UCEC	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-6.38	2.07e-09	1.03e-05	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-6.38	2.07e-09	1.03e-05	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-6.38	2.07e-09	1.03e-05	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	6.38	2.07e-09	1.03e-05	0.57	0.46	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	6.38	2.11e-09	1.05e-05	0.56	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
UCEC	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-6.38	2.14e-09	1.06e-05	-0.5	-0.46	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-6.38	2.16e-09	1.07e-05	-0.59	-0.46	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
UCEC	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	6.37	2.17e-09	1.07e-05	0.5	0.46	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	6.37	2.17e-09	1.07e-05	0.5	0.46	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	6.37	2.17e-09	1.07e-05	0.5	0.46	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
UCEC	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	6.37	2.18e-09	1.08e-05	0.58	0.46	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-6.37	2.19e-09	1.08e-05	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-6.37	2.2e-09	1.09e-05	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	6.37	2.21e-09	1.09e-05	0.69	0.46	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
UCEC	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-6.37	2.23e-09	1.1e-05	-0.49	-0.46	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
UCEC	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-6.37	2.23e-09	1.1e-05	-0.49	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
UCEC	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	6.37	2.25e-09	1.11e-05	0.52	0.46	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
UCEC	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-6.37	2.25e-09	1.11e-05	-0.55	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
UCEC	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	6.37	2.26e-09	1.11e-05	0.65	0.46	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
UCEC	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-6.37	2.26e-09	1.11e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
UCEC	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	6.37	2.27e-09	1.12e-05	0.58	0.46	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
UCEC	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	6.36	2.32e-09	1.14e-05	0.77	0.46	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
UCEC	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	6.36	2.33e-09	1.15e-05	0.54	0.46	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
UCEC	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-6.36	2.34e-09	1.15e-05	-0.66	-0.46	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
UCEC	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	6.36	2.37e-09	1.16e-05	0.69	0.46	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
UCEC	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-6.36	2.37e-09	1.17e-05	-0.51	-0.46	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
UCEC	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-6.36	2.39e-09	1.17e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-6.36	2.39e-09	1.17e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-6.36	2.39e-09	1.17e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
UCEC	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-6.36	2.39e-09	1.17e-05	-0.5	-0.46	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
UCEC	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	6.36	2.39e-09	1.17e-05	0.59	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	6.36	2.39e-09	1.17e-05	0.59	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	6.36	2.39e-09	1.17e-05	0.59	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
UCEC	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-6.36	2.39e-09	1.17e-05	-0.58	-0.46	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
UCEC	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-6.35	2.41e-09	1.18e-05	-0.48	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
UCEC	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-6.35	2.44e-09	1.19e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	6.35	2.45e-09	1.19e-05	0.59	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
UCEC	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	6.35	2.45e-09	1.19e-05	0.68	0.46	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
UCEC	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	6.35	2.47e-09	1.2e-05	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	6.35	2.52e-09	1.22e-05	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
UCEC	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	6.34	2.53e-09	1.23e-05	0.5	0.46	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
UCEC	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	6.34	2.53e-09	1.23e-05	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
UCEC	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	6.34	2.55e-09	1.24e-05	0.47	0.46	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
UCEC	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	6.34	2.57e-09	1.24e-05	0.51	0.46	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	6.34	2.57e-09	1.24e-05	0.51	0.46	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	6.34	2.57e-09	1.24e-05	0.51	0.46	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
UCEC	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-6.34	2.58e-09	1.25e-05	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
UCEC	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	6.34	2.61e-09	1.26e-05	0.59	0.46	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
UCEC	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	6.34	2.61e-09	1.26e-05	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	6.34	2.61e-09	1.26e-05	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
UCEC	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-6.34	2.62e-09	1.26e-05	-0.49	-0.46	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
UCEC	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-6.34	2.62e-09	1.26e-05	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
UCEC	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	6.34	2.64e-09	1.27e-05	0.77	0.46	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	6.34	2.64e-09	1.27e-05	0.77	0.46	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.746	rs75987655	ENSG00000273456.1	RP11-686O6.2	6.34	2.64e-09	1.27e-05	0.77	0.46	Urate levels;	chr2:202581913	chr2:202374932~202375604:-
UCEC	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	6.34	2.64e-09	1.27e-05	0.59	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
UCEC	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	6.33	2.67e-09	1.28e-05	0.54	0.46	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
UCEC	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-6.33	2.67e-09	1.28e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-6.33	2.67e-09	1.28e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-6.33	2.67e-09	1.28e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-6.33	2.67e-09	1.28e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-6.33	2.67e-09	1.28e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
UCEC	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	6.33	2.71e-09	1.3e-05	0.52	0.46	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
UCEC	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-6.33	2.71e-09	1.3e-05	-0.57	-0.46	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
UCEC	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	6.33	2.77e-09	1.33e-05	0.76	0.46	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	6.33	2.77e-09	1.33e-05	0.76	0.46	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
UCEC	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-6.33	2.78e-09	1.33e-05	-0.52	-0.46	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
UCEC	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	6.33	2.79e-09	1.34e-05	0.67	0.46	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
UCEC	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-6.32	2.81e-09	1.34e-05	-0.43	-0.46	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
UCEC	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-6.32	2.83e-09	1.35e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-6.32	2.83e-09	1.35e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
UCEC	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	6.32	2.83e-09	1.35e-05	0.54	0.46	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
UCEC	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-6.32	2.83e-09	1.35e-05	-0.42	-0.46	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
UCEC	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	6.32	2.83e-09	1.35e-05	0.67	0.46	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
UCEC	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-6.32	2.84e-09	1.36e-05	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
UCEC	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	6.32	2.88e-09	1.37e-05	0.49	0.46	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	6.32	2.88e-09	1.37e-05	0.49	0.46	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	6.32	2.88e-09	1.37e-05	0.49	0.46	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
UCEC	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	6.32	2.93e-09	1.39e-05	0.57	0.46	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
UCEC	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	6.32	2.93e-09	1.39e-05	0.57	0.46	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
UCEC	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	6.31	2.95e-09	1.4e-05	0.5	0.46	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
UCEC	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-6.31	2.95e-09	1.4e-05	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
UCEC	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	6.31	2.95e-09	1.4e-05	0.57	0.46	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
UCEC	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	6.31	2.96e-09	1.4e-05	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
UCEC	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-6.31	2.98e-09	1.41e-05	-0.47	-0.46	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
UCEC	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-6.31	2.99e-09	1.41e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-6.31	2.99e-09	1.41e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-6.31	2.99e-09	1.41e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-6.31	2.99e-09	1.41e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-6.31	2.99e-09	1.41e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
UCEC	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-6.31	2.99e-09	1.41e-05	-0.57	-0.46	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-6.31	3e-09	1.42e-05	-0.58	-0.46	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
UCEC	cis	rs806321	0.587	rs2703088	ENSG00000237152.3	DLEU7-AS1	-6.31	3.01e-09	1.42e-05	-0.57	-0.46	Multiple sclerosis;	chr13:50188808	chr13:50807856~50849905:+
UCEC	cis	rs806321	0.587	rs2740518	ENSG00000237152.3	DLEU7-AS1	-6.31	3.01e-09	1.42e-05	-0.57	-0.46	Multiple sclerosis;	chr13:50188809	chr13:50807856~50849905:+
UCEC	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	6.31	3.01e-09	1.43e-05	0.74	0.46	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
UCEC	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-6.31	3.04e-09	1.44e-05	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
UCEC	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	6.31	3.04e-09	1.44e-05	0.5	0.46	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	6.31	3.04e-09	1.44e-05	0.5	0.46	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	6.31	3.04e-09	1.44e-05	0.5	0.46	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
UCEC	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-6.31	3.06e-09	1.45e-05	-0.59	-0.46	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	6.31	3.08e-09	1.45e-05	0.61	0.46	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
UCEC	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	6.31	3.09e-09	1.46e-05	0.65	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
UCEC	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	6.3	3.19e-09	1.49e-05	0.67	0.46	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	6.3	3.19e-09	1.49e-05	0.67	0.46	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
UCEC	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-6.3	3.22e-09	1.51e-05	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-6.3	3.22e-09	1.51e-05	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	6.3	3.22e-09	1.51e-05	0.56	0.46	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	6.3	3.22e-09	1.51e-05	0.56	0.46	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	6.3	3.22e-09	1.51e-05	0.56	0.46	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	6.3	3.22e-09	1.51e-05	0.56	0.46	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	6.3	3.22e-09	1.51e-05	0.56	0.46	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	6.3	3.22e-09	1.51e-05	0.56	0.46	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-6.3	3.23e-09	1.51e-05	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
UCEC	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-6.3	3.25e-09	1.52e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
UCEC	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	6.29	3.27e-09	1.52e-05	0.5	0.46	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	6.29	3.27e-09	1.52e-05	0.5	0.46	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
UCEC	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	6.29	3.27e-09	1.53e-05	0.64	0.46	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
UCEC	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	6.29	3.28e-09	1.53e-05	0.5	0.46	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
UCEC	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	6.29	3.29e-09	1.53e-05	0.59	0.46	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
UCEC	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	6.29	3.29e-09	1.53e-05	0.59	0.46	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
UCEC	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	6.29	3.29e-09	1.53e-05	0.59	0.46	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
UCEC	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	6.29	3.29e-09	1.54e-05	0.65	0.46	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
UCEC	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-6.29	3.32e-09	1.55e-05	-0.59	-0.46	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
UCEC	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	6.29	3.32e-09	1.55e-05	0.49	0.46	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	6.29	3.33e-09	1.55e-05	0.53	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
UCEC	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-6.29	3.33e-09	1.55e-05	-0.58	-0.46	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
UCEC	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-6.29	3.33e-09	1.55e-05	-0.52	-0.46	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-6.29	3.33e-09	1.55e-05	-0.52	-0.46	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-6.29	3.33e-09	1.55e-05	-0.52	-0.46	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-6.29	3.33e-09	1.55e-05	-0.52	-0.46	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
UCEC	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	6.29	3.34e-09	1.56e-05	0.5	0.46	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
UCEC	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	6.29	3.36e-09	1.56e-05	0.7	0.46	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
UCEC	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	6.28	3.47e-09	1.61e-05	0.61	0.46	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	6.28	3.47e-09	1.61e-05	0.61	0.46	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	6.28	3.47e-09	1.61e-05	0.61	0.46	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	6.28	3.47e-09	1.61e-05	0.61	0.46	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	6.28	3.47e-09	1.61e-05	0.61	0.46	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	6.28	3.47e-09	1.61e-05	0.61	0.46	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	6.28	3.47e-09	1.61e-05	0.61	0.46	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	6.28	3.47e-09	1.61e-05	0.61	0.46	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
UCEC	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	6.28	3.47e-09	1.61e-05	0.58	0.46	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
UCEC	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	6.28	3.52e-09	1.63e-05	0.56	0.46	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
UCEC	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	6.28	3.54e-09	1.64e-05	0.57	0.46	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
UCEC	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	6.28	3.55e-09	1.64e-05	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
UCEC	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	6.28	3.55e-09	1.64e-05	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
UCEC	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	6.28	3.58e-09	1.65e-05	0.73	0.46	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
UCEC	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-6.27	3.65e-09	1.68e-05	-0.58	-0.46	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-6.27	3.65e-09	1.68e-05	-0.58	-0.46	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-6.27	3.65e-09	1.68e-05	-0.58	-0.46	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-6.27	3.65e-09	1.68e-05	-0.58	-0.46	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-6.27	3.65e-09	1.68e-05	-0.58	-0.46	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	6.27	3.65e-09	1.69e-05	0.66	0.46	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
UCEC	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-6.27	3.7e-09	1.71e-05	-0.57	-0.46	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-6.27	3.7e-09	1.71e-05	-0.57	-0.46	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
UCEC	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	6.27	3.71e-09	1.71e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	6.27	3.71e-09	1.71e-05	0.58	0.46	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
UCEC	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	6.27	3.73e-09	1.72e-05	0.5	0.46	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
UCEC	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	6.27	3.74e-09	1.72e-05	0.59	0.46	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	6.27	3.74e-09	1.72e-05	0.59	0.46	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
UCEC	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	6.27	3.74e-09	1.72e-05	0.57	0.46	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
UCEC	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	6.27	3.77e-09	1.73e-05	0.57	0.46	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	6.27	3.77e-09	1.73e-05	0.57	0.46	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
UCEC	cis	rs9402673	0.58	rs2297339	ENSG00000232876.1	CTA-212D2.2	-6.27	3.78e-09	1.74e-05	-0.49	-0.46	High light scatter reticulocyte count;Reticulocyte count;	chr6:135054853	chr6:135055033~135060550:+
UCEC	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	6.27	3.79e-09	1.74e-05	0.54	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
UCEC	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-6.26	3.8e-09	1.74e-05	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	6.26	3.82e-09	1.75e-05	0.68	0.46	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
UCEC	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	6.26	3.84e-09	1.76e-05	0.62	0.46	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
UCEC	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	6.26	3.88e-09	1.77e-05	0.5	0.46	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	6.26	3.88e-09	1.77e-05	0.5	0.46	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	6.26	3.88e-09	1.77e-05	0.5	0.46	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	6.26	3.88e-09	1.77e-05	0.5	0.46	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	6.26	3.88e-09	1.77e-05	0.5	0.46	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	6.26	3.88e-09	1.77e-05	0.5	0.46	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	6.26	3.88e-09	1.77e-05	0.5	0.46	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-6.26	3.88e-09	1.77e-05	-0.5	-0.46	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-6.26	3.88e-09	1.77e-05	-0.5	-0.46	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
UCEC	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	6.26	3.9e-09	1.78e-05	0.52	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
UCEC	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	6.26	3.9e-09	1.78e-05	0.58	0.46	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
UCEC	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	6.26	3.95e-09	1.8e-05	0.52	0.46	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
UCEC	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	6.25	4.02e-09	1.82e-05	0.5	0.46	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
UCEC	cis	rs7267979	0.868	rs6138553	ENSG00000276952.1	RP5-965G21.6	6.25	4.04e-09	1.83e-05	0.62	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25284915~25285588:-
UCEC	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-6.25	4.08e-09	1.85e-05	-0.48	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
UCEC	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-6.25	4.12e-09	1.86e-05	-0.5	-0.46	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
UCEC	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-6.25	4.13e-09	1.87e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
UCEC	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-6.25	4.13e-09	1.87e-05	-0.56	-0.46	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
UCEC	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-6.25	4.13e-09	1.87e-05	-0.66	-0.46	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
UCEC	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	6.25	4.15e-09	1.88e-05	0.5	0.46	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	6.25	4.15e-09	1.88e-05	0.5	0.46	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	6.25	4.15e-09	1.88e-05	0.5	0.46	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	6.25	4.15e-09	1.88e-05	0.5	0.46	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	6.25	4.15e-09	1.88e-05	0.5	0.46	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	6.25	4.15e-09	1.88e-05	0.5	0.46	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
UCEC	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	6.25	4.15e-09	1.88e-05	0.53	0.46	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
UCEC	cis	rs7267979	1	rs6107033	ENSG00000276952.1	RP5-965G21.6	-6.25	4.16e-09	1.88e-05	-0.61	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25284915~25285588:-
UCEC	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-6.24	4.21e-09	1.9e-05	-0.48	-0.46	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
UCEC	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	6.24	4.24e-09	1.91e-05	0.43	0.46	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
UCEC	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-6.24	4.26e-09	1.92e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-6.24	4.26e-09	1.92e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-6.24	4.26e-09	1.92e-05	-0.56	-0.46	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
UCEC	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	6.24	4.37e-09	1.96e-05	0.56	0.46	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-6.23	4.43e-09	1.99e-05	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-6.23	4.44e-09	1.99e-05	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
UCEC	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	6.23	4.44e-09	1.99e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
UCEC	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-6.23	4.55e-09	2.04e-05	-0.56	-0.45	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
UCEC	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	6.23	4.57e-09	2.05e-05	0.42	0.45	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
UCEC	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	6.23	4.57e-09	2.05e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
UCEC	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	6.23	4.61e-09	2.07e-05	0.61	0.45	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
UCEC	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	6.23	4.61e-09	2.07e-05	0.5	0.45	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
UCEC	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	6.23	4.64e-09	2.08e-05	0.49	0.45	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
UCEC	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-6.23	4.65e-09	2.08e-05	-0.57	-0.45	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
UCEC	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-6.22	4.66e-09	2.09e-05	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-6.22	4.66e-09	2.09e-05	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-6.22	4.66e-09	2.09e-05	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	6.22	4.71e-09	2.1e-05	0.59	0.45	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
UCEC	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	6.22	4.73e-09	2.11e-05	0.41	0.45	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
UCEC	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-6.22	4.73e-09	2.11e-05	-0.56	-0.45	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
UCEC	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-6.22	4.74e-09	2.12e-05	-0.47	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
UCEC	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	6.22	4.78e-09	2.13e-05	0.5	0.45	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	6.22	4.78e-09	2.13e-05	0.5	0.45	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
UCEC	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	6.22	4.78e-09	2.13e-05	0.56	0.45	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
UCEC	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-6.22	4.82e-09	2.15e-05	-0.54	-0.45	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
UCEC	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	6.22	4.82e-09	2.15e-05	0.57	0.45	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	6.22	4.87e-09	2.17e-05	0.61	0.45	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
UCEC	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	6.21	4.9e-09	2.18e-05	0.65	0.45	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
UCEC	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	6.21	4.9e-09	2.18e-05	0.53	0.45	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
UCEC	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-6.21	4.92e-09	2.19e-05	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-6.21	4.92e-09	2.19e-05	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-6.21	4.92e-09	2.19e-05	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-6.21	4.92e-09	2.19e-05	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-6.21	4.92e-09	2.19e-05	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-6.21	4.92e-09	2.19e-05	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
UCEC	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	6.21	4.92e-09	2.19e-05	0.53	0.45	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
UCEC	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-6.21	4.95e-09	2.2e-05	-0.48	-0.45	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
UCEC	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-6.21	4.99e-09	2.21e-05	-0.53	-0.45	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-6.21	4.99e-09	2.21e-05	-0.53	-0.45	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
UCEC	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	6.21	5e-09	2.22e-05	0.66	0.45	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
UCEC	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-6.21	5.01e-09	2.23e-05	-0.56	-0.45	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
UCEC	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	6.21	5.02e-09	2.23e-05	0.49	0.45	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
UCEC	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-6.21	5.05e-09	2.24e-05	-0.75	-0.45	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
UCEC	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	6.21	5.07e-09	2.25e-05	0.51	0.45	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
UCEC	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	6.21	5.1e-09	2.26e-05	0.74	0.45	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
UCEC	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	6.21	5.1e-09	2.26e-05	0.56	0.45	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
UCEC	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	6.21	5.11e-09	2.26e-05	0.54	0.45	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	6.21	5.11e-09	2.27e-05	0.42	0.45	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
UCEC	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-6.2	5.19e-09	2.3e-05	-0.57	-0.45	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-6.2	5.19e-09	2.3e-05	-0.57	-0.45	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
UCEC	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	6.2	5.2e-09	2.3e-05	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	6.2	5.2e-09	2.3e-05	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	6.2	5.2e-09	2.3e-05	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	6.2	5.2e-09	2.3e-05	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	6.2	5.2e-09	2.3e-05	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
UCEC	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-6.2	5.21e-09	2.3e-05	-0.56	-0.45	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
UCEC	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	6.2	5.24e-09	2.32e-05	0.5	0.45	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
UCEC	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	6.2	5.4e-09	2.38e-05	0.52	0.45	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
UCEC	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	6.2	5.4e-09	2.38e-05	0.52	0.45	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	6.2	5.4e-09	2.38e-05	0.52	0.45	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
UCEC	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	6.2	5.4e-09	2.38e-05	0.52	0.45	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
UCEC	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-6.2	5.4e-09	2.38e-05	-0.57	-0.45	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-6.2	5.4e-09	2.38e-05	-0.57	-0.45	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
UCEC	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-6.2	5.4e-09	2.38e-05	-0.57	-0.45	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-6.2	5.4e-09	2.38e-05	-0.57	-0.45	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
UCEC	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-6.2	5.41e-09	2.38e-05	-0.41	-0.45	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
UCEC	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	6.19	5.46e-09	2.4e-05	0.5	0.45	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
UCEC	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-6.19	5.48e-09	2.41e-05	-0.57	-0.45	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
UCEC	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-6.19	5.5e-09	2.41e-05	-0.48	-0.45	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
UCEC	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-6.19	5.58e-09	2.45e-05	-0.51	-0.45	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
UCEC	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	6.19	5.61e-09	2.46e-05	0.59	0.45	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
UCEC	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Depression;	chr6:28399886	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	6.19	5.65e-09	2.47e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
UCEC	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	6.18	5.73e-09	2.5e-05	0.54	0.45	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
UCEC	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-6.18	5.75e-09	2.51e-05	-0.49	-0.45	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
UCEC	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-6.18	5.78e-09	2.52e-05	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
UCEC	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	6.18	5.83e-09	2.54e-05	0.59	0.45	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	6.18	5.83e-09	2.54e-05	0.59	0.45	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	6.18	5.83e-09	2.54e-05	0.59	0.45	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	6.18	5.93e-09	2.58e-05	0.58	0.45	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
UCEC	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-6.18	5.94e-09	2.59e-05	-0.49	-0.45	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
UCEC	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	6.18	5.95e-09	2.59e-05	0.5	0.45	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
UCEC	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	6.17	6e-09	2.61e-05	0.7	0.45	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	6.17	6e-09	2.61e-05	0.7	0.45	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	6.17	6e-09	2.61e-05	0.7	0.45	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
UCEC	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	6.17	6.06e-09	2.64e-05	0.52	0.45	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
UCEC	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	6.17	6.06e-09	2.64e-05	0.52	0.45	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
UCEC	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	6.17	6.12e-09	2.66e-05	0.81	0.45	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
UCEC	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-6.17	6.13e-09	2.66e-05	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
UCEC	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	6.17	6.17e-09	2.67e-05	0.69	0.45	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
UCEC	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-6.17	6.21e-09	2.69e-05	-0.56	-0.45	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-6.17	6.21e-09	2.69e-05	-0.56	-0.45	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-6.17	6.21e-09	2.69e-05	-0.56	-0.45	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	6.17	6.29e-09	2.72e-05	0.55	0.45	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
UCEC	cis	rs7267979	0.903	rs6115109	ENSG00000276952.1	RP5-965G21.6	6.16	6.34e-09	2.74e-05	0.61	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.833	rs4619688	ENSG00000276952.1	RP5-965G21.6	6.16	6.34e-09	2.74e-05	0.61	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.903	rs6115118	ENSG00000276952.1	RP5-965G21.6	6.16	6.34e-09	2.74e-05	0.61	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.903	rs1118963	ENSG00000276952.1	RP5-965G21.6	6.16	6.34e-09	2.74e-05	0.61	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25284915~25285588:-
UCEC	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	6.16	6.38e-09	2.75e-05	0.58	0.45	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	6.16	6.38e-09	2.75e-05	0.58	0.45	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	6.16	6.38e-09	2.75e-05	0.58	0.45	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
UCEC	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	6.16	6.45e-09	2.78e-05	0.69	0.45	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
UCEC	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-6.16	6.46e-09	2.79e-05	-0.81	-0.45	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-6.16	6.46e-09	2.79e-05	-0.81	-0.45	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
UCEC	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-6.16	6.46e-09	2.79e-05	-0.81	-0.45	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
UCEC	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	6.16	6.59e-09	2.84e-05	0.85	0.45	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
UCEC	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	6.16	6.61e-09	2.84e-05	0.52	0.45	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
UCEC	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	6.15	6.72e-09	2.89e-05	0.56	0.45	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
UCEC	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-6.15	6.72e-09	2.89e-05	-0.42	-0.45	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
UCEC	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	6.15	6.74e-09	2.9e-05	0.45	0.45	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
UCEC	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-6.15	6.76e-09	2.9e-05	-0.56	-0.45	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
UCEC	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	6.15	6.77e-09	2.91e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	6.15	6.77e-09	2.91e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	6.15	6.77e-09	2.91e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	6.15	6.77e-09	2.91e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	6.15	6.77e-09	2.91e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	6.15	6.77e-09	2.91e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	6.15	6.77e-09	2.91e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	6.15	6.77e-09	2.91e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	6.15	6.77e-09	2.91e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
UCEC	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	6.15	6.78e-09	2.91e-05	0.53	0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
UCEC	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	6.15	6.85e-09	2.94e-05	0.56	0.45	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
UCEC	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	6.15	6.87e-09	2.94e-05	0.57	0.45	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-6.15	6.87e-09	2.94e-05	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
UCEC	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	6.15	6.96e-09	2.98e-05	0.49	0.45	Depression;	chr6:28379133	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	6.15	6.96e-09	2.98e-05	0.49	0.45	Depression;	chr6:28379168	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	6.15	6.96e-09	2.98e-05	0.49	0.45	Depression;	chr6:28386473	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	6.15	6.96e-09	2.98e-05	0.49	0.45	Depression;	chr6:28391932	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	6.15	6.96e-09	2.98e-05	0.49	0.45	Depression;	chr6:28399846	chr6:28176188~28176674:+
UCEC	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	6.14	7.03e-09	3e-05	0.58	0.45	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
UCEC	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-6.14	7.05e-09	3.01e-05	-0.63	-0.45	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
UCEC	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	6.14	7.05e-09	3.01e-05	0.49	0.45	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
UCEC	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	6.14	7.08e-09	3.03e-05	0.49	0.45	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
UCEC	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	6.14	7.14e-09	3.05e-05	0.5	0.45	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
UCEC	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-6.13	7.34e-09	3.12e-05	-0.92	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
UCEC	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-6.13	7.37e-09	3.14e-05	-0.56	-0.45	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-6.13	7.37e-09	3.14e-05	-0.56	-0.45	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
UCEC	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	6.13	7.4e-09	3.15e-05	0.6	0.45	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
UCEC	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	6.13	7.43e-09	3.16e-05	0.65	0.45	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
UCEC	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-6.13	7.53e-09	3.2e-05	-0.47	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
UCEC	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	6.13	7.58e-09	3.22e-05	0.48	0.45	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
UCEC	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-6.13	7.59e-09	3.22e-05	-0.56	-0.45	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-6.13	7.59e-09	3.22e-05	-0.56	-0.45	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-6.13	7.59e-09	3.22e-05	-0.56	-0.45	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-6.13	7.59e-09	3.22e-05	-0.56	-0.45	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	6.12	7.72e-09	3.27e-05	0.57	0.45	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
UCEC	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-6.12	7.74e-09	3.28e-05	-0.52	-0.45	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-6.12	7.74e-09	3.28e-05	-0.52	-0.45	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
UCEC	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	6.12	7.75e-09	3.28e-05	0.79	0.45	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	6.12	7.75e-09	3.28e-05	0.79	0.45	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
UCEC	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	6.12	7.78e-09	3.29e-05	0.59	0.45	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
UCEC	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	6.12	7.86e-09	3.32e-05	0.5	0.45	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
UCEC	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-6.12	7.89e-09	3.34e-05	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	6.12	7.9e-09	3.34e-05	0.48	0.45	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
UCEC	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-6.12	7.95e-09	3.36e-05	-0.52	-0.45	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	6.12	8.04e-09	3.4e-05	0.54	0.45	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	6.12	8.04e-09	3.4e-05	0.54	0.45	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
UCEC	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	6.11	8.15e-09	3.44e-05	0.56	0.45	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
UCEC	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	6.11	8.16e-09	3.44e-05	0.56	0.45	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
UCEC	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	6.11	8.19e-09	3.45e-05	0.48	0.45	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
UCEC	cis	rs7246967	0.673	rs8103012	ENSG00000198153.8	ZNF849P	-6.11	8.27e-09	3.49e-05	-0.51	-0.45	Bronchopulmonary dysplasia;	chr19:22696483	chr19:22685167~22686732:+
UCEC	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	6.11	8.32e-09	3.51e-05	0.66	0.45	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
UCEC	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	6.11	8.33e-09	3.51e-05	0.5	0.45	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	6.11	8.36e-09	3.52e-05	0.51	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
UCEC	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	6.11	8.38e-09	3.53e-05	0.52	0.45	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
UCEC	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	6.11	8.48e-09	3.57e-05	0.55	0.45	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
UCEC	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-6.1	8.51e-09	3.58e-05	-0.54	-0.45	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-6.1	8.51e-09	3.58e-05	-0.54	-0.45	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-6.1	8.51e-09	3.58e-05	-0.54	-0.45	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-6.1	8.51e-09	3.58e-05	-0.54	-0.45	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-6.1	8.66e-09	3.64e-05	-0.5	-0.45	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-6.1	8.67e-09	3.64e-05	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-6.1	8.76e-09	3.67e-05	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
UCEC	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	6.1	8.81e-09	3.69e-05	0.53	0.45	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
UCEC	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	6.1	8.81e-09	3.69e-05	0.53	0.45	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
UCEC	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	6.1	8.87e-09	3.71e-05	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	6.1	8.87e-09	3.71e-05	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	6.1	8.89e-09	3.72e-05	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	6.1	8.89e-09	3.72e-05	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	6.1	8.89e-09	3.72e-05	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	6.1	8.89e-09	3.72e-05	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
UCEC	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-6.1	8.91e-09	3.73e-05	-0.53	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
UCEC	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	6.09	8.98e-09	3.75e-05	0.45	0.45	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
UCEC	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	6.09	8.99e-09	3.75e-05	0.58	0.45	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
UCEC	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-6.09	8.99e-09	3.75e-05	-0.56	-0.45	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-6.09	8.99e-09	3.75e-05	-0.56	-0.45	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-6.09	8.99e-09	3.75e-05	-0.56	-0.45	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-6.09	8.99e-09	3.75e-05	-0.56	-0.45	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
UCEC	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-6.09	8.99e-09	3.75e-05	-0.48	-0.45	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
UCEC	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	6.09	9.06e-09	3.77e-05	0.59	0.45	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
UCEC	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	6.09	9.08e-09	3.78e-05	0.73	0.45	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
UCEC	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	6.09	9.35e-09	3.89e-05	0.49	0.45	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	6.09	9.35e-09	3.89e-05	0.49	0.45	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
UCEC	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	6.09	9.39e-09	3.9e-05	0.65	0.45	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
UCEC	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	6.08	9.42e-09	3.91e-05	0.5	0.45	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
UCEC	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-6.08	9.45e-09	3.92e-05	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	6.08	9.62e-09	3.98e-05	0.49	0.45	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
UCEC	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	6.08	9.67e-09	4e-05	0.51	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
UCEC	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	6.08	9.77e-09	4.04e-05	0.49	0.45	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
UCEC	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	6.08	9.82e-09	4.06e-05	0.57	0.45	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
UCEC	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-6.08	9.83e-09	4.07e-05	-0.6	-0.45	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
UCEC	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	6.08	9.84e-09	4.07e-05	0.64	0.45	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
UCEC	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	6.08	9.85e-09	4.07e-05	0.86	0.45	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
UCEC	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	6.08	9.86e-09	4.07e-05	0.52	0.45	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
UCEC	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-6.08	9.88e-09	4.08e-05	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
UCEC	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	6.07	9.99e-09	4.12e-05	0.49	0.45	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
UCEC	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	6.07	9.99e-09	4.12e-05	0.5	0.45	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	6.07	9.99e-09	4.12e-05	0.5	0.45	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
UCEC	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	6.07	1.01e-08	4.16e-05	0.5	0.45	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
UCEC	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-6.07	1.01e-08	4.18e-05	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
UCEC	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	6.07	1.02e-08	4.18e-05	0.56	0.45	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	6.07	1.02e-08	4.18e-05	0.56	0.45	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
UCEC	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	6.07	1.02e-08	4.19e-05	0.64	0.45	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	6.07	1.02e-08	4.19e-05	0.64	0.45	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	6.07	1.02e-08	4.19e-05	0.64	0.45	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	6.07	1.02e-08	4.19e-05	0.64	0.45	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	6.07	1.02e-08	4.19e-05	0.64	0.45	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	6.07	1.02e-08	4.19e-05	0.64	0.45	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	6.07	1.02e-08	4.19e-05	0.64	0.45	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	6.07	1.02e-08	4.19e-05	0.64	0.45	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
UCEC	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	6.07	1.02e-08	4.21e-05	0.5	0.45	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	6.07	1.02e-08	4.21e-05	0.5	0.45	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
UCEC	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	6.07	1.03e-08	4.24e-05	0.58	0.45	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
UCEC	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-6.07	1.04e-08	4.26e-05	-0.55	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
UCEC	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-6.06	1.05e-08	4.3e-05	-0.43	-0.44	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
UCEC	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	6.06	1.05e-08	4.3e-05	0.56	0.44	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
UCEC	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	6.06	1.06e-08	4.32e-05	0.49	0.44	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
UCEC	cis	rs2283792	0.846	rs240051	ENSG00000224086.5	LL22NC03-86G7.1	-6.06	1.06e-08	4.33e-05	-0.43	-0.44	Multiple sclerosis;	chr22:21909763	chr22:21938293~21977632:+
UCEC	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-6.06	1.06e-08	4.34e-05	-0.55	-0.44	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-6.06	1.06e-08	4.34e-05	-0.55	-0.44	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-6.06	1.06e-08	4.34e-05	-0.55	-0.44	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
UCEC	cis	rs1167827	0.839	rs794369	ENSG00000127957.15	PMS2P3	6.06	1.07e-08	4.35e-05	0.56	0.44	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75532853	chr7:75502930~75528148:-
UCEC	cis	rs2739330	0.731	rs2000468	ENSG00000272787.1	KB-226F1.2	-6.06	1.07e-08	4.35e-05	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23969211~23969873:+
UCEC	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	6.06	1.07e-08	4.38e-05	0.5	0.44	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
UCEC	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	6.06	1.08e-08	4.39e-05	0.63	0.44	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	6.06	1.08e-08	4.39e-05	0.63	0.44	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	6.06	1.08e-08	4.39e-05	0.63	0.44	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	6.06	1.08e-08	4.39e-05	0.63	0.44	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	6.06	1.08e-08	4.39e-05	0.63	0.44	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
UCEC	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	6.06	1.08e-08	4.39e-05	0.49	0.44	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-6.06	1.09e-08	4.42e-05	-0.51	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
UCEC	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-6.06	1.09e-08	4.44e-05	-0.59	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
UCEC	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-6.05	1.1e-08	4.49e-05	-0.54	-0.44	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
UCEC	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	6.05	1.11e-08	4.49e-05	0.5	0.44	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
UCEC	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-6.05	1.11e-08	4.51e-05	-0.55	-0.44	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
UCEC	cis	rs1930961	0.702	rs8137667	ENSG00000272977.1	CTA-390C10.10	-6.05	1.11e-08	4.52e-05	-0.86	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25512529	chr22:25476218~25479971:+
UCEC	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	6.05	1.12e-08	4.56e-05	0.64	0.44	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
UCEC	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	6.05	1.13e-08	4.56e-05	0.72	0.44	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	6.05	1.13e-08	4.56e-05	0.72	0.44	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
UCEC	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	6.05	1.13e-08	4.57e-05	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
UCEC	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	6.05	1.14e-08	4.63e-05	0.59	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
UCEC	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	6.05	1.14e-08	4.63e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
UCEC	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	6.04	1.15e-08	4.66e-05	0.51	0.44	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
UCEC	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	6.04	1.15e-08	4.66e-05	0.85	0.44	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	6.04	1.15e-08	4.66e-05	0.85	0.44	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	6.04	1.15e-08	4.66e-05	0.85	0.44	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
UCEC	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	6.04	1.15e-08	4.66e-05	0.49	0.44	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
UCEC	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	6.04	1.16e-08	4.67e-05	0.5	0.44	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
UCEC	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	6.04	1.16e-08	4.67e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	6.04	1.16e-08	4.67e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	6.04	1.16e-08	4.67e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	6.04	1.16e-08	4.67e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	6.04	1.16e-08	4.67e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	6.04	1.16e-08	4.67e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	6.04	1.16e-08	4.67e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	6.04	1.16e-08	4.67e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	6.04	1.16e-08	4.67e-05	0.47	0.44	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
UCEC	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	6.04	1.16e-08	4.68e-05	0.63	0.44	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	6.04	1.16e-08	4.68e-05	0.63	0.44	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
UCEC	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	6.04	1.16e-08	4.68e-05	0.5	0.44	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
UCEC	cis	rs1930961	0.702	rs7286366	ENSG00000272977.1	CTA-390C10.10	-6.04	1.2e-08	4.83e-05	-0.86	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25514348	chr22:25476218~25479971:+
UCEC	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-6.04	1.2e-08	4.83e-05	-0.54	-0.44	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-6.04	1.2e-08	4.83e-05	-0.54	-0.44	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-6.04	1.2e-08	4.83e-05	-0.54	-0.44	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-6.04	1.2e-08	4.83e-05	-0.54	-0.44	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-6.04	1.2e-08	4.83e-05	-0.54	-0.44	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	6.03	1.22e-08	4.88e-05	0.66	0.44	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	6.03	1.22e-08	4.88e-05	0.66	0.44	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
UCEC	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-6.03	1.22e-08	4.89e-05	-0.55	-0.44	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-6.03	1.22e-08	4.89e-05	-0.55	-0.44	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
UCEC	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	6.03	1.23e-08	4.91e-05	0.49	0.44	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
UCEC	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	6.03	1.24e-08	4.96e-05	0.59	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
UCEC	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	6.03	1.25e-08	5e-05	0.48	0.44	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
UCEC	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	6.03	1.25e-08	5e-05	0.83	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
UCEC	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-6.03	1.25e-08	5.01e-05	-0.55	-0.44	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-6.03	1.25e-08	5.01e-05	-0.55	-0.44	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-6.03	1.25e-08	5.01e-05	-0.55	-0.44	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-6.03	1.25e-08	5.01e-05	-0.55	-0.44	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
UCEC	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	6.03	1.26e-08	5.05e-05	0.49	0.44	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
UCEC	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	6.03	1.26e-08	5.05e-05	0.48	0.44	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	6.03	1.26e-08	5.05e-05	0.48	0.44	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	6.03	1.26e-08	5.05e-05	0.48	0.44	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
UCEC	cis	rs2739330	0.76	rs1007888	ENSG00000272787.1	KB-226F1.2	-6.02	1.29e-08	5.14e-05	-0.51	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23969211~23969873:+
UCEC	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-6.02	1.29e-08	5.16e-05	-0.53	-0.44	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
UCEC	cis	rs7267979	0.903	rs6115101	ENSG00000276952.1	RP5-965G21.6	6.02	1.29e-08	5.16e-05	0.61	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.868	rs6107019	ENSG00000276952.1	RP5-965G21.6	6.02	1.29e-08	5.16e-05	0.61	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25284915~25285588:-
UCEC	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	6.02	1.29e-08	5.16e-05	0.51	0.44	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-6.02	1.29e-08	5.16e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
UCEC	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	6.02	1.31e-08	5.23e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	6.02	1.33e-08	5.27e-05	0.49	0.44	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
UCEC	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	6.02	1.33e-08	5.27e-05	0.59	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
UCEC	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	6.02	1.33e-08	5.28e-05	0.66	0.44	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
UCEC	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	6.01	1.34e-08	5.33e-05	0.63	0.44	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
UCEC	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	6.01	1.34e-08	5.33e-05	0.63	0.44	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
UCEC	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	6.01	1.36e-08	5.4e-05	0.55	0.44	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
UCEC	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	6.01	1.39e-08	5.5e-05	0.55	0.44	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
UCEC	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	6.01	1.39e-08	5.52e-05	0.57	0.44	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
UCEC	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	6.01	1.39e-08	5.53e-05	0.7	0.44	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
UCEC	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	6	1.41e-08	5.59e-05	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
UCEC	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	6	1.41e-08	5.6e-05	0.76	0.44	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
UCEC	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	6	1.43e-08	5.67e-05	0.55	0.44	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
UCEC	cis	rs806321	0.619	rs1359613	ENSG00000237152.3	DLEU7-AS1	-6	1.44e-08	5.69e-05	-0.54	-0.44	Multiple sclerosis;	chr13:50192104	chr13:50807856~50849905:+
UCEC	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	6	1.44e-08	5.69e-05	0.45	0.44	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
UCEC	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	6	1.44e-08	5.7e-05	0.64	0.44	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
UCEC	cis	rs7267979	1	rs6076339	ENSG00000276952.1	RP5-965G21.6	-6	1.46e-08	5.75e-05	-0.59	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25284915~25285588:-
UCEC	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	6	1.47e-08	5.79e-05	0.38	0.44	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
UCEC	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	6	1.47e-08	5.79e-05	0.38	0.44	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
UCEC	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-5.99	1.48e-08	5.82e-05	-0.5	-0.44	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
UCEC	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	5.99	1.5e-08	5.91e-05	0.46	0.44	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
UCEC	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	5.99	1.5e-08	5.91e-05	0.64	0.44	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
UCEC	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-5.99	1.51e-08	5.93e-05	-0.74	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
UCEC	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-5.99	1.51e-08	5.94e-05	-0.47	-0.44	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-5.99	1.51e-08	5.94e-05	-0.47	-0.44	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-5.99	1.51e-08	5.94e-05	-0.47	-0.44	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
UCEC	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-5.99	1.52e-08	5.98e-05	-0.58	-0.44	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
UCEC	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-5.99	1.52e-08	5.98e-05	-0.58	-0.44	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
UCEC	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-5.99	1.52e-08	5.99e-05	-0.52	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-5.99	1.52e-08	5.99e-05	-0.52	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-5.99	1.52e-08	5.99e-05	-0.52	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-5.99	1.52e-08	5.99e-05	-0.52	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-5.99	1.52e-08	5.99e-05	-0.52	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
UCEC	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	5.99	1.54e-08	6.03e-05	0.53	0.44	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
UCEC	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-5.99	1.54e-08	6.04e-05	-0.51	-0.44	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
UCEC	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-5.99	1.54e-08	6.04e-05	-0.47	-0.44	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-5.99	1.54e-08	6.04e-05	-0.47	-0.44	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
UCEC	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-5.99	1.54e-08	6.04e-05	-0.56	-0.44	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
UCEC	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	5.98	1.55e-08	6.08e-05	0.48	0.44	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	5.98	1.55e-08	6.08e-05	0.48	0.44	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
UCEC	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	5.98	1.55e-08	6.09e-05	0.49	0.44	Depression;	chr6:28402301	chr6:28176188~28176674:+
UCEC	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	5.98	1.6e-08	6.25e-05	0.46	0.44	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
UCEC	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	5.98	1.6e-08	6.26e-05	0.77	0.44	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
UCEC	cis	rs7267979	0.706	rs6138542	ENSG00000276952.1	RP5-965G21.6	5.98	1.6e-08	6.26e-05	0.61	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25284915~25285588:-
UCEC	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-5.98	1.62e-08	6.32e-05	-0.48	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
UCEC	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	5.97	1.63e-08	6.34e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
UCEC	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-5.97	1.65e-08	6.41e-05	-0.53	-0.44	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
UCEC	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-5.97	1.65e-08	6.41e-05	-0.53	-0.44	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
UCEC	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	5.97	1.65e-08	6.42e-05	0.52	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	5.97	1.65e-08	6.42e-05	0.52	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	5.97	1.65e-08	6.42e-05	0.52	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
UCEC	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	5.97	1.65e-08	6.42e-05	0.83	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	5.97	1.65e-08	6.42e-05	0.83	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
UCEC	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-5.97	1.68e-08	6.52e-05	-0.53	-0.44	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
UCEC	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	5.97	1.68e-08	6.53e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	5.97	1.68e-08	6.53e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
UCEC	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	5.97	1.69e-08	6.54e-05	0.77	0.44	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
UCEC	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	5.97	1.69e-08	6.57e-05	0.54	0.44	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
UCEC	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-5.97	1.7e-08	6.6e-05	-0.51	-0.44	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
UCEC	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-5.96	1.71e-08	6.63e-05	-0.55	-0.44	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	5.96	1.71e-08	6.63e-05	0.55	0.44	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	5.96	1.71e-08	6.63e-05	0.55	0.44	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
UCEC	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	5.96	1.71e-08	6.64e-05	0.54	0.44	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
UCEC	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	5.96	1.71e-08	6.64e-05	0.62	0.44	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
UCEC	cis	rs7267979	0.903	rs6132819	ENSG00000276952.1	RP5-965G21.6	5.96	1.72e-08	6.65e-05	0.6	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25284915~25285588:-
UCEC	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	5.96	1.74e-08	6.75e-05	0.48	0.44	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
UCEC	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	5.96	1.75e-08	6.76e-05	0.69	0.44	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
UCEC	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-5.96	1.76e-08	6.81e-05	-0.54	-0.44	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
UCEC	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	5.96	1.76e-08	6.81e-05	0.63	0.44	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
UCEC	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-5.96	1.76e-08	6.82e-05	-0.56	-0.44	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	5.96	1.78e-08	6.87e-05	0.57	0.44	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	5.96	1.78e-08	6.87e-05	0.57	0.44	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
UCEC	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-5.96	1.78e-08	6.87e-05	-0.47	-0.44	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	5.96	1.78e-08	6.87e-05	0.47	0.44	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	5.96	1.78e-08	6.87e-05	0.47	0.44	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	5.96	1.78e-08	6.87e-05	0.47	0.44	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	5.96	1.78e-08	6.87e-05	0.47	0.44	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	5.96	1.78e-08	6.87e-05	0.47	0.44	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	5.96	1.78e-08	6.87e-05	0.47	0.44	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	5.96	1.78e-08	6.87e-05	0.47	0.44	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	5.96	1.78e-08	6.87e-05	0.47	0.44	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	5.96	1.78e-08	6.87e-05	0.47	0.44	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
UCEC	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-5.96	1.79e-08	6.9e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
UCEC	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-5.95	1.8e-08	6.91e-05	-0.73	-0.44	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
UCEC	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	5.95	1.82e-08	6.99e-05	0.52	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
UCEC	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-5.95	1.82e-08	6.99e-05	-0.42	-0.44	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
UCEC	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-5.95	1.82e-08	6.99e-05	-0.42	-0.44	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
UCEC	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	5.95	1.82e-08	6.99e-05	0.47	0.44	Depression;	chr6:28364057	chr6:28176188~28176674:+
UCEC	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-5.95	1.83e-08	7.02e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
UCEC	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	5.95	1.85e-08	7.13e-05	0.51	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
UCEC	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-5.95	1.86e-08	7.14e-05	-0.51	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
UCEC	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	5.95	1.86e-08	7.15e-05	0.57	0.44	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
UCEC	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-5.95	1.87e-08	7.17e-05	-0.43	-0.44	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
UCEC	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	5.95	1.88e-08	7.21e-05	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
UCEC	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-5.94	1.89e-08	7.26e-05	-0.52	-0.44	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
UCEC	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-5.94	1.9e-08	7.27e-05	-0.5	-0.44	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
UCEC	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
UCEC	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	5.94	1.92e-08	7.35e-05	0.48	0.44	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
UCEC	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-5.94	1.93e-08	7.35e-05	-0.53	-0.44	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
UCEC	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	5.94	1.96e-08	7.49e-05	0.48	0.44	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
UCEC	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	5.94	1.97e-08	7.5e-05	0.56	0.44	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
UCEC	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	5.93	1.98e-08	7.54e-05	0.47	0.44	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
UCEC	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-5.93	1.99e-08	7.59e-05	-0.56	-0.44	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
UCEC	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-5.93	2e-08	7.6e-05	-0.55	-0.44	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-5.93	2e-08	7.6e-05	-0.55	-0.44	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-5.93	2e-08	7.6e-05	-0.55	-0.44	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-5.93	2e-08	7.6e-05	-0.55	-0.44	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
UCEC	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-5.93	2e-08	7.61e-05	-0.49	-0.44	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
UCEC	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	5.93	2e-08	7.61e-05	0.85	0.44	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	5.93	2e-08	7.61e-05	0.85	0.44	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	5.93	2e-08	7.61e-05	0.85	0.44	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
UCEC	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-5.93	2.01e-08	7.65e-05	-0.73	-0.44	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
UCEC	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	5.93	2.01e-08	7.65e-05	0.6	0.44	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
UCEC	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	5.93	2.03e-08	7.7e-05	0.48	0.44	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
UCEC	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	5.93	2.03e-08	7.71e-05	0.53	0.44	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
UCEC	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-5.93	2.05e-08	7.79e-05	-0.56	-0.44	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
UCEC	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	5.93	2.06e-08	7.81e-05	0.49	0.44	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
UCEC	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	5.93	2.07e-08	7.84e-05	0.56	0.44	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
UCEC	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	5.93	2.07e-08	7.86e-05	0.5	0.44	Depression;	chr6:28251492	chr6:28176188~28176674:+
UCEC	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	5.92	2.09e-08	7.9e-05	0.47	0.44	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	5.92	2.09e-08	7.9e-05	0.47	0.44	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
UCEC	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	5.92	2.09e-08	7.91e-05	0.48	0.44	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
UCEC	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-5.92	2.09e-08	7.92e-05	-0.52	-0.44	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
UCEC	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	5.92	2.11e-08	8e-05	0.49	0.44	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
UCEC	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-5.92	2.13e-08	8.05e-05	-0.54	-0.44	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
UCEC	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-5.92	2.13e-08	8.05e-05	-0.54	-0.44	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
UCEC	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	5.91	2.21e-08	8.36e-05	0.69	0.44	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
UCEC	cis	rs948562	0.681	rs11822754	ENSG00000280010.1	AP001350.4	5.91	2.22e-08	8.37e-05	0.71	0.44	Lymphoma;	chr11:58665406	chr11:58627435~58628528:+
UCEC	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	5.91	2.24e-08	8.45e-05	0.46	0.44	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
UCEC	cis	rs948562	0.523	rs11827480	ENSG00000280010.1	AP001350.4	5.91	2.26e-08	8.5e-05	0.71	0.44	Lymphoma;	chr11:58665251	chr11:58627435~58628528:+
UCEC	cis	rs1167827	0.805	rs809439	ENSG00000127957.15	PMS2P3	5.91	2.28e-08	8.56e-05	0.54	0.44	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75502930~75528148:-
UCEC	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	5.91	2.28e-08	8.57e-05	0.5	0.44	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
UCEC	cis	rs2283792	0.542	rs9610500	ENSG00000228050.1	TOP3BP1	5.91	2.29e-08	8.6e-05	0.47	0.44	Multiple sclerosis;	chr22:21866877	chr22:22223187~22224566:-
UCEC	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	5.91	2.29e-08	8.6e-05	0.6	0.44	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
UCEC	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-5.9	2.3e-08	8.64e-05	-0.56	-0.44	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-5.9	2.3e-08	8.64e-05	-0.56	-0.44	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
UCEC	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-5.9	2.33e-08	8.74e-05	-0.57	-0.44	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-5.9	2.33e-08	8.74e-05	-0.57	-0.44	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
UCEC	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	5.9	2.35e-08	8.8e-05	0.55	0.44	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
UCEC	cis	rs1930961	0.702	rs8141205	ENSG00000272977.1	CTA-390C10.10	-5.9	2.35e-08	8.81e-05	-0.85	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25512200	chr22:25476218~25479971:+
UCEC	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-5.9	2.37e-08	8.87e-05	-0.55	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
UCEC	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
UCEC	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-5.9	2.4e-08	8.96e-05	-0.49	-0.43	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
UCEC	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-5.89	2.41e-08	9.01e-05	-0.56	-0.43	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	5.89	2.42e-08	9.02e-05	0.54	0.43	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
UCEC	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-5.89	2.42e-08	9.02e-05	-0.57	-0.43	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-5.89	2.42e-08	9.02e-05	-0.57	-0.43	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-5.89	2.42e-08	9.02e-05	-0.57	-0.43	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-5.89	2.42e-08	9.02e-05	-0.57	-0.43	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-5.89	2.42e-08	9.02e-05	-0.57	-0.43	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-5.89	2.42e-08	9.02e-05	-0.57	-0.43	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
UCEC	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-5.89	2.44e-08	9.11e-05	-0.56	-0.43	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
UCEC	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-5.89	2.46e-08	9.16e-05	-0.49	-0.43	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
UCEC	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	5.89	2.46e-08	9.18e-05	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
UCEC	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	5.89	2.47e-08	9.2e-05	0.73	0.43	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
UCEC	cis	rs806321	0.587	rs2765756	ENSG00000237152.3	DLEU7-AS1	-5.88	2.55e-08	9.48e-05	-0.53	-0.43	Multiple sclerosis;	chr13:50199350	chr13:50807856~50849905:+
UCEC	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-5.88	2.56e-08	9.54e-05	-0.56	-0.43	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
UCEC	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	5.88	2.57e-08	9.54e-05	0.71	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	5.88	2.57e-08	9.54e-05	0.71	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	5.88	2.57e-08	9.54e-05	0.71	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
UCEC	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	5.88	2.57e-08	9.54e-05	0.61	0.43	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
UCEC	cis	rs2739330	0.796	rs1006771	ENSG00000272787.1	KB-226F1.2	-5.88	2.57e-08	9.57e-05	-0.52	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23969211~23969873:+
UCEC	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	5.88	2.58e-08	9.6e-05	0.63	0.43	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
UCEC	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-5.88	2.61e-08	9.71e-05	-0.51	-0.43	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
UCEC	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-5.88	2.63e-08	9.75e-05	-0.51	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
UCEC	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	5.88	2.63e-08	9.75e-05	0.56	0.43	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
UCEC	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-5.88	2.63e-08	9.77e-05	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-5.88	2.63e-08	9.77e-05	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
UCEC	cis	rs6901004	0.605	rs2297939	ENSG00000271789.1	RP5-1112D6.7	-5.88	2.64e-08	9.79e-05	-0.56	-0.43	Blood metabolite levels;	chr6:111227959	chr6:111297126~111298510:+
UCEC	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-5.87	2.67e-08	9.89e-05	-0.39	-0.43	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-5.87	2.67e-08	9.89e-05	-0.39	-0.43	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
UCEC	cis	rs7267979	0.873	rs6115093	ENSG00000276952.1	RP5-965G21.6	5.87	2.7e-08	1e-04	0.61	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25284915~25285588:-
UCEC	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	5.87	2.71e-08	1e-04	0.44	0.43	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
UCEC	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-5.87	2.72e-08	0.000101	-0.62	-0.43	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
UCEC	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-5.87	2.72e-08	0.000101	-0.55	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
UCEC	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-5.87	2.73e-08	0.000101	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
UCEC	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	5.87	2.73e-08	0.000101	0.56	0.43	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	5.87	2.73e-08	0.000101	0.56	0.43	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	5.87	2.73e-08	0.000101	0.56	0.43	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	5.87	2.73e-08	0.000101	0.56	0.43	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	5.87	2.73e-08	0.000101	0.56	0.43	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	5.87	2.73e-08	0.000101	0.56	0.43	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-5.87	2.73e-08	0.000101	-0.56	-0.43	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
UCEC	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	5.87	2.74e-08	0.000101	0.52	0.43	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
UCEC	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	5.87	2.74e-08	0.000101	0.46	0.43	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	5.87	2.74e-08	0.000101	0.46	0.43	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
UCEC	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	5.87	2.74e-08	0.000101	0.57	0.43	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
UCEC	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-5.87	2.76e-08	0.000102	-0.49	-0.43	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
UCEC	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-5.87	2.76e-08	0.000102	-0.49	-0.43	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
UCEC	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-5.87	2.76e-08	0.000102	-0.49	-0.43	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
UCEC	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-5.87	2.76e-08	0.000102	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
UCEC	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	5.87	2.78e-08	0.000102	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	5.87	2.78e-08	0.000102	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	5.87	2.78e-08	0.000102	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	5.87	2.78e-08	0.000102	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	5.87	2.78e-08	0.000102	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	5.87	2.78e-08	0.000102	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	5.87	2.78e-08	0.000102	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	5.87	2.78e-08	0.000102	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	5.87	2.78e-08	0.000102	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
UCEC	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	5.86	2.82e-08	0.000104	0.47	0.43	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
UCEC	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	5.86	2.84e-08	0.000104	0.48	0.43	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
UCEC	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	5.86	2.91e-08	0.000107	0.4	0.43	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
UCEC	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	5.86	2.93e-08	0.000107	0.57	0.43	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
UCEC	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-5.86	2.93e-08	0.000108	-0.42	-0.43	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
UCEC	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-5.85	2.94e-08	0.000108	-0.55	-0.43	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
UCEC	cis	rs7267979	0.903	rs6107015	ENSG00000276952.1	RP5-965G21.6	5.85	2.98e-08	0.000109	0.6	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25284915~25285588:-
UCEC	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	5.85	3e-08	0.00011	0.47	0.43	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
UCEC	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-5.85	3.02e-08	0.00011	-0.5	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
UCEC	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	5.85	3.02e-08	0.00011	0.6	0.43	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	5.85	3.02e-08	0.00011	0.6	0.43	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	5.85	3.02e-08	0.00011	0.6	0.43	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	5.85	3.02e-08	0.00011	0.6	0.43	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
UCEC	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	5.85	3.05e-08	0.000111	0.57	0.43	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	5.85	3.05e-08	0.000111	0.57	0.43	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	5.85	3.05e-08	0.000111	0.57	0.43	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
UCEC	cis	rs4253772	0.513	rs9615345	ENSG00000277232.2	GTSE1-AS1	-5.84	3.08e-08	0.000112	-0.54	-0.43	Cholesterol, total;LDL cholesterol;	chr22:46317734	chr22:46295143~46296660:-
UCEC	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-5.84	3.08e-08	0.000112	-0.52	-0.43	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
UCEC	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	5.84	3.1e-08	0.000113	0.61	0.43	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
UCEC	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	5.84	3.11e-08	0.000113	0.58	0.43	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
UCEC	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-5.84	3.11e-08	0.000113	-0.47	-0.43	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
UCEC	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-5.84	3.13e-08	0.000113	-0.63	-0.43	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
UCEC	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-5.84	3.13e-08	0.000113	-0.48	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
UCEC	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	5.84	3.14e-08	0.000113	0.45	0.43	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
UCEC	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-5.84	3.18e-08	0.000113	-0.51	-0.43	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-5.84	3.18e-08	0.000113	-0.51	-0.43	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-5.84	3.18e-08	0.000113	-0.51	-0.43	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
UCEC	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-5.84	3.19e-08	0.000113	-0.45	-0.43	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	5.84	3.19e-08	0.000113	0.45	0.43	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	5.84	3.19e-08	0.000113	0.45	0.43	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	5.84	3.19e-08	0.000113	0.45	0.43	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	5.84	3.19e-08	0.000113	0.45	0.43	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	5.84	3.19e-08	0.000113	0.45	0.43	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	5.84	3.19e-08	0.000113	0.45	0.43	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
UCEC	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	5.84	3.19e-08	0.000113	0.62	0.43	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
UCEC	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	5.84	3.21e-08	0.000113	0.57	0.43	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
UCEC	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	5.83	3.25e-08	0.000113	0.49	0.43	Depression;	chr6:28430971	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	5.83	3.25e-08	0.000113	0.49	0.43	Depression;	chr6:28432562	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	5.83	3.27e-08	0.000114	0.48	0.43	Depression;	chr6:28431469	chr6:28176188~28176674:+
UCEC	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	5.83	3.31e-08	0.000115	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
UCEC	cis	rs7246967	0.673	rs4414616	ENSG00000198153.8	ZNF849P	-5.83	3.34e-08	0.000116	-0.48	-0.43	Bronchopulmonary dysplasia;	chr19:22649609	chr19:22685167~22686732:+
UCEC	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	5.83	3.34e-08	0.000116	0.73	0.43	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
UCEC	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-5.82	3.39e-08	0.000118	-0.51	-0.43	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-5.82	3.39e-08	0.000118	-0.51	-0.43	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-5.82	3.39e-08	0.000118	-0.51	-0.43	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-5.82	3.39e-08	0.000118	-0.51	-0.43	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-5.82	3.39e-08	0.000118	-0.51	-0.43	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
UCEC	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-5.82	3.42e-08	0.000118	-0.49	-0.43	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
UCEC	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	5.82	3.43e-08	0.000119	0.58	0.43	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	5.82	3.44e-08	0.000119	0.48	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
UCEC	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-5.82	3.45e-08	0.00012	-0.56	-0.43	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
UCEC	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	5.82	3.45e-08	0.00012	0.48	0.43	Depression;	chr6:28428413	chr6:28176188~28176674:+
UCEC	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-5.82	3.5e-08	0.000121	-0.46	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
UCEC	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-5.82	3.51e-08	0.000121	-0.55	-0.43	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
UCEC	cis	rs948562	0.681	rs11229573	ENSG00000280010.1	AP001350.4	-5.82	3.51e-08	0.000121	-0.72	-0.43	Lymphoma;	chr11:58667095	chr11:58627435~58628528:+
UCEC	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	5.81	3.58e-08	0.000123	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	5.81	3.58e-08	0.000123	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	5.81	3.58e-08	0.000123	0.87	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
UCEC	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	5.81	3.59e-08	0.000124	0.51	0.43	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
UCEC	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	5.81	3.6e-08	0.000124	0.46	0.43	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
UCEC	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-5.81	3.61e-08	0.000124	-0.53	-0.43	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-5.81	3.61e-08	0.000124	-0.53	-0.43	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-5.81	3.61e-08	0.000124	-0.53	-0.43	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-5.81	3.61e-08	0.000124	-0.53	-0.43	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
UCEC	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-5.81	3.62e-08	0.000124	-0.61	-0.43	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
UCEC	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-5.81	3.63e-08	0.000125	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
UCEC	cis	rs8062405	0.789	rs151174	ENSG00000259982.1	CDC37P1	5.81	3.64e-08	0.000125	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28700294~28701540:-
UCEC	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-5.81	3.65e-08	0.000125	-0.51	-0.43	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-5.81	3.65e-08	0.000125	-0.51	-0.43	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
UCEC	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	5.81	3.66e-08	0.000125	0.6	0.43	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
UCEC	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-5.81	3.7e-08	0.000127	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
UCEC	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-5.81	3.7e-08	0.000127	-0.58	-0.43	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-5.81	3.7e-08	0.000127	-0.58	-0.43	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
UCEC	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	5.81	3.71e-08	0.000127	0.69	0.43	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
UCEC	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
UCEC	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-5.81	3.73e-08	0.000127	-0.5	-0.43	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
UCEC	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-5.81	3.73e-08	0.000127	-0.56	-0.43	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
UCEC	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	5.81	3.74e-08	0.000128	0.54	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
UCEC	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-5.81	3.74e-08	0.000128	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
UCEC	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	5.8	3.78e-08	0.000129	0.53	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
UCEC	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-5.8	3.79e-08	0.000129	-0.54	-0.43	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
UCEC	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-5.8	3.79e-08	0.000129	-0.5	-0.43	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-5.8	3.79e-08	0.000129	-0.5	-0.43	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
UCEC	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	5.8	3.82e-08	0.00013	0.48	0.43	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
UCEC	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	5.8	3.83e-08	0.00013	0.66	0.43	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
UCEC	cis	rs7246967	0.673	rs55932152	ENSG00000198153.8	ZNF849P	-5.8	3.84e-08	0.000131	-0.49	-0.43	Bronchopulmonary dysplasia;	chr19:22690626	chr19:22685167~22686732:+
UCEC	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	5.8	3.85e-08	0.000131	0.48	0.43	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
UCEC	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-5.8	3.86e-08	0.000131	-0.52	-0.43	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-5.8	3.86e-08	0.000131	-0.52	-0.43	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
UCEC	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	5.8	3.89e-08	0.000132	0.55	0.43	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
UCEC	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-5.79	3.95e-08	0.000134	-0.5	-0.43	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
UCEC	cis	rs7267979	0.833	rs6138556	ENSG00000276952.1	RP5-965G21.6	5.79	3.96e-08	0.000135	0.58	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25284915~25285588:-
UCEC	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-5.79	3.97e-08	0.000135	-0.55	-0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
UCEC	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-5.79	3.98e-08	0.000135	-0.55	-0.43	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	5.79	3.99e-08	0.000135	0.47	0.43	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	5.79	4.01e-08	0.000136	0.43	0.43	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
UCEC	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-5.79	4.03e-08	0.000137	-0.51	-0.43	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
UCEC	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	5.79	4.04e-08	0.000137	0.53	0.43	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
UCEC	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	5.79	4.05e-08	0.000137	0.48	0.43	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
UCEC	cis	rs8005677	0.77	rs56180741	ENSG00000257285.4	RP11-298I3.1	5.79	4.05e-08	0.000137	0.43	0.43	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.828	rs3794452	ENSG00000257285.4	RP11-298I3.1	5.79	4.05e-08	0.000137	0.43	0.43	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:22929609~22955562:+
UCEC	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	5.79	4.1e-08	0.000138	0.5	0.43	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
UCEC	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-5.79	4.11e-08	0.000139	-0.57	-0.43	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
UCEC	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-5.79	4.11e-08	0.000139	-0.57	-0.43	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
UCEC	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-5.79	4.11e-08	0.000139	-0.57	-0.43	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
UCEC	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	5.79	4.12e-08	0.000139	0.5	0.43	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
UCEC	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-5.78	4.13e-08	0.000139	-0.53	-0.43	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
UCEC	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	5.78	4.14e-08	0.00014	0.64	0.43	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
UCEC	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	5.78	4.14e-08	0.00014	0.64	0.43	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
UCEC	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	5.78	4.18e-08	0.000141	0.5	0.43	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	5.78	4.18e-08	0.000141	0.5	0.43	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
UCEC	cis	rs7246967	0.611	rs12978511	ENSG00000198153.8	ZNF849P	-5.78	4.19e-08	0.000141	-0.49	-0.43	Bronchopulmonary dysplasia;	chr19:22636414	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12978964	ENSG00000198153.8	ZNF849P	-5.78	4.19e-08	0.000141	-0.49	-0.43	Bronchopulmonary dysplasia;	chr19:22636442	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs118059742	ENSG00000198153.8	ZNF849P	-5.78	4.19e-08	0.000141	-0.49	-0.43	Bronchopulmonary dysplasia;	chr19:22636644	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs56663398	ENSG00000198153.8	ZNF849P	-5.78	4.19e-08	0.000141	-0.49	-0.43	Bronchopulmonary dysplasia;	chr19:22637398	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs35731237	ENSG00000198153.8	ZNF849P	-5.78	4.19e-08	0.000141	-0.49	-0.43	Bronchopulmonary dysplasia;	chr19:22637708	chr19:22685167~22686732:+
UCEC	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	5.78	4.24e-08	0.000142	0.5	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
UCEC	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-5.78	4.24e-08	0.000143	-0.54	-0.43	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
UCEC	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-5.78	4.25e-08	0.000143	-0.51	-0.43	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
UCEC	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-5.78	4.26e-08	0.000143	-0.47	-0.43	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
UCEC	cis	rs7267979	1	rs13038834	ENSG00000276952.1	RP5-965G21.6	5.78	4.32e-08	0.000145	0.57	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25284915~25285588:-
UCEC	cis	rs806321	0.587	rs2066632	ENSG00000237152.3	DLEU7-AS1	5.78	4.32e-08	0.000145	0.56	0.43	Multiple sclerosis;	chr13:50187807	chr13:50807856~50849905:+
UCEC	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	5.77	4.35e-08	0.000146	0.61	0.43	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
UCEC	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-5.77	4.36e-08	0.000146	-0.54	-0.43	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-5.77	4.36e-08	0.000146	-0.54	-0.43	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-5.77	4.36e-08	0.000146	-0.54	-0.43	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-5.77	4.36e-08	0.000146	-0.54	-0.43	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-5.77	4.36e-08	0.000146	-0.54	-0.43	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
UCEC	cis	rs806321	0.556	rs2066634	ENSG00000237152.3	DLEU7-AS1	-5.77	4.36e-08	0.000146	-0.54	-0.43	Multiple sclerosis;	chr13:50190346	chr13:50807856~50849905:+
UCEC	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	5.77	4.37e-08	0.000146	0.57	0.43	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
UCEC	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-5.77	4.38e-08	0.000146	-0.54	-0.43	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
UCEC	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	5.77	4.38e-08	0.000146	0.42	0.43	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
UCEC	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	5.77	4.39e-08	0.000147	0.44	0.43	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
UCEC	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	5.77	4.39e-08	0.000147	0.48	0.43	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
UCEC	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	5.77	4.48e-08	0.00015	0.47	0.43	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
UCEC	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-5.77	4.49e-08	0.00015	-0.51	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
UCEC	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-5.76	4.55e-08	0.000152	-0.5	-0.43	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
UCEC	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-5.76	4.58e-08	0.000152	-0.51	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
UCEC	cis	rs806321	0.587	rs2740516	ENSG00000237152.3	DLEU7-AS1	-5.76	4.61e-08	0.000153	-0.53	-0.43	Multiple sclerosis;	chr13:50187483	chr13:50807856~50849905:+
UCEC	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	5.76	4.63e-08	0.000154	0.48	0.43	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	5.76	4.63e-08	0.000154	0.48	0.43	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
UCEC	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-5.76	4.64e-08	0.000154	-0.58	-0.43	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
UCEC	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-5.76	4.65e-08	0.000154	-0.58	-0.43	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
UCEC	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	5.76	4.65e-08	0.000154	0.49	0.43	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
UCEC	cis	rs7267979	1	rs6050566	ENSG00000276952.1	RP5-965G21.6	-5.76	4.67e-08	0.000155	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4813563	ENSG00000276952.1	RP5-965G21.6	-5.76	4.67e-08	0.000155	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs6037103	ENSG00000276952.1	RP5-965G21.6	-5.76	4.67e-08	0.000155	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.934	rs4815423	ENSG00000276952.1	RP5-965G21.6	-5.76	4.67e-08	0.000155	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815424	ENSG00000276952.1	RP5-965G21.6	-5.76	4.67e-08	0.000155	-0.55	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25284915~25285588:-
UCEC	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-5.76	4.7e-08	0.000156	-0.54	-0.43	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
UCEC	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-5.76	4.71e-08	0.000156	-0.51	-0.43	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
UCEC	cis	rs8005677	0.828	rs2295682	ENSG00000257285.4	RP11-298I3.1	5.76	4.73e-08	0.000157	0.42	0.43	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:22929609~22955562:+
UCEC	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-5.76	4.75e-08	0.000157	-0.57	-0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
UCEC	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	5.76	4.76e-08	0.000157	0.5	0.43	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
UCEC	cis	rs9549367	0.601	rs558869	ENSG00000269125.1	RP11-98F14.11	5.76	4.76e-08	0.000157	0.5	0.43	Platelet distribution width;	chr13:113195618	chr13:113165002~113165183:-
UCEC	cis	rs9549367	0.713	rs2480949	ENSG00000269125.1	RP11-98F14.11	5.76	4.76e-08	0.000157	0.5	0.43	Platelet distribution width;	chr13:113198835	chr13:113165002~113165183:-
UCEC	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	5.75	4.78e-08	0.000157	0.59	0.43	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
UCEC	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	5.75	4.78e-08	0.000157	0.49	0.43	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
UCEC	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-5.75	4.86e-08	0.00016	-0.58	-0.43	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
UCEC	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-5.75	4.86e-08	0.00016	-0.54	-0.43	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
UCEC	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	5.75	4.88e-08	0.00016	0.44	0.43	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
UCEC	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-5.75	4.88e-08	0.00016	-0.72	-0.43	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
UCEC	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-5.75	4.91e-08	0.000161	-0.48	-0.43	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
UCEC	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	5.75	4.93e-08	0.000162	0.49	0.43	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
UCEC	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-5.75	4.93e-08	0.000162	-0.6	-0.43	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
UCEC	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-5.75	4.95e-08	0.000162	-0.55	-0.43	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
UCEC	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	5.75	4.99e-08	0.000164	0.47	0.43	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
UCEC	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	5.75	5e-08	0.000164	0.6	0.43	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	5.75	5e-08	0.000164	0.6	0.43	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	5.75	5e-08	0.000164	0.6	0.43	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	5.75	5e-08	0.000164	0.6	0.43	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	5.75	5e-08	0.000164	0.6	0.43	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	5.75	5e-08	0.000164	0.6	0.43	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	5.75	5e-08	0.000164	0.6	0.43	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	5.75	5e-08	0.000164	0.6	0.43	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	5.75	5e-08	0.000164	0.6	0.43	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
UCEC	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-5.74	5.05e-08	0.000165	-0.58	-0.43	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
UCEC	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-5.74	5.06e-08	0.000165	-0.55	-0.43	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-5.74	5.06e-08	0.000165	-0.55	-0.43	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-5.74	5.06e-08	0.000165	-0.55	-0.43	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-5.74	5.06e-08	0.000165	-0.55	-0.43	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
UCEC	cis	rs4253772	0.614	rs11090859	ENSG00000277232.2	GTSE1-AS1	-5.74	5.09e-08	0.000166	-0.54	-0.43	Cholesterol, total;LDL cholesterol;	chr22:46291563	chr22:46295143~46296660:-
UCEC	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	5.74	5.13e-08	0.000167	0.5	0.43	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
UCEC	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	5.74	5.16e-08	0.000168	0.49	0.43	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
UCEC	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-5.74	5.22e-08	0.00017	-0.61	-0.43	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
UCEC	cis	rs12429206	0.587	rs17589481	ENSG00000233672.5	RNASEH2B-AS1	-5.74	5.22e-08	0.00017	-0.59	-0.43	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50892028	chr13:50862172~50910764:-
UCEC	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	5.74	5.22e-08	0.00017	0.62	0.43	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
UCEC	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-5.73	5.26e-08	0.000171	-0.54	-0.43	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
UCEC	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-5.73	5.29e-08	0.000172	-0.51	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
UCEC	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	5.73	5.29e-08	0.000172	0.52	0.43	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
UCEC	cis	rs9549367	0.673	rs575453	ENSG00000269125.1	RP11-98F14.11	5.73	5.29e-08	0.000172	0.5	0.43	Platelet distribution width;	chr13:113183557	chr13:113165002~113165183:-
UCEC	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	5.73	5.36e-08	0.000173	0.47	0.42	Height;	chr3:53082835	chr3:53064283~53065091:-
UCEC	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	5.73	5.37e-08	0.000173	0.53	0.42	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	5.73	5.37e-08	0.000173	0.53	0.42	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
UCEC	cis	rs7246967	0.673	rs12979173	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22637879	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12979848	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22637996	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs6511367	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22638468	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs7250964	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22639692	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs7250343	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22640043	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs35007247	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22640121	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs73030508	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22643230	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs73030511	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22643232	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs34682021	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22643926	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs34897132	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22644089	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs60021625	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22646752	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs59567211	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22647080	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs28787949	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22647554	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs67631531	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22647664	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.541	rs74169641	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22647774	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs56271774	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22648525	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs35740274	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22648611	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs4627499	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22649831	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs1835993	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22650235	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs1835994	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22650243	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs66620859	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22654428	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs73020703	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22661537	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12980342	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22666555	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs3951784	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22669124	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs3951785	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22669126	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs7250608	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22670254	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs4244915	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22671336	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs8104052	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22675002	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs75360744	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22675154	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12975767	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22680007	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.604	rs12975793	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22680042	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs57013651	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22680225	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12979264	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22682332	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs34795935	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22682386	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs7252925	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22683006	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs7253063	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22683095	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs7254097	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22683098	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs3902164	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22683479	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs6511374	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22683568	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs8103875	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22684060	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs4933024	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22684261	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs8104327	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22684357	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs8104564	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22684405	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs8107724	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22684612	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs12973264	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22684947	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs597906	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22685403	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs35335083	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22686790	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs8102172	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22687217	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs8102006	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22687301	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs3853652	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22689111	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs3853653	ENSG00000198153.8	ZNF849P	-5.73	5.38e-08	0.000173	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22689130	chr19:22685167~22686732:+
UCEC	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-5.73	5.45e-08	0.000175	-0.55	-0.42	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-5.73	5.45e-08	0.000175	-0.55	-0.42	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-5.73	5.45e-08	0.000175	-0.55	-0.42	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-5.73	5.45e-08	0.000175	-0.55	-0.42	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
UCEC	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-5.73	5.47e-08	0.000175	-0.48	-0.42	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
UCEC	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	5.73	5.5e-08	0.000176	0.48	0.42	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
UCEC	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	5.72	5.52e-08	0.000177	0.52	0.42	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
UCEC	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	5.72	5.56e-08	0.000178	0.53	0.42	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
UCEC	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	5.72	5.56e-08	0.000178	0.6	0.42	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
UCEC	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-5.72	5.57e-08	0.000178	-0.49	-0.42	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-5.72	5.57e-08	0.000178	-0.49	-0.42	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-5.72	5.57e-08	0.000178	-0.49	-0.42	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
UCEC	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	5.72	5.58e-08	0.000178	0.45	0.42	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
UCEC	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	5.72	5.59e-08	0.000179	0.6	0.42	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
UCEC	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-5.72	5.62e-08	0.00018	-0.55	-0.42	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
UCEC	cis	rs7246967	0.673	rs8106180	ENSG00000198153.8	ZNF849P	-5.72	5.66e-08	0.000181	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22696558	chr19:22685167~22686732:+
UCEC	cis	rs507080	0.769	rs12290522	ENSG00000255239.1	AP002954.6	5.72	5.69e-08	0.000181	0.48	0.42	Serum metabolite levels;	chr11:118615610	chr11:118688039~118690600:-
UCEC	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	5.72	5.69e-08	0.000181	0.49	0.42	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
UCEC	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	5.72	5.7e-08	0.000182	0.67	0.42	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
UCEC	cis	rs4253772	0.53	rs6008662	ENSG00000277232.2	GTSE1-AS1	-5.72	5.78e-08	0.000184	-0.53	-0.42	Cholesterol, total;LDL cholesterol;	chr22:46318020	chr22:46295143~46296660:-
UCEC	cis	rs948562	0.681	rs78570565	ENSG00000280010.1	AP001350.4	5.71	5.8e-08	0.000184	0.7	0.42	Lymphoma;	chr11:58664597	chr11:58627435~58628528:+
UCEC	cis	rs7246967	0.604	rs58536761	ENSG00000198153.8	ZNF849P	-5.71	5.82e-08	0.000185	-0.5	-0.42	Bronchopulmonary dysplasia;	chr19:22697529	chr19:22685167~22686732:+
UCEC	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-5.71	5.84e-08	0.000185	-0.51	-0.42	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
UCEC	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-5.71	5.87e-08	0.000186	-0.55	-0.42	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
UCEC	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	5.71	5.89e-08	0.000187	0.61	0.42	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
UCEC	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	5.71	5.95e-08	0.000188	0.47	0.42	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	5.71	5.95e-08	0.000188	0.47	0.42	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	5.71	5.95e-08	0.000188	0.47	0.42	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	5.71	5.95e-08	0.000188	0.47	0.42	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	5.71	5.95e-08	0.000188	0.47	0.42	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
UCEC	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-5.71	5.96e-08	0.000189	-0.58	-0.42	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
UCEC	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-5.71	5.98e-08	0.000189	-0.48	-0.42	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
UCEC	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	5.71	5.99e-08	0.00019	0.73	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
UCEC	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-5.71	6.01e-08	0.00019	-0.57	-0.42	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
UCEC	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	5.7	6.11e-08	0.000193	0.54	0.42	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
UCEC	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-5.7	6.12e-08	0.000193	-0.71	-0.42	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
UCEC	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	5.7	6.21e-08	0.000196	0.51	0.42	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
UCEC	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-5.7	6.21e-08	0.000196	-0.65	-0.42	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
UCEC	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	5.7	6.26e-08	0.000197	0.55	0.42	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
UCEC	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-5.7	6.28e-08	0.000198	-0.83	-0.42	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
UCEC	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	5.7	6.29e-08	0.000198	0.6	0.42	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	5.7	6.29e-08	0.000198	0.6	0.42	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
UCEC	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	5.7	6.3e-08	0.000198	0.44	0.42	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	5.7	6.3e-08	0.000198	0.57	0.42	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
UCEC	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-5.7	6.3e-08	0.000198	-0.54	-0.42	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-5.7	6.3e-08	0.000198	-0.54	-0.42	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-5.7	6.3e-08	0.000198	-0.54	-0.42	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
UCEC	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	5.7	6.34e-08	0.000199	0.49	0.42	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
UCEC	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	5.7	6.34e-08	2e-04	0.5	0.42	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
UCEC	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-5.7	6.35e-08	2e-04	-0.54	-0.42	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
UCEC	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-5.69	6.37e-08	2e-04	-0.62	-0.42	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
UCEC	cis	rs948562	0.681	rs10792180	ENSG00000280010.1	AP001350.4	5.69	6.45e-08	0.000202	0.7	0.42	Lymphoma;	chr11:58660116	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs5020736	ENSG00000280010.1	AP001350.4	5.69	6.45e-08	0.000202	0.7	0.42	Lymphoma;	chr11:58661000	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.627	rs5020737	ENSG00000280010.1	AP001350.4	5.69	6.45e-08	0.000202	0.7	0.42	Lymphoma;	chr11:58661003	chr11:58627435~58628528:+
UCEC	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	5.69	6.47e-08	0.000203	0.43	0.42	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
UCEC	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	5.69	6.48e-08	0.000203	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	5.69	6.48e-08	0.000203	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	5.69	6.48e-08	0.000203	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	5.69	6.48e-08	0.000203	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
UCEC	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-5.69	6.55e-08	0.000205	-0.54	-0.42	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
UCEC	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-5.69	6.56e-08	0.000205	-0.48	-0.42	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-5.69	6.56e-08	0.000205	-0.48	-0.42	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-5.69	6.56e-08	0.000205	-0.48	-0.42	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
UCEC	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	5.69	6.6e-08	0.000207	0.49	0.42	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
UCEC	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	5.69	6.61e-08	0.000207	0.79	0.42	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	5.69	6.61e-08	0.000207	0.79	0.42	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
UCEC	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-5.69	6.63e-08	0.000207	-0.57	-0.42	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
UCEC	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	5.69	6.63e-08	0.000208	0.34	0.42	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
UCEC	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	5.69	6.65e-08	0.000208	0.5	0.42	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
UCEC	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	5.69	6.65e-08	0.000208	0.46	0.42	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
UCEC	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	5.69	6.66e-08	0.000208	0.5	0.42	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
UCEC	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	5.69	6.68e-08	0.000209	0.48	0.42	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
UCEC	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-5.68	6.74e-08	0.000211	-0.53	-0.42	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-5.68	6.74e-08	0.000211	-0.53	-0.42	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-5.68	6.74e-08	0.000211	-0.53	-0.42	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
UCEC	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	5.68	6.75e-08	0.000211	0.52	0.42	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
UCEC	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	5.68	6.75e-08	0.000211	0.5	0.42	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
UCEC	cis	rs9549367	0.713	rs2476319	ENSG00000269125.1	RP11-98F14.11	5.68	6.75e-08	0.000211	0.5	0.42	Platelet distribution width;	chr13:113182205	chr13:113165002~113165183:-
UCEC	cis	rs9549367	0.713	rs553316	ENSG00000269125.1	RP11-98F14.11	5.68	6.75e-08	0.000211	0.5	0.42	Platelet distribution width;	chr13:113183701	chr13:113165002~113165183:-
UCEC	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	5.68	6.75e-08	0.000211	0.5	0.42	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
UCEC	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-5.68	6.81e-08	0.000212	-0.48	-0.42	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
UCEC	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	5.68	6.9e-08	0.000214	0.53	0.42	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
UCEC	cis	rs9549367	0.713	rs1755690	ENSG00000269125.1	RP11-98F14.11	5.68	6.92e-08	0.000215	0.49	0.42	Platelet distribution width;	chr13:113169952	chr13:113165002~113165183:-
UCEC	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	5.68	6.93e-08	0.000215	0.51	0.42	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
UCEC	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-5.68	7.01e-08	0.000217	-0.56	-0.42	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
UCEC	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	5.67	7.15e-08	0.000221	0.52	0.42	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
UCEC	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	5.67	7.15e-08	0.000221	0.52	0.42	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
UCEC	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	5.67	7.18e-08	0.000222	0.5	0.42	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
UCEC	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	5.67	7.21e-08	0.000222	0.6	0.42	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
UCEC	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	5.67	7.27e-08	0.000224	0.51	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	5.67	7.27e-08	0.000224	0.51	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
UCEC	cis	rs8005677	0.828	rs2295680	ENSG00000257285.4	RP11-298I3.1	-5.67	7.27e-08	0.000224	-0.42	-0.42	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:22929609~22955562:+
UCEC	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	5.67	7.31e-08	0.000225	0.46	0.42	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
UCEC	cis	rs7246967	0.673	rs2915932	ENSG00000198153.8	ZNF849P	-5.67	7.31e-08	0.000225	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22660899	chr19:22685167~22686732:+
UCEC	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	5.66	7.49e-08	0.00023	0.48	0.42	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
UCEC	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	5.66	7.49e-08	0.00023	0.48	0.42	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
UCEC	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-5.66	7.5e-08	0.00023	-0.57	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
UCEC	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-5.66	7.55e-08	0.000232	-0.67	-0.42	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
UCEC	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	5.66	7.59e-08	0.000233	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	5.66	7.59e-08	0.000233	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	5.66	7.59e-08	0.000233	0.86	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
UCEC	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-5.66	7.6e-08	0.000233	-0.79	-0.42	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
UCEC	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	5.66	7.6e-08	0.000233	0.46	0.42	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
UCEC	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	5.66	7.62e-08	0.000234	0.49	0.42	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	5.66	7.62e-08	0.000234	0.49	0.42	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	5.66	7.62e-08	0.000234	0.49	0.42	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
UCEC	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	5.66	7.62e-08	0.000234	0.51	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
UCEC	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-5.66	7.63e-08	0.000234	-0.5	-0.42	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
UCEC	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	5.66	7.63e-08	0.000234	0.58	0.42	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
UCEC	cis	rs7246967	0.551	rs56968124	ENSG00000198153.8	ZNF849P	-5.66	7.67e-08	0.000234	-0.47	-0.42	Bronchopulmonary dysplasia;	chr19:22631647	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs57775631	ENSG00000198153.8	ZNF849P	-5.66	7.67e-08	0.000234	-0.47	-0.42	Bronchopulmonary dysplasia;	chr19:22631659	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs2361021	ENSG00000198153.8	ZNF849P	-5.66	7.67e-08	0.000234	-0.47	-0.42	Bronchopulmonary dysplasia;	chr19:22633522	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs2361022	ENSG00000198153.8	ZNF849P	-5.66	7.67e-08	0.000234	-0.47	-0.42	Bronchopulmonary dysplasia;	chr19:22633731	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs2361023	ENSG00000198153.8	ZNF849P	-5.66	7.67e-08	0.000234	-0.47	-0.42	Bronchopulmonary dysplasia;	chr19:22634065	chr19:22685167~22686732:+
UCEC	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	5.66	7.67e-08	0.000234	0.46	0.42	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
UCEC	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-5.66	7.67e-08	0.000234	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
UCEC	cis	rs7267979	0.789	rs9927	ENSG00000276952.1	RP5-965G21.6	5.66	7.7e-08	0.000235	0.54	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25284915~25285588:-
UCEC	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-5.66	7.7e-08	0.000235	-0.59	-0.42	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-5.66	7.7e-08	0.000235	-0.59	-0.42	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-5.66	7.7e-08	0.000235	-0.59	-0.42	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-5.66	7.7e-08	0.000235	-0.59	-0.42	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-5.66	7.7e-08	0.000235	-0.59	-0.42	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-5.66	7.7e-08	0.000235	-0.59	-0.42	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-5.66	7.7e-08	0.000235	-0.59	-0.42	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
UCEC	cis	rs806321	0.531	rs2066625	ENSG00000237152.3	DLEU7-AS1	-5.66	7.7e-08	0.000235	-0.53	-0.42	Multiple sclerosis;	chr13:50180064	chr13:50807856~50849905:+
UCEC	cis	rs2239633	0.678	rs12887958	ENSG00000279656.1	RP11-298I3.6	5.65	7.78e-08	0.000237	0.52	0.42	Eosinophil percentage of white cells;Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Eosinophil percentage of granulocytes;Eosinophil counts;	chr14:23113360	chr14:23023083~23024217:-
UCEC	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	5.65	7.79e-08	0.000238	0.47	0.42	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
UCEC	cis	rs7267979	0.932	rs1985737	ENSG00000276952.1	RP5-965G21.6	5.65	7.86e-08	0.000239	0.54	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25284915~25285588:-
UCEC	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	5.65	7.92e-08	0.000241	0.47	0.42	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
UCEC	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-5.65	7.96e-08	0.000242	-0.53	-0.42	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
UCEC	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-5.65	7.96e-08	0.000242	-0.53	-0.42	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
UCEC	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-5.65	7.96e-08	0.000242	-0.53	-0.42	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-5.65	7.96e-08	0.000242	-0.53	-0.42	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
UCEC	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	5.65	8.02e-08	0.000244	0.53	0.42	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
UCEC	cis	rs7267979	1	rs6050559	ENSG00000276952.1	RP5-965G21.6	5.65	8.04e-08	0.000244	0.53	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25284915~25285588:-
UCEC	cis	rs7615952	0.688	rs7624806	ENSG00000241288.6	RP11-379B18.5	-5.65	8.06e-08	0.000245	-0.55	-0.42	Blood pressure (smoking interaction);	chr3:125880231	chr3:125827238~125916384:-
UCEC	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-5.64	8.14e-08	0.000247	-0.47	-0.42	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
UCEC	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	5.64	8.18e-08	0.000248	0.67	0.42	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
UCEC	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	5.64	8.21e-08	0.000249	0.45	0.42	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
UCEC	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-5.64	8.23e-08	0.000249	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	5.64	8.26e-08	0.00025	0.45	0.42	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
UCEC	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-5.64	8.3e-08	0.000251	-0.57	-0.42	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
UCEC	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	5.64	8.33e-08	0.000252	0.52	0.42	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
UCEC	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	5.64	8.42e-08	0.000254	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
UCEC	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	5.64	8.43e-08	0.000255	0.67	0.42	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	5.64	8.43e-08	0.000255	0.67	0.42	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	5.64	8.43e-08	0.000255	0.67	0.42	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	5.64	8.43e-08	0.000255	0.67	0.42	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
UCEC	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	5.64	8.45e-08	0.000255	0.68	0.42	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
UCEC	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	5.64	8.48e-08	0.000256	0.52	0.42	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	5.64	8.48e-08	0.000256	0.52	0.42	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	5.64	8.48e-08	0.000256	0.52	0.42	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	5.64	8.48e-08	0.000256	0.52	0.42	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	5.63	8.5e-08	0.000256	0.52	0.42	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
UCEC	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-5.63	8.52e-08	0.000257	-0.46	-0.42	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-5.63	8.66e-08	0.000261	-0.49	-0.42	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
UCEC	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-5.63	8.67e-08	0.000261	-0.53	-0.42	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
UCEC	cis	rs9543976	1	rs9543976	ENSG00000261553.4	RP11-29G8.3	5.63	8.78e-08	0.000264	0.52	0.42	Diabetic retinopathy;	chr13:75562512	chr13:75549773~75807120:+
UCEC	cis	rs8005677	0.828	rs12437151	ENSG00000257285.4	RP11-298I3.1	5.63	8.78e-08	0.000264	0.42	0.42	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:22929609~22955562:+
UCEC	cis	rs806321	0.755	rs2740520	ENSG00000237152.3	DLEU7-AS1	5.63	8.83e-08	0.000265	0.46	0.42	Multiple sclerosis;	chr13:50212227	chr13:50807856~50849905:+
UCEC	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	5.63	8.85e-08	0.000266	0.45	0.42	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	5.63	8.85e-08	0.000266	0.45	0.42	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
UCEC	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	5.63	8.85e-08	0.000266	0.56	0.42	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
UCEC	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	5.62	9.08e-08	0.000272	0.53	0.42	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
UCEC	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-5.62	9.09e-08	0.000272	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
UCEC	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-5.62	9.1e-08	0.000272	-0.46	-0.42	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	5.62	9.1e-08	0.000272	0.46	0.42	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	5.62	9.1e-08	0.000272	0.46	0.42	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	5.62	9.1e-08	0.000272	0.46	0.42	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	5.62	9.1e-08	0.000272	0.46	0.42	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	5.62	9.1e-08	0.000272	0.46	0.42	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
UCEC	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	5.62	9.12e-08	0.000272	0.54	0.42	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
UCEC	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	5.62	9.17e-08	0.000274	0.45	0.42	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
UCEC	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	5.62	9.19e-08	0.000274	0.45	0.42	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
UCEC	cis	rs7267979	0.668	rs2387977	ENSG00000276952.1	RP5-965G21.6	-5.62	9.23e-08	0.000276	-0.52	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:25284915~25285588:-
UCEC	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	5.62	9.26e-08	0.000276	0.76	0.42	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
UCEC	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-5.62	9.34e-08	0.000278	-0.58	-0.42	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
UCEC	cis	rs7246967	0.673	rs2885221	ENSG00000198153.8	ZNF849P	-5.61	9.36e-08	0.000279	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22656585	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs2885222	ENSG00000198153.8	ZNF849P	-5.61	9.36e-08	0.000279	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22657142	chr19:22685167~22686732:+
UCEC	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-5.61	9.39e-08	0.000279	-0.48	-0.42	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
UCEC	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-5.61	9.41e-08	0.00028	-0.59	-0.42	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
UCEC	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-5.61	9.43e-08	0.000281	-0.47	-0.42	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
UCEC	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	5.61	9.51e-08	0.000282	0.46	0.42	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	5.61	9.51e-08	0.000282	0.46	0.42	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	5.61	9.51e-08	0.000282	0.46	0.42	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-5.61	9.51e-08	0.000282	-0.57	-0.42	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	5.61	9.52e-08	0.000282	0.49	0.42	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	5.61	9.52e-08	0.000282	0.49	0.42	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
UCEC	cis	rs4789693	0.518	rs6502108	ENSG00000265458.1	RP13-20L14.6	-5.61	9.55e-08	0.000283	-0.43	-0.42	Glucocorticoid-induced osteonecrosis;	chr17:82417023	chr17:82454273~82458521:-
UCEC	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	5.61	9.57e-08	0.000283	0.52	0.42	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
UCEC	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	5.61	9.57e-08	0.000283	0.55	0.42	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	5.61	9.57e-08	0.000283	0.55	0.42	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
UCEC	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-5.61	9.57e-08	0.000283	-0.55	-0.42	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
UCEC	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-5.61	9.61e-08	0.000284	-0.53	-0.42	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-5.61	9.61e-08	0.000284	-0.53	-0.42	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-5.61	9.61e-08	0.000284	-0.53	-0.42	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
UCEC	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-5.61	9.61e-08	0.000284	-0.53	-0.42	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
UCEC	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-5.61	9.61e-08	0.000284	-0.53	-0.42	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
UCEC	cis	rs10232172	1	rs10261707	ENSG00000234707.2	RP11-745C15.2	5.61	9.63e-08	0.000285	0.75	0.42	Periodontal disease-related phenotypes;	chr7:54105484	chr7:54759425~54804928:+
UCEC	cis	rs7267979	1	rs2387881	ENSG00000276952.1	RP5-965G21.6	-5.61	9.71e-08	0.000287	-0.54	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25284915~25285588:-
UCEC	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	5.61	9.73e-08	0.000287	0.49	0.42	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	5.61	9.73e-08	0.000287	0.49	0.42	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	5.61	9.73e-08	0.000287	0.49	0.42	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	5.61	9.73e-08	0.000287	0.49	0.42	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	5.61	9.73e-08	0.000287	0.49	0.42	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
UCEC	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	5.61	9.79e-08	0.000289	0.44	0.42	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
UCEC	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	5.61	9.8e-08	0.000289	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
UCEC	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-5.6	9.97e-08	0.000294	-0.57	-0.42	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-5.6	9.97e-08	0.000294	-0.57	-0.42	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-5.6	9.97e-08	0.000294	-0.57	-0.42	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
UCEC	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-5.6	1e-07	0.000294	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
UCEC	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	5.6	1e-07	0.000294	0.46	0.42	Depression;	chr6:28407125	chr6:28176188~28176674:+
UCEC	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	5.6	1e-07	0.000294	0.59	0.42	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
UCEC	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	5.6	1e-07	0.000294	0.53	0.42	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
UCEC	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	5.6	1e-07	0.000295	0.54	0.42	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-5.6	1e-07	0.000295	-0.56	-0.42	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
UCEC	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	5.6	1.01e-07	0.000297	0.57	0.42	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
UCEC	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-5.6	1.03e-07	0.000301	-0.56	-0.42	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
UCEC	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	5.59	1.03e-07	0.000301	0.53	0.42	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
UCEC	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-5.59	1.03e-07	0.000302	-0.49	-0.42	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
UCEC	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	5.59	1.03e-07	0.000302	0.52	0.42	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	5.59	1.03e-07	0.000302	0.52	0.42	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
UCEC	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	5.59	1.04e-07	0.000303	0.45	0.42	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
UCEC	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	5.59	1.04e-07	0.000303	0.49	0.42	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	5.59	1.04e-07	0.000303	0.49	0.42	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	5.59	1.04e-07	0.000303	0.49	0.42	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
UCEC	cis	rs6504950	0.783	rs12936639	ENSG00000275710.1	RP11-257O5.4	5.59	1.04e-07	0.000305	0.54	0.42	Breast cancer;	chr17:55158621	chr17:54964474~54964679:+
UCEC	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	5.59	1.05e-07	0.000306	0.45	0.42	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
UCEC	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	5.59	1.05e-07	0.000306	0.56	0.42	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
UCEC	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	5.59	1.05e-07	0.000307	0.5	0.42	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
UCEC	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	5.59	1.06e-07	0.000308	0.55	0.42	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
UCEC	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.000309	-0.59	-0.42	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.000309	-0.59	-0.42	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
UCEC	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-5.59	1.06e-07	0.00031	-0.47	-0.42	Depression;	chr6:28422360	chr6:28176188~28176674:+
UCEC	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.00031	-0.59	-0.42	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.00031	-0.59	-0.42	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.00031	-0.59	-0.42	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.00031	-0.59	-0.42	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.00031	-0.59	-0.42	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.00031	-0.59	-0.42	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.00031	-0.59	-0.42	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-5.59	1.06e-07	0.00031	-0.59	-0.42	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
UCEC	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	5.59	1.07e-07	0.00031	0.54	0.42	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
UCEC	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	5.59	1.07e-07	0.000312	0.42	0.42	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
UCEC	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	5.58	1.08e-07	0.000314	0.58	0.42	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
UCEC	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	5.58	1.08e-07	0.000314	0.49	0.42	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
UCEC	cis	rs7246967	0.673	rs7250620	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22670324	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs4932784	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22691449	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs4933026	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22691690	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs73022711	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22692602	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs73022713	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22693420	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs57027767	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22693733	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs62120313	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22694381	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs7248107	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22695727	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs8102812	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22696441	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs8106215	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22696644	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs16994997	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22696808	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs34806882	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22697302	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs57736314	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22697470	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs3853649	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22697658	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs3853650	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22697688	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs3844578	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22697808	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs3925175	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22698156	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs7257333	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22698347	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs34342502	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22698626	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs7245540	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22698702	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs7246424	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22699383	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs7249685	ENSG00000198153.8	ZNF849P	-5.58	1.09e-07	0.000314	-0.48	-0.42	Bronchopulmonary dysplasia;	chr19:22699577	chr19:22685167~22686732:+
UCEC	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-5.58	1.09e-07	0.000314	-0.37	-0.42	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-5.58	1.09e-07	0.000314	-0.37	-0.42	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
UCEC	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	5.58	1.09e-07	0.000315	0.43	0.42	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
UCEC	cis	rs948562	0.657	rs11229574	ENSG00000280010.1	AP001350.4	5.58	1.09e-07	0.000315	0.69	0.42	Lymphoma;	chr11:58667837	chr11:58627435~58628528:+
UCEC	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	5.58	1.1e-07	0.000316	0.53	0.42	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
UCEC	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	5.58	1.1e-07	0.000317	0.45	0.42	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
UCEC	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-5.58	1.1e-07	0.000317	-0.37	-0.42	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
UCEC	cis	rs9828933	0.678	rs704366	ENSG00000280620.1	SCAANT1	-5.58	1.1e-07	0.000318	-0.7	-0.42	Type 2 diabetes;	chr3:63885972	chr3:63911518~63911772:-
UCEC	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	5.58	1.1e-07	0.000318	0.49	0.42	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	5.58	1.1e-07	0.000318	0.49	0.42	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
UCEC	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	5.58	1.11e-07	0.000319	0.49	0.42	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
UCEC	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	5.58	1.11e-07	0.00032	0.55	0.42	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
UCEC	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	5.58	1.11e-07	0.000321	0.44	0.42	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
UCEC	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-5.58	1.12e-07	0.000322	-0.57	-0.42	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-5.58	1.12e-07	0.000322	-0.57	-0.42	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-5.58	1.12e-07	0.000322	-0.57	-0.42	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
UCEC	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	5.58	1.12e-07	0.000322	0.51	0.42	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
UCEC	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	5.58	1.12e-07	0.000323	0.54	0.42	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
UCEC	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-5.58	1.13e-07	0.000324	-0.48	-0.42	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
UCEC	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	5.58	1.13e-07	0.000324	0.53	0.42	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
UCEC	cis	rs806321	0.501	rs2066626	ENSG00000237152.3	DLEU7-AS1	-5.58	1.13e-07	0.000324	-0.53	-0.42	Multiple sclerosis;	chr13:50180079	chr13:50807856~50849905:+
UCEC	cis	rs7267979	0.844	rs8184820	ENSG00000276952.1	RP5-965G21.6	-5.58	1.13e-07	0.000325	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs6115215	ENSG00000276952.1	RP5-965G21.6	5.57	1.13e-07	0.000326	0.54	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25284915~25285588:-
UCEC	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	5.57	1.13e-07	0.000326	0.45	0.42	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
UCEC	cis	rs7246967	0.673	rs3951783	ENSG00000198153.8	ZNF849P	-5.57	1.14e-07	0.000327	-0.49	-0.42	Bronchopulmonary dysplasia;	chr19:22656462	chr19:22685167~22686732:+
UCEC	cis	rs7267979	1	rs6515651	ENSG00000276952.1	RP5-965G21.6	-5.57	1.14e-07	0.000327	-0.54	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2424716	ENSG00000276952.1	RP5-965G21.6	5.57	1.14e-07	0.000327	0.54	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs761025	ENSG00000276952.1	RP5-965G21.6	5.57	1.14e-07	0.000327	0.54	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25284915~25285588:-
UCEC	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-5.57	1.14e-07	0.000327	-0.53	-0.42	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
UCEC	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-5.57	1.14e-07	0.000327	-0.53	-0.42	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
UCEC	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-5.57	1.14e-07	0.000327	-0.47	-0.42	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
UCEC	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-5.57	1.14e-07	0.000327	-0.61	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
UCEC	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-5.57	1.14e-07	0.000328	-0.49	-0.42	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
UCEC	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	5.57	1.15e-07	0.000329	0.47	0.42	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
UCEC	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	5.57	1.15e-07	0.000329	0.57	0.42	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
UCEC	cis	rs7267979	1	rs2500432	ENSG00000276952.1	RP5-965G21.6	5.57	1.15e-07	0.000329	0.55	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs1888997	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs3002698	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2500443	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2482928	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2482930	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2500446	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2482937	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2263204	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2500417	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2482911	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2500436	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6083856	ENSG00000276952.1	RP5-965G21.6	-5.57	1.15e-07	0.000329	-0.55	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25284915~25285588:-
UCEC	cis	rs6504950	0.783	rs7211787	ENSG00000275710.1	RP11-257O5.4	5.57	1.16e-07	0.000331	0.54	0.42	Breast cancer;	chr17:55157551	chr17:54964474~54964679:+
UCEC	cis	rs7267979	0.966	rs2151144	ENSG00000276952.1	RP5-965G21.6	-5.57	1.17e-07	0.000333	-0.54	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25284915~25285588:-
UCEC	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	5.57	1.17e-07	0.000333	0.48	0.42	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
UCEC	cis	rs7267979	0.932	rs449370	ENSG00000276952.1	RP5-965G21.6	-5.57	1.17e-07	0.000335	-0.54	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25284915~25285588:-
UCEC	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	5.57	1.17e-07	0.000335	0.48	0.41	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
UCEC	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-5.57	1.17e-07	0.000335	-0.55	-0.41	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
UCEC	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	5.57	1.18e-07	0.000336	0.49	0.41	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
UCEC	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-5.57	1.18e-07	0.000336	-0.52	-0.41	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
UCEC	cis	rs964184	0.688	rs1558860	ENSG00000254851.1	RP11-109L13.1	-5.57	1.18e-07	0.000337	-0.99	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116736652	chr11:117135528~117138582:+
UCEC	cis	rs964184	0.63	rs1558861	ENSG00000254851.1	RP11-109L13.1	-5.57	1.18e-07	0.000337	-0.99	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116736721	chr11:117135528~117138582:+
UCEC	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-5.57	1.19e-07	0.000338	-0.58	-0.41	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-5.57	1.19e-07	0.000338	-0.58	-0.41	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
UCEC	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	5.56	1.19e-07	0.000338	0.52	0.41	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
UCEC	cis	rs8005677	0.828	rs4981450	ENSG00000257285.4	RP11-298I3.1	5.56	1.19e-07	0.000339	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:22929609~22955562:+
UCEC	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	5.56	1.2e-07	0.000342	0.45	0.41	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
UCEC	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	5.56	1.2e-07	0.000342	0.49	0.41	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
UCEC	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-5.56	1.2e-07	0.000342	-0.49	-0.41	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
UCEC	cis	rs8005677	0.798	rs4982711	ENSG00000257285.4	RP11-298I3.1	5.56	1.2e-07	0.000343	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:22929609~22955562:+
UCEC	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-5.56	1.21e-07	0.000343	-0.54	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
UCEC	cis	rs7267979	1	rs6050631	ENSG00000276952.1	RP5-965G21.6	5.56	1.22e-07	0.000346	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25284915~25285588:-
UCEC	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-5.56	1.23e-07	0.000348	-0.58	-0.41	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-5.56	1.23e-07	0.000348	-0.58	-0.41	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-5.56	1.23e-07	0.000348	-0.58	-0.41	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-5.56	1.23e-07	0.000348	-0.58	-0.41	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-5.56	1.23e-07	0.000348	-0.58	-0.41	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-5.56	1.23e-07	0.000348	-0.58	-0.41	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-5.56	1.23e-07	0.000348	-0.58	-0.41	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-5.56	1.23e-07	0.000348	-0.58	-0.41	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
UCEC	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	5.56	1.23e-07	0.000349	0.55	0.41	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
UCEC	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	5.56	1.24e-07	0.000352	0.71	0.41	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
UCEC	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	5.56	1.24e-07	0.000352	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
UCEC	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	5.56	1.24e-07	0.000352	0.49	0.41	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
UCEC	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-5.56	1.24e-07	0.000352	-0.5	-0.41	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-5.56	1.24e-07	0.000352	-0.5	-0.41	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-5.56	1.24e-07	0.000352	-0.5	-0.41	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-5.56	1.24e-07	0.000352	-0.5	-0.41	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-5.56	1.24e-07	0.000352	-0.5	-0.41	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-5.56	1.24e-07	0.000352	-0.5	-0.41	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-5.56	1.24e-07	0.000352	-0.5	-0.41	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-5.56	1.24e-07	0.000352	-0.5	-0.41	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
UCEC	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-5.56	1.24e-07	0.000352	-0.56	-0.41	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
UCEC	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	5.55	1.25e-07	0.000353	0.53	0.41	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
UCEC	cis	rs7267979	0.966	rs4813557	ENSG00000276952.1	RP5-965G21.6	-5.55	1.25e-07	0.000353	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815404	ENSG00000276952.1	RP5-965G21.6	-5.55	1.25e-07	0.000353	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6083805	ENSG00000276952.1	RP5-965G21.6	-5.55	1.25e-07	0.000353	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050544	ENSG00000276952.1	RP5-965G21.6	-5.55	1.25e-07	0.000353	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs8125868	ENSG00000276952.1	RP5-965G21.6	-5.55	1.25e-07	0.000353	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6037095	ENSG00000276952.1	RP5-965G21.6	-5.55	1.25e-07	0.000353	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050562	ENSG00000276952.1	RP5-965G21.6	-5.55	1.25e-07	0.000353	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815407	ENSG00000276952.1	RP5-965G21.6	-5.55	1.25e-07	0.000353	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815408	ENSG00000276952.1	RP5-965G21.6	-5.55	1.25e-07	0.000353	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25284915~25285588:-
UCEC	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-5.55	1.25e-07	0.000354	-0.45	-0.41	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
UCEC	cis	rs7246967	0.673	rs937078	ENSG00000198153.8	ZNF849P	-5.55	1.25e-07	0.000354	-0.47	-0.41	Bronchopulmonary dysplasia;	chr19:22628865	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12978794	ENSG00000198153.8	ZNF849P	-5.55	1.25e-07	0.000354	-0.47	-0.41	Bronchopulmonary dysplasia;	chr19:22629332	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs4932782	ENSG00000198153.8	ZNF849P	-5.55	1.25e-07	0.000354	-0.47	-0.41	Bronchopulmonary dysplasia;	chr19:22629999	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs4933017	ENSG00000198153.8	ZNF849P	-5.55	1.25e-07	0.000354	-0.47	-0.41	Bronchopulmonary dysplasia;	chr19:22630178	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs66866654	ENSG00000198153.8	ZNF849P	-5.55	1.25e-07	0.000354	-0.47	-0.41	Bronchopulmonary dysplasia;	chr19:22630937	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs73028776	ENSG00000198153.8	ZNF849P	-5.55	1.25e-07	0.000354	-0.47	-0.41	Bronchopulmonary dysplasia;	chr19:22630938	chr19:22685167~22686732:+
UCEC	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	5.55	1.26e-07	0.000355	0.54	0.41	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
UCEC	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	5.55	1.26e-07	0.000355	0.54	0.41	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
UCEC	cis	rs7246967	0.611	rs62118823	ENSG00000198153.8	ZNF849P	-5.55	1.26e-07	0.000356	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22661264	chr19:22685167~22686732:+
UCEC	cis	rs7240205	0.507	rs72887333	ENSG00000275805.1	RP11-349H17.2	-5.55	1.26e-07	0.000356	-0.58	-0.41	Breast cancer;	chr18:26553232	chr18:26565723~26575626:-
UCEC	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-5.55	1.26e-07	0.000357	-0.56	-0.41	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
UCEC	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-5.55	1.27e-07	0.000358	-0.44	-0.41	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
UCEC	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-5.55	1.27e-07	0.000358	-0.49	-0.41	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
UCEC	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	5.55	1.27e-07	0.000359	0.49	0.41	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	5.55	1.27e-07	0.000359	0.44	0.41	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	5.55	1.27e-07	0.000359	0.44	0.41	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	5.55	1.27e-07	0.000359	0.44	0.41	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
UCEC	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	5.55	1.27e-07	0.000359	0.49	0.41	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	5.55	1.27e-07	0.000359	0.49	0.41	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	5.55	1.27e-07	0.000359	0.49	0.41	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	5.55	1.27e-07	0.000359	0.49	0.41	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	5.55	1.27e-07	0.000359	0.49	0.41	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	5.55	1.27e-07	0.000359	0.49	0.41	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	5.55	1.27e-07	0.000359	0.49	0.41	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	5.55	1.27e-07	0.000359	0.49	0.41	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
UCEC	cis	rs7246967	0.673	rs12984634	ENSG00000198153.8	ZNF849P	-5.55	1.28e-07	0.000361	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22650942	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs12984903	ENSG00000198153.8	ZNF849P	-5.55	1.28e-07	0.000361	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22651079	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs2099341	ENSG00000198153.8	ZNF849P	-5.55	1.28e-07	0.000361	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22651558	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs2361245	ENSG00000198153.8	ZNF849P	-5.55	1.28e-07	0.000361	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22651728	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs2082445	ENSG00000198153.8	ZNF849P	-5.55	1.28e-07	0.000361	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22651785	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs7250285	ENSG00000198153.8	ZNF849P	-5.55	1.28e-07	0.000361	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22654306	chr19:22685167~22686732:+
UCEC	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-5.55	1.29e-07	0.000363	-0.56	-0.41	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
UCEC	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	5.55	1.3e-07	0.000364	0.51	0.41	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
UCEC	cis	rs7246967	0.551	rs7248993	ENSG00000198153.8	ZNF849P	-5.55	1.3e-07	0.000365	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22666350	chr19:22685167~22686732:+
UCEC	cis	rs8005677	0.798	rs4982713	ENSG00000257285.4	RP11-298I3.1	5.55	1.3e-07	0.000365	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.798	rs35615180	ENSG00000257285.4	RP11-298I3.1	5.55	1.3e-07	0.000365	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.828	rs35085068	ENSG00000257285.4	RP11-298I3.1	5.55	1.3e-07	0.000365	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.828	rs57822749	ENSG00000257285.4	RP11-298I3.1	5.55	1.3e-07	0.000365	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.828	rs4981451	ENSG00000257285.4	RP11-298I3.1	5.55	1.3e-07	0.000365	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.798	rs4536383	ENSG00000257285.4	RP11-298I3.1	5.55	1.3e-07	0.000365	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:22929609~22955562:+
UCEC	cis	rs8005677	0.828	rs34584578	ENSG00000257285.4	RP11-298I3.1	5.55	1.3e-07	0.000365	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:22929609~22955562:+
UCEC	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-5.54	1.31e-07	0.000366	-0.43	-0.41	Height;	chr11:118703185	chr11:118704607~118750263:+
UCEC	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-5.54	1.31e-07	0.000366	-0.43	-0.41	Height;	chr11:118703207	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-5.54	1.31e-07	0.000366	-0.43	-0.41	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
UCEC	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	5.54	1.31e-07	0.000367	0.48	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
UCEC	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-5.54	1.32e-07	0.000368	-0.49	-0.41	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
UCEC	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-5.54	1.32e-07	0.000368	-0.49	-0.41	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
UCEC	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	5.54	1.32e-07	0.000369	0.43	0.41	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
UCEC	cis	rs7267979	1	rs7019	ENSG00000276952.1	RP5-965G21.6	5.54	1.32e-07	0.00037	0.55	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6115140	ENSG00000276952.1	RP5-965G21.6	5.54	1.32e-07	0.00037	0.55	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25284915~25285588:-
UCEC	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	5.54	1.33e-07	0.000373	0.53	0.41	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
UCEC	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-5.54	1.34e-07	0.000375	-0.49	-0.41	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
UCEC	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-5.54	1.34e-07	0.000376	-0.47	-0.41	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
UCEC	cis	rs55894132	1	rs55894132	ENSG00000257285.4	RP11-298I3.1	5.54	1.34e-07	0.000376	0.41	0.41	Intelligence (multi-trait analysis);	chr14:22939628	chr14:22929609~22955562:+
UCEC	cis	rs7267979	0.933	rs1130694	ENSG00000276952.1	RP5-965G21.6	5.54	1.35e-07	0.000376	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs7018	ENSG00000276952.1	RP5-965G21.6	5.54	1.35e-07	0.000376	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25284915~25285588:-
UCEC	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	5.54	1.35e-07	0.000376	0.41	0.41	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
UCEC	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	5.54	1.35e-07	0.000376	0.43	0.41	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
UCEC	cis	rs8005677	0.828	rs8016027	ENSG00000257285.4	RP11-298I3.1	5.54	1.35e-07	0.000377	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:22929609~22955562:+
UCEC	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-5.54	1.35e-07	0.000377	-0.43	-0.41	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
UCEC	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-5.54	1.35e-07	0.000378	-0.56	-0.41	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
UCEC	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	5.54	1.36e-07	0.000379	0.49	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
UCEC	cis	rs7246967	0.673	rs7249003	ENSG00000198153.8	ZNF849P	-5.54	1.37e-07	0.000381	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22705132	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12971914	ENSG00000198153.8	ZNF849P	-5.54	1.37e-07	0.000381	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22706096	chr19:22685167~22686732:+
UCEC	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-5.54	1.37e-07	0.000381	-0.48	-0.41	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
UCEC	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	5.54	1.37e-07	0.000381	0.46	0.41	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
UCEC	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	5.54	1.37e-07	0.000381	0.46	0.41	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
UCEC	cis	rs8005677	0.828	rs712486	ENSG00000257285.4	RP11-298I3.1	5.53	1.39e-07	0.000386	0.4	0.41	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:22929609~22955562:+
UCEC	cis	rs899997	0.862	rs57260218	ENSG00000261143.1	ADAMTS7P3	-5.53	1.39e-07	0.000387	-0.59	-0.41	Coronary artery disease or large artery stroke;	chr15:78681430	chr15:77976042~77993057:+
UCEC	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	5.53	1.39e-07	0.000387	0.72	0.41	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
UCEC	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-5.53	1.39e-07	0.000387	-0.58	-0.41	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-5.53	1.39e-07	0.000387	-0.58	-0.41	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-5.53	1.39e-07	0.000387	-0.58	-0.41	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
UCEC	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-5.53	1.39e-07	0.000388	-0.55	-0.41	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
UCEC	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-5.53	1.4e-07	0.000388	-0.55	-0.41	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-5.53	1.4e-07	0.000388	-0.55	-0.41	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
UCEC	cis	rs7267979	0.934	rs2261115	ENSG00000276952.1	RP5-965G21.6	5.53	1.4e-07	0.000389	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2261747	ENSG00000276952.1	RP5-965G21.6	5.53	1.4e-07	0.000389	0.52	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25284915~25285588:-
UCEC	cis	rs8005677	0.798	rs61977741	ENSG00000257285.4	RP11-298I3.1	5.53	1.4e-07	0.00039	0.41	0.41	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:22929609~22955562:+
UCEC	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-5.53	1.41e-07	0.00039	-0.49	-0.41	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-5.53	1.41e-07	0.00039	-0.49	-0.41	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-5.53	1.41e-07	0.00039	-0.49	-0.41	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-5.53	1.41e-07	0.00039	-0.49	-0.41	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
UCEC	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-5.53	1.42e-07	0.000392	-0.49	-0.41	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-5.53	1.42e-07	0.000392	-0.49	-0.41	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-5.53	1.42e-07	0.000392	-0.49	-0.41	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
UCEC	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-5.53	1.42e-07	0.000393	-0.48	-0.41	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
UCEC	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	5.53	1.43e-07	0.000394	0.45	0.41	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
UCEC	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	5.52	1.44e-07	0.000397	0.5	0.41	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
UCEC	cis	rs116927879	1	rs116927879	ENSG00000272556.1	RP11-638I8.1	-5.52	1.44e-07	0.000397	-0.51	-0.41	Subjective response to lithium treatment in bipolar disorder;	chr7:45825128	chr7:45814602~45815263:+
UCEC	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	5.52	1.45e-07	0.000399	0.72	0.41	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
UCEC	cis	rs7267979	0.932	rs2260997	ENSG00000276952.1	RP5-965G21.6	-5.52	1.46e-07	0.000402	-0.53	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25284915~25285588:-
UCEC	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	5.52	1.46e-07	0.000402	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
UCEC	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-5.52	1.47e-07	0.000404	-0.49	-0.41	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
UCEC	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-5.52	1.47e-07	0.000404	-0.48	-0.41	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	5.52	1.47e-07	0.000404	0.48	0.41	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
UCEC	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	5.52	1.47e-07	0.000404	0.43	0.41	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
UCEC	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-5.52	1.48e-07	0.000405	-0.45	-0.41	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
UCEC	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-5.52	1.48e-07	0.000405	-0.49	-0.41	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
UCEC	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	5.52	1.48e-07	0.000406	0.49	0.41	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
UCEC	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-5.52	1.49e-07	0.000407	-0.46	-0.41	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
UCEC	cis	rs7267979	0.932	rs6115214	ENSG00000276952.1	RP5-965G21.6	-5.52	1.49e-07	0.000408	-0.54	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25284915~25285588:-
UCEC	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	5.52	1.49e-07	0.000408	0.5	0.41	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
UCEC	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-5.52	1.49e-07	0.000409	-0.58	-0.41	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
UCEC	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-5.52	1.5e-07	0.00041	-0.47	-0.41	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
UCEC	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	5.52	1.5e-07	0.000411	0.48	0.41	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	5.52	1.5e-07	0.000411	0.48	0.41	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
UCEC	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-5.52	1.5e-07	0.000411	-0.53	-0.41	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-5.52	1.5e-07	0.000411	-0.53	-0.41	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
UCEC	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	5.51	1.51e-07	0.000412	0.48	0.41	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
UCEC	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	5.51	1.51e-07	0.000413	0.7	0.41	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
UCEC	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	5.51	1.51e-07	0.000413	0.44	0.41	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
UCEC	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	5.51	1.51e-07	0.000413	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
UCEC	cis	rs899997	1	rs7182567	ENSG00000261143.1	ADAMTS7P3	5.51	1.52e-07	0.000414	0.53	0.41	Coronary artery disease or large artery stroke;	chr15:78752712	chr15:77976042~77993057:+
UCEC	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-5.51	1.52e-07	0.000414	-0.53	-0.41	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
UCEC	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-5.51	1.52e-07	0.000414	-0.37	-0.41	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
UCEC	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-5.51	1.52e-07	0.000415	-0.57	-0.41	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
UCEC	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-5.51	1.53e-07	0.000416	-0.79	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
UCEC	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-5.51	1.53e-07	0.000416	-0.52	-0.41	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-5.51	1.53e-07	0.000416	-0.52	-0.41	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
UCEC	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	5.51	1.53e-07	0.000418	0.46	0.41	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
UCEC	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	5.51	1.54e-07	0.000419	0.54	0.41	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
UCEC	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	5.51	1.55e-07	0.000421	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
UCEC	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-5.51	1.55e-07	0.000422	-0.42	-0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
UCEC	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	5.51	1.55e-07	0.000422	0.45	0.41	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
UCEC	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	5.51	1.55e-07	0.000422	0.45	0.41	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
UCEC	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-5.51	1.56e-07	0.000424	-0.49	-0.41	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
UCEC	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	5.51	1.56e-07	0.000424	0.49	0.41	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
UCEC	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	5.51	1.56e-07	0.000425	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
UCEC	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-5.51	1.57e-07	0.000425	-0.56	-0.41	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
UCEC	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	5.51	1.57e-07	0.000426	0.49	0.41	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
UCEC	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	5.5	1.58e-07	0.000427	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
UCEC	cis	rs7240205	0.593	rs113592062	ENSG00000275805.1	RP11-349H17.2	-5.5	1.58e-07	0.000428	-0.52	-0.41	Breast cancer;	chr18:26566829	chr18:26565723~26575626:-
UCEC	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-5.5	1.58e-07	0.000428	-0.47	-0.41	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
UCEC	cis	rs9326246	0.643	rs2072560	ENSG00000254851.1	RP11-109L13.1	-5.5	1.59e-07	0.00043	-0.98	-0.41	Coronary artery disease;	chr11:116791110	chr11:117135528~117138582:+
UCEC	cis	rs7267979	1	rs6083862	ENSG00000276952.1	RP5-965G21.6	-5.5	1.59e-07	0.000431	-0.52	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25284915~25285588:-
UCEC	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-5.5	1.6e-07	0.000432	-0.53	-0.41	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
UCEC	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	5.5	1.6e-07	0.000432	0.46	0.41	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
UCEC	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	5.5	1.61e-07	0.000434	0.58	0.41	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
UCEC	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	5.5	1.61e-07	0.000435	0.47	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
UCEC	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	5.5	1.61e-07	0.000435	0.47	0.41	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
UCEC	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	5.5	1.61e-07	0.000436	0.48	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
UCEC	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	5.5	1.62e-07	0.000436	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
UCEC	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-5.5	1.63e-07	0.000438	-0.45	-0.41	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
UCEC	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-5.5	1.63e-07	0.000439	-0.53	-0.41	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
UCEC	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-5.5	1.63e-07	0.000439	-0.53	-0.41	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
UCEC	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	5.5	1.63e-07	0.000439	0.5	0.41	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
UCEC	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	5.5	1.63e-07	0.00044	0.7	0.41	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
UCEC	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	5.5	1.64e-07	0.000441	0.54	0.41	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
UCEC	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	5.5	1.64e-07	0.000442	0.53	0.41	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
UCEC	cis	rs964184	0.63	rs9326246	ENSG00000254851.1	RP11-109L13.1	-5.5	1.65e-07	0.000444	-0.98	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116741017	chr11:117135528~117138582:+
UCEC	cis	rs964184	0.63	rs6589566	ENSG00000254851.1	RP11-109L13.1	-5.5	1.65e-07	0.000444	-0.98	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116781707	chr11:117135528~117138582:+
UCEC	cis	rs964184	0.564	rs2266788	ENSG00000254851.1	RP11-109L13.1	-5.5	1.65e-07	0.000444	-0.98	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116789970	chr11:117135528~117138582:+
UCEC	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-5.5	1.65e-07	0.000444	-0.54	-0.41	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
UCEC	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-5.49	1.65e-07	0.000445	-0.81	-0.41	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
UCEC	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-5.49	1.65e-07	0.000445	-0.52	-0.41	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-5.49	1.65e-07	0.000445	-0.52	-0.41	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
UCEC	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-5.49	1.66e-07	0.000446	-0.5	-0.41	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
UCEC	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-5.49	1.66e-07	0.000446	-0.55	-0.41	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-5.49	1.66e-07	0.000446	-0.55	-0.41	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
UCEC	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	5.49	1.67e-07	0.000447	0.48	0.41	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
UCEC	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-5.49	1.67e-07	0.000447	-0.52	-0.41	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
UCEC	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	5.49	1.69e-07	0.000453	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
UCEC	cis	rs7267979	1	rs6132835	ENSG00000276952.1	RP5-965G21.6	5.49	1.69e-07	0.000453	0.54	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25284915~25285588:-
UCEC	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	5.49	1.7e-07	0.000453	0.55	0.41	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	5.49	1.7e-07	0.000453	0.55	0.41	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	5.49	1.7e-07	0.000453	0.55	0.41	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	5.49	1.7e-07	0.000453	0.55	0.41	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	5.49	1.7e-07	0.000453	0.55	0.41	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
UCEC	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	5.49	1.7e-07	0.000454	0.47	0.41	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
UCEC	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	5.49	1.72e-07	0.000459	0.7	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
UCEC	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-5.49	1.72e-07	0.000459	-0.58	-0.41	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
UCEC	cis	rs7240205	0.535	rs72887347	ENSG00000275805.1	RP11-349H17.2	-5.49	1.72e-07	0.00046	-0.55	-0.41	Breast cancer;	chr18:26570275	chr18:26565723~26575626:-
UCEC	cis	rs7267979	0.966	rs454723	ENSG00000276952.1	RP5-965G21.6	5.48	1.73e-07	0.000462	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25284915~25285588:-
UCEC	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-5.48	1.75e-07	0.000466	-0.58	-0.41	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-5.48	1.75e-07	0.000466	-0.58	-0.41	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-5.48	1.75e-07	0.000466	-0.58	-0.41	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
UCEC	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	5.48	1.76e-07	0.000468	0.53	0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
UCEC	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	5.48	1.76e-07	0.000468	0.53	0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
UCEC	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	5.48	1.76e-07	0.000468	0.65	0.41	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
UCEC	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	5.48	1.76e-07	0.000469	0.51	0.41	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
UCEC	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-5.48	1.77e-07	0.00047	-0.47	-0.41	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
UCEC	cis	rs7246967	0.673	rs8105441	ENSG00000198153.8	ZNF849P	-5.48	1.77e-07	0.000471	-0.48	-0.41	Bronchopulmonary dysplasia;	chr19:22708664	chr19:22685167~22686732:+
UCEC	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-5.48	1.78e-07	0.000473	-0.51	-0.41	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
UCEC	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-5.48	1.79e-07	0.000477	-0.59	-0.41	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
UCEC	cis	rs7267979	1	rs11087520	ENSG00000276952.1	RP5-965G21.6	5.48	1.79e-07	0.000477	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25284915~25285588:-
UCEC	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	5.48	1.8e-07	0.000477	0.48	0.41	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
UCEC	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-5.48	1.8e-07	0.000478	-0.55	-0.41	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
UCEC	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	5.48	1.8e-07	0.000478	0.53	0.41	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	5.48	1.8e-07	0.000478	0.53	0.41	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
UCEC	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	5.48	1.81e-07	0.00048	0.42	0.41	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	5.48	1.81e-07	0.00048	0.42	0.41	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
UCEC	cis	rs7267979	1	rs7267979	ENSG00000276952.1	RP5-965G21.6	5.47	1.82e-07	0.000483	0.52	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25284915~25285588:-
UCEC	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	5.47	1.83e-07	0.000484	0.74	0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
UCEC	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	5.47	1.83e-07	0.000485	0.42	0.41	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
UCEC	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	5.47	1.84e-07	0.000485	0.71	0.41	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
UCEC	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-5.47	1.84e-07	0.000486	-0.45	-0.41	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
UCEC	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	5.47	1.84e-07	0.000486	0.49	0.41	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
UCEC	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	5.47	1.85e-07	0.000487	0.52	0.41	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	5.47	1.85e-07	0.000487	0.52	0.41	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	5.47	1.85e-07	0.000487	0.52	0.41	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	5.47	1.85e-07	0.000487	0.52	0.41	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
UCEC	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-5.47	1.85e-07	0.000487	-0.53	-0.41	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
UCEC	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	5.47	1.86e-07	0.000489	0.7	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
UCEC	cis	rs7267979	0.844	rs6132824	ENSG00000276952.1	RP5-965G21.6	5.47	1.86e-07	0.000489	0.54	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25284915~25285588:-
UCEC	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-5.47	1.87e-07	0.000491	-0.46	-0.41	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-5.47	1.87e-07	0.000491	-0.46	-0.41	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-5.47	1.87e-07	0.000491	-0.46	-0.41	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-5.47	1.87e-07	0.000491	-0.46	-0.41	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-5.47	1.87e-07	0.000491	-0.46	-0.41	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-5.47	1.88e-07	0.000493	-0.46	-0.41	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
UCEC	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-5.47	1.88e-07	0.000494	-0.56	-0.41	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
UCEC	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	5.47	1.89e-07	0.000495	0.62	0.41	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
UCEC	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	5.47	1.89e-07	0.000495	0.44	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
UCEC	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-5.47	1.89e-07	0.000496	-0.51	-0.41	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
UCEC	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-5.47	1.89e-07	0.000496	-0.52	-0.41	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
UCEC	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	5.46	1.9e-07	0.000499	0.48	0.41	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
UCEC	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-5.46	1.91e-07	0.000499	-0.46	-0.41	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-5.46	1.91e-07	0.000499	-0.46	-0.41	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
UCEC	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	5.46	1.91e-07	5e-04	0.48	0.41	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
UCEC	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-5.46	1.91e-07	5e-04	-0.52	-0.41	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-5.46	1.91e-07	5e-04	-0.52	-0.41	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
UCEC	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-5.46	1.91e-07	5e-04	-0.52	-0.41	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
UCEC	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-5.46	1.92e-07	0.000502	-0.59	-0.41	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
UCEC	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	5.46	1.93e-07	0.000503	0.57	0.41	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
UCEC	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	5.46	1.93e-07	0.000503	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
UCEC	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	5.46	1.93e-07	0.000504	0.51	0.41	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
UCEC	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	5.46	1.93e-07	0.000505	0.52	0.41	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
UCEC	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	5.46	1.94e-07	0.000506	0.52	0.41	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
UCEC	cis	rs7246967	0.673	rs16999519	ENSG00000198153.8	ZNF849P	5.46	1.94e-07	0.000506	0.46	0.41	Bronchopulmonary dysplasia;	chr19:22631274	chr19:22685167~22686732:+
UCEC	cis	rs7267979	0.966	rs910996	ENSG00000276952.1	RP5-965G21.6	5.46	1.95e-07	0.00051	0.52	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25284915~25285588:-
UCEC	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	5.46	1.96e-07	0.000511	0.66	0.41	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	5.46	1.96e-07	0.000511	0.66	0.41	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
UCEC	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-5.46	1.96e-07	0.000512	-0.52	-0.41	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
UCEC	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	5.46	1.96e-07	0.000512	0.58	0.41	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
UCEC	cis	rs4253772	0.53	rs9627387	ENSG00000277232.2	GTSE1-AS1	-5.46	1.99e-07	0.000517	-0.49	-0.41	Cholesterol, total;LDL cholesterol;	chr22:46288781	chr22:46295143~46296660:-
UCEC	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	5.46	1.99e-07	0.000517	0.53	0.41	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
UCEC	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-5.46	1.99e-07	0.000518	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
UCEC	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	5.45	1.99e-07	0.000518	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	5.45	1.99e-07	0.000518	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
UCEC	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-5.45	2e-07	0.000521	-0.47	-0.41	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-5.45	2e-07	0.000521	-0.47	-0.41	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
UCEC	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	5.45	2.01e-07	0.000521	0.48	0.41	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
UCEC	cis	rs2739330	0.76	rs1002286	ENSG00000272787.1	KB-226F1.2	5.45	2.01e-07	0.000522	0.47	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23969211~23969873:+
UCEC	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-5.45	2.01e-07	0.000522	-0.44	-0.41	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
UCEC	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	5.45	2.01e-07	0.000523	0.46	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
UCEC	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	5.45	2.01e-07	0.000523	0.46	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
UCEC	cis	rs7267979	1	rs398036	ENSG00000276952.1	RP5-965G21.6	5.45	2.02e-07	0.000524	0.52	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs397119	ENSG00000276952.1	RP5-965G21.6	5.45	2.02e-07	0.000524	0.52	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25284915~25285588:-
UCEC	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-5.45	2.02e-07	0.000525	-0.42	-0.41	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
UCEC	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	5.45	2.02e-07	0.000525	0.46	0.41	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
UCEC	cis	rs7267979	0.966	rs416745	ENSG00000276952.1	RP5-965G21.6	5.45	2.02e-07	0.000526	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25284915~25285588:-
UCEC	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-5.45	2.04e-07	0.000529	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-5.45	2.04e-07	0.000529	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-5.45	2.04e-07	0.000529	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
UCEC	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-5.45	2.04e-07	0.000529	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
UCEC	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-5.45	2.06e-07	0.000532	-0.57	-0.41	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
UCEC	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	5.45	2.06e-07	0.000532	0.54	0.41	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	5.45	2.06e-07	0.000532	0.54	0.41	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
UCEC	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	5.45	2.07e-07	0.000534	0.75	0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
UCEC	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	5.45	2.07e-07	0.000534	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
UCEC	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	5.44	2.09e-07	0.000538	0.75	0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
UCEC	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	5.44	2.09e-07	0.000539	0.45	0.41	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
UCEC	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	5.44	2.11e-07	0.000542	0.42	0.41	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
UCEC	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-5.44	2.11e-07	0.000542	-0.58	-0.41	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
UCEC	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	5.44	2.11e-07	0.000543	0.49	0.41	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
UCEC	cis	rs964184	0.564	rs3825041	ENSG00000254851.1	RP11-109L13.1	-5.44	2.12e-07	0.000545	-0.97	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116760991	chr11:117135528~117138582:+
UCEC	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-5.44	2.13e-07	0.000547	-0.52	-0.41	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
UCEC	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-5.44	2.13e-07	0.000548	-0.48	-0.41	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
UCEC	cis	rs9326248	0.608	rs1076485	ENSG00000254851.1	RP11-109L13.1	5.44	2.14e-07	0.000549	0.61	0.41	Blood protein levels;	chr11:116901725	chr11:117135528~117138582:+
UCEC	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-5.44	2.15e-07	0.000551	-0.54	-0.41	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-5.44	2.15e-07	0.000551	-0.54	-0.41	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
UCEC	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	5.44	2.15e-07	0.000551	0.72	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	5.44	2.15e-07	0.000551	0.72	0.41	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	5.44	2.15e-07	0.000551	0.72	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
UCEC	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	5.44	2.17e-07	0.000556	0.46	0.41	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
UCEC	cis	rs806321	0.755	rs1985704	ENSG00000237152.3	DLEU7-AS1	-5.44	2.18e-07	0.000556	-0.45	-0.41	Multiple sclerosis;	chr13:50210716	chr13:50807856~50849905:+
UCEC	cis	rs806321	0.755	rs1007852	ENSG00000237152.3	DLEU7-AS1	-5.44	2.18e-07	0.000556	-0.45	-0.41	Multiple sclerosis;	chr13:50210756	chr13:50807856~50849905:+
UCEC	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	5.43	2.19e-07	0.000559	0.66	0.41	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	5.43	2.19e-07	0.000559	0.66	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	5.43	2.19e-07	0.000559	0.66	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
UCEC	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	5.43	2.19e-07	0.000559	0.42	0.41	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	5.43	2.19e-07	0.000559	0.42	0.41	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	5.43	2.19e-07	0.000559	0.42	0.41	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
UCEC	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	5.43	2.21e-07	0.000563	0.48	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
UCEC	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-5.43	2.21e-07	0.000564	-0.72	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
UCEC	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	5.43	2.23e-07	0.000569	0.7	0.41	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
UCEC	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	5.43	2.24e-07	0.000569	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
UCEC	cis	rs12681963	0.748	rs10088714	ENSG00000271869.1	RP11-51J9.5	5.43	2.24e-07	0.000569	0.41	0.41	Migraine;	chr8:30034635	chr8:30155830~30156232:-
UCEC	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	5.43	2.24e-07	0.000571	0.51	0.41	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
UCEC	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	5.43	2.25e-07	0.000571	0.41	0.41	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
UCEC	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	5.43	2.26e-07	0.000574	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
UCEC	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-5.43	2.26e-07	0.000575	-0.44	-0.41	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
UCEC	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	5.43	2.29e-07	0.00058	0.47	0.41	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	5.43	2.29e-07	0.00058	0.47	0.41	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	5.43	2.29e-07	0.00058	0.47	0.41	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
UCEC	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	5.42	2.3e-07	0.000583	0.49	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
UCEC	cis	rs7267979	0.899	rs2179459	ENSG00000276952.1	RP5-965G21.6	5.42	2.32e-07	0.000586	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs1541061	ENSG00000276952.1	RP5-965G21.6	5.42	2.32e-07	0.000586	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs6138600	ENSG00000276952.1	RP5-965G21.6	5.42	2.32e-07	0.000586	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.899	rs2104734	ENSG00000276952.1	RP5-965G21.6	5.42	2.32e-07	0.000586	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25284915~25285588:-
UCEC	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-5.42	2.32e-07	0.000587	-0.51	-0.41	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
UCEC	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	5.42	2.32e-07	0.000588	0.48	0.41	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
UCEC	cis	rs7267979	0.899	rs6115213	ENSG00000276952.1	RP5-965G21.6	5.42	2.33e-07	0.00059	0.53	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2482918	ENSG00000276952.1	RP5-965G21.6	-5.42	2.34e-07	0.000591	-0.54	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25284915~25285588:-
UCEC	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-5.42	2.35e-07	0.000593	-0.48	-0.41	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
UCEC	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	5.42	2.36e-07	0.000595	0.51	0.41	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
UCEC	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	5.42	2.37e-07	0.000598	0.47	0.41	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
UCEC	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	5.42	2.37e-07	0.000598	0.62	0.41	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	5.42	2.37e-07	0.000598	0.62	0.41	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	5.42	2.37e-07	0.000599	0.47	0.41	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
UCEC	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	5.42	2.37e-07	0.000599	0.7	0.41	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
UCEC	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-5.42	2.38e-07	6e-04	-0.41	-0.41	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
UCEC	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	5.42	2.38e-07	6e-04	0.45	0.41	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
UCEC	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	5.42	2.39e-07	0.000602	0.54	0.41	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
UCEC	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-5.42	2.4e-07	0.000604	-0.57	-0.41	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-5.42	2.4e-07	0.000604	-0.57	-0.41	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
UCEC	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-5.41	2.41e-07	0.000606	-0.55	-0.41	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
UCEC	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-5.41	2.41e-07	0.000606	-0.55	-0.41	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
UCEC	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-5.41	2.41e-07	0.000606	-0.55	-0.41	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
UCEC	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-5.41	2.41e-07	0.000606	-0.55	-0.41	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-5.41	2.41e-07	0.000606	-0.55	-0.41	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
UCEC	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-5.41	2.41e-07	0.000606	-0.55	-0.41	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
UCEC	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-5.41	2.41e-07	0.000606	-0.55	-0.41	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
UCEC	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-5.41	2.41e-07	0.000606	-0.55	-0.41	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
UCEC	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-5.41	2.41e-07	0.000606	-0.55	-0.41	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
UCEC	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	5.41	2.42e-07	0.000608	0.44	0.41	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
UCEC	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	5.41	2.43e-07	0.000611	0.45	0.41	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
UCEC	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-5.41	2.43e-07	0.000612	-0.55	-0.41	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
UCEC	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-5.41	2.44e-07	0.000613	-0.53	-0.41	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
UCEC	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-5.41	2.45e-07	0.000614	-0.5	-0.41	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
UCEC	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-5.41	2.45e-07	0.000615	-0.45	-0.41	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-5.41	2.45e-07	0.000615	-0.45	-0.41	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
UCEC	cis	rs7267979	0.903	rs2500400	ENSG00000276952.1	RP5-965G21.6	-5.41	2.45e-07	0.000615	-0.54	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25284915~25285588:-
UCEC	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	5.41	2.45e-07	0.000615	0.44	0.41	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	5.41	2.45e-07	0.000615	0.44	0.41	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	5.41	2.45e-07	0.000615	0.44	0.41	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
UCEC	cis	rs7246967	0.673	rs11881740	ENSG00000198153.8	ZNF849P	-5.41	2.45e-07	0.000616	-0.46	-0.41	Bronchopulmonary dysplasia;	chr19:22661042	chr19:22685167~22686732:+
UCEC	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	5.41	2.46e-07	0.000618	0.53	0.41	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
UCEC	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	5.41	2.47e-07	0.00062	0.5	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	5.41	2.47e-07	0.00062	0.5	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	5.41	2.47e-07	0.00062	0.5	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	5.41	2.47e-07	0.00062	0.5	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	5.41	2.47e-07	0.00062	0.5	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	5.41	2.47e-07	0.00062	0.5	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
UCEC	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-5.41	2.47e-07	0.00062	-0.57	-0.41	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
UCEC	cis	rs7267979	0.966	rs6037083	ENSG00000276952.1	RP5-965G21.6	-5.41	2.49e-07	0.000622	-0.52	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25284915~25285588:-
UCEC	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	5.41	2.49e-07	0.000623	0.56	0.41	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
UCEC	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	5.41	2.49e-07	0.000623	0.55	0.41	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
UCEC	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	5.41	2.49e-07	0.000624	0.54	0.41	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
UCEC	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-5.41	2.49e-07	0.000624	-0.47	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
UCEC	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	5.41	2.5e-07	0.000625	0.41	0.4	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
UCEC	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-5.41	2.5e-07	0.000625	-0.81	-0.4	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-5.41	2.5e-07	0.000625	-0.81	-0.4	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
UCEC	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	5.41	2.51e-07	0.000628	0.55	0.4	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
UCEC	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	5.41	2.51e-07	0.000628	0.55	0.4	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
UCEC	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	5.41	2.51e-07	0.000628	0.55	0.4	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
UCEC	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	5.4	2.52e-07	0.00063	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
UCEC	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	5.4	2.52e-07	0.00063	0.47	0.4	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
UCEC	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	5.4	2.53e-07	0.000631	0.43	0.4	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
UCEC	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-5.4	2.53e-07	0.000631	-0.8	-0.4	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	5.4	2.53e-07	0.000632	0.43	0.4	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
UCEC	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	5.4	2.53e-07	0.000632	0.46	0.4	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
UCEC	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-5.4	2.56e-07	0.000638	-0.6	-0.4	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
UCEC	cis	rs7267979	0.739	rs6138555	ENSG00000276952.1	RP5-965G21.6	5.4	2.56e-07	0.000639	0.53	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25284915~25285588:-
UCEC	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	5.4	2.58e-07	0.000644	0.62	0.4	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
UCEC	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	5.4	2.59e-07	0.000645	0.53	0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
UCEC	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-5.4	2.59e-07	0.000645	-0.58	-0.4	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
UCEC	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-5.4	2.59e-07	0.000646	-0.45	-0.4	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
UCEC	cis	rs7615952	0.673	rs34209763	ENSG00000241288.6	RP11-379B18.5	-5.4	2.59e-07	0.000646	-0.61	-0.4	Blood pressure (smoking interaction);	chr3:125880752	chr3:125827238~125916384:-
UCEC	cis	rs7615952	0.8	rs35390120	ENSG00000241288.6	RP11-379B18.5	-5.4	2.59e-07	0.000646	-0.61	-0.4	Blood pressure (smoking interaction);	chr3:125880966	chr3:125827238~125916384:-
UCEC	cis	rs7267979	1	rs453329	ENSG00000276952.1	RP5-965G21.6	5.4	2.61e-07	0.00065	0.52	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25284915~25285588:-
UCEC	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-5.4	2.61e-07	0.00065	-0.51	-0.4	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
UCEC	cis	rs4853012	1	rs4853012	ENSG00000217702.2	RP11-287D1.4	5.4	2.63e-07	0.000654	0.74	0.4	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74130583~74135395:+
UCEC	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-5.4	2.63e-07	0.000654	-0.45	-0.4	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
UCEC	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	5.4	2.63e-07	0.000654	0.47	0.4	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
UCEC	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	5.39	2.65e-07	0.000657	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
UCEC	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	5.39	2.65e-07	0.000658	0.52	0.4	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	5.39	2.65e-07	0.000659	0.52	0.4	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
UCEC	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	5.39	2.66e-07	0.00066	0.36	0.4	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
UCEC	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	5.39	2.66e-07	0.00066	0.5	0.4	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
UCEC	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	5.39	2.68e-07	0.000664	0.54	0.4	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
UCEC	cis	rs7267979	1	rs7020	ENSG00000276952.1	RP5-965G21.6	5.39	2.68e-07	0.000665	0.52	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25284915~25285588:-
UCEC	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	5.39	2.7e-07	0.000669	0.47	0.4	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
UCEC	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	5.39	2.71e-07	0.000671	0.49	0.4	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	5.39	2.71e-07	0.000671	0.49	0.4	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
UCEC	cis	rs7615952	0.611	rs2971298	ENSG00000241288.6	RP11-379B18.5	-5.39	2.72e-07	0.000673	-0.58	-0.4	Blood pressure (smoking interaction);	chr3:125883870	chr3:125827238~125916384:-
UCEC	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-5.39	2.72e-07	0.000674	-0.46	-0.4	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
UCEC	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	5.39	2.74e-07	0.000676	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
UCEC	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-5.39	2.74e-07	0.000678	-0.52	-0.4	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-5.39	2.74e-07	0.000678	-0.52	-0.4	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
UCEC	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-5.39	2.74e-07	0.000678	-0.52	-0.4	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
UCEC	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-5.39	2.75e-07	0.000678	-0.46	-0.4	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
UCEC	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-5.39	2.75e-07	0.000678	-0.46	-0.4	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
UCEC	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	5.39	2.75e-07	0.000678	0.43	0.4	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
UCEC	cis	rs7615952	0.611	rs35321002	ENSG00000241288.6	RP11-379B18.5	-5.39	2.76e-07	0.000681	-0.6	-0.4	Blood pressure (smoking interaction);	chr3:125893222	chr3:125827238~125916384:-
UCEC	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	5.39	2.76e-07	0.000681	0.68	0.4	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	5.39	2.76e-07	0.000681	0.68	0.4	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	5.39	2.76e-07	0.000681	0.68	0.4	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	5.39	2.76e-07	0.000681	0.68	0.4	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
UCEC	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	5.38	2.77e-07	0.000683	0.47	0.4	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
UCEC	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-5.38	2.77e-07	0.000683	-0.51	-0.4	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-5.38	2.77e-07	0.000683	-0.51	-0.4	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-5.38	2.77e-07	0.000683	-0.51	-0.4	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
UCEC	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	5.38	2.78e-07	0.000685	0.48	0.4	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
UCEC	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	5.38	2.78e-07	0.000685	0.53	0.4	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
UCEC	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-5.38	2.78e-07	0.000686	-0.46	-0.4	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
UCEC	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-5.38	2.78e-07	0.000686	-0.46	-0.4	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
UCEC	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	5.38	2.78e-07	0.000686	0.42	0.4	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
UCEC	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	5.38	2.79e-07	0.000686	0.43	0.4	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
UCEC	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-5.38	2.79e-07	0.000687	-0.54	-0.4	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
UCEC	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	5.38	2.8e-07	0.000688	0.43	0.4	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
UCEC	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	5.38	2.8e-07	0.000689	0.59	0.4	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	5.38	2.81e-07	0.00069	0.53	0.4	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
UCEC	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	5.38	2.82e-07	0.000693	0.64	0.4	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	5.38	2.82e-07	0.000693	0.64	0.4	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	5.38	2.82e-07	0.000693	0.64	0.4	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
UCEC	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	5.38	2.82e-07	0.000693	0.45	0.4	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
UCEC	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-5.38	2.83e-07	0.000694	-0.51	-0.4	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-5.38	2.83e-07	0.000694	-0.51	-0.4	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-5.38	2.83e-07	0.000694	-0.51	-0.4	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-5.38	2.83e-07	0.000694	-0.51	-0.4	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-5.38	2.83e-07	0.000694	-0.51	-0.4	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
UCEC	cis	rs7267979	0.932	rs6132848	ENSG00000276952.1	RP5-965G21.6	5.38	2.83e-07	0.000694	0.52	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs6115200	ENSG00000276952.1	RP5-965G21.6	5.38	2.84e-07	0.000696	0.53	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25284915~25285588:-
UCEC	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	5.38	2.84e-07	0.000697	0.46	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
UCEC	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-5.38	2.84e-07	0.000697	-0.36	-0.4	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-5.38	2.84e-07	0.000697	-0.36	-0.4	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
UCEC	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	5.38	2.85e-07	0.000698	0.49	0.4	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
UCEC	cis	rs7246967	0.673	rs2112610	ENSG00000198153.8	ZNF849P	-5.38	2.85e-07	0.000698	-0.47	-0.4	Bronchopulmonary dysplasia;	chr19:22734049	chr19:22685167~22686732:+
UCEC	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	5.38	2.85e-07	0.000698	0.52	0.4	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
UCEC	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-5.38	2.87e-07	0.000703	-0.37	-0.4	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-5.38	2.87e-07	0.000703	-0.37	-0.4	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-5.38	2.87e-07	0.000703	-0.37	-0.4	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
UCEC	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	5.38	2.88e-07	0.000705	0.49	0.4	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
UCEC	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-5.38	2.88e-07	0.000705	-0.51	-0.4	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-5.38	2.88e-07	0.000705	-0.51	-0.4	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-5.38	2.88e-07	0.000705	-0.51	-0.4	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-5.38	2.88e-07	0.000705	-0.51	-0.4	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
UCEC	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	5.37	2.9e-07	0.000709	0.47	0.4	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
UCEC	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	5.37	2.91e-07	0.00071	0.48	0.4	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	5.37	2.91e-07	0.00071	0.48	0.4	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	5.37	2.91e-07	0.00071	0.48	0.4	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
UCEC	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-5.37	2.91e-07	0.00071	-0.52	-0.4	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
UCEC	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-5.37	2.91e-07	0.00071	-0.45	-0.4	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	5.37	2.92e-07	0.000712	0.45	0.4	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	5.37	2.92e-07	0.000712	0.45	0.4	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-5.37	2.92e-07	0.000712	-0.45	-0.4	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-5.37	2.92e-07	0.000712	-0.45	-0.4	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-5.37	2.92e-07	0.000712	-0.45	-0.4	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-5.37	2.92e-07	0.000712	-0.45	-0.4	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-5.37	2.92e-07	0.000712	-0.45	-0.4	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-5.37	2.92e-07	0.000712	-0.45	-0.4	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
UCEC	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	5.37	2.92e-07	0.000712	0.42	0.4	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
UCEC	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-5.37	2.92e-07	0.000712	-0.56	-0.4	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
UCEC	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	5.37	2.92e-07	0.000713	0.47	0.4	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
UCEC	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	5.37	2.92e-07	0.000713	0.47	0.4	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	5.37	2.92e-07	0.000713	0.47	0.4	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
UCEC	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-5.37	2.93e-07	0.000716	-0.45	-0.4	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
UCEC	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-5.37	2.94e-07	0.000717	-0.47	-0.4	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
UCEC	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-5.37	2.95e-07	0.00072	-0.45	-0.4	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
UCEC	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-5.37	2.95e-07	0.00072	-0.45	-0.4	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
UCEC	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-5.37	2.95e-07	0.00072	-0.45	-0.4	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
UCEC	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	5.37	2.97e-07	0.000722	0.54	0.4	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	5.37	2.97e-07	0.000722	0.54	0.4	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	5.37	2.97e-07	0.000722	0.53	0.4	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	5.37	2.97e-07	0.000722	0.53	0.4	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	5.37	2.97e-07	0.000722	0.53	0.4	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	5.37	2.97e-07	0.000722	0.53	0.4	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	5.37	2.97e-07	0.000722	0.53	0.4	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
UCEC	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-5.37	2.97e-07	0.000722	-0.46	-0.4	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
UCEC	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-5.37	2.98e-07	0.000723	-0.56	-0.4	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
UCEC	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-5.37	2.98e-07	0.000723	-0.56	-0.4	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
UCEC	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-5.37	2.98e-07	0.000723	-0.46	-0.4	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
UCEC	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-5.37	2.98e-07	0.000723	-0.46	-0.4	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
UCEC	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-5.37	2.98e-07	0.000723	-0.46	-0.4	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
UCEC	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-5.37	2.99e-07	0.000725	-0.45	-0.4	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
UCEC	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	5.37	2.99e-07	0.000726	0.61	0.4	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
UCEC	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	5.37	3.01e-07	0.000729	0.46	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
UCEC	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-5.37	3.01e-07	0.000729	-0.45	-0.4	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
UCEC	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	5.37	3.01e-07	0.000729	0.42	0.4	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
UCEC	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-5.37	3.01e-07	0.000729	-0.46	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
UCEC	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	5.37	3.02e-07	0.000731	0.5	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
UCEC	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-5.36	3.05e-07	0.000737	-0.67	-0.4	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
UCEC	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-5.36	3.05e-07	0.000737	-0.43	-0.4	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
UCEC	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	5.36	3.05e-07	0.000737	0.53	0.4	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	5.36	3.05e-07	0.000737	0.53	0.4	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	5.36	3.05e-07	0.000737	0.53	0.4	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	5.36	3.05e-07	0.000737	0.53	0.4	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	5.36	3.05e-07	0.000737	0.53	0.4	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
UCEC	cis	rs1930961	0.702	rs28421243	ENSG00000272977.1	CTA-390C10.10	-5.36	3.06e-07	0.000739	-0.81	-0.4	Bipolar disorder with mood-incongruent psychosis;	chr22:25522823	chr22:25476218~25479971:+
UCEC	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	5.36	3.06e-07	0.000739	0.59	0.4	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
UCEC	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-5.36	3.07e-07	0.000741	-0.5	-0.4	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
UCEC	cis	rs7246967	0.673	rs1433085	ENSG00000198153.8	ZNF849P	-5.36	3.07e-07	0.000741	-0.47	-0.4	Bronchopulmonary dysplasia;	chr19:22628297	chr19:22685167~22686732:+
UCEC	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-5.36	3.08e-07	0.000743	-0.82	-0.4	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
UCEC	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	5.36	3.09e-07	0.000745	0.68	0.4	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	5.36	3.09e-07	0.000745	0.68	0.4	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
UCEC	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-5.36	3.1e-07	0.000748	-0.74	-0.4	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
UCEC	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	5.36	3.11e-07	0.000749	0.55	0.4	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
UCEC	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	5.36	3.12e-07	0.000752	0.49	0.4	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
UCEC	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-5.36	3.13e-07	0.000754	-0.55	-0.4	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
UCEC	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	5.36	3.15e-07	0.000758	0.49	0.4	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
UCEC	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-5.36	3.16e-07	0.000762	-0.48	-0.4	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
UCEC	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	5.36	3.17e-07	0.000764	0.5	0.4	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-5.36	3.17e-07	0.000764	-0.5	-0.4	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-5.36	3.17e-07	0.000764	-0.5	-0.4	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-5.36	3.17e-07	0.000764	-0.5	-0.4	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
UCEC	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	5.35	3.18e-07	0.000764	0.47	0.4	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	5.35	3.18e-07	0.000764	0.47	0.4	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
UCEC	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	5.35	3.18e-07	0.000764	0.66	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
UCEC	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-5.35	3.18e-07	0.000764	-0.45	-0.4	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-5.35	3.18e-07	0.000764	-0.45	-0.4	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
UCEC	cis	rs2239633	0.619	rs12892722	ENSG00000279656.1	RP11-298I3.6	5.35	3.18e-07	0.000766	0.5	0.4	Eosinophil percentage of white cells;Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Eosinophil percentage of granulocytes;Eosinophil counts;	chr14:23113192	chr14:23023083~23024217:-
UCEC	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	5.35	3.18e-07	0.000766	0.82	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
UCEC	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-5.35	3.19e-07	0.000766	-0.51	-0.4	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
UCEC	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	5.35	3.2e-07	0.000769	0.53	0.4	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	5.35	3.2e-07	0.000769	0.53	0.4	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
UCEC	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-5.35	3.2e-07	0.000769	-0.48	-0.4	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
UCEC	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-5.35	3.23e-07	0.000774	-0.55	-0.4	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
UCEC	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	5.35	3.23e-07	0.000774	0.67	0.4	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
UCEC	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	5.35	3.24e-07	0.000777	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	5.35	3.24e-07	0.000778	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
UCEC	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-5.35	3.25e-07	0.00078	-0.5	-0.4	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
UCEC	cis	rs7267979	1	rs2424704	ENSG00000276952.1	RP5-965G21.6	5.35	3.25e-07	0.00078	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25284915~25285588:-
UCEC	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	5.35	3.26e-07	0.00078	0.76	0.4	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
UCEC	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-5.35	3.26e-07	0.00078	-0.46	-0.4	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
UCEC	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-5.35	3.28e-07	0.000783	-0.43	-0.4	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
UCEC	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	5.35	3.28e-07	0.000783	0.5	0.4	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-5.35	3.28e-07	0.000783	-0.5	-0.4	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
UCEC	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	5.35	3.28e-07	0.000784	0.42	0.4	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	5.35	3.28e-07	0.000784	0.42	0.4	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	5.35	3.28e-07	0.000784	0.42	0.4	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	5.35	3.28e-07	0.000784	0.42	0.4	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	5.35	3.28e-07	0.000784	0.42	0.4	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
UCEC	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-5.35	3.3e-07	0.000787	-0.5	-0.4	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	5.35	3.3e-07	0.000787	0.5	0.4	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
UCEC	cis	rs1930961	0.702	rs7284654	ENSG00000272977.1	CTA-390C10.10	-5.35	3.31e-07	0.000789	-0.84	-0.4	Bipolar disorder with mood-incongruent psychosis;	chr22:25521181	chr22:25476218~25479971:+
UCEC	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	5.35	3.31e-07	0.000789	0.44	0.4	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
UCEC	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	5.35	3.32e-07	0.00079	0.66	0.4	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
UCEC	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	5.34	3.33e-07	0.000792	0.52	0.4	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
UCEC	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-5.34	3.33e-07	0.000792	-0.36	-0.4	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-5.34	3.33e-07	0.000792	-0.36	-0.4	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-5.34	3.33e-07	0.000792	-0.36	-0.4	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	5.34	3.34e-07	0.000795	0.52	0.4	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
UCEC	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	5.34	3.34e-07	0.000795	0.46	0.4	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
UCEC	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	5.34	3.35e-07	0.000797	0.42	0.4	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
UCEC	cis	rs2739330	0.76	rs5751760	ENSG00000272787.1	KB-226F1.2	-5.34	3.36e-07	0.000799	-0.49	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23969211~23969873:+
UCEC	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	5.34	3.37e-07	8e-04	0.45	0.4	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	5.34	3.37e-07	8e-04	0.45	0.4	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
UCEC	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	5.34	3.37e-07	8e-04	0.43	0.4	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
UCEC	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	5.34	3.4e-07	0.000807	0.66	0.4	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	5.34	3.4e-07	0.000807	0.66	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	5.34	3.4e-07	0.000807	0.66	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
UCEC	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-5.34	3.42e-07	0.000811	-0.46	-0.4	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
UCEC	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	5.34	3.44e-07	0.000814	0.67	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	5.34	3.44e-07	0.000814	0.67	0.4	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	5.34	3.44e-07	0.000814	0.67	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
UCEC	cis	rs7267979	0.966	rs2261790	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2261794	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2145126	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2257705	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2227892	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2257712	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2257461	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.934	rs2257464	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2257808	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2257809	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs910997	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs3002702	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2257982	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2257985	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2257988	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2257432	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2258066	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2258135	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2258201	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2258563	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2258617	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.933	rs2258728	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2258769	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2258879	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2257496	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2258884	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2259837	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2259873	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs11100	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs1046073	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2259926	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2259928	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2259956	ENSG00000276952.1	RP5-965G21.6	5.34	3.45e-07	0.000814	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2297496	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2297497	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs7343481	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6115146	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.934	rs6037085	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs6050532	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6083804	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815405	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050542	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6076336	ENSG00000276952.1	RP5-965G21.6	-5.34	3.45e-07	0.000814	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25284915~25285588:-
UCEC	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-5.34	3.47e-07	0.000818	-0.45	-0.4	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
UCEC	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-5.34	3.47e-07	0.000818	-0.37	-0.4	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
UCEC	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-5.34	3.48e-07	0.000822	-0.46	-0.4	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-5.34	3.48e-07	0.000822	-0.46	-0.4	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
UCEC	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	5.33	3.49e-07	0.000823	0.54	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
UCEC	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-5.33	3.5e-07	0.000824	-0.47	-0.4	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-5.33	3.5e-07	0.000824	-0.47	-0.4	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
UCEC	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-5.33	3.5e-07	0.000824	-0.47	-0.4	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-5.33	3.5e-07	0.000824	-0.47	-0.4	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-5.33	3.5e-07	0.000824	-0.47	-0.4	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-5.33	3.5e-07	0.000824	-0.47	-0.4	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
UCEC	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	5.33	3.51e-07	0.000826	0.45	0.4	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
UCEC	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	5.33	3.51e-07	0.000827	0.53	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
UCEC	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	5.33	3.51e-07	0.000828	0.42	0.4	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
UCEC	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	5.33	3.52e-07	0.000829	0.5	0.4	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	5.33	3.52e-07	0.000829	0.5	0.4	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
UCEC	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-5.33	3.52e-07	0.000829	-0.79	-0.4	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-5.33	3.52e-07	0.000829	-0.79	-0.4	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-5.33	3.52e-07	0.000829	-0.79	-0.4	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-5.33	3.52e-07	0.000829	-0.79	-0.4	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
UCEC	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	5.33	3.53e-07	0.00083	0.61	0.4	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
UCEC	cis	rs7267979	0.966	rs2227890	ENSG00000276952.1	RP5-965G21.6	5.33	3.54e-07	0.000832	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.934	rs2261753	ENSG00000276952.1	RP5-965G21.6	5.33	3.54e-07	0.000832	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2261784	ENSG00000276952.1	RP5-965G21.6	5.33	3.54e-07	0.000832	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2261785	ENSG00000276952.1	RP5-965G21.6	5.33	3.54e-07	0.000832	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25284915~25285588:-
UCEC	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	5.33	3.54e-07	0.000833	0.48	0.4	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
UCEC	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	5.33	3.55e-07	0.000834	0.41	0.4	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
UCEC	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	5.33	3.56e-07	0.000836	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	5.33	3.56e-07	0.000836	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
UCEC	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	5.33	3.57e-07	0.000838	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	5.33	3.57e-07	0.000838	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
UCEC	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	5.33	3.58e-07	0.00084	0.41	0.4	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	5.33	3.58e-07	0.00084	0.41	0.4	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
UCEC	cis	rs6840360	0.642	rs7684462	ENSG00000278978.1	RP11-164P12.5	-5.33	3.6e-07	0.000842	-0.47	-0.4	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.667	rs4266275	ENSG00000278978.1	RP11-164P12.5	-5.33	3.62e-07	0.000846	-0.47	-0.4	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151669786~151670503:+
UCEC	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	5.33	3.63e-07	0.000846	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-5.33	3.63e-07	0.000846	-0.43	-0.4	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-5.33	3.63e-07	0.000846	-0.43	-0.4	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
UCEC	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	5.33	3.63e-07	0.000846	0.49	0.4	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
UCEC	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	5.33	3.64e-07	0.000848	0.43	0.4	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
UCEC	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	5.33	3.64e-07	0.000849	0.5	0.4	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
UCEC	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-5.33	3.64e-07	0.000849	-0.86	-0.4	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	5.33	3.65e-07	0.00085	0.55	0.4	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
UCEC	cis	rs7267979	1	rs2257420	ENSG00000276952.1	RP5-965G21.6	5.32	3.65e-07	0.000851	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25284915~25285588:-
UCEC	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	5.32	3.66e-07	0.000853	0.67	0.4	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
UCEC	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	5.32	3.67e-07	0.000854	0.43	0.4	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
UCEC	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	5.32	3.68e-07	0.000856	0.43	0.4	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
UCEC	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-5.32	3.68e-07	0.000856	-0.71	-0.4	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
UCEC	cis	rs240993	0.809	rs11153277	ENSG00000271789.1	RP5-1112D6.7	-5.32	3.68e-07	0.000856	-0.45	-0.4	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111297126~111298510:+
UCEC	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	5.32	3.7e-07	0.000859	0.69	0.4	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
UCEC	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-5.32	3.7e-07	0.00086	-0.46	-0.4	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
UCEC	cis	rs7267979	1	rs1077889	ENSG00000276952.1	RP5-965G21.6	5.32	3.7e-07	0.00086	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25284915~25285588:-
UCEC	cis	rs8005677	0.828	rs12589539	ENSG00000257285.4	RP11-298I3.1	5.32	3.71e-07	0.000861	0.39	0.4	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:22929609~22955562:+
UCEC	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-5.32	3.72e-07	0.000863	-0.51	-0.4	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
UCEC	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-5.32	3.74e-07	0.000867	-0.5	-0.4	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
UCEC	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-5.32	3.75e-07	0.000867	-0.51	-0.4	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	5.32	3.75e-07	0.000867	0.51	0.4	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
UCEC	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	5.32	3.75e-07	0.000867	0.45	0.4	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
UCEC	cis	rs899997	0.954	rs4887091	ENSG00000261143.1	ADAMTS7P3	5.32	3.76e-07	0.000869	0.51	0.4	Coronary artery disease or large artery stroke;	chr15:78751238	chr15:77976042~77993057:+
UCEC	cis	rs899997	1	rs11632672	ENSG00000261143.1	ADAMTS7P3	5.32	3.76e-07	0.000869	0.51	0.4	Coronary artery disease or large artery stroke;	chr15:78751988	chr15:77976042~77993057:+
UCEC	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-5.32	3.76e-07	0.00087	-0.46	-0.4	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
UCEC	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	5.32	3.78e-07	0.000875	0.51	0.4	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
UCEC	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-5.32	3.79e-07	0.000875	-0.51	-0.4	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-5.32	3.79e-07	0.000875	-0.51	-0.4	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-5.32	3.79e-07	0.000875	-0.51	-0.4	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-5.32	3.79e-07	0.000875	-0.51	-0.4	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-5.32	3.79e-07	0.000875	-0.51	-0.4	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
UCEC	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	5.32	3.79e-07	0.000876	0.51	0.4	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
UCEC	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-5.32	3.8e-07	0.000878	-0.51	-0.4	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-5.32	3.8e-07	0.000878	-0.51	-0.4	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
UCEC	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	5.32	3.82e-07	0.000881	0.45	0.4	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
UCEC	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	5.31	3.83e-07	0.000882	0.52	0.4	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
UCEC	cis	rs6840360	0.642	rs7678823	ENSG00000278978.1	RP11-164P12.5	-5.31	3.84e-07	0.000884	-0.47	-0.4	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151669786~151670503:+
UCEC	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-5.31	3.86e-07	0.000889	-0.51	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
UCEC	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-5.31	3.88e-07	0.000892	-0.49	-0.4	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
UCEC	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-5.31	3.91e-07	0.000897	-0.56	-0.4	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
UCEC	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	5.31	3.91e-07	0.000898	0.45	0.4	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
UCEC	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-5.31	3.92e-07	0.000899	-0.49	-0.4	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
UCEC	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-5.31	3.93e-07	9e-04	-0.79	-0.4	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-5.31	3.93e-07	9e-04	-0.79	-0.4	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-5.31	3.93e-07	9e-04	-0.79	-0.4	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-5.31	3.93e-07	9e-04	-0.79	-0.4	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-5.31	3.93e-07	9e-04	-0.79	-0.4	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-5.31	3.93e-07	9e-04	-0.79	-0.4	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-5.31	3.93e-07	9e-04	-0.79	-0.4	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-5.31	3.93e-07	9e-04	-0.79	-0.4	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
UCEC	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	5.31	3.94e-07	0.000903	0.49	0.4	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-5.31	3.94e-07	0.000903	-0.47	-0.4	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-5.31	3.94e-07	0.000903	-0.47	-0.4	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
UCEC	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	5.31	3.97e-07	0.000908	0.48	0.4	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
UCEC	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-5.31	3.97e-07	0.000909	-0.44	-0.4	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-5.31	3.97e-07	0.000909	-0.44	-0.4	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-5.31	3.97e-07	0.000909	-0.44	-0.4	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
UCEC	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	5.31	3.99e-07	0.000912	0.42	0.4	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
UCEC	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-5.31	4e-07	0.000914	-0.47	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
UCEC	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	5.3	4.01e-07	0.000916	0.46	0.4	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
UCEC	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-5.3	4.03e-07	0.00092	-0.44	-0.4	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-5.3	4.03e-07	0.00092	-0.44	-0.4	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-5.3	4.03e-07	0.00092	-0.44	-0.4	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
UCEC	cis	rs12681963	0.748	rs1511168	ENSG00000271869.1	RP11-51J9.5	5.3	4.03e-07	0.00092	0.4	0.4	Migraine;	chr8:30036318	chr8:30155830~30156232:-
UCEC	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-5.3	4.07e-07	0.000927	-0.54	-0.4	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
UCEC	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-5.3	4.08e-07	0.00093	-0.49	-0.4	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
UCEC	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-5.3	4.08e-07	0.00093	-0.47	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-5.3	4.08e-07	0.00093	-0.47	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
UCEC	cis	rs7267979	0.773	rs6132821	ENSG00000276952.1	RP5-965G21.6	5.3	4.08e-07	0.00093	0.54	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.873	rs6132822	ENSG00000276952.1	RP5-965G21.6	5.3	4.08e-07	0.00093	0.54	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.844	rs1555330	ENSG00000276952.1	RP5-965G21.6	5.3	4.08e-07	0.00093	0.54	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.844	rs6107017	ENSG00000276952.1	RP5-965G21.6	5.3	4.08e-07	0.00093	0.54	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25284915~25285588:-
UCEC	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	5.3	4.09e-07	0.000931	0.49	0.4	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
UCEC	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-5.3	4.1e-07	0.000932	-0.36	-0.4	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
UCEC	cis	rs899997	1	rs11072793	ENSG00000261143.1	ADAMTS7P3	5.3	4.12e-07	0.000937	0.49	0.4	Coronary artery disease or large artery stroke;	chr15:78714100	chr15:77976042~77993057:+
UCEC	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	5.3	4.12e-07	0.000937	0.48	0.4	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
UCEC	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-5.3	4.13e-07	0.000938	-0.49	-0.4	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-5.3	4.13e-07	0.000938	-0.49	-0.4	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-5.3	4.13e-07	0.000938	-0.49	-0.4	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
UCEC	cis	rs7267979	0.866	rs6138609	ENSG00000276952.1	RP5-965G21.6	5.3	4.13e-07	0.000939	0.52	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25284915~25285588:-
UCEC	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-5.3	4.15e-07	0.000942	-0.71	-0.4	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
UCEC	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	5.3	4.17e-07	0.000947	0.57	0.4	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
UCEC	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-5.29	4.2e-07	0.000954	-0.52	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
UCEC	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	5.29	4.21e-07	0.000954	0.52	0.4	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
UCEC	cis	rs7267979	1	rs6050547	ENSG00000276952.1	RP5-965G21.6	-5.29	4.21e-07	0.000954	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25284915~25285588:-
UCEC	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-5.29	4.22e-07	0.000957	-0.43	-0.4	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
UCEC	cis	rs7208859	0.673	rs57432042	ENSG00000263531.1	RP13-753N3.1	5.29	4.23e-07	0.000958	0.75	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30914020	chr17:30863921~30864940:-
UCEC	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	5.29	4.24e-07	0.000962	0.52	0.4	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
UCEC	cis	rs73219805	1	rs1042992	ENSG00000228451.3	SDAD1P1	5.29	4.25e-07	0.000964	0.5	0.4	Schizophrenia;	chr8:26411675	chr8:26379259~26382953:-
UCEC	cis	rs950169	0.92	rs11637666	ENSG00000225151.9	GOLGA2P7	-5.29	4.27e-07	0.000967	-0.57	-0.4	Schizophrenia;	chr15:84035122	chr15:84199311~84230136:-
UCEC	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	5.29	4.29e-07	0.00097	0.48	0.4	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
UCEC	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-5.29	4.3e-07	0.000973	-0.51	-0.4	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
UCEC	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	5.29	4.3e-07	0.000974	0.42	0.4	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
UCEC	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	5.29	4.31e-07	0.000974	0.44	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-5.29	4.32e-07	0.000976	-0.52	-0.4	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
UCEC	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	5.29	4.33e-07	0.000979	0.45	0.4	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
UCEC	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	5.29	4.33e-07	0.000979	0.45	0.4	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
UCEC	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-5.29	4.36e-07	0.000984	-0.46	-0.4	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
UCEC	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-5.29	4.36e-07	0.000985	-0.53	-0.4	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
UCEC	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	5.29	4.36e-07	0.000985	0.5	0.4	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	5.29	4.36e-07	0.000985	0.5	0.4	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	5.29	4.36e-07	0.000985	0.5	0.4	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
UCEC	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	5.29	4.36e-07	0.000985	0.46	0.4	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
UCEC	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.29	4.38e-07	0.000989	0.52	0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
UCEC	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	5.29	4.39e-07	0.00099	0.46	0.4	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
UCEC	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-5.28	4.4e-07	0.000993	-0.45	-0.4	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
UCEC	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	5.28	4.41e-07	0.000995	0.51	0.4	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	5.28	4.41e-07	0.000995	0.51	0.4	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	5.28	4.41e-07	0.000995	0.51	0.4	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
UCEC	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	5.28	4.43e-07	0.000997	0.59	0.4	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	5.28	4.43e-07	0.000997	0.59	0.4	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	5.28	4.43e-07	0.000997	0.59	0.4	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	5.28	4.43e-07	0.000997	0.59	0.4	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	5.28	4.43e-07	0.000997	0.59	0.4	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	5.28	4.43e-07	0.000997	0.59	0.4	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	5.28	4.43e-07	0.000997	0.59	0.4	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
UCEC	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-5.28	4.43e-07	0.000997	-0.43	-0.4	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-5.28	4.43e-07	0.000997	-0.43	-0.4	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-5.28	4.43e-07	0.000997	-0.43	-0.4	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
UCEC	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	5.28	4.45e-07	0.000999	0.5	0.4	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	5.28	4.45e-07	0.000999	0.5	0.4	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	5.28	4.45e-07	0.000999	0.5	0.4	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
UCEC	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-5.28	4.49e-07	0.00101	-0.45	-0.4	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	5.28	4.53e-07	0.00102	0.45	0.4	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
UCEC	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-5.28	4.55e-07	0.00102	-0.47	-0.4	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
UCEC	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	5.28	4.55e-07	0.00102	0.63	0.4	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
UCEC	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	5.28	4.56e-07	0.00102	0.63	0.4	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
UCEC	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	5.28	4.57e-07	0.00102	0.51	0.4	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
UCEC	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-5.28	4.57e-07	0.00102	-0.51	-0.4	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
UCEC	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-5.28	4.59e-07	0.00103	-0.45	-0.4	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
UCEC	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5.27	4.6e-07	0.00103	0.52	0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
UCEC	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-5.27	4.61e-07	0.00103	-0.47	-0.4	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
UCEC	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	5.27	4.62e-07	0.00103	0.47	0.4	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
UCEC	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	5.27	4.62e-07	0.00103	0.47	0.4	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
UCEC	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	5.27	4.62e-07	0.00103	0.47	0.4	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
UCEC	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	5.27	4.63e-07	0.00103	0.57	0.4	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
UCEC	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	5.27	4.66e-07	0.00104	0.45	0.4	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
UCEC	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-5.27	4.68e-07	0.00104	-0.45	-0.4	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
UCEC	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-5.27	4.68e-07	0.00104	-0.44	-0.4	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
UCEC	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	5.27	4.71e-07	0.00105	0.76	0.4	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
UCEC	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	5.27	4.72e-07	0.00105	0.46	0.4	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	5.27	4.72e-07	0.00105	0.46	0.4	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
UCEC	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-5.27	4.73e-07	0.00105	-0.53	-0.4	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
UCEC	cis	rs6840360	0.642	rs2709842	ENSG00000278978.1	RP11-164P12.5	5.27	4.73e-07	0.00105	0.47	0.4	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151669786~151670503:+
UCEC	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-5.27	4.74e-07	0.00106	-0.44	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
UCEC	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-5.27	4.75e-07	0.00106	-0.49	-0.4	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
UCEC	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-5.27	4.75e-07	0.00106	-0.49	-0.4	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
UCEC	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-5.27	4.75e-07	0.00106	-0.54	-0.4	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
UCEC	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-5.27	4.75e-07	0.00106	-0.56	-0.4	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
UCEC	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-5.27	4.79e-07	0.00107	-0.45	-0.4	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
UCEC	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	5.27	4.8e-07	0.00107	0.41	0.4	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	5.27	4.8e-07	0.00107	0.41	0.4	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-5.27	4.8e-07	0.00107	-0.51	-0.4	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
UCEC	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-5.26	4.82e-07	0.00107	-0.5	-0.4	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-5.26	4.82e-07	0.00107	-0.5	-0.4	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-5.26	4.82e-07	0.00107	-0.5	-0.4	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
UCEC	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	5.26	4.82e-07	0.00107	0.45	0.4	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
UCEC	cis	rs7267979	1	rs2474777	ENSG00000276952.1	RP5-965G21.6	5.26	4.83e-07	0.00107	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25284915~25285588:-
UCEC	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	5.26	4.83e-07	0.00107	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
UCEC	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-5.26	4.84e-07	0.00108	-0.5	-0.4	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
UCEC	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-5.26	4.85e-07	0.00108	-0.44	-0.4	Height;	chr3:53074760	chr3:53064283~53065091:-
UCEC	cis	rs763121	0.853	rs138704	ENSG00000273076.1	RP3-508I15.22	5.26	4.86e-07	0.00108	0.44	0.4	Menopause (age at onset);	chr22:38737405	chr22:38743495~38743910:+
UCEC	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	5.26	4.87e-07	0.00108	0.52	0.4	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
UCEC	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	5.26	4.89e-07	0.00109	0.52	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
UCEC	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-5.26	4.9e-07	0.00109	-0.71	-0.4	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
UCEC	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-5.26	4.92e-07	0.00109	-0.36	-0.4	Height;	chr11:118761813	chr11:118791254~118793137:+
UCEC	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	5.26	4.93e-07	0.00109	0.43	0.4	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	5.26	4.94e-07	0.0011	0.46	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
UCEC	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-5.26	4.96e-07	0.0011	-0.53	-0.4	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-5.26	4.96e-07	0.0011	-0.53	-0.4	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
UCEC	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-5.26	4.98e-07	0.0011	-0.59	-0.4	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
UCEC	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	5.26	4.98e-07	0.0011	0.5	0.4	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
UCEC	cis	rs950169	0.92	rs34672825	ENSG00000225151.9	GOLGA2P7	-5.26	4.99e-07	0.0011	-0.58	-0.4	Schizophrenia;	chr15:84034718	chr15:84199311~84230136:-
UCEC	cis	rs7267979	0.933	rs11699203	ENSG00000276952.1	RP5-965G21.6	5.26	4.99e-07	0.0011	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.933	rs6138571	ENSG00000276952.1	RP5-965G21.6	5.26	4.99e-07	0.0011	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs448396	ENSG00000276952.1	RP5-965G21.6	5.26	4.99e-07	0.0011	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs447722	ENSG00000276952.1	RP5-965G21.6	5.26	4.99e-07	0.0011	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs422424	ENSG00000276952.1	RP5-965G21.6	5.26	4.99e-07	0.0011	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs422844	ENSG00000276952.1	RP5-965G21.6	5.26	4.99e-07	0.0011	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs401166	ENSG00000276952.1	RP5-965G21.6	5.26	4.99e-07	0.0011	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs404394	ENSG00000276952.1	RP5-965G21.6	5.26	4.99e-07	0.0011	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25284915~25285588:-
UCEC	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	5.26	5e-07	0.00111	0.57	0.4	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
UCEC	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	5.26	5.01e-07	0.00111	0.51	0.4	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	5.26	5.03e-07	0.00111	0.8	0.4	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
UCEC	cis	rs1667255	1	rs7243588	ENSG00000266521.1	RP11-650P15.1	5.25	5.05e-07	0.00112	0.43	0.4	Retinol levels;	chr18:31580649	chr18:31496645~31497195:-
UCEC	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-5.25	5.08e-07	0.00112	-0.58	-0.4	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
UCEC	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-5.25	5.09e-07	0.00112	-0.4	-0.4	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
UCEC	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	5.25	5.09e-07	0.00112	0.5	0.4	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
UCEC	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	5.25	5.1e-07	0.00113	0.53	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
UCEC	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	5.25	5.1e-07	0.00113	0.53	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
UCEC	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-5.25	5.11e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-5.25	5.12e-07	0.00113	-0.44	-0.4	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
UCEC	cis	rs7267979	1	rs6083828	ENSG00000276952.1	RP5-965G21.6	-5.25	5.15e-07	0.00113	-0.51	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25284915~25285588:-
UCEC	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-5.25	5.15e-07	0.00114	-0.46	-0.4	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
UCEC	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-5.25	5.15e-07	0.00114	-0.46	-0.4	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
UCEC	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	5.25	5.16e-07	0.00114	0.46	0.4	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
UCEC	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	5.25	5.16e-07	0.00114	0.52	0.4	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
UCEC	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-5.25	5.17e-07	0.00114	-0.46	-0.4	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
UCEC	cis	rs7267979	1	rs2424700	ENSG00000276952.1	RP5-965G21.6	5.25	5.18e-07	0.00114	0.51	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25284915~25285588:-
UCEC	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-5.25	5.18e-07	0.00114	-0.52	-0.4	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-5.25	5.19e-07	0.00114	-0.71	-0.39	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
UCEC	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	5.25	5.19e-07	0.00114	0.45	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
UCEC	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-5.25	5.21e-07	0.00115	-0.44	-0.39	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
UCEC	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-5.25	5.22e-07	0.00115	-0.51	-0.39	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
UCEC	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
UCEC	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	5.25	5.24e-07	0.00115	0.49	0.39	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
UCEC	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	5.25	5.24e-07	0.00115	0.41	0.39	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
UCEC	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-5.25	5.26e-07	0.00115	-0.47	-0.39	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
UCEC	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-5.25	5.27e-07	0.00115	-0.47	-0.39	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-5.25	5.27e-07	0.00115	-0.47	-0.39	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
UCEC	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	5.24	5.28e-07	0.00115	0.72	0.39	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
UCEC	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	5.24	5.29e-07	0.00116	0.44	0.39	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
UCEC	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-5.24	5.3e-07	0.00116	-0.46	-0.39	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
UCEC	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-5.24	5.3e-07	0.00116	-0.46	-0.39	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
UCEC	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-5.24	5.3e-07	0.00116	-0.46	-0.39	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
UCEC	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-5.24	5.31e-07	0.00116	-0.53	-0.39	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	5.24	5.31e-07	0.00116	0.53	0.39	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	5.24	5.31e-07	0.00116	0.53	0.39	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
UCEC	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	5.24	5.31e-07	0.00116	0.41	0.39	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	5.24	5.31e-07	0.00116	0.41	0.39	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	5.24	5.31e-07	0.00116	0.41	0.39	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
UCEC	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	5.24	5.31e-07	0.00116	0.62	0.39	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
UCEC	cis	rs899997	1	rs11072800	ENSG00000261143.1	ADAMTS7P3	-5.24	5.31e-07	0.00116	-0.52	-0.39	Coronary artery disease or large artery stroke;	chr15:78753515	chr15:77976042~77993057:+
UCEC	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-5.24	5.33e-07	0.00116	-0.44	-0.39	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
UCEC	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-5.24	5.34e-07	0.00116	-0.47	-0.39	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
UCEC	cis	rs4845570	0.85	rs11204892	ENSG00000203288.3	RP11-98D18.9	5.24	5.34e-07	0.00116	0.55	0.39	Coronary artery disease;	chr1:151795572	chr1:151790804~151794402:+
UCEC	cis	rs748404	0.578	rs2244746	ENSG00000205771.5	CATSPER2P1	-5.24	5.34e-07	0.00116	-0.49	-0.39	Lung cancer;	chr15:43402885	chr15:43726918~43747094:-
UCEC	cis	rs4845570	0.85	rs4504897	ENSG00000203288.3	RP11-98D18.9	5.24	5.34e-07	0.00117	0.55	0.39	Coronary artery disease;	chr1:151794375	chr1:151790804~151794402:+
UCEC	cis	rs7267979	0.932	rs6138588	ENSG00000276952.1	RP5-965G21.6	5.24	5.35e-07	0.00117	0.51	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25284915~25285588:-
UCEC	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-5.24	5.35e-07	0.00117	-0.43	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
UCEC	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	5.24	5.36e-07	0.00117	0.57	0.39	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
UCEC	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-5.24	5.38e-07	0.00117	-0.51	-0.39	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
UCEC	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	5.24	5.42e-07	0.00118	0.46	0.39	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	5.24	5.42e-07	0.00118	0.46	0.39	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	5.24	5.42e-07	0.00118	0.46	0.39	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
UCEC	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	5.24	5.44e-07	0.00118	0.49	0.39	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
UCEC	cis	rs62388641	0.636	rs35412353	ENSG00000272279.1	RP11-157J24.2	5.24	5.46e-07	0.00119	0.68	0.39	Daytime sleep phenotypes;	chr6:1529209	chr6:1528364~1528911:-
UCEC	cis	rs62388641	0.636	rs62388638	ENSG00000272279.1	RP11-157J24.2	5.24	5.46e-07	0.00119	0.68	0.39	Daytime sleep phenotypes;	chr6:1529224	chr6:1528364~1528911:-
UCEC	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	5.24	5.49e-07	0.00119	0.41	0.39	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
UCEC	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-5.24	5.49e-07	0.00119	-0.53	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
UCEC	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-5.24	5.49e-07	0.00119	-0.48	-0.39	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-5.24	5.49e-07	0.00119	-0.48	-0.39	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
UCEC	cis	rs7267979	0.966	rs7270835	ENSG00000276952.1	RP5-965G21.6	5.23	5.52e-07	0.0012	0.52	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6115191	ENSG00000276952.1	RP5-965G21.6	5.23	5.52e-07	0.0012	0.52	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6107045	ENSG00000276952.1	RP5-965G21.6	5.23	5.52e-07	0.0012	0.52	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6107046	ENSG00000276952.1	RP5-965G21.6	5.23	5.52e-07	0.0012	0.52	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6107047	ENSG00000276952.1	RP5-965G21.6	5.23	5.52e-07	0.0012	0.52	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25284915~25285588:-
UCEC	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	5.23	5.53e-07	0.0012	0.5	0.39	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	5.23	5.53e-07	0.0012	0.5	0.39	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	5.23	5.53e-07	0.0012	0.5	0.39	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
UCEC	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-5.23	5.54e-07	0.0012	-0.53	-0.39	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs2460432	ENSG00000226824.5	RP4-756H11.3	5.23	5.55e-07	0.00121	0.52	0.39	Aortic root size;	chr7:66089398	chr7:66654538~66669855:+
UCEC	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	5.23	5.58e-07	0.00121	0.44	0.39	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
UCEC	cis	rs4845570	0.92	rs1521185	ENSG00000203288.3	RP11-98D18.9	5.23	5.59e-07	0.00121	0.55	0.39	Coronary artery disease;	chr1:151791573	chr1:151790804~151794402:+
UCEC	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	5.23	5.61e-07	0.00122	0.49	0.39	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
UCEC	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-5.23	5.63e-07	0.00122	-0.46	-0.39	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
UCEC	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	5.23	5.65e-07	0.00122	0.44	0.39	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
UCEC	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	5.23	5.65e-07	0.00122	0.44	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
UCEC	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	5.23	5.65e-07	0.00122	0.5	0.39	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
UCEC	cis	rs806321	0.755	rs2765762	ENSG00000237152.3	DLEU7-AS1	-5.23	5.68e-07	0.00123	-0.43	-0.39	Multiple sclerosis;	chr13:50207120	chr13:50807856~50849905:+
UCEC	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-5.23	5.68e-07	0.00123	-0.41	-0.39	Breast cancer;	chr11:825777	chr11:779617~780755:+
UCEC	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-5.23	5.69e-07	0.00123	-0.5	-0.39	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
UCEC	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	5.23	5.69e-07	0.00123	0.45	0.39	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
UCEC	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	5.23	5.69e-07	0.00123	0.42	0.39	Height;	chr6:109471826	chr6:109382795~109383666:+
UCEC	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-5.23	5.69e-07	0.00123	-0.45	-0.39	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
UCEC	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	5.23	5.71e-07	0.00123	0.44	0.39	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
UCEC	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	5.23	5.72e-07	0.00124	0.47	0.39	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
UCEC	cis	rs3858145	0.588	rs61854837	ENSG00000233590.1	RP11-153K11.3	-5.23	5.73e-07	0.00124	-0.49	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68282613	chr10:68233251~68242379:-
UCEC	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	5.23	5.74e-07	0.00124	0.5	0.39	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	5.23	5.74e-07	0.00124	0.5	0.39	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	5.23	5.74e-07	0.00124	0.5	0.39	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-5.23	5.74e-07	0.00124	-0.5	-0.39	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
UCEC	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	5.23	5.75e-07	0.00124	0.45	0.39	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
UCEC	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	5.23	5.77e-07	0.00125	0.45	0.39	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
UCEC	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	5.22	5.78e-07	0.00125	0.44	0.39	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
UCEC	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-5.22	5.82e-07	0.00126	-0.41	-0.39	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
UCEC	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	5.22	5.84e-07	0.00126	0.48	0.39	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	5.22	5.84e-07	0.00126	0.48	0.39	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
UCEC	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-5.22	5.86e-07	0.00126	-0.44	-0.39	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
UCEC	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-5.22	5.86e-07	0.00126	-0.44	-0.39	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
UCEC	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-5.22	5.86e-07	0.00126	-0.44	-0.39	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
UCEC	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-5.22	5.86e-07	0.00126	-0.44	-0.39	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
UCEC	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-5.22	5.86e-07	0.00126	-0.44	-0.39	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
UCEC	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-5.22	5.86e-07	0.00126	-0.44	-0.39	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
UCEC	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-5.22	5.86e-07	0.00126	-0.44	-0.39	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
UCEC	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-5.22	5.86e-07	0.00126	-0.44	-0.39	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
UCEC	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	5.22	5.89e-07	0.00127	0.48	0.39	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
UCEC	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-5.22	5.9e-07	0.00127	-0.46	-0.39	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
UCEC	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-5.22	5.9e-07	0.00127	-0.46	-0.39	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
UCEC	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-5.22	5.98e-07	0.00128	-0.53	-0.39	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
UCEC	cis	rs12744310	1	rs68132196	ENSG00000235358.1	RP11-399E6.1	5.22	5.98e-07	0.00128	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41304948	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs56381773	ENSG00000235358.1	RP11-399E6.1	5.22	5.98e-07	0.00128	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305046	chr1:41242373~41284861:+
UCEC	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-5.22	5.98e-07	0.00128	-0.44	-0.39	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
UCEC	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-5.22	6.01e-07	0.00129	-0.65	-0.39	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
UCEC	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-5.22	6.02e-07	0.00129	-0.52	-0.39	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
UCEC	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-5.22	6.03e-07	0.00129	-0.44	-0.39	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
UCEC	cis	rs7267979	1	rs2424710	ENSG00000276952.1	RP5-965G21.6	5.22	6.04e-07	0.0013	0.52	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25284915~25285588:-
UCEC	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	5.22	6.05e-07	0.0013	0.43	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
UCEC	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	5.21	6.05e-07	0.0013	0.43	0.39	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
UCEC	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	5.21	6.05e-07	0.0013	0.49	0.39	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
UCEC	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	5.21	6.07e-07	0.0013	0.45	0.39	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
UCEC	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	5.21	6.11e-07	0.00131	0.42	0.39	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
UCEC	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	5.21	6.12e-07	0.00131	0.71	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
UCEC	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	5.21	6.12e-07	0.00131	0.45	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
UCEC	cis	rs7246967	0.673	rs7247191	ENSG00000198153.8	ZNF849P	-5.21	6.13e-07	0.00131	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22716783	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs34425596	ENSG00000198153.8	ZNF849P	-5.21	6.13e-07	0.00131	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22716977	chr19:22685167~22686732:+
UCEC	cis	rs9487605	1	rs9487605	ENSG00000271789.1	RP5-1112D6.7	-5.21	6.14e-07	0.00131	-0.45	-0.39	Inflammatory skin disease;	chr6:111261682	chr6:111297126~111298510:+
UCEC	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	5.21	6.14e-07	0.00131	0.44	0.39	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
UCEC	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	5.21	6.15e-07	0.00131	0.51	0.39	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
UCEC	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-5.21	6.15e-07	0.00131	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
UCEC	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	5.21	6.17e-07	0.00132	0.52	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
UCEC	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-5.21	6.19e-07	0.00132	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
UCEC	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	5.21	6.22e-07	0.00133	0.44	0.39	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
UCEC	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	5.21	6.24e-07	0.00133	0.45	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
UCEC	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	5.21	6.24e-07	0.00133	0.45	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
UCEC	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-5.21	6.25e-07	0.00133	-0.46	-0.39	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
UCEC	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	5.21	6.27e-07	0.00133	0.52	0.39	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
UCEC	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	5.21	6.3e-07	0.00134	0.48	0.39	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
UCEC	cis	rs6840360	0.642	rs7658169	ENSG00000278978.1	RP11-164P12.5	-5.21	6.3e-07	0.00134	-0.47	-0.39	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151669786~151670503:+
UCEC	cis	rs1667255	1	rs1080094	ENSG00000266521.1	RP11-650P15.1	5.2	6.33e-07	0.00135	0.43	0.39	Retinol levels;	chr18:31593832	chr18:31496645~31497195:-
UCEC	cis	rs4845570	0.92	rs11810571	ENSG00000203288.3	RP11-98D18.9	5.2	6.34e-07	0.00135	0.55	0.39	Coronary artery disease;	chr1:151789832	chr1:151790804~151794402:+
UCEC	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-5.2	6.36e-07	0.00135	-0.43	-0.39	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
UCEC	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	5.2	6.36e-07	0.00135	0.8	0.39	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	5.2	6.39e-07	0.00136	0.47	0.39	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	5.2	6.39e-07	0.00136	0.47	0.39	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
UCEC	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	5.2	6.4e-07	0.00136	0.43	0.39	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	5.2	6.4e-07	0.00136	0.43	0.39	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
UCEC	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-5.2	6.43e-07	0.00136	-0.79	-0.39	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
UCEC	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	5.2	6.58e-07	0.00139	0.43	0.39	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
UCEC	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-5.2	6.58e-07	0.0014	-0.42	-0.39	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-5.2	6.58e-07	0.0014	-0.42	-0.39	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
UCEC	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	5.2	6.6e-07	0.0014	0.71	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
UCEC	cis	rs62103177	0.525	rs9949598	ENSG00000261126.6	RP11-795F19.1	-5.2	6.6e-07	0.0014	-0.43	-0.39	Opioid sensitivity;	chr18:79993037	chr18:80046900~80095482:+
UCEC	cis	rs6840360	0.582	rs2724555	ENSG00000278978.1	RP11-164P12.5	-5.2	6.62e-07	0.0014	-0.47	-0.39	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151669786~151670503:+
UCEC	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-5.19	6.62e-07	0.0014	-0.44	-0.39	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
UCEC	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-5.19	6.63e-07	0.0014	-0.36	-0.39	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
UCEC	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-5.19	6.65e-07	0.0014	-0.84	-0.39	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-5.19	6.65e-07	0.0014	-0.84	-0.39	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-5.19	6.65e-07	0.0014	-0.84	-0.39	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-5.19	6.65e-07	0.0014	-0.84	-0.39	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-5.19	6.65e-07	0.0014	-0.84	-0.39	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
UCEC	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	5.19	6.65e-07	0.00141	0.64	0.39	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
UCEC	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	5.19	6.67e-07	0.00141	0.44	0.39	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	5.19	6.67e-07	0.00141	0.44	0.39	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
UCEC	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	5.19	6.67e-07	0.00141	0.5	0.39	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
UCEC	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-5.19	6.68e-07	0.00141	-0.42	-0.39	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
UCEC	cis	rs7246967	0.611	rs3931771	ENSG00000198153.8	ZNF849P	-5.19	6.7e-07	0.00141	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22714018	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.604	rs8107322	ENSG00000198153.8	ZNF849P	-5.19	6.7e-07	0.00141	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22714630	chr19:22685167~22686732:+
UCEC	cis	rs12744310	1	rs56096486	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305558	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs57529969	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306011	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs60825180	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306072	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.778	rs61477144	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306121	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.943	rs7521544	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306454	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs7513682	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306495	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs34008156	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307510	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12744310	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307830	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs56077539	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308270	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs55892603	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308322	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs55929643	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308540	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs34759578	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308678	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.945	rs72665690	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309564	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.945	rs72665691	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309573	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.945	rs72665692	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309707	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs72665694	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309712	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs72665698	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309917	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12036554	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312317	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12036555	ENSG00000235358.1	RP11-399E6.1	5.19	6.74e-07	0.00142	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312318	chr1:41242373~41284861:+
UCEC	cis	rs6840360	0.642	rs4235219	ENSG00000278978.1	RP11-164P12.5	-5.19	6.77e-07	0.00143	-0.47	-0.39	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs6851814	ENSG00000278978.1	RP11-164P12.5	-5.19	6.77e-07	0.00143	-0.47	-0.39	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.606	rs10028035	ENSG00000278978.1	RP11-164P12.5	-5.19	6.77e-07	0.00143	-0.47	-0.39	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151669786~151670503:+
UCEC	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	5.19	6.78e-07	0.00143	0.58	0.39	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
UCEC	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-5.19	6.79e-07	0.00143	-0.5	-0.39	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
UCEC	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	5.19	6.79e-07	0.00143	0.51	0.39	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
UCEC	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	5.19	6.8e-07	0.00143	0.44	0.39	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
UCEC	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	5.19	6.85e-07	0.00144	0.64	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
UCEC	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	5.19	6.86e-07	0.00144	0.7	0.39	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
UCEC	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	5.19	6.86e-07	0.00144	0.43	0.39	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
UCEC	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-5.19	6.87e-07	0.00144	-0.35	-0.39	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
UCEC	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-5.19	6.87e-07	0.00144	-0.35	-0.39	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
UCEC	cis	rs6840360	0.642	rs2709820	ENSG00000278978.1	RP11-164P12.5	-5.19	6.87e-07	0.00144	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151669786~151670503:+
UCEC	cis	rs763121	0.853	rs138706	ENSG00000273076.1	RP3-508I15.22	5.19	6.88e-07	0.00144	0.43	0.39	Menopause (age at onset);	chr22:38741829	chr22:38743495~38743910:+
UCEC	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	5.19	6.89e-07	0.00144	0.83	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
UCEC	cis	rs12744310	1	rs12029950	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41287493	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs35318047	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289494	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.943	rs35493284	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289517	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.943	rs12027685	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290626	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12024413	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290744	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs34027267	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291005	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12025254	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291234	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12722758	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291343	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12723893	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291368	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.945	rs1343776	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292046	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs60552457	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41293827	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12739950	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294219	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.945	rs12740093	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294329	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12038894	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294535	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12038924	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294645	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12032514	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294890	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12039767	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295188	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12731400	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295680	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12032756	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295757	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs55859000	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295769	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12030372	ENSG00000235358.1	RP11-399E6.1	5.19	6.9e-07	0.00145	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41296357	chr1:41242373~41284861:+
UCEC	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-5.19	6.91e-07	0.00145	-0.45	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
UCEC	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-5.19	6.91e-07	0.00145	-0.44	-0.39	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
UCEC	cis	rs9322193	0.923	rs4870052	ENSG00000223701.3	RAET1E-AS1	5.19	6.92e-07	0.00145	0.44	0.39	Lung cancer;	chr6:149839978	chr6:149884431~149919508:+
UCEC	cis	rs9309473	0.607	rs7586361	ENSG00000163016.8	ALMS1P	5.18	6.96e-07	0.00145	0.42	0.39	Metabolite levels;	chr2:73374478	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.607	rs6740173	ENSG00000163016.8	ALMS1P	5.18	6.96e-07	0.00145	0.42	0.39	Metabolite levels;	chr2:73375138	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	5.18	6.96e-07	0.00145	0.42	0.39	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
UCEC	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	5.18	6.97e-07	0.00146	0.56	0.39	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	5.18	6.97e-07	0.00146	0.56	0.39	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	5.18	6.97e-07	0.00146	0.56	0.39	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	5.18	6.97e-07	0.00146	0.56	0.39	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	5.18	6.97e-07	0.00146	0.56	0.39	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
UCEC	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-5.18	6.97e-07	0.00146	-0.88	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
UCEC	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-5.18	6.97e-07	0.00146	-0.6	-0.39	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
UCEC	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	5.18	6.99e-07	0.00146	0.44	0.39	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	5.18	7e-07	0.00146	0.44	0.39	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
UCEC	cis	rs9399135	0.743	rs7745098	ENSG00000232876.1	CTA-212D2.2	-5.18	7.01e-07	0.00146	-0.47	-0.39	Red blood cell count;	chr6:135093866	chr6:135055033~135060550:+
UCEC	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	5.18	7.03e-07	0.00147	0.54	0.39	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
UCEC	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-5.18	7.04e-07	0.00147	-0.44	-0.39	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-5.18	7.04e-07	0.00147	-0.44	-0.39	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
UCEC	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	5.18	7.07e-07	0.00147	0.52	0.39	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
UCEC	cis	rs9309473	0.607	rs7574291	ENSG00000163016.8	ALMS1P	5.18	7.08e-07	0.00148	0.42	0.39	Metabolite levels;	chr2:73367813	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.579	rs6728128	ENSG00000163016.8	ALMS1P	5.18	7.08e-07	0.00148	0.42	0.39	Metabolite levels;	chr2:73368854	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.607	rs7567343	ENSG00000163016.8	ALMS1P	5.18	7.08e-07	0.00148	0.42	0.39	Metabolite levels;	chr2:73369477	chr2:73644919~73685576:+
UCEC	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-5.18	7.1e-07	0.00148	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
UCEC	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	5.18	7.11e-07	0.00148	0.64	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
UCEC	cis	rs7267979	0.966	rs6050611	ENSG00000276952.1	RP5-965G21.6	5.18	7.13e-07	0.00148	0.52	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25284915~25285588:-
UCEC	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	5.18	7.16e-07	0.00149	0.44	0.39	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
UCEC	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	5.18	7.16e-07	0.00149	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
UCEC	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	5.18	7.17e-07	0.00149	0.51	0.39	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
UCEC	cis	rs7674212	1	rs7674212	ENSG00000246560.2	RP11-10L12.4	5.18	7.22e-07	0.0015	0.48	0.39	Type 2 diabetes;	chr4:103067742	chr4:102828055~102844075:+
UCEC	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-5.18	7.22e-07	0.0015	-0.52	-0.39	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
UCEC	cis	rs6840360	0.642	rs11099815	ENSG00000278978.1	RP11-164P12.5	-5.18	7.23e-07	0.0015	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151669786~151670503:+
UCEC	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-5.18	7.24e-07	0.0015	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	5.18	7.25e-07	0.00151	0.52	0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
UCEC	cis	rs7246967	0.551	rs8112442	ENSG00000198153.8	ZNF849P	-5.17	7.26e-07	0.00151	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22710567	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs73022763	ENSG00000198153.8	ZNF849P	-5.17	7.26e-07	0.00151	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22711414	chr19:22685167~22686732:+
UCEC	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-5.17	7.28e-07	0.00151	-0.83	-0.39	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
UCEC	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	5.17	7.28e-07	0.00151	0.64	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
UCEC	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	5.17	7.32e-07	0.00152	0.51	0.39	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	5.17	7.32e-07	0.00152	0.51	0.39	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	5.17	7.32e-07	0.00152	0.51	0.39	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	5.17	7.32e-07	0.00152	0.51	0.39	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	5.17	7.32e-07	0.00152	0.51	0.39	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	5.17	7.32e-07	0.00152	0.51	0.39	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	5.17	7.32e-07	0.00152	0.51	0.39	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
UCEC	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-5.17	7.36e-07	0.00152	-0.35	-0.39	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
UCEC	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-5.17	7.37e-07	0.00152	-0.46	-0.39	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
UCEC	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	5.17	7.45e-07	0.00154	0.44	0.39	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	5.17	7.48e-07	0.00155	0.43	0.39	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
UCEC	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	5.17	7.51e-07	0.00155	0.6	0.39	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
UCEC	cis	rs6840360	0.642	rs2709838	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2724580	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.693	rs28622593	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2709834	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs6845648	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2724571	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2709833	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.667	rs2709832	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2709831	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2709816	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2709817	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2709818	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs7682770	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.667	rs9994482	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs11729923	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs7676059	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs7657747	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs4696089	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs11932398	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs4263379	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs12647555	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs1899550	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs7680013	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs7680236	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs4696092	ENSG00000278978.1	RP11-164P12.5	-5.17	7.52e-07	0.00155	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2724574	ENSG00000278978.1	RP11-164P12.5	5.17	7.52e-07	0.00155	0.46	0.39	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151669786~151670503:+
UCEC	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-5.17	7.52e-07	0.00155	-0.55	-0.39	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
UCEC	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-5.17	7.57e-07	0.00156	-0.52	-0.39	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
UCEC	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-5.16	7.59e-07	0.00156	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-5.16	7.59e-07	0.00156	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-5.16	7.59e-07	0.00156	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-5.16	7.59e-07	0.00156	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-5.16	7.59e-07	0.00156	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-5.16	7.59e-07	0.00156	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-5.16	7.59e-07	0.00156	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-5.16	7.59e-07	0.00156	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
UCEC	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	5.16	7.6e-07	0.00156	0.43	0.39	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
UCEC	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-5.16	7.61e-07	0.00157	-0.62	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
UCEC	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-5.16	7.65e-07	0.00157	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
UCEC	cis	rs6840360	0.642	rs2724567	ENSG00000278978.1	RP11-164P12.5	5.16	7.67e-07	0.00158	0.46	0.39	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151669786~151670503:+
UCEC	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-5.16	7.67e-07	0.00158	-0.44	-0.39	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
UCEC	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	5.16	7.7e-07	0.00158	0.51	0.39	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
UCEC	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	5.16	7.7e-07	0.00158	0.51	0.39	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
UCEC	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	5.16	7.71e-07	0.00158	0.52	0.39	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
UCEC	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-5.16	7.71e-07	0.00158	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
UCEC	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	5.16	7.77e-07	0.00159	0.44	0.39	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
UCEC	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	5.16	7.77e-07	0.00159	0.45	0.39	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
UCEC	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-5.16	7.79e-07	0.0016	-0.44	-0.39	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	5.16	7.82e-07	0.0016	0.45	0.39	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
UCEC	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	5.16	7.82e-07	0.0016	0.41	0.39	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	5.16	7.82e-07	0.0016	0.41	0.39	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
UCEC	cis	rs7267979	1	rs2257991	ENSG00000276952.1	RP5-965G21.6	-5.16	7.84e-07	0.00161	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25284915~25285588:-
UCEC	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	5.16	7.84e-07	0.00161	0.43	0.39	Height;	chr3:53073764	chr3:53064283~53065091:-
UCEC	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	5.16	7.87e-07	0.00161	0.43	0.39	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
UCEC	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-5.16	7.93e-07	0.00162	-0.7	-0.39	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
UCEC	cis	rs6901004	0.805	rs354532	ENSG00000271789.1	RP5-1112D6.7	-5.15	7.95e-07	0.00163	-0.44	-0.39	Blood metabolite levels;	chr6:111227610	chr6:111297126~111298510:+
UCEC	cis	rs6840360	0.642	rs7677131	ENSG00000278978.1	RP11-164P12.5	-5.15	7.95e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151669786~151670503:+
UCEC	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	5.15	7.96e-07	0.00163	0.5	0.39	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
UCEC	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	5.15	7.98e-07	0.00163	0.5	0.39	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
UCEC	cis	rs12744310	1	rs12756822	ENSG00000235358.1	RP11-399E6.1	5.15	7.99e-07	0.00163	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311655	chr1:41242373~41284861:+
UCEC	cis	rs6840360	0.607	rs2724565	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2724568	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs7657670	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.606	rs2709813	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.606	rs2724550	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2709815	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2709825	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.607	rs2724547	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2724578	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.574	rs2709844	ENSG00000278978.1	RP11-164P12.5	-5.15	7.99e-07	0.00163	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151669786~151670503:+
UCEC	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-5.15	8e-07	0.00163	-0.52	-0.39	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
UCEC	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-5.15	8.01e-07	0.00163	-0.44	-0.39	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
UCEC	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	5.15	8.03e-07	0.00164	0.49	0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
UCEC	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	5.15	8.05e-07	0.00164	0.43	0.39	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
UCEC	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-5.15	8.06e-07	0.00164	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-5.15	8.06e-07	0.00164	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-5.15	8.06e-07	0.00164	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
UCEC	cis	rs7267979	0.966	rs2257233	ENSG00000276952.1	RP5-965G21.6	-5.15	8.07e-07	0.00164	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25284915~25285588:-
UCEC	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	5.15	8.12e-07	0.00165	0.47	0.39	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
UCEC	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-5.15	8.16e-07	0.00166	-0.53	-0.39	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-5.15	8.16e-07	0.00166	-0.53	-0.39	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-5.15	8.16e-07	0.00166	-0.53	-0.39	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-5.15	8.16e-07	0.00166	-0.53	-0.39	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
UCEC	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-5.15	8.18e-07	0.00166	-0.34	-0.39	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
UCEC	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	5.15	8.2e-07	0.00167	0.44	0.39	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	5.15	8.2e-07	0.00167	0.44	0.39	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
UCEC	cis	rs899997	1	rs7182993	ENSG00000261143.1	ADAMTS7P3	5.15	8.2e-07	0.00167	0.49	0.39	Coronary artery disease or large artery stroke;	chr15:78752672	chr15:77976042~77993057:+
UCEC	cis	rs899997	1	rs7182694	ENSG00000261143.1	ADAMTS7P3	5.15	8.2e-07	0.00167	0.49	0.39	Coronary artery disease or large artery stroke;	chr15:78752688	chr15:77976042~77993057:+
UCEC	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	5.15	8.22e-07	0.00167	0.43	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
UCEC	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	5.15	8.24e-07	0.00167	0.48	0.39	Height;	chr3:53073584	chr3:53064283~53065091:-
UCEC	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	5.15	8.24e-07	0.00167	0.35	0.39	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
UCEC	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-5.15	8.24e-07	0.00167	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
UCEC	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-5.15	8.25e-07	0.00168	-0.53	-0.39	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
UCEC	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	5.15	8.26e-07	0.00168	0.5	0.39	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
UCEC	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-5.15	8.26e-07	0.00168	-0.6	-0.39	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
UCEC	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-5.15	8.27e-07	0.00168	-0.52	-0.39	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
UCEC	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	5.14	8.32e-07	0.00168	0.57	0.39	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
UCEC	cis	rs492146	1	rs693733	ENSG00000243236.5	GSTA9P	-5.14	8.32e-07	0.00168	-0.52	-0.39	Epilepsy (remission after treatment);	chr6:52971958	chr6:52939726~52957521:-
UCEC	cis	rs492146	1	rs419833	ENSG00000243236.5	GSTA9P	-5.14	8.32e-07	0.00168	-0.52	-0.39	Epilepsy (remission after treatment);	chr6:52973187	chr6:52939726~52957521:-
UCEC	cis	rs492146	1	rs449690	ENSG00000243236.5	GSTA9P	-5.14	8.32e-07	0.00168	-0.52	-0.39	Epilepsy (remission after treatment);	chr6:52973360	chr6:52939726~52957521:-
UCEC	cis	rs1577917	0.687	rs13197828	ENSG00000203875.9	SNHG5	-5.14	8.34e-07	0.00169	-0.54	-0.39	Response to antipsychotic treatment;	chr6:86095912	chr6:85660950~85678736:-
UCEC	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	5.14	8.36e-07	0.00169	0.42	0.39	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
UCEC	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-5.14	8.39e-07	0.00169	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	5.14	8.39e-07	0.00169	0.42	0.39	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
UCEC	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	5.14	8.41e-07	0.00169	0.41	0.39	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
UCEC	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	5.14	8.42e-07	0.0017	0.49	0.39	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	5.14	8.42e-07	0.0017	0.49	0.39	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	5.14	8.42e-07	0.0017	0.49	0.39	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	5.14	8.42e-07	0.0017	0.49	0.39	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
UCEC	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-5.14	8.46e-07	0.0017	-0.44	-0.39	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
UCEC	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-5.14	8.46e-07	0.0017	-0.44	-0.39	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
UCEC	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-5.14	8.46e-07	0.0017	-0.44	-0.39	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
UCEC	cis	rs12744310	0.83	rs12028010	ENSG00000235358.1	RP11-399E6.1	5.14	8.47e-07	0.00171	0.62	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298799	chr1:41242373~41284861:+
UCEC	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	5.14	8.48e-07	0.00171	0.49	0.39	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	5.14	8.48e-07	0.00171	0.49	0.39	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	5.14	8.48e-07	0.00171	0.49	0.39	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	5.14	8.48e-07	0.00171	0.49	0.39	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	5.14	8.48e-07	0.00171	0.49	0.39	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	5.14	8.48e-07	0.00171	0.49	0.39	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
UCEC	cis	rs7267979	1	rs6050573	ENSG00000276952.1	RP5-965G21.6	5.14	8.5e-07	0.00171	0.51	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25284915~25285588:-
UCEC	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	5.14	8.5e-07	0.00171	0.42	0.39	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
UCEC	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	5.14	8.52e-07	0.00171	0.47	0.39	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
UCEC	cis	rs12744310	1	rs12035913	ENSG00000235358.1	RP11-399E6.1	-5.14	8.53e-07	0.00171	-0.61	-0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291385	chr1:41242373~41284861:+
UCEC	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-5.14	8.58e-07	0.00172	-0.52	-0.39	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
UCEC	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	5.14	8.59e-07	0.00172	0.42	0.39	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
UCEC	cis	rs5850	0.55	rs76983703	ENSG00000230658.1	KLHL7-AS1	5.14	8.59e-07	0.00173	0.58	0.39	Blood protein levels;	chr7:23337094	chr7:23101228~23105703:-
UCEC	cis	rs6840360	0.617	rs2724563	ENSG00000278978.1	RP11-164P12.5	-5.14	8.64e-07	0.00173	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.617	rs2724564	ENSG00000278978.1	RP11-164P12.5	-5.14	8.64e-07	0.00173	-0.46	-0.39	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151669786~151670503:+
UCEC	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-5.14	8.69e-07	0.00174	-0.51	-0.39	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-5.13	8.72e-07	0.00175	-0.5	-0.39	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-5.13	8.73e-07	0.00175	-0.76	-0.39	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
UCEC	cis	rs492146	0.819	rs5028437	ENSG00000243236.5	GSTA9P	5.13	8.75e-07	0.00175	0.5	0.39	Epilepsy (remission after treatment);	chr6:52970876	chr6:52939726~52957521:-
UCEC	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-5.13	8.75e-07	0.00175	-0.78	-0.39	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
UCEC	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	5.13	8.76e-07	0.00176	0.43	0.39	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
UCEC	cis	rs2212361	0.615	rs6483345	ENSG00000255893.1	RP11-685N10.1	-5.13	8.79e-07	0.00176	-0.36	-0.39	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94530983	chr11:94472908~94473570:-
UCEC	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	5.13	8.81e-07	0.00176	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	5.13	8.81e-07	0.00176	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	5.13	8.81e-07	0.00176	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
UCEC	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-5.13	8.81e-07	0.00176	-0.42	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
UCEC	cis	rs12744310	1	rs2364535	ENSG00000235358.1	RP11-399E6.1	5.13	8.82e-07	0.00177	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300564	chr1:41242373~41284861:+
UCEC	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	5.13	8.84e-07	0.00177	0.43	0.39	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	5.13	8.85e-07	0.00177	0.42	0.39	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
UCEC	cis	rs7246967	0.673	rs16999580	ENSG00000198153.8	ZNF849P	-5.13	8.9e-07	0.00178	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22740685	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs55684269	ENSG00000198153.8	ZNF849P	-5.13	8.9e-07	0.00178	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22741745	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12974988	ENSG00000198153.8	ZNF849P	-5.13	8.9e-07	0.00178	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22743163	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs2194112	ENSG00000198153.8	ZNF849P	-5.13	8.9e-07	0.00178	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22743387	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs34907478	ENSG00000198153.8	ZNF849P	-5.13	8.9e-07	0.00178	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22746029	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12985495	ENSG00000198153.8	ZNF849P	-5.13	8.9e-07	0.00178	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22747576	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs8103430	ENSG00000198153.8	ZNF849P	-5.13	8.9e-07	0.00178	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22748696	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs34174596	ENSG00000198153.8	ZNF849P	-5.13	8.9e-07	0.00178	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22750717	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs8103204	ENSG00000198153.8	ZNF849P	-5.13	8.9e-07	0.00178	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22753715	chr19:22685167~22686732:+
UCEC	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-5.13	8.91e-07	0.00178	-0.49	-0.39	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
UCEC	cis	rs7267979	0.966	rs6107031	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6115159	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4813562	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs6050567	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6037099	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs4815414	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6083825	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs34645895	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6115168	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6037105	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2387880	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2387882	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2387884	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6076345	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815418	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815420	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4813566	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815421	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs3761117	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs8123949	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs2184000	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs4815425	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050599	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050602	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815426	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6115182	ENSG00000276952.1	RP5-965G21.6	-5.13	8.91e-07	0.00178	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815412	ENSG00000276952.1	RP5-965G21.6	5.13	8.91e-07	0.00178	0.5	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050598	ENSG00000276952.1	RP5-965G21.6	5.13	8.91e-07	0.00178	0.5	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25284915~25285588:-
UCEC	cis	rs6840360	0.606	rs2709814	ENSG00000278978.1	RP11-164P12.5	-5.13	8.93e-07	0.00178	-0.45	-0.39	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151669786~151670503:+
UCEC	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	5.13	8.93e-07	0.00178	0.48	0.39	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
UCEC	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.82	-0.39	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-5.13	8.94e-07	0.00178	-0.76	-0.39	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	5.13	8.95e-07	0.00178	0.42	0.39	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
UCEC	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	5.13	8.96e-07	0.00178	0.53	0.39	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
UCEC	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-5.13	8.96e-07	0.00178	-0.44	-0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
UCEC	cis	rs7267979	0.966	rs6083855	ENSG00000276952.1	RP5-965G21.6	-5.13	8.99e-07	0.00179	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25284915~25285588:-
UCEC	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-5.13	9e-07	0.00179	-0.5	-0.39	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-5.13	9e-07	0.00179	-0.5	-0.39	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-5.13	9e-07	0.00179	-0.5	-0.39	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-5.13	9e-07	0.00179	-0.5	-0.39	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-5.13	9e-07	0.00179	-0.5	-0.39	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-5.13	9e-07	0.00179	-0.5	-0.39	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-5.13	9e-07	0.00179	-0.5	-0.39	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
UCEC	cis	rs34779708	0.733	rs4102764	ENSG00000230534.5	RP11-297A16.2	5.13	9.01e-07	0.00179	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35098006~35127020:-
UCEC	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-5.13	9.01e-07	0.00179	-0.47	-0.39	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-5.13	9.01e-07	0.00179	-0.47	-0.39	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-5.13	9.01e-07	0.00179	-0.47	-0.39	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-5.13	9.01e-07	0.00179	-0.47	-0.39	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-5.13	9.01e-07	0.00179	-0.47	-0.39	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-5.13	9.01e-07	0.00179	-0.47	-0.39	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
UCEC	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-5.13	9.01e-07	0.00179	-0.43	-0.39	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-5.13	9.01e-07	0.00179	-0.43	-0.39	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-5.13	9.01e-07	0.00179	-0.43	-0.39	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
UCEC	cis	rs9309473	0.607	rs7567017	ENSG00000163016.8	ALMS1P	5.13	9.02e-07	0.00179	0.42	0.39	Metabolite levels;	chr2:73369142	chr2:73644919~73685576:+
UCEC	cis	rs492146	0.819	rs677636	ENSG00000243236.5	GSTA9P	-5.13	9.05e-07	0.0018	-0.49	-0.39	Epilepsy (remission after treatment);	chr6:52972509	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.819	rs584124	ENSG00000243236.5	GSTA9P	-5.13	9.05e-07	0.0018	-0.49	-0.39	Epilepsy (remission after treatment);	chr6:52973398	chr6:52939726~52957521:-
UCEC	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	5.13	9.06e-07	0.0018	0.47	0.39	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
UCEC	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	5.13	9.07e-07	0.0018	0.45	0.39	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
UCEC	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-5.13	9.08e-07	0.0018	-0.43	-0.39	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-5.13	9.08e-07	0.0018	-0.43	-0.39	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
UCEC	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	5.12	9.11e-07	0.00181	0.49	0.39	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
UCEC	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	5.12	9.13e-07	0.00181	0.52	0.39	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
UCEC	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-5.12	9.14e-07	0.00181	-0.44	-0.39	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
UCEC	cis	rs7246967	0.673	rs34676724	ENSG00000198153.8	ZNF849P	-5.12	9.16e-07	0.00182	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22735671	chr19:22685167~22686732:+
UCEC	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-5.12	9.18e-07	0.00182	-0.43	-0.39	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
UCEC	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-5.12	9.22e-07	0.00183	-0.49	-0.39	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	5.12	9.25e-07	0.00183	0.48	0.39	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
UCEC	cis	rs7246967	0.673	rs59621958	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22757857	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.604	rs58653025	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22758815	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs16999598	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22760323	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs34726149	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22769309	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs12985825	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22770649	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs62120125	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22772297	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs2194113	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22775273	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs62120457	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22775717	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs55744741	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22777171	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs4933036	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22780267	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs35061555	ENSG00000198153.8	ZNF849P	-5.12	9.25e-07	0.00183	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22780964	chr19:22685167~22686732:+
UCEC	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-5.12	9.26e-07	0.00183	-0.44	-0.39	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
UCEC	cis	rs9309473	0.95	rs13391258	ENSG00000163016.8	ALMS1P	5.12	9.29e-07	0.00184	0.44	0.39	Metabolite levels;	chr2:73621806	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.898	rs6546861	ENSG00000163016.8	ALMS1P	5.12	9.29e-07	0.00184	0.44	0.39	Metabolite levels;	chr2:73622734	chr2:73644919~73685576:+
UCEC	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-5.12	9.29e-07	0.00184	-0.45	-0.39	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
UCEC	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-5.12	9.3e-07	0.00184	-0.45	-0.39	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
UCEC	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	5.12	9.31e-07	0.00184	0.42	0.39	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
UCEC	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-5.12	9.34e-07	0.00184	-0.36	-0.39	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
UCEC	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-5.12	9.35e-07	0.00185	-0.56	-0.39	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
UCEC	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	5.12	9.37e-07	0.00185	0.42	0.39	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
UCEC	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-5.12	9.38e-07	0.00185	-0.44	-0.39	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
UCEC	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-5.12	9.41e-07	0.00186	-0.55	-0.39	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
UCEC	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	5.12	9.43e-07	0.00186	0.42	0.39	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
UCEC	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	5.12	9.45e-07	0.00186	0.66	0.39	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
UCEC	cis	rs9309473	0.653	rs6718843	ENSG00000163016.8	ALMS1P	5.12	9.45e-07	0.00186	0.44	0.39	Metabolite levels;	chr2:73625378	chr2:73644919~73685576:+
UCEC	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	5.12	9.46e-07	0.00186	0.44	0.39	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
UCEC	cis	rs7240205	0.816	rs2019480	ENSG00000275805.1	RP11-349H17.2	5.12	9.47e-07	0.00186	0.47	0.39	Breast cancer;	chr18:26545720	chr18:26565723~26575626:-
UCEC	cis	rs7246967	0.673	rs34671960	ENSG00000198153.8	ZNF849P	-5.12	9.47e-07	0.00186	-0.46	-0.39	Bronchopulmonary dysplasia;	chr19:22765891	chr19:22685167~22686732:+
UCEC	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-5.12	9.48e-07	0.00187	-0.47	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
UCEC	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	5.12	9.48e-07	0.00187	0.45	0.39	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
UCEC	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	5.11	9.52e-07	0.00187	0.4	0.39	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
UCEC	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-5.11	9.52e-07	0.00187	-0.75	-0.39	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-5.11	9.52e-07	0.00187	-0.75	-0.39	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-5.11	9.52e-07	0.00187	-0.75	-0.39	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-5.11	9.52e-07	0.00187	-0.75	-0.39	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-5.11	9.52e-07	0.00187	-0.75	-0.39	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-5.11	9.52e-07	0.00187	-0.75	-0.39	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-5.11	9.52e-07	0.00187	-0.75	-0.39	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-5.11	9.52e-07	0.00187	-0.75	-0.39	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
UCEC	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	5.11	9.53e-07	0.00187	0.5	0.39	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
UCEC	cis	rs964184	0.507	rs6589565	ENSG00000254851.1	RP11-109L13.1	-5.11	9.54e-07	0.00188	-0.9	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116769521	chr11:117135528~117138582:+
UCEC	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	5.11	9.54e-07	0.00188	0.46	0.39	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
UCEC	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	5.11	9.54e-07	0.00188	0.49	0.39	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
UCEC	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-5.11	9.55e-07	0.00188	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
UCEC	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	5.11	9.55e-07	0.00188	0.52	0.39	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
UCEC	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	5.11	9.57e-07	0.00188	0.47	0.39	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
UCEC	cis	rs948562	0.744	rs73485969	ENSG00000280010.1	AP001350.4	5.11	9.58e-07	0.00188	0.69	0.39	Lymphoma;	chr11:58452253	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs11229474	ENSG00000280010.1	AP001350.4	5.11	9.58e-07	0.00188	0.69	0.39	Lymphoma;	chr11:58459729	chr11:58627435~58628528:+
UCEC	cis	rs8031584	0.697	rs8036176	ENSG00000260382.1	RP11-540B6.2	5.11	9.59e-07	0.00188	0.52	0.39	Huntington's disease progression;	chr15:30883066	chr15:30882267~30883231:-
UCEC	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-5.11	9.59e-07	0.00188	-0.5	-0.39	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-5.11	9.59e-07	0.00188	-0.5	-0.39	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-5.11	9.59e-07	0.00188	-0.5	-0.39	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
UCEC	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-5.11	9.6e-07	0.00189	-0.46	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
UCEC	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	5.11	9.6e-07	0.00189	0.5	0.39	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
UCEC	cis	rs7267979	0.966	rs3827014	ENSG00000276952.1	RP5-965G21.6	-5.11	9.61e-07	0.00189	-0.5	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25284915~25285588:-
UCEC	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	5.11	9.61e-07	0.00189	0.42	0.39	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	5.11	9.62e-07	0.00189	0.43	0.39	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
UCEC	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-5.11	9.65e-07	0.00189	-0.5	-0.39	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
UCEC	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	5.11	9.65e-07	0.00189	0.47	0.39	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
UCEC	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	5.11	9.66e-07	0.00189	0.41	0.39	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	5.11	9.66e-07	0.00189	0.41	0.39	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
UCEC	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-5.11	9.66e-07	0.00189	-0.57	-0.39	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-5.11	9.66e-07	0.00189	-0.57	-0.39	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-5.11	9.66e-07	0.00189	-0.57	-0.39	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-5.11	9.66e-07	0.00189	-0.57	-0.39	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
UCEC	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-5.11	9.69e-07	0.0019	-0.49	-0.39	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
UCEC	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	5.11	9.69e-07	0.0019	0.65	0.39	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
UCEC	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	5.11	9.69e-07	0.0019	0.65	0.39	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
UCEC	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	5.11	9.71e-07	0.0019	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
UCEC	cis	rs7615952	0.673	rs16834637	ENSG00000241288.6	RP11-379B18.5	-5.11	9.77e-07	0.00191	-0.58	-0.39	Blood pressure (smoking interaction);	chr3:125886628	chr3:125827238~125916384:-
UCEC	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	5.11	9.78e-07	0.00191	0.42	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
UCEC	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-5.11	9.83e-07	0.00192	-0.43	-0.39	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
UCEC	cis	rs964184	0.564	rs7350481	ENSG00000254851.1	RP11-109L13.1	-5.11	9.84e-07	0.00192	-1.11	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116715567	chr11:117135528~117138582:+
UCEC	cis	rs6840360	0.582	rs2709826	ENSG00000278978.1	RP11-164P12.5	-5.11	9.84e-07	0.00192	-0.44	-0.39	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151669786~151670503:+
UCEC	cis	rs62388641	0.624	rs13191308	ENSG00000272279.1	RP11-157J24.2	5.11	9.84e-07	0.00192	0.66	0.39	Daytime sleep phenotypes;	chr6:1529137	chr6:1528364~1528911:-
UCEC	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	5.11	9.84e-07	0.00192	0.62	0.39	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	5.11	9.84e-07	0.00192	0.62	0.39	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
UCEC	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-5.11	9.88e-07	0.00193	-0.68	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
UCEC	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-5.11	9.89e-07	0.00193	-0.58	-0.39	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
UCEC	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	5.11	9.9e-07	0.00193	0.46	0.39	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	5.11	9.9e-07	0.00193	0.46	0.39	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	5.11	9.9e-07	0.00193	0.46	0.39	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
UCEC	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-5.11	9.92e-07	0.00194	-0.63	-0.39	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
UCEC	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	5.11	9.95e-07	0.00194	0.43	0.39	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
UCEC	cis	rs12744310	1	rs12032162	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297263	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12031417	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297356	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12037588	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298283	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12037657	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298503	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.832	rs12027990	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298765	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs34190295	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300207	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.945	rs34961305	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300272	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs35812095	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300402	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs35529558	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301350	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12034357	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302557	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs7553908	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302569	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12041533	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302599	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.943	rs34862272	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302981	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs34796305	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303373	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.943	rs35972058	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303474	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.943	rs12032906	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303486	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs34315814	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303500	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12032191	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303546	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12032215	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303662	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs12035353	ENSG00000235358.1	RP11-399E6.1	5.1	1e-06	0.00195	0.61	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303665	chr1:41242373~41284861:+
UCEC	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-5.1	1e-06	0.00195	-0.47	-0.39	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
UCEC	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-5.1	1.01e-06	0.00197	-0.36	-0.39	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
UCEC	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-5.1	1.01e-06	0.00197	-0.48	-0.39	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
UCEC	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-5.1	1.01e-06	0.00197	-0.72	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
UCEC	cis	rs6683071	0.601	rs3002129	ENSG00000272750.1	RP11-378J18.8	5.1	1.01e-06	0.00197	0.51	0.39	Cognitive performance;	chr1:222681993	chr1:222658867~222661512:-
UCEC	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-5.1	1.01e-06	0.00197	-0.43	-0.39	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
UCEC	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-5.1	1.01e-06	0.00197	-0.43	-0.39	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
UCEC	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-5.1	1.01e-06	0.00197	-0.43	-0.39	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
UCEC	cis	rs7246967	0.673	rs34003335	ENSG00000198153.8	ZNF849P	-5.1	1.01e-06	0.00197	-0.47	-0.39	Bronchopulmonary dysplasia;	chr19:22742800	chr19:22685167~22686732:+
UCEC	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-5.1	1.02e-06	0.00198	-0.62	-0.39	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
UCEC	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-5.1	1.02e-06	0.00198	-0.46	-0.39	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
UCEC	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	5.1	1.02e-06	0.00199	0.43	0.39	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
UCEC	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-5.1	1.03e-06	0.002	-0.51	-0.39	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	5.1	1.03e-06	0.002	0.51	0.39	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	5.1	1.03e-06	0.002	0.51	0.39	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
UCEC	cis	rs9309473	0.95	rs6705977	ENSG00000163016.8	ALMS1P	5.1	1.03e-06	0.002	0.44	0.39	Metabolite levels;	chr2:73622043	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs6711001	ENSG00000163016.8	ALMS1P	5.1	1.03e-06	0.002	0.44	0.39	Metabolite levels;	chr2:73623693	chr2:73644919~73685576:+
UCEC	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	5.1	1.04e-06	0.00201	0.63	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
UCEC	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-5.1	1.04e-06	0.00201	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-5.1	1.04e-06	0.00201	-0.52	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
UCEC	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-5.1	1.04e-06	0.00202	-0.49	-0.39	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-5.1	1.04e-06	0.00202	-0.49	-0.39	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
UCEC	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	5.1	1.04e-06	0.00202	0.41	0.39	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
UCEC	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	5.1	1.04e-06	0.00202	0.42	0.39	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
UCEC	cis	rs6908034	0.654	rs6456272	ENSG00000228412.5	RP4-625H18.2	-5.09	1.04e-06	0.00202	-0.51	-0.39	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804805	chr6:19802164~19804752:-
UCEC	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-5.09	1.04e-06	0.00202	-0.53	-0.39	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
UCEC	cis	rs1062177	0.526	rs2964593	ENSG00000213433.5	RPLP1P6	5.09	1.04e-06	0.00202	0.41	0.39	Preschool internalizing problems;	chr5:151735068	chr5:151765859~151766378:-
UCEC	cis	rs7267979	1	rs4815417	ENSG00000276952.1	RP5-965G21.6	-5.09	1.04e-06	0.00203	-0.49	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25284915~25285588:-
UCEC	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	5.09	1.05e-06	0.00203	0.45	0.39	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
UCEC	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-5.09	1.05e-06	0.00203	-0.39	-0.39	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
UCEC	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-5.09	1.05e-06	0.00203	-0.39	-0.39	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
UCEC	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-5.09	1.05e-06	0.00204	-0.46	-0.39	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
UCEC	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	5.09	1.06e-06	0.00205	0.63	0.38	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
UCEC	cis	rs7240205	0.853	rs34288695	ENSG00000275805.1	RP11-349H17.2	5.09	1.06e-06	0.00205	0.46	0.38	Breast cancer;	chr18:26563122	chr18:26565723~26575626:-
UCEC	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-5.09	1.06e-06	0.00206	-0.45	-0.38	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
UCEC	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	5.09	1.07e-06	0.00206	0.54	0.38	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-5.09	1.07e-06	0.00206	-0.4	-0.38	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
UCEC	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	5.09	1.07e-06	0.00207	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
UCEC	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	5.09	1.07e-06	0.00207	0.43	0.38	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
UCEC	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-5.09	1.07e-06	0.00207	-0.4	-0.38	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
UCEC	cis	rs6840360	0.642	rs6843639	ENSG00000278978.1	RP11-164P12.5	-5.09	1.08e-06	0.00207	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs28666858	ENSG00000278978.1	RP11-164P12.5	-5.09	1.08e-06	0.00207	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs10857260	ENSG00000278978.1	RP11-164P12.5	-5.09	1.08e-06	0.00207	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151669786~151670503:+
UCEC	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-5.09	1.08e-06	0.00208	-0.47	-0.38	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
UCEC	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00208	0.5	0.38	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-5.09	1.08e-06	0.00208	-0.5	-0.38	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
UCEC	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-5.09	1.08e-06	0.00208	-0.42	-0.38	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	5.09	1.08e-06	0.00209	0.5	0.38	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	5.09	1.09e-06	0.00209	0.68	0.38	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
UCEC	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	5.09	1.09e-06	0.00209	0.48	0.38	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
UCEC	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	5.09	1.09e-06	0.00209	0.39	0.38	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	5.09	1.09e-06	0.00209	0.39	0.38	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	5.09	1.09e-06	0.00209	0.39	0.38	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	5.09	1.09e-06	0.00209	0.39	0.38	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
UCEC	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	5.09	1.09e-06	0.00209	0.44	0.38	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
UCEC	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	5.09	1.09e-06	0.00209	0.51	0.38	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	5.08	1.1e-06	0.00211	0.47	0.38	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
UCEC	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	5.08	1.1e-06	0.00211	0.51	0.38	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	5.08	1.1e-06	0.00211	0.51	0.38	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	5.08	1.1e-06	0.00211	0.51	0.38	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	5.08	1.1e-06	0.00211	0.51	0.38	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	5.08	1.1e-06	0.00211	0.51	0.38	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-5.08	1.1e-06	0.00211	-0.4	-0.38	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
UCEC	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	5.08	1.11e-06	0.00212	0.53	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
UCEC	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-5.08	1.11e-06	0.00212	-0.4	-0.38	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
UCEC	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-5.08	1.11e-06	0.00213	-0.51	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
UCEC	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
UCEC	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-5.08	1.11e-06	0.00213	-0.5	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
UCEC	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-5.08	1.11e-06	0.00213	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-5.08	1.11e-06	0.00213	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-5.08	1.11e-06	0.00213	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-5.08	1.11e-06	0.00213	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-5.08	1.11e-06	0.00213	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
UCEC	cis	rs492146	0.819	rs612483	ENSG00000243236.5	GSTA9P	5.08	1.11e-06	0.00213	0.49	0.38	Epilepsy (remission after treatment);	chr6:52975160	chr6:52939726~52957521:-
UCEC	cis	rs7615952	0.688	rs17334074	ENSG00000241288.6	RP11-379B18.5	5.08	1.11e-06	0.00213	0.55	0.38	Blood pressure (smoking interaction);	chr3:125821617	chr3:125827238~125916384:-
UCEC	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-5.08	1.11e-06	0.00213	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	5.08	1.11e-06	0.00213	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
UCEC	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-5.08	1.11e-06	0.00213	-0.44	-0.38	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
UCEC	cis	rs3758785	0.621	rs7128673	ENSG00000255893.1	RP11-685N10.1	-5.08	1.12e-06	0.00213	-0.37	-0.38	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94453072	chr11:94472908~94473570:-
UCEC	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	5.08	1.12e-06	0.00213	0.45	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
UCEC	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	5.08	1.12e-06	0.00214	0.46	0.38	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
UCEC	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	5.08	1.12e-06	0.00214	0.45	0.38	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
UCEC	cis	rs7246967	0.673	rs60675447	ENSG00000198153.8	ZNF849P	-5.08	1.12e-06	0.00214	-0.45	-0.38	Bronchopulmonary dysplasia;	chr19:22628090	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.673	rs56725192	ENSG00000198153.8	ZNF849P	-5.08	1.12e-06	0.00214	-0.45	-0.38	Bronchopulmonary dysplasia;	chr19:22628136	chr19:22685167~22686732:+
UCEC	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	5.08	1.12e-06	0.00214	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
UCEC	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	5.08	1.12e-06	0.00214	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
UCEC	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	5.08	1.12e-06	0.00214	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
UCEC	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	5.08	1.12e-06	0.00214	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
UCEC	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	5.08	1.12e-06	0.00214	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
UCEC	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	5.08	1.12e-06	0.00214	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
UCEC	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	5.08	1.12e-06	0.00214	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
UCEC	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	5.08	1.12e-06	0.00214	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
UCEC	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	5.08	1.12e-06	0.00214	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
UCEC	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	5.08	1.13e-06	0.00215	0.52	0.38	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
UCEC	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	5.08	1.13e-06	0.00215	0.43	0.38	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
UCEC	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-5.08	1.13e-06	0.00215	-0.66	-0.38	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
UCEC	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.13e-06	0.00215	-0.5	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-5.08	1.13e-06	0.00215	-0.5	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
UCEC	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	5.08	1.13e-06	0.00216	0.44	0.38	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
UCEC	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-5.08	1.13e-06	0.00216	-0.49	-0.38	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
UCEC	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	5.08	1.13e-06	0.00216	0.42	0.38	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	5.08	1.13e-06	0.00216	0.42	0.38	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
UCEC	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	5.07	1.14e-06	0.00218	0.4	0.38	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
UCEC	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	5.07	1.15e-06	0.00218	0.65	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
UCEC	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	5.07	1.15e-06	0.00218	0.4	0.38	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	5.07	1.15e-06	0.00218	0.4	0.38	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	5.07	1.15e-06	0.00218	0.4	0.38	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	5.07	1.15e-06	0.00218	0.4	0.38	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	5.07	1.15e-06	0.00218	0.4	0.38	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	5.07	1.15e-06	0.00218	0.4	0.38	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	5.07	1.15e-06	0.00218	0.4	0.38	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
UCEC	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	5.07	1.15e-06	0.00218	0.81	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	5.07	1.15e-06	0.00218	0.81	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	5.07	1.15e-06	0.00218	0.81	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
UCEC	cis	rs4789693	0.872	rs28612648	ENSG00000265458.1	RP13-20L14.6	5.07	1.15e-06	0.00219	0.45	0.38	Glucocorticoid-induced osteonecrosis;	chr17:82445510	chr17:82454273~82458521:-
UCEC	cis	rs6840360	0.642	rs56301462	ENSG00000278978.1	RP11-164P12.5	-5.07	1.15e-06	0.00219	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151530976	chr4:151669786~151670503:+
UCEC	cis	rs7267979	0.903	rs2474769	ENSG00000276952.1	RP5-965G21.6	5.07	1.15e-06	0.00219	0.5	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25284915~25285588:-
UCEC	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	5.07	1.16e-06	0.0022	0.41	0.38	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
UCEC	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	5.07	1.16e-06	0.0022	0.56	0.38	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
UCEC	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	5.07	1.16e-06	0.0022	0.43	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	5.07	1.16e-06	0.0022	0.43	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	5.07	1.16e-06	0.0022	0.43	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	5.07	1.16e-06	0.0022	0.43	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	5.07	1.16e-06	0.0022	0.43	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
UCEC	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	5.07	1.16e-06	0.00221	0.66	0.38	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
UCEC	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	5.07	1.16e-06	0.00221	0.66	0.38	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
UCEC	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-5.07	1.17e-06	0.00221	-0.44	-0.38	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
UCEC	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	5.07	1.17e-06	0.00221	0.43	0.38	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	5.07	1.17e-06	0.00221	0.5	0.38	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	5.07	1.17e-06	0.00221	0.5	0.38	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
UCEC	cis	rs6840360	0.642	rs2709819	ENSG00000278978.1	RP11-164P12.5	-5.07	1.17e-06	0.00222	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151669786~151670503:+
UCEC	cis	rs7267979	0.903	rs2474766	ENSG00000276952.1	RP5-965G21.6	5.07	1.17e-06	0.00222	0.5	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25284915~25285588:-
UCEC	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	5.07	1.18e-06	0.00222	0.54	0.38	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
UCEC	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-5.07	1.18e-06	0.00223	-0.47	-0.38	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
UCEC	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-5.07	1.19e-06	0.00224	-0.48	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
UCEC	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	5.07	1.19e-06	0.00224	0.42	0.38	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
UCEC	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	5.07	1.19e-06	0.00224	0.43	0.38	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
UCEC	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-5.07	1.19e-06	0.00224	-0.48	-0.38	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
UCEC	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	5.07	1.19e-06	0.00224	0.41	0.38	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
UCEC	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-5.07	1.19e-06	0.00224	-0.53	-0.38	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
UCEC	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-5.06	1.19e-06	0.00225	-0.35	-0.38	Height;	chr11:118749988	chr11:118791254~118793137:+
UCEC	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	5.06	1.19e-06	0.00225	0.66	0.38	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
UCEC	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-5.06	1.2e-06	0.00226	-0.74	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
UCEC	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	5.06	1.2e-06	0.00226	0.48	0.38	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	5.06	1.2e-06	0.00226	0.48	0.38	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
UCEC	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-5.06	1.2e-06	0.00226	-0.53	-0.38	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
UCEC	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-5.06	1.2e-06	0.00226	-0.46	-0.38	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
UCEC	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	5.06	1.2e-06	0.00226	0.54	0.38	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
UCEC	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	5.06	1.2e-06	0.00227	0.48	0.38	Depression;	chr6:28110525	chr6:28115628~28116551:+
UCEC	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	5.06	1.2e-06	0.00227	0.55	0.38	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
UCEC	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-5.06	1.21e-06	0.00227	-0.5	-0.38	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
UCEC	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	5.06	1.21e-06	0.00228	0.39	0.38	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	5.06	1.21e-06	0.00228	0.39	0.38	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
UCEC	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	5.06	1.21e-06	0.00228	0.48	0.38	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	5.06	1.21e-06	0.00228	0.51	0.38	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
UCEC	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-5.06	1.21e-06	0.00228	-0.41	-0.38	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-5.06	1.21e-06	0.00228	-0.41	-0.38	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-5.06	1.21e-06	0.00228	-0.41	-0.38	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-5.06	1.21e-06	0.00228	-0.41	-0.38	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
UCEC	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-5.06	1.22e-06	0.00228	-0.53	-0.38	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
UCEC	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	5.06	1.22e-06	0.00228	0.42	0.38	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
UCEC	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	5.06	1.22e-06	0.00229	1.1	0.38	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
UCEC	cis	rs7267979	1	rs6083844	ENSG00000276952.1	RP5-965G21.6	-5.06	1.23e-06	0.0023	-0.5	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25284915~25285588:-
UCEC	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-5.06	1.23e-06	0.0023	-0.48	-0.38	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-5.06	1.23e-06	0.0023	-0.48	-0.38	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
UCEC	cis	rs10232172	0.63	rs1405440	ENSG00000234707.2	RP11-745C15.2	-5.06	1.23e-06	0.0023	-0.53	-0.38	Periodontal disease-related phenotypes;	chr7:54095791	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs1405441	ENSG00000234707.2	RP11-745C15.2	-5.06	1.23e-06	0.0023	-0.53	-0.38	Periodontal disease-related phenotypes;	chr7:54095814	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs1405442	ENSG00000234707.2	RP11-745C15.2	-5.06	1.23e-06	0.0023	-0.53	-0.38	Periodontal disease-related phenotypes;	chr7:54095870	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.591	rs6964160	ENSG00000234707.2	RP11-745C15.2	-5.06	1.23e-06	0.0023	-0.53	-0.38	Periodontal disease-related phenotypes;	chr7:54096187	chr7:54759425~54804928:+
UCEC	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-5.06	1.23e-06	0.0023	-0.48	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
UCEC	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-5.06	1.23e-06	0.0023	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	5.06	1.23e-06	0.0023	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
UCEC	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-5.06	1.24e-06	0.00231	-0.4	-0.38	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
UCEC	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	5.06	1.24e-06	0.00231	0.39	0.38	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
UCEC	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	5.06	1.24e-06	0.00232	0.45	0.38	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
UCEC	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-5.05	1.25e-06	0.00233	-0.4	-0.38	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
UCEC	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	5.05	1.25e-06	0.00233	0.49	0.38	Height;	chr3:53085313	chr3:53064283~53065091:-
UCEC	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-5.05	1.25e-06	0.00234	-0.43	-0.38	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-5.05	1.25e-06	0.00234	-0.43	-0.38	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
UCEC	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-5.05	1.25e-06	0.00234	-0.35	-0.38	Height;	chr11:118764443	chr11:118791254~118793137:+
UCEC	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	5.05	1.25e-06	0.00234	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
UCEC	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	5.05	1.26e-06	0.00234	0.4	0.38	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
UCEC	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	5.05	1.26e-06	0.00234	0.81	0.38	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-5.05	1.26e-06	0.00234	-0.81	-0.38	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-5.05	1.26e-06	0.00234	-0.81	-0.38	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-5.05	1.26e-06	0.00234	-0.81	-0.38	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-5.05	1.26e-06	0.00234	-0.81	-0.38	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-5.05	1.26e-06	0.00234	-0.81	-0.38	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-5.05	1.26e-06	0.00234	-0.81	-0.38	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-5.05	1.26e-06	0.00234	-0.81	-0.38	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-5.05	1.26e-06	0.00234	-0.81	-0.38	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
UCEC	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-5.05	1.26e-06	0.00234	-0.41	-0.38	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-5.05	1.26e-06	0.00234	-0.41	-0.38	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	5.05	1.26e-06	0.00234	0.41	0.38	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
UCEC	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-5.05	1.26e-06	0.00235	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
UCEC	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	5.05	1.26e-06	0.00235	0.46	0.38	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
UCEC	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	5.05	1.27e-06	0.00235	0.7	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
UCEC	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	5.05	1.27e-06	0.00235	0.43	0.38	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
UCEC	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	5.05	1.27e-06	0.00236	0.47	0.38	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
UCEC	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	5.05	1.27e-06	0.00236	0.53	0.38	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	5.05	1.27e-06	0.00236	0.53	0.38	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
UCEC	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-5.05	1.28e-06	0.00237	-0.52	-0.38	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-5.05	1.28e-06	0.00237	-0.52	-0.38	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
UCEC	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	5.05	1.28e-06	0.00237	0.51	0.38	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
UCEC	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-5.05	1.28e-06	0.00237	-0.53	-0.38	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
UCEC	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-5.05	1.28e-06	0.00237	-0.53	-0.38	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
UCEC	cis	rs7674212	0.833	rs61075040	ENSG00000246560.2	RP11-10L12.4	5.05	1.28e-06	0.00238	0.48	0.38	Type 2 diabetes;	chr4:103052804	chr4:102828055~102844075:+
UCEC	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	5.05	1.29e-06	0.00238	0.58	0.38	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
UCEC	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-5.05	1.29e-06	0.00238	-0.48	-0.38	Depression;	chr6:28091242	chr6:28115628~28116551:+
UCEC	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-5.05	1.29e-06	0.00239	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-5.05	1.29e-06	0.00239	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-5.05	1.29e-06	0.00239	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-5.05	1.29e-06	0.00239	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-5.05	1.29e-06	0.00239	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-5.05	1.29e-06	0.00239	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-5.05	1.29e-06	0.00239	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
UCEC	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-5.05	1.29e-06	0.00239	-0.53	-0.38	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
UCEC	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	5.05	1.3e-06	0.0024	0.4	0.38	Height;	chr6:109443332	chr6:109382795~109383666:+
UCEC	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	5.05	1.3e-06	0.0024	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
UCEC	cis	rs12744310	1	rs56409354	ENSG00000235358.1	RP11-399E6.1	5.05	1.3e-06	0.0024	0.61	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307299	chr1:41242373~41284861:+
UCEC	cis	rs6901004	0.803	rs354539	ENSG00000271789.1	RP5-1112D6.7	-5.05	1.3e-06	0.0024	-0.47	-0.38	Blood metabolite levels;	chr6:111196626	chr6:111297126~111298510:+
UCEC	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-5.05	1.3e-06	0.0024	-0.43	-0.38	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
UCEC	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-5.05	1.3e-06	0.0024	-0.46	-0.38	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
UCEC	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-5.05	1.3e-06	0.0024	-0.43	-0.38	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
UCEC	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	5.04	1.3e-06	0.00241	0.48	0.38	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
UCEC	cis	rs2739330	0.731	rs4822450	ENSG00000272787.1	KB-226F1.2	-5.04	1.3e-06	0.00241	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23969211~23969873:+
UCEC	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-5.04	1.31e-06	0.00241	-0.46	-0.38	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
UCEC	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-5.04	1.31e-06	0.00241	-0.46	-0.38	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
UCEC	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	5.04	1.31e-06	0.00241	0.41	0.38	Height;	chr6:109476101	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	5.04	1.31e-06	0.00241	0.41	0.38	Height;	chr6:109477209	chr6:109382795~109383666:+
UCEC	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-5.04	1.31e-06	0.00241	-0.41	-0.38	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
UCEC	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	5.04	1.31e-06	0.00242	0.81	0.38	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
UCEC	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-5.04	1.32e-06	0.00242	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-5.04	1.32e-06	0.00242	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-5.04	1.32e-06	0.00242	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-5.04	1.32e-06	0.00242	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-5.04	1.32e-06	0.00242	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-5.04	1.32e-06	0.00242	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-5.04	1.32e-06	0.00242	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-5.04	1.32e-06	0.00242	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-5.04	1.32e-06	0.00242	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
UCEC	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-5.04	1.32e-06	0.00243	-0.53	-0.38	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
UCEC	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	5.04	1.32e-06	0.00243	0.41	0.38	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
UCEC	cis	rs686320	1	rs616599	ENSG00000245532.5	NEAT1	5.04	1.32e-06	0.00243	0.53	0.38	Hip circumference adjusted for BMI;	chr11:65486554	chr11:65422774~65445540:+
UCEC	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-5.04	1.32e-06	0.00244	-0.47	-0.38	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
UCEC	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	5.04	1.33e-06	0.00244	0.46	0.38	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
UCEC	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-5.04	1.33e-06	0.00244	-0.42	-0.38	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
UCEC	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	5.04	1.33e-06	0.00244	0.4	0.38	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
UCEC	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	5.04	1.33e-06	0.00244	0.42	0.38	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
UCEC	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	5.04	1.33e-06	0.00245	0.42	0.38	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
UCEC	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	5.04	1.33e-06	0.00245	0.45	0.38	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
UCEC	cis	rs6840360	0.642	rs1596290	ENSG00000278978.1	RP11-164P12.5	-5.04	1.34e-06	0.00246	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151669786~151670503:+
UCEC	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-5.04	1.34e-06	0.00246	-0.43	-0.38	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-5.04	1.34e-06	0.00246	-0.43	-0.38	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-5.04	1.34e-06	0.00246	-0.43	-0.38	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
UCEC	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-5.04	1.34e-06	0.00246	-0.41	-0.38	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
UCEC	cis	rs7615952	0.558	rs17334039	ENSG00000241288.6	RP11-379B18.5	-5.04	1.35e-06	0.00247	-0.55	-0.38	Blood pressure (smoking interaction);	chr3:125821465	chr3:125827238~125916384:-
UCEC	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-5.04	1.35e-06	0.00247	-0.51	-0.38	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
UCEC	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	5.04	1.35e-06	0.00248	0.44	0.38	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
UCEC	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-5.04	1.35e-06	0.00248	-0.47	-0.38	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
UCEC	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	5.04	1.35e-06	0.00248	0.43	0.38	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
UCEC	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	5.04	1.35e-06	0.00248	0.51	0.38	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	5.04	1.35e-06	0.00248	0.51	0.38	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	5.04	1.35e-06	0.00248	0.51	0.38	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	5.04	1.35e-06	0.00248	0.51	0.38	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
UCEC	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	5.04	1.35e-06	0.00248	0.51	0.38	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
UCEC	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-5.04	1.35e-06	0.00248	-0.52	-0.38	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
UCEC	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	5.04	1.36e-06	0.00248	0.41	0.38	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
UCEC	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	5.04	1.36e-06	0.00248	0.41	0.38	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
UCEC	cis	rs763121	0.853	rs1062687	ENSG00000273076.1	RP3-508I15.22	5.04	1.36e-06	0.00248	0.42	0.38	Menopause (age at onset);	chr22:38738710	chr22:38743495~38743910:+
UCEC	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	5.04	1.36e-06	0.00249	0.46	0.38	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
UCEC	cis	rs9309473	0.687	rs6710659	ENSG00000163016.8	ALMS1P	5.04	1.36e-06	0.00249	0.41	0.38	Metabolite levels;	chr2:73380382	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	5.04	1.36e-06	0.00249	0.41	0.38	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	5.04	1.36e-06	0.00249	0.41	0.38	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	5.04	1.36e-06	0.00249	0.41	0.38	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
UCEC	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	5.03	1.36e-06	0.0025	0.53	0.38	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
UCEC	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	5.03	1.37e-06	0.0025	0.41	0.38	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
UCEC	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-5.03	1.37e-06	0.0025	-0.47	-0.38	Depression;	chr6:28113616	chr6:28115628~28116551:+
UCEC	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-5.03	1.37e-06	0.00251	-0.45	-0.38	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
UCEC	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-5.03	1.38e-06	0.00252	-0.46	-0.38	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
UCEC	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-5.03	1.38e-06	0.00252	-0.35	-0.38	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-5.03	1.38e-06	0.00252	-0.35	-0.38	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
UCEC	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	5.03	1.38e-06	0.00252	0.43	0.38	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
UCEC	cis	rs7267979	1	rs6050555	ENSG00000276952.1	RP5-965G21.6	-5.03	1.38e-06	0.00253	-0.49	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25284915~25285588:-
UCEC	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-5.03	1.39e-06	0.00253	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-5.03	1.39e-06	0.00253	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	5.03	1.39e-06	0.00253	0.42	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
UCEC	cis	rs9393777	0.777	rs35984974	ENSG00000216901.1	AL022393.7	5.03	1.39e-06	0.00253	0.64	0.38	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28176188~28176674:+
UCEC	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-5.03	1.39e-06	0.00253	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-5.03	1.39e-06	0.00254	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
UCEC	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	5.03	1.39e-06	0.00254	0.54	0.38	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	5.03	1.39e-06	0.00254	0.54	0.38	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
UCEC	cis	rs6840360	0.642	rs2709828	ENSG00000278978.1	RP11-164P12.5	-5.03	1.4e-06	0.00254	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2724551	ENSG00000278978.1	RP11-164P12.5	-5.03	1.4e-06	0.00254	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.667	rs2709829	ENSG00000278978.1	RP11-164P12.5	-5.03	1.4e-06	0.00254	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151669786~151670503:+
UCEC	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-5.03	1.4e-06	0.00255	-0.48	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
UCEC	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	5.03	1.4e-06	0.00255	0.41	0.38	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
UCEC	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	5.03	1.4e-06	0.00255	0.62	0.38	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
UCEC	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	5.03	1.4e-06	0.00255	0.5	0.38	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
UCEC	cis	rs6840360	0.642	rs2709822	ENSG00000278978.1	RP11-164P12.5	-5.03	1.4e-06	0.00255	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151669786~151670503:+
UCEC	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	5.03	1.4e-06	0.00256	0.48	0.38	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
UCEC	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	5.03	1.4e-06	0.00256	0.41	0.38	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
UCEC	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	5.03	1.42e-06	0.00258	0.47	0.38	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
UCEC	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	5.03	1.42e-06	0.00259	0.49	0.38	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
UCEC	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	5.02	1.43e-06	0.00259	0.43	0.38	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
UCEC	cis	rs10232172	0.673	rs6946331	ENSG00000234707.2	RP11-745C15.2	-5.02	1.43e-06	0.00259	-0.54	-0.38	Periodontal disease-related phenotypes;	chr7:54096615	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs6963860	ENSG00000234707.2	RP11-745C15.2	-5.02	1.43e-06	0.00259	-0.54	-0.38	Periodontal disease-related phenotypes;	chr7:54096728	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.541	rs4452751	ENSG00000234707.2	RP11-745C15.2	-5.02	1.43e-06	0.00259	-0.54	-0.38	Periodontal disease-related phenotypes;	chr7:54096966	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs1526784	ENSG00000234707.2	RP11-745C15.2	-5.02	1.43e-06	0.00259	-0.54	-0.38	Periodontal disease-related phenotypes;	chr7:54097001	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs1526785	ENSG00000234707.2	RP11-745C15.2	-5.02	1.43e-06	0.00259	-0.54	-0.38	Periodontal disease-related phenotypes;	chr7:54097227	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs1405443	ENSG00000234707.2	RP11-745C15.2	-5.02	1.43e-06	0.00259	-0.54	-0.38	Periodontal disease-related phenotypes;	chr7:54097534	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs4593485	ENSG00000234707.2	RP11-745C15.2	-5.02	1.43e-06	0.00259	-0.54	-0.38	Periodontal disease-related phenotypes;	chr7:54097599	chr7:54759425~54804928:+
UCEC	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-5.02	1.43e-06	0.0026	-0.43	-0.38	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
UCEC	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-5.02	1.43e-06	0.00261	-0.48	-0.38	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
UCEC	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	5.02	1.44e-06	0.00261	0.41	0.38	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
UCEC	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-5.02	1.44e-06	0.00261	-0.79	-0.38	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
UCEC	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	5.02	1.45e-06	0.00262	0.42	0.38	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
UCEC	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	5.02	1.45e-06	0.00262	0.62	0.38	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
UCEC	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-5.02	1.45e-06	0.00263	-0.43	-0.38	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
UCEC	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-5.02	1.45e-06	0.00263	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
UCEC	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	5.02	1.45e-06	0.00263	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	5.02	1.45e-06	0.00263	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	5.02	1.45e-06	0.00263	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
UCEC	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	5.02	1.45e-06	0.00263	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
UCEC	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-5.02	1.45e-06	0.00263	-0.74	-0.38	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-5.02	1.45e-06	0.00263	-0.74	-0.38	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-5.02	1.45e-06	0.00263	-0.74	-0.38	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-5.02	1.45e-06	0.00263	-0.74	-0.38	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-5.02	1.45e-06	0.00263	-0.74	-0.38	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-5.02	1.45e-06	0.00263	-0.74	-0.38	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	5.02	1.45e-06	0.00263	0.74	0.38	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
UCEC	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-5.02	1.46e-06	0.00264	-0.5	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-5.02	1.46e-06	0.00264	-0.5	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-5.02	1.46e-06	0.00264	-0.5	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
UCEC	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-5.02	1.46e-06	0.00264	-0.42	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
UCEC	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-5.02	1.46e-06	0.00264	-0.47	-0.38	Depression;	chr6:28126588	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-5.02	1.46e-06	0.00264	-0.47	-0.38	Depression;	chr6:28126953	chr6:28115628~28116551:+
UCEC	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	5.02	1.46e-06	0.00264	0.43	0.38	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
UCEC	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	5.02	1.46e-06	0.00264	0.43	0.38	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
UCEC	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-5.02	1.46e-06	0.00265	-0.49	-0.38	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
UCEC	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	5.02	1.46e-06	0.00265	0.44	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
UCEC	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	5.02	1.46e-06	0.00265	0.76	0.38	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-5.02	1.47e-06	0.00266	-0.4	-0.38	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
UCEC	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	5.02	1.48e-06	0.00266	0.48	0.38	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	5.02	1.48e-06	0.00266	0.48	0.38	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	5.02	1.48e-06	0.00266	0.48	0.38	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
UCEC	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-5.02	1.48e-06	0.00267	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
UCEC	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-5.02	1.48e-06	0.00268	-0.53	-0.38	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
UCEC	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-5.02	1.49e-06	0.00268	-0.46	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
UCEC	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	5.01	1.49e-06	0.00268	0.42	0.38	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
UCEC	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-5.01	1.5e-06	0.0027	-0.47	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-5.01	1.5e-06	0.0027	-0.47	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-5.01	1.5e-06	0.0027	-0.47	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-5.01	1.5e-06	0.0027	-0.47	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-5.01	1.5e-06	0.0027	-0.47	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
UCEC	cis	rs2115630	0.905	rs1975277	ENSG00000225151.9	GOLGA2P7	5.01	1.5e-06	0.0027	0.42	0.38	P wave terminal force;	chr15:84786327	chr15:84199311~84230136:-
UCEC	cis	rs7267979	0.816	rs3746337	ENSG00000276952.1	RP5-965G21.6	5.01	1.5e-06	0.00271	0.51	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:25284915~25285588:-
UCEC	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	5.01	1.5e-06	0.00271	0.48	0.38	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	5.01	1.5e-06	0.00271	0.48	0.38	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	5.01	1.5e-06	0.00271	0.48	0.38	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	5.01	1.5e-06	0.00271	0.48	0.38	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	5.01	1.5e-06	0.00271	0.48	0.38	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	5.01	1.5e-06	0.00271	0.48	0.38	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	5.01	1.5e-06	0.00271	0.48	0.38	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
UCEC	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-5.01	1.51e-06	0.00271	-0.5	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
UCEC	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	5.01	1.51e-06	0.00271	0.45	0.38	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
UCEC	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	5.01	1.51e-06	0.00271	0.45	0.38	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
UCEC	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	5.01	1.51e-06	0.00271	0.41	0.38	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
UCEC	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-5.01	1.51e-06	0.00272	-0.45	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
UCEC	cis	rs6840360	0.582	rs2709812	ENSG00000278978.1	RP11-164P12.5	5.01	1.52e-06	0.00272	0.44	0.38	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151669786~151670503:+
UCEC	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	5.01	1.52e-06	0.00273	0.54	0.38	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
UCEC	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-5.01	1.52e-06	0.00273	-0.56	-0.38	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-5.01	1.52e-06	0.00273	-0.56	-0.38	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
UCEC	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	5.01	1.53e-06	0.00275	0.4	0.38	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	5.01	1.53e-06	0.00275	0.4	0.38	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	5.01	1.53e-06	0.00275	0.4	0.38	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
UCEC	cis	rs999944	0.882	rs1509522	ENSG00000234572.1	AC007880.1	5.01	1.54e-06	0.00275	0.98	0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:64825080	chr2:64846130~64863626:-
UCEC	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	5.01	1.54e-06	0.00275	0.43	0.38	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
UCEC	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-5.01	1.54e-06	0.00276	-0.55	-0.38	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
UCEC	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-5.01	1.54e-06	0.00276	-0.82	-0.38	Gout;	chr7:66671562	chr7:66654538~66669855:+
UCEC	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-5.01	1.54e-06	0.00276	-0.53	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
UCEC	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	5.01	1.54e-06	0.00276	0.48	0.38	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	5.01	1.54e-06	0.00276	0.48	0.38	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
UCEC	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	5.01	1.55e-06	0.00276	0.47	0.38	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
UCEC	cis	rs7267979	0.549	rs11698185	ENSG00000276952.1	RP5-965G21.6	5.01	1.55e-06	0.00277	0.56	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:25284915~25285588:-
UCEC	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	5.01	1.55e-06	0.00277	0.45	0.38	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
UCEC	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-5	1.56e-06	0.00278	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
UCEC	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	5	1.56e-06	0.00278	0.47	0.38	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
UCEC	cis	rs2739330	0.791	rs9612520	ENSG00000272787.1	KB-226F1.2	-5	1.56e-06	0.00279	-0.47	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23969211~23969873:+
UCEC	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	5	1.56e-06	0.00279	0.44	0.38	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
UCEC	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	5	1.57e-06	0.0028	0.65	0.38	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
UCEC	cis	rs7240205	0.853	rs4555225	ENSG00000275805.1	RP11-349H17.2	-5	1.57e-06	0.0028	-0.47	-0.38	Breast cancer;	chr18:26561892	chr18:26565723~26575626:-
UCEC	cis	rs7240205	0.853	rs58806199	ENSG00000275805.1	RP11-349H17.2	-5	1.57e-06	0.0028	-0.47	-0.38	Breast cancer;	chr18:26562683	chr18:26565723~26575626:-
UCEC	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-5	1.57e-06	0.0028	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
UCEC	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	5	1.57e-06	0.0028	0.42	0.38	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
UCEC	cis	rs4845570	0.92	rs3811414	ENSG00000203288.3	RP11-98D18.9	-5	1.57e-06	0.0028	-0.52	-0.38	Coronary artery disease;	chr1:151790770	chr1:151790804~151794402:+
UCEC	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	5	1.57e-06	0.0028	0.4	0.38	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
UCEC	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-5	1.58e-06	0.00281	-0.82	-0.38	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-5	1.58e-06	0.00281	-0.82	-0.38	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-5	1.58e-06	0.00281	-0.82	-0.38	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-5	1.58e-06	0.00281	-0.82	-0.38	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-5	1.58e-06	0.00281	-0.82	-0.38	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-5	1.58e-06	0.00281	-0.82	-0.38	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
UCEC	cis	rs748404	0.578	rs1058298	ENSG00000205771.5	CATSPER2P1	-5	1.58e-06	0.00281	-0.49	-0.38	Lung cancer;	chr15:43408732	chr15:43726918~43747094:-
UCEC	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	5	1.59e-06	0.00282	1.04	0.38	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
UCEC	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	5	1.59e-06	0.00283	0.48	0.38	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
UCEC	cis	rs6840360	0.642	rs7676493	ENSG00000278978.1	RP11-164P12.5	-5	1.59e-06	0.00283	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs11735957	ENSG00000278978.1	RP11-164P12.5	-5	1.59e-06	0.00283	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs11099819	ENSG00000278978.1	RP11-164P12.5	-5	1.59e-06	0.00283	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs11726254	ENSG00000278978.1	RP11-164P12.5	-5	1.59e-06	0.00283	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2053566	ENSG00000278978.1	RP11-164P12.5	-5	1.59e-06	0.00283	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.607	rs1561918	ENSG00000278978.1	RP11-164P12.5	-5	1.59e-06	0.00283	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs1443089	ENSG00000278978.1	RP11-164P12.5	-5	1.59e-06	0.00283	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151669786~151670503:+
UCEC	cis	rs9545047	0.604	rs9574416	ENSG00000227354.5	RBM26-AS1	-5	1.59e-06	0.00283	-0.37	-0.38	Schizophrenia;	chr13:79388577	chr13:79406309~79424328:+
UCEC	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-5	1.6e-06	0.00284	-0.46	-0.38	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
UCEC	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	5	1.6e-06	0.00284	0.8	0.38	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	5	1.6e-06	0.00284	0.8	0.38	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	5	1.6e-06	0.00284	0.8	0.38	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-5	1.6e-06	0.00284	-0.8	-0.38	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-5	1.6e-06	0.00284	-0.8	-0.38	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-5	1.6e-06	0.00284	-0.8	-0.38	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-5	1.6e-06	0.00284	-0.8	-0.38	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-5	1.6e-06	0.00284	-0.8	-0.38	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
UCEC	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	5	1.61e-06	0.00285	0.64	0.38	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
UCEC	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	5	1.61e-06	0.00285	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
UCEC	cis	rs6840360	0.642	rs1470280	ENSG00000278978.1	RP11-164P12.5	-5	1.61e-06	0.00285	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151669786~151670503:+
UCEC	cis	rs2276314	0.857	rs4799408	ENSG00000267627.4	RP11-905K4.1	5	1.61e-06	0.00285	0.41	0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35951803~35966118:-
UCEC	cis	rs10232172	0.591	rs1526750	ENSG00000234707.2	RP11-745C15.2	-5	1.61e-06	0.00286	-0.5	-0.38	Periodontal disease-related phenotypes;	chr7:54086910	chr7:54759425~54804928:+
UCEC	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-5	1.62e-06	0.00286	-0.49	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
UCEC	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	5	1.62e-06	0.00286	0.56	0.38	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
UCEC	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	5	1.62e-06	0.00287	0.39	0.38	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
UCEC	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-4.99	1.63e-06	0.00288	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	4.99	1.63e-06	0.00288	0.51	0.38	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
UCEC	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	4.99	1.63e-06	0.00288	0.42	0.38	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
UCEC	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	4.99	1.63e-06	0.00288	0.38	0.38	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
UCEC	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-4.99	1.64e-06	0.00289	-0.4	-0.38	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
UCEC	cis	rs763121	0.853	rs138709	ENSG00000273076.1	RP3-508I15.22	4.99	1.64e-06	0.00289	0.41	0.38	Menopause (age at onset);	chr22:38743211	chr22:38743495~38743910:+
UCEC	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-4.99	1.64e-06	0.0029	-0.48	-0.38	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
UCEC	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	4.99	1.64e-06	0.0029	0.52	0.38	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
UCEC	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-4.99	1.64e-06	0.0029	-0.76	-0.38	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	4.99	1.64e-06	0.0029	0.76	0.38	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-4.99	1.64e-06	0.0029	-0.76	-0.38	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	4.99	1.64e-06	0.0029	0.76	0.38	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	4.99	1.64e-06	0.0029	0.76	0.38	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	4.99	1.64e-06	0.0029	0.76	0.38	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	4.99	1.64e-06	0.0029	0.76	0.38	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
UCEC	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-4.99	1.65e-06	0.0029	-0.52	-0.38	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
UCEC	cis	rs8062405	0.756	rs151301	ENSG00000259982.1	CDC37P1	4.99	1.65e-06	0.0029	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28700294~28701540:-
UCEC	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-4.99	1.65e-06	0.00291	-0.48	-0.38	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-4.99	1.65e-06	0.00291	-0.48	-0.38	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
UCEC	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	4.99	1.65e-06	0.00291	0.42	0.38	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	4.99	1.65e-06	0.00291	0.42	0.38	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
UCEC	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-4.99	1.65e-06	0.00291	-0.38	-0.38	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
UCEC	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-4.99	1.66e-06	0.00293	-0.48	-0.38	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
UCEC	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-4.99	1.67e-06	0.00293	-0.43	-0.38	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
UCEC	cis	rs7246967	0.673	rs9677019	ENSG00000198153.8	ZNF849P	-4.99	1.67e-06	0.00294	-0.44	-0.38	Bronchopulmonary dysplasia;	chr19:22729857	chr19:22685167~22686732:+
UCEC	cis	rs2732480	0.577	rs2634681	ENSG00000226413.2	OR8T1P	-4.99	1.68e-06	0.00296	-0.49	-0.38	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48442030~48442947:-
UCEC	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	4.99	1.7e-06	0.00298	0.51	0.38	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
UCEC	cis	rs6840360	0.642	rs1470281	ENSG00000278978.1	RP11-164P12.5	-4.99	1.7e-06	0.00298	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151669786~151670503:+
UCEC	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	4.98	1.7e-06	0.00299	0.49	0.38	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
UCEC	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	4.98	1.71e-06	0.00299	0.42	0.38	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
UCEC	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	4.98	1.71e-06	0.00299	0.41	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	4.98	1.71e-06	0.00299	0.41	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-4.98	1.71e-06	0.00299	-0.41	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
UCEC	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-4.98	1.71e-06	0.00299	-0.43	-0.38	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-4.98	1.71e-06	0.00299	-0.43	-0.38	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
UCEC	cis	rs999944	0.825	rs1990780	ENSG00000234572.1	AC007880.1	4.98	1.72e-06	0.003	0.97	0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:64827439	chr2:64846130~64863626:-
UCEC	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	4.98	1.72e-06	0.003	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	4.98	1.72e-06	0.003	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
UCEC	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	4.98	1.72e-06	0.00301	0.55	0.38	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-4.98	1.72e-06	0.00301	-0.55	-0.38	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
UCEC	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	4.98	1.72e-06	0.00301	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
UCEC	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-4.98	1.73e-06	0.00302	-0.41	-0.38	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
UCEC	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	4.98	1.73e-06	0.00302	0.45	0.38	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
UCEC	cis	rs12478296	1	rs12478296	ENSG00000261186.2	RP11-341N2.1	4.98	1.73e-06	0.00302	0.51	0.38	Obesity-related traits;	chr2:242106609	chr2:242087351~242088457:-
UCEC	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	4.98	1.73e-06	0.00302	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	4.98	1.73e-06	0.00302	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	4.98	1.73e-06	0.00302	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	4.98	1.73e-06	0.00302	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	4.98	1.73e-06	0.00302	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
UCEC	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-4.98	1.73e-06	0.00302	-0.82	-0.38	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-4.98	1.73e-06	0.00302	-0.82	-0.38	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
UCEC	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-4.98	1.74e-06	0.00303	-0.5	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-4.98	1.74e-06	0.00303	-0.52	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
UCEC	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-4.98	1.74e-06	0.00304	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
UCEC	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	4.98	1.74e-06	0.00304	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
UCEC	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	4.98	1.74e-06	0.00304	0.43	0.38	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
UCEC	cis	rs6901004	0.935	rs1150078	ENSG00000271789.1	RP5-1112D6.7	4.98	1.74e-06	0.00304	0.46	0.38	Blood metabolite levels;	chr6:111239098	chr6:111297126~111298510:+
UCEC	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-4.98	1.75e-06	0.00305	-0.43	-0.38	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
UCEC	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	4.98	1.75e-06	0.00305	0.42	0.38	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	4.98	1.75e-06	0.00305	0.42	0.38	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	4.98	1.75e-06	0.00305	0.43	0.38	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	4.98	1.75e-06	0.00305	0.43	0.38	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
UCEC	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	4.98	1.75e-06	0.00305	0.65	0.38	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
UCEC	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	4.98	1.76e-06	0.00306	0.45	0.38	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
UCEC	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	4.98	1.76e-06	0.00306	0.37	0.38	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
UCEC	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	4.98	1.76e-06	0.00306	0.55	0.38	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
UCEC	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	4.98	1.76e-06	0.00306	0.55	0.38	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
UCEC	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	4.98	1.76e-06	0.00306	0.46	0.38	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
UCEC	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-4.98	1.76e-06	0.00307	-0.49	-0.38	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-4.98	1.76e-06	0.00307	-0.49	-0.38	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-4.98	1.76e-06	0.00307	-0.49	-0.38	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
UCEC	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	4.98	1.77e-06	0.00307	0.42	0.38	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	4.98	1.77e-06	0.00308	0.42	0.38	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
UCEC	cis	rs7846314	0.536	rs35914442	ENSG00000254432.1	RP11-33I11.2	-4.98	1.77e-06	0.00308	-0.57	-0.38	Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Myeloid white cell count;Neutrophil percentage of granulocytes;Granulocyte count;Sum basophil neutrophil counts;Granulocyte percentage of myeloid white cells;Neutrophil count;White blood cell count;	chr8:60724328	chr8:60808735~60809606:-
UCEC	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-4.98	1.77e-06	0.00308	-0.47	-0.38	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-4.98	1.77e-06	0.00308	-0.47	-0.38	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-4.98	1.77e-06	0.00308	-0.47	-0.38	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-4.98	1.77e-06	0.00308	-0.47	-0.38	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
UCEC	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-4.98	1.77e-06	0.00308	-0.47	-0.38	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
UCEC	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-4.97	1.78e-06	0.0031	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
UCEC	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-4.97	1.78e-06	0.0031	-0.4	-0.38	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
UCEC	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	4.97	1.78e-06	0.0031	0.41	0.38	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
UCEC	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	4.97	1.79e-06	0.0031	0.79	0.38	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
UCEC	cis	rs9309473	0.898	rs10170786	ENSG00000163016.8	ALMS1P	4.97	1.79e-06	0.0031	0.42	0.38	Metabolite levels;	chr2:73585861	chr2:73644919~73685576:+
UCEC	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-4.97	1.79e-06	0.0031	-0.42	-0.38	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-4.97	1.79e-06	0.0031	-0.42	-0.38	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
UCEC	cis	rs6840360	0.582	rs2709823	ENSG00000278978.1	RP11-164P12.5	-4.97	1.79e-06	0.0031	-0.45	-0.38	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151669786~151670503:+
UCEC	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-4.97	1.79e-06	0.00311	-0.44	-0.38	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
UCEC	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-4.97	1.79e-06	0.00311	-0.39	-0.38	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
UCEC	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	4.97	1.8e-06	0.00311	0.34	0.38	Height;	chr11:118758322	chr11:118791254~118793137:+
UCEC	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
UCEC	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
UCEC	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-4.97	1.8e-06	0.00311	-0.4	-0.38	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
UCEC	cis	rs951266	0.505	rs11639372	ENSG00000261143.1	ADAMTS7P3	4.97	1.8e-06	0.00312	0.49	0.38	Post bronchodilator FEV1/FVC ratio;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Pre bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78674313	chr15:77976042~77993057:+
UCEC	cis	rs492146	0.967	rs400804	ENSG00000243236.5	GSTA9P	-4.97	1.8e-06	0.00312	-0.48	-0.38	Epilepsy (remission after treatment);	chr6:52972292	chr6:52939726~52957521:-
UCEC	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-4.97	1.81e-06	0.00313	-0.51	-0.38	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-4.97	1.81e-06	0.00313	-0.51	-0.38	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-4.97	1.81e-06	0.00313	-0.51	-0.38	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-4.97	1.81e-06	0.00313	-0.51	-0.38	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-4.97	1.81e-06	0.00313	-0.51	-0.38	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-4.97	1.81e-06	0.00313	-0.51	-0.38	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-4.97	1.81e-06	0.00313	-0.51	-0.38	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
UCEC	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-4.97	1.81e-06	0.00313	-0.42	-0.38	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
UCEC	cis	rs964184	0.63	rs2075290	ENSG00000254851.1	RP11-109L13.1	-4.97	1.81e-06	0.00313	-0.83	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116782580	chr11:117135528~117138582:+
UCEC	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	4.97	1.81e-06	0.00313	0.61	0.38	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	4.97	1.81e-06	0.00313	0.61	0.38	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	4.97	1.81e-06	0.00313	0.61	0.38	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
UCEC	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	4.97	1.82e-06	0.00314	0.44	0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-4.97	1.82e-06	0.00314	-0.44	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
UCEC	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	4.97	1.82e-06	0.00314	0.46	0.38	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
UCEC	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-4.97	1.82e-06	0.00315	-0.51	-0.38	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
UCEC	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-4.97	1.82e-06	0.00315	-0.48	-0.38	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
UCEC	cis	rs6840360	0.582	rs2709827	ENSG00000278978.1	RP11-164P12.5	-4.97	1.83e-06	0.00316	-0.43	-0.38	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151669786~151670503:+
UCEC	cis	rs7267979	0.932	rs4280527	ENSG00000276952.1	RP5-965G21.6	4.97	1.83e-06	0.00316	0.5	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050609	ENSG00000276952.1	RP5-965G21.6	-4.97	1.83e-06	0.00317	-0.49	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25284915~25285588:-
UCEC	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-4.97	1.84e-06	0.00318	-0.48	-0.38	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-4.97	1.84e-06	0.00318	-0.48	-0.38	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
UCEC	cis	rs7240205	0.853	rs10432165	ENSG00000275805.1	RP11-349H17.2	-4.97	1.85e-06	0.00319	-0.47	-0.38	Breast cancer;	chr18:26555361	chr18:26565723~26575626:-
UCEC	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	4.97	1.85e-06	0.00319	0.4	0.38	Height;	chr6:109454233	chr6:109382795~109383666:+
UCEC	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-4.97	1.85e-06	0.00319	-0.43	-0.38	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
UCEC	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-4.97	1.85e-06	0.00319	-0.42	-0.38	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-4.97	1.85e-06	0.00319	-0.42	-0.38	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-4.97	1.85e-06	0.00319	-0.42	-0.38	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-4.97	1.85e-06	0.00319	-0.42	-0.38	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
UCEC	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-4.97	1.85e-06	0.00319	-0.47	-0.38	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
UCEC	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-4.97	1.85e-06	0.00319	-0.42	-0.38	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
UCEC	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-4.97	1.85e-06	0.0032	-0.51	-0.38	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
UCEC	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	4.97	1.85e-06	0.0032	0.54	0.38	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	4.97	1.85e-06	0.0032	0.54	0.38	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
UCEC	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	4.97	1.86e-06	0.0032	0.52	0.38	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
UCEC	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	4.97	1.86e-06	0.0032	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
UCEC	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	4.96	1.86e-06	0.0032	0.43	0.38	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
UCEC	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	4.96	1.86e-06	0.00321	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	4.96	1.86e-06	0.00321	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	4.96	1.86e-06	0.00321	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	4.96	1.86e-06	0.00321	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	4.96	1.86e-06	0.00321	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
UCEC	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	4.96	1.86e-06	0.00321	0.42	0.38	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
UCEC	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-4.96	1.86e-06	0.00321	-0.41	-0.38	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
UCEC	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-4.96	1.87e-06	0.00322	-0.76	-0.38	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-4.96	1.87e-06	0.00322	-0.79	-0.38	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-4.96	1.87e-06	0.00322	-0.79	-0.38	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-4.96	1.87e-06	0.00322	-0.79	-0.38	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
UCEC	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	4.96	1.87e-06	0.00322	0.48	0.38	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
UCEC	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	4.96	1.87e-06	0.00322	0.38	0.38	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	4.96	1.87e-06	0.00322	0.38	0.38	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
UCEC	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-4.96	1.88e-06	0.00323	-0.51	-0.38	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
UCEC	cis	rs948562	0.744	rs11229438	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58423730	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs11229440	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58426719	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs11229444	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58430400	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs11229449	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58434155	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs111377246	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58436505	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs113707421	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58449669	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs11229468	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58451300	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs113392266	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58452278	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs74406537	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58452887	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs12363774	ENSG00000280010.1	AP001350.4	4.96	1.89e-06	0.00324	0.71	0.38	Lymphoma;	chr11:58457562	chr11:58627435~58628528:+
UCEC	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-4.96	1.89e-06	0.00325	-0.47	-0.38	Depression;	chr6:28136698	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-4.96	1.89e-06	0.00325	-0.47	-0.38	Depression;	chr6:28136856	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-4.96	1.89e-06	0.00325	-0.47	-0.38	Depression;	chr6:28137418	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-4.96	1.89e-06	0.00325	-0.47	-0.38	Depression;	chr6:28138363	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-4.96	1.89e-06	0.00325	-0.47	-0.38	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-4.96	1.89e-06	0.00325	-0.47	-0.38	Depression;	chr6:28138981	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-4.96	1.89e-06	0.00325	-0.47	-0.38	Depression;	chr6:28139012	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-4.96	1.89e-06	0.00325	-0.47	-0.38	Depression;	chr6:28139876	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-4.96	1.89e-06	0.00325	-0.47	-0.38	Depression;	chr6:28139998	chr6:28115628~28116551:+
UCEC	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-4.96	1.89e-06	0.00325	-0.41	-0.38	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
UCEC	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-4.96	1.9e-06	0.00325	-0.47	-0.38	Depression;	chr6:28139049	chr6:28115628~28116551:+
UCEC	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	4.96	1.9e-06	0.00325	0.38	0.38	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
UCEC	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-4.96	1.9e-06	0.00326	-0.53	-0.38	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
UCEC	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	4.96	1.91e-06	0.00327	0.46	0.38	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
UCEC	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	4.96	1.91e-06	0.00327	0.46	0.38	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
UCEC	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-4.96	1.91e-06	0.00327	-0.52	-0.38	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
UCEC	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-4.96	1.91e-06	0.00328	-0.42	-0.38	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
UCEC	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	4.96	1.92e-06	0.00328	0.45	0.38	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	4.96	1.92e-06	0.00328	0.45	0.38	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
UCEC	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-4.96	1.92e-06	0.00328	-0.45	-0.38	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-4.96	1.92e-06	0.00328	-0.45	-0.38	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
UCEC	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-4.96	1.92e-06	0.00329	-0.42	-0.38	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
UCEC	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	4.96	1.92e-06	0.00329	0.53	0.38	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
UCEC	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-4.96	1.92e-06	0.00329	-0.44	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-4.96	1.92e-06	0.00329	-0.44	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-4.96	1.92e-06	0.00329	-0.44	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
UCEC	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-4.96	1.94e-06	0.00331	-0.4	-0.38	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
UCEC	cis	rs7267979	1	rs2424712	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2424714	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2424715	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050617	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.933	rs2387887	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050626	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6037121	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs1047171	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050629	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050630	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050632	ENSG00000276952.1	RP5-965G21.6	4.96	1.94e-06	0.00332	0.49	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25284915~25285588:-
UCEC	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	4.96	1.94e-06	0.00332	0.45	0.38	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
UCEC	cis	rs2739330	0.627	rs9608219	ENSG00000272787.1	KB-226F1.2	-4.95	1.94e-06	0.00332	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23969211~23969873:+
UCEC	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	4.95	1.95e-06	0.00334	0.45	0.38	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
UCEC	cis	rs10232172	0.778	rs59482255	ENSG00000234707.2	RP11-745C15.2	-4.95	1.96e-06	0.00334	-0.61	-0.38	Periodontal disease-related phenotypes;	chr7:54102933	chr7:54759425~54804928:+
UCEC	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	4.95	1.96e-06	0.00334	0.5	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
UCEC	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	4.95	1.96e-06	0.00334	0.5	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
UCEC	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	4.95	1.96e-06	0.00334	0.5	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
UCEC	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-4.95	1.96e-06	0.00334	-0.74	-0.38	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-4.95	1.96e-06	0.00334	-0.74	-0.38	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-4.95	1.96e-06	0.00334	-0.74	-0.38	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-4.95	1.96e-06	0.00334	-0.74	-0.38	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-4.95	1.96e-06	0.00334	-0.74	-0.38	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-4.95	1.96e-06	0.00334	-0.74	-0.38	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-4.95	1.96e-06	0.00334	-0.74	-0.38	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-4.95	1.96e-06	0.00334	-0.74	-0.38	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
UCEC	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-4.95	1.97e-06	0.00335	-0.5	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
UCEC	cis	rs938295	1	rs938295	ENSG00000236045.1	RP3-467K16.7	-4.95	1.97e-06	0.00335	-0.53	-0.38	Gut microbiota (bacterial taxa);	chr1:15760765	chr1:15334166~15335464:-
UCEC	cis	rs7674212	1	rs7691873	ENSG00000246560.2	RP11-10L12.4	-4.95	1.97e-06	0.00336	-0.46	-0.38	Type 2 diabetes;	chr4:103066742	chr4:102828055~102844075:+
UCEC	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-4.95	1.97e-06	0.00336	-0.72	-0.38	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-4.95	1.97e-06	0.00336	-0.72	-0.38	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-4.95	1.97e-06	0.00336	-0.72	-0.38	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-4.95	1.97e-06	0.00336	-0.72	-0.38	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-4.95	1.97e-06	0.00336	-0.72	-0.38	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
UCEC	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	4.95	1.98e-06	0.00337	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	4.95	1.98e-06	0.00337	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	4.95	1.98e-06	0.00337	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
UCEC	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-4.95	1.98e-06	0.00337	-0.53	-0.38	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
UCEC	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	4.95	1.99e-06	0.00338	0.39	0.38	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
UCEC	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-4.95	1.99e-06	0.00338	-0.5	-0.38	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
UCEC	cis	rs617219	0.613	rs1038992	ENSG00000245556.2	SCAMP1-AS1	-4.95	1.99e-06	0.00339	-0.35	-0.38	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79312825	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.574	rs6864184	ENSG00000245556.2	SCAMP1-AS1	-4.95	1.99e-06	0.00339	-0.35	-0.38	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79313532	chr5:78342365~78360507:-
UCEC	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-4.95	2e-06	0.00339	-0.5	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-4.95	2e-06	0.00339	-0.5	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
UCEC	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	4.95	2e-06	0.00339	0.53	0.38	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	4.95	2e-06	0.00339	0.53	0.38	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	4.95	2e-06	0.00339	0.53	0.38	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
UCEC	cis	rs6840360	0.642	rs7666571	ENSG00000278978.1	RP11-164P12.5	-4.95	2e-06	0.00339	-0.44	-0.38	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151669786~151670503:+
UCEC	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	4.95	2e-06	0.00339	0.42	0.38	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
UCEC	cis	rs4784934	0.921	rs4784938	ENSG00000260186.4	RP11-481J2.2	4.95	2.01e-06	0.00341	0.5	0.38	QT interval;	chr16:58433949	chr16:58421326~58462470:+
UCEC	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-4.95	2.01e-06	0.00341	-0.45	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-4.95	2.01e-06	0.00341	-0.45	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
UCEC	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	4.95	2.02e-06	0.00343	0.57	0.38	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	4.95	2.02e-06	0.00343	0.57	0.38	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
UCEC	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00345	-0.5	-0.38	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00345	-0.5	-0.38	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00345	-0.5	-0.38	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00345	-0.5	-0.38	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00345	-0.5	-0.38	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00345	-0.5	-0.38	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	4.94	2.04e-06	0.00345	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
UCEC	cis	rs7267979	1	rs2856	ENSG00000276952.1	RP5-965G21.6	4.94	2.04e-06	0.00346	0.5	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25284915~25285588:-
UCEC	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00346	-0.76	-0.38	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00346	-0.76	-0.38	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00346	-0.76	-0.38	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00346	-0.76	-0.38	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00346	-0.76	-0.38	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00346	-0.76	-0.38	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00346	-0.76	-0.38	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00346	-0.76	-0.38	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-4.94	2.04e-06	0.00346	-0.76	-0.38	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
UCEC	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	4.94	2.04e-06	0.00346	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
UCEC	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	4.94	2.05e-06	0.00346	0.53	0.38	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	4.94	2.05e-06	0.00346	0.53	0.38	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
UCEC	cis	rs7267979	1	rs6115153	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs7268053	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6083809	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050561	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6083813	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815406	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs6083817	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs6050564	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs6083818	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815409	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs4815411	ENSG00000276952.1	RP5-965G21.6	-4.94	2.05e-06	0.00346	-0.48	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25284915~25285588:-
UCEC	cis	rs7267979	1	rs10966	ENSG00000276952.1	RP5-965G21.6	4.94	2.05e-06	0.00346	0.48	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs6037097	ENSG00000276952.1	RP5-965G21.6	4.94	2.05e-06	0.00346	0.48	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.933	rs2261109	ENSG00000276952.1	RP5-965G21.6	4.94	2.05e-06	0.00347	0.47	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2261698	ENSG00000276952.1	RP5-965G21.6	4.94	2.05e-06	0.00347	0.47	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.966	rs2261720	ENSG00000276952.1	RP5-965G21.6	4.94	2.05e-06	0.00347	0.47	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25284915~25285588:-
UCEC	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	4.94	2.05e-06	0.00347	0.42	0.38	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
UCEC	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-4.94	2.05e-06	0.00347	-0.47	-0.38	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
UCEC	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-4.94	2.05e-06	0.00347	-0.47	-0.38	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
UCEC	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	4.94	2.06e-06	0.00348	0.45	0.38	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
UCEC	cis	rs1930961	0.85	rs5996945	ENSG00000272942.1	CTA-246H3.12	4.94	2.06e-06	0.00348	0.46	0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25434324~25435070:-
UCEC	cis	rs10232172	0.63	rs1524390	ENSG00000234707.2	RP11-745C15.2	-4.94	2.06e-06	0.00348	-0.5	-0.38	Periodontal disease-related phenotypes;	chr7:54090951	chr7:54759425~54804928:+
UCEC	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-4.94	2.06e-06	0.00349	-0.52	-0.38	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
UCEC	cis	rs7267979	1	rs6050590	ENSG00000276952.1	RP5-965G21.6	-4.94	2.06e-06	0.00349	-0.49	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25284915~25285588:-
UCEC	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	4.94	2.07e-06	0.0035	0.47	0.38	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
UCEC	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-4.94	2.07e-06	0.0035	-0.72	-0.38	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-4.94	2.07e-06	0.0035	-0.72	-0.38	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
UCEC	cis	rs4713118	0.506	rs9366697	ENSG00000216901.1	AL022393.7	4.94	2.07e-06	0.0035	0.4	0.38	Parkinson's disease;	chr6:27665239	chr6:28176188~28176674:+
UCEC	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-4.94	2.08e-06	0.0035	-0.43	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
UCEC	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-4.94	2.08e-06	0.0035	-0.45	-0.38	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
UCEC	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-4.94	2.09e-06	0.00351	-0.47	-0.38	Depression;	chr6:28133900	chr6:28115628~28116551:+
UCEC	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	4.94	2.09e-06	0.00352	0.44	0.38	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	4.94	2.09e-06	0.00352	0.44	0.38	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	4.94	2.09e-06	0.00352	0.44	0.38	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	4.94	2.09e-06	0.00352	0.44	0.38	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	4.94	2.09e-06	0.00352	0.44	0.38	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	4.94	2.09e-06	0.00352	0.44	0.38	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	4.94	2.09e-06	0.00352	0.44	0.38	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
UCEC	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	4.94	2.09e-06	0.00352	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	4.94	2.09e-06	0.00352	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	4.94	2.09e-06	0.00352	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	4.94	2.09e-06	0.00352	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	4.94	2.09e-06	0.00352	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	4.94	2.09e-06	0.00352	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
UCEC	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-4.94	2.09e-06	0.00353	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
UCEC	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	4.94	2.1e-06	0.00353	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
UCEC	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	4.94	2.1e-06	0.00354	0.49	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
UCEC	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-4.94	2.11e-06	0.00354	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
UCEC	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-4.94	2.11e-06	0.00354	-0.52	-0.37	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
UCEC	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-4.94	2.11e-06	0.00354	-0.72	-0.37	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
UCEC	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-4.94	2.11e-06	0.00355	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
UCEC	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	4.94	2.12e-06	0.00356	0.42	0.37	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
UCEC	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-4.93	2.12e-06	0.00356	-0.42	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
UCEC	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-4.93	2.13e-06	0.00357	-0.5	-0.37	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
UCEC	cis	rs6840360	0.582	rs1372976	ENSG00000278978.1	RP11-164P12.5	-4.93	2.13e-06	0.00357	-0.44	-0.37	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs1443090	ENSG00000278978.1	RP11-164P12.5	-4.93	2.13e-06	0.00357	-0.44	-0.37	Intelligence (multi-trait analysis);	chr4:151530667	chr4:151669786~151670503:+
UCEC	cis	rs492146	0.783	rs613764	ENSG00000243236.5	GSTA9P	-4.93	2.13e-06	0.00357	-0.48	-0.37	Epilepsy (remission after treatment);	chr6:52975437	chr6:52939726~52957521:-
UCEC	cis	rs2581828	0.931	rs2336722	ENSG00000242142.1	SERBP1P3	4.93	2.13e-06	0.00358	0.43	0.37	Crohn's disease;	chr3:53105961	chr3:53064283~53065091:-
UCEC	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	4.93	2.13e-06	0.00358	0.5	0.37	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
UCEC	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	4.93	2.14e-06	0.00359	0.56	0.37	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
UCEC	cis	rs6840360	0.557	rs1143036	ENSG00000278978.1	RP11-164P12.5	-4.93	2.14e-06	0.00359	-0.44	-0.37	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151669786~151670503:+
UCEC	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	4.93	2.14e-06	0.00359	0.42	0.37	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
UCEC	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-4.93	2.15e-06	0.0036	-0.48	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-4.93	2.15e-06	0.0036	-0.48	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
UCEC	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-4.93	2.15e-06	0.0036	-0.51	-0.37	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
UCEC	cis	rs2739330	0.791	rs4822458	ENSG00000272787.1	KB-226F1.2	-4.93	2.15e-06	0.00361	-0.45	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23969211~23969873:+
UCEC	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	4.93	2.15e-06	0.00361	0.39	0.37	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
UCEC	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	4.93	2.15e-06	0.00361	0.4	0.37	Height;	chr6:109458989	chr6:109382795~109383666:+
UCEC	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-4.93	2.16e-06	0.00361	-0.39	-0.37	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
UCEC	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-4.93	2.16e-06	0.00361	-0.45	-0.37	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
UCEC	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	4.93	2.16e-06	0.00363	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
UCEC	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-4.93	2.17e-06	0.00363	-0.74	-0.37	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
UCEC	cis	rs10232172	0.63	rs1358210	ENSG00000234707.2	RP11-745C15.2	-4.93	2.17e-06	0.00364	-0.5	-0.37	Periodontal disease-related phenotypes;	chr7:54092339	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs6972096	ENSG00000234707.2	RP11-745C15.2	-4.93	2.17e-06	0.00364	-0.5	-0.37	Periodontal disease-related phenotypes;	chr7:54092874	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs6971225	ENSG00000234707.2	RP11-745C15.2	-4.93	2.17e-06	0.00364	-0.5	-0.37	Periodontal disease-related phenotypes;	chr7:54093002	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.591	rs11765735	ENSG00000234707.2	RP11-745C15.2	-4.93	2.17e-06	0.00364	-0.5	-0.37	Periodontal disease-related phenotypes;	chr7:54093988	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.673	rs1526782	ENSG00000234707.2	RP11-745C15.2	-4.93	2.17e-06	0.00364	-0.5	-0.37	Periodontal disease-related phenotypes;	chr7:54094569	chr7:54759425~54804928:+
UCEC	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	4.93	2.17e-06	0.00364	0.49	0.37	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
UCEC	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-4.93	2.18e-06	0.00365	-0.54	-0.37	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
UCEC	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-4.93	2.18e-06	0.00365	-0.45	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
UCEC	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-4.93	2.18e-06	0.00365	-0.78	-0.37	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-4.93	2.18e-06	0.00365	-0.78	-0.37	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	4.93	2.18e-06	0.00365	0.76	0.37	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	4.93	2.19e-06	0.00367	0.39	0.37	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
UCEC	cis	rs492146	1	rs380646	ENSG00000243236.5	GSTA9P	-4.93	2.19e-06	0.00367	-0.49	-0.37	Epilepsy (remission after treatment);	chr6:52972842	chr6:52939726~52957521:-
UCEC	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	4.93	2.2e-06	0.00368	0.39	0.37	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
UCEC	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-4.93	2.22e-06	0.00369	-0.49	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
UCEC	cis	rs492146	1	rs428957	ENSG00000243236.5	GSTA9P	-4.92	2.22e-06	0.0037	-0.49	-0.37	Epilepsy (remission after treatment);	chr6:52974387	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.967	rs387853	ENSG00000243236.5	GSTA9P	-4.92	2.22e-06	0.0037	-0.49	-0.37	Epilepsy (remission after treatment);	chr6:52975456	chr6:52939726~52957521:-
UCEC	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-4.92	2.22e-06	0.0037	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-4.92	2.22e-06	0.0037	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-4.92	2.22e-06	0.0037	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
UCEC	cis	rs617219	0.574	rs7702523	ENSG00000245556.2	SCAMP1-AS1	-4.92	2.23e-06	0.0037	-0.35	-0.37	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79325018	chr5:78342365~78360507:-
UCEC	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	4.92	2.23e-06	0.00371	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	4.92	2.23e-06	0.00371	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
UCEC	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-4.92	2.23e-06	0.00372	-0.38	-0.37	Height;	chr6:109432968	chr6:109382795~109383666:+
UCEC	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	4.92	2.23e-06	0.00372	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
UCEC	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	4.92	2.24e-06	0.00372	0.48	0.37	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
UCEC	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-4.92	2.24e-06	0.00372	-0.58	-0.37	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
UCEC	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-4.92	2.24e-06	0.00372	-0.42	-0.37	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
UCEC	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	4.92	2.24e-06	0.00373	0.41	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	4.92	2.25e-06	0.00374	0.4	0.37	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
UCEC	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	4.92	2.25e-06	0.00374	0.4	0.37	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
UCEC	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	4.92	2.25e-06	0.00374	0.4	0.37	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
UCEC	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-4.92	2.25e-06	0.00374	-0.42	-0.37	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
UCEC	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	4.92	2.25e-06	0.00374	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
UCEC	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-4.92	2.26e-06	0.00375	-0.45	-0.37	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
UCEC	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-4.92	2.26e-06	0.00375	-0.46	-0.37	Depression;	chr6:28123153	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-4.92	2.26e-06	0.00375	-0.46	-0.37	Depression;	chr6:28124529	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-4.92	2.26e-06	0.00375	-0.46	-0.37	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-4.92	2.26e-06	0.00375	-0.46	-0.37	Depression;	chr6:28127577	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-4.92	2.26e-06	0.00375	-0.46	-0.37	Depression;	chr6:28131566	chr6:28115628~28116551:+
UCEC	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	4.92	2.26e-06	0.00375	0.44	0.37	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
UCEC	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-4.92	2.26e-06	0.00376	-0.4	-0.37	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
UCEC	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	4.92	2.27e-06	0.00376	0.45	0.37	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
UCEC	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	4.92	2.28e-06	0.00378	0.38	0.37	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
UCEC	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	4.92	2.28e-06	0.00378	0.38	0.37	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
UCEC	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-4.92	2.28e-06	0.00378	-0.51	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-4.92	2.28e-06	0.00378	-0.51	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
UCEC	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	4.92	2.28e-06	0.00378	0.39	0.37	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	4.92	2.28e-06	0.00378	0.39	0.37	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	4.92	2.28e-06	0.00378	0.39	0.37	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	4.92	2.28e-06	0.00378	0.39	0.37	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	4.92	2.28e-06	0.00378	0.39	0.37	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
UCEC	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-4.92	2.28e-06	0.00378	-0.47	-0.37	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
UCEC	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	4.92	2.28e-06	0.00378	0.42	0.37	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
UCEC	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-4.92	2.28e-06	0.00378	-0.43	-0.37	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-4.92	2.28e-06	0.00378	-0.43	-0.37	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-4.92	2.28e-06	0.00378	-0.43	-0.37	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
UCEC	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	4.92	2.29e-06	0.00379	0.4	0.37	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
UCEC	cis	rs9309473	0.948	rs7566385	ENSG00000163016.8	ALMS1P	4.92	2.29e-06	0.00379	0.42	0.37	Metabolite levels;	chr2:73529690	chr2:73644919~73685576:+
UCEC	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-4.92	2.29e-06	0.0038	-0.49	-0.37	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
UCEC	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	4.92	2.3e-06	0.0038	0.81	0.37	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-4.92	2.3e-06	0.0038	-0.72	-0.37	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-4.92	2.3e-06	0.0038	-0.72	-0.37	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
UCEC	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-4.92	2.3e-06	0.00381	-0.45	-0.37	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
UCEC	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-4.92	2.31e-06	0.00382	-0.43	-0.37	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-4.92	2.31e-06	0.00382	-0.43	-0.37	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-4.92	2.31e-06	0.00382	-0.43	-0.37	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-4.92	2.31e-06	0.00382	-0.43	-0.37	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-4.92	2.31e-06	0.00382	-0.43	-0.37	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-4.92	2.31e-06	0.00382	-0.43	-0.37	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
UCEC	cis	rs7267979	0.966	rs2261795	ENSG00000276952.1	RP5-965G21.6	4.92	2.31e-06	0.00383	0.48	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25284915~25285588:-
UCEC	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	4.91	2.32e-06	0.00383	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	4.91	2.32e-06	0.00383	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
UCEC	cis	rs3858145	0.588	rs78041174	ENSG00000233590.1	RP11-153K11.3	-4.91	2.32e-06	0.00383	-0.47	-0.37	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68233251~68242379:-
UCEC	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	4.91	2.32e-06	0.00383	0.4	0.37	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	4.91	2.32e-06	0.00383	0.4	0.37	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	4.91	2.32e-06	0.00383	0.4	0.37	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
UCEC	cis	rs617219	0.574	rs7722286	ENSG00000245556.2	SCAMP1-AS1	-4.91	2.32e-06	0.00383	-0.35	-0.37	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79320202	chr5:78342365~78360507:-
UCEC	cis	rs948562	0.744	rs11229485	ENSG00000280010.1	AP001350.4	4.91	2.33e-06	0.00383	0.71	0.37	Lymphoma;	chr11:58465381	chr11:58627435~58628528:+
UCEC	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	4.91	2.33e-06	0.00383	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	4.91	2.33e-06	0.00383	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	4.91	2.33e-06	0.00383	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	4.91	2.33e-06	0.00383	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	4.91	2.33e-06	0.00383	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	4.91	2.33e-06	0.00383	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
UCEC	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	4.91	2.33e-06	0.00384	0.47	0.37	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
UCEC	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	4.91	2.33e-06	0.00384	0.39	0.37	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
UCEC	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-4.91	2.34e-06	0.00385	-0.43	-0.37	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-4.91	2.34e-06	0.00385	-0.43	-0.37	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
UCEC	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	4.91	2.34e-06	0.00385	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
UCEC	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-4.91	2.34e-06	0.00385	-0.43	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
UCEC	cis	rs4713118	0.869	rs4713121	ENSG00000216901.1	AL022393.7	4.91	2.35e-06	0.00387	0.44	0.37	Parkinson's disease;	chr6:27754285	chr6:28176188~28176674:+
UCEC	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-4.91	2.37e-06	0.0039	-0.79	-0.37	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
UCEC	cis	rs7267979	0.549	rs6138536	ENSG00000276952.1	RP5-965G21.6	4.91	2.39e-06	0.00391	0.55	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:25284915~25285588:-
UCEC	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-4.91	2.39e-06	0.00391	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
UCEC	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	4.91	2.39e-06	0.00391	0.56	0.37	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
UCEC	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	4.91	2.39e-06	0.00391	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	4.91	2.39e-06	0.00391	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	4.91	2.39e-06	0.00391	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
UCEC	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-4.91	2.4e-06	0.00392	-0.47	-0.37	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
UCEC	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	4.91	2.4e-06	0.00392	0.45	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
UCEC	cis	rs7246967	0.541	rs16999009	ENSG00000198153.8	ZNF849P	4.91	2.41e-06	0.00393	0.44	0.37	Bronchopulmonary dysplasia;	chr19:22726856	chr19:22685167~22686732:+
UCEC	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	4.91	2.41e-06	0.00393	0.44	0.37	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
UCEC	cis	rs617219	0.552	rs6891335	ENSG00000245556.2	SCAMP1-AS1	-4.91	2.41e-06	0.00393	-0.34	-0.37	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79327287	chr5:78342365~78360507:-
UCEC	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	4.91	2.41e-06	0.00393	0.59	0.37	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
UCEC	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	4.91	2.41e-06	0.00394	0.39	0.37	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	4.91	2.41e-06	0.00394	0.39	0.37	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	4.91	2.41e-06	0.00394	0.39	0.37	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	4.91	2.41e-06	0.00394	0.39	0.37	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	4.91	2.41e-06	0.00394	0.39	0.37	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
UCEC	cis	rs948562	0.947	rs73470773	ENSG00000280010.1	AP001350.4	4.9	2.42e-06	0.00395	0.68	0.37	Lymphoma;	chr11:58648100	chr11:58627435~58628528:+
UCEC	cis	rs899997	1	rs11633170	ENSG00000261143.1	ADAMTS7P3	-4.9	2.43e-06	0.00396	-0.51	-0.37	Coronary artery disease or large artery stroke;	chr15:78712300	chr15:77976042~77993057:+
UCEC	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	4.9	2.43e-06	0.00396	0.48	0.37	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
UCEC	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-4.9	2.44e-06	0.00397	-0.39	-0.37	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
UCEC	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-4.9	2.44e-06	0.00397	-0.39	-0.37	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
UCEC	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-4.9	2.44e-06	0.00397	-0.48	-0.37	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
UCEC	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-4.9	2.44e-06	0.00397	-0.54	-0.37	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
UCEC	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	4.9	2.44e-06	0.00397	0.43	0.37	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
UCEC	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	4.9	2.44e-06	0.00398	0.42	0.37	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
UCEC	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	4.9	2.45e-06	0.00398	0.63	0.37	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
UCEC	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	4.9	2.45e-06	0.00398	0.48	0.37	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
UCEC	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-4.9	2.45e-06	0.00398	-0.42	-0.37	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
UCEC	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-4.9	2.45e-06	0.00399	-0.35	-0.37	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	4.9	2.46e-06	0.004	0.45	0.37	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	4.9	2.47e-06	0.00402	0.46	0.37	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	4.9	2.47e-06	0.00402	0.46	0.37	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
UCEC	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-4.9	2.47e-06	0.00402	-0.42	-0.37	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
UCEC	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-4.9	2.48e-06	0.00403	-0.47	-0.37	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
UCEC	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-4.9	2.48e-06	0.00404	-0.48	-0.37	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
UCEC	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	4.9	2.48e-06	0.00404	0.5	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	4.9	2.49e-06	0.00404	0.53	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
UCEC	cis	rs7246967	0.673	rs9676498	ENSG00000198153.8	ZNF849P	-4.9	2.49e-06	0.00404	-0.43	-0.37	Bronchopulmonary dysplasia;	chr19:22727708	chr19:22685167~22686732:+
UCEC	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	4.9	2.49e-06	0.00405	0.58	0.37	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
UCEC	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-4.9	2.5e-06	0.00406	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
UCEC	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	4.9	2.51e-06	0.00407	0.52	0.37	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
UCEC	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	4.9	2.52e-06	0.00408	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
UCEC	cis	rs2276314	1	rs1789513	ENSG00000267627.4	RP11-905K4.1	4.9	2.52e-06	0.00408	0.43	0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35951803~35966118:-
UCEC	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	4.89	2.54e-06	0.00411	0.5	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
UCEC	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-4.89	2.54e-06	0.00411	-0.43	-0.37	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
UCEC	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	4.89	2.55e-06	0.00413	0.6	0.37	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
UCEC	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	4.89	2.55e-06	0.00413	0.41	0.37	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
UCEC	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	4.89	2.55e-06	0.00413	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	4.89	2.55e-06	0.00413	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
UCEC	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	4.89	2.57e-06	0.00416	0.41	0.37	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
UCEC	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	4.89	2.57e-06	0.00416	0.41	0.37	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
UCEC	cis	rs6840360	0.642	rs2724567	ENSG00000270265.1	RP11-731D1.4	4.89	2.58e-06	0.00417	0.36	0.37	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151333775~151353224:-
UCEC	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	4.89	2.58e-06	0.00417	0.45	0.37	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
UCEC	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	4.89	2.58e-06	0.00417	0.45	0.37	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
UCEC	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	4.89	2.58e-06	0.00417	0.45	0.37	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
UCEC	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-4.89	2.59e-06	0.00418	-0.43	-0.37	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-4.89	2.59e-06	0.00418	-0.43	-0.37	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-4.89	2.59e-06	0.00418	-0.43	-0.37	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
UCEC	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	4.89	2.59e-06	0.00418	0.42	0.37	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	4.89	2.59e-06	0.00418	0.42	0.37	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
UCEC	cis	rs7208859	0.673	rs9889755	ENSG00000264538.5	SUZ12P1	4.89	2.59e-06	0.00418	0.49	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30709299~30790908:+
UCEC	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	4.89	2.59e-06	0.00419	0.41	0.37	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
UCEC	cis	rs617219	0.574	rs11952003	ENSG00000245556.2	SCAMP1-AS1	-4.89	2.6e-06	0.0042	-0.35	-0.37	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79310273	chr5:78342365~78360507:-
UCEC	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-4.89	2.6e-06	0.0042	-0.38	-0.37	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
UCEC	cis	rs7615952	0.688	rs12638240	ENSG00000241288.6	RP11-379B18.5	-4.89	2.6e-06	0.0042	-0.54	-0.37	Blood pressure (smoking interaction);	chr3:125822395	chr3:125827238~125916384:-
UCEC	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	4.89	2.61e-06	0.00421	0.47	0.37	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
UCEC	cis	rs507080	0.961	rs642497	ENSG00000278376.1	RP11-158I9.8	-4.89	2.61e-06	0.00421	-0.36	-0.37	Serum metabolite levels;	chr11:118680075	chr11:118791254~118793137:+
UCEC	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-4.89	2.61e-06	0.00421	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-4.89	2.61e-06	0.00421	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-4.89	2.61e-06	0.00421	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-4.89	2.61e-06	0.00421	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
UCEC	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-4.89	2.61e-06	0.00421	-0.45	-0.37	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
UCEC	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	4.89	2.62e-06	0.00422	0.48	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
UCEC	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	4.89	2.63e-06	0.00424	0.41	0.37	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
UCEC	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-4.89	2.63e-06	0.00424	-0.48	-0.37	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-4.89	2.63e-06	0.00424	-0.48	-0.37	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
UCEC	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	4.89	2.64e-06	0.00425	0.47	0.37	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
UCEC	cis	rs6137726	0.613	rs910956	ENSG00000277901.1	RP5-851M4.1	4.89	2.64e-06	0.00425	0.58	0.37	Amyotrophic lateral sclerosis (sporadic);	chr20:22652517	chr20:23320958~23325352:-
UCEC	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	4.89	2.64e-06	0.00425	0.42	0.37	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
UCEC	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	4.88	2.65e-06	0.00426	0.38	0.37	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
UCEC	cis	rs6840360	0.642	rs2709820	ENSG00000270265.1	RP11-731D1.4	-4.88	2.65e-06	0.00426	-0.36	-0.37	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151333775~151353224:-
UCEC	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-4.88	2.65e-06	0.00426	-0.5	-0.37	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-4.88	2.65e-06	0.00426	-0.5	-0.37	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-4.88	2.65e-06	0.00426	-0.5	-0.37	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
UCEC	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-4.88	2.66e-06	0.00428	-0.42	-0.37	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
UCEC	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	4.88	2.66e-06	0.00428	0.48	0.37	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	4.88	2.67e-06	0.00429	0.4	0.37	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
UCEC	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-4.88	2.67e-06	0.00429	-0.54	-0.37	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
UCEC	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	4.88	2.67e-06	0.00429	0.45	0.37	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
UCEC	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	4.88	2.68e-06	0.0043	0.41	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
UCEC	cis	rs6840360	0.642	rs7698816	ENSG00000278978.1	RP11-164P12.5	-4.88	2.68e-06	0.0043	-0.44	-0.37	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151669786~151670503:+
UCEC	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	4.88	2.68e-06	0.00431	0.47	0.37	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
UCEC	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	4.88	2.68e-06	0.00431	0.4	0.37	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
UCEC	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-4.88	2.69e-06	0.00431	-0.53	-0.37	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
UCEC	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-4.88	2.69e-06	0.00432	-0.43	-0.37	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
UCEC	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-4.88	2.7e-06	0.00434	-0.46	-0.37	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
UCEC	cis	rs12928939	0.911	rs12919271	ENSG00000260886.1	TAT-AS1	4.88	2.71e-06	0.00434	0.45	0.37	Post bronchodilator FEV1;	chr16:71758793	chr16:71565789~71578187:+
UCEC	cis	rs12928939	0.862	rs7197104	ENSG00000260886.1	TAT-AS1	4.88	2.71e-06	0.00434	0.45	0.37	Post bronchodilator FEV1;	chr16:71760158	chr16:71565789~71578187:+
UCEC	cis	rs12928939	1	rs12928939	ENSG00000260886.1	TAT-AS1	4.88	2.71e-06	0.00434	0.45	0.37	Post bronchodilator FEV1;	chr16:71766142	chr16:71565789~71578187:+
UCEC	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-4.88	2.71e-06	0.00434	-0.38	-0.37	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
UCEC	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-4.88	2.71e-06	0.00434	-0.45	-0.37	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
UCEC	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-4.88	2.71e-06	0.00434	-0.45	-0.37	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
UCEC	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	4.88	2.71e-06	0.00434	0.39	0.37	Height;	chr6:109447092	chr6:109382795~109383666:+
UCEC	cis	rs7267979	0.714	rs6132825	ENSG00000276952.1	RP5-965G21.6	4.88	2.71e-06	0.00434	0.48	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:25284915~25285588:-
UCEC	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-4.88	2.71e-06	0.00434	-0.43	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-4.88	2.71e-06	0.00434	-0.43	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
UCEC	cis	rs2739330	0.76	rs5751761	ENSG00000272787.1	KB-226F1.2	4.88	2.72e-06	0.00435	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23969211~23969873:+
UCEC	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	4.88	2.72e-06	0.00435	0.41	0.37	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
UCEC	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	4.88	2.72e-06	0.00435	0.4	0.37	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
UCEC	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-4.88	2.72e-06	0.00436	-0.46	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-4.88	2.72e-06	0.00436	-0.46	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-4.88	2.72e-06	0.00436	-0.46	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
UCEC	cis	rs9400467	0.508	rs11153283	ENSG00000271789.1	RP5-1112D6.7	-4.88	2.73e-06	0.00436	-0.43	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111275940	chr6:111297126~111298510:+
UCEC	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	4.88	2.73e-06	0.00436	0.39	0.37	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
UCEC	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	4.88	2.74e-06	0.00438	0.52	0.37	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	4.88	2.74e-06	0.00438	0.52	0.37	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	4.88	2.74e-06	0.00438	0.52	0.37	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
UCEC	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-4.88	2.74e-06	0.00438	-0.42	-0.37	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
UCEC	cis	rs7246967	0.551	rs16998998	ENSG00000198153.8	ZNF849P	-4.88	2.75e-06	0.00439	-0.43	-0.37	Bronchopulmonary dysplasia;	chr19:22728314	chr19:22685167~22686732:+
UCEC	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-4.88	2.75e-06	0.00439	-0.42	-0.37	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
UCEC	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-4.88	2.75e-06	0.00439	-0.47	-0.37	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
UCEC	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-4.88	2.75e-06	0.00439	-0.4	-0.37	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
UCEC	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	4.88	2.76e-06	0.0044	0.4	0.37	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
UCEC	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	4.88	2.76e-06	0.0044	0.44	0.37	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	4.88	2.76e-06	0.0044	0.44	0.37	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	4.88	2.76e-06	0.0044	0.44	0.37	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	4.88	2.76e-06	0.0044	0.44	0.37	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	4.88	2.76e-06	0.0044	0.44	0.37	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	4.88	2.76e-06	0.0044	0.44	0.37	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
UCEC	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-4.88	2.76e-06	0.0044	-0.52	-0.37	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
UCEC	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	4.87	2.76e-06	0.00441	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	4.87	2.76e-06	0.00441	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
UCEC	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-4.87	2.77e-06	0.00441	-0.45	-0.37	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
UCEC	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	4.87	2.77e-06	0.00442	0.4	0.37	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
UCEC	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-4.87	2.77e-06	0.00442	-0.4	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
UCEC	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-4.87	2.77e-06	0.00442	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
UCEC	cis	rs34034915	1	rs34034915	ENSG00000216901.1	AL022393.7	4.87	2.78e-06	0.00442	0.42	0.37	Hepatitis A;	chr6:27752924	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.527	rs36042294	ENSG00000216901.1	AL022393.7	4.87	2.78e-06	0.00442	0.42	0.37	Parkinson's disease;	chr6:27752933	chr6:28176188~28176674:+
UCEC	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	4.87	2.78e-06	0.00442	0.4	0.37	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
UCEC	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-4.87	2.78e-06	0.00443	-0.5	-0.37	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
UCEC	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-4.87	2.78e-06	0.00443	-0.44	-0.37	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
UCEC	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-4.87	2.78e-06	0.00443	-0.4	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
UCEC	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	4.87	2.78e-06	0.00443	0.4	0.37	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
UCEC	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-4.87	2.79e-06	0.00443	-0.5	-0.37	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
UCEC	cis	rs9309473	1	rs2421555	ENSG00000163016.8	ALMS1P	4.87	2.79e-06	0.00444	0.42	0.37	Metabolite levels;	chr2:73589828	chr2:73644919~73685576:+
UCEC	cis	rs9601248	0.529	rs2783126	ENSG00000227354.5	RBM26-AS1	4.87	2.79e-06	0.00444	0.42	0.37	Major depressive disorder;	chr13:79584566	chr13:79406309~79424328:+
UCEC	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-4.87	2.79e-06	0.00444	-0.44	-0.37	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
UCEC	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	4.87	2.79e-06	0.00444	0.41	0.37	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs13427832	ENSG00000163016.8	ALMS1P	4.87	2.79e-06	0.00444	0.41	0.37	Metabolite levels;	chr2:73617691	chr2:73644919~73685576:+
UCEC	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-4.87	2.8e-06	0.00445	-0.52	-0.37	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
UCEC	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-4.87	2.8e-06	0.00445	-0.79	-0.37	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
UCEC	cis	rs7246967	0.673	rs6511383	ENSG00000198153.8	ZNF849P	-4.87	2.8e-06	0.00446	-0.44	-0.37	Bronchopulmonary dysplasia;	chr19:22774098	chr19:22685167~22686732:+
UCEC	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	4.87	2.8e-06	0.00446	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
UCEC	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	4.87	2.8e-06	0.00446	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	4.87	2.8e-06	0.00446	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	4.87	2.8e-06	0.00446	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	4.87	2.8e-06	0.00446	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	4.87	2.8e-06	0.00446	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	4.87	2.8e-06	0.00446	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	4.87	2.8e-06	0.00446	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
UCEC	cis	rs1667284	0.967	rs895888	ENSG00000266521.1	RP11-650P15.1	4.87	2.81e-06	0.00446	0.43	0.37	Problematic alcohol use in trauma-exposed individuals;	chr18:31648224	chr18:31496645~31497195:-
UCEC	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-4.87	2.81e-06	0.00446	-0.43	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
UCEC	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	4.87	2.81e-06	0.00447	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
UCEC	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	4.87	2.81e-06	0.00447	0.43	0.37	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
UCEC	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	4.87	2.81e-06	0.00447	0.45	0.37	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
UCEC	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	4.87	2.81e-06	0.00447	0.39	0.37	Height;	chr6:109470427	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	4.87	2.81e-06	0.00447	0.39	0.37	Height;	chr6:109470900	chr6:109382795~109383666:+
UCEC	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-4.87	2.82e-06	0.00447	-0.4	-0.37	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
UCEC	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	4.87	2.82e-06	0.00448	0.42	0.37	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
UCEC	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	4.87	2.82e-06	0.00448	0.41	0.37	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
UCEC	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-4.87	2.82e-06	0.00448	-0.42	-0.37	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
UCEC	cis	rs6840360	0.642	rs10454251	ENSG00000278978.1	RP11-164P12.5	-4.87	2.82e-06	0.00448	-0.44	-0.37	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151669786~151670503:+
UCEC	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-4.87	2.83e-06	0.00449	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
UCEC	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	4.87	2.84e-06	0.0045	0.51	0.37	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	4.87	2.84e-06	0.0045	0.51	0.37	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	4.87	2.84e-06	0.0045	0.51	0.37	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
UCEC	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	4.87	2.84e-06	0.0045	0.41	0.37	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	4.87	2.84e-06	0.0045	0.41	0.37	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
UCEC	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-4.87	2.84e-06	0.0045	-0.42	-0.37	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-4.87	2.84e-06	0.0045	-0.42	-0.37	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
UCEC	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-4.87	2.84e-06	0.00451	-0.34	-0.37	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-4.87	2.85e-06	0.00451	-0.5	-0.37	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-4.87	2.85e-06	0.00451	-0.5	-0.37	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
UCEC	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	4.87	2.86e-06	0.00452	0.46	0.37	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
UCEC	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	4.87	2.86e-06	0.00452	0.39	0.37	Height;	chr6:109462738	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	4.87	2.86e-06	0.00452	0.39	0.37	Height;	chr6:109464011	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	4.87	2.86e-06	0.00452	0.39	0.37	Height;	chr6:109465777	chr6:109382795~109383666:+
UCEC	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-4.87	2.86e-06	0.00453	-0.47	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
UCEC	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-4.87	2.86e-06	0.00453	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-4.87	2.86e-06	0.00453	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-4.87	2.86e-06	0.00453	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-4.87	2.86e-06	0.00453	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-4.87	2.86e-06	0.00453	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-4.87	2.86e-06	0.00453	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-4.87	2.86e-06	0.00453	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-4.87	2.86e-06	0.00453	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-4.87	2.86e-06	0.00453	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
UCEC	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-4.87	2.86e-06	0.00453	-0.72	-0.37	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
UCEC	cis	rs507080	0.961	rs642530	ENSG00000278376.1	RP11-158I9.8	-4.87	2.86e-06	0.00453	-0.35	-0.37	Serum metabolite levels;	chr11:118680047	chr11:118791254~118793137:+
UCEC	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-4.87	2.87e-06	0.00453	-0.38	-0.37	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
UCEC	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	4.87	2.87e-06	0.00454	0.41	0.37	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
UCEC	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-4.87	2.87e-06	0.00454	-0.49	-0.37	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
UCEC	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	4.87	2.87e-06	0.00454	0.43	0.37	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
UCEC	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	4.86	2.89e-06	0.00456	0.41	0.37	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
UCEC	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-4.86	2.89e-06	0.00456	-0.75	-0.37	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
UCEC	cis	rs938295	1	rs12091731	ENSG00000236045.1	RP3-467K16.7	4.86	2.9e-06	0.00457	0.53	0.37	Gut microbiota (bacterial taxa);	chr1:15761329	chr1:15334166~15335464:-
UCEC	cis	rs4713118	0.615	rs57252182	ENSG00000216901.1	AL022393.7	4.86	2.9e-06	0.00457	0.42	0.37	Parkinson's disease;	chr6:27752470	chr6:28176188~28176674:+
UCEC	cis	rs12928939	0.954	rs8057568	ENSG00000260886.1	TAT-AS1	4.86	2.9e-06	0.00458	0.45	0.37	Post bronchodilator FEV1;	chr16:71778092	chr16:71565789~71578187:+
UCEC	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	4.86	2.9e-06	0.00458	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
UCEC	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	4.86	2.9e-06	0.00458	0.52	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
UCEC	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-4.86	2.9e-06	0.00458	-0.36	-0.37	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
UCEC	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-4.86	2.91e-06	0.00459	-0.78	-0.37	Gout;	chr7:66645053	chr7:66654538~66669855:+
UCEC	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-4.86	2.91e-06	0.00459	-0.78	-0.37	Gout;	chr7:66654674	chr7:66654538~66669855:+
UCEC	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-4.86	2.91e-06	0.00459	-0.78	-0.37	Gout;	chr7:66661502	chr7:66654538~66669855:+
UCEC	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	4.86	2.92e-06	0.0046	0.41	0.37	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	4.86	2.92e-06	0.0046	0.41	0.37	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
UCEC	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-4.86	2.92e-06	0.0046	-0.4	-0.37	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
UCEC	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-4.86	2.92e-06	0.0046	-0.4	-0.37	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
UCEC	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-4.86	2.92e-06	0.0046	-0.79	-0.37	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-4.86	2.92e-06	0.0046	-0.79	-0.37	Gout;	chr7:66642037	chr7:66654538~66669855:+
UCEC	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-4.86	2.93e-06	0.00461	-0.42	-0.37	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
UCEC	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	4.86	2.93e-06	0.00461	0.48	0.37	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
UCEC	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	4.86	2.93e-06	0.00462	0.43	0.37	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
UCEC	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-4.86	2.94e-06	0.00463	-0.53	-0.37	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
UCEC	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	4.86	2.94e-06	0.00463	0.5	0.37	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	4.86	2.94e-06	0.00463	0.5	0.37	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	4.86	2.94e-06	0.00463	0.5	0.37	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	4.86	2.94e-06	0.00463	0.5	0.37	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	4.86	2.94e-06	0.00463	0.5	0.37	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	4.86	2.94e-06	0.00463	0.5	0.37	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
UCEC	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	4.86	2.95e-06	0.00463	0.4	0.37	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	4.86	2.95e-06	0.00463	0.4	0.37	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
UCEC	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	4.86	2.95e-06	0.00463	0.53	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
UCEC	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	4.86	2.96e-06	0.00464	0.45	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
UCEC	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	4.86	2.96e-06	0.00464	0.45	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
UCEC	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	4.86	2.96e-06	0.00464	0.45	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
UCEC	cis	rs9907295	1	rs9889274	ENSG00000270871.1	AC015849.19	4.86	2.96e-06	0.00464	0.61	0.37	Fibroblast growth factor basic levels;	chr17:35910397	chr17:35816717~35830293:-
UCEC	cis	rs9907295	1	rs9891064	ENSG00000270871.1	AC015849.19	4.86	2.96e-06	0.00464	0.61	0.37	Fibroblast growth factor basic levels;	chr17:35913045	chr17:35816717~35830293:-
UCEC	cis	rs9907295	1	rs9899870	ENSG00000270871.1	AC015849.19	4.86	2.96e-06	0.00464	0.61	0.37	Fibroblast growth factor basic levels;	chr17:35914438	chr17:35816717~35830293:-
UCEC	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	4.86	2.96e-06	0.00464	0.52	0.37	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	4.86	2.96e-06	0.00464	0.52	0.37	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
UCEC	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	4.86	2.96e-06	0.00464	0.43	0.37	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
UCEC	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-4.86	2.96e-06	0.00465	-0.44	-0.37	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
UCEC	cis	rs9309473	1	rs10189574	ENSG00000163016.8	ALMS1P	4.86	2.97e-06	0.00465	0.41	0.37	Metabolite levels;	chr2:73471391	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	4.86	2.97e-06	0.00466	0.44	0.37	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	4.86	2.97e-06	0.00466	0.44	0.37	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
UCEC	cis	rs12478296	1	rs56292923	ENSG00000261186.2	RP11-341N2.1	-4.86	2.97e-06	0.00466	-0.51	-0.37	Obesity-related traits;	chr2:242097835	chr2:242087351~242088457:-
UCEC	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-4.86	2.97e-06	0.00466	-0.49	-0.37	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-4.86	2.97e-06	0.00466	-0.49	-0.37	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-4.86	2.97e-06	0.00466	-0.49	-0.37	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
UCEC	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-4.86	2.98e-06	0.00467	-0.71	-0.37	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-4.86	2.98e-06	0.00467	-0.71	-0.37	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-4.86	2.98e-06	0.00467	-0.71	-0.37	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-4.86	2.98e-06	0.00467	-0.71	-0.37	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-4.86	2.98e-06	0.00467	-0.71	-0.37	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
UCEC	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	4.86	3e-06	0.0047	0.48	0.37	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
UCEC	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	4.86	3e-06	0.0047	0.41	0.37	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
UCEC	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	4.86	3.01e-06	0.0047	0.91	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	4.86	3.01e-06	0.0047	0.91	0.37	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
UCEC	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-4.85	3.01e-06	0.00471	-0.45	-0.37	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
UCEC	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	4.85	3.02e-06	0.00473	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
UCEC	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	4.85	3.03e-06	0.00473	0.41	0.37	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
UCEC	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	4.85	3.03e-06	0.00473	0.43	0.37	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	4.85	3.03e-06	0.00473	0.43	0.37	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
UCEC	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-4.85	3.03e-06	0.00474	-0.52	-0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
UCEC	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-4.85	3.04e-06	0.00475	-0.55	-0.37	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	4.85	3.04e-06	0.00475	0.55	0.37	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	4.85	3.04e-06	0.00475	0.55	0.37	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	4.85	3.04e-06	0.00475	0.55	0.37	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	4.85	3.04e-06	0.00475	0.55	0.37	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	4.85	3.04e-06	0.00475	0.55	0.37	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
UCEC	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-4.85	3.04e-06	0.00475	-0.42	-0.37	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-4.85	3.04e-06	0.00475	-0.42	-0.37	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-4.85	3.04e-06	0.00475	-0.42	-0.37	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-4.85	3.04e-06	0.00475	-0.42	-0.37	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-4.85	3.04e-06	0.00475	-0.42	-0.37	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-4.85	3.04e-06	0.00475	-0.42	-0.37	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-4.85	3.04e-06	0.00475	-0.42	-0.37	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-4.85	3.04e-06	0.00475	-0.42	-0.37	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-4.85	3.04e-06	0.00475	-0.42	-0.37	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.961	rs600969	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118675087	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.922	rs12577485	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118676793	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.961	rs1784298	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118677956	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.961	rs4938522	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118677962	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.961	rs4938523	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118678129	chr11:118791254~118793137:+
UCEC	cis	rs507080	1	rs659969	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118679094	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.883	rs656575	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118679199	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.961	rs656505	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118679245	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.961	rs660489	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118679255	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.961	rs543327	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118679276	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.961	rs543413	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118679308	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.961	rs673770	ENSG00000278376.1	RP11-158I9.8	-4.85	3.05e-06	0.00475	-0.36	-0.37	Serum metabolite levels;	chr11:118679892	chr11:118791254~118793137:+
UCEC	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-4.85	3.05e-06	0.00475	-0.49	-0.37	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
UCEC	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	4.85	3.05e-06	0.00475	0.45	0.37	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
UCEC	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	4.85	3.05e-06	0.00475	0.39	0.37	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
UCEC	cis	rs9400467	0.528	rs11153280	ENSG00000271789.1	RP5-1112D6.7	-4.85	3.06e-06	0.00477	-0.43	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111297126~111298510:+
UCEC	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-4.85	3.07e-06	0.00478	-0.5	-0.37	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
UCEC	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-4.85	3.07e-06	0.00478	-0.41	-0.37	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
UCEC	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-4.85	3.07e-06	0.00478	-0.5	-0.37	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-4.85	3.07e-06	0.00478	-0.5	-0.37	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-4.85	3.07e-06	0.00478	-0.5	-0.37	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-4.85	3.07e-06	0.00478	-0.5	-0.37	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-4.85	3.07e-06	0.00478	-0.5	-0.37	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-4.85	3.07e-06	0.00478	-0.5	-0.37	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
UCEC	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	4.85	3.08e-06	0.00478	0.41	0.37	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
UCEC	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-4.85	3.08e-06	0.00478	-0.4	-0.37	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-4.85	3.08e-06	0.00478	-0.4	-0.37	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
UCEC	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-4.85	3.08e-06	0.00478	-0.4	-0.37	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
UCEC	cis	rs7246967	0.542	rs56355379	ENSG00000198153.8	ZNF849P	-4.85	3.08e-06	0.00479	-0.43	-0.37	Bronchopulmonary dysplasia;	chr19:22717653	chr19:22685167~22686732:+
UCEC	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	4.85	3.08e-06	0.00479	0.46	0.37	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
UCEC	cis	rs686320	1	rs72643572	ENSG00000245532.5	NEAT1	4.85	3.09e-06	0.00481	0.51	0.37	Hip circumference adjusted for BMI;	chr11:65483496	chr11:65422774~65445540:+
UCEC	cis	rs686320	1	rs3132770	ENSG00000245532.5	NEAT1	4.85	3.09e-06	0.00481	0.51	0.37	Hip circumference adjusted for BMI;	chr11:65483846	chr11:65422774~65445540:+
UCEC	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	4.85	3.1e-06	0.00482	0.65	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
UCEC	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	4.85	3.11e-06	0.00483	0.41	0.37	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
UCEC	cis	rs4789693	0.938	rs8078595	ENSG00000265458.1	RP13-20L14.6	4.85	3.11e-06	0.00483	0.45	0.37	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82454273~82458521:-
UCEC	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-4.85	3.12e-06	0.00485	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
UCEC	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	4.85	3.12e-06	0.00485	0.4	0.37	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
UCEC	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	4.85	3.12e-06	0.00485	0.72	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
UCEC	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-4.85	3.12e-06	0.00485	-0.38	-0.37	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
UCEC	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-4.85	3.12e-06	0.00485	-0.38	-0.37	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
UCEC	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-4.85	3.12e-06	0.00485	-0.38	-0.37	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
UCEC	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	4.85	3.12e-06	0.00485	0.42	0.37	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-4.85	3.14e-06	0.00488	-0.54	-0.37	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
UCEC	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-4.84	3.14e-06	0.00488	-0.42	-0.37	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
UCEC	cis	rs7246967	0.673	rs36029703	ENSG00000198153.8	ZNF849P	-4.84	3.15e-06	0.00488	-0.43	-0.37	Bronchopulmonary dysplasia;	chr19:22723386	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.551	rs7249473	ENSG00000198153.8	ZNF849P	-4.84	3.15e-06	0.00488	-0.43	-0.37	Bronchopulmonary dysplasia;	chr19:22723892	chr19:22685167~22686732:+
UCEC	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-4.84	3.15e-06	0.00489	-0.44	-0.37	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
UCEC	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-4.84	3.15e-06	0.00489	-0.44	-0.37	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
UCEC	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-4.84	3.15e-06	0.00489	-0.44	-0.37	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
UCEC	cis	rs9309473	1	rs58603761	ENSG00000163016.8	ALMS1P	4.84	3.18e-06	0.00492	0.41	0.37	Metabolite levels;	chr2:73499478	chr2:73644919~73685576:+
UCEC	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-4.84	3.18e-06	0.00493	-0.39	-0.37	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-4.84	3.18e-06	0.00493	-0.39	-0.37	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
UCEC	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-4.84	3.19e-06	0.00493	-0.44	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
UCEC	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-4.84	3.19e-06	0.00494	-0.71	-0.37	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
UCEC	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	4.84	3.19e-06	0.00494	0.41	0.37	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
UCEC	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	4.84	3.19e-06	0.00494	0.44	0.37	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
UCEC	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	4.84	3.19e-06	0.00494	0.44	0.37	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
UCEC	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	4.84	3.19e-06	0.00494	0.44	0.37	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
UCEC	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	4.84	3.19e-06	0.00494	0.44	0.37	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
UCEC	cis	rs492146	1	rs426169	ENSG00000243236.5	GSTA9P	-4.84	3.2e-06	0.00495	-0.48	-0.37	Epilepsy (remission after treatment);	chr6:52975090	chr6:52939726~52957521:-
UCEC	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	4.84	3.2e-06	0.00496	0.47	0.37	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
UCEC	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	4.84	3.21e-06	0.00497	0.38	0.37	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
UCEC	cis	rs4253772	0.55	rs739164	ENSG00000277232.2	GTSE1-AS1	4.84	3.22e-06	0.00498	0.45	0.37	Cholesterol, total;LDL cholesterol;	chr22:46288661	chr22:46295143~46296660:-
UCEC	cis	rs9545047	0.837	rs9601242	ENSG00000227354.5	RBM26-AS1	4.84	3.22e-06	0.00498	0.41	0.37	Schizophrenia;	chr13:79561543	chr13:79406309~79424328:+
UCEC	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-4.84	3.22e-06	0.00498	-0.49	-0.37	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
UCEC	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-4.84	3.22e-06	0.00499	-0.51	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
UCEC	cis	rs6840360	0.642	rs7678823	ENSG00000270265.1	RP11-731D1.4	-4.84	3.23e-06	0.00499	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151333775~151353224:-
UCEC	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	4.84	3.23e-06	0.00499	0.44	0.37	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
UCEC	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-4.84	3.23e-06	0.00499	-0.46	-0.37	Depression;	chr6:28089816	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-4.84	3.23e-06	0.00499	-0.46	-0.37	Depression;	chr6:28090857	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-4.84	3.23e-06	0.00499	-0.46	-0.37	Depression;	chr6:28091439	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-4.84	3.23e-06	0.00499	-0.46	-0.37	Depression;	chr6:28091659	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-4.84	3.23e-06	0.00499	-0.46	-0.37	Depression;	chr6:28092227	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-4.84	3.23e-06	0.00499	-0.46	-0.37	Depression;	chr6:28093966	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-4.84	3.23e-06	0.00499	-0.46	-0.37	Depression;	chr6:28094014	chr6:28115628~28116551:+
UCEC	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-4.84	3.23e-06	0.00499	-0.42	-0.37	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
UCEC	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-4.84	3.24e-06	0.005	-0.73	-0.37	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-4.84	3.24e-06	0.005	-0.73	-0.37	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-4.84	3.24e-06	0.005	-0.73	-0.37	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-4.84	3.24e-06	0.005	-0.73	-0.37	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
UCEC	cis	rs9309473	0.632	rs7599076	ENSG00000163016.8	ALMS1P	4.84	3.25e-06	0.00501	0.39	0.37	Metabolite levels;	chr2:73358391	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.583	rs11126397	ENSG00000163016.8	ALMS1P	4.84	3.25e-06	0.00501	0.39	0.37	Metabolite levels;	chr2:73361605	chr2:73644919~73685576:+
UCEC	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-4.84	3.25e-06	0.00501	-0.77	-0.37	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
UCEC	cis	rs7077415	0.818	rs12259937	ENSG00000235618.6	FAM21EP	-4.84	3.25e-06	0.00501	-0.65	-0.37	Cerebrospinal fluid biomarker levels;	chr10:50257024	chr10:50021182~50067803:-
UCEC	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	4.84	3.25e-06	0.00501	0.4	0.37	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
UCEC	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-4.84	3.27e-06	0.00503	-0.46	-0.37	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
UCEC	cis	rs492146	1	rs375872	ENSG00000243236.5	GSTA9P	-4.84	3.27e-06	0.00503	-0.47	-0.37	Epilepsy (remission after treatment);	chr6:52970119	chr6:52939726~52957521:-
UCEC	cis	rs507080	1	rs507080	ENSG00000278376.1	RP11-158I9.8	-4.84	3.27e-06	0.00503	-0.35	-0.37	Serum metabolite levels;	chr11:118678873	chr11:118791254~118793137:+
UCEC	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-4.84	3.27e-06	0.00504	-0.34	-0.37	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
UCEC	cis	rs9400467	0.528	rs10872066	ENSG00000271789.1	RP5-1112D6.7	-4.84	3.27e-06	0.00504	-0.43	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111297126~111298510:+
UCEC	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	4.84	3.27e-06	0.00504	0.42	0.37	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	4.84	3.27e-06	0.00504	0.42	0.37	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
UCEC	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-4.84	3.28e-06	0.00504	-0.45	-0.37	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-4.84	3.28e-06	0.00504	-0.45	-0.37	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
UCEC	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-4.83	3.29e-06	0.00506	-0.45	-0.37	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
UCEC	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	4.83	3.29e-06	0.00506	0.5	0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
UCEC	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	4.83	3.29e-06	0.00506	0.53	0.37	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
UCEC	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-4.83	3.3e-06	0.00508	-0.46	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
UCEC	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-4.83	3.3e-06	0.00508	-0.46	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
UCEC	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-4.83	3.3e-06	0.00508	-0.46	-0.37	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
UCEC	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	4.83	3.31e-06	0.00509	0.47	0.37	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
UCEC	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-4.83	3.31e-06	0.00509	-0.42	-0.37	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
UCEC	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	4.83	3.32e-06	0.00509	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	4.83	3.32e-06	0.00509	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
UCEC	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	4.83	3.32e-06	0.00509	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	4.83	3.32e-06	0.00509	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	4.83	3.32e-06	0.00509	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	4.83	3.32e-06	0.00509	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	4.83	3.32e-06	0.00509	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	4.83	3.32e-06	0.00509	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	4.83	3.32e-06	0.00509	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	4.83	3.32e-06	0.00509	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
UCEC	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-4.83	3.32e-06	0.0051	-0.44	-0.37	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
UCEC	cis	rs7267979	0.934	rs113469203	ENSG00000276952.1	RP5-965G21.6	-4.83	3.33e-06	0.00511	-0.49	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25362622	chr20:25284915~25285588:-
UCEC	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-4.83	3.34e-06	0.00512	-0.4	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
UCEC	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-4.83	3.34e-06	0.00512	-0.46	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
UCEC	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	4.83	3.34e-06	0.00512	0.4	0.37	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	4.83	3.34e-06	0.00512	0.4	0.37	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	4.83	3.34e-06	0.00512	0.4	0.37	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	4.83	3.34e-06	0.00512	0.4	0.37	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	4.83	3.34e-06	0.00512	0.4	0.37	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
UCEC	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	4.83	3.35e-06	0.00513	0.45	0.37	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
UCEC	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	4.83	3.35e-06	0.00513	0.46	0.37	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
UCEC	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	4.83	3.35e-06	0.00514	0.4	0.37	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
UCEC	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	4.83	3.36e-06	0.00514	0.52	0.37	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
UCEC	cis	rs964184	0.63	rs2160669	ENSG00000254851.1	RP11-109L13.1	-4.83	3.36e-06	0.00514	-0.8	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116776891	chr11:117135528~117138582:+
UCEC	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-4.83	3.36e-06	0.00514	-0.46	-0.37	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
UCEC	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-4.83	3.37e-06	0.00515	-0.34	-0.37	Height;	chr11:118746590	chr11:118791254~118793137:+
UCEC	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-4.83	3.37e-06	0.00515	-0.41	-0.37	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
UCEC	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28099759	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28100648	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28104824	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28107222	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28108492	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28110254	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28111382	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28111650	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28113851	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28114487	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28114933	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28115743	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Depression;	chr6:28116411	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-4.83	3.37e-06	0.00515	-0.45	-0.37	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
UCEC	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	4.83	3.37e-06	0.00516	0.4	0.37	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
UCEC	cis	rs938295	1	rs12081206	ENSG00000236045.1	RP3-467K16.7	-4.83	3.37e-06	0.00516	-0.52	-0.37	Gut microbiota (bacterial taxa);	chr1:15761236	chr1:15334166~15335464:-
UCEC	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-4.83	3.39e-06	0.00518	-0.5	-0.37	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-4.83	3.39e-06	0.00518	-0.5	-0.37	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
UCEC	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	4.83	3.4e-06	0.0052	0.41	0.37	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
UCEC	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-4.83	3.42e-06	0.00522	-0.51	-0.37	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
UCEC	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-4.83	3.42e-06	0.00522	-0.42	-0.37	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-4.83	3.42e-06	0.00522	-0.42	-0.37	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
UCEC	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-4.83	3.42e-06	0.00522	-0.52	-0.37	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
UCEC	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-4.83	3.43e-06	0.00523	-0.49	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
UCEC	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	4.82	3.44e-06	0.00525	0.38	0.37	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	4.82	3.44e-06	0.00525	0.38	0.37	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
UCEC	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-4.82	3.44e-06	0.00525	-0.41	-0.37	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
UCEC	cis	rs4787951	0.583	rs3024577	ENSG00000261736.1	AC002551.1	4.82	3.44e-06	0.00525	0.33	0.37	Eosinophil percentage of white cells;	chr16:27346882	chr16:27643199~27644663:+
UCEC	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	4.82	3.45e-06	0.00526	0.65	0.37	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
UCEC	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	4.82	3.46e-06	0.00527	0.44	0.37	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
UCEC	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-4.82	3.46e-06	0.00527	-0.38	-0.37	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
UCEC	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-4.82	3.46e-06	0.00527	-0.45	-0.37	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-4.82	3.46e-06	0.00527	-0.45	-0.37	Depression;	chr6:28112175	chr6:28115628~28116551:+
UCEC	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	4.82	3.47e-06	0.00528	0.46	0.37	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	4.82	3.47e-06	0.00528	0.46	0.37	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	4.82	3.47e-06	0.00528	0.46	0.37	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
UCEC	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	4.82	3.49e-06	0.0053	0.39	0.37	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
UCEC	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	4.82	3.49e-06	0.00531	0.48	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
UCEC	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-4.82	3.5e-06	0.00531	-0.42	-0.37	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
UCEC	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-4.82	3.5e-06	0.00531	-0.46	-0.37	Depression;	chr6:28082231	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-4.82	3.5e-06	0.00531	-0.46	-0.37	Depression;	chr6:28082261	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-4.82	3.5e-06	0.00531	-0.46	-0.37	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-4.82	3.5e-06	0.00531	-0.46	-0.37	Depression;	chr6:28082984	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-4.82	3.5e-06	0.00531	-0.46	-0.37	Depression;	chr6:28083994	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-4.82	3.5e-06	0.00531	-0.46	-0.37	Depression;	chr6:28084025	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-4.82	3.5e-06	0.00531	-0.46	-0.37	Depression;	chr6:28085319	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-4.82	3.5e-06	0.00532	-0.45	-0.37	Depression;	chr6:28079011	chr6:28115628~28116551:+
UCEC	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	4.82	3.51e-06	0.00534	0.53	0.37	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
UCEC	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	4.82	3.51e-06	0.00534	0.46	0.37	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
UCEC	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-4.82	3.52e-06	0.00534	-0.48	-0.37	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
UCEC	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-4.82	3.52e-06	0.00534	-0.45	-0.37	Depression;	chr6:28096077	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-4.82	3.52e-06	0.00534	-0.45	-0.37	Depression;	chr6:28096855	chr6:28115628~28116551:+
UCEC	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-4.82	3.52e-06	0.00534	-0.41	-0.37	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
UCEC	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	4.82	3.52e-06	0.00534	0.41	0.37	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	4.82	3.52e-06	0.00534	0.41	0.37	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	4.82	3.52e-06	0.00534	0.41	0.37	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	4.82	3.52e-06	0.00534	0.41	0.37	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	4.82	3.52e-06	0.00534	0.41	0.37	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	4.82	3.52e-06	0.00534	0.41	0.37	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	4.82	3.52e-06	0.00534	0.41	0.37	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	4.82	3.52e-06	0.00534	0.41	0.37	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
UCEC	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-4.82	3.52e-06	0.00534	-0.47	-0.37	Depression;	chr6:28140307	chr6:28115628~28116551:+
UCEC	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	4.82	3.53e-06	0.00535	0.49	0.37	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
UCEC	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	4.82	3.53e-06	0.00536	0.54	0.37	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
UCEC	cis	rs763121	0.819	rs138700	ENSG00000273076.1	RP3-508I15.22	4.82	3.54e-06	0.00536	0.46	0.37	Menopause (age at onset);	chr22:38733994	chr22:38743495~38743910:+
UCEC	cis	rs6840360	0.642	rs2709838	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2724580	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.693	rs28622593	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2709834	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs6845648	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2724571	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2709833	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.667	rs2709832	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2709831	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2709816	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2709817	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2709818	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs7682770	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.667	rs9994482	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs11729923	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs7676059	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs7657747	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs4696089	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs11932398	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs4263379	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs12647555	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs1899550	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs7680013	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs7680236	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs4696092	ENSG00000270265.1	RP11-731D1.4	-4.82	3.54e-06	0.00536	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2724574	ENSG00000270265.1	RP11-731D1.4	4.82	3.54e-06	0.00536	0.35	0.37	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151333775~151353224:-
UCEC	cis	rs12468226	0.689	rs73989733	ENSG00000273456.1	RP11-686O6.2	4.82	3.54e-06	0.00536	0.52	0.37	Urate levels;	chr2:202115241	chr2:202374932~202375604:-
UCEC	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	4.82	3.55e-06	0.00538	0.42	0.37	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
UCEC	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-4.82	3.55e-06	0.00538	-0.73	-0.37	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
UCEC	cis	rs948562	0.569	rs74810062	ENSG00000280010.1	AP001350.4	4.82	3.56e-06	0.00539	0.69	0.37	Lymphoma;	chr11:58446218	chr11:58627435~58628528:+
UCEC	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	4.82	3.56e-06	0.00539	0.46	0.37	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	4.82	3.56e-06	0.00539	0.46	0.37	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
UCEC	cis	rs948562	0.535	rs11229439	ENSG00000280010.1	AP001350.4	4.82	3.58e-06	0.00541	0.69	0.37	Lymphoma;	chr11:58425138	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.585	rs11229477	ENSG00000280010.1	AP001350.4	4.82	3.58e-06	0.00541	0.69	0.37	Lymphoma;	chr11:58461125	chr11:58627435~58628528:+
UCEC	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	4.81	3.58e-06	0.00542	0.4	0.37	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
UCEC	cis	rs922692	1	rs4887077	ENSG00000261143.1	ADAMTS7P3	-4.81	3.58e-06	0.00542	-0.49	-0.37	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78686022	chr15:77976042~77993057:+
UCEC	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-4.81	3.58e-06	0.00542	-0.5	-0.37	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
UCEC	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-4.81	3.59e-06	0.00542	-0.48	-0.37	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
UCEC	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-4.81	3.6e-06	0.00542	-0.4	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
UCEC	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	4.81	3.6e-06	0.00542	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
UCEC	cis	rs6840360	0.642	rs6855845	ENSG00000278978.1	RP11-164P12.5	-4.81	3.6e-06	0.00542	-0.43	-0.37	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs2034061	ENSG00000278978.1	RP11-164P12.5	-4.81	3.6e-06	0.00542	-0.43	-0.37	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs7677131	ENSG00000270265.1	RP11-731D1.4	-4.81	3.6e-06	0.00542	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151333775~151353224:-
UCEC	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-4.81	3.61e-06	0.00543	-0.46	-0.37	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	4.81	3.61e-06	0.00543	0.46	0.37	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	4.81	3.61e-06	0.00543	0.46	0.37	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
UCEC	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-4.81	3.61e-06	0.00544	-0.49	-0.37	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-4.81	3.61e-06	0.00544	-0.49	-0.37	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
UCEC	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-4.81	3.61e-06	0.00544	-0.52	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
UCEC	cis	rs7914558	0.966	rs11191438	ENSG00000272912.1	RP11-724N1.1	-4.81	3.61e-06	0.00544	-0.36	-0.37	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878107	chr10:102914585~102915404:+
UCEC	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-4.81	3.62e-06	0.00544	-0.33	-0.37	Height;	chr11:118760944	chr11:118791254~118793137:+
UCEC	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	4.81	3.62e-06	0.00545	0.41	0.37	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
UCEC	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	4.81	3.62e-06	0.00545	0.42	0.37	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
UCEC	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	4.81	3.63e-06	0.00546	0.46	0.37	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
UCEC	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-4.81	3.63e-06	0.00546	-0.71	-0.37	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
UCEC	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	4.81	3.64e-06	0.00547	0.51	0.37	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
UCEC	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	4.81	3.64e-06	0.00547	0.4	0.37	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
UCEC	cis	rs16828019	0.929	rs35883594	ENSG00000235358.1	RP11-399E6.1	4.81	3.64e-06	0.00547	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41242373~41284861:+
UCEC	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	4.81	3.64e-06	0.00547	0.39	0.37	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	4.81	3.65e-06	0.00548	0.39	0.37	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
UCEC	cis	rs617219	0.574	rs7704383	ENSG00000245556.2	SCAMP1-AS1	-4.81	3.65e-06	0.00548	-0.34	-0.37	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79306649	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.613	rs4704555	ENSG00000245556.2	SCAMP1-AS1	-4.81	3.65e-06	0.00548	-0.34	-0.37	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79311236	chr5:78342365~78360507:-
UCEC	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	4.81	3.65e-06	0.00548	0.49	0.37	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
UCEC	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-4.81	3.65e-06	0.00548	-0.38	-0.37	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
UCEC	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	4.81	3.66e-06	0.00548	0.45	0.37	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
UCEC	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	4.81	3.67e-06	0.00548	0.46	0.37	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
UCEC	cis	rs617219	0.613	rs10043008	ENSG00000245556.2	SCAMP1-AS1	-4.81	3.67e-06	0.00548	-0.34	-0.37	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79291091	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.613	rs10072296	ENSG00000245556.2	SCAMP1-AS1	-4.81	3.67e-06	0.00548	-0.34	-0.37	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79299047	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.574	rs7722789	ENSG00000245556.2	SCAMP1-AS1	-4.81	3.67e-06	0.00548	-0.34	-0.37	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79320544	chr5:78342365~78360507:-
UCEC	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	4.81	3.67e-06	0.00549	0.4	0.37	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	4.81	3.67e-06	0.00549	0.4	0.37	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-4.81	3.67e-06	0.00549	-0.4	-0.37	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
UCEC	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-4.81	3.67e-06	0.00549	-0.41	-0.37	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
UCEC	cis	rs964184	0.63	rs7930786	ENSG00000254851.1	RP11-109L13.1	-4.81	3.68e-06	0.0055	-0.8	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116754011	chr11:117135528~117138582:+
UCEC	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-4.81	3.68e-06	0.0055	-0.33	-0.37	Height;	chr11:118747911	chr11:118791254~118793137:+
UCEC	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	4.81	3.69e-06	0.0055	0.38	0.37	Height;	chr6:109440234	chr6:109382795~109383666:+
UCEC	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	4.81	3.69e-06	0.00551	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
UCEC	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-4.81	3.69e-06	0.00551	-0.41	-0.37	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
UCEC	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-4.81	3.7e-06	0.00553	-0.71	-0.37	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
UCEC	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-4.81	3.7e-06	0.00553	-0.34	-0.37	Height;	chr11:118742526	chr11:118791254~118793137:+
UCEC	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	4.81	3.71e-06	0.00554	0.4	0.37	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	4.81	3.71e-06	0.00554	0.4	0.37	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	4.81	3.71e-06	0.00554	0.4	0.37	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	4.81	3.71e-06	0.00554	0.4	0.37	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	4.81	3.71e-06	0.00554	0.44	0.37	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	4.81	3.71e-06	0.00554	0.44	0.37	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-4.81	3.72e-06	0.00554	-0.48	-0.37	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-4.81	3.72e-06	0.00554	-0.48	-0.37	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
UCEC	cis	rs7846314	0.536	rs35149496	ENSG00000254432.1	RP11-33I11.2	-4.81	3.72e-06	0.00555	-0.56	-0.37	Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Myeloid white cell count;Neutrophil percentage of granulocytes;Granulocyte count;Sum basophil neutrophil counts;Granulocyte percentage of myeloid white cells;Neutrophil count;White blood cell count;	chr8:60789001	chr8:60808735~60809606:-
UCEC	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-4.81	3.73e-06	0.00556	-0.45	-0.37	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
UCEC	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	4.81	3.73e-06	0.00556	0.44	0.37	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	4.81	3.73e-06	0.00556	0.44	0.37	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	4.81	3.73e-06	0.00556	0.44	0.37	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
UCEC	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	4.81	3.74e-06	0.00557	0.49	0.37	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	4.8	3.74e-06	0.00557	0.46	0.37	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
UCEC	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	4.8	3.74e-06	0.00557	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	4.8	3.74e-06	0.00557	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	4.8	3.74e-06	0.00557	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	4.8	3.74e-06	0.00557	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	4.8	3.74e-06	0.00557	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	4.8	3.74e-06	0.00557	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
UCEC	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-4.8	3.74e-06	0.00557	-0.46	-0.37	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
UCEC	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	4.8	3.75e-06	0.00558	0.39	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
UCEC	cis	rs6840360	0.607	rs2724565	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2724568	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs7657670	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.606	rs2709813	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.606	rs2724550	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2709815	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2709825	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.607	rs2724547	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2724578	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.574	rs2709844	ENSG00000270265.1	RP11-731D1.4	-4.8	3.76e-06	0.0056	-0.35	-0.37	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151333775~151353224:-
UCEC	cis	rs964184	0.63	rs10750096	ENSG00000254851.1	RP11-109L13.1	-4.8	3.77e-06	0.0056	-0.8	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116786072	chr11:117135528~117138582:+
UCEC	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	4.8	3.77e-06	0.0056	0.39	0.37	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
UCEC	cis	rs999944	0.882	rs1008631	ENSG00000234572.1	AC007880.1	4.8	3.79e-06	0.00563	0.9	0.37	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:64823416	chr2:64846130~64863626:-
UCEC	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	4.8	3.8e-06	0.00564	0.42	0.37	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
UCEC	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	4.8	3.81e-06	0.00565	0.69	0.37	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
UCEC	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-4.8	3.81e-06	0.00565	-0.45	-0.37	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
UCEC	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	4.8	3.81e-06	0.00565	0.55	0.37	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
UCEC	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	4.8	3.81e-06	0.00566	0.46	0.37	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	4.8	3.81e-06	0.00566	0.46	0.37	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	4.8	3.81e-06	0.00566	0.46	0.37	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	4.8	3.81e-06	0.00566	0.46	0.37	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	4.8	3.81e-06	0.00566	0.46	0.37	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	4.8	3.81e-06	0.00566	0.46	0.37	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	4.8	3.81e-06	0.00566	0.46	0.37	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	4.8	3.81e-06	0.00566	0.46	0.37	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	4.8	3.81e-06	0.00566	0.46	0.37	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
UCEC	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	4.8	3.82e-06	0.00566	0.46	0.37	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	4.8	3.82e-06	0.00566	0.46	0.37	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	4.8	3.82e-06	0.00566	0.46	0.37	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
UCEC	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	4.8	3.83e-06	0.00568	0.43	0.37	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
UCEC	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	4.8	3.84e-06	0.00569	1.02	0.37	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
UCEC	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	4.8	3.85e-06	0.00569	0.42	0.37	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	4.8	3.85e-06	0.00569	0.42	0.37	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	4.8	3.85e-06	0.00569	0.42	0.37	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
UCEC	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	4.8	3.85e-06	0.0057	0.38	0.37	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
UCEC	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	4.8	3.85e-06	0.0057	0.46	0.37	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
UCEC	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	4.8	3.86e-06	0.00571	0.43	0.37	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
UCEC	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00571	-0.47	-0.37	Depression;	chr6:28096845	chr6:28115628~28116551:+
UCEC	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	4.8	3.87e-06	0.00572	0.47	0.37	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-4.8	3.87e-06	0.00572	-0.48	-0.37	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-4.8	3.87e-06	0.00572	-0.48	-0.37	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
UCEC	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-4.8	3.87e-06	0.00572	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
UCEC	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	4.8	3.87e-06	0.00572	0.44	0.37	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
UCEC	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-4.8	3.88e-06	0.00573	-0.76	-0.37	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-4.8	3.88e-06	0.00573	-0.49	-0.37	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
UCEC	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	4.8	3.89e-06	0.00574	0.4	0.37	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
UCEC	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-4.8	3.9e-06	0.00576	-0.46	-0.37	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
UCEC	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	4.79	3.91e-06	0.00577	0.38	0.37	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
UCEC	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-4.79	3.92e-06	0.00579	-0.56	-0.37	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
UCEC	cis	rs6840360	0.607	rs6815320	ENSG00000278978.1	RP11-164P12.5	-4.79	3.92e-06	0.00579	-0.43	-0.37	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151669786~151670503:+
UCEC	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-4.79	3.93e-06	0.00579	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-4.79	3.93e-06	0.00579	-0.49	-0.37	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-4.79	3.93e-06	0.00579	-0.49	-0.37	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	4.79	3.93e-06	0.00579	0.48	0.37	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
UCEC	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	4.79	3.93e-06	0.00579	0.42	0.37	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
UCEC	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	4.79	3.95e-06	0.00582	0.43	0.37	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
UCEC	cis	rs9527	0.615	rs11191401	ENSG00000236937.2	PTGES3P4	4.79	3.96e-06	0.00583	0.42	0.37	Arsenic metabolism;	chr10:102813646	chr10:102845595~102845950:+
UCEC	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	4.79	3.97e-06	0.00583	0.77	0.37	Gout;	chr7:66682070	chr7:66654538~66669855:+
UCEC	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	4.79	3.97e-06	0.00583	0.77	0.37	Gout;	chr7:66682162	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66679692	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66692349	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66693028	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66693433	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66694214	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66701371	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66702658	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66706390	chr7:66654538~66669855:+
UCEC	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66710076	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66715944	chr7:66654538~66669855:+
UCEC	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66721259	chr7:66654538~66669855:+
UCEC	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-4.79	3.97e-06	0.00583	-0.77	-0.37	Gout;	chr7:66732812	chr7:66654538~66669855:+
UCEC	cis	rs7267979	0.866	rs2424699	ENSG00000276952.1	RP5-965G21.6	4.79	3.97e-06	0.00584	0.5	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:25284915~25285588:-
UCEC	cis	rs36032232	1	rs36032232	ENSG00000240163.1	RP11-745A24.1	4.79	3.98e-06	0.00584	0.74	0.37	Blood protein levels;	chr15:60484792	chr15:60390371~60390682:+
UCEC	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-4.79	4.01e-06	0.00588	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
UCEC	cis	rs7246967	0.611	rs16999571	ENSG00000198153.8	ZNF849P	-4.79	4.02e-06	0.00589	-0.42	-0.37	Bronchopulmonary dysplasia;	chr19:22721962	chr19:22685167~22686732:+
UCEC	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	4.79	4.02e-06	0.00589	0.57	0.37	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
UCEC	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-4.79	4.03e-06	0.00591	-0.71	-0.37	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
UCEC	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-4.79	4.04e-06	0.00591	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
UCEC	cis	rs4845570	1	rs4845579	ENSG00000203288.3	RP11-98D18.9	-4.79	4.04e-06	0.00591	-0.5	-0.37	Coronary artery disease;	chr1:151797662	chr1:151790804~151794402:+
UCEC	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-4.79	4.05e-06	0.00592	-0.42	-0.37	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
UCEC	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-4.79	4.05e-06	0.00592	-0.46	-0.37	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
UCEC	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	4.79	4.05e-06	0.00592	0.49	0.37	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
UCEC	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	4.79	4.05e-06	0.00592	0.42	0.37	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	4.79	4.05e-06	0.00592	0.42	0.37	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
UCEC	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	4.79	4.05e-06	0.00593	0.44	0.37	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
UCEC	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	4.79	4.06e-06	0.00593	0.38	0.37	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
UCEC	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-4.79	4.06e-06	0.00593	-0.45	-0.37	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
UCEC	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	4.79	4.07e-06	0.00594	0.49	0.37	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
UCEC	cis	rs1930961	1	rs6004673	ENSG00000272942.1	CTA-246H3.12	-4.79	4.07e-06	0.00595	-0.49	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25434324~25435070:-
UCEC	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	4.78	4.09e-06	0.00597	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
UCEC	cis	rs67478160	0.619	rs3742365	ENSG00000270108.1	RP11-73M18.6	-4.78	4.09e-06	0.00597	-0.4	-0.36	Schizophrenia;	chr14:103731914	chr14:103687576~103688127:+
UCEC	cis	rs268134	0.689	rs7561064	ENSG00000281920.1	RP11-418H16.1	-4.78	4.1e-06	0.00598	-0.52	-0.36	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65339715	chr2:65623272~65628424:+
UCEC	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	4.78	4.11e-06	0.00599	0.66	0.36	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
UCEC	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	4.78	4.12e-06	0.00601	0.4	0.36	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	4.78	4.12e-06	0.00601	0.4	0.36	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
UCEC	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-4.78	4.13e-06	0.00602	-0.34	-0.36	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-4.78	4.13e-06	0.00602	-0.34	-0.36	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-4.78	4.13e-06	0.00602	-0.34	-0.36	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-4.78	4.13e-06	0.00602	-0.38	-0.36	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-4.78	4.13e-06	0.00602	-0.38	-0.36	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-4.78	4.13e-06	0.00602	-0.38	-0.36	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-4.78	4.13e-06	0.00602	-0.38	-0.36	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
UCEC	cis	rs7208859	0.573	rs73277960	ENSG00000264538.5	SUZ12P1	-4.78	4.14e-06	0.00603	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.623	rs73263788	ENSG00000264538.5	SUZ12P1	-4.78	4.14e-06	0.00603	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs12949860	ENSG00000264538.5	SUZ12P1	-4.78	4.14e-06	0.00603	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30709299~30790908:+
UCEC	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-4.78	4.15e-06	0.00604	-0.41	-0.36	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
UCEC	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-4.78	4.16e-06	0.00606	-0.44	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
UCEC	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-4.78	4.16e-06	0.00606	-0.44	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
UCEC	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-4.78	4.16e-06	0.00606	-0.44	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
UCEC	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	4.78	4.17e-06	0.00607	0.46	0.36	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	4.78	4.17e-06	0.00607	0.46	0.36	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	4.78	4.17e-06	0.00607	0.46	0.36	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
UCEC	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-4.78	4.17e-06	0.00607	-0.33	-0.36	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
UCEC	cis	rs9907295	0.901	rs28739295	ENSG00000270871.1	AC015849.19	4.78	4.19e-06	0.00609	0.61	0.36	Fibroblast growth factor basic levels;	chr17:35895812	chr17:35816717~35830293:-
UCEC	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	4.78	4.2e-06	0.00611	0.44	0.36	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
UCEC	cis	rs6840360	0.87	rs6814554	ENSG00000278978.1	RP11-164P12.5	-4.78	4.21e-06	0.00611	-0.44	-0.36	Intelligence (multi-trait analysis);	chr4:151533182	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.901	rs1946999	ENSG00000278978.1	RP11-164P12.5	-4.78	4.21e-06	0.00611	-0.44	-0.36	Intelligence (multi-trait analysis);	chr4:151534187	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.901	rs6826799	ENSG00000278978.1	RP11-164P12.5	-4.78	4.21e-06	0.00611	-0.44	-0.36	Intelligence (multi-trait analysis);	chr4:151534548	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.87	rs1372978	ENSG00000278978.1	RP11-164P12.5	-4.78	4.21e-06	0.00611	-0.44	-0.36	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.901	rs1443094	ENSG00000278978.1	RP11-164P12.5	-4.78	4.21e-06	0.00611	-0.44	-0.36	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151669786~151670503:+
UCEC	cis	rs56114371	0.53	rs2056923	ENSG00000216901.1	AL022393.7	4.78	4.22e-06	0.00613	0.5	0.36	Breast cancer;	chr6:27722160	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	4.78	4.24e-06	0.00616	0.45	0.36	Depression;	chr6:28086929	chr6:28115628~28116551:+
UCEC	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-4.78	4.25e-06	0.00617	-0.56	-0.36	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
UCEC	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	4.78	4.25e-06	0.00618	0.46	0.36	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
UCEC	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-4.77	4.27e-06	0.0062	-0.49	-0.36	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
UCEC	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	4.77	4.28e-06	0.0062	0.57	0.36	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
UCEC	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-4.77	4.28e-06	0.00621	-0.71	-0.36	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
UCEC	cis	rs36032232	1	rs35649654	ENSG00000240163.1	RP11-745A24.1	4.77	4.29e-06	0.00621	0.74	0.36	Blood protein levels;	chr15:60488062	chr15:60390371~60390682:+
UCEC	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-4.77	4.3e-06	0.00623	-0.41	-0.36	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
UCEC	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	4.77	4.3e-06	0.00623	0.4	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
UCEC	cis	rs9907295	0.901	rs2107540	ENSG00000270871.1	AC015849.19	4.77	4.3e-06	0.00624	0.61	0.36	Fibroblast growth factor basic levels;	chr17:35893516	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.901	rs56294660	ENSG00000270871.1	AC015849.19	4.77	4.3e-06	0.00624	0.61	0.36	Fibroblast growth factor basic levels;	chr17:35901470	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.901	rs28550999	ENSG00000270871.1	AC015849.19	4.77	4.3e-06	0.00624	0.61	0.36	Fibroblast growth factor basic levels;	chr17:35902887	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.901	rs74780070	ENSG00000270871.1	AC015849.19	4.77	4.3e-06	0.00624	0.61	0.36	Fibroblast growth factor basic levels;	chr17:35903521	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.786	rs56344830	ENSG00000270871.1	AC015849.19	4.77	4.3e-06	0.00624	0.61	0.36	Fibroblast growth factor basic levels;	chr17:35903951	chr17:35816717~35830293:-
UCEC	cis	rs948562	0.573	rs73479901	ENSG00000280010.1	AP001350.4	4.77	4.31e-06	0.00625	0.64	0.36	Lymphoma;	chr11:58276171	chr11:58627435~58628528:+
UCEC	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-4.77	4.33e-06	0.00627	-0.42	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
UCEC	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	4.77	4.36e-06	0.0063	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
UCEC	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	4.77	4.36e-06	0.00631	0.39	0.36	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
UCEC	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-4.77	4.37e-06	0.00632	-0.38	-0.36	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
UCEC	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	4.77	4.39e-06	0.00633	0.39	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
UCEC	cis	rs4713118	0.869	rs6922574	ENSG00000216901.1	AL022393.7	4.77	4.39e-06	0.00633	0.42	0.36	Parkinson's disease;	chr6:27725224	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs9348775	ENSG00000216901.1	AL022393.7	4.77	4.39e-06	0.00633	0.42	0.36	Parkinson's disease;	chr6:27727550	chr6:28176188~28176674:+
UCEC	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	4.77	4.39e-06	0.00634	1.01	0.36	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
UCEC	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-4.77	4.39e-06	0.00634	-0.36	-0.36	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
UCEC	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-4.77	4.4e-06	0.00634	-0.51	-0.36	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
UCEC	cis	rs12744310	1	rs12035012	ENSG00000235358.1	RP11-399E6.1	4.77	4.4e-06	0.00634	0.6	0.36	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41284976	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs1343775	ENSG00000235358.1	RP11-399E6.1	4.77	4.4e-06	0.00634	0.6	0.36	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292321	chr1:41242373~41284861:+
UCEC	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	4.77	4.4e-06	0.00635	0.37	0.36	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
UCEC	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-4.77	4.41e-06	0.00636	-0.41	-0.36	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-4.77	4.41e-06	0.00636	-0.41	-0.36	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
UCEC	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-4.77	4.41e-06	0.00636	-0.46	-0.36	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-4.77	4.41e-06	0.00636	-0.46	-0.36	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-4.77	4.41e-06	0.00636	-0.46	-0.36	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
UCEC	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-4.77	4.41e-06	0.00636	-0.38	-0.36	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
UCEC	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-4.77	4.41e-06	0.00636	-0.38	-0.36	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
UCEC	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-4.77	4.42e-06	0.00637	-0.38	-0.36	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
UCEC	cis	rs948562	0.744	rs78111333	ENSG00000280010.1	AP001350.4	4.77	4.42e-06	0.00637	0.72	0.36	Lymphoma;	chr11:58482474	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.744	rs12361887	ENSG00000280010.1	AP001350.4	4.77	4.42e-06	0.00637	0.72	0.36	Lymphoma;	chr11:58488205	chr11:58627435~58628528:+
UCEC	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	4.77	4.43e-06	0.00638	0.41	0.36	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	4.77	4.43e-06	0.00638	0.41	0.36	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
UCEC	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-4.76	4.45e-06	0.0064	-0.4	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-4.76	4.45e-06	0.00641	-0.4	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
UCEC	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-4.76	4.46e-06	0.00642	-0.42	-0.36	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
UCEC	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	4.76	4.46e-06	0.00642	0.43	0.36	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
UCEC	cis	rs7267979	1	rs6050565	ENSG00000276952.1	RP5-965G21.6	-4.76	4.47e-06	0.00643	-0.47	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25284915~25285588:-
UCEC	cis	rs9400467	0.528	rs465796	ENSG00000271789.1	RP5-1112D6.7	-4.76	4.47e-06	0.00644	-0.43	-0.36	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111297126~111298510:+
UCEC	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	4.76	4.5e-06	0.00646	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
UCEC	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-4.76	4.5e-06	0.00647	-0.49	-0.36	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
UCEC	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-4.76	4.51e-06	0.00647	-0.49	-0.36	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
UCEC	cis	rs492146	1	rs492146	ENSG00000243236.5	GSTA9P	-4.76	4.51e-06	0.00648	-0.48	-0.36	Epilepsy (remission after treatment);	chr6:52971097	chr6:52939726~52957521:-
UCEC	cis	rs6840360	0.642	rs7658169	ENSG00000270265.1	RP11-731D1.4	-4.76	4.51e-06	0.00648	-0.35	-0.36	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151333775~151353224:-
UCEC	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	4.76	4.51e-06	0.00648	0.39	0.36	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
UCEC	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	4.76	4.52e-06	0.00648	0.5	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	4.76	4.52e-06	0.00648	0.5	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	4.76	4.52e-06	0.00648	0.5	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
UCEC	cis	rs12928939	0.911	rs7202840	ENSG00000260886.1	TAT-AS1	4.76	4.53e-06	0.0065	0.45	0.36	Post bronchodilator FEV1;	chr16:71790811	chr16:71565789~71578187:+
UCEC	cis	rs12928939	0.911	rs77823468	ENSG00000260886.1	TAT-AS1	4.76	4.53e-06	0.0065	0.45	0.36	Post bronchodilator FEV1;	chr16:71794713	chr16:71565789~71578187:+
UCEC	cis	rs12928939	0.911	rs12917983	ENSG00000260886.1	TAT-AS1	4.76	4.53e-06	0.0065	0.45	0.36	Post bronchodilator FEV1;	chr16:71801340	chr16:71565789~71578187:+
UCEC	cis	rs12928939	0.768	rs71386932	ENSG00000260886.1	TAT-AS1	4.76	4.53e-06	0.0065	0.44	0.36	Post bronchodilator FEV1;	chr16:71782288	chr16:71565789~71578187:+
UCEC	cis	rs12928939	0.911	rs8051878	ENSG00000260886.1	TAT-AS1	4.76	4.53e-06	0.0065	0.44	0.36	Post bronchodilator FEV1;	chr16:71784528	chr16:71565789~71578187:+
UCEC	cis	rs12928939	0.911	rs11645704	ENSG00000260886.1	TAT-AS1	4.76	4.53e-06	0.0065	0.44	0.36	Post bronchodilator FEV1;	chr16:71792708	chr16:71565789~71578187:+
UCEC	cis	rs12928939	0.911	rs11645725	ENSG00000260886.1	TAT-AS1	4.76	4.53e-06	0.0065	0.44	0.36	Post bronchodilator FEV1;	chr16:71792980	chr16:71565789~71578187:+
UCEC	cis	rs12928939	0.954	rs34998650	ENSG00000260886.1	TAT-AS1	4.76	4.53e-06	0.0065	0.44	0.36	Post bronchodilator FEV1;	chr16:71795426	chr16:71565789~71578187:+
UCEC	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	4.76	4.54e-06	0.0065	1.01	0.36	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
UCEC	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	4.76	4.55e-06	0.00652	0.46	0.36	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	4.76	4.55e-06	0.00652	0.46	0.36	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	4.76	4.55e-06	0.00652	0.46	0.36	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	4.76	4.56e-06	0.00653	0.46	0.36	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
UCEC	cis	rs6104690	0.687	rs6131140	ENSG00000270792.4	RP11-103J8.1	-4.76	4.56e-06	0.00653	-0.52	-0.36	Bladder cancer;	chr20:10998442	chr20:10672928~10994924:+
UCEC	cis	rs440932	0.798	rs330942	ENSG00000253893.2	FAM85B	-4.76	4.56e-06	0.00653	-0.41	-0.36	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8167819~8226614:-
UCEC	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-4.76	4.61e-06	0.00657	-0.6	-0.36	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
UCEC	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	4.76	4.61e-06	0.00657	0.46	0.36	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	4.76	4.61e-06	0.00657	0.46	0.36	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	4.76	4.61e-06	0.00657	0.46	0.36	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	4.76	4.61e-06	0.00657	0.46	0.36	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	4.76	4.61e-06	0.00657	0.46	0.36	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	4.76	4.61e-06	0.00657	0.46	0.36	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
UCEC	cis	rs1387259	0.69	rs1601985	ENSG00000226413.2	OR8T1P	4.76	4.61e-06	0.00657	0.51	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48442030~48442947:-
UCEC	cis	rs1387259	0.723	rs2732488	ENSG00000226413.2	OR8T1P	4.76	4.61e-06	0.00657	0.51	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48442030~48442947:-
UCEC	cis	rs1387259	0.758	rs2634670	ENSG00000226413.2	OR8T1P	4.76	4.61e-06	0.00657	0.51	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48442030~48442947:-
UCEC	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	4.76	4.61e-06	0.00658	0.4	0.36	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	4.76	4.61e-06	0.00658	0.4	0.36	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
UCEC	cis	rs34286592	1	rs13331733	ENSG00000238045.8	AC009133.12	4.76	4.62e-06	0.00659	0.6	0.36	Multiple sclerosis;	chr16:29837096	chr16:29808636~29821252:-
UCEC	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	4.76	4.62e-06	0.00659	0.44	0.36	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	4.76	4.62e-06	0.00659	0.44	0.36	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	4.76	4.62e-06	0.00659	0.44	0.36	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
UCEC	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	4.76	4.62e-06	0.00659	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
UCEC	cis	rs10232172	1	rs6971688	ENSG00000234707.2	RP11-745C15.2	4.75	4.65e-06	0.00662	0.66	0.36	Periodontal disease-related phenotypes;	chr7:54106704	chr7:54759425~54804928:+
UCEC	cis	rs4789693	0.808	rs12935995	ENSG00000265458.1	RP13-20L14.6	4.75	4.67e-06	0.00664	0.43	0.36	Glucocorticoid-induced osteonecrosis;	chr17:82437007	chr17:82454273~82458521:-
UCEC	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-4.75	4.67e-06	0.00665	-0.42	-0.36	Height;	chr11:118809363	chr11:118704607~118750263:+
UCEC	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	4.75	4.68e-06	0.00666	0.45	0.36	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	4.75	4.68e-06	0.00666	0.45	0.36	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-4.75	4.68e-06	0.00666	-0.45	-0.36	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
UCEC	cis	rs2276314	1	rs62101367	ENSG00000267627.4	RP11-905K4.1	-4.75	4.69e-06	0.00666	-0.42	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35951803~35966118:-
UCEC	cis	rs948562	1	rs79475579	ENSG00000280010.1	AP001350.4	4.75	4.69e-06	0.00666	0.75	0.36	Lymphoma;	chr11:58528427	chr11:58627435~58628528:+
UCEC	cis	rs948562	1	rs111901203	ENSG00000280010.1	AP001350.4	4.75	4.69e-06	0.00666	0.75	0.36	Lymphoma;	chr11:58530069	chr11:58627435~58628528:+
UCEC	cis	rs7246967	0.673	rs2361260	ENSG00000198153.8	ZNF849P	4.75	4.69e-06	0.00667	0.43	0.36	Bronchopulmonary dysplasia;	chr19:22731342	chr19:22685167~22686732:+
UCEC	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	4.75	4.69e-06	0.00667	0.39	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	4.75	4.69e-06	0.00667	0.39	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
UCEC	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	4.75	4.7e-06	0.00667	0.4	0.36	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
UCEC	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-4.75	4.7e-06	0.00667	-0.56	-0.36	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
UCEC	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	4.75	4.72e-06	0.00669	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	4.75	4.72e-06	0.00669	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	4.75	4.72e-06	0.00669	0.57	0.36	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	4.75	4.72e-06	0.00669	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	4.75	4.72e-06	0.00669	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	4.75	4.72e-06	0.00669	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	4.75	4.72e-06	0.00669	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	4.75	4.72e-06	0.00669	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
UCEC	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-4.75	4.72e-06	0.00669	-0.43	-0.36	Height;	chr2:46640019	chr2:46668870~46670778:+
UCEC	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	4.75	4.72e-06	0.0067	0.44	0.36	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
UCEC	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-4.75	4.72e-06	0.0067	-0.41	-0.36	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
UCEC	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	4.75	4.73e-06	0.00671	0.38	0.36	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
UCEC	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	4.75	4.75e-06	0.00673	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
UCEC	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-4.75	4.77e-06	0.00676	-0.41	-0.36	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
UCEC	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-4.75	4.77e-06	0.00676	-0.41	-0.36	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
UCEC	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	4.75	4.77e-06	0.00677	0.5	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
UCEC	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	4.75	4.78e-06	0.00678	0.54	0.36	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	4.75	4.78e-06	0.00678	0.54	0.36	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
UCEC	cis	rs9309473	0.898	rs11126403	ENSG00000163016.8	ALMS1P	4.75	4.78e-06	0.00678	0.41	0.36	Metabolite levels;	chr2:73569796	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.898	rs11126404	ENSG00000163016.8	ALMS1P	4.75	4.78e-06	0.00678	0.41	0.36	Metabolite levels;	chr2:73569797	chr2:73644919~73685576:+
UCEC	cis	rs1667255	1	rs1375446	ENSG00000266521.1	RP11-650P15.1	4.75	4.79e-06	0.00679	0.4	0.36	Retinol levels;	chr18:31577372	chr18:31496645~31497195:-
UCEC	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-4.75	4.79e-06	0.00679	-0.43	-0.36	Height;	chr2:46636733	chr2:46668870~46670778:+
UCEC	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	4.75	4.82e-06	0.00682	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
UCEC	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	4.75	4.83e-06	0.00682	0.62	0.36	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
UCEC	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-4.75	4.84e-06	0.00684	-0.41	-0.36	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
UCEC	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	4.74	4.85e-06	0.00685	0.58	0.36	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	4.74	4.85e-06	0.00685	0.58	0.36	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	4.74	4.85e-06	0.00685	0.58	0.36	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
UCEC	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	4.74	4.85e-06	0.00686	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
UCEC	cis	rs6840360	0.642	rs1372977	ENSG00000278978.1	RP11-164P12.5	-4.74	4.86e-06	0.00687	-0.42	-0.36	Intelligence (multi-trait analysis);	chr4:151531246	chr4:151669786~151670503:+
UCEC	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	4.74	4.86e-06	0.00687	0.52	0.36	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
UCEC	cis	rs763121	0.853	rs138702	ENSG00000273076.1	RP3-508I15.22	-4.74	4.87e-06	0.00687	-0.44	-0.36	Menopause (age at onset);	chr22:38736596	chr22:38743495~38743910:+
UCEC	cis	rs6840360	0.617	rs2724563	ENSG00000270265.1	RP11-731D1.4	-4.74	4.88e-06	0.00688	-0.35	-0.36	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.617	rs2724564	ENSG00000270265.1	RP11-731D1.4	-4.74	4.88e-06	0.00688	-0.35	-0.36	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151333775~151353224:-
UCEC	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-4.74	4.88e-06	0.00689	-0.74	-0.36	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
UCEC	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-4.74	4.88e-06	0.00689	-0.4	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
UCEC	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	4.74	4.89e-06	0.0069	0.46	0.36	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
UCEC	cis	rs12478296	0.786	rs28802397	ENSG00000261186.2	RP11-341N2.1	-4.74	4.9e-06	0.00691	-0.5	-0.36	Obesity-related traits;	chr2:242107579	chr2:242087351~242088457:-
UCEC	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	4.74	4.9e-06	0.00692	0.41	0.36	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
UCEC	cis	rs7267979	0.932	rs367666	ENSG00000276952.1	RP5-965G21.6	4.74	4.93e-06	0.00695	0.47	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25284915~25285588:-
UCEC	cis	rs7246967	0.673	rs34376806	ENSG00000198153.8	ZNF849P	-4.74	4.95e-06	0.00697	-0.43	-0.36	Bronchopulmonary dysplasia;	chr19:22718059	chr19:22685167~22686732:+
UCEC	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	4.74	4.95e-06	0.00697	0.46	0.36	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
UCEC	cis	rs16828019	1	rs16828019	ENSG00000235358.1	RP11-399E6.1	4.74	4.96e-06	0.00698	1.01	0.36	Intelligence (multi-trait analysis);	chr1:41279363	chr1:41242373~41284861:+
UCEC	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-4.74	4.96e-06	0.00698	-0.41	-0.36	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
UCEC	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	4.74	4.96e-06	0.00698	0.8	0.36	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
UCEC	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	4.74	4.96e-06	0.00698	0.45	0.36	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
UCEC	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	4.74	4.96e-06	0.00698	0.45	0.36	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
UCEC	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	4.74	4.96e-06	0.00698	0.45	0.36	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	4.74	4.96e-06	0.00698	0.45	0.36	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	4.74	4.96e-06	0.00698	0.45	0.36	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
UCEC	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-4.74	4.96e-06	0.00698	-0.45	-0.36	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
UCEC	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-4.74	4.96e-06	0.00698	-0.45	-0.36	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-4.74	4.96e-06	0.00698	-0.45	-0.36	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
UCEC	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	4.74	4.96e-06	0.00698	0.47	0.36	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
UCEC	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	4.74	4.96e-06	0.00698	0.44	0.36	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
UCEC	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-4.74	4.97e-06	0.00699	-0.74	-0.36	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-4.74	4.97e-06	0.00699	-0.74	-0.36	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
UCEC	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-4.74	4.97e-06	0.00699	-0.45	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
UCEC	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	4.74	4.98e-06	0.007	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	4.74	4.98e-06	0.007	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	4.74	4.98e-06	0.007	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
UCEC	cis	rs7208859	0.673	rs73277964	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs11652409	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs9896095	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.573	rs58920731	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs73277984	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs73277986	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs12103588	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.614	rs9914534	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs4131618	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs11658344	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.623	rs9900144	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.573	rs11656121	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.623	rs11650973	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs56085216	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs11650305	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs11654914	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30709299~30790908:+
UCEC	cis	rs7208859	0.673	rs9914271	ENSG00000264538.5	SUZ12P1	-4.74	4.98e-06	0.007	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30709299~30790908:+
UCEC	cis	rs9309473	1	rs10184268	ENSG00000163016.8	ALMS1P	4.74	4.99e-06	0.00701	0.4	0.36	Metabolite levels;	chr2:73399916	chr2:73644919~73685576:+
UCEC	cis	rs2276314	1	rs1540042	ENSG00000267627.4	RP11-905K4.1	-4.74	4.99e-06	0.00701	-0.4	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35951803~35966118:-
UCEC	cis	rs72901758	0.768	rs72901766	ENSG00000279570.1	CTD-2357A8.2	4.74	5e-06	0.00701	0.48	0.36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78249122	chr17:78691266~78691979:-
UCEC	cis	rs72901758	0.768	rs11659046	ENSG00000279570.1	CTD-2357A8.2	4.74	5e-06	0.00701	0.48	0.36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78249637	chr17:78691266~78691979:-
UCEC	cis	rs2445284	0.874	rs17497	ENSG00000229534.1	HNRNPA1P53	-4.74	5.01e-06	0.00703	-0.43	-0.36	Sickle cell anemia (haemolysis);	chr11:5036378	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.773	rs2445266	ENSG00000229534.1	HNRNPA1P53	-4.74	5.01e-06	0.00703	-0.43	-0.36	Sickle cell anemia (haemolysis);	chr11:5036598	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.838	rs2445267	ENSG00000229534.1	HNRNPA1P53	-4.74	5.01e-06	0.00703	-0.43	-0.36	Sickle cell anemia (haemolysis);	chr11:5036826	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs1463372	ENSG00000229534.1	HNRNPA1P53	-4.74	5.01e-06	0.00703	-0.43	-0.36	Sickle cell anemia (haemolysis);	chr11:5037041	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs1463373	ENSG00000229534.1	HNRNPA1P53	-4.74	5.01e-06	0.00703	-0.43	-0.36	Sickle cell anemia (haemolysis);	chr11:5037111	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs1463374	ENSG00000229534.1	HNRNPA1P53	-4.74	5.01e-06	0.00703	-0.43	-0.36	Sickle cell anemia (haemolysis);	chr11:5037160	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2445268	ENSG00000229534.1	HNRNPA1P53	-4.74	5.01e-06	0.00703	-0.43	-0.36	Sickle cell anemia (haemolysis);	chr11:5037287	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499970	ENSG00000229534.1	HNRNPA1P53	-4.74	5.01e-06	0.00703	-0.43	-0.36	Sickle cell anemia (haemolysis);	chr11:5037386	chr11:5571247~5572192:-
UCEC	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	4.74	5.01e-06	0.00703	0.41	0.36	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
UCEC	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	4.74	5.01e-06	0.00703	0.56	0.36	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
UCEC	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	4.74	5.02e-06	0.00704	0.54	0.36	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
UCEC	cis	rs948562	0.947	rs73470778	ENSG00000280010.1	AP001350.4	4.74	5.02e-06	0.00705	0.66	0.36	Lymphoma;	chr11:58650594	chr11:58627435~58628528:+
UCEC	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-4.74	5.04e-06	0.00706	-0.34	-0.36	Height;	chr11:118737916	chr11:118791254~118793137:+
UCEC	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-4.74	5.04e-06	0.00707	-0.34	-0.36	Height;	chr11:118786602	chr11:118791254~118793137:+
UCEC	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-4.74	5.05e-06	0.00707	-0.44	-0.36	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
UCEC	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	4.73	5.06e-06	0.00709	0.5	0.36	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
UCEC	cis	rs4835473	0.864	rs56084830	ENSG00000251600.4	RP11-673E1.1	-4.73	5.08e-06	0.00711	-0.4	-0.36	Immature fraction of reticulocytes;	chr4:143791943	chr4:143912331~143982454:+
UCEC	cis	rs1667255	1	rs1667244	ENSG00000266521.1	RP11-650P15.1	-4.73	5.09e-06	0.00711	-0.39	-0.36	Retinol levels;	chr18:31587942	chr18:31496645~31497195:-
UCEC	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	4.73	5.09e-06	0.00711	0.41	0.36	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
UCEC	cis	rs7674212	0.541	rs2720471	ENSG00000246560.2	RP11-10L12.4	4.73	5.1e-06	0.00712	0.43	0.36	Type 2 diabetes;	chr4:103102683	chr4:102828055~102844075:+
UCEC	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-4.73	5.11e-06	0.00712	-0.42	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-4.73	5.11e-06	0.00712	-0.42	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
UCEC	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	4.73	5.11e-06	0.00712	0.48	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
UCEC	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-4.73	5.11e-06	0.00712	-0.41	-0.36	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
UCEC	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	4.73	5.11e-06	0.00713	0.43	0.36	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
UCEC	cis	rs12220777	0.585	rs75995665	ENSG00000230091.5	TMEM254-AS1	4.73	5.11e-06	0.00713	0.61	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80017462	chr10:80046860~80078912:-
UCEC	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	4.73	5.12e-06	0.00713	0.42	0.36	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
UCEC	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-4.73	5.12e-06	0.00713	-0.76	-0.36	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-4.73	5.12e-06	0.00713	-0.76	-0.36	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-4.73	5.12e-06	0.00713	-0.76	-0.36	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-4.73	5.12e-06	0.00713	-0.76	-0.36	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-4.73	5.12e-06	0.00713	-0.76	-0.36	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-4.73	5.12e-06	0.00713	-0.76	-0.36	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-4.73	5.12e-06	0.00713	-0.76	-0.36	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
UCEC	cis	rs9309473	0.583	rs6546822	ENSG00000163016.8	ALMS1P	4.73	5.12e-06	0.00714	0.38	0.36	Metabolite levels;	chr2:73347970	chr2:73644919~73685576:+
UCEC	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-4.73	5.12e-06	0.00714	-0.4	-0.36	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-4.73	5.12e-06	0.00714	-0.4	-0.36	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-4.73	5.12e-06	0.00714	-0.4	-0.36	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
UCEC	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	4.73	5.13e-06	0.00715	0.46	0.36	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
UCEC	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	4.73	5.14e-06	0.00716	0.42	0.36	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
UCEC	cis	rs6840360	0.642	rs7682837	ENSG00000278978.1	RP11-164P12.5	-4.73	5.15e-06	0.00716	-0.42	-0.36	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151669786~151670503:+
UCEC	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	4.73	5.15e-06	0.00716	0.47	0.36	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
UCEC	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	4.73	5.16e-06	0.00716	0.41	0.36	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
UCEC	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-4.73	5.16e-06	0.00717	-0.4	-0.36	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
UCEC	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	4.73	5.16e-06	0.00717	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
UCEC	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-4.73	5.16e-06	0.00717	-0.38	-0.36	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
UCEC	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-4.73	5.16e-06	0.00717	-0.78	-0.36	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-4.73	5.16e-06	0.00717	-0.78	-0.36	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-4.73	5.16e-06	0.00717	-0.78	-0.36	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-4.73	5.16e-06	0.00717	-0.78	-0.36	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
UCEC	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-4.73	5.17e-06	0.00717	-0.5	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
UCEC	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	4.73	5.17e-06	0.00718	0.44	0.36	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
UCEC	cis	rs617219	0.574	rs1870057	ENSG00000245556.2	SCAMP1-AS1	-4.73	5.19e-06	0.0072	-0.34	-0.36	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79297381	chr5:78342365~78360507:-
UCEC	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	4.73	5.2e-06	0.00722	0.45	0.36	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
UCEC	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-4.73	5.22e-06	0.00723	-0.42	-0.36	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
UCEC	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	4.73	5.22e-06	0.00723	0.4	0.36	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	4.73	5.22e-06	0.00723	0.4	0.36	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
UCEC	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-4.73	5.23e-06	0.00724	-0.45	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
UCEC	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	4.73	5.23e-06	0.00725	1.03	0.36	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
UCEC	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	4.73	5.24e-06	0.00725	0.37	0.36	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
UCEC	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-4.73	5.24e-06	0.00725	-0.34	-0.36	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
UCEC	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	4.73	5.25e-06	0.00726	0.42	0.36	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
UCEC	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	4.73	5.25e-06	0.00726	0.45	0.36	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	4.73	5.25e-06	0.00726	0.45	0.36	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	4.73	5.25e-06	0.00726	0.45	0.36	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	4.73	5.25e-06	0.00726	0.45	0.36	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
UCEC	cis	rs12744310	0.887	rs12037129	ENSG00000235358.1	RP11-399E6.1	4.72	5.28e-06	0.00729	0.59	0.36	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41328629	chr1:41242373~41284861:+
UCEC	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	4.72	5.3e-06	0.00731	0.6	0.36	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	4.72	5.3e-06	0.00731	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	4.72	5.3e-06	0.00731	0.6	0.36	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	4.72	5.3e-06	0.00731	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	4.72	5.3e-06	0.00731	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	4.72	5.3e-06	0.00731	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
UCEC	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	4.72	5.31e-06	0.00732	0.37	0.36	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
UCEC	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-4.72	5.32e-06	0.00732	-0.5	-0.36	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
UCEC	cis	rs36032232	1	rs35316323	ENSG00000240163.1	RP11-745A24.1	4.72	5.32e-06	0.00732	0.74	0.36	Blood protein levels;	chr15:60487069	chr15:60390371~60390682:+
UCEC	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-4.72	5.32e-06	0.00732	-0.45	-0.36	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
UCEC	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	4.72	5.32e-06	0.00732	0.37	0.36	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
UCEC	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	4.72	5.32e-06	0.00732	0.48	0.36	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
UCEC	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-4.72	5.32e-06	0.00732	-0.46	-0.36	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
UCEC	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	4.72	5.33e-06	0.00733	0.35	0.36	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
UCEC	cis	rs9309473	1	rs11689392	ENSG00000163016.8	ALMS1P	4.72	5.34e-06	0.00734	0.4	0.36	Metabolite levels;	chr2:73394898	chr2:73644919~73685576:+
UCEC	cis	rs2739330	0.703	rs5760112	ENSG00000272787.1	KB-226F1.2	-4.72	5.34e-06	0.00734	-0.44	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23969211~23969873:+
UCEC	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-4.72	5.34e-06	0.00734	-0.39	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	4.72	5.35e-06	0.00735	0.39	0.36	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
UCEC	cis	rs948562	0.681	rs10750901	ENSG00000280010.1	AP001350.4	4.72	5.35e-06	0.00735	0.6	0.36	Lymphoma;	chr11:58660110	chr11:58627435~58628528:+
UCEC	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-4.72	5.37e-06	0.00738	-0.43	-0.36	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
UCEC	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	4.72	5.38e-06	0.00739	0.42	0.36	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
UCEC	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	4.72	5.38e-06	0.00739	0.44	0.36	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
UCEC	cis	rs948562	1	rs76435840	ENSG00000280010.1	AP001350.4	4.72	5.39e-06	0.0074	0.75	0.36	Lymphoma;	chr11:58518508	chr11:58627435~58628528:+
UCEC	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	4.72	5.4e-06	0.00742	0.4	0.36	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
UCEC	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	4.72	5.41e-06	0.00742	0.42	0.36	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
UCEC	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	4.72	5.41e-06	0.00742	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	4.72	5.41e-06	0.00742	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	4.72	5.41e-06	0.00742	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	4.72	5.41e-06	0.00742	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
UCEC	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-4.72	5.41e-06	0.00742	-0.51	-0.36	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
UCEC	cis	rs17050244	0.51	rs72964731	ENSG00000227788.1	AC012363.8	-4.72	5.42e-06	0.00742	-0.81	-0.36	Age-related macular degeneration;	chr2:120519038	chr2:120211727~120212862:+
UCEC	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	4.72	5.43e-06	0.00743	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
UCEC	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	4.72	5.43e-06	0.00743	0.47	0.36	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	4.72	5.43e-06	0.00743	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
UCEC	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	4.72	5.43e-06	0.00743	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
UCEC	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	4.72	5.43e-06	0.00743	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
UCEC	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-4.72	5.44e-06	0.00743	-0.48	-0.36	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
UCEC	cis	rs9907295	1	rs11080360	ENSG00000270871.1	AC015849.19	4.72	5.44e-06	0.00743	0.6	0.36	Fibroblast growth factor basic levels;	chr17:35916086	chr17:35816717~35830293:-
UCEC	cis	rs9907295	1	rs11869976	ENSG00000270871.1	AC015849.19	4.72	5.44e-06	0.00743	0.6	0.36	Fibroblast growth factor basic levels;	chr17:35916492	chr17:35816717~35830293:-
UCEC	cis	rs948562	0.744	rs11229479	ENSG00000280010.1	AP001350.4	4.72	5.45e-06	0.00744	0.68	0.36	Lymphoma;	chr11:58463158	chr11:58627435~58628528:+
UCEC	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	4.72	5.45e-06	0.00744	0.39	0.36	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
UCEC	cis	rs7267979	0.753	rs400357	ENSG00000276952.1	RP5-965G21.6	4.72	5.45e-06	0.00745	0.47	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25284915~25285588:-
UCEC	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-4.72	5.45e-06	0.00745	-0.39	-0.36	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
UCEC	cis	rs6104690	0.687	rs6040282	ENSG00000270792.4	RP11-103J8.1	-4.72	5.46e-06	0.00746	-0.52	-0.36	Bladder cancer;	chr20:11003457	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.687	rs6033007	ENSG00000270792.4	RP11-103J8.1	-4.72	5.46e-06	0.00746	-0.52	-0.36	Bladder cancer;	chr20:11004003	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.687	rs6040285	ENSG00000270792.4	RP11-103J8.1	-4.72	5.46e-06	0.00746	-0.52	-0.36	Bladder cancer;	chr20:11004303	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.687	rs2026605	ENSG00000270792.4	RP11-103J8.1	-4.72	5.46e-06	0.00746	-0.52	-0.36	Bladder cancer;	chr20:11005322	chr20:10672928~10994924:+
UCEC	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	4.72	5.48e-06	0.00747	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
UCEC	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-4.72	5.48e-06	0.00747	-0.42	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
UCEC	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-4.72	5.49e-06	0.00749	-0.45	-0.36	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
UCEC	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-4.71	5.51e-06	0.00751	-0.33	-0.36	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
UCEC	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	4.71	5.52e-06	0.00753	0.37	0.36	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
UCEC	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-4.71	5.52e-06	0.00753	-0.55	-0.36	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
UCEC	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	4.71	5.53e-06	0.00753	0.52	0.36	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	4.71	5.53e-06	0.00753	0.52	0.36	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
UCEC	cis	rs948562	0.573	rs4459322	ENSG00000280010.1	AP001350.4	-4.71	5.53e-06	0.00753	-0.65	-0.36	Lymphoma;	chr11:58295694	chr11:58627435~58628528:+
UCEC	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	4.71	5.53e-06	0.00753	0.42	0.36	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
UCEC	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-4.71	5.53e-06	0.00753	-0.46	-0.36	Depression;	chr6:28140454	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-4.71	5.53e-06	0.00753	-0.46	-0.36	Depression;	chr6:28141189	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-4.71	5.53e-06	0.00753	-0.46	-0.36	Depression;	chr6:28141484	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-4.71	5.53e-06	0.00753	-0.46	-0.36	Depression;	chr6:28143758	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-4.71	5.53e-06	0.00753	-0.46	-0.36	Depression;	chr6:28144784	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-4.71	5.53e-06	0.00753	-0.46	-0.36	Depression;	chr6:28145952	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	4.71	5.53e-06	0.00753	0.46	0.36	Depression;	chr6:28142370	chr6:28115628~28116551:+
UCEC	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	4.71	5.53e-06	0.00754	0.44	0.36	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
UCEC	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-4.71	5.55e-06	0.00755	-0.44	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
UCEC	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-4.71	5.55e-06	0.00755	-0.44	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
UCEC	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-4.71	5.55e-06	0.00755	-0.44	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
UCEC	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-4.71	5.55e-06	0.00755	-0.33	-0.36	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
UCEC	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	4.71	5.56e-06	0.00756	0.51	0.36	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
UCEC	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-4.71	5.56e-06	0.00756	-0.73	-0.36	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-4.71	5.56e-06	0.00756	-0.73	-0.36	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-4.71	5.56e-06	0.00756	-0.73	-0.36	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-4.71	5.56e-06	0.00756	-0.73	-0.36	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-4.71	5.56e-06	0.00756	-0.73	-0.36	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-4.71	5.56e-06	0.00756	-0.73	-0.36	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-4.71	5.56e-06	0.00756	-0.73	-0.36	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-4.71	5.56e-06	0.00756	-0.73	-0.36	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-4.71	5.56e-06	0.00756	-0.73	-0.36	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	4.71	5.56e-06	0.00756	0.73	0.36	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
UCEC	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-4.71	5.57e-06	0.00757	-0.41	-0.36	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
UCEC	cis	rs3858145	0.588	rs61854831	ENSG00000233590.1	RP11-153K11.3	-4.71	5.58e-06	0.00758	-0.46	-0.36	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68233251~68242379:-
UCEC	cis	rs3858145	0.588	rs55888445	ENSG00000233590.1	RP11-153K11.3	-4.71	5.58e-06	0.00758	-0.46	-0.36	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68233251~68242379:-
UCEC	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-4.71	5.59e-06	0.00758	-0.44	-0.36	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
UCEC	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-4.71	5.59e-06	0.00758	-0.43	-0.36	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-4.71	5.59e-06	0.00758	-0.43	-0.36	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	4.71	5.59e-06	0.00758	0.43	0.36	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
UCEC	cis	rs763121	0.962	rs6001159	ENSG00000273076.1	RP3-508I15.22	4.71	5.59e-06	0.00758	0.38	0.36	Menopause (age at onset);	chr22:38570482	chr22:38743495~38743910:+
UCEC	cis	rs763121	0.853	rs2072798	ENSG00000273076.1	RP3-508I15.22	4.71	5.59e-06	0.00758	0.47	0.36	Menopause (age at onset);	chr22:38752478	chr22:38743495~38743910:+
UCEC	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-4.71	5.59e-06	0.00759	-0.43	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
UCEC	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	4.71	5.59e-06	0.00759	0.43	0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
UCEC	cis	rs7208859	0.673	rs11654331	ENSG00000264538.5	SUZ12P1	-4.71	5.6e-06	0.00759	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30709299~30790908:+
UCEC	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	4.71	5.62e-06	0.00761	0.37	0.36	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	4.71	5.62e-06	0.00761	0.37	0.36	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	4.71	5.62e-06	0.00761	0.37	0.36	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.962	rs2275045	ENSG00000223701.3	RAET1E-AS1	4.71	5.62e-06	0.00761	0.37	0.36	Lung cancer;	chr6:149842775	chr6:149884431~149919508:+
UCEC	cis	rs2276314	0.857	rs16967327	ENSG00000267627.4	RP11-905K4.1	-4.71	5.62e-06	0.00761	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.857	rs62101393	ENSG00000267627.4	RP11-905K4.1	-4.71	5.62e-06	0.00761	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.857	rs62101394	ENSG00000267627.4	RP11-905K4.1	-4.71	5.62e-06	0.00761	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.857	rs4799409	ENSG00000267627.4	RP11-905K4.1	-4.71	5.62e-06	0.00761	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.857	rs28791905	ENSG00000267627.4	RP11-905K4.1	-4.71	5.62e-06	0.00761	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.762	rs3826600	ENSG00000267627.4	RP11-905K4.1	-4.71	5.62e-06	0.00761	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.857	rs72883058	ENSG00000267627.4	RP11-905K4.1	-4.71	5.62e-06	0.00761	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35951803~35966118:-
UCEC	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	4.71	5.62e-06	0.00762	0.39	0.36	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
UCEC	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	4.71	5.65e-06	0.00765	0.41	0.36	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
UCEC	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	4.71	5.66e-06	0.00765	0.39	0.36	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
UCEC	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	4.71	5.66e-06	0.00765	0.46	0.36	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	4.71	5.66e-06	0.00765	0.46	0.36	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
UCEC	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-4.71	5.67e-06	0.00766	-0.39	-0.36	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
UCEC	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	4.71	5.7e-06	0.0077	0.45	0.36	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
UCEC	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	4.71	5.7e-06	0.0077	0.48	0.36	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
UCEC	cis	rs7399018	0.643	rs6580810	ENSG00000261308.1	FIGNL2	-4.71	5.71e-06	0.00771	-0.44	-0.36	Cisplatin-induced ototoxicity;	chr12:51216694	chr12:51820459~51822415:-
UCEC	cis	rs7399018	0.739	rs6580811	ENSG00000261308.1	FIGNL2	-4.71	5.71e-06	0.00771	-0.44	-0.36	Cisplatin-induced ototoxicity;	chr12:51218717	chr12:51820459~51822415:-
UCEC	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	4.71	5.72e-06	0.00772	0.42	0.36	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
UCEC	cis	rs524281	0.731	rs10896075	ENSG00000255320.1	RP11-755F10.1	-4.71	5.72e-06	0.00772	-0.53	-0.36	Electroencephalogram traits;	chr11:66024742	chr11:66244840~66246239:-
UCEC	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-4.7	5.76e-06	0.00774	-0.49	-0.36	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
UCEC	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-4.7	5.76e-06	0.00774	-0.51	-0.36	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
UCEC	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	4.7	5.78e-06	0.00776	0.39	0.36	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
UCEC	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	4.7	5.78e-06	0.00776	0.39	0.36	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
UCEC	cis	rs1667284	0.967	rs1667281	ENSG00000266521.1	RP11-650P15.1	4.7	5.78e-06	0.00777	0.42	0.36	Problematic alcohol use in trauma-exposed individuals;	chr18:31640793	chr18:31496645~31497195:-
UCEC	cis	rs1667284	1	rs1612691	ENSG00000266521.1	RP11-650P15.1	4.7	5.78e-06	0.00777	0.42	0.36	Problematic alcohol use in trauma-exposed individuals;	chr18:31640955	chr18:31496645~31497195:-
UCEC	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	4.7	5.79e-06	0.00777	0.54	0.36	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
UCEC	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-4.7	5.8e-06	0.00779	-0.45	-0.36	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
UCEC	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-4.7	5.8e-06	0.00779	-0.45	-0.36	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
UCEC	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	4.7	5.8e-06	0.00779	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
UCEC	cis	rs7246967	0.673	rs34126042	ENSG00000198153.8	ZNF849P	-4.7	5.81e-06	0.0078	-0.42	-0.36	Bronchopulmonary dysplasia;	chr19:22726416	chr19:22685167~22686732:+
UCEC	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-4.7	5.81e-06	0.0078	-0.41	-0.36	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
UCEC	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	4.7	5.83e-06	0.00782	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
UCEC	cis	rs6840360	0.642	rs2709842	ENSG00000270265.1	RP11-731D1.4	4.7	5.83e-06	0.00783	0.34	0.36	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151333775~151353224:-
UCEC	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	4.7	5.83e-06	0.00783	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
UCEC	cis	rs4713118	0.513	rs6915987	ENSG00000216901.1	AL022393.7	-4.7	5.85e-06	0.00784	-0.4	-0.36	Parkinson's disease;	chr6:27547997	chr6:28176188~28176674:+
UCEC	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-4.7	5.87e-06	0.00787	-0.7	-0.36	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
UCEC	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-4.7	5.88e-06	0.00789	-0.45	-0.36	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
UCEC	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-4.7	5.89e-06	0.00789	-0.52	-0.36	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
UCEC	cis	rs2732480	0.577	rs2732457	ENSG00000226413.2	OR8T1P	-4.7	5.9e-06	0.00791	-0.52	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48442030~48442947:-
UCEC	cis	rs10788972	0.844	rs7555099	ENSG00000225183.1	RP4-758J24.4	-4.7	5.93e-06	0.00794	-0.42	-0.36	Parkinson disease and lewy body pathology;	chr1:54096243	chr1:54089856~54090093:+
UCEC	cis	rs10788972	0.844	rs6588502	ENSG00000225183.1	RP4-758J24.4	-4.7	5.93e-06	0.00794	-0.42	-0.36	Parkinson disease and lewy body pathology;	chr1:54097483	chr1:54089856~54090093:+
UCEC	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-4.7	5.93e-06	0.00794	-0.43	-0.36	Height;	chr2:46631182	chr2:46668870~46670778:+
UCEC	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-4.7	5.94e-06	0.00795	-0.34	-0.36	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
UCEC	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-4.7	5.94e-06	0.00795	-0.34	-0.36	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
UCEC	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-4.7	5.94e-06	0.00795	-0.43	-0.36	Height;	chr2:46627225	chr2:46668870~46670778:+
UCEC	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	4.7	5.94e-06	0.00796	0.48	0.36	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
UCEC	cis	rs763121	0.719	rs138699	ENSG00000273076.1	RP3-508I15.22	4.7	5.96e-06	0.00797	0.46	0.36	Menopause (age at onset);	chr22:38733703	chr22:38743495~38743910:+
UCEC	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	4.7	5.97e-06	0.00799	0.47	0.36	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
UCEC	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	4.7	5.97e-06	0.00799	0.42	0.36	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
UCEC	cis	rs7176527	0.519	rs12148368	ENSG00000259570.1	RP11-671M22.4	-4.7	5.98e-06	0.008	-0.47	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84394512~84395514:+
UCEC	cis	rs9309473	0.583	rs6718864	ENSG00000163016.8	ALMS1P	4.7	5.99e-06	0.008	0.38	0.36	Metabolite levels;	chr2:73347463	chr2:73644919~73685576:+
UCEC	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	4.69	6.01e-06	0.00803	0.52	0.36	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
UCEC	cis	rs492146	0.729	rs426013	ENSG00000243236.5	GSTA9P	-4.69	6.01e-06	0.00803	-0.46	-0.36	Epilepsy (remission after treatment);	chr6:52975947	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.756	rs374275	ENSG00000243236.5	GSTA9P	-4.69	6.01e-06	0.00803	-0.46	-0.36	Epilepsy (remission after treatment);	chr6:52975999	chr6:52939726~52957521:-
UCEC	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	4.69	6.02e-06	0.00805	0.49	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
UCEC	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	4.69	6.03e-06	0.00805	0.47	0.36	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
UCEC	cis	rs2276314	1	rs16967317	ENSG00000267627.4	RP11-905K4.1	-4.69	6.03e-06	0.00805	-0.41	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35951803~35966118:-
UCEC	cis	rs9601248	0.508	rs9601240	ENSG00000227354.5	RBM26-AS1	4.69	6.05e-06	0.00807	0.4	0.36	Major depressive disorder;	chr13:79558238	chr13:79406309~79424328:+
UCEC	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-4.69	6.05e-06	0.00808	-0.39	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
UCEC	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	4.69	6.07e-06	0.00811	0.53	0.36	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
UCEC	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-4.69	6.08e-06	0.00811	-0.46	-0.36	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
UCEC	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-4.69	6.08e-06	0.00811	-0.43	-0.36	Height;	chr2:46630262	chr2:46668870~46670778:+
UCEC	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	4.69	6.11e-06	0.00815	0.43	0.36	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
UCEC	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-4.69	6.11e-06	0.00815	-0.46	-0.36	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
UCEC	cis	rs4938303	0.671	rs2008915	ENSG00000254851.1	RP11-109L13.1	-4.69	6.13e-06	0.00817	-0.53	-0.36	Triglycerides;	chr11:116732418	chr11:117135528~117138582:+
UCEC	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-4.69	6.14e-06	0.00818	-0.39	-0.36	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
UCEC	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-4.69	6.14e-06	0.00818	-0.39	-0.36	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
UCEC	cis	rs7267979	0.868	rs6138550	ENSG00000276952.1	RP5-965G21.6	4.69	6.15e-06	0.0082	0.46	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.903	rs6050481	ENSG00000276952.1	RP5-965G21.6	4.69	6.15e-06	0.0082	0.46	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.834	rs6115100	ENSG00000276952.1	RP5-965G21.6	4.69	6.15e-06	0.0082	0.46	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25284915~25285588:-
UCEC	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-4.69	6.16e-06	0.00821	-0.79	-0.36	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-4.69	6.16e-06	0.00821	-0.79	-0.36	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
UCEC	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-4.69	6.17e-06	0.00822	-0.44	-0.36	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
UCEC	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-4.69	6.18e-06	0.00823	-0.46	-0.36	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
UCEC	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	4.69	6.18e-06	0.00823	0.38	0.36	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
UCEC	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-4.69	6.19e-06	0.00823	-0.34	-0.36	Height;	chr11:118781100	chr11:118791254~118793137:+
UCEC	cis	rs617219	0.574	rs7732681	ENSG00000245556.2	SCAMP1-AS1	-4.69	6.19e-06	0.00824	-0.34	-0.36	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79299423	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.574	rs3930426	ENSG00000245556.2	SCAMP1-AS1	-4.69	6.19e-06	0.00824	-0.34	-0.36	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79301712	chr5:78342365~78360507:-
UCEC	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	4.69	6.2e-06	0.00825	0.39	0.36	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
UCEC	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	4.69	6.2e-06	0.00825	0.45	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
UCEC	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	4.69	6.2e-06	0.00825	0.38	0.36	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
UCEC	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-4.69	6.21e-06	0.00826	-0.5	-0.36	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-4.69	6.21e-06	0.00826	-0.5	-0.36	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
UCEC	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-4.69	6.23e-06	0.00828	-0.45	-0.36	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
UCEC	cis	rs4693167	0.504	rs6814048	ENSG00000248196.1	RP11-476C8.2	-4.68	6.27e-06	0.00832	-0.34	-0.36	Blood protein levels;	chr4:87532759	chr4:87166844~87167734:+
UCEC	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-4.68	6.27e-06	0.00832	-0.55	-0.36	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
UCEC	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	4.68	6.27e-06	0.00832	0.37	0.36	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
UCEC	cis	rs6710503	0.823	rs56139148	ENSG00000271936.1	RP11-443B20.1	-4.68	6.28e-06	0.00833	-0.43	-0.36	Lung cancer in ever smokers;Breast cancer;	chr2:24750898	chr2:24825610~24826717:+
UCEC	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-4.68	6.29e-06	0.00834	-0.38	-0.36	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
UCEC	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-4.68	6.29e-06	0.00834	-0.49	-0.36	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-4.68	6.29e-06	0.00834	-0.49	-0.36	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
UCEC	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-4.68	6.3e-06	0.00835	-0.48	-0.36	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
UCEC	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-4.68	6.3e-06	0.00835	-0.48	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
UCEC	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-4.68	6.3e-06	0.00835	-0.48	-0.36	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
UCEC	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-4.68	6.3e-06	0.00835	-0.48	-0.36	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
UCEC	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	4.68	6.3e-06	0.00835	0.48	0.36	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
UCEC	cis	rs6840360	0.667	rs4266275	ENSG00000270265.1	RP11-731D1.4	-4.68	6.32e-06	0.00838	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151333775~151353224:-
UCEC	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	4.68	6.34e-06	0.0084	0.4	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
UCEC	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-4.68	6.34e-06	0.0084	-0.35	-0.36	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
UCEC	cis	rs6840360	0.539	rs1443087	ENSG00000278978.1	RP11-164P12.5	-4.68	6.35e-06	0.00841	-0.42	-0.36	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.642	rs1443088	ENSG00000278978.1	RP11-164P12.5	-4.68	6.35e-06	0.00841	-0.42	-0.36	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151669786~151670503:+
UCEC	cis	rs7208859	0.673	rs11655623	ENSG00000264538.5	SUZ12P1	-4.68	6.36e-06	0.00842	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30709299~30790908:+
UCEC	cis	rs6137726	0.652	rs6036175	ENSG00000277901.1	RP5-851M4.1	4.68	6.39e-06	0.00842	0.47	0.36	Amyotrophic lateral sclerosis (sporadic);	chr20:22682100	chr20:23320958~23325352:-
UCEC	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	4.68	6.4e-06	0.00842	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
UCEC	cis	rs8089364	0.917	rs1942872	ENSG00000267742.1	FAM60CP	-4.68	6.4e-06	0.00843	-0.32	-0.36	Body mass index;Type 2 diabetes;	chr18:60201132	chr18:60016778~60017441:-
UCEC	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	4.68	6.42e-06	0.00845	0.49	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
UCEC	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-4.68	6.43e-06	0.00846	-0.72	-0.36	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-4.68	6.43e-06	0.00846	-0.72	-0.36	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
UCEC	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	4.68	6.43e-06	0.00846	0.42	0.36	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	4.68	6.43e-06	0.00846	0.42	0.36	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	4.68	6.43e-06	0.00846	0.42	0.36	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	4.68	6.43e-06	0.00846	0.42	0.36	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	4.68	6.43e-06	0.00846	0.42	0.36	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	4.68	6.43e-06	0.00846	0.42	0.36	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	4.68	6.43e-06	0.00846	0.42	0.36	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	4.68	6.43e-06	0.00846	0.42	0.36	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
UCEC	cis	rs6124878	1	rs6124878	ENSG00000255438.2	CTD-2653D5.1	4.68	6.44e-06	0.00847	0.8	0.36	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr20:46869084	chr20:47677901~47686297:+
UCEC	cis	rs1667284	1	rs1667284	ENSG00000266521.1	RP11-650P15.1	-4.68	6.47e-06	0.0085	-0.41	-0.36	Problematic alcohol use in trauma-exposed individuals;	chr18:31646245	chr18:31496645~31497195:-
UCEC	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	4.68	6.49e-06	0.00852	0.45	0.36	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
UCEC	cis	rs6840360	0.642	rs2709828	ENSG00000270265.1	RP11-731D1.4	-4.68	6.5e-06	0.00853	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2724551	ENSG00000270265.1	RP11-731D1.4	-4.68	6.5e-06	0.00853	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.667	rs2709829	ENSG00000270265.1	RP11-731D1.4	-4.68	6.5e-06	0.00853	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151333775~151353224:-
UCEC	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-4.68	6.5e-06	0.00854	-0.43	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
UCEC	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-4.68	6.52e-06	0.00855	-0.42	-0.36	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-4.68	6.52e-06	0.00855	-0.42	-0.36	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
UCEC	cis	rs9545047	0.604	rs1616547	ENSG00000227354.5	RBM26-AS1	4.68	6.52e-06	0.00855	0.35	0.36	Schizophrenia;	chr13:79411901	chr13:79406309~79424328:+
UCEC	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-4.68	6.52e-06	0.00855	-0.37	-0.36	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
UCEC	cis	rs6840360	0.606	rs2709814	ENSG00000270265.1	RP11-731D1.4	-4.68	6.53e-06	0.00856	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151333775~151353224:-
UCEC	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	4.68	6.53e-06	0.00857	0.46	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
UCEC	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-4.67	6.54e-06	0.00858	-0.4	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
UCEC	cis	rs922692	1	rs922692	ENSG00000261143.1	ADAMTS7P3	4.67	6.55e-06	0.00859	0.5	0.36	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78691872	chr15:77976042~77993057:+
UCEC	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-4.67	6.57e-06	0.00861	-0.35	-0.36	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
UCEC	cis	rs507080	0.922	rs12788848	ENSG00000278376.1	RP11-158I9.8	-4.67	6.62e-06	0.00866	-0.35	-0.36	Serum metabolite levels;	chr11:118683079	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.922	rs4474473	ENSG00000278376.1	RP11-158I9.8	-4.67	6.62e-06	0.00866	-0.35	-0.36	Serum metabolite levels;	chr11:118683180	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.922	rs12796373	ENSG00000278376.1	RP11-158I9.8	-4.67	6.62e-06	0.00866	-0.35	-0.36	Serum metabolite levels;	chr11:118684230	chr11:118791254~118793137:+
UCEC	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-4.67	6.63e-06	0.00868	-0.62	-0.36	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
UCEC	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-4.67	6.64e-06	0.00869	-0.4	-0.36	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
UCEC	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-4.67	6.65e-06	0.0087	-0.39	-0.36	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
UCEC	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	4.67	6.67e-06	0.00872	0.43	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
UCEC	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	4.67	6.68e-06	0.00873	0.37	0.36	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
UCEC	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	4.67	6.68e-06	0.00873	0.37	0.36	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
UCEC	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	4.67	6.68e-06	0.00873	0.37	0.36	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
UCEC	cis	rs4273100	1	rs4924986	ENSG00000228157.4	AC007952.5	-4.67	6.68e-06	0.00873	-0.54	-0.36	Schizophrenia;	chr17:19339154	chr17:19092974~19096837:+
UCEC	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-4.67	6.69e-06	0.00874	-0.37	-0.36	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-4.67	6.69e-06	0.00874	-0.37	-0.36	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
UCEC	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-4.67	6.7e-06	0.00875	-0.56	-0.36	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
UCEC	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-4.67	6.71e-06	0.00876	-0.46	-0.36	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
UCEC	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-4.67	6.71e-06	0.00876	-0.46	-0.36	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
UCEC	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-4.67	6.71e-06	0.00876	-0.46	-0.36	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
UCEC	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-4.67	6.71e-06	0.00876	-0.46	-0.36	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
UCEC	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-4.67	6.73e-06	0.00878	-0.37	-0.36	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
UCEC	cis	rs8141529	0.748	rs132533	ENSG00000272858.1	CTA-292E10.8	4.67	6.74e-06	0.0088	0.48	0.36	Lymphocyte counts;	chr22:28903583	chr22:28814914~28815662:+
UCEC	cis	rs6840360	0.642	rs7684462	ENSG00000270265.1	RP11-731D1.4	-4.67	6.75e-06	0.00881	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151333775~151353224:-
UCEC	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-4.67	6.78e-06	0.00884	-0.41	-0.36	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
UCEC	cis	rs240993	0.909	rs11153279	ENSG00000271789.1	RP5-1112D6.7	4.67	6.79e-06	0.00885	0.41	0.36	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111297126~111298510:+
UCEC	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	4.67	6.79e-06	0.00885	0.41	0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
UCEC	cis	rs12478296	0.892	rs60042638	ENSG00000261186.2	RP11-341N2.1	-4.66	6.81e-06	0.00888	-0.49	-0.36	Obesity-related traits;	chr2:242096556	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs6739247	ENSG00000261186.2	RP11-341N2.1	-4.66	6.81e-06	0.00888	-0.49	-0.36	Obesity-related traits;	chr2:242097038	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs12474070	ENSG00000261186.2	RP11-341N2.1	-4.66	6.81e-06	0.00888	-0.49	-0.36	Obesity-related traits;	chr2:242097587	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs56102931	ENSG00000261186.2	RP11-341N2.1	-4.66	6.81e-06	0.00888	-0.49	-0.36	Obesity-related traits;	chr2:242097785	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs55732177	ENSG00000261186.2	RP11-341N2.1	-4.66	6.81e-06	0.00888	-0.49	-0.36	Obesity-related traits;	chr2:242097855	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs55758933	ENSG00000261186.2	RP11-341N2.1	-4.66	6.81e-06	0.00888	-0.49	-0.36	Obesity-related traits;	chr2:242098138	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs55717005	ENSG00000261186.2	RP11-341N2.1	-4.66	6.81e-06	0.00888	-0.49	-0.36	Obesity-related traits;	chr2:242098920	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs55814222	ENSG00000261186.2	RP11-341N2.1	-4.66	6.81e-06	0.00888	-0.49	-0.36	Obesity-related traits;	chr2:242099015	chr2:242087351~242088457:-
UCEC	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	4.66	6.81e-06	0.00888	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
UCEC	cis	rs4713118	0.869	rs9468214	ENSG00000216901.1	AL022393.7	4.66	6.83e-06	0.00889	0.41	0.36	Parkinson's disease;	chr6:27745520	chr6:28176188~28176674:+
UCEC	cis	rs763121	0.813	rs2179143	ENSG00000273076.1	RP3-508I15.22	4.66	6.83e-06	0.00889	0.37	0.36	Menopause (age at onset);	chr22:38641979	chr22:38743495~38743910:+
UCEC	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	4.66	6.84e-06	0.00891	0.51	0.36	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
UCEC	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	4.66	6.85e-06	0.00891	0.42	0.36	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	4.66	6.85e-06	0.00891	0.42	0.36	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	4.66	6.85e-06	0.00891	0.42	0.36	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	4.66	6.85e-06	0.00891	0.42	0.36	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	4.66	6.85e-06	0.00891	0.42	0.36	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
UCEC	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-4.66	6.86e-06	0.00892	-0.43	-0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
UCEC	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-4.66	6.88e-06	0.00895	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
UCEC	cis	rs9532669	0.963	rs9532662	ENSG00000239827.7	SUGT1P3	-4.66	6.89e-06	0.00896	-0.33	-0.36	Cervical cancer;	chr13:40926215	chr13:40908159~40921774:-
UCEC	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	4.66	6.9e-06	0.00897	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
UCEC	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	4.66	6.9e-06	0.00897	0.52	0.36	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
UCEC	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	4.66	6.91e-06	0.00899	0.42	0.36	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
UCEC	cis	rs2276314	1	rs4799832	ENSG00000267627.4	RP11-905K4.1	-4.66	6.91e-06	0.00899	-0.4	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35951803~35966118:-
UCEC	cis	rs2276314	1	rs8086395	ENSG00000267627.4	RP11-905K4.1	-4.66	6.91e-06	0.00899	-0.4	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.947	rs3898595	ENSG00000267627.4	RP11-905K4.1	-4.66	6.91e-06	0.00899	-0.4	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35951803~35966118:-
UCEC	cis	rs2276314	1	rs4799834	ENSG00000267627.4	RP11-905K4.1	-4.66	6.91e-06	0.00899	-0.4	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35951803~35966118:-
UCEC	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-4.66	6.92e-06	0.009	-0.56	-0.36	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-4.66	6.92e-06	0.009	-0.56	-0.36	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
UCEC	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-4.66	6.94e-06	0.00902	-0.44	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
UCEC	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	4.66	6.96e-06	0.00904	0.4	0.36	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
UCEC	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	4.66	6.96e-06	0.00904	0.38	0.36	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
UCEC	cis	rs5760092	0.572	rs738806	ENSG00000272787.1	KB-226F1.2	-4.66	6.96e-06	0.00904	-0.49	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23969211~23969873:+
UCEC	cis	rs12681963	0.748	rs6468070	ENSG00000271869.1	RP11-51J9.5	4.66	6.96e-06	0.00904	0.35	0.36	Migraine;	chr8:30039082	chr8:30155830~30156232:-
UCEC	cis	rs2276314	0.857	rs8097597	ENSG00000267627.4	RP11-905K4.1	-4.66	6.98e-06	0.00906	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35951803~35966118:-
UCEC	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-4.66	6.99e-06	0.00907	-0.45	-0.36	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
UCEC	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-4.66	6.99e-06	0.00907	-0.45	-0.36	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
UCEC	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-4.66	6.99e-06	0.00907	-0.45	-0.36	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
UCEC	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-4.66	7.01e-06	0.00909	-0.47	-0.36	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
UCEC	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-4.66	7.04e-06	0.00912	-0.4	-0.36	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
UCEC	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	4.66	7.04e-06	0.00913	0.38	0.36	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
UCEC	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-4.66	7.06e-06	0.00915	-0.39	-0.36	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
UCEC	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-4.66	7.07e-06	0.00916	-0.73	-0.36	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
UCEC	cis	rs4693167	0.504	rs1031796	ENSG00000248196.1	RP11-476C8.2	-4.66	7.08e-06	0.00916	-0.35	-0.36	Blood protein levels;	chr4:87530427	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs10028069	ENSG00000248196.1	RP11-476C8.2	-4.66	7.08e-06	0.00916	-0.35	-0.36	Blood protein levels;	chr4:87535386	chr4:87166844~87167734:+
UCEC	cis	rs6840360	0.642	rs6843639	ENSG00000270265.1	RP11-731D1.4	-4.66	7.09e-06	0.00916	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs28666858	ENSG00000270265.1	RP11-731D1.4	-4.66	7.09e-06	0.00916	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs10857260	ENSG00000270265.1	RP11-731D1.4	-4.66	7.09e-06	0.00916	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151333775~151353224:-
UCEC	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-4.66	7.09e-06	0.00916	-0.41	-0.36	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
UCEC	cis	rs507080	0.922	rs519848	ENSG00000278376.1	RP11-158I9.8	-4.66	7.09e-06	0.00916	-0.35	-0.36	Serum metabolite levels;	chr11:118682006	chr11:118791254~118793137:+
UCEC	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	4.66	7.09e-06	0.00917	0.62	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
UCEC	cis	rs9309473	0.607	rs6720094	ENSG00000163016.8	ALMS1P	4.66	7.1e-06	0.00918	0.37	0.36	Metabolite levels;	chr2:73360948	chr2:73644919~73685576:+
UCEC	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-4.65	7.11e-06	0.00919	-0.38	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-4.65	7.11e-06	0.00919	-0.38	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	4.65	7.14e-06	0.00921	0.37	0.36	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
UCEC	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	4.65	7.17e-06	0.00924	0.47	0.36	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
UCEC	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	4.65	7.17e-06	0.00925	0.42	0.36	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
UCEC	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-4.65	7.18e-06	0.00926	-0.39	-0.36	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	4.65	7.18e-06	0.00926	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	4.65	7.18e-06	0.00926	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	4.65	7.18e-06	0.00926	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
UCEC	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-4.65	7.19e-06	0.00927	-0.44	-0.36	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
UCEC	cis	rs2732480	0.577	rs2732448	ENSG00000226413.2	OR8T1P	4.65	7.21e-06	0.00929	0.51	0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.577	rs2732466	ENSG00000226413.2	OR8T1P	4.65	7.21e-06	0.00929	0.51	0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.557	rs2634682	ENSG00000226413.2	OR8T1P	4.65	7.21e-06	0.00929	0.51	0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.577	rs2634680	ENSG00000226413.2	OR8T1P	4.65	7.21e-06	0.00929	0.51	0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.577	rs2634678	ENSG00000226413.2	OR8T1P	4.65	7.21e-06	0.00929	0.51	0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.577	rs2732479	ENSG00000226413.2	OR8T1P	4.65	7.21e-06	0.00929	0.51	0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.537	rs1061986	ENSG00000226413.2	OR8T1P	4.65	7.21e-06	0.00929	0.51	0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48442030~48442947:-
UCEC	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	4.65	7.21e-06	0.00929	0.97	0.36	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
UCEC	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-4.65	7.24e-06	0.00932	-0.42	-0.36	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-4.65	7.24e-06	0.00932	-0.42	-0.36	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-4.65	7.24e-06	0.00932	-0.42	-0.36	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-4.65	7.24e-06	0.00932	-0.42	-0.36	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-4.65	7.24e-06	0.00932	-0.42	-0.36	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
UCEC	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	4.65	7.26e-06	0.00935	0.4	0.36	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
UCEC	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	4.65	7.28e-06	0.00936	0.59	0.36	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	4.65	7.28e-06	0.00936	0.59	0.36	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	4.65	7.28e-06	0.00936	0.59	0.36	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	4.65	7.28e-06	0.00936	0.59	0.36	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	4.65	7.28e-06	0.00936	0.59	0.36	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	4.65	7.28e-06	0.00936	0.59	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	4.65	7.28e-06	0.00936	0.59	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
UCEC	cis	rs7674212	0.57	rs6841136	ENSG00000246560.2	RP11-10L12.4	4.65	7.3e-06	0.00938	0.41	0.36	Type 2 diabetes;	chr4:103182352	chr4:102828055~102844075:+
UCEC	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	4.65	7.31e-06	0.00938	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	4.65	7.31e-06	0.00938	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	4.65	7.31e-06	0.00938	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	4.65	7.31e-06	0.00938	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	4.65	7.31e-06	0.00938	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	4.65	7.31e-06	0.00938	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	4.65	7.31e-06	0.00938	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	4.65	7.31e-06	0.00938	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	4.65	7.31e-06	0.00938	0.39	0.36	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
UCEC	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	4.65	7.32e-06	0.0094	0.6	0.36	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
UCEC	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-4.65	7.33e-06	0.0094	-0.48	-0.36	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
UCEC	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-4.65	7.34e-06	0.00941	-0.73	-0.36	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-4.65	7.34e-06	0.00941	-0.73	-0.36	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-4.65	7.34e-06	0.00941	-0.73	-0.36	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-4.65	7.34e-06	0.00941	-0.73	-0.36	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
UCEC	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	4.65	7.34e-06	0.00941	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
UCEC	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-4.65	7.34e-06	0.00941	-0.43	-0.36	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
UCEC	cis	rs7267979	0.932	rs417130	ENSG00000276952.1	RP5-965G21.6	4.65	7.36e-06	0.00943	0.46	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs6037125	ENSG00000276952.1	RP5-965G21.6	4.65	7.36e-06	0.00943	0.46	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs372678	ENSG00000276952.1	RP5-965G21.6	4.65	7.36e-06	0.00943	0.46	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25284915~25285588:-
UCEC	cis	rs4713118	0.615	rs9295747	ENSG00000216901.1	AL022393.7	-4.65	7.4e-06	0.00947	-0.4	-0.36	Parkinson's disease;	chr6:27769214	chr6:28176188~28176674:+
UCEC	cis	rs6840360	0.642	rs1596290	ENSG00000270265.1	RP11-731D1.4	-4.64	7.42e-06	0.00949	-0.34	-0.36	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151333775~151353224:-
UCEC	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-4.64	7.42e-06	0.0095	-0.42	-0.36	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
UCEC	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	4.64	7.43e-06	0.0095	0.45	0.36	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	4.64	7.44e-06	0.00951	0.45	0.36	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
UCEC	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	4.64	7.44e-06	0.00952	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
UCEC	cis	rs492146	0.765	rs367836	ENSG00000243236.5	GSTA9P	-4.64	7.44e-06	0.00952	-0.45	-0.36	Epilepsy (remission after treatment);	chr6:52978333	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.765	rs670960	ENSG00000243236.5	GSTA9P	-4.64	7.44e-06	0.00952	-0.45	-0.36	Epilepsy (remission after treatment);	chr6:52978998	chr6:52939726~52957521:-
UCEC	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	4.64	7.46e-06	0.00953	0.45	0.36	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
UCEC	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-4.64	7.47e-06	0.00954	-0.4	-0.36	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-4.64	7.47e-06	0.00954	-0.4	-0.36	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-4.64	7.47e-06	0.00954	-0.4	-0.36	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-4.64	7.47e-06	0.00954	-0.4	-0.36	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-4.64	7.47e-06	0.00954	-0.4	-0.36	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-4.64	7.47e-06	0.00954	-0.4	-0.36	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
UCEC	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-4.64	7.47e-06	0.00955	-0.42	-0.36	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
UCEC	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-4.64	7.47e-06	0.00955	-0.45	-0.36	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
UCEC	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	4.64	7.47e-06	0.00955	0.37	0.36	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
UCEC	cis	rs4713118	0.911	rs9461406	ENSG00000216901.1	AL022393.7	-4.64	7.5e-06	0.00958	-0.43	-0.36	Parkinson's disease;	chr6:27751985	chr6:28176188~28176674:+
UCEC	cis	rs8141529	0.748	rs2064261	ENSG00000272858.1	CTA-292E10.8	-4.64	7.5e-06	0.00958	-0.47	-0.36	Lymphocyte counts;	chr22:28891742	chr22:28814914~28815662:+
UCEC	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-4.64	7.51e-06	0.00959	-0.42	-0.36	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
UCEC	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-4.64	7.52e-06	0.0096	-0.4	-0.36	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-4.64	7.52e-06	0.0096	-0.4	-0.36	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
UCEC	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	4.64	7.52e-06	0.00961	0.43	0.36	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
UCEC	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-4.64	7.54e-06	0.00963	-0.34	-0.36	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
UCEC	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-4.64	7.54e-06	0.00963	-0.34	-0.36	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
UCEC	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	4.64	7.55e-06	0.00963	0.39	0.36	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
UCEC	cis	rs6137726	0.652	rs2209796	ENSG00000277901.1	RP5-851M4.1	-4.64	7.59e-06	0.00968	-0.48	-0.36	Amyotrophic lateral sclerosis (sporadic);	chr20:22678812	chr20:23320958~23325352:-
UCEC	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	4.64	7.6e-06	0.00969	0.44	0.36	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
UCEC	cis	rs492146	0.765	rs672281	ENSG00000243236.5	GSTA9P	-4.64	7.6e-06	0.00969	-0.46	-0.36	Epilepsy (remission after treatment);	chr6:52979247	chr6:52939726~52957521:-
UCEC	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	4.64	7.61e-06	0.0097	0.44	0.36	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
UCEC	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	4.64	7.62e-06	0.00972	0.43	0.36	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
UCEC	cis	rs62025270	0.688	rs56388190	ENSG00000202081.1	RNU6-1280P	-4.64	7.62e-06	0.00972	-0.44	-0.36	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85651522~85651628:-
UCEC	cis	rs9376098	0.698	rs2050020	ENSG00000232876.1	CTA-212D2.2	-4.64	7.66e-06	0.00974	-0.43	-0.36	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135142915	chr6:135055033~135060550:+
UCEC	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	4.64	7.66e-06	0.00974	0.62	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
UCEC	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	4.64	7.71e-06	0.0098	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
UCEC	cis	rs507080	0.922	rs4938524	ENSG00000278376.1	RP11-158I9.8	-4.64	7.71e-06	0.0098	-0.34	-0.36	Serum metabolite levels;	chr11:118681365	chr11:118791254~118793137:+
UCEC	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	4.64	7.72e-06	0.0098	0.52	0.36	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	4.64	7.72e-06	0.0098	0.52	0.36	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
UCEC	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-4.64	7.72e-06	0.00981	-0.38	-0.36	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
UCEC	cis	rs617219	0.613	rs6453436	ENSG00000245556.2	SCAMP1-AS1	-4.63	7.74e-06	0.00983	-0.35	-0.35	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79330641	chr5:78342365~78360507:-
UCEC	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-4.63	7.75e-06	0.00983	-0.41	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-4.63	7.75e-06	0.00983	-0.41	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-4.63	7.75e-06	0.00983	-0.41	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
UCEC	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	4.63	7.75e-06	0.00983	0.38	0.35	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
UCEC	cis	rs6840360	0.642	rs2709822	ENSG00000270265.1	RP11-731D1.4	-4.63	7.77e-06	0.00986	-0.34	-0.35	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151333775~151353224:-
UCEC	cis	rs1667284	0.935	rs1791171	ENSG00000266521.1	RP11-650P15.1	4.63	7.79e-06	0.00987	0.41	0.35	Problematic alcohol use in trauma-exposed individuals;	chr18:31636194	chr18:31496645~31497195:-
UCEC	cis	rs1667284	0.967	rs1791221	ENSG00000266521.1	RP11-650P15.1	4.63	7.79e-06	0.00988	0.41	0.35	Problematic alcohol use in trauma-exposed individuals;	chr18:31639928	chr18:31496645~31497195:-
UCEC	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	4.63	7.8e-06	0.00989	0.39	0.35	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	4.63	7.8e-06	0.00989	0.39	0.35	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
UCEC	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	4.63	7.82e-06	0.0099	0.45	0.35	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-4.63	7.83e-06	0.00991	-0.55	-0.35	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-4.63	7.83e-06	0.00991	-0.55	-0.35	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-4.63	7.83e-06	0.00991	-0.55	-0.35	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-4.63	7.83e-06	0.00991	-0.55	-0.35	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
UCEC	cis	rs6840360	0.642	rs4235219	ENSG00000270265.1	RP11-731D1.4	-4.63	7.83e-06	0.00991	-0.34	-0.35	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs6851814	ENSG00000270265.1	RP11-731D1.4	-4.63	7.83e-06	0.00991	-0.34	-0.35	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.606	rs10028035	ENSG00000270265.1	RP11-731D1.4	-4.63	7.83e-06	0.00991	-0.34	-0.35	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151333775~151353224:-
UCEC	cis	rs6901004	0.803	rs4947107	ENSG00000271789.1	RP5-1112D6.7	-4.63	7.84e-06	0.00991	-0.44	-0.35	Blood metabolite levels;	chr6:111121302	chr6:111297126~111298510:+
UCEC	cis	rs948562	0.744	rs60998298	ENSG00000280010.1	AP001350.4	4.63	7.85e-06	0.00993	0.73	0.35	Lymphoma;	chr11:58534382	chr11:58627435~58628528:+
UCEC	cis	rs11848070	1	rs11848070	ENSG00000258951.1	KRT18P7	-4.63	7.86e-06	0.00994	-0.59	-0.35	Alzheimer's disease (late onset);	chr14:71040884	chr14:70594552~70595770:+
UCEC	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	4.63	7.86e-06	0.00994	0.38	0.35	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
UCEC	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	4.63	7.87e-06	0.00995	0.4	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
UCEC	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	4.63	7.87e-06	0.00995	0.4	0.35	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-4.63	7.88e-06	0.00996	-0.48	-0.35	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-4.63	7.88e-06	0.00996	-0.48	-0.35	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
UCEC	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-4.63	7.88e-06	0.00996	-0.48	-0.35	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
UCEC	cis	rs4713118	0.869	rs10214440	ENSG00000216901.1	AL022393.7	4.63	7.88e-06	0.00996	0.41	0.35	Parkinson's disease;	chr6:27734661	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs6902689	ENSG00000216901.1	AL022393.7	4.63	7.88e-06	0.00996	0.41	0.35	Parkinson's disease;	chr6:27741662	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs9283883	ENSG00000216901.1	AL022393.7	4.63	7.88e-06	0.00996	0.41	0.35	Parkinson's disease;	chr6:27747691	chr6:28176188~28176674:+
UCEC	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	4.63	7.89e-06	0.00997	0.38	0.35	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
UCEC	cis	rs4713118	0.523	rs2179096	ENSG00000216901.1	AL022393.7	4.63	7.9e-06	0.00998	0.4	0.35	Parkinson's disease;	chr6:27698141	chr6:28176188~28176674:+
UCEC	cis	rs9309473	0.687	rs6706409	ENSG00000163016.8	ALMS1P	-4.63	7.9e-06	0.00998	-0.37	-0.35	Metabolite levels;	chr2:73379380	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.579	rs1852644	ENSG00000163016.8	ALMS1P	4.63	7.9e-06	0.00998	0.37	0.35	Metabolite levels;	chr2:73370590	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.687	rs6546827	ENSG00000163016.8	ALMS1P	4.63	7.9e-06	0.00998	0.37	0.35	Metabolite levels;	chr2:73379365	chr2:73644919~73685576:+
UCEC	cis	rs11886999	0.951	rs11551400	ENSG00000231584.7	FAHD2CP	-4.63	7.9e-06	0.00999	-0.45	-0.35	Cardiac Troponin-T levels;	chr2:96248898	chr2:96010551~96023380:+
UCEC	cis	rs2991971	0.729	rs10890328	ENSG00000280836.1	AL355480.1	-4.63	7.91e-06	0.00999	-0.4	-0.35	High light scatter reticulocyte count;	chr1:45439711	chr1:45581219~45581321:-
UCEC	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	4.63	7.91e-06	0.01	0.39	0.35	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
UCEC	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	4.63	7.92e-06	0.01	0.4	0.35	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
UCEC	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-4.63	7.93e-06	0.01	-0.44	-0.35	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
UCEC	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-4.63	7.93e-06	0.01	-0.35	-0.35	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
UCEC	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	4.63	7.93e-06	0.01	0.42	0.35	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	4.63	7.93e-06	0.01	0.42	0.35	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	4.63	7.93e-06	0.01	0.42	0.35	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	4.63	7.93e-06	0.01	0.42	0.35	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	4.63	7.93e-06	0.01	0.42	0.35	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	4.63	7.93e-06	0.01	0.42	0.35	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	4.63	7.93e-06	0.01	0.42	0.35	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
UCEC	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	4.63	7.95e-06	0.01	0.55	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
UCEC	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-4.63	7.95e-06	0.01	-0.39	-0.35	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
UCEC	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	4.63	7.95e-06	0.01	0.35	0.35	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
UCEC	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-4.63	7.96e-06	0.01	-0.44	-0.35	Depression;	chr6:28070115	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-4.63	7.96e-06	0.01	-0.44	-0.35	Depression;	chr6:28071237	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-4.63	7.96e-06	0.01	-0.44	-0.35	Depression;	chr6:28071808	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-4.63	7.96e-06	0.01	-0.44	-0.35	Depression;	chr6:28074687	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-4.63	7.96e-06	0.01	-0.44	-0.35	Depression;	chr6:28076559	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-4.63	7.96e-06	0.01	-0.44	-0.35	Depression;	chr6:28076704	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-4.63	7.96e-06	0.01	-0.44	-0.35	Depression;	chr6:28078391	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-4.63	7.96e-06	0.01	-0.44	-0.35	Depression;	chr6:28080757	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-4.63	7.96e-06	0.01	-0.44	-0.35	Depression;	chr6:28080760	chr6:28115628~28116551:+
UCEC	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-4.63	7.99e-06	0.0101	-0.44	-0.35	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-4.63	7.99e-06	0.0101	-0.44	-0.35	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
UCEC	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	4.63	8.03e-06	0.0101	0.39	0.35	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
UCEC	cis	rs763121	0.853	rs5750677	ENSG00000273076.1	RP3-508I15.22	4.63	8.03e-06	0.0101	0.47	0.35	Menopause (age at onset);	chr22:38751710	chr22:38743495~38743910:+
UCEC	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-4.63	8.04e-06	0.0101	-0.41	-0.35	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
UCEC	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-4.63	8.04e-06	0.0101	-0.56	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
UCEC	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	4.63	8.05e-06	0.0101	0.43	0.35	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	4.63	8.05e-06	0.0101	0.43	0.35	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	4.63	8.05e-06	0.0101	0.43	0.35	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	4.63	8.05e-06	0.0101	0.43	0.35	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
UCEC	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	4.63	8.06e-06	0.0101	0.46	0.35	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
UCEC	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	4.62	8.07e-06	0.0101	0.39	0.35	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	4.62	8.07e-06	0.0101	0.39	0.35	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	4.62	8.07e-06	0.0101	0.39	0.35	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
UCEC	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	4.62	8.07e-06	0.0101	0.39	0.35	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
UCEC	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	4.62	8.07e-06	0.0101	0.39	0.35	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
UCEC	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-4.62	8.13e-06	0.0102	-0.39	-0.35	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
UCEC	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	4.62	8.14e-06	0.0102	0.37	0.35	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
UCEC	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-4.62	8.15e-06	0.0102	-0.44	-0.35	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
UCEC	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	4.62	8.16e-06	0.0102	0.54	0.35	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
UCEC	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	4.62	8.16e-06	0.0103	0.45	0.35	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
UCEC	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	4.62	8.18e-06	0.0103	0.45	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
UCEC	cis	rs948562	0.519	rs4127347	ENSG00000280010.1	AP001350.4	4.62	8.18e-06	0.0103	0.63	0.35	Lymphoma;	chr11:58282283	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.573	rs77894570	ENSG00000280010.1	AP001350.4	4.62	8.18e-06	0.0103	0.63	0.35	Lymphoma;	chr11:58283639	chr11:58627435~58628528:+
UCEC	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	4.62	8.18e-06	0.0103	0.45	0.35	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
UCEC	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-4.62	8.19e-06	0.0103	-0.48	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
UCEC	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-4.62	8.19e-06	0.0103	-0.44	-0.35	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
UCEC	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	4.62	8.21e-06	0.0103	0.45	0.35	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
UCEC	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-4.62	8.21e-06	0.0103	-0.39	-0.35	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
UCEC	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	4.62	8.22e-06	0.0103	0.44	0.35	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
UCEC	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	4.62	8.22e-06	0.0103	0.34	0.35	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
UCEC	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	4.62	8.24e-06	0.0103	0.51	0.35	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
UCEC	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-4.62	8.25e-06	0.0103	-0.38	-0.35	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
UCEC	cis	rs948562	0.573	rs17471365	ENSG00000280010.1	AP001350.4	-4.62	8.26e-06	0.0104	-0.66	-0.35	Lymphoma;	chr11:58275959	chr11:58627435~58628528:+
UCEC	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-4.62	8.26e-06	0.0104	-0.36	-0.35	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
UCEC	cis	rs36032232	1	rs35673098	ENSG00000240163.1	RP11-745A24.1	4.62	8.27e-06	0.0104	0.67	0.35	Blood protein levels;	chr15:60452459	chr15:60390371~60390682:+
UCEC	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	4.62	8.29e-06	0.0104	0.38	0.35	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
UCEC	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	4.62	8.29e-06	0.0104	0.38	0.35	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
UCEC	cis	rs4713118	0.591	rs2056924	ENSG00000216901.1	AL022393.7	4.62	8.3e-06	0.0104	0.4	0.35	Parkinson's disease;	chr6:27722395	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-4.62	8.31e-06	0.0104	-0.55	-0.35	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
UCEC	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	4.62	8.34e-06	0.0104	0.45	0.35	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
UCEC	cis	rs7208859	0.673	rs11656462	ENSG00000264538.5	SUZ12P1	-4.62	8.34e-06	0.0104	-0.49	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30709299~30790908:+
UCEC	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	4.62	8.34e-06	0.0104	0.42	0.35	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	4.62	8.34e-06	0.0104	0.42	0.35	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	4.62	8.34e-06	0.0104	0.42	0.35	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	4.62	8.34e-06	0.0104	0.42	0.35	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-4.62	8.34e-06	0.0104	-0.42	-0.35	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	4.62	8.34e-06	0.0104	0.42	0.35	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
UCEC	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-4.62	8.37e-06	0.0105	-0.4	-0.35	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
UCEC	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-4.62	8.38e-06	0.0105	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
UCEC	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	4.62	8.39e-06	0.0105	0.46	0.35	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	4.62	8.4e-06	0.0105	0.45	0.35	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
UCEC	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-4.62	8.4e-06	0.0105	-0.48	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
UCEC	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-4.62	8.4e-06	0.0105	-0.48	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
UCEC	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-4.62	8.4e-06	0.0105	-0.41	-0.35	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-4.62	8.4e-06	0.0105	-0.41	-0.35	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
UCEC	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-4.62	8.41e-06	0.0105	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-4.62	8.41e-06	0.0105	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-4.62	8.41e-06	0.0105	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
UCEC	cis	rs4789693	1	rs4789693	ENSG00000265458.1	RP13-20L14.6	4.61	8.42e-06	0.0105	0.39	0.35	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82454273~82458521:-
UCEC	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	4.61	8.47e-06	0.0106	0.42	0.35	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
UCEC	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	4.61	8.47e-06	0.0106	0.39	0.35	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
UCEC	cis	rs7914558	0.646	rs7897654	ENSG00000272912.1	RP11-724N1.1	-4.61	8.48e-06	0.0106	-0.37	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902701	chr10:102914585~102915404:+
UCEC	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-4.61	8.49e-06	0.0106	-0.39	-0.35	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
UCEC	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-4.61	8.49e-06	0.0106	-0.39	-0.35	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
UCEC	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	4.61	8.5e-06	0.0106	0.45	0.35	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	4.61	8.5e-06	0.0106	0.45	0.35	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
UCEC	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	4.61	8.51e-06	0.0106	0.46	0.35	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
UCEC	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-4.61	8.51e-06	0.0106	-0.43	-0.35	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-4.61	8.51e-06	0.0106	-0.43	-0.35	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
UCEC	cis	rs6840360	0.642	rs2709819	ENSG00000270265.1	RP11-731D1.4	-4.61	8.53e-06	0.0106	-0.34	-0.35	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151333775~151353224:-
UCEC	cis	rs2276314	0.857	rs28651028	ENSG00000267627.4	RP11-905K4.1	-4.61	8.54e-06	0.0106	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35951803~35966118:-
UCEC	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	4.61	8.55e-06	0.0106	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
UCEC	cis	rs950169	0.84	rs35522895	ENSG00000225151.9	GOLGA2P7	-4.61	8.57e-06	0.0107	-0.51	-0.35	Schizophrenia;	chr15:84259297	chr15:84199311~84230136:-
UCEC	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	4.61	8.59e-06	0.0107	0.39	0.35	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	4.61	8.59e-06	0.0107	0.39	0.35	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
UCEC	cis	rs7674212	0.541	rs4699051	ENSG00000246560.2	RP11-10L12.4	4.61	8.6e-06	0.0107	0.4	0.35	Type 2 diabetes;	chr4:103193237	chr4:102828055~102844075:+
UCEC	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-4.61	8.6e-06	0.0107	-0.43	-0.35	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-4.61	8.6e-06	0.0107	-0.43	-0.35	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
UCEC	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	4.61	8.62e-06	0.0107	0.47	0.35	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
UCEC	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	4.61	8.62e-06	0.0107	0.45	0.35	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	4.61	8.62e-06	0.0107	0.45	0.35	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	4.61	8.62e-06	0.0107	0.45	0.35	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
UCEC	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	4.61	8.63e-06	0.0107	0.41	0.35	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	4.61	8.63e-06	0.0107	0.41	0.35	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
UCEC	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	4.61	8.64e-06	0.0107	0.37	0.35	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
UCEC	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-4.61	8.65e-06	0.0108	-0.44	-0.35	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
UCEC	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	4.61	8.66e-06	0.0108	0.47	0.35	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
UCEC	cis	rs4693167	0.504	rs1031794	ENSG00000248196.1	RP11-476C8.2	-4.61	8.67e-06	0.0108	-0.34	-0.35	Blood protein levels;	chr4:87530030	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs12501773	ENSG00000248196.1	RP11-476C8.2	-4.61	8.67e-06	0.0108	-0.34	-0.35	Blood protein levels;	chr4:87532479	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs6814277	ENSG00000248196.1	RP11-476C8.2	-4.61	8.67e-06	0.0108	-0.34	-0.35	Blood protein levels;	chr4:87532883	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs6839829	ENSG00000248196.1	RP11-476C8.2	-4.61	8.67e-06	0.0108	-0.34	-0.35	Blood protein levels;	chr4:87532896	chr4:87166844~87167734:+
UCEC	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-4.61	8.67e-06	0.0108	-0.37	-0.35	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
UCEC	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-4.61	8.68e-06	0.0108	-0.6	-0.35	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
UCEC	cis	rs8089364	0.917	rs12954782	ENSG00000267742.1	FAM60CP	-4.61	8.71e-06	0.0108	-0.32	-0.35	Body mass index;Type 2 diabetes;	chr18:60196859	chr18:60016778~60017441:-
UCEC	cis	rs2276314	0.857	rs9304155	ENSG00000267627.4	RP11-905K4.1	-4.61	8.71e-06	0.0108	-0.4	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.857	rs59649576	ENSG00000267627.4	RP11-905K4.1	-4.61	8.71e-06	0.0108	-0.4	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35951803~35966118:-
UCEC	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-4.61	8.72e-06	0.0108	-0.43	-0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
UCEC	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	4.61	8.73e-06	0.0108	0.37	0.35	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
UCEC	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	4.61	8.76e-06	0.0109	0.52	0.35	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
UCEC	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	4.61	8.77e-06	0.0109	0.33	0.35	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
UCEC	cis	rs7177699	0.557	rs12898712	ENSG00000261143.1	ADAMTS7P3	-4.6	8.79e-06	0.0109	-0.45	-0.35	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820280	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.557	rs12898452	ENSG00000261143.1	ADAMTS7P3	-4.6	8.79e-06	0.0109	-0.45	-0.35	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820286	chr15:77976042~77993057:+
UCEC	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-4.6	8.83e-06	0.0109	-0.39	-0.35	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
UCEC	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	4.6	8.86e-06	0.011	0.36	0.35	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
UCEC	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-4.6	8.86e-06	0.011	-0.41	-0.35	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-4.6	8.86e-06	0.011	-0.41	-0.35	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-4.6	8.86e-06	0.011	-0.41	-0.35	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-4.6	8.86e-06	0.011	-0.41	-0.35	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-4.6	8.86e-06	0.011	-0.41	-0.35	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.869	rs9295743	ENSG00000216901.1	AL022393.7	4.6	8.88e-06	0.011	0.4	0.35	Parkinson's disease;	chr6:27747323	chr6:28176188~28176674:+
UCEC	cis	rs9309473	0.607	rs1522926	ENSG00000163016.8	ALMS1P	4.6	8.89e-06	0.011	0.37	0.35	Metabolite levels;	chr2:73364113	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.555	rs2901437	ENSG00000163016.8	ALMS1P	4.6	8.89e-06	0.011	0.37	0.35	Metabolite levels;	chr2:73369896	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.687	rs10165862	ENSG00000163016.8	ALMS1P	4.6	8.89e-06	0.011	0.37	0.35	Metabolite levels;	chr2:73383615	chr2:73644919~73685576:+
UCEC	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-4.6	8.91e-06	0.011	-0.47	-0.35	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
UCEC	cis	rs847851	0.55	rs67413993	ENSG00000219023.1	RP3-340B19.2	-4.6	8.92e-06	0.011	-0.44	-0.35	Colonoscopy-negative controls vs population controls;	chr6:34976147	chr6:35555873~35556264:+
UCEC	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-4.6	8.94e-06	0.011	-0.38	-0.35	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
UCEC	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-4.6	8.94e-06	0.011	-0.4	-0.35	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-4.6	8.94e-06	0.011	-0.4	-0.35	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-4.6	8.94e-06	0.011	-0.4	-0.35	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
UCEC	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	4.6	8.94e-06	0.011	0.39	0.35	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
UCEC	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-4.6	8.94e-06	0.011	-0.43	-0.35	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
UCEC	cis	rs10232172	0.818	rs10254078	ENSG00000234707.2	RP11-745C15.2	4.6	8.96e-06	0.0111	0.66	0.35	Periodontal disease-related phenotypes;	chr7:54104148	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.908	rs11238296	ENSG00000234707.2	RP11-745C15.2	4.6	8.96e-06	0.0111	0.66	0.35	Periodontal disease-related phenotypes;	chr7:54104787	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.818	rs10258189	ENSG00000234707.2	RP11-745C15.2	4.6	8.96e-06	0.0111	0.66	0.35	Periodontal disease-related phenotypes;	chr7:54105223	chr7:54759425~54804928:+
UCEC	cis	rs10232172	1	rs13241378	ENSG00000234707.2	RP11-745C15.2	4.6	8.96e-06	0.0111	0.66	0.35	Periodontal disease-related phenotypes;	chr7:54106020	chr7:54759425~54804928:+
UCEC	cis	rs10232172	1	rs13241388	ENSG00000234707.2	RP11-745C15.2	4.6	8.96e-06	0.0111	0.66	0.35	Periodontal disease-related phenotypes;	chr7:54106029	chr7:54759425~54804928:+
UCEC	cis	rs6901004	0.803	rs1022092	ENSG00000271789.1	RP5-1112D6.7	-4.6	8.96e-06	0.0111	-0.44	-0.35	Blood metabolite levels;	chr6:111106083	chr6:111297126~111298510:+
UCEC	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-4.6	8.96e-06	0.0111	-0.51	-0.35	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
UCEC	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-4.6	8.98e-06	0.0111	-0.5	-0.35	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
UCEC	cis	rs4713118	0.513	rs2294480	ENSG00000216901.1	AL022393.7	4.6	9.01e-06	0.0111	0.39	0.35	Parkinson's disease;	chr6:27616182	chr6:28176188~28176674:+
UCEC	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	4.6	9.02e-06	0.0111	0.62	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
UCEC	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-4.6	9.04e-06	0.0111	-0.33	-0.35	Height;	chr11:118773873	chr11:118791254~118793137:+
UCEC	cis	rs7177699	0.557	rs12898292	ENSG00000261143.1	ADAMTS7P3	-4.6	9.04e-06	0.0111	-0.45	-0.35	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820261	chr15:77976042~77993057:+
UCEC	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	4.6	9.05e-06	0.0112	0.39	0.35	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
UCEC	cis	rs9400467	0.528	rs456865	ENSG00000271789.1	RP5-1112D6.7	-4.6	9.07e-06	0.0112	-0.42	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111297126~111298510:+
UCEC	cis	rs9400467	0.508	rs1676863	ENSG00000271789.1	RP5-1112D6.7	-4.6	9.07e-06	0.0112	-0.42	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111297126~111298510:+
UCEC	cis	rs9400467	0.528	rs457492	ENSG00000271789.1	RP5-1112D6.7	-4.6	9.07e-06	0.0112	-0.42	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111297126~111298510:+
UCEC	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	4.6	9.07e-06	0.0112	0.39	0.35	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	4.6	9.07e-06	0.0112	0.39	0.35	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	4.6	9.07e-06	0.0112	0.39	0.35	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
UCEC	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	4.6	9.08e-06	0.0112	0.45	0.35	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
UCEC	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-4.6	9.09e-06	0.0112	-0.36	-0.35	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-4.6	9.09e-06	0.0112	-0.36	-0.35	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-4.6	9.09e-06	0.0112	-0.36	-0.35	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-4.6	9.09e-06	0.0112	-0.36	-0.35	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-4.6	9.09e-06	0.0112	-0.36	-0.35	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-4.6	9.09e-06	0.0112	-0.36	-0.35	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-4.6	9.09e-06	0.0112	-0.36	-0.35	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
UCEC	cis	rs6840360	0.642	rs11099815	ENSG00000270265.1	RP11-731D1.4	-4.6	9.11e-06	0.0112	-0.34	-0.35	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151333775~151353224:-
UCEC	cis	rs7246967	0.673	rs368144	ENSG00000198153.8	ZNF849P	-4.6	9.12e-06	0.0112	-0.45	-0.35	Bronchopulmonary dysplasia;	chr19:22817985	chr19:22685167~22686732:+
UCEC	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-4.6	9.15e-06	0.0112	-0.44	-0.35	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
UCEC	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-4.59	9.15e-06	0.0113	-0.38	-0.35	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
UCEC	cis	rs62025270	0.688	rs62025272	ENSG00000202081.1	RNU6-1280P	-4.59	9.16e-06	0.0113	-0.44	-0.35	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85651522~85651628:-
UCEC	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	4.59	9.16e-06	0.0113	0.42	0.35	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
UCEC	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-4.59	9.17e-06	0.0113	-0.49	-0.35	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-4.59	9.17e-06	0.0113	-0.49	-0.35	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-4.59	9.17e-06	0.0113	-0.49	-0.35	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-4.59	9.17e-06	0.0113	-0.49	-0.35	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
UCEC	cis	rs948562	0.793	rs79869893	ENSG00000280010.1	AP001350.4	4.59	9.17e-06	0.0113	0.73	0.35	Lymphoma;	chr11:58514409	chr11:58627435~58628528:+
UCEC	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-4.59	9.2e-06	0.0113	-0.48	-0.35	Depression;	chr6:28135913	chr6:28115628~28116551:+
UCEC	cis	rs9926296	0.605	rs1800287	ENSG00000260259.1	RP11-368I7.4	-4.59	9.24e-06	0.0113	-0.32	-0.35	Vitiligo;	chr16:89792117	chr16:89682620~89686569:-
UCEC	cis	rs9926296	0.605	rs6500453	ENSG00000260259.1	RP11-368I7.4	-4.59	9.24e-06	0.0113	-0.32	-0.35	Vitiligo;	chr16:89792249	chr16:89682620~89686569:-
UCEC	cis	rs2276314	1	rs4573997	ENSG00000267627.4	RP11-905K4.1	-4.59	9.27e-06	0.0114	-0.41	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35951803~35966118:-
UCEC	cis	rs3858145	0.5	rs4633337	ENSG00000233590.1	RP11-153K11.3	4.59	9.29e-06	0.0114	0.44	0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285970	chr10:68233251~68242379:-
UCEC	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	4.59	9.31e-06	0.0114	0.37	0.35	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
UCEC	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	4.59	9.32e-06	0.0114	0.47	0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
UCEC	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	4.59	9.33e-06	0.0114	0.39	0.35	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
UCEC	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-4.59	9.33e-06	0.0114	-0.41	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-4.59	9.33e-06	0.0114	-0.41	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
UCEC	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	4.59	9.35e-06	0.0114	0.4	0.35	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
UCEC	cis	rs12468226	0.808	rs73992849	ENSG00000273456.1	RP11-686O6.2	4.59	9.36e-06	0.0115	0.49	0.35	Urate levels;	chr2:202152444	chr2:202374932~202375604:-
UCEC	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-4.59	9.37e-06	0.0115	-0.53	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
UCEC	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	4.59	9.37e-06	0.0115	0.46	0.35	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
UCEC	cis	rs1876905	0.68	rs9384787	ENSG00000271789.1	RP5-1112D6.7	4.59	9.37e-06	0.0115	0.47	0.35	Mean corpuscular hemoglobin;	chr6:111113707	chr6:111297126~111298510:+
UCEC	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-4.59	9.38e-06	0.0115	-0.32	-0.35	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
UCEC	cis	rs7208859	0.673	rs57432042	ENSG00000264538.5	SUZ12P1	-4.59	9.38e-06	0.0115	-0.55	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30914020	chr17:30709299~30790908:+
UCEC	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	4.59	9.4e-06	0.0115	0.47	0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
UCEC	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-4.59	9.52e-06	0.0116	-0.65	-0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
UCEC	cis	rs6137726	0.568	rs910960	ENSG00000277901.1	RP5-851M4.1	4.58	9.55e-06	0.0117	0.57	0.35	Amyotrophic lateral sclerosis (sporadic);	chr20:22647249	chr20:23320958~23325352:-
UCEC	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	4.58	9.57e-06	0.0117	0.4	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	4.58	9.57e-06	0.0117	0.4	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-4.58	9.58e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	4.58	9.58e-06	0.0117	0.41	0.35	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
UCEC	cis	rs6840360	0.582	rs2709826	ENSG00000270265.1	RP11-731D1.4	-4.58	9.58e-06	0.0117	-0.33	-0.35	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151333775~151353224:-
UCEC	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	4.58	9.58e-06	0.0117	0.53	0.35	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
UCEC	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	4.58	9.61e-06	0.0117	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
UCEC	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-4.58	9.61e-06	0.0117	-0.38	-0.35	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-4.58	9.61e-06	0.0117	-0.38	-0.35	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-4.58	9.62e-06	0.0117	-0.41	-0.35	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	4.58	9.64e-06	0.0117	0.42	0.35	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
UCEC	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-4.58	9.65e-06	0.0117	-0.45	-0.35	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
UCEC	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	4.58	9.66e-06	0.0118	0.41	0.35	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
UCEC	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	4.58	9.67e-06	0.0118	0.42	0.35	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
UCEC	cis	rs1667284	1	rs1667283	ENSG00000266521.1	RP11-650P15.1	4.58	9.7e-06	0.0118	0.41	0.35	Problematic alcohol use in trauma-exposed individuals;	chr18:31643658	chr18:31496645~31497195:-
UCEC	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-4.58	9.71e-06	0.0118	-0.5	-0.35	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
UCEC	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	4.58	9.71e-06	0.0118	0.41	0.35	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
UCEC	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	4.58	9.72e-06	0.0118	0.38	0.35	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	4.58	9.72e-06	0.0118	0.38	0.35	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
UCEC	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	4.58	9.73e-06	0.0118	0.51	0.35	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
UCEC	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-4.58	9.73e-06	0.0118	-0.42	-0.35	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-4.58	9.73e-06	0.0118	-0.42	-0.35	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
UCEC	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	4.58	9.76e-06	0.0119	0.52	0.35	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
UCEC	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	4.58	9.77e-06	0.0119	0.42	0.35	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
UCEC	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	4.58	9.78e-06	0.0119	0.47	0.35	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	4.58	9.78e-06	0.0119	0.47	0.35	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	4.58	9.78e-06	0.0119	0.47	0.35	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
UCEC	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-4.58	9.81e-06	0.0119	-0.41	-0.35	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
UCEC	cis	rs4713118	0.869	rs2056925	ENSG00000216901.1	AL022393.7	4.58	9.84e-06	0.0119	0.41	0.35	Parkinson's disease;	chr6:27723126	chr6:28176188~28176674:+
UCEC	cis	rs440932	1	rs440932	ENSG00000253893.2	FAM85B	-4.58	9.88e-06	0.012	-0.43	-0.35	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8167819~8226614:-
UCEC	cis	rs6840360	0.582	rs2724555	ENSG00000270265.1	RP11-731D1.4	-4.58	9.91e-06	0.012	-0.34	-0.35	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151333775~151353224:-
UCEC	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	4.58	9.92e-06	0.012	0.4	0.35	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
UCEC	cis	rs922692	1	rs12901913	ENSG00000261143.1	ADAMTS7P3	4.58	9.92e-06	0.012	0.5	0.35	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78689006	chr15:77976042~77993057:+
UCEC	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	4.58	9.95e-06	0.012	0.85	0.35	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	4.58	9.95e-06	0.012	0.85	0.35	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	4.58	9.95e-06	0.012	0.85	0.35	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	4.58	9.95e-06	0.012	0.85	0.35	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
UCEC	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	4.57	9.98e-06	0.0121	0.38	0.35	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
UCEC	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	4.57	9.98e-06	0.0121	0.38	0.35	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
UCEC	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	4.57	1e-05	0.0121	0.38	0.35	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
UCEC	cis	rs6137726	0.652	rs6082784	ENSG00000277901.1	RP5-851M4.1	-4.57	1e-05	0.0121	-0.47	-0.35	Amyotrophic lateral sclerosis (sporadic);	chr20:22679757	chr20:23320958~23325352:-
UCEC	cis	rs3858145	0.588	rs736535	ENSG00000233590.1	RP11-153K11.3	-4.57	1e-05	0.0121	-0.45	-0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284159	chr10:68233251~68242379:-
UCEC	cis	rs3858145	0.588	rs4142048	ENSG00000233590.1	RP11-153K11.3	-4.57	1e-05	0.0121	-0.45	-0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284274	chr10:68233251~68242379:-
UCEC	cis	rs3858145	0.588	rs4142049	ENSG00000233590.1	RP11-153K11.3	-4.57	1e-05	0.0121	-0.45	-0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284695	chr10:68233251~68242379:-
UCEC	cis	rs3858145	0.588	rs7081284	ENSG00000233590.1	RP11-153K11.3	-4.57	1e-05	0.0121	-0.45	-0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285035	chr10:68233251~68242379:-
UCEC	cis	rs3858145	0.588	rs2305083	ENSG00000233590.1	RP11-153K11.3	-4.57	1e-05	0.0121	-0.45	-0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285180	chr10:68233251~68242379:-
UCEC	cis	rs2732480	0.517	rs2634676	ENSG00000226413.2	OR8T1P	4.57	1e-05	0.0121	0.5	0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.577	rs1489109	ENSG00000226413.2	OR8T1P	4.57	1e-05	0.0121	0.5	0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.577	rs1489108	ENSG00000226413.2	OR8T1P	4.57	1e-05	0.0121	0.5	0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48442030~48442947:-
UCEC	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	4.57	1e-05	0.0121	0.4	0.35	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
UCEC	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-4.57	1.01e-05	0.0122	-0.38	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
UCEC	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-4.57	1.01e-05	0.0122	-0.38	-0.35	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
UCEC	cis	rs7674212	0.865	rs1481279	ENSG00000246560.2	RP11-10L12.4	-4.57	1.01e-05	0.0122	-0.42	-0.35	Type 2 diabetes;	chr4:103056781	chr4:102828055~102844075:+
UCEC	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	4.57	1.01e-05	0.0122	0.47	0.35	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
UCEC	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	4.57	1.01e-05	0.0122	0.36	0.35	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	4.57	1.01e-05	0.0122	0.36	0.35	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
UCEC	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-4.57	1.01e-05	0.0122	-0.38	-0.35	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-4.57	1.01e-05	0.0122	-0.4	-0.35	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
UCEC	cis	rs2276314	1	rs2298716	ENSG00000267627.4	RP11-905K4.1	-4.57	1.02e-05	0.0123	-0.41	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35951803~35966118:-
UCEC	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-4.57	1.02e-05	0.0123	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
UCEC	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-4.57	1.02e-05	0.0123	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
UCEC	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-4.57	1.02e-05	0.0123	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
UCEC	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-4.57	1.02e-05	0.0123	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
UCEC	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-4.57	1.02e-05	0.0123	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
UCEC	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-4.57	1.02e-05	0.0123	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
UCEC	cis	rs6840360	0.642	rs7698816	ENSG00000270265.1	RP11-731D1.4	-4.57	1.02e-05	0.0123	-0.34	-0.35	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151333775~151353224:-
UCEC	cis	rs10232172	1	rs17172291	ENSG00000234707.2	RP11-745C15.2	-4.57	1.03e-05	0.0123	-0.62	-0.35	Periodontal disease-related phenotypes;	chr7:54107760	chr7:54759425~54804928:+
UCEC	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-4.57	1.03e-05	0.0123	-0.44	-0.35	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
UCEC	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-4.57	1.03e-05	0.0123	-0.4	-0.35	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
UCEC	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	4.57	1.03e-05	0.0123	0.45	0.35	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
UCEC	cis	rs617219	0.574	rs13177425	ENSG00000245556.2	SCAMP1-AS1	-4.57	1.03e-05	0.0124	-0.34	-0.35	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79329766	chr5:78342365~78360507:-
UCEC	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	4.57	1.03e-05	0.0124	0.43	0.35	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	4.57	1.03e-05	0.0124	0.44	0.35	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
UCEC	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-4.57	1.03e-05	0.0124	-0.4	-0.35	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
UCEC	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	4.57	1.03e-05	0.0124	0.44	0.35	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
UCEC	cis	rs6940116	1	rs6940116	ENSG00000216901.1	AL022393.7	4.57	1.03e-05	0.0124	0.48	0.35	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28176188~28176674:+
UCEC	cis	rs4693167	0.504	rs10023409	ENSG00000248196.1	RP11-476C8.2	-4.57	1.04e-05	0.0125	-0.33	-0.35	Blood protein levels;	chr4:87532285	chr4:87166844~87167734:+
UCEC	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	4.56	1.04e-05	0.0125	0.51	0.35	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
UCEC	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-4.56	1.04e-05	0.0125	-0.43	-0.35	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-4.56	1.04e-05	0.0125	-0.43	-0.35	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-4.56	1.04e-05	0.0125	-0.43	-0.35	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-4.56	1.04e-05	0.0125	-0.43	-0.35	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
UCEC	cis	rs2276314	0.857	rs62101402	ENSG00000267627.4	RP11-905K4.1	-4.56	1.04e-05	0.0125	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35951803~35966118:-
UCEC	cis	rs9400467	0.528	rs240954	ENSG00000271789.1	RP5-1112D6.7	-4.56	1.04e-05	0.0125	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111338619	chr6:111297126~111298510:+
UCEC	cis	rs7760535	0.764	rs240994	ENSG00000271789.1	RP5-1112D6.7	-4.56	1.04e-05	0.0125	-0.41	-0.35	Metabolic traits;	chr6:111354554	chr6:111297126~111298510:+
UCEC	cis	rs7760535	0.794	rs463860	ENSG00000271789.1	RP5-1112D6.7	-4.56	1.04e-05	0.0125	-0.41	-0.35	Metabolic traits;	chr6:111370518	chr6:111297126~111298510:+
UCEC	cis	rs8089364	0.876	rs8097210	ENSG00000267742.1	FAM60CP	-4.56	1.04e-05	0.0125	-0.3	-0.35	Body mass index;Type 2 diabetes;	chr18:60189902	chr18:60016778~60017441:-
UCEC	cis	rs8089364	1	rs8089364	ENSG00000267742.1	FAM60CP	-4.56	1.04e-05	0.0125	-0.3	-0.35	Body mass index;Type 2 diabetes;	chr18:60191596	chr18:60016778~60017441:-
UCEC	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	4.56	1.05e-05	0.0125	0.52	0.35	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
UCEC	cis	rs2991971	0.776	rs12139364	ENSG00000280836.1	AL355480.1	4.56	1.05e-05	0.0126	0.4	0.35	High light scatter reticulocyte count;	chr1:45424483	chr1:45581219~45581321:-
UCEC	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-4.56	1.05e-05	0.0126	-0.49	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
UCEC	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	4.56	1.05e-05	0.0126	0.74	0.35	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	4.56	1.05e-05	0.0126	0.74	0.35	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	4.56	1.05e-05	0.0126	0.74	0.35	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	4.56	1.05e-05	0.0126	0.74	0.35	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	4.56	1.05e-05	0.0126	0.74	0.35	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-4.56	1.05e-05	0.0126	-0.74	-0.35	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-4.56	1.05e-05	0.0126	-0.74	-0.35	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-4.56	1.05e-05	0.0126	-0.74	-0.35	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-4.56	1.05e-05	0.0126	-0.74	-0.35	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
UCEC	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-4.56	1.05e-05	0.0126	-0.74	-0.35	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
UCEC	cis	rs7605378	0.528	rs1704191	ENSG00000232732.8	AC073043.1	-4.56	1.05e-05	0.0126	-0.45	-0.35	Osteoporosis;	chr2:199951670	chr2:199867396~199911159:-
UCEC	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	4.56	1.05e-05	0.0126	0.45	0.35	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	4.56	1.05e-05	0.0126	0.45	0.35	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
UCEC	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	4.56	1.05e-05	0.0126	0.5	0.35	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
UCEC	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-4.56	1.06e-05	0.0126	-0.32	-0.35	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-4.56	1.06e-05	0.0126	-0.32	-0.35	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
UCEC	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	4.56	1.06e-05	0.0126	0.44	0.35	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
UCEC	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	4.56	1.06e-05	0.0127	0.44	0.35	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
UCEC	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-4.56	1.06e-05	0.0127	-0.42	-0.35	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
UCEC	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-4.56	1.06e-05	0.0127	-0.5	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
UCEC	cis	rs7246967	0.673	rs407989	ENSG00000198153.8	ZNF849P	4.56	1.06e-05	0.0127	0.45	0.35	Bronchopulmonary dysplasia;	chr19:22808784	chr19:22685167~22686732:+
UCEC	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	4.56	1.07e-05	0.0127	0.38	0.35	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
UCEC	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	4.56	1.07e-05	0.0127	0.42	0.35	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
UCEC	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	4.56	1.07e-05	0.0127	0.42	0.35	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
UCEC	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-4.56	1.07e-05	0.0127	-0.34	-0.35	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
UCEC	cis	rs11690935	0.571	rs13020884	ENSG00000224553.1	AC008065.1	4.56	1.07e-05	0.0128	0.38	0.35	Schizophrenia;	chr2:172036795	chr2:171374931~171375278:-
UCEC	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-4.56	1.07e-05	0.0128	-0.42	-0.35	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
UCEC	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	4.56	1.07e-05	0.0128	0.44	0.35	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	4.56	1.07e-05	0.0128	0.44	0.35	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	4.56	1.07e-05	0.0128	0.44	0.35	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	4.56	1.07e-05	0.0128	0.44	0.35	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	4.56	1.07e-05	0.0128	0.44	0.35	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	4.56	1.07e-05	0.0128	0.44	0.35	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-4.56	1.07e-05	0.0128	-0.44	-0.35	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
UCEC	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	4.56	1.07e-05	0.0128	0.36	0.35	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
UCEC	cis	rs948562	0.573	rs7480262	ENSG00000280010.1	AP001350.4	4.56	1.08e-05	0.0128	0.62	0.35	Lymphoma;	chr11:58296313	chr11:58627435~58628528:+
UCEC	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-4.56	1.08e-05	0.0129	-0.43	-0.35	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
UCEC	cis	rs7674212	0.772	rs13113099	ENSG00000246560.2	RP11-10L12.4	4.56	1.08e-05	0.0129	0.42	0.35	Type 2 diabetes;	chr4:103052965	chr4:102828055~102844075:+
UCEC	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	4.56	1.08e-05	0.0129	0.36	0.35	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
UCEC	cis	rs2283792	0.745	rs5756306	ENSG00000228050.1	TOP3BP1	-4.56	1.08e-05	0.0129	-0.35	-0.35	Multiple sclerosis;	chr22:21978846	chr22:22223187~22224566:-
UCEC	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-4.56	1.08e-05	0.0129	-0.36	-0.35	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
UCEC	cis	rs7267979	0.932	rs928121	ENSG00000276952.1	RP5-965G21.6	4.56	1.08e-05	0.0129	0.45	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25284915~25285588:-
UCEC	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	4.55	1.08e-05	0.0129	0.39	0.35	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
UCEC	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-4.55	1.08e-05	0.0129	-0.7	-0.35	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
UCEC	cis	rs12744310	0.945	rs72665696	ENSG00000235358.1	RP11-399E6.1	4.55	1.09e-05	0.0129	0.58	0.35	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309757	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.943	rs12751511	ENSG00000235358.1	RP11-399E6.1	4.55	1.09e-05	0.0129	0.58	0.35	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41310731	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs34073585	ENSG00000235358.1	RP11-399E6.1	4.55	1.09e-05	0.0129	0.58	0.35	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311527	chr1:41242373~41284861:+
UCEC	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	4.55	1.09e-05	0.0129	0.39	0.35	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
UCEC	cis	rs4693167	0.504	rs10025744	ENSG00000248196.1	RP11-476C8.2	4.55	1.09e-05	0.0129	0.33	0.35	Blood protein levels;	chr4:87538147	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs6820007	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87533368	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs7663162	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87533473	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs7689069	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87533989	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs7664223	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87533995	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs10004849	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87534109	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs10035086	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87534290	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs10013222	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87534295	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs10013080	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87534317	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs10013230	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87534330	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs11938999	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87534529	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs4693835	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87537616	chr4:87166844~87167734:+
UCEC	cis	rs4693167	0.504	rs4693171	ENSG00000248196.1	RP11-476C8.2	-4.55	1.09e-05	0.0129	-0.33	-0.35	Blood protein levels;	chr4:87538371	chr4:87166844~87167734:+
UCEC	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-4.55	1.09e-05	0.0129	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
UCEC	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-4.55	1.09e-05	0.0129	-0.39	-0.35	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
UCEC	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	4.55	1.09e-05	0.013	0.36	0.35	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	4.55	1.09e-05	0.013	0.36	0.35	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
UCEC	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	4.55	1.09e-05	0.013	0.36	0.35	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
UCEC	cis	rs7760535	0.735	rs240974	ENSG00000271789.1	RP5-1112D6.7	-4.55	1.09e-05	0.013	-0.41	-0.35	Metabolic traits;	chr6:111328113	chr6:111297126~111298510:+
UCEC	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	4.55	1.09e-05	0.013	0.42	0.35	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
UCEC	cis	rs9876781	0.507	rs1824362	ENSG00000229759.1	MRPS18AP1	-4.55	1.1e-05	0.013	-0.37	-0.35	Longevity;	chr3:48360459	chr3:48256350~48256938:-
UCEC	cis	rs9926296	0.568	rs1230	ENSG00000260259.1	RP11-368I7.4	4.55	1.1e-05	0.013	0.32	0.35	Vitiligo;	chr16:89738447	chr16:89682620~89686569:-
UCEC	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	4.55	1.1e-05	0.0131	0.7	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
UCEC	cis	rs796395	0.901	rs3009947	ENSG00000232480.1	TGFB2-AS1	4.55	1.1e-05	0.0131	0.38	0.35	Post bronchodilator FEV1/FVC ratio;	chr1:218515813	chr1:218344196~218345678:-
UCEC	cis	rs8141529	0.748	rs6519766	ENSG00000272858.1	CTA-292E10.8	4.55	1.1e-05	0.0131	0.46	0.35	Lymphocyte counts;	chr22:28874003	chr22:28814914~28815662:+
UCEC	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-4.55	1.1e-05	0.0131	-0.42	-0.35	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-4.55	1.1e-05	0.0131	-0.42	-0.35	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-4.55	1.1e-05	0.0131	-0.42	-0.35	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-4.55	1.1e-05	0.0131	-0.42	-0.35	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-4.55	1.1e-05	0.0131	-0.42	-0.35	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
UCEC	cis	rs507080	0.961	rs34413584	ENSG00000278376.1	RP11-158I9.8	-4.55	1.1e-05	0.0131	-0.34	-0.35	Serum metabolite levels;	chr11:118675072	chr11:118791254~118793137:+
UCEC	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-4.55	1.11e-05	0.0131	-0.39	-0.35	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
UCEC	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	4.55	1.11e-05	0.0131	0.44	0.35	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
UCEC	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-4.55	1.11e-05	0.0131	-0.46	-0.35	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
UCEC	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-4.55	1.11e-05	0.0131	-0.39	-0.35	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-4.55	1.11e-05	0.0132	-0.39	-0.35	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
UCEC	cis	rs7605378	0.528	rs281767	ENSG00000232732.8	AC073043.1	-4.55	1.11e-05	0.0132	-0.45	-0.35	Osteoporosis;	chr2:199958558	chr2:199867396~199911159:-
UCEC	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
UCEC	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-4.55	1.12e-05	0.0132	-0.48	-0.35	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
UCEC	cis	rs7267979	0.509	rs6115218	ENSG00000276952.1	RP5-965G21.6	4.55	1.12e-05	0.0132	0.48	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25284915~25285588:-
UCEC	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	4.55	1.12e-05	0.0132	0.41	0.35	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
UCEC	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-4.55	1.12e-05	0.0132	-0.36	-0.35	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-4.55	1.12e-05	0.0132	-0.36	-0.35	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-4.55	1.12e-05	0.0132	-0.36	-0.35	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-4.55	1.12e-05	0.0132	-0.36	-0.35	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-4.55	1.12e-05	0.0132	-0.36	-0.35	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
UCEC	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	4.55	1.12e-05	0.0133	0.45	0.35	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
UCEC	cis	rs6137726	0.524	rs1203923	ENSG00000277901.1	RP5-851M4.1	-4.55	1.12e-05	0.0133	-0.45	-0.35	Amyotrophic lateral sclerosis (sporadic);	chr20:22605190	chr20:23320958~23325352:-
UCEC	cis	rs8089364	0.917	rs921971	ENSG00000267742.1	FAM60CP	-4.55	1.12e-05	0.0133	-0.31	-0.35	Body mass index;Type 2 diabetes;	chr18:60194430	chr18:60016778~60017441:-
UCEC	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-4.55	1.12e-05	0.0133	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
UCEC	cis	rs7267979	1	rs12428	ENSG00000276952.1	RP5-965G21.6	-4.55	1.12e-05	0.0133	-0.46	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25284915~25285588:-
UCEC	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	4.55	1.12e-05	0.0133	0.43	0.35	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
UCEC	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	4.55	1.13e-05	0.0133	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
UCEC	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	4.54	1.13e-05	0.0133	0.4	0.35	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
UCEC	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	4.54	1.13e-05	0.0133	0.38	0.35	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
UCEC	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	4.54	1.13e-05	0.0133	0.43	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
UCEC	cis	rs10165862	0.572	rs11674212	ENSG00000163016.8	ALMS1P	4.54	1.13e-05	0.0133	0.48	0.35	Intelligence (multi-trait analysis);	chr2:73684053	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	4.54	1.13e-05	0.0133	0.4	0.35	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
UCEC	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	4.54	1.13e-05	0.0133	0.39	0.35	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
UCEC	cis	rs6137726	0.524	rs1203941	ENSG00000277901.1	RP5-851M4.1	4.54	1.14e-05	0.0134	0.46	0.35	Amyotrophic lateral sclerosis (sporadic);	chr20:22615951	chr20:23320958~23325352:-
UCEC	cis	rs6137726	0.524	rs1203945	ENSG00000277901.1	RP5-851M4.1	4.54	1.14e-05	0.0134	0.46	0.35	Amyotrophic lateral sclerosis (sporadic);	chr20:22616255	chr20:23320958~23325352:-
UCEC	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-4.54	1.14e-05	0.0134	-0.43	-0.35	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
UCEC	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	4.54	1.14e-05	0.0134	0.38	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-4.54	1.14e-05	0.0134	-0.4	-0.35	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-4.54	1.14e-05	0.0134	-0.51	-0.35	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-4.54	1.14e-05	0.0134	-0.51	-0.35	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-4.54	1.14e-05	0.0134	-0.51	-0.35	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-4.54	1.14e-05	0.0134	-0.51	-0.35	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-4.54	1.14e-05	0.0134	-0.51	-0.35	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	4.54	1.14e-05	0.0134	0.51	0.35	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
UCEC	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-4.54	1.14e-05	0.0134	-0.42	-0.35	Height;	chr2:46629946	chr2:46668870~46670778:+
UCEC	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	4.54	1.14e-05	0.0134	0.45	0.35	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
UCEC	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	4.54	1.15e-05	0.0135	0.38	0.35	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
UCEC	cis	rs6901004	0.803	rs1150083	ENSG00000271789.1	RP5-1112D6.7	-4.54	1.15e-05	0.0135	-0.41	-0.35	Blood metabolite levels;	chr6:111189564	chr6:111297126~111298510:+
UCEC	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	4.54	1.15e-05	0.0135	0.46	0.35	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
UCEC	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-4.54	1.15e-05	0.0135	-0.35	-0.35	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
UCEC	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	4.54	1.15e-05	0.0135	0.38	0.35	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
UCEC	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	4.54	1.15e-05	0.0135	0.36	0.35	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
UCEC	cis	rs2404602	0.655	rs10444809	ENSG00000259422.1	RP11-593F23.1	-4.54	1.15e-05	0.0135	-0.42	-0.35	Blood metabolite levels;	chr15:76832195	chr15:76174891~76181486:-
UCEC	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-4.54	1.15e-05	0.0135	-0.44	-0.35	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
UCEC	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	4.54	1.15e-05	0.0135	0.38	0.35	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
UCEC	cis	rs2732480	0.577	rs2732481	ENSG00000226413.2	OR8T1P	4.54	1.15e-05	0.0135	0.5	0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.557	rs2732484	ENSG00000226413.2	OR8T1P	4.54	1.15e-05	0.0135	0.5	0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.577	rs2732486	ENSG00000226413.2	OR8T1P	4.54	1.15e-05	0.0135	0.5	0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48442030~48442947:-
UCEC	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	4.54	1.15e-05	0.0135	0.43	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
UCEC	cis	rs9309473	0.583	rs6705203	ENSG00000163016.8	ALMS1P	4.54	1.16e-05	0.0136	0.39	0.35	Metabolite levels;	chr2:73347472	chr2:73644919~73685576:+
UCEC	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	4.54	1.16e-05	0.0136	0.46	0.35	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
UCEC	cis	rs6496044	0.507	rs410522	ENSG00000202081.1	RNU6-1280P	-4.54	1.16e-05	0.0136	-0.38	-0.35	Interstitial lung disease;	chr15:85663813	chr15:85651522~85651628:-
UCEC	cis	rs4693167	0.504	rs4693837	ENSG00000248196.1	RP11-476C8.2	-4.54	1.16e-05	0.0136	-0.34	-0.35	Blood protein levels;	chr4:87541085	chr4:87166844~87167734:+
UCEC	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	4.54	1.16e-05	0.0136	0.69	0.35	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
UCEC	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	4.54	1.16e-05	0.0136	0.36	0.35	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
UCEC	cis	rs17826219	0.706	rs57698184	ENSG00000266490.1	CTD-2349P21.9	4.54	1.16e-05	0.0136	0.48	0.35	Body mass index;	chr17:30737900	chr17:30792372~30792833:+
UCEC	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	4.54	1.16e-05	0.0136	0.36	0.35	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
UCEC	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-4.54	1.16e-05	0.0136	-0.35	-0.35	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
UCEC	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	4.54	1.16e-05	0.0136	0.35	0.35	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
UCEC	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-4.54	1.16e-05	0.0136	-0.4	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
UCEC	cis	rs62103177	0.673	rs36087369	ENSG00000261126.6	RP11-795F19.1	4.54	1.16e-05	0.0136	0.41	0.35	Opioid sensitivity;	chr18:79829596	chr18:80046900~80095482:+
UCEC	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	4.54	1.17e-05	0.0137	0.38	0.35	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
UCEC	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	4.54	1.17e-05	0.0137	0.45	0.35	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
UCEC	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	4.54	1.17e-05	0.0137	0.47	0.35	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
UCEC	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-4.54	1.17e-05	0.0137	-0.42	-0.35	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
UCEC	cis	rs6901004	0.839	rs783086	ENSG00000271789.1	RP5-1112D6.7	-4.54	1.17e-05	0.0137	-0.42	-0.35	Blood metabolite levels;	chr6:111240510	chr6:111297126~111298510:+
UCEC	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-4.54	1.17e-05	0.0137	-0.37	-0.35	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
UCEC	cis	rs240993	0.909	rs240991	ENSG00000271789.1	RP5-1112D6.7	-4.54	1.18e-05	0.0137	-0.39	-0.35	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111297126~111298510:+
UCEC	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-4.54	1.18e-05	0.0137	-0.37	-0.35	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
UCEC	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-4.54	1.18e-05	0.0137	-0.44	-0.35	Height;	chr3:53084188	chr3:53064283~53065091:-
UCEC	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	4.53	1.18e-05	0.0138	0.38	0.35	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	4.53	1.18e-05	0.0138	0.39	0.35	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
UCEC	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	4.53	1.18e-05	0.0138	0.39	0.35	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
UCEC	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	4.53	1.18e-05	0.0138	0.42	0.35	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
UCEC	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	4.53	1.18e-05	0.0138	0.69	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
UCEC	cis	rs1790761	0.505	rs7103713	ENSG00000184224.3	C11orf72	-4.53	1.19e-05	0.0138	-0.38	-0.35	Mean corpuscular volume;	chr11:67570771	chr11:67602880~67606706:-
UCEC	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-4.53	1.19e-05	0.0138	-0.38	-0.35	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
UCEC	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-4.53	1.19e-05	0.0139	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
UCEC	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-4.53	1.19e-05	0.0139	-0.44	-0.35	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
UCEC	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-4.53	1.19e-05	0.0139	-0.39	-0.35	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
UCEC	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-4.53	1.19e-05	0.0139	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-4.53	1.19e-05	0.0139	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-4.53	1.19e-05	0.0139	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-4.53	1.19e-05	0.0139	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-4.53	1.19e-05	0.0139	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
UCEC	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	4.53	1.19e-05	0.0139	0.44	0.35	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
UCEC	cis	rs2445284	0.715	rs1840635	ENSG00000229534.1	HNRNPA1P53	-4.53	1.19e-05	0.0139	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5027575	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.715	rs1598504	ENSG00000229534.1	HNRNPA1P53	-4.53	1.19e-05	0.0139	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5027655	chr11:5571247~5572192:-
UCEC	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-4.53	1.19e-05	0.0139	-0.43	-0.35	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
UCEC	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	4.53	1.2e-05	0.0139	0.36	0.35	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
UCEC	cis	rs9788721	0.504	rs1996371	ENSG00000261143.1	ADAMTS7P3	4.53	1.2e-05	0.0139	0.47	0.35	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78664464	chr15:77976042~77993057:+
UCEC	cis	rs763121	0.962	rs138711	ENSG00000273076.1	RP3-508I15.22	4.53	1.2e-05	0.0139	0.5	0.35	Menopause (age at onset);	chr22:38743908	chr22:38743495~38743910:+
UCEC	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-4.53	1.2e-05	0.0139	-0.4	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-4.53	1.2e-05	0.0139	-0.4	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-4.53	1.2e-05	0.0139	-0.4	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-4.53	1.2e-05	0.0139	-0.4	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-4.53	1.2e-05	0.0139	-0.4	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-4.53	1.2e-05	0.0139	-0.4	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
UCEC	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-4.53	1.2e-05	0.0139	-0.4	-0.35	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
UCEC	cis	rs9400467	0.528	rs6933627	ENSG00000271789.1	RP5-1112D6.7	-4.53	1.2e-05	0.014	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111297126~111298510:+
UCEC	cis	rs9907295	0.901	rs9898132	ENSG00000270871.1	AC015849.19	4.53	1.2e-05	0.014	0.54	0.35	Fibroblast growth factor basic levels;	chr17:35869187	chr17:35816717~35830293:-
UCEC	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-4.53	1.2e-05	0.014	-0.44	-0.35	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
UCEC	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	4.53	1.21e-05	0.014	0.4	0.35	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
UCEC	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-4.53	1.21e-05	0.014	-0.38	-0.35	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
UCEC	cis	rs4713118	0.568	rs9468213	ENSG00000216901.1	AL022393.7	4.53	1.21e-05	0.0141	0.39	0.35	Parkinson's disease;	chr6:27738401	chr6:28176188~28176674:+
UCEC	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-4.53	1.21e-05	0.0141	-0.41	-0.35	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
UCEC	cis	rs10232172	1	rs6951801	ENSG00000234707.2	RP11-745C15.2	4.53	1.21e-05	0.0141	0.62	0.35	Periodontal disease-related phenotypes;	chr7:54106377	chr7:54759425~54804928:+
UCEC	cis	rs10232172	1	rs10267268	ENSG00000234707.2	RP11-745C15.2	4.53	1.21e-05	0.0141	0.62	0.35	Periodontal disease-related phenotypes;	chr7:54107808	chr7:54759425~54804928:+
UCEC	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	4.53	1.21e-05	0.0141	0.43	0.35	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
UCEC	cis	rs268134	0.53	rs34665164	ENSG00000281920.1	RP11-418H16.1	-4.53	1.21e-05	0.0141	-0.62	-0.35	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65372150	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs62139125	ENSG00000281920.1	RP11-418H16.1	-4.53	1.21e-05	0.0141	-0.62	-0.35	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65373188	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs62139126	ENSG00000281920.1	RP11-418H16.1	-4.53	1.21e-05	0.0141	-0.62	-0.35	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65376292	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs62139127	ENSG00000281920.1	RP11-418H16.1	-4.53	1.21e-05	0.0141	-0.62	-0.35	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65376303	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs62139128	ENSG00000281920.1	RP11-418H16.1	-4.53	1.21e-05	0.0141	-0.62	-0.35	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65376529	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs34723587	ENSG00000281920.1	RP11-418H16.1	-4.53	1.21e-05	0.0141	-0.62	-0.35	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65377150	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs34928603	ENSG00000281920.1	RP11-418H16.1	-4.53	1.21e-05	0.0141	-0.62	-0.35	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65377777	chr2:65623272~65628424:+
UCEC	cis	rs492146	0.729	rs644100	ENSG00000243236.5	GSTA9P	-4.53	1.22e-05	0.0141	-0.44	-0.35	Epilepsy (remission after treatment);	chr6:52977573	chr6:52939726~52957521:-
UCEC	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-4.53	1.22e-05	0.0141	-0.48	-0.35	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
UCEC	cis	rs1667255	1	rs1080093	ENSG00000266521.1	RP11-650P15.1	4.53	1.22e-05	0.0141	0.37	0.35	Retinol levels;	chr18:31593717	chr18:31496645~31497195:-
UCEC	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-4.53	1.22e-05	0.0141	-0.48	-0.35	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
UCEC	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-4.53	1.22e-05	0.0141	-0.48	-0.35	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
UCEC	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-4.53	1.22e-05	0.0141	-0.4	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
UCEC	cis	rs7267979	0.932	rs6107052	ENSG00000276952.1	RP5-965G21.6	4.53	1.22e-05	0.0141	0.45	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25284915~25285588:-
UCEC	cis	rs9287719	0.837	rs4233882	ENSG00000234818.1	AC092687.5	4.53	1.22e-05	0.0142	0.47	0.35	Prostate cancer;	chr2:10615438	chr2:10589166~10604830:+
UCEC	cis	rs7605378	0.528	rs281787	ENSG00000232732.8	AC073043.1	4.53	1.22e-05	0.0142	0.44	0.35	Osteoporosis;	chr2:199919515	chr2:199867396~199911159:-
UCEC	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-4.53	1.23e-05	0.0142	-0.44	-0.35	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-4.53	1.23e-05	0.0142	-0.44	-0.35	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
UCEC	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	4.52	1.23e-05	0.0142	0.42	0.35	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	4.52	1.23e-05	0.0142	0.42	0.35	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	4.52	1.23e-05	0.0142	0.42	0.35	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	4.52	1.23e-05	0.0142	0.42	0.35	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	4.52	1.23e-05	0.0142	0.42	0.35	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
UCEC	cis	rs9322193	0.923	rs958953	ENSG00000223701.3	RAET1E-AS1	4.52	1.23e-05	0.0143	0.36	0.35	Lung cancer;	chr6:149840735	chr6:149884431~149919508:+
UCEC	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-4.52	1.23e-05	0.0143	-0.47	-0.35	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
UCEC	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-4.52	1.24e-05	0.0143	-0.39	-0.35	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
UCEC	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	4.52	1.24e-05	0.0143	0.42	0.35	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
UCEC	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-4.52	1.24e-05	0.0144	-0.38	-0.35	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
UCEC	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-4.52	1.24e-05	0.0144	-0.38	-0.35	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
UCEC	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-4.52	1.24e-05	0.0144	-0.38	-0.35	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
UCEC	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	4.52	1.24e-05	0.0144	0.44	0.35	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
UCEC	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-4.52	1.24e-05	0.0144	-0.44	-0.35	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
UCEC	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	4.52	1.25e-05	0.0144	0.36	0.35	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
UCEC	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-4.52	1.25e-05	0.0144	-0.38	-0.35	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
UCEC	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	4.52	1.25e-05	0.0145	0.4	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
UCEC	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	4.52	1.26e-05	0.0145	0.45	0.35	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	4.52	1.26e-05	0.0145	0.45	0.35	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	4.52	1.26e-05	0.0145	0.45	0.35	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	4.52	1.26e-05	0.0145	0.45	0.35	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	4.52	1.26e-05	0.0145	0.45	0.35	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	4.52	1.26e-05	0.0145	0.45	0.35	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	4.52	1.26e-05	0.0145	0.45	0.35	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	4.52	1.26e-05	0.0145	0.45	0.35	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
UCEC	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	4.52	1.26e-05	0.0145	0.37	0.35	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	4.52	1.26e-05	0.0145	0.37	0.35	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	4.52	1.26e-05	0.0145	0.37	0.35	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
UCEC	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	4.52	1.26e-05	0.0145	0.38	0.35	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
UCEC	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.42	-0.35	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
UCEC	cis	rs6137726	0.508	rs975525	ENSG00000277901.1	RP5-851M4.1	4.52	1.26e-05	0.0145	0.51	0.35	Amyotrophic lateral sclerosis (sporadic);	chr20:22659774	chr20:23320958~23325352:-
UCEC	cis	rs1850744	0.702	rs13136217	ENSG00000163612.10	FAM86KP	-4.52	1.26e-05	0.0145	-0.81	-0.35	Economic and political preferences;	chr4:9720668	chr4:9153296~9165451:+
UCEC	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.36	-0.35	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
UCEC	cis	rs10232172	0.686	rs11769522	ENSG00000234707.2	RP11-745C15.2	-4.52	1.26e-05	0.0145	-0.53	-0.35	Periodontal disease-related phenotypes;	chr7:54103808	chr7:54759425~54804928:+
UCEC	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	4.52	1.26e-05	0.0145	0.36	0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
UCEC	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-4.52	1.26e-05	0.0145	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-4.52	1.26e-05	0.0145	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-4.52	1.26e-05	0.0145	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-4.52	1.26e-05	0.0145	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-4.52	1.26e-05	0.0145	-0.39	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.0145	-0.4	-0.35	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	4.52	1.27e-05	0.0146	0.36	0.35	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	4.52	1.27e-05	0.0146	0.36	0.35	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	4.52	1.27e-05	0.0146	0.36	0.35	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	4.52	1.27e-05	0.0146	0.36	0.35	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	4.52	1.27e-05	0.0146	0.36	0.35	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-4.52	1.27e-05	0.0146	-0.36	-0.35	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-4.52	1.27e-05	0.0146	-0.36	-0.35	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
UCEC	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	4.52	1.27e-05	0.0146	0.38	0.35	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	4.52	1.27e-05	0.0146	0.38	0.35	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	4.52	1.27e-05	0.0146	0.38	0.35	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	4.52	1.27e-05	0.0146	0.38	0.35	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	4.52	1.27e-05	0.0146	0.38	0.35	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	4.52	1.27e-05	0.0146	0.38	0.35	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	4.52	1.27e-05	0.0146	0.38	0.35	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
UCEC	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	4.52	1.27e-05	0.0146	0.56	0.35	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
UCEC	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-4.52	1.27e-05	0.0146	-0.31	-0.35	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-4.52	1.27e-05	0.0146	-0.31	-0.35	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
UCEC	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	4.52	1.27e-05	0.0146	0.41	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
UCEC	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-4.52	1.28e-05	0.0146	-0.47	-0.35	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
UCEC	cis	rs11971779	0.68	rs7808740	ENSG00000273391.1	RP11-634H22.1	4.52	1.28e-05	0.0147	0.39	0.35	Diisocyanate-induced asthma;	chr7:139344209	chr7:139359032~139359566:-
UCEC	cis	rs948562	0.69	rs78776290	ENSG00000280010.1	AP001350.4	4.52	1.28e-05	0.0147	0.66	0.35	Lymphoma;	chr11:58334410	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.69	rs73484144	ENSG00000280010.1	AP001350.4	4.52	1.28e-05	0.0147	0.66	0.35	Lymphoma;	chr11:58337718	chr11:58627435~58628528:+
UCEC	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-4.52	1.28e-05	0.0147	-0.36	-0.35	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
UCEC	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-4.51	1.28e-05	0.0147	-0.44	-0.35	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
UCEC	cis	rs9287719	0.837	rs4331474	ENSG00000234818.1	AC092687.5	4.51	1.28e-05	0.0147	0.47	0.35	Prostate cancer;	chr2:10615457	chr2:10589166~10604830:+
UCEC	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	4.51	1.28e-05	0.0147	0.4	0.35	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
UCEC	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	4.51	1.28e-05	0.0147	0.55	0.35	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
UCEC	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	4.51	1.28e-05	0.0147	0.43	0.35	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
UCEC	cis	rs7240205	0.853	rs4404156	ENSG00000275805.1	RP11-349H17.2	4.51	1.29e-05	0.0147	0.42	0.35	Breast cancer;	chr18:26563490	chr18:26565723~26575626:-
UCEC	cis	rs2445284	0.874	rs2445269	ENSG00000229534.1	HNRNPA1P53	-4.51	1.29e-05	0.0148	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5037434	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.838	rs2445270	ENSG00000229534.1	HNRNPA1P53	-4.51	1.29e-05	0.0148	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5037466	chr11:5571247~5572192:-
UCEC	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-4.51	1.29e-05	0.0148	-0.49	-0.35	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
UCEC	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	4.51	1.29e-05	0.0148	0.37	0.35	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
UCEC	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-4.51	1.29e-05	0.0148	-0.72	-0.35	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
UCEC	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	4.51	1.29e-05	0.0148	0.4	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
UCEC	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-4.51	1.29e-05	0.0148	-0.4	-0.35	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
UCEC	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	4.51	1.29e-05	0.0148	0.39	0.35	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
UCEC	cis	rs4906332	1	rs4900574	ENSG00000244691.1	RPL10AP1	4.51	1.29e-05	0.0148	0.44	0.35	Coronary artery disease;	chr14:103412687	chr14:103412119~103412761:-
UCEC	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-4.51	1.29e-05	0.0148	-0.38	-0.35	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
UCEC	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	4.51	1.29e-05	0.0148	0.43	0.35	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
UCEC	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	4.51	1.3e-05	0.0148	0.49	0.35	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
UCEC	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0148	-0.39	-0.35	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
UCEC	cis	rs9309473	0.583	rs6709853	ENSG00000163016.8	ALMS1P	4.51	1.3e-05	0.0148	0.36	0.35	Metabolite levels;	chr2:73348937	chr2:73644919~73685576:+
UCEC	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	4.51	1.3e-05	0.0148	0.42	0.35	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
UCEC	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-4.51	1.3e-05	0.0149	-0.55	-0.35	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
UCEC	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.4	-0.35	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
UCEC	cis	rs4713118	0.869	rs9461405	ENSG00000216901.1	AL022393.7	4.51	1.3e-05	0.0149	0.4	0.35	Parkinson's disease;	chr6:27751596	chr6:28176188~28176674:+
UCEC	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	4.51	1.3e-05	0.0149	0.4	0.35	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
UCEC	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.39	-0.35	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.39	-0.35	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.39	-0.35	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.39	-0.35	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.39	-0.35	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.4	-0.35	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.4	-0.35	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.4	-0.35	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.4	-0.35	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.4	-0.35	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.4	-0.35	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-4.51	1.3e-05	0.0149	-0.4	-0.35	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
UCEC	cis	rs10232172	0.591	rs34350090	ENSG00000234707.2	RP11-745C15.2	-4.51	1.31e-05	0.0149	-0.53	-0.35	Periodontal disease-related phenotypes;	chr7:54102846	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.778	rs17172287	ENSG00000234707.2	RP11-745C15.2	-4.51	1.31e-05	0.0149	-0.53	-0.35	Periodontal disease-related phenotypes;	chr7:54102960	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.778	rs62445364	ENSG00000234707.2	RP11-745C15.2	-4.51	1.31e-05	0.0149	-0.53	-0.35	Periodontal disease-related phenotypes;	chr7:54103168	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.722	rs2877197	ENSG00000234707.2	RP11-745C15.2	-4.51	1.31e-05	0.0149	-0.53	-0.35	Periodontal disease-related phenotypes;	chr7:54103186	chr7:54759425~54804928:+
UCEC	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	4.51	1.31e-05	0.0149	0.49	0.35	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
UCEC	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	4.51	1.31e-05	0.015	0.36	0.35	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
UCEC	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	4.51	1.32e-05	0.015	0.36	0.35	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
UCEC	cis	rs7176527	0.579	rs366717	ENSG00000259570.1	RP11-671M22.4	-4.51	1.32e-05	0.015	-0.5	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84394512~84395514:+
UCEC	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-4.51	1.32e-05	0.015	-0.37	-0.35	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
UCEC	cis	rs2276314	1	rs2298715	ENSG00000267627.4	RP11-905K4.1	-4.51	1.32e-05	0.015	-0.41	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35951803~35966118:-
UCEC	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-4.51	1.32e-05	0.015	-0.41	-0.35	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
UCEC	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-4.51	1.32e-05	0.015	-0.37	-0.35	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
UCEC	cis	rs34286592	1	rs13332078	ENSG00000238045.8	AC009133.12	4.51	1.32e-05	0.015	0.58	0.35	Multiple sclerosis;	chr16:29839384	chr16:29808636~29821252:-
UCEC	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	4.51	1.32e-05	0.015	0.42	0.35	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	4.51	1.32e-05	0.015	0.42	0.35	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
UCEC	cis	rs948562	1	rs3829218	ENSG00000280010.1	AP001350.4	4.51	1.32e-05	0.015	0.7	0.35	Lymphoma;	chr11:58563836	chr11:58627435~58628528:+
UCEC	cis	rs948562	1	rs11229535	ENSG00000280010.1	AP001350.4	4.51	1.32e-05	0.015	0.7	0.35	Lymphoma;	chr11:58580913	chr11:58627435~58628528:+
UCEC	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	4.51	1.32e-05	0.015	0.44	0.35	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-4.51	1.32e-05	0.0151	-0.37	-0.35	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
UCEC	cis	rs11690935	0.527	rs7586556	ENSG00000224553.1	AC008065.1	4.51	1.32e-05	0.0151	0.38	0.35	Schizophrenia;	chr2:172036983	chr2:171374931~171375278:-
UCEC	cis	rs11690935	0.571	rs1008151	ENSG00000224553.1	AC008065.1	4.51	1.32e-05	0.0151	0.38	0.35	Schizophrenia;	chr2:172047370	chr2:171374931~171375278:-
UCEC	cis	rs7177699	0.557	rs11072807	ENSG00000261143.1	ADAMTS7P3	-4.51	1.32e-05	0.0151	-0.44	-0.35	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78819175	chr15:77976042~77993057:+
UCEC	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	4.51	1.33e-05	0.0151	0.38	0.35	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
UCEC	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-4.51	1.33e-05	0.0151	-0.35	-0.35	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
UCEC	cis	rs7914558	0.966	rs10883817	ENSG00000272912.1	RP11-724N1.1	-4.51	1.33e-05	0.0151	-0.33	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102995674	chr10:102914585~102915404:+
UCEC	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-4.5	1.33e-05	0.0151	-0.31	-0.35	Height;	chr11:118703185	chr11:118791254~118793137:+
UCEC	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-4.5	1.33e-05	0.0151	-0.31	-0.35	Height;	chr11:118703207	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-4.5	1.33e-05	0.0151	-0.31	-0.35	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
UCEC	cis	rs10740039	0.583	rs10740042	ENSG00000254271.1	RP11-131N11.4	4.5	1.33e-05	0.0152	0.44	0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60736828	chr10:60734342~60741828:+
UCEC	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-4.5	1.34e-05	0.0152	-0.37	-0.35	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
UCEC	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-4.5	1.34e-05	0.0152	-0.51	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
UCEC	cis	rs4356203	1	rs4356203	ENSG00000272034.1	SNORD14A	4.5	1.34e-05	0.0152	0.37	0.35	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17138601	chr11:17074654~17074744:-
UCEC	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	4.5	1.34e-05	0.0152	0.37	0.35	Height;	chr6:109370985	chr6:109382795~109383666:+
UCEC	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-4.5	1.34e-05	0.0152	-0.32	-0.35	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-4.5	1.34e-05	0.0152	-0.32	-0.35	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
UCEC	cis	rs12220777	1	rs11201297	ENSG00000230091.5	TMEM254-AS1	4.5	1.34e-05	0.0152	0.58	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033993	chr10:80046860~80078912:-
UCEC	cis	rs922692	1	rs72743199	ENSG00000261143.1	ADAMTS7P3	4.5	1.34e-05	0.0152	0.48	0.35	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78683513	chr15:77976042~77993057:+
UCEC	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-4.5	1.34e-05	0.0152	-0.36	-0.35	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
UCEC	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	4.5	1.35e-05	0.0153	0.39	0.35	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
UCEC	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	4.5	1.35e-05	0.0153	0.44	0.35	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	4.5	1.35e-05	0.0153	0.44	0.35	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	4.5	1.35e-05	0.0153	0.44	0.35	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	4.5	1.35e-05	0.0153	0.44	0.35	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	4.5	1.35e-05	0.0153	0.44	0.35	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
UCEC	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-4.5	1.35e-05	0.0153	-0.33	-0.35	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
UCEC	cis	rs6840360	0.642	rs6535803	ENSG00000278978.1	RP11-164P12.5	-4.5	1.35e-05	0.0153	-0.41	-0.35	Intelligence (multi-trait analysis);	chr4:151520762	chr4:151669786~151670503:+
UCEC	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	4.5	1.35e-05	0.0153	0.44	0.35	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
UCEC	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	4.5	1.35e-05	0.0153	0.37	0.35	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
UCEC	cis	rs11690935	0.549	rs62183819	ENSG00000224553.1	AC008065.1	4.5	1.35e-05	0.0153	0.38	0.35	Schizophrenia;	chr2:172039610	chr2:171374931~171375278:-
UCEC	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	4.5	1.35e-05	0.0153	0.36	0.35	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
UCEC	cis	rs28386778	0.897	rs2727295	ENSG00000240280.5	TCAM1P	-4.5	1.36e-05	0.0153	-0.35	-0.35	Prudent dietary pattern;	chr17:63810333	chr17:63849292~63864379:+
UCEC	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	4.5	1.36e-05	0.0154	0.42	0.35	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
UCEC	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-4.5	1.36e-05	0.0154	-0.43	-0.35	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-4.5	1.36e-05	0.0154	-0.43	-0.35	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
UCEC	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	4.5	1.36e-05	0.0154	0.42	0.35	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	4.5	1.36e-05	0.0154	0.42	0.35	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
UCEC	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-4.5	1.37e-05	0.0154	-0.68	-0.35	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
UCEC	cis	rs9532669	0.963	rs9532681	ENSG00000239827.7	SUGT1P3	-4.5	1.37e-05	0.0154	-0.34	-0.35	Cervical cancer;	chr13:40951633	chr13:40908159~40921774:-
UCEC	cis	rs9532669	0.926	rs4516083	ENSG00000239827.7	SUGT1P3	-4.5	1.37e-05	0.0154	-0.34	-0.35	Cervical cancer;	chr13:40951783	chr13:40908159~40921774:-
UCEC	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-4.5	1.37e-05	0.0154	-0.46	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
UCEC	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	4.5	1.37e-05	0.0154	0.37	0.35	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
UCEC	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-4.5	1.37e-05	0.0155	-0.41	-0.35	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
UCEC	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	4.5	1.37e-05	0.0155	0.52	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
UCEC	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	4.5	1.37e-05	0.0155	0.44	0.35	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
UCEC	cis	rs951266	0.505	rs4886579	ENSG00000261143.1	ADAMTS7P3	4.5	1.37e-05	0.0155	0.47	0.35	Post bronchodilator FEV1/FVC ratio;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Pre bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78676914	chr15:77976042~77993057:+
UCEC	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-4.5	1.37e-05	0.0155	-0.34	-0.35	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
UCEC	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-4.5	1.38e-05	0.0155	-0.42	-0.35	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
UCEC	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-4.5	1.38e-05	0.0156	-0.36	-0.35	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-4.5	1.38e-05	0.0156	-0.36	-0.35	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-4.5	1.38e-05	0.0156	-0.36	-0.35	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
UCEC	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	4.5	1.38e-05	0.0156	0.43	0.35	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
UCEC	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	4.5	1.39e-05	0.0156	0.38	0.35	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
UCEC	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-4.5	1.39e-05	0.0156	-0.4	-0.35	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
UCEC	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-4.49	1.39e-05	0.0156	-0.32	-0.35	Height;	chr11:118737823	chr11:118791254~118793137:+
UCEC	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	4.49	1.39e-05	0.0156	0.47	0.35	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
UCEC	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	4.49	1.39e-05	0.0157	0.45	0.35	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
UCEC	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	4.49	1.39e-05	0.0157	0.44	0.35	Depression;	chr6:28167882	chr6:28115628~28116551:+
UCEC	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-4.49	1.39e-05	0.0157	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
UCEC	cis	rs638893	0.541	rs498912	ENSG00000278376.1	RP11-158I9.8	-4.49	1.39e-05	0.0157	-0.44	-0.35	Vitiligo;	chr11:118706288	chr11:118791254~118793137:+
UCEC	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-4.49	1.4e-05	0.0157	-0.36	-0.35	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-4.49	1.4e-05	0.0157	-0.36	-0.35	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
UCEC	cis	rs62103177	0.608	rs4442895	ENSG00000261126.6	RP11-795F19.1	-4.49	1.4e-05	0.0157	-0.4	-0.35	Opioid sensitivity;	chr18:80066399	chr18:80046900~80095482:+
UCEC	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	4.49	1.4e-05	0.0157	0.38	0.35	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
UCEC	cis	rs2445284	0.845	rs3100785	ENSG00000229534.1	HNRNPA1P53	-4.49	1.4e-05	0.0157	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5054380	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs3100786	ENSG00000229534.1	HNRNPA1P53	-4.49	1.4e-05	0.0157	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5054555	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.739	rs2500045	ENSG00000229534.1	HNRNPA1P53	-4.49	1.4e-05	0.0157	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5055319	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500046	ENSG00000229534.1	HNRNPA1P53	-4.49	1.4e-05	0.0157	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5055427	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2445325	ENSG00000229534.1	HNRNPA1P53	-4.49	1.4e-05	0.0157	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5055698	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2445327	ENSG00000229534.1	HNRNPA1P53	-4.49	1.4e-05	0.0157	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5056263	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2500049	ENSG00000229534.1	HNRNPA1P53	-4.49	1.4e-05	0.0157	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5056620	chr11:5571247~5572192:-
UCEC	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	4.49	1.4e-05	0.0157	0.41	0.35	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
UCEC	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	4.49	1.4e-05	0.0157	0.41	0.35	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
UCEC	cis	rs10946940	0.897	rs6456801	ENSG00000216901.1	AL022393.7	4.49	1.4e-05	0.0157	0.37	0.35	Systemic lupus erythematosus;	chr6:27657753	chr6:28176188~28176674:+
UCEC	cis	rs7267979	0.866	rs437635	ENSG00000276952.1	RP5-965G21.6	4.49	1.4e-05	0.0157	0.45	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.899	rs442834	ENSG00000276952.1	RP5-965G21.6	4.49	1.4e-05	0.0157	0.45	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs417110	ENSG00000276952.1	RP5-965G21.6	4.49	1.4e-05	0.0157	0.45	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs449703	ENSG00000276952.1	RP5-965G21.6	4.49	1.4e-05	0.0157	0.45	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs446649	ENSG00000276952.1	RP5-965G21.6	4.49	1.4e-05	0.0157	0.45	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.932	rs431579	ENSG00000276952.1	RP5-965G21.6	4.49	1.4e-05	0.0157	0.45	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25284915~25285588:-
UCEC	cis	rs9319321	0.715	rs7995334	ENSG00000277368.1	RP11-380N8.7	-4.49	1.4e-05	0.0157	-0.36	-0.35	Asthma (toluene diisocyanate-induced);	chr13:26834912	chr13:26222191~26222654:+
UCEC	cis	rs9309473	0.607	rs6716776	ENSG00000163016.8	ALMS1P	4.49	1.4e-05	0.0157	0.39	0.35	Metabolite levels;	chr2:73360585	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.607	rs2421488	ENSG00000163016.8	ALMS1P	4.49	1.4e-05	0.0157	0.39	0.35	Metabolite levels;	chr2:73363497	chr2:73644919~73685576:+
UCEC	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	4.49	1.41e-05	0.0158	0.45	0.35	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
UCEC	cis	rs7177699	0.557	rs12898293	ENSG00000261143.1	ADAMTS7P3	-4.49	1.41e-05	0.0158	-0.45	-0.35	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820226	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.557	rs12898578	ENSG00000261143.1	ADAMTS7P3	-4.49	1.41e-05	0.0158	-0.45	-0.35	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820232	chr15:77976042~77993057:+
UCEC	cis	rs1113500	0.565	rs1781071	ENSG00000226822.1	RP11-356N1.2	4.49	1.41e-05	0.0158	0.47	0.35	Growth-regulated protein alpha levels;	chr1:108028412	chr1:108071482~108074519:+
UCEC	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	4.49	1.41e-05	0.0158	0.42	0.35	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
UCEC	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-4.49	1.42e-05	0.0159	-0.37	-0.35	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
UCEC	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-4.49	1.42e-05	0.0159	-0.37	-0.35	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
UCEC	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	4.49	1.42e-05	0.0159	0.52	0.35	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
UCEC	cis	rs10788972	0.787	rs6674720	ENSG00000225183.1	RP4-758J24.4	-4.49	1.42e-05	0.0159	-0.4	-0.35	Parkinson disease and lewy body pathology;	chr1:54073666	chr1:54089856~54090093:+
UCEC	cis	rs10788972	0.779	rs7516791	ENSG00000225183.1	RP4-758J24.4	-4.49	1.42e-05	0.0159	-0.4	-0.35	Parkinson disease and lewy body pathology;	chr1:54086202	chr1:54089856~54090093:+
UCEC	cis	rs10788972	0.815	rs9651202	ENSG00000225183.1	RP4-758J24.4	-4.49	1.42e-05	0.0159	-0.4	-0.35	Parkinson disease and lewy body pathology;	chr1:54087534	chr1:54089856~54090093:+
UCEC	cis	rs10788972	0.815	rs1981039	ENSG00000225183.1	RP4-758J24.4	-4.49	1.42e-05	0.0159	-0.4	-0.35	Parkinson disease and lewy body pathology;	chr1:54089732	chr1:54089856~54090093:+
UCEC	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	4.49	1.42e-05	0.0159	0.35	0.35	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
UCEC	cis	rs1555322	0.53	rs2425049	ENSG00000269202.1	RP4-614O4.12	-4.49	1.42e-05	0.0159	-0.36	-0.35	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35201747~35203288:-
UCEC	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	4.49	1.42e-05	0.0159	0.43	0.35	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
UCEC	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	4.49	1.42e-05	0.0159	0.36	0.35	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
UCEC	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	4.49	1.42e-05	0.0159	0.36	0.35	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
UCEC	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	4.49	1.42e-05	0.0159	0.43	0.35	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	4.49	1.42e-05	0.0159	0.39	0.35	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	4.49	1.42e-05	0.0159	0.45	0.35	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
UCEC	cis	rs9907295	1	rs9904675	ENSG00000270871.1	AC015849.19	4.49	1.42e-05	0.0159	0.56	0.35	Fibroblast growth factor basic levels;	chr17:35921435	chr17:35816717~35830293:-
UCEC	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-4.49	1.43e-05	0.016	-0.45	-0.35	Depression;	chr6:28147378	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-4.49	1.43e-05	0.016	-0.45	-0.35	Depression;	chr6:28147406	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-4.49	1.43e-05	0.016	-0.45	-0.35	Depression;	chr6:28148143	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-4.49	1.43e-05	0.016	-0.45	-0.35	Depression;	chr6:28149979	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-4.49	1.43e-05	0.016	-0.45	-0.35	Depression;	chr6:28151096	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-4.49	1.43e-05	0.016	-0.45	-0.35	Depression;	chr6:28152885	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-4.49	1.43e-05	0.016	-0.45	-0.35	Depression;	chr6:28153120	chr6:28115628~28116551:+
UCEC	cis	rs2445284	0.715	rs2442424	ENSG00000229534.1	HNRNPA1P53	-4.49	1.43e-05	0.016	-0.42	-0.35	Sickle cell anemia (haemolysis);	chr11:5028719	chr11:5571247~5572192:-
UCEC	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	4.49	1.43e-05	0.016	0.35	0.35	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	4.49	1.43e-05	0.016	0.35	0.35	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	4.49	1.43e-05	0.016	0.35	0.35	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	4.49	1.43e-05	0.016	0.35	0.35	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
UCEC	cis	rs7177699	0.525	rs56076311	ENSG00000261143.1	ADAMTS7P3	4.49	1.43e-05	0.016	0.43	0.35	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78822778	chr15:77976042~77993057:+
UCEC	cis	rs1113500	0.748	rs1781048	ENSG00000226822.1	RP11-356N1.2	4.49	1.43e-05	0.016	0.43	0.35	Growth-regulated protein alpha levels;	chr1:108012428	chr1:108071482~108074519:+
UCEC	cis	rs4713118	0.869	rs9366700	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27729172	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs6456802	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27730576	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs9393851	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27731802	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs9461400	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27732780	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs9295742	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27735053	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs9461401	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27735512	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs6914924	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27743751	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs6930992	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27744341	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs6901520	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27746796	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs9283880	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27747464	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs9283881	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27747476	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.869	rs9283882	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.016	0.4	0.35	Parkinson's disease;	chr6:27747479	chr6:28176188~28176674:+
UCEC	cis	rs9376098	0.698	rs7756303	ENSG00000232876.1	CTA-212D2.2	-4.49	1.43e-05	0.016	-0.41	-0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135148846	chr6:135055033~135060550:+
UCEC	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-4.49	1.43e-05	0.016	-0.42	-0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
UCEC	cis	rs4693167	0.504	rs2169501	ENSG00000248196.1	RP11-476C8.2	-4.49	1.44e-05	0.016	-0.33	-0.35	Blood protein levels;	chr4:87540484	chr4:87166844~87167734:+
UCEC	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-4.49	1.44e-05	0.0161	-0.44	-0.34	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
UCEC	cis	rs6137726	0.524	rs1203944	ENSG00000277901.1	RP5-851M4.1	-4.49	1.44e-05	0.0161	-0.44	-0.34	Amyotrophic lateral sclerosis (sporadic);	chr20:22616241	chr20:23320958~23325352:-
UCEC	cis	rs4693167	0.504	rs2010017	ENSG00000248196.1	RP11-476C8.2	-4.49	1.44e-05	0.0161	-0.33	-0.34	Blood protein levels;	chr4:87531711	chr4:87166844~87167734:+
UCEC	cis	rs8141529	1	rs8141529	ENSG00000226471.5	CTA-292E10.6	-4.49	1.44e-05	0.0161	-0.41	-0.34	Lymphocyte counts;	chr22:28873704	chr22:28800683~28848559:+
UCEC	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-4.49	1.44e-05	0.0161	-0.36	-0.34	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
UCEC	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	4.49	1.44e-05	0.0161	0.36	0.34	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
UCEC	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	4.49	1.44e-05	0.0161	0.44	0.34	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	4.49	1.44e-05	0.0161	0.44	0.34	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	4.49	1.44e-05	0.0161	0.44	0.34	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	4.49	1.44e-05	0.0161	0.44	0.34	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
UCEC	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	4.49	1.44e-05	0.0161	0.44	0.34	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
UCEC	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	4.49	1.44e-05	0.0161	0.36	0.34	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
UCEC	cis	rs763121	0.853	rs2267395	ENSG00000273076.1	RP3-508I15.22	4.48	1.45e-05	0.0162	0.37	0.34	Menopause (age at onset);	chr22:38717898	chr22:38743495~38743910:+
UCEC	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-4.48	1.45e-05	0.0162	-0.42	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
UCEC	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-4.48	1.45e-05	0.0162	-0.39	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-4.48	1.45e-05	0.0162	-0.39	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
UCEC	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	4.48	1.45e-05	0.0162	0.49	0.34	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
UCEC	cis	rs1113500	0.524	rs12145813	ENSG00000226822.1	RP11-356N1.2	4.48	1.45e-05	0.0162	0.49	0.34	Growth-regulated protein alpha levels;	chr1:108027282	chr1:108071482~108074519:+
UCEC	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	4.48	1.45e-05	0.0162	0.38	0.34	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
UCEC	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-4.48	1.46e-05	0.0162	-0.55	-0.34	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
UCEC	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	4.48	1.46e-05	0.0162	0.52	0.34	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
UCEC	cis	rs11971779	0.68	rs2355787	ENSG00000273391.1	RP11-634H22.1	-4.48	1.46e-05	0.0162	-0.38	-0.34	Diisocyanate-induced asthma;	chr7:139405182	chr7:139359032~139359566:-
UCEC	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	4.48	1.46e-05	0.0162	0.46	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
UCEC	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	4.48	1.46e-05	0.0162	0.46	0.34	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
UCEC	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	4.48	1.46e-05	0.0162	0.45	0.34	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
UCEC	cis	rs7208859	0.573	rs7223803	ENSG00000266490.1	CTD-2349P21.9	4.48	1.46e-05	0.0162	0.52	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.5	rs2449749	ENSG00000266490.1	CTD-2349P21.9	4.48	1.46e-05	0.0162	0.52	0.34	Body mass index;	chr17:30751280	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9894709	ENSG00000266490.1	CTD-2349P21.9	4.48	1.46e-05	0.0162	0.52	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9896603	ENSG00000266490.1	CTD-2349P21.9	4.48	1.46e-05	0.0162	0.52	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.636	rs4055314	ENSG00000266490.1	CTD-2349P21.9	4.48	1.46e-05	0.0162	0.52	0.34	Body mass index;	chr17:30752751	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs8080882	ENSG00000266490.1	CTD-2349P21.9	4.48	1.46e-05	0.0162	0.52	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30792372~30792833:+
UCEC	cis	rs10946940	0.93	rs12215012	ENSG00000216901.1	AL022393.7	-4.48	1.46e-05	0.0163	-0.37	-0.34	Systemic lupus erythematosus;	chr6:27539715	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-4.48	1.46e-05	0.0163	-0.41	-0.34	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
UCEC	cis	rs6104690	0.687	rs12479526	ENSG00000270792.4	RP11-103J8.1	-4.48	1.46e-05	0.0163	-0.51	-0.34	Bladder cancer;	chr20:11001336	chr20:10672928~10994924:+
UCEC	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	4.48	1.46e-05	0.0163	0.36	0.34	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
UCEC	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	4.48	1.47e-05	0.0163	0.43	0.34	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
UCEC	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	4.48	1.47e-05	0.0163	0.36	0.34	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	4.48	1.47e-05	0.0163	0.4	0.34	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
UCEC	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-4.48	1.47e-05	0.0163	-0.45	-0.34	Depression;	chr6:28161802	chr6:28115628~28116551:+
UCEC	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-4.48	1.47e-05	0.0164	-0.45	-0.34	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
UCEC	cis	rs34286592	1	rs34127220	ENSG00000238045.8	AC009133.12	4.48	1.47e-05	0.0164	0.55	0.34	Multiple sclerosis;	chr16:29831570	chr16:29808636~29821252:-
UCEC	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	4.48	1.48e-05	0.0164	0.41	0.34	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
UCEC	cis	rs12478296	1	rs59036157	ENSG00000261186.2	RP11-341N2.1	-4.48	1.48e-05	0.0164	-0.48	-0.34	Obesity-related traits;	chr2:242098077	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs56323081	ENSG00000261186.2	RP11-341N2.1	-4.48	1.48e-05	0.0164	-0.48	-0.34	Obesity-related traits;	chr2:242098656	chr2:242087351~242088457:-
UCEC	cis	rs1555322	0.53	rs2425053	ENSG00000269202.1	RP4-614O4.12	-4.48	1.48e-05	0.0164	-0.37	-0.34	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35201747~35203288:-
UCEC	cis	rs847851	0.583	rs3823437	ENSG00000219023.1	RP3-340B19.2	-4.48	1.48e-05	0.0164	-0.31	-0.34	Colonoscopy-negative controls vs population controls;	chr6:35042032	chr6:35555873~35556264:+
UCEC	cis	rs948562	0.69	rs57922517	ENSG00000280010.1	AP001350.4	4.48	1.48e-05	0.0164	0.65	0.34	Lymphoma;	chr11:58334054	chr11:58627435~58628528:+
UCEC	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-4.48	1.48e-05	0.0164	-0.48	-0.34	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
UCEC	cis	rs4789693	0.809	rs8071692	ENSG00000265458.1	RP13-20L14.6	4.48	1.48e-05	0.0165	0.4	0.34	Glucocorticoid-induced osteonecrosis;	chr17:82434457	chr17:82454273~82458521:-
UCEC	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-4.48	1.48e-05	0.0165	-0.4	-0.34	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
UCEC	cis	rs34286592	0.929	rs1057452	ENSG00000260853.1	RP11-264B17.2	-4.48	1.49e-05	0.0165	-0.3	-0.34	Multiple sclerosis;	chr16:29822393	chr16:28956687~28966883:-
UCEC	cis	rs9545047	0.604	rs7336581	ENSG00000227354.5	RBM26-AS1	4.48	1.49e-05	0.0165	0.34	0.34	Schizophrenia;	chr13:79385739	chr13:79406309~79424328:+
UCEC	cis	rs2276314	1	rs56050783	ENSG00000267627.4	RP11-905K4.1	-4.48	1.49e-05	0.0166	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35951803~35966118:-
UCEC	cis	rs2276314	1	rs58054756	ENSG00000267627.4	RP11-905K4.1	-4.48	1.49e-05	0.0166	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35951803~35966118:-
UCEC	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	4.48	1.49e-05	0.0166	0.41	0.34	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
UCEC	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-4.48	1.5e-05	0.0166	-0.45	-0.34	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
UCEC	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-4.48	1.5e-05	0.0166	-0.39	-0.34	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-4.48	1.5e-05	0.0166	-0.39	-0.34	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
UCEC	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-4.48	1.5e-05	0.0166	-0.37	-0.34	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
UCEC	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-4.48	1.5e-05	0.0166	-0.44	-0.34	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
UCEC	cis	rs2281636	0.723	rs11190195	ENSG00000233690.1	EBAG9P1	-4.48	1.5e-05	0.0166	-0.32	-0.34	Obesity-related traits;	chr10:99626710	chr10:99697407~99697949:-
UCEC	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	4.48	1.5e-05	0.0166	0.44	0.34	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
UCEC	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	4.48	1.5e-05	0.0166	0.38	0.34	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	4.48	1.5e-05	0.0166	0.38	0.34	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
UCEC	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-4.48	1.5e-05	0.0166	-0.32	-0.34	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
UCEC	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-4.48	1.5e-05	0.0166	-0.32	-0.34	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
UCEC	cis	rs7914558	1	rs7896547	ENSG00000272912.1	RP11-724N1.1	-4.48	1.5e-05	0.0166	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107201	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.933	rs2066323	ENSG00000272912.1	RP11-724N1.1	-4.48	1.5e-05	0.0166	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103111604	chr10:102914585~102915404:+
UCEC	cis	rs7914558	1	rs7899084	ENSG00000272912.1	RP11-724N1.1	-4.48	1.5e-05	0.0166	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103112790	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs10748837	ENSG00000272912.1	RP11-724N1.1	-4.48	1.5e-05	0.0166	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103120479	chr10:102914585~102915404:+
UCEC	cis	rs9532669	0.926	rs9525418	ENSG00000239827.7	SUGT1P3	4.48	1.51e-05	0.0167	0.35	0.34	Cervical cancer;	chr13:40879081	chr13:40908159~40921774:-
UCEC	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-4.48	1.51e-05	0.0167	-0.33	-0.34	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
UCEC	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-4.48	1.51e-05	0.0167	-0.4	-0.34	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
UCEC	cis	rs2688608	0.904	rs2675669	ENSG00000271816.1	BMS1P4	4.47	1.51e-05	0.0167	0.39	0.34	Inflammatory bowel disease;	chr10:73894114	chr10:73699151~73730487:-
UCEC	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	4.47	1.51e-05	0.0167	0.4	0.34	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
UCEC	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	4.47	1.51e-05	0.0167	0.42	0.34	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
UCEC	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	4.47	1.51e-05	0.0167	0.37	0.34	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
UCEC	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	4.47	1.51e-05	0.0167	0.37	0.34	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
UCEC	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	4.47	1.52e-05	0.0168	0.51	0.34	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
UCEC	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-4.47	1.52e-05	0.0168	-0.33	-0.34	Height;	chr11:118791319	chr11:118791254~118793137:+
UCEC	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-4.47	1.52e-05	0.0168	-0.41	-0.34	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
UCEC	cis	rs8141529	0.748	rs2064261	ENSG00000226471.5	CTA-292E10.6	-4.47	1.52e-05	0.0168	-0.41	-0.34	Lymphocyte counts;	chr22:28891742	chr22:28800683~28848559:+
UCEC	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-4.47	1.53e-05	0.0168	-0.41	-0.34	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
UCEC	cis	rs847851	0.617	rs3807051	ENSG00000219023.1	RP3-340B19.2	-4.47	1.53e-05	0.0169	-0.4	-0.34	Colonoscopy-negative controls vs population controls;	chr6:34954662	chr6:35555873~35556264:+
UCEC	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-4.47	1.53e-05	0.0169	-0.46	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
UCEC	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	4.47	1.53e-05	0.0169	0.39	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
UCEC	cis	rs72901758	0.662	rs56326958	ENSG00000279570.1	CTD-2357A8.2	4.47	1.53e-05	0.0169	0.47	0.34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78254358	chr17:78691266~78691979:-
UCEC	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	4.47	1.53e-05	0.0169	0.42	0.34	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
UCEC	cis	rs10946940	0.965	rs6910838	ENSG00000216901.1	AL022393.7	-4.47	1.53e-05	0.0169	-0.37	-0.34	Systemic lupus erythematosus;	chr6:27547740	chr6:28176188~28176674:+
UCEC	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	4.47	1.53e-05	0.0169	0.45	0.34	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
UCEC	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	4.47	1.53e-05	0.0169	0.37	0.34	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
UCEC	cis	rs7208859	0.673	rs75142521	ENSG00000264538.5	SUZ12P1	-4.47	1.54e-05	0.0169	-0.5	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30709299~30790908:+
UCEC	cis	rs2732480	0.577	rs2634693	ENSG00000226413.2	OR8T1P	4.47	1.54e-05	0.0169	0.51	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.577	rs2634691	ENSG00000226413.2	OR8T1P	4.47	1.54e-05	0.0169	0.51	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48442030~48442947:-
UCEC	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-4.47	1.54e-05	0.0169	-0.45	-0.34	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
UCEC	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-4.47	1.54e-05	0.0169	-0.46	-0.34	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
UCEC	cis	rs9400467	0.508	rs11153293	ENSG00000271789.1	RP5-1112D6.7	-4.47	1.54e-05	0.0169	-0.42	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111297126~111298510:+
UCEC	cis	rs9400467	0.508	rs11756643	ENSG00000271789.1	RP5-1112D6.7	-4.47	1.54e-05	0.0169	-0.42	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111297126~111298510:+
UCEC	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-4.47	1.54e-05	0.017	-0.45	-0.34	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
UCEC	cis	rs1790761	0.505	rs7927657	ENSG00000184224.3	C11orf72	-4.47	1.54e-05	0.017	-0.37	-0.34	Mean corpuscular volume;	chr11:67579517	chr11:67602880~67606706:-
UCEC	cis	rs1790761	0.505	rs7941395	ENSG00000184224.3	C11orf72	-4.47	1.54e-05	0.017	-0.37	-0.34	Mean corpuscular volume;	chr11:67579946	chr11:67602880~67606706:-
UCEC	cis	rs1790761	0.505	rs7941648	ENSG00000184224.3	C11orf72	-4.47	1.54e-05	0.017	-0.37	-0.34	Mean corpuscular volume;	chr11:67580124	chr11:67602880~67606706:-
UCEC	cis	rs1790761	0.505	rs7945035	ENSG00000184224.3	C11orf72	-4.47	1.54e-05	0.017	-0.37	-0.34	Mean corpuscular volume;	chr11:67580691	chr11:67602880~67606706:-
UCEC	cis	rs1790761	0.505	rs2370141	ENSG00000184224.3	C11orf72	-4.47	1.54e-05	0.017	-0.37	-0.34	Mean corpuscular volume;	chr11:67581058	chr11:67602880~67606706:-
UCEC	cis	rs1790761	0.505	rs17593068	ENSG00000184224.3	C11orf72	-4.47	1.54e-05	0.017	-0.37	-0.34	Mean corpuscular volume;	chr11:67583461	chr11:67602880~67606706:-
UCEC	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	4.47	1.54e-05	0.017	0.41	0.34	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
UCEC	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-4.47	1.54e-05	0.017	-0.55	-0.34	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
UCEC	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	4.47	1.54e-05	0.017	0.4	0.34	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
UCEC	cis	rs189798	0.807	rs330905	ENSG00000253893.2	FAM85B	-4.47	1.55e-05	0.017	-0.41	-0.34	Myopia (pathological);	chr8:9136041	chr8:8167819~8226614:-
UCEC	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	4.47	1.55e-05	0.017	0.41	0.34	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
UCEC	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	4.47	1.55e-05	0.017	0.51	0.34	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	4.47	1.55e-05	0.017	0.51	0.34	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
UCEC	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	4.47	1.55e-05	0.0171	0.38	0.34	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
UCEC	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-4.47	1.55e-05	0.0171	-0.43	-0.34	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
UCEC	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-4.47	1.55e-05	0.0171	-0.43	-0.34	Height;	chr3:53085518	chr3:53064283~53065091:-
UCEC	cis	rs9376098	0.698	rs6924521	ENSG00000232876.1	CTA-212D2.2	-4.47	1.56e-05	0.0171	-0.42	-0.34	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146277	chr6:135055033~135060550:+
UCEC	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-4.47	1.56e-05	0.0171	-0.33	-0.34	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
UCEC	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-4.47	1.56e-05	0.0171	-0.37	-0.34	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
UCEC	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-4.47	1.56e-05	0.0171	-0.37	-0.34	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
UCEC	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-4.47	1.56e-05	0.0171	-0.35	-0.34	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-4.47	1.56e-05	0.0171	-0.35	-0.34	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	4.47	1.56e-05	0.0171	0.35	0.34	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	4.47	1.56e-05	0.0171	0.35	0.34	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	4.47	1.56e-05	0.0171	0.35	0.34	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	4.47	1.56e-05	0.0171	0.35	0.34	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	4.47	1.56e-05	0.0171	0.35	0.34	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	4.47	1.56e-05	0.0171	0.35	0.34	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	4.47	1.56e-05	0.0171	0.35	0.34	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	4.47	1.56e-05	0.0171	0.35	0.34	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	4.47	1.56e-05	0.0171	0.35	0.34	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
UCEC	cis	rs9926296	0.585	rs6500441	ENSG00000260259.1	RP11-368I7.4	-4.47	1.56e-05	0.0172	-0.32	-0.34	Vitiligo;	chr16:89762261	chr16:89682620~89686569:-
UCEC	cis	rs948562	0.657	rs11229358	ENSG00000280010.1	AP001350.4	4.47	1.57e-05	0.0172	0.65	0.34	Lymphoma;	chr11:58314088	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.69	rs11229359	ENSG00000280010.1	AP001350.4	4.47	1.57e-05	0.0172	0.65	0.34	Lymphoma;	chr11:58314613	chr11:58627435~58628528:+
UCEC	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-4.47	1.57e-05	0.0172	-0.45	-0.34	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
UCEC	cis	rs7267979	0.868	rs6138546	ENSG00000276952.1	RP5-965G21.6	4.47	1.57e-05	0.0172	0.45	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25284915~25285588:-
UCEC	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	4.47	1.57e-05	0.0172	0.44	0.34	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
UCEC	cis	rs2688608	0.869	rs2633308	ENSG00000271816.1	BMS1P4	4.46	1.57e-05	0.0172	0.4	0.34	Inflammatory bowel disease;	chr10:73894146	chr10:73699151~73730487:-
UCEC	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-4.46	1.57e-05	0.0172	-0.35	-0.34	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-4.46	1.57e-05	0.0172	-0.35	-0.34	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-4.46	1.57e-05	0.0172	-0.35	-0.34	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-4.46	1.57e-05	0.0172	-0.35	-0.34	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-4.46	1.57e-05	0.0172	-0.35	-0.34	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
UCEC	cis	rs6901004	0.803	rs168522	ENSG00000271789.1	RP5-1112D6.7	-4.46	1.57e-05	0.0173	-0.4	-0.34	Blood metabolite levels;	chr6:111185425	chr6:111297126~111298510:+
UCEC	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-4.46	1.57e-05	0.0173	-0.32	-0.34	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
UCEC	cis	rs763121	0.853	rs1056610	ENSG00000273076.1	RP3-508I15.22	-4.46	1.58e-05	0.0173	-0.38	-0.34	Menopause (age at onset);	chr22:38684073	chr22:38743495~38743910:+
UCEC	cis	rs7309	0.967	rs3754970	ENSG00000227403.1	AC009299.3	-4.46	1.58e-05	0.0173	-0.45	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161235325	chr2:161244739~161249050:+
UCEC	cis	rs9527	0.615	rs10883781	ENSG00000236937.2	PTGES3P4	4.46	1.58e-05	0.0173	0.39	0.34	Arsenic metabolism;	chr10:102821373	chr10:102845595~102845950:+
UCEC	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	4.46	1.58e-05	0.0173	0.47	0.34	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
UCEC	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-4.46	1.58e-05	0.0173	-0.32	-0.34	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
UCEC	cis	rs7914558	0.966	rs10786719	ENSG00000272912.1	RP11-724N1.1	4.46	1.58e-05	0.0173	0.34	0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878235	chr10:102914585~102915404:+
UCEC	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-4.46	1.58e-05	0.0173	-0.4	-0.34	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
UCEC	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-4.46	1.59e-05	0.0174	-0.46	-0.34	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
UCEC	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	4.46	1.59e-05	0.0174	0.37	0.34	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
UCEC	cis	rs9532669	0.926	rs2875421	ENSG00000239827.7	SUGT1P3	-4.46	1.59e-05	0.0174	-0.32	-0.34	Cervical cancer;	chr13:40936536	chr13:40908159~40921774:-
UCEC	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	4.46	1.59e-05	0.0174	0.51	0.34	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
UCEC	cis	rs7914558	0.646	rs12768205	ENSG00000272912.1	RP11-724N1.1	-4.46	1.59e-05	0.0174	-0.36	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102888092	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.646	rs10883795	ENSG00000272912.1	RP11-724N1.1	-4.46	1.59e-05	0.0174	-0.36	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894820	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.646	rs10883796	ENSG00000272912.1	RP11-724N1.1	-4.46	1.59e-05	0.0174	-0.36	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895558	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.646	rs4363528	ENSG00000272912.1	RP11-724N1.1	-4.46	1.59e-05	0.0174	-0.36	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895758	chr10:102914585~102915404:+
UCEC	cis	rs524281	0.731	rs3829937	ENSG00000255320.1	RP11-755F10.1	4.46	1.59e-05	0.0174	0.57	0.34	Electroencephalogram traits;	chr11:66020195	chr11:66244840~66246239:-
UCEC	cis	rs524281	0.731	rs10791838	ENSG00000255320.1	RP11-755F10.1	4.46	1.59e-05	0.0174	0.57	0.34	Electroencephalogram traits;	chr11:66022383	chr11:66244840~66246239:-
UCEC	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-4.46	1.59e-05	0.0174	-0.44	-0.34	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-4.46	1.59e-05	0.0174	-0.44	-0.34	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
UCEC	cis	rs7605378	0.528	rs7592587	ENSG00000232732.8	AC073043.1	-4.46	1.59e-05	0.0174	-0.42	-0.34	Osteoporosis;	chr2:199921793	chr2:199867396~199911159:-
UCEC	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-4.46	1.59e-05	0.0174	-0.42	-0.34	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
UCEC	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-4.46	1.6e-05	0.0175	-0.44	-0.34	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
UCEC	cis	rs80130819	0.748	rs7953726	ENSG00000226413.2	OR8T1P	4.46	1.6e-05	0.0175	0.55	0.34	Prostate cancer;	chr12:48217974	chr12:48442030~48442947:-
UCEC	cis	rs80130819	0.636	rs4760623	ENSG00000226413.2	OR8T1P	4.46	1.6e-05	0.0175	0.55	0.34	Prostate cancer;	chr12:48225473	chr12:48442030~48442947:-
UCEC	cis	rs9876781	0.559	rs11130167	ENSG00000229759.1	MRPS18AP1	4.46	1.6e-05	0.0175	0.37	0.34	Longevity;	chr3:48358570	chr3:48256350~48256938:-
UCEC	cis	rs9601248	0.529	rs9545142	ENSG00000227354.5	RBM26-AS1	4.46	1.6e-05	0.0175	0.38	0.34	Major depressive disorder;	chr13:79588420	chr13:79406309~79424328:+
UCEC	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	4.46	1.6e-05	0.0175	0.51	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	4.46	1.6e-05	0.0175	0.51	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
UCEC	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	4.46	1.6e-05	0.0175	0.4	0.34	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
UCEC	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	4.46	1.6e-05	0.0175	0.35	0.34	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
UCEC	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-4.46	1.61e-05	0.0175	-0.42	-0.34	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
UCEC	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-4.46	1.61e-05	0.0175	-0.46	-0.34	Height;	chr3:53080524	chr3:53064283~53065091:-
UCEC	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-4.46	1.61e-05	0.0176	-0.37	-0.34	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
UCEC	cis	rs1555322	0.53	rs6058224	ENSG00000269202.1	RP4-614O4.12	-4.46	1.61e-05	0.0176	-0.37	-0.34	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35201747~35203288:-
UCEC	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-4.46	1.61e-05	0.0176	-0.5	-0.34	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
UCEC	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-4.46	1.61e-05	0.0176	-0.41	-0.34	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
UCEC	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	4.46	1.62e-05	0.0176	0.39	0.34	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
UCEC	cis	rs617219	0.596	rs2131977	ENSG00000245556.2	SCAMP1-AS1	-4.46	1.62e-05	0.0176	-0.33	-0.34	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79318093	chr5:78342365~78360507:-
UCEC	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	4.46	1.62e-05	0.0176	0.43	0.34	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
UCEC	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	4.46	1.62e-05	0.0176	0.36	0.34	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
UCEC	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	4.46	1.62e-05	0.0176	0.44	0.34	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
UCEC	cis	rs2275606	0.92	rs71566450	ENSG00000233452.5	STXBP5-AS1	4.46	1.62e-05	0.0176	0.62	0.34	Leprosy;	chr6:146592301	chr6:146841901~147204614:-
UCEC	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	4.46	1.62e-05	0.0177	0.43	0.34	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
UCEC	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	4.46	1.62e-05	0.0177	0.58	0.34	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
UCEC	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	4.46	1.63e-05	0.0177	0.37	0.34	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
UCEC	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-4.46	1.63e-05	0.0177	-0.36	-0.34	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-4.46	1.63e-05	0.0177	-0.36	-0.34	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
UCEC	cis	rs6840360	0.642	rs1470280	ENSG00000270265.1	RP11-731D1.4	-4.46	1.63e-05	0.0177	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151333775~151353224:-
UCEC	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-4.46	1.63e-05	0.0177	-0.47	-0.34	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
UCEC	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-4.46	1.63e-05	0.0177	-0.36	-0.34	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	4.46	1.63e-05	0.0177	0.35	0.34	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	4.46	1.63e-05	0.0177	0.35	0.34	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	4.46	1.63e-05	0.0177	0.35	0.34	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	4.46	1.63e-05	0.0177	0.35	0.34	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	4.46	1.63e-05	0.0177	0.35	0.34	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	4.46	1.63e-05	0.0177	0.35	0.34	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	4.46	1.63e-05	0.0177	0.35	0.34	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
UCEC	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	4.46	1.63e-05	0.0178	0.44	0.34	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
UCEC	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	4.46	1.63e-05	0.0178	0.44	0.34	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
UCEC	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	4.46	1.63e-05	0.0178	0.44	0.34	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
UCEC	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	4.46	1.63e-05	0.0178	0.44	0.34	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
UCEC	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	4.46	1.63e-05	0.0178	0.44	0.34	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
UCEC	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	4.46	1.64e-05	0.0178	0.57	0.34	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	4.46	1.64e-05	0.0178	0.57	0.34	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	4.46	1.64e-05	0.0178	0.57	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	4.46	1.64e-05	0.0178	0.57	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
UCEC	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-4.45	1.64e-05	0.0178	-0.47	-0.34	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
UCEC	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	4.45	1.64e-05	0.0178	0.45	0.34	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
UCEC	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-4.45	1.64e-05	0.0178	-0.34	-0.34	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
UCEC	cis	rs9532669	0.926	rs7331435	ENSG00000239827.7	SUGT1P3	4.45	1.64e-05	0.0178	0.33	0.34	Cervical cancer;	chr13:40862396	chr13:40908159~40921774:-
UCEC	cis	rs3785356	0.524	rs3024622	ENSG00000261736.1	AC002551.1	4.45	1.64e-05	0.0178	0.32	0.34	Eosinophil counts;Sum eosinophil basophil counts;	chr16:27354132	chr16:27643199~27644663:+
UCEC	cis	rs11690935	0.632	rs12987931	ENSG00000224553.1	AC008065.1	4.45	1.64e-05	0.0179	0.37	0.34	Schizophrenia;	chr2:172036045	chr2:171374931~171375278:-
UCEC	cis	rs12530	0.715	rs5749416	ENSG00000230736.2	RP1-149A16.3	4.45	1.65e-05	0.0179	0.49	0.34	IgG glycosylation;	chr22:32381136	chr22:32376664~32384343:+
UCEC	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-4.45	1.65e-05	0.0179	-0.38	-0.34	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
UCEC	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	4.45	1.65e-05	0.0179	0.51	0.34	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
UCEC	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-4.45	1.65e-05	0.0179	-0.43	-0.34	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
UCEC	cis	rs2732480	0.557	rs2732441	ENSG00000226413.2	OR8T1P	4.45	1.65e-05	0.0179	0.51	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48442030~48442947:-
UCEC	cis	rs8141529	0.702	rs469990	ENSG00000272858.1	CTA-292E10.8	-4.45	1.65e-05	0.0179	-0.44	-0.34	Lymphocyte counts;	chr22:28908212	chr22:28814914~28815662:+
UCEC	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-4.45	1.65e-05	0.0179	-0.42	-0.34	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
UCEC	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	4.45	1.65e-05	0.0179	0.37	0.34	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
UCEC	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-4.45	1.65e-05	0.0179	-0.37	-0.34	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
UCEC	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-4.45	1.65e-05	0.0179	-0.45	-0.34	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
UCEC	cis	rs617219	0.552	rs7736709	ENSG00000245556.2	SCAMP1-AS1	-4.45	1.65e-05	0.0179	-0.34	-0.34	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79328809	chr5:78342365~78360507:-
UCEC	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	4.45	1.66e-05	0.0179	0.45	0.34	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	4.45	1.66e-05	0.0179	0.45	0.34	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
UCEC	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	4.45	1.66e-05	0.0179	0.45	0.34	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
UCEC	cis	rs12744310	1	rs12031169	ENSG00000235358.1	RP11-399E6.1	4.45	1.66e-05	0.018	0.57	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302579	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.943	rs35502198	ENSG00000235358.1	RP11-399E6.1	4.45	1.66e-05	0.018	0.57	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302869	chr1:41242373~41284861:+
UCEC	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-4.45	1.66e-05	0.018	-0.38	-0.34	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-4.45	1.66e-05	0.018	-0.38	-0.34	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
UCEC	cis	rs507080	0.961	rs520543	ENSG00000278376.1	RP11-158I9.8	-4.45	1.66e-05	0.018	-0.33	-0.34	Serum metabolite levels;	chr11:118667448	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.922	rs4589335	ENSG00000278376.1	RP11-158I9.8	-4.45	1.66e-05	0.018	-0.33	-0.34	Serum metabolite levels;	chr11:118668431	chr11:118791254~118793137:+
UCEC	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-4.45	1.66e-05	0.018	-0.52	-0.34	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
UCEC	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	4.45	1.67e-05	0.018	0.59	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
UCEC	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-4.45	1.67e-05	0.0181	-0.41	-0.34	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
UCEC	cis	rs9532669	0.963	rs9562238	ENSG00000239827.7	SUGT1P3	-4.45	1.67e-05	0.0181	-0.32	-0.34	Cervical cancer;	chr13:40924785	chr13:40908159~40921774:-
UCEC	cis	rs9532669	0.963	rs2324739	ENSG00000239827.7	SUGT1P3	-4.45	1.67e-05	0.0181	-0.32	-0.34	Cervical cancer;	chr13:40925479	chr13:40908159~40921774:-
UCEC	cis	rs12439619	0.846	rs7496227	ENSG00000255769.6	GOLGA2P10	-4.45	1.67e-05	0.0181	-0.46	-0.34	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472993~82513950:-
UCEC	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	4.45	1.67e-05	0.0181	0.49	0.34	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
UCEC	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-4.45	1.67e-05	0.0181	-0.41	-0.34	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
UCEC	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-4.45	1.67e-05	0.0181	-0.41	-0.34	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
UCEC	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-4.45	1.67e-05	0.0181	-0.4	-0.34	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
UCEC	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-4.45	1.67e-05	0.0181	-0.35	-0.34	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
UCEC	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-4.45	1.68e-05	0.0181	-0.45	-0.34	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
UCEC	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	4.45	1.68e-05	0.0181	0.42	0.34	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	4.45	1.68e-05	0.0181	0.42	0.34	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
UCEC	cis	rs9545047	0.901	rs1212082	ENSG00000227354.5	RBM26-AS1	4.45	1.68e-05	0.0181	0.38	0.34	Schizophrenia;	chr13:79552633	chr13:79406309~79424328:+
UCEC	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	4.45	1.68e-05	0.0181	0.44	0.34	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
UCEC	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	4.45	1.68e-05	0.0182	0.36	0.34	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	4.45	1.68e-05	0.0182	0.36	0.34	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	4.45	1.68e-05	0.0182	0.36	0.34	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	4.45	1.68e-05	0.0182	0.36	0.34	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
UCEC	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	4.45	1.68e-05	0.0182	0.36	0.34	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	4.45	1.68e-05	0.0182	0.37	0.34	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
UCEC	cis	rs7552806	1	rs7552806	ENSG00000176754.11	LINC00303	-4.45	1.69e-05	0.0182	-0.64	-0.34	Dental caries;	chr1:204814890	chr1:204032447~204041265:-
UCEC	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	4.45	1.69e-05	0.0182	0.36	0.34	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
UCEC	cis	rs8089364	0.917	rs12969709	ENSG00000267742.1	FAM60CP	4.45	1.69e-05	0.0182	0.3	0.34	Body mass index;Type 2 diabetes;	chr18:60192330	chr18:60016778~60017441:-
UCEC	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-4.45	1.69e-05	0.0182	-0.4	-0.34	Height;	chr2:46615271	chr2:46668870~46670778:+
UCEC	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-4.45	1.69e-05	0.0182	-0.4	-0.34	Height;	chr2:46616492	chr2:46668870~46670778:+
UCEC	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-4.45	1.69e-05	0.0182	-0.41	-0.34	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
UCEC	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	4.45	1.69e-05	0.0182	0.49	0.34	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
UCEC	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	4.45	1.69e-05	0.0183	0.57	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
UCEC	cis	rs9376098	0.698	rs6908307	ENSG00000232876.1	CTA-212D2.2	-4.45	1.69e-05	0.0183	-0.41	-0.34	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135141542	chr6:135055033~135060550:+
UCEC	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-4.45	1.7e-05	0.0183	-0.45	-0.34	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
UCEC	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-4.45	1.7e-05	0.0183	-0.4	-0.34	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-4.45	1.7e-05	0.0183	-0.4	-0.34	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	4.45	1.7e-05	0.0183	0.4	0.34	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
UCEC	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	4.45	1.7e-05	0.0184	0.4	0.34	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	4.45	1.7e-05	0.0184	0.4	0.34	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
UCEC	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-4.44	1.71e-05	0.0184	-0.45	-0.34	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
UCEC	cis	rs4699052	0.625	rs28498687	ENSG00000248740.4	RP11-328K4.1	4.44	1.71e-05	0.0184	0.36	0.34	Testicular germ cell tumor;	chr4:103412574	chr4:103256159~103453658:+
UCEC	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-4.44	1.71e-05	0.0184	-0.43	-0.34	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
UCEC	cis	rs10946940	0.965	rs6915266	ENSG00000216901.1	AL022393.7	-4.44	1.71e-05	0.0184	-0.36	-0.34	Systemic lupus erythematosus;	chr6:27560864	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.862	rs6460290	ENSG00000236529.1	RP13-254B10.1	-4.44	1.71e-05	0.0184	-0.38	-0.34	Aortic root size;	chr7:66344119	chr7:65840212~65840596:+
UCEC	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	4.44	1.71e-05	0.0184	0.39	0.34	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
UCEC	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-4.44	1.71e-05	0.0184	-0.38	-0.34	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
UCEC	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	4.44	1.72e-05	0.0184	0.44	0.34	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	4.44	1.72e-05	0.0184	0.44	0.34	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
UCEC	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	4.44	1.72e-05	0.0185	0.41	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
UCEC	cis	rs6430585	0.528	rs309133	ENSG00000231890.6	DARS-AS1	-4.44	1.72e-05	0.0185	-0.45	-0.34	Corneal structure;	chr2:135994272	chr2:135985176~136022593:+
UCEC	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	4.44	1.72e-05	0.0185	0.86	0.34	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
UCEC	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	4.44	1.72e-05	0.0185	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-4.44	1.72e-05	0.0185	-0.35	-0.34	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-4.44	1.72e-05	0.0185	-0.35	-0.34	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
UCEC	cis	rs4713118	0.869	rs7773070	ENSG00000216901.1	AL022393.7	4.44	1.72e-05	0.0185	0.39	0.34	Parkinson's disease;	chr6:27761048	chr6:28176188~28176674:+
UCEC	cis	rs6901004	0.803	rs354545	ENSG00000271789.1	RP5-1112D6.7	-4.44	1.73e-05	0.0185	-0.4	-0.34	Blood metabolite levels;	chr6:111210209	chr6:111297126~111298510:+
UCEC	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	4.44	1.73e-05	0.0185	0.35	0.34	Height;	chr6:109332929	chr6:109382795~109383666:+
UCEC	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	4.44	1.73e-05	0.0185	0.61	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
UCEC	cis	rs4713118	0.866	rs9468217	ENSG00000216901.1	AL022393.7	4.44	1.73e-05	0.0186	0.42	0.34	Parkinson's disease;	chr6:27758688	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.911	rs9295746	ENSG00000216901.1	AL022393.7	4.44	1.73e-05	0.0186	0.42	0.34	Parkinson's disease;	chr6:27762285	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	4.44	1.73e-05	0.0186	0.41	0.34	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
UCEC	cis	rs948562	0.895	rs11229537	ENSG00000280010.1	AP001350.4	4.44	1.73e-05	0.0186	0.69	0.34	Lymphoma;	chr11:58585392	chr11:58627435~58628528:+
UCEC	cis	rs7605378	0.528	rs281780	ENSG00000232732.8	AC073043.1	-4.44	1.73e-05	0.0186	-0.44	-0.34	Osteoporosis;	chr2:199891608	chr2:199867396~199911159:-
UCEC	cis	rs7605378	0.528	rs1704190	ENSG00000232732.8	AC073043.1	-4.44	1.73e-05	0.0186	-0.44	-0.34	Osteoporosis;	chr2:199895906	chr2:199867396~199911159:-
UCEC	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	4.44	1.73e-05	0.0186	0.38	0.34	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
UCEC	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	4.44	1.74e-05	0.0186	0.37	0.34	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
UCEC	cis	rs9322193	0.923	rs9688452	ENSG00000223701.3	RAET1E-AS1	4.44	1.74e-05	0.0186	0.37	0.34	Lung cancer;	chr6:149658764	chr6:149884431~149919508:+
UCEC	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	4.44	1.74e-05	0.0186	0.35	0.34	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
UCEC	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	4.44	1.74e-05	0.0187	0.4	0.34	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	4.44	1.74e-05	0.0187	0.4	0.34	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
UCEC	cis	rs617219	0.671	rs2607144	ENSG00000245556.2	SCAMP1-AS1	4.44	1.75e-05	0.0187	0.32	0.34	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79260975	chr5:78342365~78360507:-
UCEC	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-4.44	1.75e-05	0.0187	-0.48	-0.34	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
UCEC	cis	rs9376098	0.698	rs9494155	ENSG00000232876.1	CTA-212D2.2	-4.44	1.75e-05	0.0187	-0.41	-0.34	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135147753	chr6:135055033~135060550:+
UCEC	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	4.44	1.75e-05	0.0187	0.45	0.34	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
UCEC	cis	rs7688540	0.8	rs10003142	ENSG00000211553.1	AC253576.2	-4.44	1.75e-05	0.0187	-0.4	-0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:136461~136568:+
UCEC	cis	rs7688540	0.771	rs11723803	ENSG00000211553.1	AC253576.2	-4.44	1.75e-05	0.0187	-0.4	-0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:136461~136568:+
UCEC	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	4.44	1.75e-05	0.0187	0.41	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
UCEC	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-4.44	1.75e-05	0.0187	-0.36	-0.34	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
UCEC	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-4.44	1.75e-05	0.0187	-0.35	-0.34	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
UCEC	cis	rs11585386	1	rs11585386	ENSG00000201321.1	RNA5S9	-4.44	1.76e-05	0.0187	-0.31	-0.34	Aging;	chr1:228883401	chr1:228628148~228628266:-
UCEC	cis	rs9545047	0.604	rs9318634	ENSG00000227354.5	RBM26-AS1	-4.44	1.76e-05	0.0187	-0.34	-0.34	Schizophrenia;	chr13:79369303	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.547	rs1590465	ENSG00000227354.5	RBM26-AS1	-4.44	1.76e-05	0.0187	-0.34	-0.34	Schizophrenia;	chr13:79393998	chr13:79406309~79424328:+
UCEC	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	4.44	1.76e-05	0.0187	0.42	0.34	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
UCEC	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	4.44	1.76e-05	0.0188	0.39	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
UCEC	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-4.44	1.76e-05	0.0188	-0.39	-0.34	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
UCEC	cis	rs6840360	0.642	rs7676493	ENSG00000270265.1	RP11-731D1.4	-4.44	1.76e-05	0.0188	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs11735957	ENSG00000270265.1	RP11-731D1.4	-4.44	1.76e-05	0.0188	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs11099819	ENSG00000270265.1	RP11-731D1.4	-4.44	1.76e-05	0.0188	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs11726254	ENSG00000270265.1	RP11-731D1.4	-4.44	1.76e-05	0.0188	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2053566	ENSG00000270265.1	RP11-731D1.4	-4.44	1.76e-05	0.0188	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.607	rs1561918	ENSG00000270265.1	RP11-731D1.4	-4.44	1.76e-05	0.0188	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs1443089	ENSG00000270265.1	RP11-731D1.4	-4.44	1.76e-05	0.0188	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151333775~151353224:-
UCEC	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-4.44	1.76e-05	0.0188	-0.37	-0.34	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
UCEC	cis	rs507080	0.845	rs613377	ENSG00000278376.1	RP11-158I9.8	-4.44	1.76e-05	0.0188	-0.33	-0.34	Serum metabolite levels;	chr11:118685375	chr11:118791254~118793137:+
UCEC	cis	rs1667284	0.935	rs1791161	ENSG00000266521.1	RP11-650P15.1	4.44	1.76e-05	0.0188	0.4	0.34	Problematic alcohol use in trauma-exposed individuals;	chr18:31624247	chr18:31496645~31497195:-
UCEC	cis	rs3741578	0.702	rs10506348	ENSG00000274569.1	RP11-121C6.4	4.44	1.77e-05	0.0188	0.47	0.34	Asthma;	chr12:56937586	chr12:56413647~56414045:-
UCEC	cis	rs7208859	0.623	rs55814012	ENSG00000266490.1	CTD-2349P21.9	4.44	1.77e-05	0.0188	0.51	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30792372~30792833:+
UCEC	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-4.44	1.77e-05	0.0188	-0.42	-0.34	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-4.44	1.77e-05	0.0188	-0.42	-0.34	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-4.44	1.77e-05	0.0188	-0.42	-0.34	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
UCEC	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-4.44	1.77e-05	0.0189	-0.44	-0.34	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-4.44	1.77e-05	0.0189	-0.44	-0.34	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
UCEC	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	4.44	1.77e-05	0.0189	0.44	0.34	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
UCEC	cis	rs7240205	0.853	rs10454719	ENSG00000275805.1	RP11-349H17.2	-4.44	1.77e-05	0.0189	-0.42	-0.34	Breast cancer;	chr18:26559666	chr18:26565723~26575626:-
UCEC	cis	rs6901004	0.803	rs354544	ENSG00000271789.1	RP5-1112D6.7	-4.44	1.77e-05	0.0189	-0.4	-0.34	Blood metabolite levels;	chr6:111209956	chr6:111297126~111298510:+
UCEC	cis	rs9527	0.662	rs10786714	ENSG00000236937.2	PTGES3P4	4.44	1.78e-05	0.0189	0.37	0.34	Arsenic metabolism;	chr10:102838849	chr10:102845595~102845950:+
UCEC	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	4.44	1.78e-05	0.0189	0.4	0.34	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
UCEC	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	4.44	1.78e-05	0.0189	0.38	0.34	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
UCEC	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	4.44	1.78e-05	0.0189	0.39	0.34	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
UCEC	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-4.44	1.78e-05	0.0189	-0.37	-0.34	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
UCEC	cis	rs12780046	0.656	rs34813071	ENSG00000229278.1	RP11-483F11.7	4.43	1.78e-05	0.0189	0.63	0.34	Non-glioblastoma glioma;	chr10:99350003	chr10:99651989~99653905:-
UCEC	cis	rs17471911	0.541	rs17111543	ENSG00000229278.1	RP11-483F11.7	4.43	1.78e-05	0.0189	0.63	0.34	Neuroticism;	chr10:99350153	chr10:99651989~99653905:-
UCEC	cis	rs9907295	0.685	rs9909050	ENSG00000270871.1	AC015849.19	4.43	1.78e-05	0.0189	0.51	0.34	Fibroblast growth factor basic levels;	chr17:35887129	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.901	rs59338510	ENSG00000270871.1	AC015849.19	4.43	1.78e-05	0.0189	0.51	0.34	Fibroblast growth factor basic levels;	chr17:35888098	chr17:35816717~35830293:-
UCEC	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-4.43	1.78e-05	0.019	-0.39	-0.34	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
UCEC	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-4.43	1.78e-05	0.019	-0.46	-0.34	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
UCEC	cis	rs763121	0.853	rs10135	ENSG00000273076.1	RP3-508I15.22	-4.43	1.78e-05	0.019	-0.37	-0.34	Menopause (age at onset);	chr22:38686169	chr22:38743495~38743910:+
UCEC	cis	rs3020736	0.5	rs6002597	ENSG00000205702.9	CYP2D7	-4.43	1.79e-05	0.019	-0.4	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs7292241	ENSG00000205702.9	CYP2D7	-4.43	1.79e-05	0.019	-0.4	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs6002603	ENSG00000205702.9	CYP2D7	-4.43	1.79e-05	0.019	-0.4	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42140203~42144577:-
UCEC	cis	rs3020736	0.5	rs5996111	ENSG00000205702.9	CYP2D7	-4.43	1.79e-05	0.019	-0.4	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42140203~42144577:-
UCEC	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-4.43	1.79e-05	0.019	-0.4	-0.34	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-4.43	1.79e-05	0.019	-0.4	-0.34	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
UCEC	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-4.43	1.79e-05	0.019	-0.56	-0.34	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
UCEC	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-4.43	1.79e-05	0.019	-0.45	-0.34	AIDS;	chr2:105300178	chr2:105324210~105330529:+
UCEC	cis	rs2273788	0.837	rs13297520	ENSG00000204173.9	LRRC37A5P	4.43	1.79e-05	0.019	0.47	0.34	Monocyte count;	chr9:111588861	chr9:111602831~111631289:-
UCEC	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	4.43	1.8e-05	0.0191	0.42	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
UCEC	cis	rs2276314	1	rs2276314	ENSG00000267627.4	RP11-905K4.1	4.43	1.8e-05	0.0191	0.39	0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35951803~35966118:-
UCEC	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	4.43	1.8e-05	0.0191	0.39	0.34	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-4.43	1.8e-05	0.0191	-0.37	-0.34	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
UCEC	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-4.43	1.8e-05	0.0191	-0.49	-0.34	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
UCEC	cis	rs7246967	0.673	rs4933027	ENSG00000198153.8	ZNF849P	4.43	1.8e-05	0.0191	0.39	0.34	Bronchopulmonary dysplasia;	chr19:22721170	chr19:22685167~22686732:+
UCEC	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	4.43	1.8e-05	0.0191	0.61	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	4.43	1.8e-05	0.0191	0.61	0.34	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	4.43	1.8e-05	0.0191	0.61	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	4.43	1.8e-05	0.0191	0.61	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	4.43	1.8e-05	0.0191	0.61	0.34	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	4.43	1.8e-05	0.0191	0.61	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
UCEC	cis	rs12681963	0.925	rs7845133	ENSG00000271869.1	RP11-51J9.5	-4.43	1.8e-05	0.0191	-0.33	-0.34	Migraine;	chr8:30098071	chr8:30155830~30156232:-
UCEC	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	4.43	1.8e-05	0.0191	0.4	0.34	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
UCEC	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-4.43	1.8e-05	0.0191	-0.4	-0.34	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
UCEC	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	4.43	1.8e-05	0.0191	0.39	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-4.43	1.8e-05	0.0191	-0.39	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
UCEC	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-4.43	1.8e-05	0.0191	-0.37	-0.34	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
UCEC	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-4.43	1.8e-05	0.0191	-0.37	-0.34	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
UCEC	cis	rs6840360	0.582	rs2709823	ENSG00000270265.1	RP11-731D1.4	-4.43	1.81e-05	0.0191	-0.33	-0.34	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151333775~151353224:-
UCEC	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	4.43	1.81e-05	0.0191	0.36	0.34	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
UCEC	cis	rs2445284	0.845	rs2500026	ENSG00000229534.1	HNRNPA1P53	-4.43	1.81e-05	0.0192	-0.42	-0.34	Sickle cell anemia (haemolysis);	chr11:5048038	chr11:5571247~5572192:-
UCEC	cis	rs7760535	0.794	rs12529158	ENSG00000271789.1	RP5-1112D6.7	4.43	1.81e-05	0.0192	0.41	0.34	Metabolic traits;	chr6:111501244	chr6:111297126~111298510:+
UCEC	cis	rs2276314	0.857	rs6507158	ENSG00000267627.4	RP11-905K4.1	-4.43	1.81e-05	0.0192	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35951803~35966118:-
UCEC	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-4.43	1.82e-05	0.0192	-0.4	-0.34	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
UCEC	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	4.43	1.82e-05	0.0192	0.43	0.34	Height;	chr3:53091453	chr3:53064283~53065091:-
UCEC	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-4.43	1.82e-05	0.0193	-0.39	-0.34	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-4.43	1.82e-05	0.0193	-0.39	-0.34	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
UCEC	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	4.43	1.82e-05	0.0193	0.45	0.34	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
UCEC	cis	rs7688540	0.8	rs73793597	ENSG00000211553.1	AC253576.2	-4.43	1.83e-05	0.0193	-0.4	-0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:136461~136568:+
UCEC	cis	rs7688540	0.8	rs61792060	ENSG00000211553.1	AC253576.2	-4.43	1.83e-05	0.0193	-0.4	-0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:136461~136568:+
UCEC	cis	rs2976388	0.669	rs2976391	ENSG00000253931.1	RP11-909N17.2	4.43	1.83e-05	0.0193	0.35	0.34	Urinary tract infection frequency;	chr8:142681306	chr8:143412749~143417054:+
UCEC	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	4.43	1.83e-05	0.0193	0.35	0.34	Height;	chr6:109358227	chr6:109382795~109383666:+
UCEC	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-4.43	1.83e-05	0.0193	-0.44	-0.34	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
UCEC	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	4.43	1.84e-05	0.0194	0.39	0.34	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
UCEC	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	4.43	1.84e-05	0.0194	0.51	0.34	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
UCEC	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-4.43	1.84e-05	0.0195	-0.43	-0.34	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
UCEC	cis	rs12744310	0.887	rs12724625	ENSG00000235358.1	RP11-399E6.1	4.43	1.85e-05	0.0195	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316598	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12041352	ENSG00000235358.1	RP11-399E6.1	4.43	1.85e-05	0.0195	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317109	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs28566545	ENSG00000235358.1	RP11-399E6.1	4.43	1.85e-05	0.0195	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317561	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs16828067	ENSG00000235358.1	RP11-399E6.1	4.43	1.85e-05	0.0195	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317880	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs16828071	ENSG00000235358.1	RP11-399E6.1	4.43	1.85e-05	0.0195	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317931	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs67483852	ENSG00000235358.1	RP11-399E6.1	4.43	1.85e-05	0.0195	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41318793	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs36015391	ENSG00000235358.1	RP11-399E6.1	4.43	1.85e-05	0.0195	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319133	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs28399806	ENSG00000235358.1	RP11-399E6.1	4.43	1.85e-05	0.0195	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319299	chr1:41242373~41284861:+
UCEC	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-4.43	1.85e-05	0.0195	-0.47	-0.34	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
UCEC	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	4.43	1.85e-05	0.0195	0.44	0.34	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
UCEC	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-4.43	1.85e-05	0.0195	-0.35	-0.34	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
UCEC	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-4.42	1.86e-05	0.0196	-0.73	-0.34	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
UCEC	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-4.42	1.86e-05	0.0196	-0.45	-0.34	Depression;	chr6:28159925	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-4.42	1.86e-05	0.0196	-0.45	-0.34	Depression;	chr6:28159932	chr6:28115628~28116551:+
UCEC	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	4.42	1.86e-05	0.0196	0.36	0.34	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
UCEC	cis	rs875971	0.862	rs778724	ENSG00000236529.1	RP13-254B10.1	4.42	1.86e-05	0.0196	0.39	0.34	Aortic root size;	chr7:66364304	chr7:65840212~65840596:+
UCEC	cis	rs62103177	0.584	rs9956207	ENSG00000261126.6	RP11-795F19.1	-4.42	1.86e-05	0.0196	-0.4	-0.34	Opioid sensitivity;	chr18:80210509	chr18:80046900~80095482:+
UCEC	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-4.42	1.86e-05	0.0196	-0.36	-0.34	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
UCEC	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-4.42	1.86e-05	0.0196	-0.39	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
UCEC	cis	rs7177699	0.534	rs4387568	ENSG00000261143.1	ADAMTS7P3	4.42	1.86e-05	0.0197	0.43	0.34	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78817172	chr15:77976042~77993057:+
UCEC	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	4.42	1.87e-05	0.0197	0.44	0.34	Height;	chr3:53072864	chr3:53064283~53065091:-
UCEC	cis	rs1659258	0.649	rs6728787	ENSG00000253998.3	IGKV2-29	-4.42	1.87e-05	0.0197	-0.51	-0.34	Visceral fat;	chr2:88275308	chr2:89234174~89234912:-
UCEC	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	4.42	1.87e-05	0.0197	0.39	0.34	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	4.42	1.87e-05	0.0197	0.39	0.34	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	4.42	1.87e-05	0.0197	0.39	0.34	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	4.42	1.87e-05	0.0197	0.39	0.34	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	4.42	1.87e-05	0.0197	0.39	0.34	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	4.42	1.87e-05	0.0197	0.39	0.34	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
UCEC	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-4.42	1.87e-05	0.0197	-0.39	-0.34	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	4.42	1.88e-05	0.0197	0.38	0.34	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
UCEC	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	4.42	1.88e-05	0.0198	0.36	0.34	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
UCEC	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-4.42	1.88e-05	0.0198	-0.33	-0.34	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
UCEC	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-4.42	1.88e-05	0.0198	-0.48	-0.34	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
UCEC	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-4.42	1.88e-05	0.0198	-0.48	-0.34	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
UCEC	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-4.42	1.88e-05	0.0198	-0.45	-0.34	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
UCEC	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
UCEC	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	4.42	1.88e-05	0.0198	0.86	0.34	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
UCEC	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-4.42	1.88e-05	0.0198	-0.35	-0.34	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-4.42	1.88e-05	0.0198	-0.35	-0.34	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-4.42	1.88e-05	0.0198	-0.35	-0.34	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
UCEC	cis	rs11971779	0.68	rs11765421	ENSG00000273391.1	RP11-634H22.1	4.42	1.89e-05	0.0198	0.38	0.34	Diisocyanate-induced asthma;	chr7:139340348	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.715	rs10265	ENSG00000273391.1	RP11-634H22.1	4.42	1.89e-05	0.0198	0.38	0.34	Diisocyanate-induced asthma;	chr7:139341406	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs6965143	ENSG00000273391.1	RP11-634H22.1	4.42	1.89e-05	0.0198	0.38	0.34	Diisocyanate-induced asthma;	chr7:139341862	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs11771715	ENSG00000273391.1	RP11-634H22.1	4.42	1.89e-05	0.0198	0.38	0.34	Diisocyanate-induced asthma;	chr7:139342750	chr7:139359032~139359566:-
UCEC	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	4.42	1.89e-05	0.0198	0.42	0.34	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	4.42	1.89e-05	0.0198	0.42	0.34	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	4.42	1.89e-05	0.0198	0.42	0.34	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	4.42	1.89e-05	0.0198	0.42	0.34	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	4.42	1.89e-05	0.0198	0.42	0.34	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
UCEC	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	4.42	1.89e-05	0.0198	0.42	0.34	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	4.42	1.89e-05	0.0198	0.42	0.34	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	4.42	1.89e-05	0.0198	0.42	0.34	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	4.42	1.89e-05	0.0198	0.42	0.34	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	4.42	1.89e-05	0.0198	0.42	0.34	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	4.42	1.89e-05	0.0198	0.42	0.34	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	4.42	1.89e-05	0.0198	0.42	0.34	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
UCEC	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	4.42	1.89e-05	0.0198	0.4	0.34	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
UCEC	cis	rs7916697	0.52	rs12265247	ENSG00000233590.1	RP11-153K11.3	-4.42	1.89e-05	0.0199	-0.38	-0.34	Optic disc area;	chr10:68278641	chr10:68233251~68242379:-
UCEC	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28154567	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28156691	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28158424	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28159056	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28159666	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28159843	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28162053	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28162598	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28163375	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28163759	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28164580	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28164825	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28164948	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28165025	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28165528	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28168434	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28169019	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28169249	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28169676	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28169755	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28169791	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28170075	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28173770	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28174809	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28175233	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28176973	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0199	-0.44	-0.34	Depression;	chr6:28180209	chr6:28115628~28116551:+
UCEC	cis	rs7914558	0.621	rs7896290	ENSG00000272912.1	RP11-724N1.1	-4.42	1.9e-05	0.0199	-0.36	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102896258	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.621	rs12219346	ENSG00000272912.1	RP11-724N1.1	-4.42	1.9e-05	0.0199	-0.36	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102897543	chr10:102914585~102915404:+
UCEC	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-4.42	1.9e-05	0.0199	-0.64	-0.34	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
UCEC	cis	rs7246967	0.544	rs420861	ENSG00000198153.8	ZNF849P	-4.42	1.9e-05	0.0199	-0.43	-0.34	Bronchopulmonary dysplasia;	chr19:22823102	chr19:22685167~22686732:+
UCEC	cis	rs4789693	0.546	rs7220204	ENSG00000265458.1	RP13-20L14.6	4.42	1.9e-05	0.0199	0.38	0.34	Glucocorticoid-induced osteonecrosis;	chr17:82418254	chr17:82454273~82458521:-
UCEC	cis	rs7267979	0.808	rs84816	ENSG00000276952.1	RP5-965G21.6	4.42	1.9e-05	0.0199	0.44	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25284915~25285588:-
UCEC	cis	rs1667255	1	rs2704058	ENSG00000266521.1	RP11-650P15.1	-4.42	1.91e-05	0.02	-0.38	-0.34	Retinol levels;	chr18:31577605	chr18:31496645~31497195:-
UCEC	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-4.42	1.91e-05	0.02	-0.45	-0.34	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
UCEC	cis	rs6840360	0.557	rs1143036	ENSG00000270265.1	RP11-731D1.4	-4.42	1.91e-05	0.02	-0.33	-0.34	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151333775~151353224:-
UCEC	cis	rs9400467	0.5	rs1361425	ENSG00000271789.1	RP5-1112D6.7	-4.42	1.91e-05	0.02	-0.4	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111151040	chr6:111297126~111298510:+
UCEC	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	4.42	1.91e-05	0.02	0.39	0.34	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
UCEC	cis	rs9545047	0.604	rs9601226	ENSG00000227354.5	RBM26-AS1	-4.42	1.91e-05	0.02	-0.34	-0.34	Schizophrenia;	chr13:79403400	chr13:79406309~79424328:+
UCEC	cis	rs853679	0.55	rs1233701	ENSG00000216901.1	AL022393.7	-4.42	1.91e-05	0.02	-0.41	-0.34	Depression;	chr6:28200948	chr6:28176188~28176674:+
UCEC	cis	rs2115630	1	rs8037423	ENSG00000225151.9	GOLGA2P7	4.42	1.92e-05	0.0201	0.37	0.34	P wave terminal force;	chr15:84812263	chr15:84199311~84230136:-
UCEC	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	4.42	1.92e-05	0.0201	0.41	0.34	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
UCEC	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	4.42	1.92e-05	0.0201	0.38	0.34	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
UCEC	cis	rs4845570	1	rs4845356	ENSG00000203288.3	RP11-98D18.9	4.42	1.92e-05	0.0201	0.49	0.34	Coronary artery disease;	chr1:151786747	chr1:151790804~151794402:+
UCEC	cis	rs6137726	0.508	rs2424456	ENSG00000277901.1	RP5-851M4.1	4.42	1.92e-05	0.0201	0.5	0.34	Amyotrophic lateral sclerosis (sporadic);	chr20:22663024	chr20:23320958~23325352:-
UCEC	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-4.42	1.92e-05	0.0201	-0.37	-0.34	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
UCEC	cis	rs4713118	0.869	rs7776351	ENSG00000216901.1	AL022393.7	-4.42	1.93e-05	0.0201	-0.39	-0.34	Parkinson's disease;	chr6:27758952	chr6:28176188~28176674:+
UCEC	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-4.42	1.93e-05	0.0202	-0.43	-0.34	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
UCEC	cis	rs7240205	0.853	rs1941160	ENSG00000275805.1	RP11-349H17.2	4.42	1.93e-05	0.0202	0.43	0.34	Breast cancer;	chr18:26553529	chr18:26565723~26575626:-
UCEC	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	4.42	1.93e-05	0.0202	0.44	0.34	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
UCEC	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-4.42	1.93e-05	0.0202	-0.36	-0.34	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
UCEC	cis	rs10232172	0.749	rs1357731	ENSG00000234707.2	RP11-745C15.2	-4.42	1.93e-05	0.0202	-0.52	-0.34	Periodontal disease-related phenotypes;	chr7:54104860	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.749	rs1524414	ENSG00000234707.2	RP11-745C15.2	-4.42	1.93e-05	0.0202	-0.52	-0.34	Periodontal disease-related phenotypes;	chr7:54105249	chr7:54759425~54804928:+
UCEC	cis	rs2276314	0.857	rs28435069	ENSG00000267627.4	RP11-905K4.1	-4.41	1.93e-05	0.0202	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.857	rs8087539	ENSG00000267627.4	RP11-905K4.1	-4.41	1.93e-05	0.0202	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35951803~35966118:-
UCEC	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	4.41	1.93e-05	0.0202	0.38	0.34	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
UCEC	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	4.41	1.93e-05	0.0202	0.39	0.34	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
UCEC	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	4.41	1.93e-05	0.0202	0.39	0.34	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
UCEC	cis	rs62025270	0.632	rs62022915	ENSG00000202081.1	RNU6-1280P	-4.41	1.93e-05	0.0202	-0.47	-0.34	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85651522~85651628:-
UCEC	cis	rs9400467	0.528	rs56827	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.93e-05	0.0202	-0.4	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111297126~111298510:+
UCEC	cis	rs7246967	0.673	rs427709	ENSG00000198153.8	ZNF849P	-4.41	1.93e-05	0.0202	-0.44	-0.34	Bronchopulmonary dysplasia;	chr19:22815361	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.736	rs2617779	ENSG00000198153.8	ZNF849P	-4.41	1.93e-05	0.0202	-0.44	-0.34	Bronchopulmonary dysplasia;	chr19:22815519	chr19:22685167~22686732:+
UCEC	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	4.41	1.93e-05	0.0202	0.42	0.34	Depression;	chr6:28200948	chr6:28115628~28116551:+
UCEC	cis	rs2445284	0.874	rs2445246	ENSG00000229534.1	HNRNPA1P53	-4.41	1.94e-05	0.0202	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5026350	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2263547	ENSG00000229534.1	HNRNPA1P53	-4.41	1.94e-05	0.0202	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5027075	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2263549	ENSG00000229534.1	HNRNPA1P53	-4.41	1.94e-05	0.0202	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5027119	chr11:5571247~5572192:-
UCEC	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-4.41	1.94e-05	0.0202	-0.46	-0.34	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
UCEC	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-4.41	1.94e-05	0.0203	-0.43	-0.34	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
UCEC	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-4.41	1.94e-05	0.0203	-0.43	-0.34	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
UCEC	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-4.41	1.95e-05	0.0203	-0.41	-0.34	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
UCEC	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-4.41	1.95e-05	0.0203	-0.42	-0.34	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
UCEC	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	4.41	1.96e-05	0.0204	0.44	0.34	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
UCEC	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-4.41	1.96e-05	0.0204	-0.37	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-4.41	1.96e-05	0.0204	-0.37	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
UCEC	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-4.41	1.96e-05	0.0205	-0.4	-0.34	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
UCEC	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	4.41	1.96e-05	0.0205	0.37	0.34	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	4.41	1.96e-05	0.0205	0.37	0.34	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
UCEC	cis	rs2281636	0.6	rs56901709	ENSG00000233690.1	EBAG9P1	4.41	1.97e-05	0.0205	0.31	0.34	Obesity-related traits;	chr10:99639205	chr10:99697407~99697949:-
UCEC	cis	rs2445284	0.874	rs2499984	ENSG00000229534.1	HNRNPA1P53	-4.41	1.97e-05	0.0205	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5040311	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.715	rs2263550	ENSG00000229534.1	HNRNPA1P53	-4.41	1.97e-05	0.0205	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5027163	chr11:5571247~5572192:-
UCEC	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	4.41	1.98e-05	0.0206	0.51	0.34	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
UCEC	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-4.41	1.98e-05	0.0206	-0.39	-0.34	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
UCEC	cis	rs5771069	0.897	rs137858	ENSG00000235111.1	RP1-29C18.8	-4.41	1.98e-05	0.0206	-0.34	-0.34	Ulcerative colitis;	chr22:50007172	chr22:49612657~49615716:-
UCEC	cis	rs7665090	0.714	rs5026475	ENSG00000246560.2	RP11-10L12.4	4.41	1.98e-05	0.0206	0.42	0.34	Primary biliary cholangitis;	chr4:102633664	chr4:102828055~102844075:+
UCEC	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-4.41	1.98e-05	0.0206	-0.42	-0.34	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
UCEC	cis	rs17826219	0.568	rs2626985	ENSG00000266490.1	CTD-2349P21.9	4.41	1.98e-05	0.0206	0.48	0.34	Body mass index;	chr17:30750419	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.636	rs7221463	ENSG00000266490.1	CTD-2349P21.9	4.41	1.98e-05	0.0206	0.48	0.34	Body mass index;	chr17:30753533	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs7219712	ENSG00000266490.1	CTD-2349P21.9	4.41	1.98e-05	0.0206	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.573	rs8078656	ENSG00000266490.1	CTD-2349P21.9	4.41	1.98e-05	0.0206	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30792372~30792833:+
UCEC	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	4.41	1.98e-05	0.0206	0.39	0.34	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	4.41	1.98e-05	0.0206	0.39	0.34	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
UCEC	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	4.41	1.98e-05	0.0206	0.39	0.34	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
UCEC	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-4.41	1.99e-05	0.0206	-0.38	-0.34	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-4.41	1.99e-05	0.0206	-0.38	-0.34	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
UCEC	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	4.41	1.99e-05	0.0207	0.44	0.34	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	4.41	1.99e-05	0.0207	0.44	0.34	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
UCEC	cis	rs11971779	0.68	rs6467837	ENSG00000273391.1	RP11-634H22.1	4.41	1.99e-05	0.0207	0.38	0.34	Diisocyanate-induced asthma;	chr7:139338829	chr7:139359032~139359566:-
UCEC	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	4.41	1.99e-05	0.0207	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
UCEC	cis	rs73219805	0.838	rs17055172	ENSG00000228451.3	SDAD1P1	-4.41	1.99e-05	0.0207	-0.43	-0.34	Schizophrenia;	chr8:26368096	chr8:26379259~26382953:-
UCEC	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	4.41	1.99e-05	0.0207	0.39	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-4.41	1.99e-05	0.0207	-0.39	-0.34	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
UCEC	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	4.41	1.99e-05	0.0207	0.52	0.34	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	4.41	1.99e-05	0.0207	0.52	0.34	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
UCEC	cis	rs62025270	0.632	rs1807309	ENSG00000202081.1	RNU6-1280P	-4.41	1.99e-05	0.0207	-0.47	-0.34	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85651522~85651628:-
UCEC	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	4.41	1.99e-05	0.0207	0.42	0.34	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
UCEC	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-4.41	2e-05	0.0207	-0.36	-0.34	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
UCEC	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	4.41	2e-05	0.0207	0.45	0.34	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
UCEC	cis	rs847851	0.583	rs3800424	ENSG00000219023.1	RP3-340B19.2	4.41	2e-05	0.0207	0.3	0.34	Colonoscopy-negative controls vs population controls;	chr6:35043669	chr6:35555873~35556264:+
UCEC	cis	rs6840360	0.606	rs2709814	ENSG00000251611.1	RP11-610P16.1	-4.41	2e-05	0.0207	-0.28	-0.34	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151407551~151408835:-
UCEC	cis	rs7177699	0.557	rs9806363	ENSG00000261143.1	ADAMTS7P3	4.41	2e-05	0.0207	0.43	0.34	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78817960	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.557	rs4380028	ENSG00000261143.1	ADAMTS7P3	4.41	2e-05	0.0207	0.43	0.34	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78818751	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.557	rs7403593	ENSG00000261143.1	ADAMTS7P3	4.41	2e-05	0.0207	0.43	0.34	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78819620	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.557	rs7403728	ENSG00000261143.1	ADAMTS7P3	4.41	2e-05	0.0207	0.43	0.34	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78819674	chr15:77976042~77993057:+
UCEC	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-4.41	2e-05	0.0208	-0.4	-0.34	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-4.41	2e-05	0.0208	-0.4	-0.34	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-4.41	2e-05	0.0208	-0.4	-0.34	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-4.41	2e-05	0.0208	-0.4	-0.34	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-4.41	2e-05	0.0208	-0.4	-0.34	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-4.41	2e-05	0.0208	-0.4	-0.34	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-4.41	2e-05	0.0208	-0.4	-0.34	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
UCEC	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-4.41	2.01e-05	0.0208	-0.32	-0.34	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-4.41	2.01e-05	0.0208	-0.32	-0.34	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-4.41	2.01e-05	0.0208	-0.32	-0.34	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
UCEC	cis	rs9309473	0.615	rs62153183	ENSG00000163016.8	ALMS1P	4.41	2.01e-05	0.0208	0.51	0.34	Metabolite levels;	chr2:73536239	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	4.41	2.01e-05	0.0208	0.51	0.34	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	4.41	2.01e-05	0.0208	0.51	0.34	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	4.41	2.01e-05	0.0208	0.51	0.34	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-4.41	2.01e-05	0.0208	-0.32	-0.34	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
UCEC	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	4.4	2.01e-05	0.0208	0.43	0.34	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	4.4	2.01e-05	0.0208	0.43	0.34	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
UCEC	cis	rs6137726	0.508	rs2145058	ENSG00000277901.1	RP5-851M4.1	4.4	2.01e-05	0.0208	0.5	0.34	Amyotrophic lateral sclerosis (sporadic);	chr20:22660132	chr20:23320958~23325352:-
UCEC	cis	rs80130819	0.748	rs10747531	ENSG00000226413.2	OR8T1P	4.4	2.01e-05	0.0208	0.55	0.34	Prostate cancer;	chr12:48238497	chr12:48442030~48442947:-
UCEC	cis	rs12744310	0.887	rs1892419	ENSG00000235358.1	RP11-399E6.1	4.4	2.02e-05	0.0209	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315479	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs1892420	ENSG00000235358.1	RP11-399E6.1	4.4	2.02e-05	0.0209	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315738	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs28541673	ENSG00000235358.1	RP11-399E6.1	4.4	2.02e-05	0.0209	0.54	0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316322	chr1:41242373~41284861:+
UCEC	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-4.4	2.02e-05	0.0209	-0.5	-0.34	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
UCEC	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-4.4	2.02e-05	0.0209	-0.38	-0.34	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
UCEC	cis	rs10232172	0.778	rs12533567	ENSG00000234707.2	RP11-745C15.2	4.4	2.02e-05	0.0209	0.5	0.34	Periodontal disease-related phenotypes;	chr7:54099885	chr7:54759425~54804928:+
UCEC	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-4.4	2.02e-05	0.0209	-0.36	-0.34	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
UCEC	cis	rs7914558	1	rs12255047	ENSG00000272912.1	RP11-724N1.1	-4.4	2.02e-05	0.0209	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103000995	chr10:102914585~102915404:+
UCEC	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	4.4	2.02e-05	0.0209	0.4	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
UCEC	cis	rs2001144	0.51	rs9480825	ENSG00000225093.1	RPL3P7	4.4	2.03e-05	0.0209	0.43	0.34	Major depressive disorder;	chr6:108010017	chr6:108004357~108005568:-
UCEC	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	4.4	2.03e-05	0.0209	0.33	0.34	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
UCEC	cis	rs7208859	0.623	rs59447372	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs8079891	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs73267858	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs56095789	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs11656844	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs11652533	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs11652631	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.524	rs77498725	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.573	rs73267865	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.524	rs59923796	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.5	rs57005940	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Body mass index;	chr17:30739311	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.573	rs73267872	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs56812022	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.524	rs57670615	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.5	rs2874724	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Body mass index;	chr17:30745415	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.568	rs9898097	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Body mass index;	chr17:30745654	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9911490	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs7503542	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.573	rs11656278	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs6505207	ENSG00000266490.1	CTD-2349P21.9	4.4	2.03e-05	0.0209	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30792372~30792833:+
UCEC	cis	rs7914558	1	rs1926030	ENSG00000272912.1	RP11-724N1.1	-4.4	2.03e-05	0.021	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103095899	chr10:102914585~102915404:+
UCEC	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	4.4	2.03e-05	0.021	0.39	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
UCEC	cis	rs7208859	0.673	rs3816780	ENSG00000264538.5	SUZ12P1	-4.4	2.04e-05	0.021	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30709299~30790908:+
UCEC	cis	rs2445284	0.715	rs2445247	ENSG00000229534.1	HNRNPA1P53	-4.4	2.04e-05	0.021	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5026759	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.691	rs2263546	ENSG00000229534.1	HNRNPA1P53	-4.4	2.04e-05	0.021	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5026947	chr11:5571247~5572192:-
UCEC	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-4.4	2.04e-05	0.021	-0.41	-0.34	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
UCEC	cis	rs2839619	0.524	rs9982622	ENSG00000225731.1	AP001627.1	-4.4	2.04e-05	0.0211	-0.38	-0.34	Biochemical measures;	chr21:42997454	chr21:42733594~42741758:-
UCEC	cis	rs62025270	0.547	rs338520	ENSG00000202081.1	RNU6-1280P	4.4	2.04e-05	0.0211	0.43	0.34	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85651522~85651628:-
UCEC	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	4.4	2.04e-05	0.0211	0.41	0.34	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	4.4	2.04e-05	0.0211	0.41	0.34	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	4.4	2.04e-05	0.0211	0.41	0.34	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	4.4	2.04e-05	0.0211	0.41	0.34	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	4.4	2.04e-05	0.0211	0.41	0.34	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	4.4	2.04e-05	0.0211	0.41	0.34	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	4.4	2.04e-05	0.0211	0.41	0.34	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	4.4	2.04e-05	0.0211	0.41	0.34	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	4.4	2.04e-05	0.0211	0.41	0.34	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
UCEC	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	4.4	2.05e-05	0.0211	0.32	0.34	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
UCEC	cis	rs7208859	0.573	rs79505916	ENSG00000266490.1	CTD-2349P21.9	4.4	2.05e-05	0.0211	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30792372~30792833:+
UCEC	cis	rs6740462	0.568	rs35528432	ENSG00000281920.1	RP11-418H16.1	-4.4	2.05e-05	0.0211	-0.61	-0.34	Inflammatory bowel disease;Crohn's disease;	chr2:65425723	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs34635563	ENSG00000281920.1	RP11-418H16.1	-4.4	2.05e-05	0.0211	-0.61	-0.34	Inflammatory bowel disease;Crohn's disease;	chr2:65427964	chr2:65623272~65628424:+
UCEC	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	4.4	2.05e-05	0.0212	0.4	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
UCEC	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	4.4	2.05e-05	0.0212	0.5	0.34	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
UCEC	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-4.4	2.06e-05	0.0212	-0.3	-0.34	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
UCEC	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	4.4	2.06e-05	0.0212	0.39	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	4.4	2.06e-05	0.0212	0.32	0.34	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
UCEC	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-4.4	2.06e-05	0.0212	-0.46	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
UCEC	cis	rs853679	0.55	rs1233699	ENSG00000216901.1	AL022393.7	4.4	2.06e-05	0.0212	0.39	0.34	Depression;	chr6:28201380	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.862	rs7783779	ENSG00000236529.1	RP13-254B10.1	-4.4	2.06e-05	0.0212	-0.39	-0.34	Aortic root size;	chr7:66331639	chr7:65840212~65840596:+
UCEC	cis	rs492146	0.902	rs385636	ENSG00000243236.5	GSTA9P	-4.4	2.06e-05	0.0212	-0.45	-0.34	Epilepsy (remission after treatment);	chr6:52976139	chr6:52939726~52957521:-
UCEC	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	4.4	2.06e-05	0.0212	0.51	0.34	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
UCEC	cis	rs73219805	0.671	rs13267955	ENSG00000228451.3	SDAD1P1	-4.4	2.07e-05	0.0213	-0.44	-0.34	Schizophrenia;	chr8:26367077	chr8:26379259~26382953:-
UCEC	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	4.4	2.07e-05	0.0213	0.6	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
UCEC	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	4.4	2.07e-05	0.0213	0.37	0.34	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
UCEC	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	4.4	2.07e-05	0.0213	0.37	0.34	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
UCEC	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	4.4	2.07e-05	0.0213	0.42	0.34	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
UCEC	cis	rs763121	0.853	rs2267393	ENSG00000273076.1	RP3-508I15.22	4.4	2.07e-05	0.0213	0.36	0.34	Menopause (age at onset);	chr22:38705614	chr22:38743495~38743910:+
UCEC	cis	rs763121	0.853	rs2267394	ENSG00000273076.1	RP3-508I15.22	4.4	2.07e-05	0.0213	0.36	0.34	Menopause (age at onset);	chr22:38705628	chr22:38743495~38743910:+
UCEC	cis	rs2275606	0.841	rs34321971	ENSG00000233452.5	STXBP5-AS1	4.4	2.07e-05	0.0213	0.61	0.34	Leprosy;	chr6:146593701	chr6:146841901~147204614:-
UCEC	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-4.4	2.08e-05	0.0214	-0.45	-0.34	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
UCEC	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-4.4	2.08e-05	0.0214	-0.4	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
UCEC	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-4.4	2.09e-05	0.0214	-0.47	-0.34	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
UCEC	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-4.4	2.09e-05	0.0214	-0.37	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-4.4	2.09e-05	0.0214	-0.37	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-4.4	2.09e-05	0.0214	-0.37	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
UCEC	cis	rs6840360	0.582	rs2709827	ENSG00000270265.1	RP11-731D1.4	-4.4	2.09e-05	0.0214	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151333775~151353224:-
UCEC	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-4.4	2.09e-05	0.0214	-0.41	-0.34	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
UCEC	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	4.4	2.09e-05	0.0214	0.41	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
UCEC	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-4.4	2.09e-05	0.0214	-0.35	-0.34	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-4.4	2.09e-05	0.0214	-0.35	-0.34	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
UCEC	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-4.4	2.09e-05	0.0214	-0.4	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
UCEC	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-4.4	2.09e-05	0.0214	-0.4	-0.34	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
UCEC	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-4.4	2.09e-05	0.0214	-0.4	-0.34	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
UCEC	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	4.4	2.09e-05	0.0214	0.41	0.34	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
UCEC	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	4.39	2.1e-05	0.0214	0.86	0.34	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
UCEC	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	4.39	2.1e-05	0.0214	0.86	0.34	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
UCEC	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	4.39	2.1e-05	0.0214	0.36	0.34	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	4.39	2.1e-05	0.0214	0.36	0.34	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	4.39	2.1e-05	0.0214	0.36	0.34	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	4.39	2.1e-05	0.0214	0.36	0.34	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	4.39	2.1e-05	0.0214	0.36	0.34	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	4.39	2.1e-05	0.0214	0.36	0.34	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	4.39	2.1e-05	0.0214	0.36	0.34	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
UCEC	cis	rs3741578	0.702	rs725956	ENSG00000274569.1	RP11-121C6.4	4.39	2.1e-05	0.0214	0.47	0.34	Asthma;	chr12:56938152	chr12:56413647~56414045:-
UCEC	cis	rs3741578	0.702	rs1813812	ENSG00000274569.1	RP11-121C6.4	4.39	2.1e-05	0.0214	0.47	0.34	Asthma;	chr12:56939611	chr12:56413647~56414045:-
UCEC	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
UCEC	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	4.39	2.1e-05	0.0214	0.44	0.34	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
UCEC	cis	rs6740462	0.58	rs268120	ENSG00000281920.1	RP11-418H16.1	4.39	2.1e-05	0.0215	0.42	0.34	Inflammatory bowel disease;Crohn's disease;	chr2:65377780	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.58	rs268134	ENSG00000281920.1	RP11-418H16.1	4.39	2.1e-05	0.0215	0.42	0.34	Inflammatory bowel disease;Crohn's disease;	chr2:65381229	chr2:65623272~65628424:+
UCEC	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	4.39	2.1e-05	0.0215	0.4	0.34	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
UCEC	cis	rs425277	0.585	rs3107157	ENSG00000268575.1	RP1-283E3.8	4.39	2.1e-05	0.0215	0.36	0.34	Height;	chr1:2130530	chr1:1702736~1737688:-
UCEC	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-4.39	2.11e-05	0.0215	-0.36	-0.34	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
UCEC	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-4.39	2.11e-05	0.0215	-0.43	-0.34	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
UCEC	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-4.39	2.11e-05	0.0215	-0.4	-0.34	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
UCEC	cis	rs9876781	0.559	rs7630053	ENSG00000229759.1	MRPS18AP1	4.39	2.11e-05	0.0215	0.37	0.34	Longevity;	chr3:48357096	chr3:48256350~48256938:-
UCEC	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-4.39	2.11e-05	0.0216	-0.42	-0.34	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
UCEC	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-4.39	2.12e-05	0.0216	-0.38	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-4.39	2.12e-05	0.0216	-0.38	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
UCEC	cis	rs875971	0.862	rs2088653	ENSG00000236529.1	RP13-254B10.1	-4.39	2.12e-05	0.0216	-0.39	-0.34	Aortic root size;	chr7:66343621	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6460293	ENSG00000236529.1	RP13-254B10.1	-4.39	2.12e-05	0.0216	-0.39	-0.34	Aortic root size;	chr7:66345205	chr7:65840212~65840596:+
UCEC	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-4.39	2.12e-05	0.0216	-0.3	-0.34	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
UCEC	cis	rs10232172	0.778	rs2049563	ENSG00000234707.2	RP11-745C15.2	-4.39	2.12e-05	0.0216	-0.52	-0.34	Periodontal disease-related phenotypes;	chr7:54101750	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.778	rs2049564	ENSG00000234707.2	RP11-745C15.2	-4.39	2.12e-05	0.0216	-0.52	-0.34	Periodontal disease-related phenotypes;	chr7:54101820	chr7:54759425~54804928:+
UCEC	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	4.39	2.13e-05	0.0216	0.37	0.34	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
UCEC	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-4.39	2.13e-05	0.0217	-0.42	-0.34	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
UCEC	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	4.39	2.13e-05	0.0217	0.41	0.34	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
UCEC	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-4.39	2.13e-05	0.0217	-0.54	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
UCEC	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	4.39	2.13e-05	0.0217	0.44	0.34	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	4.39	2.13e-05	0.0217	0.44	0.34	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	4.39	2.13e-05	0.0217	0.44	0.34	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	4.39	2.13e-05	0.0217	0.44	0.34	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	4.39	2.13e-05	0.0217	0.44	0.34	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
UCEC	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	4.39	2.13e-05	0.0217	0.44	0.34	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
UCEC	cis	rs7605378	0.528	rs281791	ENSG00000232732.8	AC073043.1	4.39	2.13e-05	0.0217	0.44	0.34	Osteoporosis;	chr2:199985679	chr2:199867396~199911159:-
UCEC	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	4.39	2.13e-05	0.0217	0.41	0.34	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
UCEC	cis	rs7177699	0.557	rs7176187	ENSG00000261143.1	ADAMTS7P3	-4.39	2.14e-05	0.0217	-0.44	-0.34	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78829031	chr15:77976042~77993057:+
UCEC	cis	rs11971779	0.648	rs4732367	ENSG00000273391.1	RP11-634H22.1	4.39	2.14e-05	0.0218	0.37	0.34	Diisocyanate-induced asthma;	chr7:139343356	chr7:139359032~139359566:-
UCEC	cis	rs2445284	0.691	rs2445254	ENSG00000229534.1	HNRNPA1P53	-4.39	2.14e-05	0.0218	-0.4	-0.34	Sickle cell anemia (haemolysis);	chr11:5030499	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.715	rs2445255	ENSG00000229534.1	HNRNPA1P53	-4.39	2.14e-05	0.0218	-0.4	-0.34	Sickle cell anemia (haemolysis);	chr11:5030589	chr11:5571247~5572192:-
UCEC	cis	rs3931020	0.745	rs7555459	ENSG00000272864.1	RP11-17E13.2	-4.39	2.14e-05	0.0218	-0.38	-0.34	Resistin levels;	chr1:74808022	chr1:74698769~74699333:-
UCEC	cis	rs8005677	0.611	rs11624528	ENSG00000257285.4	RP11-298I3.1	4.39	2.14e-05	0.0218	0.34	0.34	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:22929609~22955562:+
UCEC	cis	rs617219	0.613	rs3733886	ENSG00000245556.2	SCAMP1-AS1	4.39	2.15e-05	0.0218	0.32	0.34	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79325845	chr5:78342365~78360507:-
UCEC	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	4.39	2.15e-05	0.0218	0.44	0.34	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
UCEC	cis	rs948562	0.947	rs1938601	ENSG00000280010.1	AP001350.4	4.39	2.15e-05	0.0219	0.69	0.34	Lymphoma;	chr11:58646988	chr11:58627435~58628528:+
UCEC	cis	rs9788721	0.501	rs1021071	ENSG00000261143.1	ADAMTS7P3	4.39	2.15e-05	0.0219	0.45	0.34	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78675837	chr15:77976042~77993057:+
UCEC	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-4.39	2.15e-05	0.0219	-0.38	-0.34	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-4.39	2.15e-05	0.0219	-0.38	-0.34	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-4.39	2.15e-05	0.0219	-0.38	-0.34	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-4.39	2.15e-05	0.0219	-0.38	-0.34	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
UCEC	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	4.39	2.15e-05	0.0219	0.35	0.34	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
UCEC	cis	rs638893	0.541	rs553188	ENSG00000278376.1	RP11-158I9.8	-4.39	2.16e-05	0.0219	-0.43	-0.34	Vitiligo;	chr11:118706053	chr11:118791254~118793137:+
UCEC	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	4.39	2.16e-05	0.0219	0.41	0.34	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
UCEC	cis	rs2739330	0.761	rs5760176	ENSG00000272787.1	KB-226F1.2	4.39	2.16e-05	0.0219	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23969211~23969873:+
UCEC	cis	rs6104690	0.687	rs2038992	ENSG00000270792.4	RP11-103J8.1	-4.39	2.16e-05	0.0219	-0.5	-0.34	Bladder cancer;	chr20:11005772	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.687	rs2327328	ENSG00000270792.4	RP11-103J8.1	-4.39	2.16e-05	0.0219	-0.5	-0.34	Bladder cancer;	chr20:11006170	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.64	rs2026606	ENSG00000270792.4	RP11-103J8.1	-4.39	2.16e-05	0.0219	-0.5	-0.34	Bladder cancer;	chr20:11006592	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.64	rs2026607	ENSG00000270792.4	RP11-103J8.1	-4.39	2.16e-05	0.0219	-0.5	-0.34	Bladder cancer;	chr20:11006604	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.687	rs2026608	ENSG00000270792.4	RP11-103J8.1	-4.39	2.16e-05	0.0219	-0.5	-0.34	Bladder cancer;	chr20:11006684	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.687	rs6131142	ENSG00000270792.4	RP11-103J8.1	-4.39	2.16e-05	0.0219	-0.5	-0.34	Bladder cancer;	chr20:11006750	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.687	rs2148715	ENSG00000270792.4	RP11-103J8.1	-4.39	2.16e-05	0.0219	-0.5	-0.34	Bladder cancer;	chr20:11007612	chr20:10672928~10994924:+
UCEC	cis	rs6104690	0.663	rs2182648	ENSG00000270792.4	RP11-103J8.1	-4.39	2.16e-05	0.0219	-0.5	-0.34	Bladder cancer;	chr20:11007857	chr20:10672928~10994924:+
UCEC	cis	rs948562	0.793	rs79170562	ENSG00000280010.1	AP001350.4	4.39	2.17e-05	0.022	0.69	0.34	Lymphoma;	chr11:58604081	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.793	rs1944051	ENSG00000280010.1	AP001350.4	4.39	2.17e-05	0.022	0.69	0.34	Lymphoma;	chr11:58607820	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.793	rs1800169	ENSG00000280010.1	AP001350.4	4.39	2.17e-05	0.022	0.69	0.34	Lymphoma;	chr11:58624028	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.696	rs17568220	ENSG00000280010.1	AP001350.4	4.39	2.17e-05	0.022	0.69	0.34	Lymphoma;	chr11:58627550	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.74	rs12361770	ENSG00000280010.1	AP001350.4	4.39	2.17e-05	0.022	0.69	0.34	Lymphoma;	chr11:58666759	chr11:58627435~58628528:+
UCEC	cis	rs9876781	0.874	rs56298324	ENSG00000229759.1	MRPS18AP1	-4.39	2.17e-05	0.022	-0.34	-0.34	Longevity;	chr3:48393626	chr3:48256350~48256938:-
UCEC	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-4.39	2.17e-05	0.022	-0.35	-0.34	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
UCEC	cis	rs6840360	0.582	rs1372976	ENSG00000251611.1	RP11-610P16.1	-4.39	2.17e-05	0.022	-0.28	-0.34	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs1443090	ENSG00000251611.1	RP11-610P16.1	-4.39	2.17e-05	0.022	-0.28	-0.34	Intelligence (multi-trait analysis);	chr4:151530667	chr4:151407551~151408835:-
UCEC	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-4.39	2.17e-05	0.022	-0.47	-0.34	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
UCEC	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-4.39	2.17e-05	0.022	-0.38	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
UCEC	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	4.39	2.18e-05	0.0221	0.41	0.34	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
UCEC	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	4.38	2.18e-05	0.0221	0.41	0.34	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	4.38	2.18e-05	0.0221	0.41	0.34	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
UCEC	cis	rs2842992	0.672	rs7738253	ENSG00000237927.1	RP3-393E18.2	-4.38	2.18e-05	0.0221	-0.44	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159772885	chr6:159586955~159589169:-
UCEC	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	4.38	2.19e-05	0.0221	0.37	0.34	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
UCEC	cis	rs11697848	0.867	rs79264127	ENSG00000234693.1	RP4-530I15.6	4.38	2.19e-05	0.0221	0.9	0.34	Systemic lupus erythematosus;	chr20:49990000	chr20:50645471~50662275:+
UCEC	cis	rs6137726	0.508	rs4815131	ENSG00000277901.1	RP5-851M4.1	4.38	2.19e-05	0.0222	0.49	0.34	Amyotrophic lateral sclerosis (sporadic);	chr20:22658994	chr20:23320958~23325352:-
UCEC	cis	rs9309473	0.583	rs11899517	ENSG00000163016.8	ALMS1P	4.38	2.19e-05	0.0222	0.37	0.34	Metabolite levels;	chr2:73346133	chr2:73644919~73685576:+
UCEC	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	4.38	2.19e-05	0.0222	0.37	0.34	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	4.38	2.19e-05	0.0222	0.37	0.34	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	4.38	2.19e-05	0.0222	0.37	0.34	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	4.38	2.19e-05	0.0222	0.37	0.34	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	4.38	2.19e-05	0.0222	0.37	0.34	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
UCEC	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-4.38	2.19e-05	0.0222	-0.32	-0.34	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-4.38	2.19e-05	0.0222	-0.32	-0.34	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-4.38	2.19e-05	0.0222	-0.32	-0.34	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-4.38	2.19e-05	0.0222	-0.32	-0.34	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-4.38	2.19e-05	0.0222	-0.32	-0.34	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-4.38	2.19e-05	0.0222	-0.32	-0.34	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
UCEC	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	4.38	2.19e-05	0.0222	0.35	0.34	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
UCEC	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-4.38	2.2e-05	0.0222	-0.44	-0.34	AIDS;	chr2:105311539	chr2:105324210~105330529:+
UCEC	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-4.38	2.2e-05	0.0222	-0.44	-0.34	AIDS;	chr2:105321650	chr2:105324210~105330529:+
UCEC	cis	rs951266	0.505	rs12902602	ENSG00000261143.1	ADAMTS7P3	4.38	2.2e-05	0.0222	0.46	0.34	Post bronchodilator FEV1/FVC ratio;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Pre bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78675059	chr15:77976042~77993057:+
UCEC	cis	rs6840360	0.642	rs7666571	ENSG00000251611.1	RP11-610P16.1	-4.38	2.2e-05	0.0222	-0.28	-0.34	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151407551~151408835:-
UCEC	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-4.38	2.2e-05	0.0222	-0.44	-0.34	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
UCEC	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	4.38	2.2e-05	0.0222	0.43	0.34	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
UCEC	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-4.38	2.2e-05	0.0222	-0.33	-0.34	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
UCEC	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	4.38	2.2e-05	0.0222	0.4	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
UCEC	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	4.38	2.2e-05	0.0222	0.4	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
UCEC	cis	rs2732480	0.538	rs1387260	ENSG00000226413.2	OR8T1P	4.38	2.2e-05	0.0222	0.5	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48442030~48442947:-
UCEC	cis	rs2445284	0.874	rs2445263	ENSG00000229534.1	HNRNPA1P53	-4.38	2.2e-05	0.0222	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5033827	chr11:5571247~5572192:-
UCEC	cis	rs9788721	0.504	rs12899135	ENSG00000261143.1	ADAMTS7P3	4.38	2.2e-05	0.0223	0.46	0.34	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78662037	chr15:77976042~77993057:+
UCEC	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	4.38	2.2e-05	0.0223	0.35	0.34	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
UCEC	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	4.38	2.2e-05	0.0223	0.96	0.34	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
UCEC	cis	rs2445284	0.874	rs2442409	ENSG00000229534.1	HNRNPA1P53	-4.38	2.2e-05	0.0223	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5034635	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2499968	ENSG00000229534.1	HNRNPA1P53	-4.38	2.2e-05	0.0223	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5035116	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs1463370	ENSG00000229534.1	HNRNPA1P53	-4.38	2.2e-05	0.0223	-0.41	-0.34	Sickle cell anemia (haemolysis);	chr11:5035305	chr11:5571247~5572192:-
UCEC	cis	rs10208649	0.908	rs76073574	ENSG00000233266.1	HMGB1P31	4.38	2.2e-05	0.0223	0.96	0.34	Body mass index;	chr2:53980525	chr2:54051334~54051760:+
UCEC	cis	rs2976388	0.647	rs2572898	ENSG00000253931.1	RP11-909N17.2	4.38	2.2e-05	0.0223	0.34	0.34	Urinary tract infection frequency;	chr8:142700856	chr8:143412749~143417054:+
UCEC	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-4.38	2.2e-05	0.0223	-0.48	-0.34	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
UCEC	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-4.38	2.21e-05	0.0223	-0.36	-0.34	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
UCEC	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	4.38	2.21e-05	0.0223	0.41	0.34	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
UCEC	cis	rs10232172	0.778	rs1524386	ENSG00000234707.2	RP11-745C15.2	-4.38	2.21e-05	0.0223	-0.51	-0.34	Periodontal disease-related phenotypes;	chr7:54099223	chr7:54759425~54804928:+
UCEC	cis	rs1979541	0.688	rs6913508	ENSG00000233893.1	EZR-AS1	4.38	2.22e-05	0.0224	0.51	0.34	Lipoprotein (a) levels;	chr6:158690914	chr6:158818011~158820593:+
UCEC	cis	rs10232172	0.778	rs12537357	ENSG00000234707.2	RP11-745C15.2	-4.38	2.22e-05	0.0224	-0.51	-0.34	Periodontal disease-related phenotypes;	chr7:54100312	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.778	rs35369011	ENSG00000234707.2	RP11-745C15.2	-4.38	2.22e-05	0.0224	-0.51	-0.34	Periodontal disease-related phenotypes;	chr7:54100575	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.778	rs1918119	ENSG00000234707.2	RP11-745C15.2	-4.38	2.22e-05	0.0224	-0.51	-0.34	Periodontal disease-related phenotypes;	chr7:54101083	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.778	rs1526767	ENSG00000234707.2	RP11-745C15.2	-4.38	2.22e-05	0.0224	-0.51	-0.34	Periodontal disease-related phenotypes;	chr7:54101549	chr7:54759425~54804928:+
UCEC	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	4.38	2.22e-05	0.0224	0.44	0.34	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
UCEC	cis	rs62025270	0.688	rs62025298	ENSG00000202081.1	RNU6-1280P	-4.38	2.22e-05	0.0224	-0.47	-0.34	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85651522~85651628:-
UCEC	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-4.38	2.22e-05	0.0224	-0.36	-0.34	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
UCEC	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	4.38	2.23e-05	0.0225	0.36	0.34	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
UCEC	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-4.38	2.23e-05	0.0225	-0.45	-0.34	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-4.38	2.23e-05	0.0225	-0.45	-0.34	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
UCEC	cis	rs763121	1	rs138464	ENSG00000273076.1	RP3-508I15.22	-4.38	2.23e-05	0.0225	-0.37	-0.34	Menopause (age at onset);	chr22:38510427	chr22:38743495~38743910:+
UCEC	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	4.38	2.23e-05	0.0225	0.32	0.34	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
UCEC	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	4.38	2.23e-05	0.0225	0.48	0.34	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
UCEC	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	4.38	2.23e-05	0.0225	0.49	0.34	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
UCEC	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-4.38	2.23e-05	0.0225	-0.43	-0.34	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
UCEC	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-4.38	2.23e-05	0.0225	-0.43	-0.34	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
UCEC	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-4.38	2.23e-05	0.0225	-0.43	-0.34	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
UCEC	cis	rs2115630	0.936	rs8033459	ENSG00000225151.9	GOLGA2P7	4.38	2.23e-05	0.0225	0.38	0.34	P wave terminal force;	chr15:84710027	chr15:84199311~84230136:-
UCEC	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	4.38	2.24e-05	0.0225	0.52	0.34	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
UCEC	cis	rs6901004	0.935	rs9487602	ENSG00000271789.1	RP5-1112D6.7	4.38	2.24e-05	0.0225	0.38	0.34	Blood metabolite levels;	chr6:111239743	chr6:111297126~111298510:+
UCEC	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-4.38	2.24e-05	0.0225	-0.39	-0.34	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
UCEC	cis	rs12304921	0.513	rs3751275	ENSG00000277201.1	AC087884.1	-4.38	2.24e-05	0.0225	-0.35	-0.34	Type 2 diabetes;	chr12:51125004	chr12:51049921~51050025:+
UCEC	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	4.38	2.24e-05	0.0225	0.44	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
UCEC	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	4.38	2.24e-05	0.0225	0.27	0.34	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
UCEC	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-4.38	2.24e-05	0.0226	-0.41	-0.34	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-4.38	2.24e-05	0.0226	-0.41	-0.34	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-4.38	2.24e-05	0.0226	-0.41	-0.34	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-4.38	2.24e-05	0.0226	-0.41	-0.34	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
UCEC	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	4.38	2.25e-05	0.0226	0.32	0.34	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
UCEC	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-4.38	2.25e-05	0.0226	-0.38	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-4.38	2.25e-05	0.0226	-0.38	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
UCEC	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	4.38	2.25e-05	0.0226	0.48	0.34	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
UCEC	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	4.38	2.25e-05	0.0227	0.41	0.34	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
UCEC	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-4.38	2.25e-05	0.0227	-0.31	-0.34	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
UCEC	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-4.38	2.25e-05	0.0227	-0.44	-0.34	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
UCEC	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	4.38	2.25e-05	0.0227	0.35	0.34	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
UCEC	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-4.38	2.26e-05	0.0227	-0.37	-0.34	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-4.38	2.26e-05	0.0227	-0.38	-0.34	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-4.38	2.26e-05	0.0227	-0.38	-0.34	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
UCEC	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	4.38	2.27e-05	0.0228	0.4	0.34	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
UCEC	cis	rs1185460	0.967	rs1786690	ENSG00000278376.1	RP11-158I9.8	-4.38	2.27e-05	0.0228	-0.29	-0.34	Coronary artery disease;	chr11:119071357	chr11:118791254~118793137:+
UCEC	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	4.37	2.27e-05	0.0228	0.47	0.34	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
UCEC	cis	rs72901758	0.768	rs1567237	ENSG00000279570.1	CTD-2357A8.2	-4.37	2.28e-05	0.0229	-0.39	-0.34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78250213	chr17:78691266~78691979:-
UCEC	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	4.37	2.28e-05	0.0229	0.41	0.34	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
UCEC	cis	rs1396485	0.505	rs6863132	ENSG00000249249.1	AC010226.4	4.37	2.28e-05	0.0229	0.55	0.34	Inflammatory biomarkers;	chr5:116076710	chr5:115602057~115620659:+
UCEC	cis	rs9907295	0.748	rs78672421	ENSG00000270871.1	AC015849.19	4.37	2.28e-05	0.0229	0.52	0.34	Fibroblast growth factor basic levels;	chr17:35837325	chr17:35816717~35830293:-
UCEC	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	4.37	2.28e-05	0.0229	0.35	0.34	Height;	chr6:109392096	chr6:109382795~109383666:+
UCEC	cis	rs507080	0.883	rs692750	ENSG00000278376.1	RP11-158I9.8	-4.37	2.28e-05	0.0229	-0.33	-0.34	Serum metabolite levels;	chr11:118667599	chr11:118791254~118793137:+
UCEC	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	4.37	2.28e-05	0.0229	0.36	0.34	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
UCEC	cis	rs7240205	0.853	rs2000649	ENSG00000275805.1	RP11-349H17.2	4.37	2.29e-05	0.023	0.43	0.34	Breast cancer;	chr18:26552897	chr18:26565723~26575626:-
UCEC	cis	rs6137726	0.524	rs1203942	ENSG00000277901.1	RP5-851M4.1	4.37	2.29e-05	0.023	0.45	0.34	Amyotrophic lateral sclerosis (sporadic);	chr20:22615997	chr20:23320958~23325352:-
UCEC	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	4.37	2.29e-05	0.023	0.38	0.34	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
UCEC	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	4.37	2.29e-05	0.023	0.38	0.34	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
UCEC	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-4.37	2.3e-05	0.023	-0.43	-0.34	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
UCEC	cis	rs7170668	1	rs10162686	ENSG00000260521.2	CTD-2576F9.1	-4.37	2.3e-05	0.023	-0.36	-0.34	Motion sickness;	chr15:95471854	chr15:94855474~94856914:+
UCEC	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-4.37	2.3e-05	0.0231	-0.41	-0.34	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
UCEC	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-4.37	2.3e-05	0.0231	-0.39	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
UCEC	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	4.37	2.3e-05	0.0231	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	4.37	2.3e-05	0.0231	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
UCEC	cis	rs709400	0.859	rs942863	ENSG00000259775.1	RP11-45P15.4	4.37	2.3e-05	0.0231	0.43	0.34	Body mass index;	chr14:103554931	chr14:103331674~103332367:-
UCEC	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	4.37	2.31e-05	0.0231	0.71	0.34	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
UCEC	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	4.37	2.31e-05	0.0232	0.52	0.34	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
UCEC	cis	rs9429544	1	rs9429544	ENSG00000232450.1	RP4-730K3.3	4.37	2.31e-05	0.0232	0.4	0.34	Mean corpuscular hemoglobin;	chr1:114390243	chr1:113698884~113699631:-
UCEC	cis	rs951266	0.505	rs11072785	ENSG00000261143.1	ADAMTS7P3	4.37	2.32e-05	0.0232	0.45	0.34	Post bronchodilator FEV1/FVC ratio;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Pre bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78675887	chr15:77976042~77993057:+
UCEC	cis	rs17826219	0.5	rs117560728	ENSG00000266490.1	CTD-2349P21.9	4.37	2.32e-05	0.0233	0.53	0.34	Body mass index;	chr17:30743920	chr17:30792372~30792833:+
UCEC	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-4.37	2.32e-05	0.0233	-0.42	-0.34	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
UCEC	cis	rs9545047	0.868	rs1208049	ENSG00000227354.5	RBM26-AS1	4.37	2.32e-05	0.0233	0.37	0.34	Schizophrenia;	chr13:79570220	chr13:79406309~79424328:+
UCEC	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-4.37	2.33e-05	0.0233	-0.41	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
UCEC	cis	rs9545047	0.604	rs9601227	ENSG00000227354.5	RBM26-AS1	-4.37	2.33e-05	0.0233	-0.33	-0.34	Schizophrenia;	chr13:79420805	chr13:79406309~79424328:+
UCEC	cis	rs4253772	0.591	rs12167567	ENSG00000277232.2	GTSE1-AS1	-4.37	2.33e-05	0.0233	-0.4	-0.34	Cholesterol, total;LDL cholesterol;	chr22:46264045	chr22:46295143~46296660:-
UCEC	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	4.37	2.33e-05	0.0233	0.3	0.34	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
UCEC	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	4.37	2.33e-05	0.0233	0.4	0.34	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	4.37	2.33e-05	0.0233	0.4	0.34	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
UCEC	cis	rs7914558	1	rs67908413	ENSG00000272912.1	RP11-724N1.1	-4.37	2.34e-05	0.0234	-0.32	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:102914585~102915404:+
UCEC	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	4.37	2.34e-05	0.0234	0.37	0.34	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
UCEC	cis	rs9907295	0.71	rs4796113	ENSG00000270871.1	AC015849.19	4.37	2.34e-05	0.0234	0.52	0.34	Fibroblast growth factor basic levels;	chr17:35832562	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.818	rs4796114	ENSG00000270871.1	AC015849.19	4.37	2.34e-05	0.0234	0.52	0.34	Fibroblast growth factor basic levels;	chr17:35832653	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.818	rs3785764	ENSG00000270871.1	AC015849.19	4.37	2.34e-05	0.0234	0.52	0.34	Fibroblast growth factor basic levels;	chr17:35833760	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.901	rs78905197	ENSG00000270871.1	AC015849.19	4.37	2.34e-05	0.0234	0.52	0.34	Fibroblast growth factor basic levels;	chr17:35850189	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.901	rs3760326	ENSG00000270871.1	AC015849.19	4.37	2.34e-05	0.0234	0.52	0.34	Fibroblast growth factor basic levels;	chr17:35853493	chr17:35816717~35830293:-
UCEC	cis	rs7760535	0.826	rs3851229	ENSG00000271789.1	RP5-1112D6.7	-4.37	2.34e-05	0.0234	-0.4	-0.34	Metabolic traits;	chr6:111533457	chr6:111297126~111298510:+
UCEC	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	4.37	2.34e-05	0.0234	0.37	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
UCEC	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	4.37	2.35e-05	0.0234	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	4.37	2.35e-05	0.0234	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	4.37	2.35e-05	0.0234	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
UCEC	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	4.37	2.35e-05	0.0234	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
UCEC	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-4.37	2.35e-05	0.0235	-0.43	-0.34	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
UCEC	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-4.37	2.36e-05	0.0235	-0.46	-0.34	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
UCEC	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	4.37	2.36e-05	0.0235	0.45	0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
UCEC	cis	rs9309473	0.528	rs6546820	ENSG00000163016.8	ALMS1P	4.37	2.36e-05	0.0235	0.36	0.34	Metabolite levels;	chr2:73326269	chr2:73644919~73685576:+
UCEC	cis	rs6840360	0.642	rs6855845	ENSG00000270265.1	RP11-731D1.4	-4.37	2.36e-05	0.0236	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs2034061	ENSG00000270265.1	RP11-731D1.4	-4.37	2.36e-05	0.0236	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151333775~151353224:-
UCEC	cis	rs4789693	0.938	rs12952655	ENSG00000265458.1	RP13-20L14.6	-4.37	2.36e-05	0.0236	-0.4	-0.34	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82454273~82458521:-
UCEC	cis	rs113835537	0.597	rs2305534	ENSG00000255517.5	CTD-3074O7.5	-4.37	2.36e-05	0.0236	-0.46	-0.34	Airway imaging phenotypes;	chr11:66545732	chr11:66473490~66480233:-
UCEC	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	4.36	2.37e-05	0.0236	0.34	0.34	Height;	chr6:109426518	chr6:109382795~109383666:+
UCEC	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-4.36	2.37e-05	0.0236	-0.31	-0.34	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
UCEC	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	4.36	2.37e-05	0.0236	0.49	0.34	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
UCEC	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-4.36	2.37e-05	0.0237	-0.36	-0.34	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
UCEC	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-4.36	2.37e-05	0.0237	-0.36	-0.34	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
UCEC	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-4.36	2.37e-05	0.0237	-0.42	-0.34	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
UCEC	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-4.36	2.37e-05	0.0237	-0.45	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
UCEC	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-4.36	2.37e-05	0.0237	-0.45	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
UCEC	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-4.36	2.37e-05	0.0237	-0.45	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
UCEC	cis	rs9545047	0.604	rs7319212	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79365404	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs7319252	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79365471	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs9318633	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79369113	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs12872328	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79370489	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs2182010	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79370618	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs35476664	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79375462	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.564	rs7336186	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79385497	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs2182009	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79397781	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs4605023	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79398700	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs9565496	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79398751	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs12877507	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79401822	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs9574419	ENSG00000227354.5	RBM26-AS1	-4.36	2.38e-05	0.0238	-0.33	-0.34	Schizophrenia;	chr13:79402337	chr13:79406309~79424328:+
UCEC	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-4.36	2.38e-05	0.0238	-0.39	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-4.36	2.38e-05	0.0238	-0.39	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
UCEC	cis	rs7914558	1	rs7911789	ENSG00000272912.1	RP11-724N1.1	-4.36	2.39e-05	0.0238	-0.32	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102996617	chr10:102914585~102915404:+
UCEC	cis	rs6840360	0.607	rs6815320	ENSG00000270265.1	RP11-731D1.4	-4.36	2.39e-05	0.0238	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151333775~151353224:-
UCEC	cis	rs7605378	0.528	rs812760	ENSG00000232732.8	AC073043.1	-4.36	2.4e-05	0.0239	-0.43	-0.34	Osteoporosis;	chr2:199859649	chr2:199867396~199911159:-
UCEC	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-4.36	2.4e-05	0.0239	-0.41	-0.34	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
UCEC	cis	rs10232172	1	rs12530783	ENSG00000234707.2	RP11-745C15.2	4.36	2.4e-05	0.0239	0.61	0.34	Periodontal disease-related phenotypes;	chr7:54108238	chr7:54759425~54804928:+
UCEC	cis	rs10232172	1	rs3902027	ENSG00000234707.2	RP11-745C15.2	4.36	2.4e-05	0.0239	0.61	0.34	Periodontal disease-related phenotypes;	chr7:54108672	chr7:54759425~54804928:+
UCEC	cis	rs10232172	1	rs1965517	ENSG00000234707.2	RP11-745C15.2	4.36	2.4e-05	0.0239	0.61	0.34	Periodontal disease-related phenotypes;	chr7:54109419	chr7:54759425~54804928:+
UCEC	cis	rs10232172	1	rs1965518	ENSG00000234707.2	RP11-745C15.2	-4.36	2.4e-05	0.0239	-0.61	-0.34	Periodontal disease-related phenotypes;	chr7:54109378	chr7:54759425~54804928:+
UCEC	cis	rs3734266	0.639	rs7739385	ENSG00000272288.4	RP11-140K17.3	-4.36	2.4e-05	0.0239	-0.35	-0.34	Systemic lupus erythematosus;	chr6:34899701	chr6:34696317~34697470:+
UCEC	cis	rs3734266	0.702	rs16895659	ENSG00000272288.4	RP11-140K17.3	-4.36	2.4e-05	0.0239	-0.35	-0.34	Systemic lupus erythematosus;	chr6:34923091	chr6:34696317~34697470:+
UCEC	cis	rs3734266	0.702	rs28360525	ENSG00000272288.4	RP11-140K17.3	-4.36	2.4e-05	0.0239	-0.35	-0.34	Systemic lupus erythematosus;	chr6:34923261	chr6:34696317~34697470:+
UCEC	cis	rs3734266	0.702	rs6457797	ENSG00000272288.4	RP11-140K17.3	-4.36	2.4e-05	0.0239	-0.35	-0.34	Systemic lupus erythematosus;	chr6:34929397	chr6:34696317~34697470:+
UCEC	cis	rs3734266	0.702	rs6457798	ENSG00000272288.4	RP11-140K17.3	-4.36	2.4e-05	0.0239	-0.35	-0.34	Systemic lupus erythematosus;	chr6:34929422	chr6:34696317~34697470:+
UCEC	cis	rs875971	0.755	rs10228885	ENSG00000236529.1	RP13-254B10.1	-4.36	2.41e-05	0.024	-0.39	-0.34	Aortic root size;	chr7:66315542	chr7:65840212~65840596:+
UCEC	cis	rs7692976	0.552	rs7699288	ENSG00000166530.8	HSBP1P2	-4.36	2.41e-05	0.024	-0.34	-0.34	Reticulocyte count;Reticulocyte fraction of red cells;	chr4:110021121	chr4:110251871~110252099:-
UCEC	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	4.36	2.41e-05	0.024	0.44	0.34	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	4.36	2.41e-05	0.024	0.44	0.34	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	4.36	2.41e-05	0.024	0.44	0.34	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
UCEC	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-4.36	2.41e-05	0.024	-0.45	-0.34	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
UCEC	cis	rs73219805	1	rs73219805	ENSG00000228451.3	SDAD1P1	-4.36	2.41e-05	0.024	-0.42	-0.34	Schizophrenia;	chr8:26415252	chr8:26379259~26382953:-
UCEC	cis	rs2276314	0.857	rs28431958	ENSG00000267627.4	RP11-905K4.1	-4.36	2.42e-05	0.024	-0.4	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35951803~35966118:-
UCEC	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	4.36	2.42e-05	0.0241	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
UCEC	cis	rs7246967	0.544	rs400275	ENSG00000198153.8	ZNF849P	-4.36	2.43e-05	0.0241	-0.42	-0.34	Bronchopulmonary dysplasia;	chr19:22833054	chr19:22685167~22686732:+
UCEC	cis	rs11671005	0.61	rs11669345	ENSG00000142396.9	ERVK3-1	4.36	2.43e-05	0.0241	0.53	0.34	Mean platelet volume;	chr19:58550892	chr19:58305319~58315663:+
UCEC	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	4.36	2.43e-05	0.0242	0.36	0.34	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
UCEC	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-4.36	2.43e-05	0.0242	-0.4	-0.34	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
UCEC	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	4.36	2.44e-05	0.0242	0.39	0.34	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
UCEC	cis	rs9907295	0.688	rs2251660	ENSG00000270977.1	AC015849.16	-4.36	2.44e-05	0.0242	-0.37	-0.34	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35893707~35911023:-
UCEC	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-4.36	2.44e-05	0.0242	-0.36	-0.34	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
UCEC	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	4.36	2.44e-05	0.0242	0.4	0.34	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	4.36	2.44e-05	0.0242	0.4	0.34	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	4.36	2.44e-05	0.0242	0.4	0.34	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	4.36	2.44e-05	0.0242	0.4	0.34	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	4.36	2.44e-05	0.0242	0.4	0.34	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	4.36	2.44e-05	0.0242	0.36	0.34	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
UCEC	cis	rs72901758	0.768	rs72901762	ENSG00000279570.1	CTD-2357A8.2	4.36	2.45e-05	0.0242	0.4	0.34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78248845	chr17:78691266~78691979:-
UCEC	cis	rs875971	1	rs2077593	ENSG00000236529.1	RP13-254B10.1	4.36	2.45e-05	0.0242	0.38	0.34	Aortic root size;	chr7:66427543	chr7:65840212~65840596:+
UCEC	cis	rs8141529	1	rs132534	ENSG00000272858.1	CTA-292E10.8	4.36	2.45e-05	0.0243	0.46	0.34	Lymphocyte counts;	chr22:28903818	chr22:28814914~28815662:+
UCEC	cis	rs12468226	0.752	rs34829484	ENSG00000273456.1	RP11-686O6.2	-4.36	2.45e-05	0.0243	-0.47	-0.34	Urate levels;	chr2:202137267	chr2:202374932~202375604:-
UCEC	cis	rs853679	0.506	rs1150693	ENSG00000216901.1	AL022393.7	4.36	2.45e-05	0.0243	0.42	0.34	Depression;	chr6:28206812	chr6:28176188~28176674:+
UCEC	cis	rs2115630	1	rs6496452	ENSG00000225151.9	GOLGA2P7	4.36	2.46e-05	0.0243	0.36	0.34	P wave terminal force;	chr15:84829414	chr15:84199311~84230136:-
UCEC	cis	rs6840360	0.642	rs1470280	ENSG00000251611.1	RP11-610P16.1	-4.36	2.46e-05	0.0243	-0.28	-0.34	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151407551~151408835:-
UCEC	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-4.36	2.46e-05	0.0244	-0.35	-0.34	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
UCEC	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-4.36	2.46e-05	0.0244	-0.35	-0.34	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
UCEC	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-4.36	2.46e-05	0.0244	-0.43	-0.34	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-4.36	2.46e-05	0.0244	-0.43	-0.34	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
UCEC	cis	rs2991971	0.81	rs2036021	ENSG00000280836.1	AL355480.1	4.36	2.46e-05	0.0244	0.38	0.34	High light scatter reticulocyte count;	chr1:45435698	chr1:45581219~45581321:-
UCEC	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	4.35	2.47e-05	0.0244	0.35	0.34	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
UCEC	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-4.35	2.47e-05	0.0244	-0.43	-0.34	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
UCEC	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-4.35	2.47e-05	0.0244	-0.35	-0.34	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
UCEC	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	4.35	2.47e-05	0.0245	0.4	0.34	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
UCEC	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	4.35	2.47e-05	0.0245	0.4	0.34	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
UCEC	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-4.35	2.47e-05	0.0245	-0.37	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
UCEC	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-4.35	2.47e-05	0.0245	-0.39	-0.34	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-4.35	2.47e-05	0.0245	-0.39	-0.34	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
UCEC	cis	rs7914558	0.966	rs12571568	ENSG00000272912.1	RP11-724N1.1	-4.35	2.48e-05	0.0245	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103131639	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs12766205	ENSG00000272912.1	RP11-724N1.1	-4.35	2.48e-05	0.0245	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103133811	chr10:102914585~102915404:+
UCEC	cis	rs7914558	1	rs10883837	ENSG00000272912.1	RP11-724N1.1	-4.35	2.48e-05	0.0245	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103136729	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs746293	ENSG00000272912.1	RP11-724N1.1	-4.35	2.48e-05	0.0245	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103137497	chr10:102914585~102915404:+
UCEC	cis	rs7914558	1	rs11191577	ENSG00000272912.1	RP11-724N1.1	-4.35	2.48e-05	0.0245	-0.33	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103142408	chr10:102914585~102915404:+
UCEC	cis	rs2445284	0.715	rs2259733	ENSG00000229534.1	HNRNPA1P53	-4.35	2.48e-05	0.0245	-0.4	-0.34	Sickle cell anemia (haemolysis);	chr11:5031921	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.715	rs2442421	ENSG00000229534.1	HNRNPA1P53	-4.35	2.48e-05	0.0245	-0.4	-0.34	Sickle cell anemia (haemolysis);	chr11:5032482	chr11:5571247~5572192:-
UCEC	cis	rs853679	0.55	rs1150692	ENSG00000216901.1	AL022393.7	4.35	2.48e-05	0.0245	0.4	0.34	Depression;	chr6:28206179	chr6:28176188~28176674:+
UCEC	cis	rs6137726	0.524	rs1007458	ENSG00000277901.1	RP5-851M4.1	4.35	2.48e-05	0.0245	0.44	0.34	Amyotrophic lateral sclerosis (sporadic);	chr20:22607038	chr20:23320958~23325352:-
UCEC	cis	rs6137726	0.524	rs995734	ENSG00000277901.1	RP5-851M4.1	4.35	2.48e-05	0.0245	0.44	0.34	Amyotrophic lateral sclerosis (sporadic);	chr20:22607370	chr20:23320958~23325352:-
UCEC	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-4.35	2.48e-05	0.0245	-0.35	-0.34	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
UCEC	cis	rs6137726	0.613	rs747912	ENSG00000277901.1	RP5-851M4.1	4.35	2.48e-05	0.0245	0.41	0.34	Amyotrophic lateral sclerosis (sporadic);	chr20:22652422	chr20:23320958~23325352:-
UCEC	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-4.35	2.49e-05	0.0245	-0.32	-0.34	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
UCEC	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-4.35	2.49e-05	0.0245	-0.35	-0.34	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
UCEC	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-4.35	2.49e-05	0.0245	-0.35	-0.34	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
UCEC	cis	rs6908034	0.654	rs6456272	ENSG00000227116.1	RP3-471C18.1	4.35	2.49e-05	0.0245	0.38	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804805	chr6:19730427~19734567:-
UCEC	cis	rs12478296	0.792	rs57482298	ENSG00000261186.2	RP11-341N2.1	-4.35	2.49e-05	0.0245	-0.48	-0.34	Obesity-related traits;	chr2:242068997	chr2:242087351~242088457:-
UCEC	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-4.35	2.49e-05	0.0245	-0.43	-0.34	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
UCEC	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-4.35	2.5e-05	0.0245	-0.38	-0.34	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
UCEC	cis	rs7177699	0.557	rs55870734	ENSG00000261143.1	ADAMTS7P3	4.35	2.5e-05	0.0246	0.42	0.34	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78825575	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.557	rs7178051	ENSG00000261143.1	ADAMTS7P3	-4.35	2.5e-05	0.0246	-0.42	-0.34	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78825954	chr15:77976042~77993057:+
UCEC	cis	rs7240205	0.853	rs6508448	ENSG00000275805.1	RP11-349H17.2	4.35	2.5e-05	0.0246	0.42	0.34	Breast cancer;	chr18:26556863	chr18:26565723~26575626:-
UCEC	cis	rs10895275	0.961	rs4475891	ENSG00000277459.1	RP11-732A21.3	-4.35	2.51e-05	0.0246	-0.33	-0.34	Migraine;	chr11:102225551	chr11:102109827~102110457:-
UCEC	cis	rs10895275	0.961	rs7124247	ENSG00000277459.1	RP11-732A21.3	-4.35	2.51e-05	0.0246	-0.33	-0.34	Migraine;	chr11:102225685	chr11:102109827~102110457:-
UCEC	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-4.35	2.51e-05	0.0246	-0.31	-0.34	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
UCEC	cis	rs847851	0.617	rs9368844	ENSG00000219023.1	RP3-340B19.2	-4.35	2.52e-05	0.0247	-0.39	-0.34	Colonoscopy-negative controls vs population controls;	chr6:35010253	chr6:35555873~35556264:+
UCEC	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-4.35	2.52e-05	0.0247	-0.4	-0.34	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
UCEC	cis	rs6840360	0.642	rs7666571	ENSG00000270265.1	RP11-731D1.4	-4.35	2.52e-05	0.0247	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151333775~151353224:-
UCEC	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-4.35	2.53e-05	0.0248	-0.42	-0.34	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
UCEC	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-4.35	2.53e-05	0.0248	-0.34	-0.34	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
UCEC	cis	rs7674212	0.57	rs2069274	ENSG00000246560.2	RP11-10L12.4	4.35	2.53e-05	0.0248	0.39	0.34	Type 2 diabetes;	chr4:103099624	chr4:102828055~102844075:+
UCEC	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-4.35	2.53e-05	0.0248	-0.39	-0.34	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
UCEC	cis	rs492146	0.765	rs597348	ENSG00000243236.5	GSTA9P	-4.35	2.53e-05	0.0248	-0.42	-0.34	Epilepsy (remission after treatment);	chr6:52980599	chr6:52939726~52957521:-
UCEC	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-4.35	2.53e-05	0.0248	-0.44	-0.34	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
UCEC	cis	rs847851	0.617	rs11970238	ENSG00000219023.1	RP3-340B19.2	-4.35	2.53e-05	0.0248	-0.39	-0.34	Colonoscopy-negative controls vs population controls;	chr6:34977366	chr6:35555873~35556264:+
UCEC	cis	rs847851	0.617	rs9394265	ENSG00000219023.1	RP3-340B19.2	-4.35	2.53e-05	0.0248	-0.39	-0.34	Colonoscopy-negative controls vs population controls;	chr6:34982497	chr6:35555873~35556264:+
UCEC	cis	rs847851	0.617	rs9380478	ENSG00000219023.1	RP3-340B19.2	-4.35	2.53e-05	0.0248	-0.39	-0.34	Colonoscopy-negative controls vs population controls;	chr6:34993034	chr6:35555873~35556264:+
UCEC	cis	rs847851	0.569	rs3800439	ENSG00000219023.1	RP3-340B19.2	-4.35	2.53e-05	0.0248	-0.39	-0.34	Colonoscopy-negative controls vs population controls;	chr6:34993629	chr6:35555873~35556264:+
UCEC	cis	rs847851	0.617	rs73403805	ENSG00000219023.1	RP3-340B19.2	-4.35	2.53e-05	0.0248	-0.39	-0.34	Colonoscopy-negative controls vs population controls;	chr6:34996947	chr6:35555873~35556264:+
UCEC	cis	rs9876781	0.559	rs7611415	ENSG00000229759.1	MRPS18AP1	4.35	2.54e-05	0.0249	0.37	0.34	Longevity;	chr3:48363659	chr3:48256350~48256938:-
UCEC	cis	rs617219	0.671	rs2591388	ENSG00000245556.2	SCAMP1-AS1	4.35	2.54e-05	0.0249	0.32	0.34	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79261418	chr5:78342365~78360507:-
UCEC	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	4.35	2.55e-05	0.025	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
UCEC	cis	rs3002131	0.688	rs3008650	ENSG00000272750.1	RP11-378J18.8	-4.35	2.55e-05	0.025	-0.42	-0.34	Interleukin-10 levels;	chr1:222589873	chr1:222658867~222661512:-
UCEC	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	4.35	2.55e-05	0.025	0.38	0.34	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	4.35	2.56e-05	0.025	0.37	0.34	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-4.35	2.56e-05	0.025	-0.35	-0.34	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
UCEC	cis	rs7267979	0.932	rs2387891	ENSG00000276952.1	RP5-965G21.6	4.35	2.56e-05	0.025	0.44	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25284915~25285588:-
UCEC	cis	rs9545047	1	rs2484345	ENSG00000227354.5	RBM26-AS1	-4.34	2.57e-05	0.0251	-0.37	-0.34	Schizophrenia;	chr13:79427913	chr13:79406309~79424328:+
UCEC	cis	rs8141529	0.748	rs1318025	ENSG00000272858.1	CTA-292E10.8	-4.34	2.57e-05	0.0251	-0.44	-0.34	Lymphocyte counts;	chr22:28887769	chr22:28814914~28815662:+
UCEC	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-4.34	2.57e-05	0.0251	-0.39	-0.34	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
UCEC	cis	rs492146	0.765	rs423475	ENSG00000243236.5	GSTA9P	-4.34	2.57e-05	0.0251	-0.42	-0.34	Epilepsy (remission after treatment);	chr6:52979785	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.765	rs419427	ENSG00000243236.5	GSTA9P	-4.34	2.57e-05	0.0251	-0.42	-0.34	Epilepsy (remission after treatment);	chr6:52980088	chr6:52939726~52957521:-
UCEC	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	4.34	2.57e-05	0.0251	0.37	0.34	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
UCEC	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-4.34	2.57e-05	0.0252	-0.53	-0.34	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
UCEC	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	4.34	2.58e-05	0.0252	0.42	0.34	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	4.34	2.58e-05	0.0252	0.42	0.34	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	4.34	2.58e-05	0.0252	0.42	0.34	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	4.34	2.58e-05	0.0252	0.42	0.34	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
UCEC	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	4.34	2.58e-05	0.0252	0.43	0.34	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	4.34	2.58e-05	0.0252	0.43	0.34	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	4.34	2.58e-05	0.0252	0.43	0.34	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
UCEC	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-4.34	2.58e-05	0.0252	-0.38	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
UCEC	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-4.34	2.58e-05	0.0252	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
UCEC	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-4.34	2.58e-05	0.0252	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
UCEC	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	4.34	2.58e-05	0.0252	0.36	0.34	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	4.34	2.58e-05	0.0252	0.36	0.34	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	4.34	2.58e-05	0.0252	0.36	0.34	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
UCEC	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	4.34	2.58e-05	0.0252	0.4	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
UCEC	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	4.34	2.58e-05	0.0252	0.38	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
UCEC	cis	rs34286592	0.929	rs35901559	ENSG00000238045.8	AC009133.12	4.34	2.58e-05	0.0252	0.54	0.34	Multiple sclerosis;	chr16:29818294	chr16:29808636~29821252:-
UCEC	cis	rs34286592	0.929	rs11864180	ENSG00000238045.8	AC009133.12	4.34	2.58e-05	0.0252	0.54	0.34	Multiple sclerosis;	chr16:29819508	chr16:29808636~29821252:-
UCEC	cis	rs34286592	0.929	rs9923649	ENSG00000238045.8	AC009133.12	4.34	2.58e-05	0.0252	0.54	0.34	Multiple sclerosis;	chr16:29820817	chr16:29808636~29821252:-
UCEC	cis	rs5771069	0.931	rs5771222	ENSG00000235111.1	RP1-29C18.8	4.34	2.59e-05	0.0253	0.34	0.34	Ulcerative colitis;	chr22:50007275	chr22:49612657~49615716:-
UCEC	cis	rs9863	0.862	rs6488912	ENSG00000269938.1	RP11-214K3.20	-4.34	2.59e-05	0.0253	-0.39	-0.34	White blood cell count;	chr12:123958205	chr12:123968023~123968579:-
UCEC	cis	rs6840360	0.582	rs1372976	ENSG00000270265.1	RP11-731D1.4	-4.34	2.59e-05	0.0253	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151333775~151353224:-
UCEC	cis	rs6840360	0.642	rs1443090	ENSG00000270265.1	RP11-731D1.4	-4.34	2.59e-05	0.0253	-0.32	-0.34	Intelligence (multi-trait analysis);	chr4:151530667	chr4:151333775~151353224:-
UCEC	cis	rs17826219	0.706	rs8075357	ENSG00000266490.1	CTD-2349P21.9	4.34	2.59e-05	0.0253	0.46	0.34	Body mass index;	chr17:30730179	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.706	rs61643715	ENSG00000266490.1	CTD-2349P21.9	4.34	2.59e-05	0.0253	0.46	0.34	Body mass index;	chr17:30730744	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.636	rs8080829	ENSG00000266490.1	CTD-2349P21.9	4.34	2.59e-05	0.0253	0.46	0.34	Body mass index;	chr17:30731712	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.706	rs9893922	ENSG00000266490.1	CTD-2349P21.9	4.34	2.59e-05	0.0253	0.46	0.34	Body mass index;	chr17:30741407	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.5	rs9891256	ENSG00000266490.1	CTD-2349P21.9	4.34	2.59e-05	0.0253	0.46	0.34	Body mass index;	chr17:30745674	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	4.34	2.59e-05	0.0253	0.46	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	4.34	2.59e-05	0.0253	0.46	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
UCEC	cis	rs10232172	1	rs1464761	ENSG00000234707.2	RP11-745C15.2	4.34	2.6e-05	0.0253	0.61	0.34	Periodontal disease-related phenotypes;	chr7:54109613	chr7:54759425~54804928:+
UCEC	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	4.34	2.6e-05	0.0254	0.39	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
UCEC	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	4.34	2.6e-05	0.0254	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
UCEC	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-4.34	2.6e-05	0.0254	-0.41	-0.34	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
UCEC	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-4.34	2.61e-05	0.0254	-0.37	-0.34	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
UCEC	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	4.34	2.61e-05	0.0254	0.56	0.34	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
UCEC	cis	rs524281	0.731	rs10791840	ENSG00000255320.1	RP11-755F10.1	4.34	2.61e-05	0.0254	0.56	0.34	Electroencephalogram traits;	chr11:66035912	chr11:66244840~66246239:-
UCEC	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-4.34	2.62e-05	0.0255	-0.46	-0.33	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
UCEC	cis	rs2276314	0.857	rs28530656	ENSG00000267627.4	RP11-905K4.1	4.34	2.62e-05	0.0255	0.37	0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35951803~35966118:-
UCEC	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-4.34	2.62e-05	0.0255	-0.32	-0.33	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
UCEC	cis	rs36032232	0.632	rs74890957	ENSG00000240163.1	RP11-745A24.1	4.34	2.63e-05	0.0256	0.7	0.33	Blood protein levels;	chr15:60542645	chr15:60390371~60390682:+
UCEC	cis	rs847851	0.517	rs2049316	ENSG00000219023.1	RP3-340B19.2	-4.34	2.63e-05	0.0256	-0.37	-0.33	Colonoscopy-negative controls vs population controls;	chr6:35041376	chr6:35555873~35556264:+
UCEC	cis	rs2445284	0.817	rs2445328	ENSG00000229534.1	HNRNPA1P53	-4.34	2.63e-05	0.0256	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5056853	chr11:5571247~5572192:-
UCEC	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-4.34	2.63e-05	0.0256	-0.53	-0.33	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
UCEC	cis	rs6802315	0.573	rs7635993	ENSG00000272247.1	RP11-379F4.9	-4.34	2.63e-05	0.0256	-0.37	-0.33	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158801257~158801935:-
UCEC	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	4.34	2.63e-05	0.0256	0.36	0.33	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	4.34	2.63e-05	0.0256	0.36	0.33	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	4.34	2.63e-05	0.0256	0.36	0.33	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
UCEC	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	4.34	2.64e-05	0.0256	0.5	0.33	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
UCEC	cis	rs9527	0.59	rs1475642	ENSG00000236937.2	PTGES3P4	-4.34	2.64e-05	0.0256	-0.39	-0.33	Arsenic metabolism;	chr10:102786426	chr10:102845595~102845950:+
UCEC	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	4.34	2.64e-05	0.0256	0.55	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
UCEC	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-4.34	2.64e-05	0.0256	-0.34	-0.33	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
UCEC	cis	rs62103177	0.535	rs62101568	ENSG00000261126.6	RP11-795F19.1	4.34	2.64e-05	0.0257	0.38	0.33	Opioid sensitivity;	chr18:80176788	chr18:80046900~80095482:+
UCEC	cis	rs507080	0.885	rs693037	ENSG00000278376.1	RP11-158I9.8	-4.34	2.64e-05	0.0257	-0.33	-0.33	Serum metabolite levels;	chr11:118682617	chr11:118791254~118793137:+
UCEC	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-4.34	2.64e-05	0.0257	-0.31	-0.33	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
UCEC	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-4.34	2.64e-05	0.0257	-0.41	-0.33	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
UCEC	cis	rs9450351	0.744	rs7760309	ENSG00000203875.9	SNHG5	-4.34	2.65e-05	0.0257	-0.57	-0.33	Interferon gamma-induced protein 10 levels;	chr6:85744305	chr6:85660950~85678736:-
UCEC	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	4.34	2.65e-05	0.0257	0.48	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
UCEC	cis	rs9828933	0.577	rs704374	ENSG00000280620.1	SCAANT1	-4.34	2.65e-05	0.0257	-0.57	-0.33	Type 2 diabetes;	chr3:63880271	chr3:63911518~63911772:-
UCEC	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-4.34	2.66e-05	0.0258	-0.39	-0.33	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
UCEC	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-4.34	2.66e-05	0.0258	-0.39	-0.33	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
UCEC	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-4.34	2.66e-05	0.0258	-0.47	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
UCEC	cis	rs7267979	0.528	rs6076366	ENSG00000276952.1	RP5-965G21.6	-4.34	2.66e-05	0.0258	-0.43	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:25284915~25285588:-
UCEC	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	4.34	2.67e-05	0.0259	0.38	0.33	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	4.34	2.67e-05	0.0259	0.38	0.33	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	4.34	2.67e-05	0.0259	0.38	0.33	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	4.34	2.67e-05	0.0259	0.38	0.33	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	4.34	2.67e-05	0.0259	0.38	0.33	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-4.34	2.67e-05	0.0259	-0.41	-0.33	Depression;	chr6:28206179	chr6:28115628~28116551:+
UCEC	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-4.34	2.67e-05	0.0259	-0.33	-0.33	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
UCEC	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-4.34	2.67e-05	0.0259	-0.38	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-4.34	2.67e-05	0.0259	-0.38	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-4.34	2.67e-05	0.0259	-0.38	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-4.34	2.67e-05	0.0259	-0.38	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
UCEC	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-4.34	2.67e-05	0.0259	-0.38	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
UCEC	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	4.34	2.67e-05	0.0259	0.29	0.33	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
UCEC	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	4.33	2.67e-05	0.0259	0.49	0.33	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
UCEC	cis	rs6137726	0.524	rs1203947	ENSG00000277901.1	RP5-851M4.1	4.33	2.67e-05	0.0259	0.44	0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22621725	chr20:23320958~23325352:-
UCEC	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-4.33	2.67e-05	0.0259	-0.41	-0.33	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
UCEC	cis	rs9876781	0.559	rs13073692	ENSG00000229759.1	MRPS18AP1	4.33	2.67e-05	0.0259	0.37	0.33	Longevity;	chr3:48361812	chr3:48256350~48256938:-
UCEC	cis	rs2976388	0.692	rs2978983	ENSG00000253931.1	RP11-909N17.2	4.33	2.67e-05	0.0259	0.34	0.33	Urinary tract infection frequency;	chr8:142684424	chr8:143412749~143417054:+
UCEC	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-4.33	2.68e-05	0.0259	-0.36	-0.33	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
UCEC	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	4.33	2.68e-05	0.0259	0.37	0.33	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
UCEC	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	4.33	2.68e-05	0.0259	0.38	0.33	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
UCEC	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	4.33	2.68e-05	0.026	0.39	0.33	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs4717292	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66430611	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs2420591	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66447394	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.895	rs10755833	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66448930	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs12668936	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66449417	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.895	rs12698520	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66453720	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.895	rs1833495	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66456608	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs6945032	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66457499	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.929	rs12673810	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66458866	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs35149210	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66464938	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.929	rs34406470	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66464969	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs6961155	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66468308	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs7789768	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66473993	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs1363055	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66478288	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs9691480	ENSG00000236529.1	RP13-254B10.1	4.33	2.68e-05	0.026	0.38	0.33	Aortic root size;	chr7:66479319	chr7:65840212~65840596:+
UCEC	cis	rs6728302	0.655	rs882098	ENSG00000172799.5	ZBTB8OSP2	-4.33	2.68e-05	0.026	-0.53	-0.33	Height;	chr2:232244147	chr2:231433923~231434426:-
UCEC	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	4.33	2.68e-05	0.026	0.4	0.33	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
UCEC	cis	rs709400	0.859	rs7693	ENSG00000259775.1	RP11-45P15.4	4.33	2.68e-05	0.026	0.42	0.33	Body mass index;	chr14:103557367	chr14:103331674~103332367:-
UCEC	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-4.33	2.69e-05	0.026	-0.43	-0.33	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
UCEC	cis	rs16828019	0.777	rs35080169	ENSG00000235358.1	RP11-399E6.1	4.33	2.7e-05	0.0261	0.91	0.33	Intelligence (multi-trait analysis);	chr1:40989287	chr1:41242373~41284861:+
UCEC	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	4.33	2.7e-05	0.0261	0.86	0.33	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
UCEC	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	4.33	2.7e-05	0.0261	0.5	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
UCEC	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0261	0.36	0.33	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0261	0.36	0.33	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
UCEC	cis	rs492146	0.765	rs673197	ENSG00000243236.5	GSTA9P	-4.33	2.7e-05	0.0261	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52979459	chr6:52939726~52957521:-
UCEC	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	4.33	2.7e-05	0.0261	0.37	0.33	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	4.33	2.71e-05	0.0261	0.32	0.33	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
UCEC	cis	rs2276314	1	rs9304154	ENSG00000267627.4	RP11-905K4.1	-4.33	2.71e-05	0.0262	-0.39	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35951803~35966118:-
UCEC	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-4.33	2.71e-05	0.0262	-0.43	-0.33	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
UCEC	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	4.33	2.71e-05	0.0262	0.43	0.33	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
UCEC	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	4.33	2.71e-05	0.0262	0.43	0.33	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
UCEC	cis	rs617219	0.671	rs2591392	ENSG00000245556.2	SCAMP1-AS1	4.33	2.72e-05	0.0262	0.32	0.33	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79250470	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.671	rs6414979	ENSG00000245556.2	SCAMP1-AS1	4.33	2.72e-05	0.0262	0.32	0.33	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79252187	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.671	rs12189188	ENSG00000245556.2	SCAMP1-AS1	4.33	2.72e-05	0.0262	0.32	0.33	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79256489	chr5:78342365~78360507:-
UCEC	cis	rs763121	0.815	rs4821799	ENSG00000273076.1	RP3-508I15.22	4.33	2.72e-05	0.0262	0.35	0.33	Menopause (age at onset);	chr22:38625321	chr22:38743495~38743910:+
UCEC	cis	rs7674212	0.54	rs2711897	ENSG00000246560.2	RP11-10L12.4	4.33	2.72e-05	0.0262	0.39	0.33	Type 2 diabetes;	chr4:103102410	chr4:102828055~102844075:+
UCEC	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	4.33	2.72e-05	0.0262	0.4	0.33	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
UCEC	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-4.33	2.72e-05	0.0262	-0.37	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
UCEC	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-4.33	2.72e-05	0.0262	-0.4	-0.33	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
UCEC	cis	rs1113500	0.58	rs1781058	ENSG00000226822.1	RP11-356N1.2	4.33	2.73e-05	0.0263	0.42	0.33	Growth-regulated protein alpha levels;	chr1:108021437	chr1:108071482~108074519:+
UCEC	cis	rs12986413	0.789	rs12980348	ENSG00000267283.1	AC005306.3	4.33	2.73e-05	0.0263	0.31	0.33	Height;	chr19:2181608	chr19:1989401~1990370:+
UCEC	cis	rs948562	0.69	rs7342155	ENSG00000280010.1	AP001350.4	4.33	2.73e-05	0.0263	0.65	0.33	Lymphoma;	chr11:58348171	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.69	rs79894420	ENSG00000280010.1	AP001350.4	4.33	2.73e-05	0.0263	0.65	0.33	Lymphoma;	chr11:58349359	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.69	rs12361133	ENSG00000280010.1	AP001350.4	4.33	2.73e-05	0.0263	0.65	0.33	Lymphoma;	chr11:58357532	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.69	rs11229391	ENSG00000280010.1	AP001350.4	4.33	2.73e-05	0.0263	0.65	0.33	Lymphoma;	chr11:58382503	chr11:58627435~58628528:+
UCEC	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	4.33	2.73e-05	0.0263	0.5	0.33	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
UCEC	cis	rs2732480	0.538	rs2732462	ENSG00000226413.2	OR8T1P	4.33	2.73e-05	0.0263	0.48	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48442030~48442947:-
UCEC	cis	rs62025270	0.576	rs62022947	ENSG00000202081.1	RNU6-1280P	-4.33	2.73e-05	0.0263	-0.45	-0.33	Idiopathic pulmonary fibrosis;	chr15:85728091	chr15:85651522~85651628:-
UCEC	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-4.33	2.73e-05	0.0263	-0.31	-0.33	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
UCEC	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	4.33	2.73e-05	0.0263	0.42	0.33	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
UCEC	cis	rs1535454	1	rs1535454	ENSG00000273061.1	CDC37L1-AS1	-4.33	2.73e-05	0.0263	-0.6	-0.33	Obesity-related traits;	chr9:5410723	chr9:4676600~4679502:-
UCEC	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	4.33	2.73e-05	0.0263	0.42	0.33	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	4.33	2.73e-05	0.0263	0.42	0.33	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
UCEC	cis	rs4253772	0.591	rs6007748	ENSG00000277232.2	GTSE1-AS1	-4.33	2.74e-05	0.0263	-0.39	-0.33	Cholesterol, total;LDL cholesterol;	chr22:46261901	chr22:46295143~46296660:-
UCEC	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	4.33	2.74e-05	0.0264	0.35	0.33	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
UCEC	cis	rs10946940	0.896	rs12208078	ENSG00000216901.1	AL022393.7	-4.33	2.74e-05	0.0264	-0.37	-0.33	Systemic lupus erythematosus;	chr6:27530802	chr6:28176188~28176674:+
UCEC	cis	rs10946940	0.965	rs10946935	ENSG00000216901.1	AL022393.7	-4.33	2.74e-05	0.0264	-0.37	-0.33	Systemic lupus erythematosus;	chr6:27533566	chr6:28176188~28176674:+
UCEC	cis	rs9545047	0.567	rs9574420	ENSG00000227354.5	RBM26-AS1	-4.33	2.74e-05	0.0264	-0.33	-0.33	Schizophrenia;	chr13:79404342	chr13:79406309~79424328:+
UCEC	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	4.33	2.74e-05	0.0264	0.42	0.33	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	4.33	2.74e-05	0.0264	0.32	0.33	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
UCEC	cis	rs9876781	0.559	rs1841178	ENSG00000229759.1	MRPS18AP1	4.33	2.74e-05	0.0264	0.37	0.33	Longevity;	chr3:48355556	chr3:48256350~48256938:-
UCEC	cis	rs73086581	0.891	rs73084555	ENSG00000229539.1	RP11-119B16.2	4.33	2.74e-05	0.0264	0.72	0.33	Response to antidepressants in depression;	chr20:3913153	chr20:3888239~3888868:-
UCEC	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-4.33	2.75e-05	0.0264	-0.42	-0.33	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
UCEC	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-4.33	2.75e-05	0.0264	-0.44	-0.33	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
UCEC	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	4.33	2.75e-05	0.0265	0.32	0.33	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.767	rs12668005	ENSG00000236529.1	RP13-254B10.1	4.33	2.75e-05	0.0265	0.41	0.33	Aortic root size;	chr7:66444034	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs11765791	ENSG00000236529.1	RP13-254B10.1	4.33	2.75e-05	0.0265	0.41	0.33	Aortic root size;	chr7:66471587	chr7:65840212~65840596:+
UCEC	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	4.33	2.76e-05	0.0265	0.36	0.33	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	4.33	2.76e-05	0.0265	0.36	0.33	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	4.33	2.76e-05	0.0265	0.36	0.33	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
UCEC	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-4.33	2.76e-05	0.0265	-0.46	-0.33	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-4.33	2.76e-05	0.0265	-0.46	-0.33	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
UCEC	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	4.33	2.76e-05	0.0265	0.39	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
UCEC	cis	rs6051080	1	rs6051080	ENSG00000125804.12	FAM182A	4.33	2.76e-05	0.0265	0.36	0.33	Colorectal or endometrial cancer;	chr20:25995038	chr20:26054655~26086917:+
UCEC	cis	rs3813567	0.759	rs12595350	ENSG00000261143.1	ADAMTS7P3	-4.33	2.76e-05	0.0265	-0.61	-0.33	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78661122	chr15:77976042~77993057:+
UCEC	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-4.33	2.76e-05	0.0265	-0.38	-0.33	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
UCEC	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	4.33	2.76e-05	0.0266	0.38	0.33	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
UCEC	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	4.33	2.77e-05	0.0266	0.35	0.33	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
UCEC	cis	rs12744310	0.887	rs2363810	ENSG00000235358.1	RP11-399E6.1	4.33	2.77e-05	0.0266	0.51	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41318201	chr1:41242373~41284861:+
UCEC	cis	rs12986413	0.763	rs12983357	ENSG00000267283.1	AC005306.3	4.33	2.77e-05	0.0266	0.31	0.33	Height;	chr19:2170869	chr19:1989401~1990370:+
UCEC	cis	rs12986413	0.789	rs12976923	ENSG00000267283.1	AC005306.3	4.33	2.77e-05	0.0266	0.31	0.33	Height;	chr19:2173137	chr19:1989401~1990370:+
UCEC	cis	rs6430585	0.528	rs309122	ENSG00000231890.6	DARS-AS1	-4.33	2.77e-05	0.0266	-0.43	-0.33	Corneal structure;	chr2:136004283	chr2:135985176~136022593:+
UCEC	cis	rs948562	0.523	rs12362065	ENSG00000280010.1	AP001350.4	4.33	2.77e-05	0.0266	0.63	0.33	Lymphoma;	chr11:58287727	chr11:58627435~58628528:+
UCEC	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	4.32	2.78e-05	0.0267	0.51	0.33	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	4.32	2.78e-05	0.0267	0.51	0.33	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	4.32	2.78e-05	0.0267	0.51	0.33	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
UCEC	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	4.32	2.79e-05	0.0267	0.39	0.33	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
UCEC	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	4.32	2.79e-05	0.0267	0.39	0.33	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
UCEC	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-4.32	2.79e-05	0.0268	-0.44	-0.33	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
UCEC	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-4.32	2.79e-05	0.0268	-0.46	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
UCEC	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-4.32	2.79e-05	0.0268	-0.46	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
UCEC	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	4.32	2.79e-05	0.0268	0.42	0.33	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	4.32	2.79e-05	0.0268	0.42	0.33	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	4.32	2.79e-05	0.0268	0.42	0.33	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	4.32	2.79e-05	0.0268	0.42	0.33	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	4.32	2.79e-05	0.0268	0.42	0.33	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
UCEC	cis	rs7589014	0.925	rs4674357	ENSG00000232719.1	RP11-13J8.1	-4.32	2.79e-05	0.0268	-0.73	-0.33	Intelligence;	chr2:200722468	chr2:201101382~201103136:+
UCEC	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-4.32	2.79e-05	0.0268	-0.37	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
UCEC	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-4.32	2.8e-05	0.0268	-0.46	-0.33	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
UCEC	cis	rs7177699	0.557	rs3971829	ENSG00000261143.1	ADAMTS7P3	-4.32	2.8e-05	0.0268	-0.43	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78816710	chr15:77976042~77993057:+
UCEC	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	4.32	2.8e-05	0.0268	0.43	0.33	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
UCEC	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	4.32	2.8e-05	0.0268	0.4	0.33	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	4.32	2.8e-05	0.0268	0.4	0.33	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	4.32	2.8e-05	0.0268	0.4	0.33	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	4.32	2.8e-05	0.0268	0.4	0.33	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	4.32	2.8e-05	0.0268	0.4	0.33	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	4.32	2.8e-05	0.0268	0.4	0.33	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	4.32	2.8e-05	0.0268	0.4	0.33	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
UCEC	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	4.32	2.8e-05	0.0268	0.42	0.33	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
UCEC	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-4.32	2.8e-05	0.0269	-0.36	-0.33	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
UCEC	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	4.32	2.81e-05	0.0269	0.41	0.33	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	4.32	2.81e-05	0.0269	0.41	0.33	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	4.32	2.81e-05	0.0269	0.41	0.33	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	4.32	2.81e-05	0.0269	0.41	0.33	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	4.32	2.81e-05	0.0269	0.41	0.33	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
UCEC	cis	rs2243480	0.522	rs1638736	ENSG00000226824.5	RP4-756H11.3	-4.32	2.81e-05	0.0269	-0.83	-0.33	Diabetic kidney disease;	chr7:66627321	chr7:66654538~66669855:+
UCEC	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-4.32	2.81e-05	0.0269	-0.42	-0.33	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
UCEC	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	4.32	2.81e-05	0.0269	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
UCEC	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-4.32	2.81e-05	0.0269	-0.46	-0.33	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
UCEC	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-4.32	2.82e-05	0.0269	-0.45	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
UCEC	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	4.32	2.82e-05	0.027	0.42	0.33	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
UCEC	cis	rs867186	0.535	rs6058220	ENSG00000126005.14	MMP24-AS1	-4.32	2.83e-05	0.027	-0.61	-0.33	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35271461	chr20:35216462~35278131:-
UCEC	cis	rs7914558	1	rs7067970	ENSG00000272912.1	RP11-724N1.1	-4.32	2.84e-05	0.0271	-0.33	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103154113	chr10:102914585~102915404:+
UCEC	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	4.32	2.84e-05	0.0271	0.38	0.33	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
UCEC	cis	rs492146	0.765	rs316141	ENSG00000243236.5	GSTA9P	-4.32	2.84e-05	0.0271	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52981360	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.765	rs316140	ENSG00000243236.5	GSTA9P	-4.32	2.84e-05	0.0271	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52981390	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.691	rs316138	ENSG00000243236.5	GSTA9P	-4.32	2.84e-05	0.0271	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52981621	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.765	rs622902	ENSG00000243236.5	GSTA9P	-4.32	2.84e-05	0.0271	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52981676	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.765	rs316132	ENSG00000243236.5	GSTA9P	-4.32	2.84e-05	0.0271	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52983168	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.765	rs316131	ENSG00000243236.5	GSTA9P	-4.32	2.84e-05	0.0271	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52983351	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.729	rs316130	ENSG00000243236.5	GSTA9P	-4.32	2.84e-05	0.0271	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52983402	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.765	rs316129	ENSG00000243236.5	GSTA9P	-4.32	2.84e-05	0.0271	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52984107	chr6:52939726~52957521:-
UCEC	cis	rs1974653	0.781	rs175164	ENSG00000236540.6	AC006547.13	-4.32	2.84e-05	0.0271	-0.39	-0.33	Schizophrenia;	chr22:20128039	chr22:20058030~20070569:-
UCEC	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-4.32	2.85e-05	0.0271	-0.44	-0.33	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
UCEC	cis	rs6840360	0.642	rs2709842	ENSG00000251611.1	RP11-610P16.1	4.32	2.85e-05	0.0271	0.28	0.33	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151407551~151408835:-
UCEC	cis	rs11971779	0.938	rs28477480	ENSG00000273391.1	RP11-634H22.1	-4.32	2.85e-05	0.0272	-0.4	-0.33	Diisocyanate-induced asthma;	chr7:139351312	chr7:139359032~139359566:-
UCEC	cis	rs7397814	0.558	rs4764447	ENSG00000255753.1	RP11-22B23.2	-4.32	2.85e-05	0.0272	-0.41	-0.33	IgG glycosylation;	chr12:9426513	chr12:9314402~9316173:-
UCEC	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	4.32	2.85e-05	0.0272	0.42	0.33	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	4.32	2.85e-05	0.0272	0.42	0.33	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	4.32	2.85e-05	0.0272	0.42	0.33	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	4.32	2.85e-05	0.0272	0.42	0.33	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	4.32	2.85e-05	0.0272	0.42	0.33	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
UCEC	cis	rs8141529	0.719	rs5762880	ENSG00000272858.1	CTA-292E10.8	-4.32	2.85e-05	0.0272	-0.44	-0.33	Lymphocyte counts;	chr22:28891828	chr22:28814914~28815662:+
UCEC	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-4.32	2.85e-05	0.0272	-0.65	-0.33	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
UCEC	cis	rs4784934	0.959	rs2042401	ENSG00000260186.4	RP11-481J2.2	4.32	2.86e-05	0.0272	0.48	0.33	QT interval;	chr16:58430171	chr16:58421326~58462470:+
UCEC	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-4.32	2.86e-05	0.0272	-0.35	-0.33	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-4.32	2.86e-05	0.0272	-0.35	-0.33	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
UCEC	cis	rs11971779	0.68	rs6947215	ENSG00000273391.1	RP11-634H22.1	4.32	2.86e-05	0.0273	0.37	0.33	Diisocyanate-induced asthma;	chr7:139341892	chr7:139359032~139359566:-
UCEC	cis	rs9907295	1	rs11653051	ENSG00000270871.1	AC015849.19	4.32	2.86e-05	0.0273	0.47	0.33	Fibroblast growth factor basic levels;	chr17:35909166	chr17:35816717~35830293:-
UCEC	cis	rs9309473	0.607	rs1403412	ENSG00000163016.8	ALMS1P	4.32	2.86e-05	0.0273	0.35	0.33	Metabolite levels;	chr2:73370964	chr2:73644919~73685576:+
UCEC	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-4.32	2.86e-05	0.0273	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
UCEC	cis	rs2276314	0.947	rs16967319	ENSG00000267627.4	RP11-905K4.1	-4.32	2.87e-05	0.0273	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35951803~35966118:-
UCEC	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	4.32	2.87e-05	0.0273	0.41	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
UCEC	cis	rs2732480	0.577	rs2634684	ENSG00000226413.2	OR8T1P	-4.32	2.87e-05	0.0273	-0.47	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48442030~48442947:-
UCEC	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-4.32	2.87e-05	0.0273	-0.3	-0.33	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
UCEC	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	4.32	2.87e-05	0.0273	0.38	0.33	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	4.32	2.87e-05	0.0273	0.38	0.33	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	4.32	2.87e-05	0.0273	0.38	0.33	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
UCEC	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-4.32	2.87e-05	0.0273	-0.38	-0.33	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
UCEC	cis	rs17826219	0.706	rs28469200	ENSG00000266490.1	CTD-2349P21.9	4.32	2.87e-05	0.0273	0.44	0.33	Body mass index;	chr17:30806554	chr17:30792372~30792833:+
UCEC	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-4.32	2.87e-05	0.0273	-0.31	-0.33	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
UCEC	cis	rs7688540	0.76	rs28460123	ENSG00000211553.1	AC253576.2	-4.32	2.88e-05	0.0274	-0.39	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:136461~136568:+
UCEC	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	4.32	2.88e-05	0.0274	0.31	0.33	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
UCEC	cis	rs2445284	0.874	rs2499972	ENSG00000229534.1	HNRNPA1P53	-4.32	2.88e-05	0.0274	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5038186	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499973	ENSG00000229534.1	HNRNPA1P53	-4.32	2.88e-05	0.0274	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5038190	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499974	ENSG00000229534.1	HNRNPA1P53	-4.32	2.88e-05	0.0274	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5038213	chr11:5571247~5572192:-
UCEC	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-4.32	2.88e-05	0.0274	-0.31	-0.33	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
UCEC	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-4.32	2.88e-05	0.0274	-0.44	-0.33	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
UCEC	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	4.32	2.88e-05	0.0274	0.49	0.33	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
UCEC	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	4.32	2.88e-05	0.0274	0.49	0.33	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
UCEC	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	4.32	2.88e-05	0.0274	0.49	0.33	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
UCEC	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	4.32	2.89e-05	0.0274	0.43	0.33	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
UCEC	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	4.32	2.89e-05	0.0275	0.34	0.33	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
UCEC	cis	rs7592578	0.771	rs62181034	ENSG00000272979.1	RP11-647K16.1	-4.32	2.89e-05	0.0275	-0.57	-0.33	Diastolic blood pressure;	chr2:190490237	chr2:190454092~190454521:-
UCEC	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-4.32	2.89e-05	0.0275	-0.36	-0.33	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
UCEC	cis	rs11971779	0.941	rs28395455	ENSG00000273391.1	RP11-634H22.1	4.32	2.89e-05	0.0275	0.4	0.33	Diisocyanate-induced asthma;	chr7:139351240	chr7:139359032~139359566:-
UCEC	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-4.32	2.89e-05	0.0275	-0.72	-0.33	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
UCEC	cis	rs9863	0.501	rs10773048	ENSG00000269938.1	RP11-214K3.20	4.32	2.89e-05	0.0275	0.4	0.33	White blood cell count;	chr12:123959862	chr12:123968023~123968579:-
UCEC	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-4.32	2.89e-05	0.0275	-0.43	-0.33	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
UCEC	cis	rs113835537	0.597	rs11227527	ENSG00000255517.5	CTD-3074O7.5	-4.31	2.89e-05	0.0275	-0.46	-0.33	Airway imaging phenotypes;	chr11:66545555	chr11:66473490~66480233:-
UCEC	cis	rs7674212	0.539	rs7676041	ENSG00000246560.2	RP11-10L12.4	4.31	2.9e-05	0.0275	0.39	0.33	Type 2 diabetes;	chr4:103205264	chr4:102828055~102844075:+
UCEC	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	4.31	2.9e-05	0.0276	0.42	0.33	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
UCEC	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	4.31	2.9e-05	0.0276	0.44	0.33	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
UCEC	cis	rs12928939	0.723	rs71403864	ENSG00000260886.1	TAT-AS1	4.31	2.9e-05	0.0276	0.37	0.33	Post bronchodilator FEV1;	chr16:71661127	chr16:71565789~71578187:+
UCEC	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-4.31	2.9e-05	0.0276	-0.31	-0.33	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
UCEC	cis	rs4253772	0.591	rs6519994	ENSG00000277232.2	GTSE1-AS1	4.31	2.9e-05	0.0276	0.39	0.33	Cholesterol, total;LDL cholesterol;	chr22:46260908	chr22:46295143~46296660:-
UCEC	cis	rs28386778	0.562	rs721575	ENSG00000240280.5	TCAM1P	4.31	2.91e-05	0.0276	0.37	0.33	Prudent dietary pattern;	chr17:63705560	chr17:63849292~63864379:+
UCEC	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	4.31	2.91e-05	0.0277	0.39	0.33	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
UCEC	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	4.31	2.92e-05	0.0277	0.52	0.33	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
UCEC	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-4.31	2.92e-05	0.0277	-0.41	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
UCEC	cis	rs1387259	0.69	rs1601985	ENSG00000273765.1	RP11-370I10.11	4.31	2.92e-05	0.0277	0.42	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48360920~48361377:+
UCEC	cis	rs1387259	0.723	rs2732488	ENSG00000273765.1	RP11-370I10.11	4.31	2.92e-05	0.0277	0.42	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48360920~48361377:+
UCEC	cis	rs1387259	0.758	rs2634670	ENSG00000273765.1	RP11-370I10.11	4.31	2.92e-05	0.0277	0.42	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48360920~48361377:+
UCEC	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	4.31	2.92e-05	0.0277	0.39	0.33	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
UCEC	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	4.31	2.93e-05	0.0278	0.35	0.33	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
UCEC	cis	rs948562	0.947	rs60767173	ENSG00000280010.1	AP001350.4	4.31	2.93e-05	0.0278	0.55	0.33	Lymphoma;	chr11:58634074	chr11:58627435~58628528:+
UCEC	cis	rs10232172	0.778	rs1918118	ENSG00000234707.2	RP11-745C15.2	4.31	2.93e-05	0.0278	0.5	0.33	Periodontal disease-related phenotypes;	chr7:54100991	chr7:54759425~54804928:+
UCEC	cis	rs7674212	0.539	rs6821617	ENSG00000246560.2	RP11-10L12.4	4.31	2.93e-05	0.0278	0.39	0.33	Type 2 diabetes;	chr4:103207253	chr4:102828055~102844075:+
UCEC	cis	rs875971	0.862	rs1981799	ENSG00000236529.1	RP13-254B10.1	4.31	2.94e-05	0.0278	0.37	0.33	Aortic root size;	chr7:66490572	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs2277911	ENSG00000236529.1	RP13-254B10.1	4.31	2.94e-05	0.0278	0.37	0.33	Aortic root size;	chr7:66493638	chr7:65840212~65840596:+
UCEC	cis	rs12478296	0.786	rs72620862	ENSG00000261186.2	RP11-341N2.1	-4.31	2.94e-05	0.0278	-0.45	-0.33	Obesity-related traits;	chr2:242102636	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs66466023	ENSG00000261186.2	RP11-341N2.1	-4.31	2.94e-05	0.0278	-0.45	-0.33	Obesity-related traits;	chr2:242104000	chr2:242087351~242088457:-
UCEC	cis	rs12478296	0.901	rs56318767	ENSG00000261186.2	RP11-341N2.1	-4.31	2.94e-05	0.0278	-0.45	-0.33	Obesity-related traits;	chr2:242104440	chr2:242087351~242088457:-
UCEC	cis	rs6840360	0.642	rs2724577	ENSG00000270265.1	RP11-731D1.4	-4.31	2.94e-05	0.0278	-0.38	-0.33	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151333775~151353224:-
UCEC	cis	rs7267979	0.932	rs424487	ENSG00000276952.1	RP5-965G21.6	4.31	2.94e-05	0.0278	0.43	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25284915~25285588:-
UCEC	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	4.31	2.94e-05	0.0278	0.32	0.33	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
UCEC	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	4.31	2.94e-05	0.0278	0.32	0.33	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
UCEC	cis	rs9532669	0.89	rs2324738	ENSG00000239827.7	SUGT1P3	-4.31	2.94e-05	0.0279	-0.31	-0.33	Cervical cancer;	chr13:40925242	chr13:40908159~40921774:-
UCEC	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	4.31	2.94e-05	0.0279	0.42	0.33	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	4.31	2.94e-05	0.0279	0.42	0.33	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
UCEC	cis	rs2976388	0.609	rs2717605	ENSG00000253931.1	RP11-909N17.2	4.31	2.94e-05	0.0279	0.35	0.33	Urinary tract infection frequency;	chr8:142719597	chr8:143412749~143417054:+
UCEC	cis	rs2976388	0.609	rs2572907	ENSG00000253931.1	RP11-909N17.2	4.31	2.94e-05	0.0279	0.35	0.33	Urinary tract infection frequency;	chr8:142720520	chr8:143412749~143417054:+
UCEC	cis	rs2976388	0.609	rs2572908	ENSG00000253931.1	RP11-909N17.2	4.31	2.94e-05	0.0279	0.35	0.33	Urinary tract infection frequency;	chr8:142721218	chr8:143412749~143417054:+
UCEC	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-4.31	2.94e-05	0.0279	-0.34	-0.33	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
UCEC	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	4.31	2.94e-05	0.0279	0.36	0.33	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	4.31	2.94e-05	0.0279	0.36	0.33	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	4.31	2.94e-05	0.0279	0.36	0.33	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
UCEC	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-4.31	2.95e-05	0.0279	-0.42	-0.33	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-4.31	2.95e-05	0.0279	-0.42	-0.33	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-4.31	2.95e-05	0.0279	-0.42	-0.33	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
UCEC	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-4.31	2.95e-05	0.0279	-0.39	-0.33	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
UCEC	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	4.31	2.95e-05	0.0279	0.43	0.33	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
UCEC	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-4.31	2.95e-05	0.0279	-0.38	-0.33	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-4.31	2.95e-05	0.0279	-0.38	-0.33	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-4.31	2.95e-05	0.0279	-0.38	-0.33	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
UCEC	cis	rs6901004	0.803	rs9400470	ENSG00000271789.1	RP5-1112D6.7	-4.31	2.95e-05	0.0279	-0.39	-0.33	Blood metabolite levels;	chr6:111156928	chr6:111297126~111298510:+
UCEC	cis	rs9545047	0.935	rs2783119	ENSG00000227354.5	RBM26-AS1	4.31	2.96e-05	0.0279	0.37	0.33	Schizophrenia;	chr13:79524983	chr13:79406309~79424328:+
UCEC	cis	rs12744310	0.887	rs17362424	ENSG00000235358.1	RP11-399E6.1	-4.31	2.96e-05	0.028	-0.57	-0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41328731	chr1:41242373~41284861:+
UCEC	cis	rs2991971	0.81	rs6657237	ENSG00000280836.1	AL355480.1	-4.31	2.97e-05	0.028	-0.38	-0.33	High light scatter reticulocyte count;	chr1:45454436	chr1:45581219~45581321:-
UCEC	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	4.31	2.97e-05	0.028	0.42	0.33	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
UCEC	cis	rs9601248	0.529	rs2783125	ENSG00000227354.5	RBM26-AS1	4.31	2.97e-05	0.0281	0.38	0.33	Major depressive disorder;	chr13:79583755	chr13:79406309~79424328:+
UCEC	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-4.31	2.97e-05	0.0281	-0.41	-0.33	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
UCEC	cis	rs76228276	0.737	rs76858490	ENSG00000253217.1	KB-1991G8.1	4.31	2.97e-05	0.0281	0.74	0.33	Childhood ear infection;	chr8:99816765	chr8:100337595~100350707:+
UCEC	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-4.31	2.98e-05	0.0281	-0.39	-0.33	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
UCEC	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-4.31	2.98e-05	0.0281	-0.41	-0.33	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-4.31	2.98e-05	0.0281	-0.41	-0.33	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
UCEC	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	4.31	2.98e-05	0.0282	0.41	0.33	Depression;	chr6:28199145	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-4.31	2.98e-05	0.0282	-0.41	-0.33	Depression;	chr6:28197321	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-4.31	2.98e-05	0.0282	-0.41	-0.33	Depression;	chr6:28197412	chr6:28115628~28116551:+
UCEC	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-4.31	2.98e-05	0.0282	-0.41	-0.33	Depression;	chr6:28198669	chr6:28115628~28116551:+
UCEC	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	4.31	2.98e-05	0.0282	0.39	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
UCEC	cis	rs677325	0.604	rs58591914	ENSG00000232498.1	RP5-1011O1.2	4.31	2.99e-05	0.0282	0.51	0.33	Subjective well-being (multi-trait analysis);	chr1:191605501	chr1:192517639~192567217:-
UCEC	cis	rs677325	0.604	rs6694676	ENSG00000232498.1	RP5-1011O1.2	4.31	2.99e-05	0.0282	0.51	0.33	Subjective well-being (multi-trait analysis);	chr1:191606217	chr1:192517639~192567217:-
UCEC	cis	rs677325	0.604	rs16833617	ENSG00000232498.1	RP5-1011O1.2	4.31	2.99e-05	0.0282	0.51	0.33	Subjective well-being (multi-trait analysis);	chr1:191606774	chr1:192517639~192567217:-
UCEC	cis	rs9545047	0.901	rs7982263	ENSG00000227354.5	RBM26-AS1	-4.31	2.99e-05	0.0282	-0.37	-0.33	Schizophrenia;	chr13:79486939	chr13:79406309~79424328:+
UCEC	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-4.31	2.99e-05	0.0282	-0.43	-0.33	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
UCEC	cis	rs6137726	0.524	rs1203921	ENSG00000277901.1	RP5-851M4.1	4.31	2.99e-05	0.0282	0.44	0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22604846	chr20:23320958~23325352:-
UCEC	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-4.31	2.99e-05	0.0282	-0.35	-0.33	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-4.31	2.99e-05	0.0282	-0.35	-0.33	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-4.31	2.99e-05	0.0282	-0.35	-0.33	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-4.31	2.99e-05	0.0282	-0.35	-0.33	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
UCEC	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-4.31	3e-05	0.0283	-0.35	-0.33	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
UCEC	cis	rs4789693	0.938	rs4789694	ENSG00000265458.1	RP13-20L14.6	-4.31	3e-05	0.0283	-0.41	-0.33	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82454273~82458521:-
UCEC	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-4.31	3.01e-05	0.0283	-0.36	-0.33	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
UCEC	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	4.31	3.01e-05	0.0283	0.4	0.33	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
UCEC	cis	rs28386778	0.897	rs11654841	ENSG00000240280.5	TCAM1P	-4.3	3.01e-05	0.0284	-0.41	-0.33	Prudent dietary pattern;	chr17:63760899	chr17:63849292~63864379:+
UCEC	cis	rs6137726	0.569	rs2180553	ENSG00000277901.1	RP5-851M4.1	4.3	3.02e-05	0.0284	0.41	0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22651781	chr20:23320958~23325352:-
UCEC	cis	rs2445284	0.874	rs2499975	ENSG00000229534.1	HNRNPA1P53	-4.3	3.02e-05	0.0284	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5038549	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499976	ENSG00000229534.1	HNRNPA1P53	-4.3	3.02e-05	0.0284	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5038651	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2034835	ENSG00000229534.1	HNRNPA1P53	-4.3	3.02e-05	0.0284	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5039322	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2034837	ENSG00000229534.1	HNRNPA1P53	-4.3	3.02e-05	0.0284	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5039579	chr11:5571247~5572192:-
UCEC	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	4.3	3.02e-05	0.0284	0.4	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
UCEC	cis	rs6137726	0.524	rs6137704	ENSG00000277901.1	RP5-851M4.1	4.3	3.03e-05	0.0285	0.42	0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22639060	chr20:23320958~23325352:-
UCEC	cis	rs7914558	1	rs10509757	ENSG00000272912.1	RP11-724N1.1	-4.3	3.03e-05	0.0285	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:102914585~102915404:+
UCEC	cis	rs6048205	0.764	rs61520093	ENSG00000277901.1	RP5-851M4.1	-4.3	3.03e-05	0.0285	-0.59	-0.33	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr20:22540218	chr20:23320958~23325352:-
UCEC	cis	rs4073582	0.555	rs521109	ENSG00000255320.1	RP11-755F10.1	-4.3	3.03e-05	0.0285	-0.45	-0.33	Gout;	chr11:66263477	chr11:66244840~66246239:-
UCEC	cis	rs4073582	0.516	rs1151539	ENSG00000255320.1	RP11-755F10.1	-4.3	3.03e-05	0.0285	-0.45	-0.33	Gout;	chr11:66264189	chr11:66244840~66246239:-
UCEC	cis	rs4073582	0.595	rs528842	ENSG00000255320.1	RP11-755F10.1	-4.3	3.03e-05	0.0285	-0.45	-0.33	Gout;	chr11:66264919	chr11:66244840~66246239:-
UCEC	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-4.3	3.03e-05	0.0285	-0.38	-0.33	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
UCEC	cis	rs9545047	0.584	rs1886494	ENSG00000227354.5	RBM26-AS1	-4.3	3.03e-05	0.0285	-0.34	-0.33	Schizophrenia;	chr13:79403005	chr13:79406309~79424328:+
UCEC	cis	rs926937	0.622	rs6005500	ENSG00000213707.2	HMGB1P10	-4.3	3.04e-05	0.0285	-0.51	-0.33	Age-related cataracts;	chr22:27529117	chr22:26560526~26561088:+
UCEC	cis	rs875971	0.545	rs1638735	ENSG00000236529.1	RP13-254B10.1	4.3	3.04e-05	0.0286	0.5	0.33	Aortic root size;	chr7:66630751	chr7:65840212~65840596:+
UCEC	cis	rs4266144	1	rs4561781	ENSG00000241770.1	RP11-555M1.3	4.3	3.04e-05	0.0286	0.41	0.33	Coronary artery disease;	chr3:157135154	chr3:157163452~157169133:+
UCEC	cis	rs7246967	0.608	rs396440	ENSG00000198153.8	ZNF849P	-4.3	3.04e-05	0.0286	-0.42	-0.33	Bronchopulmonary dysplasia;	chr19:22820164	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.608	rs433579	ENSG00000198153.8	ZNF849P	-4.3	3.04e-05	0.0286	-0.42	-0.33	Bronchopulmonary dysplasia;	chr19:22820325	chr19:22685167~22686732:+
UCEC	cis	rs875971	0.862	rs6944374	ENSG00000236529.1	RP13-254B10.1	-4.3	3.04e-05	0.0286	-0.38	-0.33	Aortic root size;	chr7:66221942	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-4.3	3.05e-05	0.0286	-0.5	-0.33	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-4.3	3.05e-05	0.0286	-0.5	-0.33	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
UCEC	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	4.3	3.05e-05	0.0286	0.39	0.33	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
UCEC	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	4.3	3.05e-05	0.0287	0.4	0.33	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	4.3	3.05e-05	0.0287	0.4	0.33	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	4.3	3.05e-05	0.0287	0.4	0.33	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	4.3	3.05e-05	0.0287	0.4	0.33	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	4.3	3.05e-05	0.0287	0.4	0.33	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	4.3	3.05e-05	0.0287	0.4	0.33	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
UCEC	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	4.3	3.06e-05	0.0287	0.39	0.33	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
UCEC	cis	rs268134	0.53	rs34820212	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65350186	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs35315862	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65351913	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs13011574	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65354918	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs17704661	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65358683	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs62139122	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65360492	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs17534034	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65367062	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs17534153	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65371088	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs36188795	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65391134	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs35312858	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65391501	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs36044502	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65391595	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs35162271	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65394623	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs17475676	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65395010	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs34073446	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65397338	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs62141062	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65400703	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs35839181	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65400878	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs35837416	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65400957	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs13023210	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65405641	chr2:65623272~65628424:+
UCEC	cis	rs268134	0.53	rs13029865	ENSG00000281920.1	RP11-418H16.1	-4.3	3.06e-05	0.0287	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65406771	chr2:65623272~65628424:+
UCEC	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-4.3	3.06e-05	0.0287	-0.61	-0.33	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
UCEC	cis	rs875971	0.545	rs4718348	ENSG00000236529.1	RP13-254B10.1	4.3	3.06e-05	0.0287	0.51	0.33	Aortic root size;	chr7:66441589	chr7:65840212~65840596:+
UCEC	cis	rs2991971	0.782	rs10789463	ENSG00000280836.1	AL355480.1	-4.3	3.06e-05	0.0287	-0.37	-0.33	High light scatter reticulocyte count;	chr1:45462176	chr1:45581219~45581321:-
UCEC	cis	rs2243480	0.522	rs12698511	ENSG00000226824.5	RP4-756H11.3	-4.3	3.06e-05	0.0287	-0.85	-0.33	Diabetic kidney disease;	chr7:66009932	chr7:66654538~66669855:+
UCEC	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-4.3	3.06e-05	0.0287	-0.85	-0.33	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
UCEC	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-4.3	3.06e-05	0.0287	-0.85	-0.33	Gout;	chr7:66723871	chr7:66654538~66669855:+
UCEC	cis	rs7267979	0.565	rs13040726	ENSG00000276952.1	RP5-965G21.6	-4.3	3.06e-05	0.0287	-0.43	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:25284915~25285588:-
UCEC	cis	rs3785356	0.524	rs3024619	ENSG00000261736.1	AC002551.1	-4.3	3.06e-05	0.0287	-0.31	-0.33	Eosinophil counts;Sum eosinophil basophil counts;	chr16:27353485	chr16:27643199~27644663:+
UCEC	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0287	-0.37	-0.33	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0287	-0.37	-0.33	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0287	-0.38	-0.33	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0287	-0.38	-0.33	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0287	-0.38	-0.33	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0287	-0.38	-0.33	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0287	-0.38	-0.33	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0287	-0.38	-0.33	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
UCEC	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	4.3	3.07e-05	0.0287	0.37	0.33	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
UCEC	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0288	-0.38	-0.33	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-4.3	3.07e-05	0.0288	-0.38	-0.33	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
UCEC	cis	rs9545047	0.716	rs9565500	ENSG00000227354.5	RBM26-AS1	-4.3	3.08e-05	0.0288	-0.34	-0.33	Schizophrenia;	chr13:79433416	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.692	rs314694	ENSG00000227354.5	RBM26-AS1	-4.3	3.08e-05	0.0288	-0.34	-0.33	Schizophrenia;	chr13:79432467	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.716	rs416660	ENSG00000227354.5	RBM26-AS1	-4.3	3.08e-05	0.0288	-0.34	-0.33	Schizophrenia;	chr13:79432726	chr13:79406309~79424328:+
UCEC	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	4.3	3.08e-05	0.0288	0.37	0.33	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
UCEC	cis	rs875971	0.862	rs778736	ENSG00000236529.1	RP13-254B10.1	4.3	3.08e-05	0.0288	0.39	0.33	Aortic root size;	chr7:66348861	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs1875057	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66266868	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6960446	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66268272	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.789	rs10260426	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66271055	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.79	rs10257911	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66278783	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs7796162	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66280771	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs2901152	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66300017	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs10263690	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66301466	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs10250544	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66301574	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.895	rs12531677	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66304099	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs7798630	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66306492	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs11984115	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66308872	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs3893216	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66325720	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6958294	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66329809	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs2088655	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66330724	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.895	rs10447522	ENSG00000236529.1	RP13-254B10.1	-4.3	3.08e-05	0.0288	-0.39	-0.33	Aortic root size;	chr7:66331087	chr7:65840212~65840596:+
UCEC	cis	rs6137726	0.62	rs1571249	ENSG00000277901.1	RP5-851M4.1	-4.3	3.08e-05	0.0288	-0.46	-0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22682719	chr20:23320958~23325352:-
UCEC	cis	rs7914558	0.646	rs7100709	ENSG00000272912.1	RP11-724N1.1	-4.3	3.08e-05	0.0288	-0.35	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102889972	chr10:102914585~102915404:+
UCEC	cis	rs12887734	0.524	rs722637	ENSG00000270108.1	RP11-73M18.6	4.3	3.09e-05	0.0289	0.38	0.33	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103795386	chr14:103687576~103688127:+
UCEC	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	4.3	3.1e-05	0.029	0.38	0.33	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	4.3	3.1e-05	0.029	0.38	0.33	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
UCEC	cis	rs9400467	0.528	rs12190634	ENSG00000271789.1	RP5-1112D6.7	-4.3	3.1e-05	0.029	-0.4	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111297126~111298510:+
UCEC	cis	rs7615952	0.673	rs34072288	ENSG00000241288.6	RP11-379B18.5	-4.3	3.1e-05	0.029	-0.69	-0.33	Blood pressure (smoking interaction);	chr3:125825186	chr3:125827238~125916384:-
UCEC	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-4.3	3.11e-05	0.029	-0.37	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
UCEC	cis	rs7177699	0.557	rs4433781	ENSG00000261143.1	ADAMTS7P3	4.3	3.11e-05	0.029	0.41	0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78829493	chr15:77976042~77993057:+
UCEC	cis	rs2276314	0.802	rs9963714	ENSG00000267627.4	RP11-905K4.1	-4.3	3.11e-05	0.029	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.802	rs4799838	ENSG00000267627.4	RP11-905K4.1	-4.3	3.11e-05	0.029	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.748	rs4799839	ENSG00000267627.4	RP11-905K4.1	-4.3	3.11e-05	0.029	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.857	rs28375959	ENSG00000267627.4	RP11-905K4.1	-4.3	3.11e-05	0.029	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35951803~35966118:-
UCEC	cis	rs2276314	0.857	rs3737474	ENSG00000267627.4	RP11-905K4.1	-4.3	3.11e-05	0.029	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35951803~35966118:-
UCEC	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-4.3	3.11e-05	0.029	-0.41	-0.33	Depression;	chr6:28205175	chr6:28115628~28116551:+
UCEC	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	4.3	3.11e-05	0.029	0.37	0.33	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	4.3	3.11e-05	0.029	0.37	0.33	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
UCEC	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
UCEC	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	4.3	3.12e-05	0.029	0.81	0.33	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
UCEC	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	4.3	3.12e-05	0.029	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
UCEC	cis	rs7177699	0.557	rs7164479	ENSG00000261143.1	ADAMTS7P3	-4.3	3.12e-05	0.029	-0.42	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78830712	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.526	rs7165042	ENSG00000261143.1	ADAMTS7P3	-4.3	3.12e-05	0.029	-0.42	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78830996	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.581	rs7165081	ENSG00000261143.1	ADAMTS7P3	-4.3	3.12e-05	0.029	-0.42	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831054	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.526	rs7165733	ENSG00000261143.1	ADAMTS7P3	-4.3	3.12e-05	0.029	-0.42	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831163	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.526	rs7182529	ENSG00000261143.1	ADAMTS7P3	-4.3	3.12e-05	0.029	-0.42	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831289	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.55	rs7182716	ENSG00000261143.1	ADAMTS7P3	-4.3	3.12e-05	0.029	-0.42	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831411	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.581	rs7181432	ENSG00000261143.1	ADAMTS7P3	-4.3	3.12e-05	0.029	-0.42	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831437	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.55	rs7182103	ENSG00000261143.1	ADAMTS7P3	-4.3	3.12e-05	0.029	-0.42	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831604	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.526	rs7166764	ENSG00000261143.1	ADAMTS7P3	-4.3	3.12e-05	0.0291	-0.42	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831167	chr15:77976042~77993057:+
UCEC	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-4.3	3.12e-05	0.0291	-0.4	-0.33	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
UCEC	cis	rs4253772	0.637	rs9627350	ENSG00000277232.2	GTSE1-AS1	-4.3	3.12e-05	0.0291	-0.4	-0.33	Cholesterol, total;LDL cholesterol;	chr22:46267120	chr22:46295143~46296660:-
UCEC	cis	rs7267979	0.816	rs6076358	ENSG00000276952.1	RP5-965G21.6	-4.3	3.12e-05	0.0291	-0.43	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25284915~25285588:-
UCEC	cis	rs12681963	0.702	rs2136958	ENSG00000271869.1	RP11-51J9.5	-4.3	3.13e-05	0.0291	-0.31	-0.33	Migraine;	chr8:30054156	chr8:30155830~30156232:-
UCEC	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	4.3	3.13e-05	0.0291	0.37	0.33	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
UCEC	cis	rs6968355	0.799	rs2017598	ENSG00000237513.1	RP11-325F22.2	-4.3	3.13e-05	0.0292	-0.66	-0.33	Myopia (pathological);	chr7:104952522	chr7:104941063~104962334:+
UCEC	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	4.29	3.14e-05	0.0292	0.43	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
UCEC	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	4.29	3.14e-05	0.0292	0.4	0.33	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
UCEC	cis	rs617219	0.71	rs2607142	ENSG00000245556.2	SCAMP1-AS1	4.29	3.14e-05	0.0292	0.3	0.33	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79262125	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.71	rs2607141	ENSG00000245556.2	SCAMP1-AS1	4.29	3.14e-05	0.0292	0.3	0.33	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79262812	chr5:78342365~78360507:-
UCEC	cis	rs875971	0.83	rs12673450	ENSG00000236529.1	RP13-254B10.1	4.29	3.15e-05	0.0293	0.42	0.33	Aortic root size;	chr7:66544233	chr7:65840212~65840596:+
UCEC	cis	rs4713118	0.955	rs9468203	ENSG00000216901.1	AL022393.7	4.29	3.15e-05	0.0293	0.37	0.33	Parkinson's disease;	chr6:27720888	chr6:28176188~28176674:+
UCEC	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-4.29	3.15e-05	0.0293	-0.38	-0.33	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-4.29	3.15e-05	0.0293	-0.38	-0.33	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-4.29	3.15e-05	0.0293	-0.38	-0.33	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-4.29	3.15e-05	0.0293	-0.38	-0.33	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
UCEC	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-4.29	3.15e-05	0.0293	-0.44	-0.33	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-4.29	3.15e-05	0.0293	-0.44	-0.33	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
UCEC	cis	rs9545047	0.716	rs314693	ENSG00000227354.5	RBM26-AS1	-4.29	3.16e-05	0.0294	-0.34	-0.33	Schizophrenia;	chr13:79432792	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.716	rs314692	ENSG00000227354.5	RBM26-AS1	-4.29	3.16e-05	0.0294	-0.34	-0.33	Schizophrenia;	chr13:79433091	chr13:79406309~79424328:+
UCEC	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-4.29	3.16e-05	0.0294	-0.35	-0.33	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
UCEC	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	4.29	3.16e-05	0.0294	0.46	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
UCEC	cis	rs10232172	0.778	rs6956263	ENSG00000234707.2	RP11-745C15.2	-4.29	3.16e-05	0.0294	-0.5	-0.33	Periodontal disease-related phenotypes;	chr7:54097982	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.778	rs12533519	ENSG00000234707.2	RP11-745C15.2	-4.29	3.16e-05	0.0294	-0.5	-0.33	Periodontal disease-related phenotypes;	chr7:54099660	chr7:54759425~54804928:+
UCEC	cis	rs34443463	0.787	rs670271	ENSG00000235613.2	NSRP1P1	-4.29	3.16e-05	0.0294	-0.39	-0.33	Lung cancer;	chr1:78559254	chr1:77847110~77848802:+
UCEC	cis	rs6901004	0.803	rs11153272	ENSG00000271789.1	RP5-1112D6.7	-4.29	3.16e-05	0.0294	-0.39	-0.33	Blood metabolite levels;	chr6:111158336	chr6:111297126~111298510:+
UCEC	cis	rs2976388	0.647	rs2572906	ENSG00000253931.1	RP11-909N17.2	4.29	3.17e-05	0.0294	0.35	0.33	Urinary tract infection frequency;	chr8:142716851	chr8:143412749~143417054:+
UCEC	cis	rs507080	0.922	rs4936433	ENSG00000278376.1	RP11-158I9.8	4.29	3.17e-05	0.0294	0.32	0.33	Serum metabolite levels;	chr11:118681711	chr11:118791254~118793137:+
UCEC	cis	rs2276314	0.947	rs4799831	ENSG00000267627.4	RP11-905K4.1	-4.29	3.17e-05	0.0295	-0.38	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35951803~35966118:-
UCEC	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-4.29	3.17e-05	0.0295	-0.31	-0.33	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
UCEC	cis	rs9400467	0.528	rs1989574	ENSG00000271789.1	RP5-1112D6.7	-4.29	3.18e-05	0.0295	-0.4	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111297126~111298510:+
UCEC	cis	rs9400467	0.508	rs11153294	ENSG00000271789.1	RP5-1112D6.7	-4.29	3.18e-05	0.0295	-0.4	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111297126~111298510:+
UCEC	cis	rs9400467	0.528	rs7451051	ENSG00000271789.1	RP5-1112D6.7	-4.29	3.18e-05	0.0295	-0.4	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111297126~111298510:+
UCEC	cis	rs7914558	0.966	rs1591915	ENSG00000272912.1	RP11-724N1.1	-4.29	3.18e-05	0.0296	-0.33	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102887092	chr10:102914585~102915404:+
UCEC	cis	rs9309473	0.513	rs62149782	ENSG00000163016.8	ALMS1P	4.29	3.19e-05	0.0296	0.48	0.33	Metabolite levels;	chr2:73591901	chr2:73644919~73685576:+
UCEC	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-4.29	3.19e-05	0.0296	-0.37	-0.33	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
UCEC	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	4.29	3.19e-05	0.0296	0.76	0.33	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
UCEC	cis	rs875971	1	rs6460296	ENSG00000236529.1	RP13-254B10.1	4.29	3.2e-05	0.0297	0.37	0.33	Aortic root size;	chr7:66430152	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.895	rs4718349	ENSG00000236529.1	RP13-254B10.1	4.29	3.2e-05	0.0297	0.37	0.33	Aortic root size;	chr7:66444024	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs2042133	ENSG00000236529.1	RP13-254B10.1	4.29	3.2e-05	0.0297	0.37	0.33	Aortic root size;	chr7:66466935	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs2161065	ENSG00000236529.1	RP13-254B10.1	4.29	3.2e-05	0.0297	0.37	0.33	Aortic root size;	chr7:66467918	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs12698521	ENSG00000236529.1	RP13-254B10.1	4.29	3.2e-05	0.0297	0.37	0.33	Aortic root size;	chr7:66474502	chr7:65840212~65840596:+
UCEC	cis	rs853679	0.628	rs9368560	ENSG00000216901.1	AL022393.7	4.29	3.2e-05	0.0297	0.4	0.33	Depression;	chr6:28192182	chr6:28176188~28176674:+
UCEC	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-4.29	3.2e-05	0.0297	-0.38	-0.33	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
UCEC	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-4.29	3.2e-05	0.0297	-0.38	-0.33	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
UCEC	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-4.29	3.21e-05	0.0297	-0.41	-0.33	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
UCEC	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	4.29	3.21e-05	0.0297	0.4	0.33	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
UCEC	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	4.29	3.21e-05	0.0298	0.48	0.33	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
UCEC	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	4.29	3.21e-05	0.0298	0.48	0.33	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
UCEC	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	4.29	3.21e-05	0.0298	0.48	0.33	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
UCEC	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	4.29	3.21e-05	0.0298	0.48	0.33	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
UCEC	cis	rs6710503	0.569	rs11682130	ENSG00000271936.1	RP11-443B20.1	4.29	3.21e-05	0.0298	0.39	0.33	Lung cancer in ever smokers;Breast cancer;	chr2:24724181	chr2:24825610~24826717:+
UCEC	cis	rs847851	0.617	rs9394267	ENSG00000219023.1	RP3-340B19.2	4.29	3.21e-05	0.0298	0.38	0.33	Colonoscopy-negative controls vs population controls;	chr6:34992983	chr6:35555873~35556264:+
UCEC	cis	rs948562	0.681	rs5020735	ENSG00000280010.1	AP001350.4	4.29	3.22e-05	0.0299	0.63	0.33	Lymphoma;	chr11:58660994	chr11:58627435~58628528:+
UCEC	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0299	-0.47	-0.33	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
UCEC	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-4.29	3.23e-05	0.0299	-0.32	-0.33	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-4.29	3.23e-05	0.0299	-0.32	-0.33	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-4.29	3.23e-05	0.0299	-0.32	-0.33	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-4.29	3.23e-05	0.0299	-0.32	-0.33	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
UCEC	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-4.29	3.23e-05	0.0299	-0.4	-0.33	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
UCEC	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	4.29	3.23e-05	0.0299	0.37	0.33	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
UCEC	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-4.29	3.23e-05	0.0299	-0.3	-0.33	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-4.29	3.23e-05	0.0299	-0.3	-0.33	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
UCEC	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	4.29	3.24e-05	0.03	0.8	0.33	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
UCEC	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-4.29	3.24e-05	0.03	-0.47	-0.33	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
UCEC	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	4.29	3.24e-05	0.03	0.34	0.33	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
UCEC	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	4.29	3.25e-05	0.03	0.44	0.33	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
UCEC	cis	rs7177699	0.534	rs7403708	ENSG00000261143.1	ADAMTS7P3	4.29	3.25e-05	0.03	0.42	0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831543	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.557	rs10083696	ENSG00000261143.1	ADAMTS7P3	4.29	3.25e-05	0.03	0.42	0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831674	chr15:77976042~77993057:+
UCEC	cis	rs7177699	0.557	rs10083697	ENSG00000261143.1	ADAMTS7P3	4.29	3.25e-05	0.03	0.42	0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831697	chr15:77976042~77993057:+
UCEC	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	4.29	3.25e-05	0.0301	0.26	0.33	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
UCEC	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	4.29	3.25e-05	0.0301	0.39	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
UCEC	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	4.29	3.25e-05	0.0301	0.5	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
UCEC	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	4.29	3.25e-05	0.0301	0.5	0.33	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
UCEC	cis	rs948562	1	rs12365551	ENSG00000280010.1	AP001350.4	4.29	3.25e-05	0.0301	0.68	0.33	Lymphoma;	chr11:58590895	chr11:58627435~58628528:+
UCEC	cis	rs7914558	0.902	rs3736922	ENSG00000272912.1	RP11-724N1.1	4.29	3.26e-05	0.0301	0.31	0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103090875	chr10:102914585~102915404:+
UCEC	cis	rs10895275	0.649	rs2846836	ENSG00000277459.1	RP11-732A21.3	-4.29	3.26e-05	0.0301	-0.32	-0.33	Migraine;	chr11:102234942	chr11:102109827~102110457:-
UCEC	cis	rs3734266	0.702	rs4646933	ENSG00000272288.4	RP11-140K17.3	-4.29	3.26e-05	0.0301	-0.35	-0.33	Systemic lupus erythematosus;	chr6:34882883	chr6:34696317~34697470:+
UCEC	cis	rs3734266	0.702	rs1051115	ENSG00000272288.4	RP11-140K17.3	-4.29	3.26e-05	0.0301	-0.35	-0.33	Systemic lupus erythematosus;	chr6:34887971	chr6:34696317~34697470:+
UCEC	cis	rs7674212	0.539	rs6850461	ENSG00000246560.2	RP11-10L12.4	4.28	3.27e-05	0.0302	0.38	0.33	Type 2 diabetes;	chr4:103198884	chr4:102828055~102844075:+
UCEC	cis	rs7674212	0.539	rs6533056	ENSG00000246560.2	RP11-10L12.4	4.28	3.27e-05	0.0302	0.38	0.33	Type 2 diabetes;	chr4:103199840	chr4:102828055~102844075:+
UCEC	cis	rs7674212	0.539	rs2866635	ENSG00000246560.2	RP11-10L12.4	4.28	3.27e-05	0.0302	0.38	0.33	Type 2 diabetes;	chr4:103200419	chr4:102828055~102844075:+
UCEC	cis	rs7674212	0.539	rs6815783	ENSG00000246560.2	RP11-10L12.4	4.28	3.27e-05	0.0302	0.38	0.33	Type 2 diabetes;	chr4:103200989	chr4:102828055~102844075:+
UCEC	cis	rs28386778	0.829	rs1877317	ENSG00000240280.5	TCAM1P	-4.28	3.27e-05	0.0302	-0.39	-0.33	Prudent dietary pattern;	chr17:63699119	chr17:63849292~63864379:+
UCEC	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-4.28	3.28e-05	0.0302	-0.43	-0.33	AIDS;	chr2:105333211	chr2:105324210~105330529:+
UCEC	cis	rs867186	0.535	rs2275274	ENSG00000126005.14	MMP24-AS1	-4.28	3.28e-05	0.0302	-0.61	-0.33	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35269741	chr20:35216462~35278131:-
UCEC	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-4.28	3.29e-05	0.0303	-0.4	-0.33	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-4.28	3.29e-05	0.0303	-0.4	-0.33	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-4.28	3.29e-05	0.0303	-0.4	-0.33	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-4.28	3.29e-05	0.0303	-0.4	-0.33	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-4.28	3.29e-05	0.0303	-0.4	-0.33	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
UCEC	cis	rs7177699	0.55	rs4468572	ENSG00000261143.1	ADAMTS7P3	4.28	3.29e-05	0.0303	0.41	0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78832133	chr15:77976042~77993057:+
UCEC	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-4.28	3.29e-05	0.0304	-0.45	-0.33	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
UCEC	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	4.28	3.29e-05	0.0304	0.39	0.33	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
UCEC	cis	rs9545047	0.901	rs73235963	ENSG00000227354.5	RBM26-AS1	4.28	3.3e-05	0.0304	0.36	0.33	Schizophrenia;	chr13:79562805	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.935	rs2484343	ENSG00000227354.5	RBM26-AS1	4.28	3.3e-05	0.0304	0.36	0.33	Schizophrenia;	chr13:79563587	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.868	rs2476173	ENSG00000227354.5	RBM26-AS1	4.28	3.3e-05	0.0304	0.36	0.33	Schizophrenia;	chr13:79565740	chr13:79406309~79424328:+
UCEC	cis	rs922692	1	rs11638372	ENSG00000261143.1	ADAMTS7P3	-4.28	3.3e-05	0.0304	-0.44	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78691217	chr15:77976042~77993057:+
UCEC	cis	rs7914558	0.966	rs10450373	ENSG00000272912.1	RP11-724N1.1	-4.28	3.3e-05	0.0304	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102968859	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs2065977	ENSG00000272912.1	RP11-724N1.1	-4.28	3.3e-05	0.0304	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102969658	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs12569617	ENSG00000272912.1	RP11-724N1.1	-4.28	3.3e-05	0.0304	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102970239	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.933	rs1538204	ENSG00000272912.1	RP11-724N1.1	-4.28	3.3e-05	0.0304	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102974136	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs7096269	ENSG00000272912.1	RP11-724N1.1	-4.28	3.3e-05	0.0304	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102976964	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.933	rs10883814	ENSG00000272912.1	RP11-724N1.1	-4.28	3.3e-05	0.0304	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102977647	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs1971589	ENSG00000272912.1	RP11-724N1.1	-4.28	3.3e-05	0.0304	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102984649	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs1890185	ENSG00000272912.1	RP11-724N1.1	-4.28	3.3e-05	0.0304	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988961	chr10:102914585~102915404:+
UCEC	cis	rs28386778	0.897	rs6504177	ENSG00000240280.5	TCAM1P	-4.28	3.3e-05	0.0304	-0.36	-0.33	Prudent dietary pattern;	chr17:63735295	chr17:63849292~63864379:+
UCEC	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	4.28	3.3e-05	0.0305	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
UCEC	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	4.28	3.3e-05	0.0305	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
UCEC	cis	rs12478296	0.786	rs55876934	ENSG00000261186.2	RP11-341N2.1	-4.28	3.31e-05	0.0305	-0.46	-0.33	Obesity-related traits;	chr2:242091665	chr2:242087351~242088457:-
UCEC	cis	rs12478296	0.681	rs55802421	ENSG00000261186.2	RP11-341N2.1	-4.28	3.31e-05	0.0305	-0.46	-0.33	Obesity-related traits;	chr2:242091811	chr2:242087351~242088457:-
UCEC	cis	rs12478296	0.681	rs56357900	ENSG00000261186.2	RP11-341N2.1	-4.28	3.31e-05	0.0305	-0.46	-0.33	Obesity-related traits;	chr2:242091815	chr2:242087351~242088457:-
UCEC	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	4.28	3.31e-05	0.0305	0.36	0.33	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
UCEC	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-4.28	3.31e-05	0.0305	-0.37	-0.33	Migraine;	chr4:56852029	chr4:56960927~56961373:-
UCEC	cis	rs9400467	0.528	rs445349	ENSG00000271789.1	RP5-1112D6.7	4.28	3.32e-05	0.0305	0.4	0.33	Amino acid levels;Blood metabolite levels;	chr6:111340899	chr6:111297126~111298510:+
UCEC	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	4.28	3.32e-05	0.0306	0.37	0.33	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
UCEC	cis	rs853679	0.55	rs9295762	ENSG00000216901.1	AL022393.7	-4.28	3.33e-05	0.0306	-0.39	-0.33	Depression;	chr6:28187640	chr6:28176188~28176674:+
UCEC	cis	rs12744310	0.887	rs12042464	ENSG00000235358.1	RP11-399E6.1	-4.28	3.33e-05	0.0306	-0.53	-0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321182	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12040046	ENSG00000235358.1	RP11-399E6.1	-4.28	3.33e-05	0.0306	-0.53	-0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331911	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12047875	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319504	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs35932978	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319773	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs35021924	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321235	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs35592291	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41325599	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs2363811	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326193	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12026778	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326602	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs4453028	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326851	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.83	rs4406620	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327093	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs35436312	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327686	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs1316274	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327986	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs72667608	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41329101	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs72667610	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41329138	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs35410722	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41330592	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs34539673	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331145	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs35690915	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41332327	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12728217	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41332597	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12732820	ENSG00000235358.1	RP11-399E6.1	4.28	3.33e-05	0.0306	0.53	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333101	chr1:41242373~41284861:+
UCEC	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-4.28	3.34e-05	0.0307	-0.41	-0.33	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
UCEC	cis	rs62025270	0.688	rs17577869	ENSG00000202081.1	RNU6-1280P	-4.28	3.34e-05	0.0307	-0.44	-0.33	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85651522~85651628:-
UCEC	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-4.28	3.35e-05	0.0307	-0.33	-0.33	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
UCEC	cis	rs12304921	0.549	rs11169689	ENSG00000277201.1	AC087884.1	4.28	3.35e-05	0.0308	0.31	0.33	Type 2 diabetes;	chr12:51049778	chr12:51049921~51050025:+
UCEC	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-4.28	3.35e-05	0.0308	-0.31	-0.33	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-4.28	3.35e-05	0.0308	-0.31	-0.33	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-4.28	3.35e-05	0.0308	-0.31	-0.33	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-4.28	3.35e-05	0.0308	-0.31	-0.33	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
UCEC	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	4.28	3.36e-05	0.0308	0.4	0.33	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
UCEC	cis	rs73081554	0.611	rs35975336	ENSG00000272360.1	RP11-359I18.5	-4.28	3.36e-05	0.0308	-0.47	-0.33	Rheumatoid arthritis;	chr3:58465907	chr3:58490830~58491291:-
UCEC	cis	rs948562	0.69	rs58085299	ENSG00000280010.1	AP001350.4	4.28	3.36e-05	0.0308	0.63	0.33	Lymphoma;	chr11:58302836	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.637	rs12361789	ENSG00000280010.1	AP001350.4	4.28	3.36e-05	0.0308	0.63	0.33	Lymphoma;	chr11:58309816	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.69	rs73481989	ENSG00000280010.1	AP001350.4	4.28	3.36e-05	0.0308	0.63	0.33	Lymphoma;	chr11:58310587	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.69	rs113456492	ENSG00000280010.1	AP001350.4	4.28	3.36e-05	0.0308	0.63	0.33	Lymphoma;	chr11:58311351	chr11:58627435~58628528:+
UCEC	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-4.28	3.36e-05	0.0308	-0.42	-0.33	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
UCEC	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-4.28	3.36e-05	0.0308	-0.42	-0.33	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
UCEC	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-4.28	3.36e-05	0.0308	-0.42	-0.33	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
UCEC	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-4.28	3.36e-05	0.0308	-0.42	-0.33	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
UCEC	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-4.28	3.36e-05	0.0308	-0.42	-0.33	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
UCEC	cis	rs948562	0.744	rs11229484	ENSG00000280010.1	AP001350.4	4.28	3.36e-05	0.0308	0.55	0.33	Lymphoma;	chr11:58464724	chr11:58627435~58628528:+
UCEC	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	4.28	3.36e-05	0.0308	0.36	0.33	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
UCEC	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-4.28	3.36e-05	0.0308	-0.42	-0.33	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
UCEC	cis	rs2976388	0.647	rs2164307	ENSG00000253931.1	RP11-909N17.2	4.28	3.36e-05	0.0308	0.35	0.33	Urinary tract infection frequency;	chr8:142707413	chr8:143412749~143417054:+
UCEC	cis	rs2976388	0.573	rs1529865	ENSG00000253931.1	RP11-909N17.2	4.28	3.36e-05	0.0308	0.35	0.33	Urinary tract infection frequency;	chr8:142707753	chr8:143412749~143417054:+
UCEC	cis	rs2976388	0.609	rs1560986	ENSG00000253931.1	RP11-909N17.2	4.28	3.36e-05	0.0308	0.35	0.33	Urinary tract infection frequency;	chr8:142708357	chr8:143412749~143417054:+
UCEC	cis	rs2976388	0.609	rs2376491	ENSG00000253931.1	RP11-909N17.2	4.28	3.36e-05	0.0308	0.35	0.33	Urinary tract infection frequency;	chr8:142709516	chr8:143412749~143417054:+
UCEC	cis	rs2976388	0.609	rs2585148	ENSG00000253931.1	RP11-909N17.2	4.28	3.36e-05	0.0308	0.35	0.33	Urinary tract infection frequency;	chr8:142714775	chr8:143412749~143417054:+
UCEC	cis	rs2976388	0.565	rs2572905	ENSG00000253931.1	RP11-909N17.2	4.28	3.36e-05	0.0308	0.35	0.33	Urinary tract infection frequency;	chr8:142715686	chr8:143412749~143417054:+
UCEC	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-4.28	3.37e-05	0.0308	-0.31	-0.33	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-4.28	3.37e-05	0.0308	-0.31	-0.33	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
UCEC	cis	rs6840360	0.642	rs56301462	ENSG00000270265.1	RP11-731D1.4	-4.28	3.37e-05	0.0308	-0.31	-0.33	Intelligence (multi-trait analysis);	chr4:151530976	chr4:151333775~151353224:-
UCEC	cis	rs875971	0.545	rs316316	ENSG00000236529.1	RP13-254B10.1	-4.28	3.37e-05	0.0308	-0.48	-0.33	Aortic root size;	chr7:66149270	chr7:65840212~65840596:+
UCEC	cis	rs9611565	0.879	rs2235845	ENSG00000233903.2	Z83851.4	-4.28	3.38e-05	0.0309	-0.41	-0.33	Vitiligo;	chr22:41333290	chr22:42276355~42277052:+
UCEC	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-4.28	3.38e-05	0.0309	-0.39	-0.33	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
UCEC	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-4.28	3.38e-05	0.0309	-0.39	-0.33	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
UCEC	cis	rs6901004	0.803	rs9387000	ENSG00000271789.1	RP5-1112D6.7	-4.28	3.38e-05	0.0309	-0.39	-0.33	Blood metabolite levels;	chr6:111138738	chr6:111297126~111298510:+
UCEC	cis	rs10888838	0.618	rs13571	ENSG00000198711.5	SSBP3-AS1	-4.28	3.38e-05	0.0309	-0.34	-0.33	Mitochondrial DNA levels;	chr1:54216247	chr1:54236440~54239063:+
UCEC	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-4.28	3.38e-05	0.0309	-0.4	-0.33	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
UCEC	cis	rs2445284	0.715	rs2445249	ENSG00000229534.1	HNRNPA1P53	-4.28	3.38e-05	0.0309	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5027347	chr11:5571247~5572192:-
UCEC	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	4.28	3.38e-05	0.0309	0.38	0.33	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	4.28	3.38e-05	0.0309	0.38	0.33	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	4.28	3.38e-05	0.0309	0.38	0.33	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	4.28	3.38e-05	0.0309	0.38	0.33	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
UCEC	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-4.28	3.39e-05	0.031	-0.3	-0.33	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-4.28	3.39e-05	0.031	-0.31	-0.33	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
UCEC	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-4.28	3.39e-05	0.031	-0.34	-0.33	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
UCEC	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	4.28	3.39e-05	0.031	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
UCEC	cis	rs4073582	0.595	rs1151540	ENSG00000255320.1	RP11-755F10.1	-4.28	3.4e-05	0.031	-0.45	-0.33	Gout;	chr11:66274336	chr11:66244840~66246239:-
UCEC	cis	rs7914558	0.646	rs7909286	ENSG00000272912.1	RP11-724N1.1	-4.27	3.41e-05	0.0311	-0.35	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899235	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.646	rs7909591	ENSG00000272912.1	RP11-724N1.1	-4.27	3.41e-05	0.0311	-0.35	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899261	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.621	rs10786722	ENSG00000272912.1	RP11-724N1.1	-4.27	3.41e-05	0.0311	-0.35	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900311	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.646	rs1046778	ENSG00000272912.1	RP11-724N1.1	-4.27	3.41e-05	0.0311	-0.35	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102901727	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.646	rs11191459	ENSG00000272912.1	RP11-724N1.1	-4.27	3.41e-05	0.0311	-0.35	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902361	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.646	rs10883799	ENSG00000272912.1	RP11-724N1.1	-4.27	3.41e-05	0.0311	-0.35	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102903553	chr10:102914585~102915404:+
UCEC	cis	rs10043228	1	rs62384189	ENSG00000249249.1	AC010226.4	4.27	3.41e-05	0.0311	0.64	0.33	Asthma or chronic obstructive pulmonary disease;	chr5:116174694	chr5:115602057~115620659:+
UCEC	cis	rs12304921	0.549	rs10876140	ENSG00000277201.1	AC087884.1	4.27	3.41e-05	0.0311	0.33	0.33	Type 2 diabetes;	chr12:51119539	chr12:51049921~51050025:+
UCEC	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	4.27	3.41e-05	0.0311	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
UCEC	cis	rs7177699	0.525	rs7402376	ENSG00000261143.1	ADAMTS7P3	4.27	3.41e-05	0.0311	0.41	0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78821228	chr15:77976042~77993057:+
UCEC	cis	rs875971	0.965	rs7794930	ENSG00000236529.1	RP13-254B10.1	-4.27	3.42e-05	0.0312	-0.38	-0.33	Aortic root size;	chr7:66313559	chr7:65840212~65840596:+
UCEC	cis	rs7615952	0.8	rs12489350	ENSG00000241288.6	RP11-379B18.5	-4.27	3.42e-05	0.0312	-0.41	-0.33	Blood pressure (smoking interaction);	chr3:125925273	chr3:125827238~125916384:-
UCEC	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	4.27	3.42e-05	0.0312	0.37	0.33	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
UCEC	cis	rs465969	1	rs1407644	ENSG00000230177.1	RP5-1112D6.4	-4.27	3.43e-05	0.0312	-0.54	-0.33	Psoriasis;	chr6:111480895	chr6:111277932~111278742:+
UCEC	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	4.27	3.43e-05	0.0312	0.42	0.33	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	4.27	3.43e-05	0.0312	0.42	0.33	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
UCEC	cis	rs62025270	0.688	rs62025297	ENSG00000202081.1	RNU6-1280P	-4.27	3.43e-05	0.0312	-0.45	-0.33	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85651522~85651628:-
UCEC	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-4.27	3.44e-05	0.0313	-0.4	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
UCEC	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	4.27	3.44e-05	0.0313	0.42	0.33	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
UCEC	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	4.27	3.45e-05	0.0313	0.94	0.33	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
UCEC	cis	rs34286592	1	rs3976455	ENSG00000238045.8	AC009133.12	4.27	3.45e-05	0.0313	0.53	0.33	Multiple sclerosis;	chr16:29850126	chr16:29808636~29821252:-
UCEC	cis	rs875971	1	rs7789554	ENSG00000236529.1	RP13-254B10.1	4.27	3.45e-05	0.0314	0.37	0.33	Aortic root size;	chr7:66481051	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.895	rs1974769	ENSG00000236529.1	RP13-254B10.1	4.27	3.45e-05	0.0314	0.37	0.33	Aortic root size;	chr7:66485627	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.895	rs6460300	ENSG00000236529.1	RP13-254B10.1	4.27	3.45e-05	0.0314	0.37	0.33	Aortic root size;	chr7:66487937	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs7803416	ENSG00000236529.1	RP13-254B10.1	4.27	3.45e-05	0.0314	0.37	0.33	Aortic root size;	chr7:66489212	chr7:65840212~65840596:+
UCEC	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-4.27	3.45e-05	0.0314	-0.35	-0.33	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
UCEC	cis	rs1155865	0.524	rs76649318	ENSG00000250075.4	RP11-584P21.2	-4.27	3.46e-05	0.0314	-0.73	-0.33	Cognitive test performance;	chr4:67027029	chr4:67417305~67468251:-
UCEC	cis	rs268134	0.53	rs35662928	ENSG00000281920.1	RP11-418H16.1	-4.27	3.46e-05	0.0314	-0.59	-0.33	Systemic lupus erythematosus;Educational attainment (years of education);	chr2:65367480	chr2:65623272~65628424:+
UCEC	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-4.27	3.46e-05	0.0315	-0.36	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
UCEC	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-4.27	3.46e-05	0.0315	-0.36	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
UCEC	cis	rs5771069	0.896	rs137862	ENSG00000235111.1	RP1-29C18.8	-4.27	3.46e-05	0.0315	-0.34	-0.33	Ulcerative colitis;	chr22:50008121	chr22:49612657~49615716:-
UCEC	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-4.27	3.46e-05	0.0315	-0.4	-0.33	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
UCEC	cis	rs62103177	0.81	rs62103195	ENSG00000261126.6	RP11-795F19.1	4.27	3.47e-05	0.0315	0.52	0.33	Opioid sensitivity;	chr18:79869693	chr18:80046900~80095482:+
UCEC	cis	rs6840360	0.642	rs1470281	ENSG00000270265.1	RP11-731D1.4	-4.27	3.47e-05	0.0315	-0.31	-0.33	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151333775~151353224:-
UCEC	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	4.27	3.47e-05	0.0316	0.35	0.33	Height;	chr6:109382188	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	4.27	3.47e-05	0.0316	0.35	0.33	Height;	chr6:109383239	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	4.27	3.47e-05	0.0316	0.35	0.33	Height;	chr6:109383248	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	4.27	3.47e-05	0.0316	0.35	0.33	Height;	chr6:109383848	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	4.27	3.47e-05	0.0316	0.35	0.33	Height;	chr6:109384807	chr6:109382795~109383666:+
UCEC	cis	rs11818084	0.564	rs7908500	ENSG00000278831.1	RP11-12J10.4	-4.27	3.47e-05	0.0316	-0.31	-0.33	Clozapine-induced cytotoxicity;	chr10:124291442	chr10:124623353~124624079:+
UCEC	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	4.27	3.48e-05	0.0316	0.47	0.33	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
UCEC	cis	rs4073582	0.595	rs474005	ENSG00000255320.1	RP11-755F10.1	-4.27	3.48e-05	0.0316	-0.45	-0.33	Gout;	chr11:66265830	chr11:66244840~66246239:-
UCEC	cis	rs4073582	0.595	rs2508657	ENSG00000255320.1	RP11-755F10.1	-4.27	3.48e-05	0.0316	-0.45	-0.33	Gout;	chr11:66276427	chr11:66244840~66246239:-
UCEC	cis	rs7611238	0.933	rs56132877	ENSG00000237418.1	AC069257.6	-4.27	3.48e-05	0.0316	-0.29	-0.33	Body mass index;	chr3:195315854	chr3:196298061~196298215:-
UCEC	cis	rs7611238	0.933	rs55927338	ENSG00000237418.1	AC069257.6	-4.27	3.48e-05	0.0316	-0.29	-0.33	Body mass index;	chr3:195315856	chr3:196298061~196298215:-
UCEC	cis	rs6104690	0.595	rs6033009	ENSG00000270792.4	RP11-103J8.1	-4.27	3.48e-05	0.0316	-0.49	-0.33	Bladder cancer;	chr20:11010033	chr20:10672928~10994924:+
UCEC	cis	rs8141529	0.748	rs7287918	ENSG00000272858.1	CTA-292E10.8	-4.27	3.48e-05	0.0316	-0.44	-0.33	Lymphocyte counts;	chr22:28885722	chr22:28814914~28815662:+
UCEC	cis	rs2732480	0.5	rs12829841	ENSG00000226413.2	OR8T1P	4.27	3.48e-05	0.0316	0.49	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48442030~48442947:-
UCEC	cis	rs2732480	0.523	rs34286639	ENSG00000226413.2	OR8T1P	4.27	3.48e-05	0.0316	0.49	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48442030~48442947:-
UCEC	cis	rs1387259	0.929	rs11168484	ENSG00000226413.2	OR8T1P	4.27	3.48e-05	0.0316	0.49	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48442030~48442947:-
UCEC	cis	rs677325	0.604	rs6665749	ENSG00000232498.1	RP5-1011O1.2	4.27	3.48e-05	0.0316	0.51	0.33	Subjective well-being (multi-trait analysis);	chr1:191608464	chr1:192517639~192567217:-
UCEC	cis	rs10946940	0.965	rs6921256	ENSG00000216901.1	AL022393.7	4.27	3.49e-05	0.0316	0.35	0.33	Systemic lupus erythematosus;	chr6:27619739	chr6:28176188~28176674:+
UCEC	cis	rs36032232	0.714	rs66787641	ENSG00000240163.1	RP11-745A24.1	4.27	3.49e-05	0.0317	0.69	0.33	Blood protein levels;	chr15:60531131	chr15:60390371~60390682:+
UCEC	cis	rs36032232	0.714	rs10519052	ENSG00000240163.1	RP11-745A24.1	4.27	3.49e-05	0.0317	0.69	0.33	Blood protein levels;	chr15:60531218	chr15:60390371~60390682:+
UCEC	cis	rs34286592	0.929	rs8058824	ENSG00000238045.8	AC009133.12	4.27	3.49e-05	0.0317	0.53	0.33	Multiple sclerosis;	chr16:29817389	chr16:29808636~29821252:-
UCEC	cis	rs2445284	0.874	rs2445274	ENSG00000229534.1	HNRNPA1P53	-4.27	3.5e-05	0.0317	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5040114	chr11:5571247~5572192:-
UCEC	cis	rs6137726	0.524	rs2424439	ENSG00000277901.1	RP5-851M4.1	4.27	3.5e-05	0.0317	0.41	0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22639402	chr20:23320958~23325352:-
UCEC	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-4.27	3.5e-05	0.0317	-0.37	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
UCEC	cis	rs2445284	0.874	rs2445272	ENSG00000229534.1	HNRNPA1P53	-4.27	3.5e-05	0.0317	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5037906	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499971	ENSG00000229534.1	HNRNPA1P53	-4.27	3.5e-05	0.0317	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5038001	chr11:5571247~5572192:-
UCEC	cis	rs1020064	0.636	rs2576726	ENSG00000235319.1	AC012360.4	-4.27	3.5e-05	0.0317	-0.43	-0.33	AIDS;	chr2:105319955	chr2:105324210~105330529:+
UCEC	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	4.27	3.5e-05	0.0317	0.42	0.33	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	4.27	3.5e-05	0.0317	0.42	0.33	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
UCEC	cis	rs9326246	0.598	rs481843	ENSG00000254851.1	RP11-109L13.1	4.27	3.5e-05	0.0317	0.89	0.33	Coronary artery disease;	chr11:116655150	chr11:117135528~117138582:+
UCEC	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-4.27	3.51e-05	0.0318	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-4.27	3.51e-05	0.0318	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
UCEC	cis	rs9545047	0.553	rs7332004	ENSG00000227354.5	RBM26-AS1	-4.27	3.52e-05	0.0318	-0.33	-0.33	Schizophrenia;	chr13:79364128	chr13:79406309~79424328:+
UCEC	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-4.27	3.53e-05	0.0319	-0.38	-0.33	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
UCEC	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	4.27	3.53e-05	0.0319	0.39	0.33	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
UCEC	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	4.27	3.53e-05	0.0319	0.4	0.33	Depression;	chr6:28205232	chr6:28115628~28116551:+
UCEC	cis	rs2976388	0.647	rs2082801	ENSG00000253931.1	RP11-909N17.2	4.27	3.53e-05	0.0319	0.34	0.33	Urinary tract infection frequency;	chr8:142705043	chr8:143412749~143417054:+
UCEC	cis	rs62025270	1	rs62025270	ENSG00000202081.1	RNU6-1280P	-4.27	3.53e-05	0.0319	-0.45	-0.33	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85651522~85651628:-
UCEC	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-4.27	3.53e-05	0.0319	-0.31	-0.33	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
UCEC	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-4.27	3.53e-05	0.0319	-0.31	-0.33	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
UCEC	cis	rs9527	0.662	rs743575	ENSG00000236937.2	PTGES3P4	4.26	3.54e-05	0.0319	0.36	0.33	Arsenic metabolism;	chr10:102835149	chr10:102845595~102845950:+
UCEC	cis	rs9527	0.662	rs4919687	ENSG00000236937.2	PTGES3P4	4.26	3.54e-05	0.0319	0.36	0.33	Arsenic metabolism;	chr10:102835491	chr10:102845595~102845950:+
UCEC	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-4.26	3.54e-05	0.032	-0.43	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
UCEC	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-4.26	3.54e-05	0.032	-0.44	-0.33	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-4.26	3.54e-05	0.032	-0.44	-0.33	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-4.26	3.54e-05	0.032	-0.44	-0.33	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-4.26	3.54e-05	0.032	-0.44	-0.33	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
UCEC	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	4.26	3.55e-05	0.032	0.47	0.33	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	4.26	3.55e-05	0.032	0.47	0.33	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	4.26	3.55e-05	0.032	0.47	0.33	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
UCEC	cis	rs7688540	0.8	rs2353599	ENSG00000211553.1	AC253576.2	-4.26	3.55e-05	0.0321	-0.4	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:136461~136568:+
UCEC	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-4.26	3.55e-05	0.0321	-0.39	-0.33	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-4.26	3.55e-05	0.0321	-0.39	-0.33	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-4.26	3.55e-05	0.0321	-0.39	-0.33	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-4.26	3.55e-05	0.0321	-0.39	-0.33	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
UCEC	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-4.26	3.56e-05	0.0321	-0.51	-0.33	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
UCEC	cis	rs7240205	0.818	rs4264473	ENSG00000275805.1	RP11-349H17.2	4.26	3.56e-05	0.0321	0.4	0.33	Breast cancer;	chr18:26565915	chr18:26565723~26575626:-
UCEC	cis	rs9545047	0.604	rs9565497	ENSG00000227354.5	RBM26-AS1	-4.26	3.56e-05	0.0321	-0.33	-0.33	Schizophrenia;	chr13:79406330	chr13:79406309~79424328:+
UCEC	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-4.26	3.56e-05	0.0322	-0.45	-0.33	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
UCEC	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	4.26	3.56e-05	0.0322	0.37	0.33	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
UCEC	cis	rs1185460	1	rs1784305	ENSG00000278376.1	RP11-158I9.8	-4.26	3.58e-05	0.0322	-0.29	-0.33	Coronary artery disease;	chr11:119071338	chr11:118791254~118793137:+
UCEC	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	4.26	3.59e-05	0.0323	0.39	0.33	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
UCEC	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-4.26	3.59e-05	0.0323	-0.39	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
UCEC	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-4.26	3.59e-05	0.0323	-0.31	-0.33	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-4.26	3.59e-05	0.0323	-0.31	-0.33	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-4.26	3.59e-05	0.0323	-0.31	-0.33	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
UCEC	cis	rs2976388	0.632	rs2585139	ENSG00000253931.1	RP11-909N17.2	4.26	3.59e-05	0.0324	0.34	0.33	Urinary tract infection frequency;	chr8:142726757	chr8:143412749~143417054:+
UCEC	cis	rs62025270	0.522	rs338519	ENSG00000202081.1	RNU6-1280P	-4.26	3.6e-05	0.0324	-0.4	-0.33	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85651522~85651628:-
UCEC	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	4.26	3.6e-05	0.0324	0.48	0.33	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
UCEC	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	4.26	3.6e-05	0.0324	0.34	0.33	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	4.26	3.6e-05	0.0324	0.34	0.33	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
UCEC	cis	rs12986413	0.789	rs12985980	ENSG00000267283.1	AC005306.3	4.26	3.61e-05	0.0325	0.3	0.33	Height;	chr19:2165198	chr19:1989401~1990370:+
UCEC	cis	rs12986413	0.789	rs12982744	ENSG00000267283.1	AC005306.3	4.26	3.61e-05	0.0325	0.3	0.33	Height;	chr19:2177194	chr19:1989401~1990370:+
UCEC	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-4.26	3.61e-05	0.0325	-0.41	-0.33	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
UCEC	cis	rs7654585	1	rs4692025	ENSG00000281501.1	SEPSECS-AS1	-4.26	3.62e-05	0.0326	-0.37	-0.33	Obesity-related traits;	chr4:25948137	chr4:25160641~25201440:+
UCEC	cis	rs4713118	0.516	rs6931858	ENSG00000216901.1	AL022393.7	4.26	3.62e-05	0.0326	0.39	0.33	Parkinson's disease;	chr6:28110633	chr6:28176188~28176674:+
UCEC	cis	rs12744310	1	rs12030762	ENSG00000235358.1	RP11-399E6.1	4.26	3.64e-05	0.0327	0.57	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301089	chr1:41242373~41284861:+
UCEC	cis	rs12744310	1	rs55707527	ENSG00000235358.1	RP11-399E6.1	4.26	3.64e-05	0.0327	0.57	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303441	chr1:41242373~41284861:+
UCEC	cis	rs924607	1	rs12523022	ENSG00000188242.4	PP7080	-4.26	3.64e-05	0.0327	-0.37	-0.33	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr5:598528	chr5:466124~473098:-
UCEC	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-4.26	3.64e-05	0.0328	-0.38	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
UCEC	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-4.26	3.64e-05	0.0328	-0.48	-0.33	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
UCEC	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-4.26	3.64e-05	0.0328	-0.48	-0.33	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
UCEC	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-4.26	3.65e-05	0.0328	-0.41	-0.33	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
UCEC	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	4.26	3.65e-05	0.0328	0.51	0.33	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
UCEC	cis	rs10232172	0.778	rs1404210	ENSG00000234707.2	RP11-745C15.2	-4.26	3.65e-05	0.0328	-0.49	-0.33	Periodontal disease-related phenotypes;	chr7:54111387	chr7:54759425~54804928:+
UCEC	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	4.26	3.66e-05	0.0328	0.39	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
UCEC	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	4.26	3.66e-05	0.0329	0.41	0.33	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
UCEC	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	4.26	3.67e-05	0.0329	0.4	0.33	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
UCEC	cis	rs9545047	0.604	rs1856997	ENSG00000227354.5	RBM26-AS1	4.26	3.67e-05	0.0329	0.35	0.33	Schizophrenia;	chr13:79287487	chr13:79406309~79424328:+
UCEC	cis	rs10946940	0.965	rs9393830	ENSG00000216901.1	AL022393.7	4.26	3.67e-05	0.033	0.35	0.33	Systemic lupus erythematosus;	chr6:27619248	chr6:28176188~28176674:+
UCEC	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	4.26	3.67e-05	0.033	0.36	0.33	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	4.26	3.67e-05	0.033	0.36	0.33	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
UCEC	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	4.26	3.68e-05	0.033	0.55	0.33	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
UCEC	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-4.26	3.68e-05	0.033	-0.55	-0.33	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
UCEC	cis	rs875971	0.895	rs3857684	ENSG00000236529.1	RP13-254B10.1	4.26	3.68e-05	0.033	0.37	0.33	Aortic root size;	chr7:66473171	chr7:65840212~65840596:+
UCEC	cis	rs62025270	0.632	rs56153788	ENSG00000202081.1	RNU6-1280P	-4.26	3.68e-05	0.033	-0.45	-0.33	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85651522~85651628:-
UCEC	cis	rs794185	0.625	rs1844123	ENSG00000229241.1	PNPT1P1	4.26	3.68e-05	0.033	0.38	0.33	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471177	chr3:3981981~3984295:-
UCEC	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	4.25	3.68e-05	0.033	0.36	0.33	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
UCEC	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-4.25	3.69e-05	0.0331	-0.34	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
UCEC	cis	rs229541	1	rs229531	ENSG00000237862.1	RP1-63G5.7	4.25	3.69e-05	0.0331	0.4	0.33	Type 1 diabetes;	chr22:37189696	chr22:37352190~37354839:-
UCEC	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	4.25	3.69e-05	0.0331	0.37	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
UCEC	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	4.25	3.69e-05	0.0331	0.38	0.33	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
UCEC	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	4.25	3.69e-05	0.0331	0.38	0.33	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
UCEC	cis	rs7592578	0.679	rs59929070	ENSG00000272979.1	RP11-647K16.1	-4.25	3.69e-05	0.0331	-0.53	-0.33	Diastolic blood pressure;	chr2:190463126	chr2:190454092~190454521:-
UCEC	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-4.25	3.7e-05	0.0331	-0.32	-0.33	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
UCEC	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	4.25	3.7e-05	0.0332	0.77	0.33	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	4.25	3.7e-05	0.0332	0.77	0.33	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	4.25	3.7e-05	0.0332	0.77	0.33	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	4.25	3.7e-05	0.0332	0.77	0.33	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
UCEC	cis	rs11971779	0.616	rs6467836	ENSG00000273391.1	RP11-634H22.1	4.25	3.7e-05	0.0332	0.36	0.33	Diisocyanate-induced asthma;	chr7:139338771	chr7:139359032~139359566:-
UCEC	cis	rs12986413	0.789	rs12971884	ENSG00000267283.1	AC005306.3	4.25	3.7e-05	0.0332	0.3	0.33	Height;	chr19:2160260	chr19:1989401~1990370:+
UCEC	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-4.25	3.7e-05	0.0332	-0.39	-0.33	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-4.25	3.7e-05	0.0332	-0.39	-0.33	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-4.25	3.7e-05	0.0332	-0.39	-0.33	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-4.25	3.7e-05	0.0332	-0.39	-0.33	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-4.25	3.7e-05	0.0332	-0.39	-0.33	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
UCEC	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-4.25	3.7e-05	0.0332	-0.39	-0.33	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
UCEC	cis	rs8089364	0.917	rs11665563	ENSG00000267742.1	FAM60CP	4.25	3.71e-05	0.0332	0.31	0.33	Body mass index;Type 2 diabetes;	chr18:60208801	chr18:60016778~60017441:-
UCEC	cis	rs34286592	1	rs13331733	ENSG00000260853.1	RP11-264B17.2	4.25	3.71e-05	0.0332	0.27	0.33	Multiple sclerosis;	chr16:29837096	chr16:28956687~28966883:-
UCEC	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	4.25	3.71e-05	0.0332	0.42	0.33	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
UCEC	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	4.25	3.72e-05	0.0333	0.44	0.33	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
UCEC	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	4.25	3.72e-05	0.0333	0.44	0.33	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
UCEC	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	4.25	3.72e-05	0.0333	0.38	0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
UCEC	cis	rs617219	0.671	rs1062326	ENSG00000245556.2	SCAMP1-AS1	-4.25	3.73e-05	0.0333	-0.31	-0.33	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79321711	chr5:78342365~78360507:-
UCEC	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	4.25	3.73e-05	0.0334	0.37	0.33	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
UCEC	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-4.25	3.73e-05	0.0334	-0.58	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
UCEC	cis	rs7267979	0.565	rs3752273	ENSG00000276952.1	RP5-965G21.6	-4.25	3.74e-05	0.0334	-0.42	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.565	rs958075	ENSG00000276952.1	RP5-965G21.6	-4.25	3.74e-05	0.0334	-0.42	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:25284915~25285588:-
UCEC	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	4.25	3.74e-05	0.0335	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
UCEC	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-4.25	3.75e-05	0.0335	-0.43	-0.33	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
UCEC	cis	rs7914558	0.932	rs4307650	ENSG00000272912.1	RP11-724N1.1	-4.25	3.75e-05	0.0335	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103200095	chr10:102914585~102915404:+
UCEC	cis	rs34286592	0.929	rs11863748	ENSG00000238045.8	AC009133.12	4.25	3.75e-05	0.0335	0.54	0.33	Multiple sclerosis;	chr16:29824267	chr16:29808636~29821252:-
UCEC	cis	rs6948404	0.786	rs7781875	ENSG00000225739.1	NPM1P18	4.25	3.75e-05	0.0336	0.51	0.33	HIV-1 viral setpoint;	chr7:36537095	chr7:36818959~36819690:+
UCEC	cis	rs6948404	0.786	rs7798695	ENSG00000225739.1	NPM1P18	4.25	3.75e-05	0.0336	0.51	0.33	HIV-1 viral setpoint;	chr7:36537101	chr7:36818959~36819690:+
UCEC	cis	rs4253772	0.591	rs6007740	ENSG00000277232.2	GTSE1-AS1	4.25	3.76e-05	0.0336	0.4	0.33	Cholesterol, total;LDL cholesterol;	chr22:46258426	chr22:46295143~46296660:-
UCEC	cis	rs6901004	0.803	rs1040903	ENSG00000271789.1	RP5-1112D6.7	-4.25	3.76e-05	0.0336	-0.38	-0.33	Blood metabolite levels;	chr6:111148950	chr6:111297126~111298510:+
UCEC	cis	rs9545047	0.604	rs7983344	ENSG00000227354.5	RBM26-AS1	-4.25	3.77e-05	0.0337	-0.33	-0.33	Schizophrenia;	chr13:79299295	chr13:79406309~79424328:+
UCEC	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	4.25	3.77e-05	0.0337	0.36	0.33	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
UCEC	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-4.25	3.78e-05	0.0338	-0.39	-0.33	Depression;	chr6:28201380	chr6:28115628~28116551:+
UCEC	cis	rs1707322	1	rs1707303	ENSG00000280836.1	AL355480.1	4.25	3.78e-05	0.0338	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.895	rs7788984	ENSG00000236529.1	RP13-254B10.1	4.25	3.78e-05	0.0338	0.39	0.33	Aortic root size;	chr7:66450629	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-4.25	3.79e-05	0.0338	-0.5	-0.33	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-4.25	3.79e-05	0.0338	-0.5	-0.33	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-4.25	3.79e-05	0.0338	-0.5	-0.33	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-4.25	3.79e-05	0.0338	-0.5	-0.33	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-4.25	3.79e-05	0.0338	-0.5	-0.33	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-4.25	3.79e-05	0.0338	-0.5	-0.33	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
UCEC	cis	rs6840360	0.642	rs6843639	ENSG00000251611.1	RP11-610P16.1	-4.25	3.79e-05	0.0339	-0.28	-0.33	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs28666858	ENSG00000251611.1	RP11-610P16.1	-4.25	3.79e-05	0.0339	-0.28	-0.33	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs10857260	ENSG00000251611.1	RP11-610P16.1	-4.25	3.79e-05	0.0339	-0.28	-0.33	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151407551~151408835:-
UCEC	cis	rs875971	0.964	rs6978429	ENSG00000236529.1	RP13-254B10.1	4.25	3.8e-05	0.0339	0.36	0.33	Aortic root size;	chr7:66494889	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs4718357	ENSG00000236529.1	RP13-254B10.1	4.25	3.8e-05	0.0339	0.36	0.33	Aortic root size;	chr7:66495891	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.929	rs12535036	ENSG00000236529.1	RP13-254B10.1	4.25	3.8e-05	0.0339	0.36	0.33	Aortic root size;	chr7:66499076	chr7:65840212~65840596:+
UCEC	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	4.25	3.8e-05	0.0339	0.8	0.33	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
UCEC	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	4.25	3.8e-05	0.0339	0.8	0.33	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
UCEC	cis	rs2281636	0.723	rs3740078	ENSG00000233690.1	EBAG9P1	4.25	3.8e-05	0.0339	0.31	0.33	Obesity-related traits;	chr10:99685834	chr10:99697407~99697949:-
UCEC	cis	rs2281636	0.723	rs11190246	ENSG00000233690.1	EBAG9P1	4.25	3.8e-05	0.0339	0.31	0.33	Obesity-related traits;	chr10:99691854	chr10:99697407~99697949:-
UCEC	cis	rs6024905	0.722	rs2275954	ENSG00000196756.10	SNHG17	-4.25	3.8e-05	0.0339	-0.38	-0.33	Bipolar disorder and schizophrenia;	chr20:38334265	chr20:38420588~38435353:-
UCEC	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	4.25	3.8e-05	0.0339	0.31	0.33	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
UCEC	cis	rs507080	0.961	rs4457789	ENSG00000278376.1	RP11-158I9.8	-4.25	3.8e-05	0.0339	-0.32	-0.33	Serum metabolite levels;	chr11:118668461	chr11:118791254~118793137:+
UCEC	cis	rs71361173	0.579	rs1395813	ENSG00000263982.1	RP11-504I13.3	4.25	3.8e-05	0.0339	0.4	0.33	Interleukin-12p70 levels;	chr18:76028932	chr18:76372717~76378275:+
UCEC	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-4.25	3.8e-05	0.0339	-0.37	-0.33	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
UCEC	cis	rs6887276	0.504	rs1003136	ENSG00000245937.6	LINC01184	4.25	3.81e-05	0.034	0.35	0.33	Height;	chr5:128012123	chr5:127940426~128083172:-
UCEC	cis	rs6137726	0.652	rs6075934	ENSG00000277901.1	RP5-851M4.1	-4.25	3.82e-05	0.034	-0.41	-0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22673477	chr20:23320958~23325352:-
UCEC	cis	rs2281636	0.723	rs1128642	ENSG00000233690.1	EBAG9P1	4.25	3.82e-05	0.034	0.31	0.33	Obesity-related traits;	chr10:99711938	chr10:99697407~99697949:-
UCEC	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	4.25	3.82e-05	0.034	0.4	0.33	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	4.25	3.82e-05	0.034	0.4	0.33	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	4.25	3.82e-05	0.034	0.4	0.33	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	4.25	3.82e-05	0.034	0.4	0.33	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
UCEC	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-4.25	3.82e-05	0.034	-0.44	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
UCEC	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	4.25	3.82e-05	0.034	0.35	0.33	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
UCEC	cis	rs7688540	0.8	rs9328738	ENSG00000211553.1	AC253576.2	4.25	3.82e-05	0.0341	0.4	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:136461~136568:+
UCEC	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	4.25	3.83e-05	0.0341	0.4	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
UCEC	cis	rs6740462	0.568	rs34875083	ENSG00000281920.1	RP11-418H16.1	-4.25	3.83e-05	0.0341	-0.59	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65428368	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.522	rs35153344	ENSG00000281920.1	RP11-418H16.1	-4.25	3.83e-05	0.0341	-0.59	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65428801	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs71424182	ENSG00000281920.1	RP11-418H16.1	-4.25	3.83e-05	0.0341	-0.59	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65431001	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs35520113	ENSG00000281920.1	RP11-418H16.1	-4.25	3.83e-05	0.0341	-0.59	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65432881	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs35493230	ENSG00000281920.1	RP11-418H16.1	-4.25	3.83e-05	0.0341	-0.59	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65433000	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs34720345	ENSG00000281920.1	RP11-418H16.1	-4.25	3.83e-05	0.0341	-0.59	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65433580	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.537	rs62141109	ENSG00000281920.1	RP11-418H16.1	-4.25	3.83e-05	0.0341	-0.59	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65434317	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs34004859	ENSG00000281920.1	RP11-418H16.1	-4.25	3.83e-05	0.0341	-0.59	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65435871	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.537	rs62141110	ENSG00000281920.1	RP11-418H16.1	-4.25	3.83e-05	0.0341	-0.59	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65436452	chr2:65623272~65628424:+
UCEC	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-4.24	3.83e-05	0.0341	-0.45	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
UCEC	cis	rs2115630	0.967	rs10438428	ENSG00000225151.9	GOLGA2P7	4.24	3.83e-05	0.0341	0.35	0.33	P wave terminal force;	chr15:84787514	chr15:84199311~84230136:-
UCEC	cis	rs6968355	0.789	rs2430480	ENSG00000237513.1	RP11-325F22.2	-4.24	3.84e-05	0.0341	-0.65	-0.33	Myopia (pathological);	chr7:104953901	chr7:104941063~104962334:+
UCEC	cis	rs1465618	0.945	rs4340576	ENSG00000279873.2	LINC01126	4.24	3.84e-05	0.0342	0.32	0.33	Prostate cancer;Prostate cancer (SNP x SNP interaction);Age-related hearing impairment (SNP x SNP interaction);	chr2:43328367	chr2:43227210~43228855:+
UCEC	cis	rs6840360	0.642	rs6535803	ENSG00000270265.1	RP11-731D1.4	-4.24	3.85e-05	0.0342	-0.32	-0.33	Intelligence (multi-trait analysis);	chr4:151520762	chr4:151333775~151353224:-
UCEC	cis	rs9429544	0.955	rs9429742	ENSG00000232450.1	RP4-730K3.3	4.24	3.85e-05	0.0343	0.4	0.33	Mean corpuscular hemoglobin;	chr1:114380168	chr1:113698884~113699631:-
UCEC	cis	rs7267979	0.604	rs242130	ENSG00000276952.1	RP5-965G21.6	-4.24	3.86e-05	0.0343	-0.41	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:25284915~25285588:-
UCEC	cis	rs8141529	0.748	rs5762882	ENSG00000272858.1	CTA-292E10.8	-4.24	3.86e-05	0.0343	-0.43	-0.33	Lymphocyte counts;	chr22:28894692	chr22:28814914~28815662:+
UCEC	cis	rs8141529	0.702	rs8137262	ENSG00000272858.1	CTA-292E10.8	-4.24	3.86e-05	0.0343	-0.43	-0.33	Lymphocyte counts;	chr22:28896147	chr22:28814914~28815662:+
UCEC	cis	rs875971	1	rs7781698	ENSG00000236529.1	RP13-254B10.1	4.24	3.86e-05	0.0343	0.38	0.33	Aortic root size;	chr7:66431325	chr7:65840212~65840596:+
UCEC	cis	rs9907295	1	rs9907295	ENSG00000270871.1	AC015849.19	4.24	3.86e-05	0.0343	0.52	0.33	Fibroblast growth factor basic levels;	chr17:35930309	chr17:35816717~35830293:-
UCEC	cis	rs2281636	0.723	rs2150916	ENSG00000233690.1	EBAG9P1	4.24	3.86e-05	0.0343	0.31	0.33	Obesity-related traits;	chr10:99692737	chr10:99697407~99697949:-
UCEC	cis	rs9847710	0.733	rs2581806	ENSG00000242142.1	SERBP1P3	4.24	3.86e-05	0.0343	0.43	0.33	Ulcerative colitis;	chr3:53029344	chr3:53064283~53065091:-
UCEC	cis	rs2445284	1	rs2445299	ENSG00000229534.1	HNRNPA1P53	-4.24	3.86e-05	0.0343	-0.41	-0.33	Sickle cell anemia (haemolysis);	chr11:5009867	chr11:5571247~5572192:-
UCEC	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-4.24	3.86e-05	0.0344	-0.4	-0.33	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
UCEC	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-4.24	3.86e-05	0.0344	-0.41	-0.33	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
UCEC	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-4.24	3.86e-05	0.0344	-0.41	-0.33	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
UCEC	cis	rs2281558	0.876	rs2281562	ENSG00000276952.1	RP5-965G21.6	4.24	3.87e-05	0.0344	0.55	0.33	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25292726	chr20:25284915~25285588:-
UCEC	cis	rs6840360	0.642	rs2709819	ENSG00000251611.1	RP11-610P16.1	-4.24	3.87e-05	0.0344	-0.28	-0.33	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151407551~151408835:-
UCEC	cis	rs7267979	0.745	rs6132845	ENSG00000276952.1	RP5-965G21.6	4.24	3.87e-05	0.0344	0.41	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25284915~25285588:-
UCEC	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	4.24	3.87e-05	0.0344	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
UCEC	cis	rs853679	0.598	rs9380054	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28099759	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.547	rs2116981	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Parkinson's disease;	chr6:28100173	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs9368552	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28100648	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs2281588	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28104824	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.542	rs34131763	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28107222	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs35193936	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28108492	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs36078605	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28110254	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs9393891	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28111382	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs9468286	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28111650	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs9380055	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28113851	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs9368553	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28114487	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs9368554	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28114933	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs4713137	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28115743	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs9348793	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Depression;	chr6:28116411	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.586	rs6905516	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Parkinson's disease;	chr6:28118700	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.586	rs6905522	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Parkinson's disease;	chr6:28118701	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.586	rs9468290	ENSG00000216901.1	AL022393.7	4.24	3.87e-05	0.0344	0.39	0.33	Parkinson's disease;	chr6:28119896	chr6:28176188~28176674:+
UCEC	cis	rs7240205	0.657	rs1111207	ENSG00000275805.1	RP11-349H17.2	-4.24	3.87e-05	0.0344	-0.38	-0.33	Breast cancer;	chr18:26545893	chr18:26565723~26575626:-
UCEC	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	4.24	3.87e-05	0.0344	0.35	0.33	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	4.24	3.87e-05	0.0344	0.35	0.33	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	4.24	3.88e-05	0.0344	0.41	0.33	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	4.24	3.88e-05	0.0344	0.41	0.33	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	4.24	3.88e-05	0.0344	0.41	0.33	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	4.24	3.88e-05	0.0344	0.41	0.33	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	4.24	3.88e-05	0.0344	0.34	0.33	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
UCEC	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-4.24	3.88e-05	0.0344	-0.38	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
UCEC	cis	rs62103177	0.81	rs62103178	ENSG00000261126.6	RP11-795F19.1	4.24	3.88e-05	0.0344	0.51	0.33	Opioid sensitivity;	chr18:79864555	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.713	rs62103186	ENSG00000261126.6	RP11-795F19.1	4.24	3.88e-05	0.0344	0.51	0.33	Opioid sensitivity;	chr18:79867574	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.81	rs62103187	ENSG00000261126.6	RP11-795F19.1	4.24	3.88e-05	0.0344	0.51	0.33	Opioid sensitivity;	chr18:79867633	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.81	rs62103188	ENSG00000261126.6	RP11-795F19.1	4.24	3.88e-05	0.0344	0.51	0.33	Opioid sensitivity;	chr18:79867661	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.81	rs62103189	ENSG00000261126.6	RP11-795F19.1	4.24	3.88e-05	0.0344	0.51	0.33	Opioid sensitivity;	chr18:79867815	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.81	rs62103191	ENSG00000261126.6	RP11-795F19.1	4.24	3.88e-05	0.0344	0.51	0.33	Opioid sensitivity;	chr18:79868769	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.81	rs62103192	ENSG00000261126.6	RP11-795F19.1	4.24	3.88e-05	0.0344	0.51	0.33	Opioid sensitivity;	chr18:79869050	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.733	rs62103193	ENSG00000261126.6	RP11-795F19.1	4.24	3.88e-05	0.0344	0.51	0.33	Opioid sensitivity;	chr18:79869217	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.81	rs62103194	ENSG00000261126.6	RP11-795F19.1	4.24	3.88e-05	0.0344	0.51	0.33	Opioid sensitivity;	chr18:79869482	chr18:80046900~80095482:+
UCEC	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-4.24	3.89e-05	0.0345	-0.45	-0.33	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
UCEC	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-4.24	3.89e-05	0.0345	-0.46	-0.33	QT interval;	chr16:28824579	chr16:28700294~28701540:-
UCEC	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	4.24	3.89e-05	0.0345	0.45	0.33	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
UCEC	cis	rs2445284	0.817	rs1902316	ENSG00000229534.1	HNRNPA1P53	-4.24	3.9e-05	0.0345	-0.4	-0.33	Sickle cell anemia (haemolysis);	chr11:5048604	chr11:5571247~5572192:-
UCEC	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	4.24	3.9e-05	0.0345	0.39	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
UCEC	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	4.24	3.9e-05	0.0346	0.45	0.33	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
UCEC	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-4.24	3.9e-05	0.0346	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
UCEC	cis	rs4845570	1	rs4845570	ENSG00000203288.3	RP11-98D18.9	4.24	3.91e-05	0.0346	0.47	0.33	Coronary artery disease;	chr1:151786628	chr1:151790804~151794402:+
UCEC	cis	rs9545047	0.716	rs418150	ENSG00000227354.5	RBM26-AS1	-4.24	3.91e-05	0.0346	-0.33	-0.33	Schizophrenia;	chr13:79432675	chr13:79406309~79424328:+
UCEC	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-4.24	3.91e-05	0.0346	-0.37	-0.33	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
UCEC	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	4.24	3.92e-05	0.0347	0.46	0.33	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	4.24	3.92e-05	0.0347	0.46	0.33	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
UCEC	cis	rs7688540	0.8	rs61794998	ENSG00000211553.1	AC253576.2	-4.24	3.92e-05	0.0347	-0.39	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:136461~136568:+
UCEC	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	4.24	3.92e-05	0.0347	0.38	0.33	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
UCEC	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	4.24	3.93e-05	0.0347	0.32	0.33	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
UCEC	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-4.24	3.93e-05	0.0347	-0.4	-0.33	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
UCEC	cis	rs875971	0.895	rs6460278	ENSG00000236529.1	RP13-254B10.1	-4.24	3.93e-05	0.0347	-0.38	-0.33	Aortic root size;	chr7:66197749	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6460279	ENSG00000236529.1	RP13-254B10.1	-4.24	3.93e-05	0.0347	-0.38	-0.33	Aortic root size;	chr7:66197774	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs28491091	ENSG00000236529.1	RP13-254B10.1	-4.24	3.93e-05	0.0347	-0.38	-0.33	Aortic root size;	chr7:66204077	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6952182	ENSG00000236529.1	RP13-254B10.1	-4.24	3.93e-05	0.0347	-0.38	-0.33	Aortic root size;	chr7:66218330	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6964437	ENSG00000236529.1	RP13-254B10.1	-4.24	3.93e-05	0.0347	-0.38	-0.33	Aortic root size;	chr7:66221457	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6460282	ENSG00000236529.1	RP13-254B10.1	-4.24	3.93e-05	0.0347	-0.38	-0.33	Aortic root size;	chr7:66226259	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.825	rs6951503	ENSG00000236529.1	RP13-254B10.1	-4.24	3.93e-05	0.0347	-0.38	-0.33	Aortic root size;	chr7:66253949	chr7:65840212~65840596:+
UCEC	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-4.24	3.94e-05	0.0347	-0.64	-0.33	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
UCEC	cis	rs492146	0.935	rs492825	ENSG00000243236.5	GSTA9P	-4.24	3.94e-05	0.0348	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52980595	chr6:52939726~52957521:-
UCEC	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	4.24	3.94e-05	0.0348	0.39	0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
UCEC	cis	rs12478296	1	rs56136197	ENSG00000261186.2	RP11-341N2.1	-4.24	3.95e-05	0.0348	-0.45	-0.33	Obesity-related traits;	chr2:242101726	chr2:242087351~242088457:-
UCEC	cis	rs12478296	1	rs56387669	ENSG00000261186.2	RP11-341N2.1	-4.24	3.95e-05	0.0348	-0.45	-0.33	Obesity-related traits;	chr2:242101738	chr2:242087351~242088457:-
UCEC	cis	rs62103177	0.513	rs9945153	ENSG00000261126.6	RP11-795F19.1	4.24	3.95e-05	0.0348	0.44	0.33	Opioid sensitivity;	chr18:79838450	chr18:80046900~80095482:+
UCEC	cis	rs875971	0.862	rs1981799	ENSG00000224316.1	RP11-479O9.2	4.24	3.95e-05	0.0349	0.33	0.33	Aortic root size;	chr7:66490572	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.964	rs2277911	ENSG00000224316.1	RP11-479O9.2	4.24	3.95e-05	0.0349	0.33	0.33	Aortic root size;	chr7:66493638	chr7:65773620~65802067:+
UCEC	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	4.24	3.95e-05	0.0349	0.34	0.33	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
UCEC	cis	rs492146	0.935	rs405729	ENSG00000243236.5	GSTA9P	-4.24	3.95e-05	0.0349	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52977983	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.935	rs316135	ENSG00000243236.5	GSTA9P	-4.24	3.95e-05	0.0349	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52981979	chr6:52939726~52957521:-
UCEC	cis	rs1593	0.531	rs4253326	ENSG00000233110.1	RP11-301L8.2	-4.24	3.96e-05	0.0349	-0.32	-0.33	Activated partial thromboplastin time;	chr4:186257445	chr4:185587909~185594003:+
UCEC	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	4.24	3.96e-05	0.0349	0.32	0.33	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
UCEC	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	4.24	3.96e-05	0.0349	0.32	0.33	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-4.24	3.96e-05	0.0349	-0.38	-0.33	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	4.24	3.96e-05	0.0349	0.38	0.33	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
UCEC	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-4.24	3.96e-05	0.0349	-0.33	-0.33	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
UCEC	cis	rs875971	0.964	rs6978429	ENSG00000224316.1	RP11-479O9.2	4.24	3.96e-05	0.0349	0.33	0.33	Aortic root size;	chr7:66494889	chr7:65773620~65802067:+
UCEC	cis	rs875971	1	rs4718357	ENSG00000224316.1	RP11-479O9.2	4.24	3.96e-05	0.0349	0.33	0.33	Aortic root size;	chr7:66495891	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.929	rs12535036	ENSG00000224316.1	RP11-479O9.2	4.24	3.96e-05	0.0349	0.33	0.33	Aortic root size;	chr7:66499076	chr7:65773620~65802067:+
UCEC	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-4.24	3.96e-05	0.0349	-0.42	-0.33	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
UCEC	cis	rs10895275	0.961	rs10895276	ENSG00000277459.1	RP11-732A21.3	-4.24	3.97e-05	0.0349	-0.31	-0.33	Migraine;	chr11:102212964	chr11:102109827~102110457:-
UCEC	cis	rs7560272	0.723	rs13386124	ENSG00000163016.8	ALMS1P	4.24	3.97e-05	0.0349	0.32	0.33	Schizophrenia;	chr2:73544568	chr2:73644919~73685576:+
UCEC	cis	rs111326718	1	rs111326718	ENSG00000272912.1	RP11-724N1.1	-4.24	3.97e-05	0.0349	-0.31	-0.33	Reticulocyte count;	chr10:103011454	chr10:102914585~102915404:+
UCEC	cis	rs2274273	0.588	rs7145727	ENSG00000258413.1	RP11-665C16.6	-4.24	3.97e-05	0.0349	-0.41	-0.33	Protein biomarker;	chr14:55380855	chr14:55262767~55272075:-
UCEC	cis	rs9319321	0.688	rs943715	ENSG00000277368.1	RP11-380N8.7	-4.24	3.97e-05	0.0349	-0.35	-0.33	Asthma (toluene diisocyanate-induced);	chr13:26840716	chr13:26222191~26222654:+
UCEC	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	4.24	3.97e-05	0.035	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
UCEC	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	4.24	3.97e-05	0.035	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
UCEC	cis	rs9545047	0.604	rs11620233	ENSG00000227354.5	RBM26-AS1	-4.24	3.97e-05	0.035	-0.33	-0.33	Schizophrenia;	chr13:79373871	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs7331872	ENSG00000227354.5	RBM26-AS1	-4.24	3.97e-05	0.035	-0.33	-0.33	Schizophrenia;	chr13:79388717	chr13:79406309~79424328:+
UCEC	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-4.24	3.98e-05	0.035	-0.45	-0.33	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-4.24	3.98e-05	0.035	-0.45	-0.33	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-4.24	3.98e-05	0.035	-0.45	-0.33	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-4.24	3.98e-05	0.035	-0.45	-0.33	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-4.24	3.98e-05	0.035	-0.45	-0.33	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-4.24	3.98e-05	0.035	-0.45	-0.33	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
UCEC	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-4.24	3.98e-05	0.035	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
UCEC	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	4.23	3.98e-05	0.035	0.36	0.33	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	4.23	3.98e-05	0.035	0.36	0.33	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
UCEC	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-4.23	3.99e-05	0.035	-0.35	-0.33	Height;	chr11:118742526	chr11:118704607~118750263:+
UCEC	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	4.23	4e-05	0.0351	0.36	0.33	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	4.23	4e-05	0.0351	0.36	0.33	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	4.23	4e-05	0.0351	0.36	0.33	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	4.23	4e-05	0.0351	0.36	0.33	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	4.23	4e-05	0.0351	0.36	0.33	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	4.23	4e-05	0.0351	0.36	0.33	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	4.23	4e-05	0.0351	0.36	0.33	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
UCEC	cis	rs9876781	0.53	rs35516531	ENSG00000229759.1	MRPS18AP1	4.23	4e-05	0.0351	0.36	0.33	Longevity;	chr3:48364275	chr3:48256350~48256938:-
UCEC	cis	rs9876781	0.559	rs1903144	ENSG00000229759.1	MRPS18AP1	4.23	4e-05	0.0351	0.36	0.33	Longevity;	chr3:48364907	chr3:48256350~48256938:-
UCEC	cis	rs6840360	0.582	rs4696259	ENSG00000278978.1	RP11-164P12.5	-4.23	4e-05	0.0351	-0.39	-0.33	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151669786~151670503:+
UCEC	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	4.23	4.01e-05	0.0352	0.41	0.33	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
UCEC	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	4.23	4.01e-05	0.0352	0.41	0.33	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
UCEC	cis	rs4713118	0.662	rs149970	ENSG00000216901.1	AL022393.7	4.23	4.01e-05	0.0352	0.36	0.33	Parkinson's disease;	chr6:28012442	chr6:28176188~28176674:+
UCEC	cis	rs10895275	1	rs10895275	ENSG00000277459.1	RP11-732A21.3	-4.23	4.02e-05	0.0352	-0.31	-0.33	Migraine;	chr11:102212877	chr11:102109827~102110457:-
UCEC	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-4.23	4.02e-05	0.0352	-0.36	-0.33	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
UCEC	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	4.23	4.02e-05	0.0353	0.37	0.33	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
UCEC	cis	rs4713118	0.539	rs200967	ENSG00000219392.1	RP1-265C24.5	-4.23	4.02e-05	0.0353	-0.38	-0.33	Parkinson's disease;	chr6:27894349	chr6:28115628~28116551:+
UCEC	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-4.23	4.03e-05	0.0353	-0.34	-0.33	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
UCEC	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-4.23	4.03e-05	0.0353	-0.37	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
UCEC	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	4.23	4.03e-05	0.0353	0.35	0.33	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
UCEC	cis	rs28386778	0.966	rs2854161	ENSG00000240280.5	TCAM1P	4.23	4.04e-05	0.0354	0.36	0.33	Prudent dietary pattern;	chr17:63898733	chr17:63849292~63864379:+
UCEC	cis	rs13053175	1	rs13053175	ENSG00000278420.1	MIR6819	4.23	4.04e-05	0.0354	0.37	0.33	Longevity;	chr22:37217269	chr22:36286847~36286907:-
UCEC	cis	rs2991971	0.747	rs2492841	ENSG00000280836.1	AL355480.1	-4.23	4.04e-05	0.0354	-0.37	-0.33	High light scatter reticulocyte count;	chr1:45429219	chr1:45581219~45581321:-
UCEC	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-4.23	4.04e-05	0.0354	-0.35	-0.33	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
UCEC	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	4.23	4.05e-05	0.0355	0.35	0.33	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
UCEC	cis	rs2001144	0.51	rs7770621	ENSG00000225093.1	RPL3P7	-4.23	4.05e-05	0.0355	-0.42	-0.33	Major depressive disorder;	chr6:108011147	chr6:108004357~108005568:-
UCEC	cis	rs2976388	0.609	rs2717602	ENSG00000253931.1	RP11-909N17.2	4.23	4.05e-05	0.0355	0.34	0.33	Urinary tract infection frequency;	chr8:142724265	chr8:143412749~143417054:+
UCEC	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-4.23	4.05e-05	0.0355	-0.45	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
UCEC	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	4.23	4.06e-05	0.0355	0.39	0.33	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
UCEC	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-4.23	4.06e-05	0.0356	-0.37	-0.33	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
UCEC	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	4.23	4.07e-05	0.0356	0.32	0.33	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
UCEC	cis	rs11959928	0.733	rs700230	ENSG00000249740.1	OSMR-AS1	4.23	4.07e-05	0.0356	0.42	0.33	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr5:39361971	chr5:38736055~38845829:-
UCEC	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-4.23	4.07e-05	0.0356	-0.36	-0.33	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
UCEC	cis	rs492146	0.935	rs375887	ENSG00000243236.5	GSTA9P	-4.23	4.08e-05	0.0357	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52978679	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.935	rs316139	ENSG00000243236.5	GSTA9P	-4.23	4.08e-05	0.0357	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52981574	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.902	rs316136	ENSG00000243236.5	GSTA9P	-4.23	4.08e-05	0.0357	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52981971	chr6:52939726~52957521:-
UCEC	cis	rs492146	0.935	rs316128	ENSG00000243236.5	GSTA9P	-4.23	4.08e-05	0.0357	-0.42	-0.33	Epilepsy (remission after treatment);	chr6:52984348	chr6:52939726~52957521:-
UCEC	cis	rs71281886	1	rs71281886	ENSG00000229759.1	MRPS18AP1	4.23	4.08e-05	0.0357	0.39	0.33	Breast cancer;	chr3:48311088	chr3:48256350~48256938:-
UCEC	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	4.23	4.08e-05	0.0357	0.48	0.33	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
UCEC	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	4.23	4.08e-05	0.0357	0.46	0.33	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
UCEC	cis	rs9856151	0.559	rs1225036	ENSG00000250608.1	RP11-933H2.4	4.23	4.08e-05	0.0357	0.39	0.33	Body mass index;	chr3:131928950	chr3:131325092~131381475:-
UCEC	cis	rs948562	0.947	rs2298607	ENSG00000280010.1	AP001350.4	4.23	4.09e-05	0.0357	0.52	0.33	Lymphoma;	chr11:58637026	chr11:58627435~58628528:+
UCEC	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	4.23	4.09e-05	0.0358	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
UCEC	cis	rs17001868	1	rs73167022	ENSG00000272834.1	RP5-1042K10.13	4.23	4.1e-05	0.0358	0.58	0.33	Mammographic density (dense area);	chr22:40401252	chr22:40415003~40415445:+
UCEC	cis	rs617219	0.613	rs4704556	ENSG00000245556.2	SCAMP1-AS1	-4.23	4.1e-05	0.0358	-0.32	-0.33	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79311324	chr5:78342365~78360507:-
UCEC	cis	rs4253772	0.55	rs6007761	ENSG00000277232.2	GTSE1-AS1	4.23	4.1e-05	0.0358	0.41	0.33	Cholesterol, total;LDL cholesterol;	chr22:46274497	chr22:46295143~46296660:-
UCEC	cis	rs4713118	0.513	rs200971	ENSG00000219392.1	RP1-265C24.5	-4.23	4.1e-05	0.0358	-0.38	-0.33	Parkinson's disease;	chr6:27891126	chr6:28115628~28116551:+
UCEC	cis	rs10232172	1	rs12667362	ENSG00000234707.2	RP11-745C15.2	4.23	4.11e-05	0.0359	0.6	0.33	Periodontal disease-related phenotypes;	chr7:54110417	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.818	rs12673976	ENSG00000234707.2	RP11-745C15.2	4.23	4.11e-05	0.0359	0.6	0.33	Periodontal disease-related phenotypes;	chr7:54110422	chr7:54759425~54804928:+
UCEC	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	4.23	4.11e-05	0.0359	0.4	0.33	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
UCEC	cis	rs4713118	0.955	rs9468200	ENSG00000216901.1	AL022393.7	4.23	4.11e-05	0.0359	0.38	0.33	Parkinson's disease;	chr6:27715284	chr6:28176188~28176674:+
UCEC	cis	rs794185	0.657	rs2633846	ENSG00000229241.1	PNPT1P1	4.23	4.12e-05	0.0359	0.37	0.33	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471781	chr3:3981981~3984295:-
UCEC	cis	rs806321	0.755	rs1965800	ENSG00000237152.3	DLEU7-AS1	-4.23	4.12e-05	0.036	-0.37	-0.33	Multiple sclerosis;	chr13:50210599	chr13:50807856~50849905:+
UCEC	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-4.23	4.13e-05	0.0361	-0.38	-0.33	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
UCEC	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-4.23	4.14e-05	0.0361	-0.35	-0.33	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
UCEC	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-4.23	4.14e-05	0.0361	-0.35	-0.33	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
UCEC	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	4.23	4.14e-05	0.0361	0.35	0.33	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
UCEC	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-4.23	4.14e-05	0.0361	-0.32	-0.33	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
UCEC	cis	rs4713118	0.955	rs34752872	ENSG00000216901.1	AL022393.7	4.23	4.14e-05	0.0361	0.38	0.33	Parkinson's disease;	chr6:27715465	chr6:28176188~28176674:+
UCEC	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	4.23	4.14e-05	0.0361	0.42	0.33	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
UCEC	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-4.23	4.14e-05	0.0361	-0.44	-0.33	Height;	chr3:53093751	chr3:53064283~53065091:-
UCEC	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-4.22	4.15e-05	0.0361	-0.36	-0.33	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
UCEC	cis	rs7592578	0.771	rs1128723	ENSG00000272979.1	RP11-647K16.1	-4.22	4.15e-05	0.0361	-0.56	-0.33	Diastolic blood pressure;	chr2:190501981	chr2:190454092~190454521:-
UCEC	cis	rs7592578	0.771	rs75579212	ENSG00000272979.1	RP11-647K16.1	-4.22	4.15e-05	0.0361	-0.56	-0.33	Diastolic blood pressure;	chr2:190511849	chr2:190454092~190454521:-
UCEC	cis	rs7592578	0.771	rs12053190	ENSG00000272979.1	RP11-647K16.1	-4.22	4.15e-05	0.0361	-0.56	-0.33	Diastolic blood pressure;	chr2:190518622	chr2:190454092~190454521:-
UCEC	cis	rs7592578	0.771	rs10432434	ENSG00000272979.1	RP11-647K16.1	-4.22	4.15e-05	0.0361	-0.56	-0.33	Diastolic blood pressure;	chr2:190522353	chr2:190454092~190454521:-
UCEC	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-4.22	4.16e-05	0.0362	-0.35	-0.33	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
UCEC	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-4.22	4.16e-05	0.0362	-0.34	-0.33	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
UCEC	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-4.22	4.16e-05	0.0362	-0.46	-0.33	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-4.22	4.16e-05	0.0362	-0.46	-0.33	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-4.22	4.16e-05	0.0362	-0.46	-0.33	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-4.22	4.16e-05	0.0362	-0.46	-0.33	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-4.22	4.16e-05	0.0362	-0.46	-0.33	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
UCEC	cis	rs6840360	0.642	rs7678823	ENSG00000251611.1	RP11-610P16.1	-4.22	4.16e-05	0.0362	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151407551~151408835:-
UCEC	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-4.22	4.17e-05	0.0363	-0.37	-0.33	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
UCEC	cis	rs67478160	0.619	rs8018062	ENSG00000270108.1	RP11-73M18.6	-4.22	4.18e-05	0.0363	-0.35	-0.33	Schizophrenia;	chr14:103815617	chr14:103687576~103688127:+
UCEC	cis	rs67478160	0.643	rs2223937	ENSG00000270108.1	RP11-73M18.6	-4.22	4.18e-05	0.0363	-0.35	-0.33	Schizophrenia;	chr14:103820043	chr14:103687576~103688127:+
UCEC	cis	rs67478160	0.643	rs4900600	ENSG00000270108.1	RP11-73M18.6	-4.22	4.18e-05	0.0363	-0.35	-0.33	Schizophrenia;	chr14:103825502	chr14:103687576~103688127:+
UCEC	cis	rs8089364	0.758	rs34633411	ENSG00000267742.1	FAM60CP	-4.22	4.18e-05	0.0363	-0.3	-0.33	Body mass index;Type 2 diabetes;	chr18:60187461	chr18:60016778~60017441:-
UCEC	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	4.22	4.18e-05	0.0363	0.41	0.33	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
UCEC	cis	rs6901004	0.605	rs2297939	ENSG00000272356.1	RP5-1112D6.8	-4.22	4.18e-05	0.0364	-0.38	-0.33	Blood metabolite levels;	chr6:111227959	chr6:111309203~111313517:+
UCEC	cis	rs2991971	0.967	rs12743512	ENSG00000280836.1	AL355480.1	-4.22	4.19e-05	0.0364	-0.37	-0.33	High light scatter reticulocyte count;	chr1:45488361	chr1:45581219~45581321:-
UCEC	cis	rs10946940	0.965	rs4713112	ENSG00000216901.1	AL022393.7	-4.22	4.19e-05	0.0364	-0.35	-0.33	Systemic lupus erythematosus;	chr6:27549054	chr6:28176188~28176674:+
UCEC	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-4.22	4.19e-05	0.0364	-0.38	-0.33	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
UCEC	cis	rs12817549	0.967	rs2363080	ENSG00000258274.1	RP11-887P2.5	4.22	4.2e-05	0.0365	0.44	0.33	Hip circumference adjusted for BMI;	chr12:93746687	chr12:93707791~93737823:-
UCEC	cis	rs7240205	0.818	rs12964926	ENSG00000275805.1	RP11-349H17.2	4.22	4.2e-05	0.0365	0.4	0.33	Breast cancer;	chr18:26567363	chr18:26565723~26575626:-
UCEC	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	4.22	4.2e-05	0.0365	0.44	0.33	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.825	rs1000464	ENSG00000236529.1	RP13-254B10.1	-4.22	4.21e-05	0.0365	-0.38	-0.33	Aortic root size;	chr7:66312922	chr7:65840212~65840596:+
UCEC	cis	rs11959928	0.703	rs700233	ENSG00000249740.1	OSMR-AS1	4.22	4.22e-05	0.0366	0.43	0.33	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr5:39364452	chr5:38736055~38845829:-
UCEC	cis	rs7077415	0.818	rs12255028	ENSG00000235618.6	FAM21EP	4.22	4.22e-05	0.0367	0.56	0.33	Cerebrospinal fluid biomarker levels;	chr10:50264922	chr10:50021182~50067803:-
UCEC	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
UCEC	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-4.22	4.23e-05	0.0367	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
UCEC	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	4.22	4.23e-05	0.0367	0.3	0.33	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
UCEC	cis	rs6137726	0.703	rs1571251	ENSG00000277901.1	RP5-851M4.1	4.22	4.24e-05	0.0367	0.46	0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22688144	chr20:23320958~23325352:-
UCEC	cis	rs229541	1	rs229536	ENSG00000237862.1	RP1-63G5.7	4.22	4.24e-05	0.0368	0.4	0.33	Type 1 diabetes;	chr22:37193829	chr22:37352190~37354839:-
UCEC	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-4.22	4.24e-05	0.0368	-0.37	-0.33	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-4.22	4.24e-05	0.0368	-0.37	-0.33	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-4.22	4.24e-05	0.0368	-0.37	-0.33	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-4.22	4.24e-05	0.0368	-0.37	-0.33	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
UCEC	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	4.22	4.24e-05	0.0368	0.39	0.33	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
UCEC	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	4.22	4.24e-05	0.0368	0.39	0.33	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
UCEC	cis	rs9545047	0.935	rs2760102	ENSG00000227354.5	RBM26-AS1	4.22	4.25e-05	0.0368	0.36	0.33	Schizophrenia;	chr13:79555193	chr13:79406309~79424328:+
UCEC	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-4.22	4.25e-05	0.0368	-0.45	-0.33	QT interval;	chr16:28877088	chr16:28700294~28701540:-
UCEC	cis	rs9400467	0.528	rs6568680	ENSG00000271789.1	RP5-1112D6.7	-4.22	4.25e-05	0.0368	-0.41	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111297126~111298510:+
UCEC	cis	rs16828019	0.561	rs12025777	ENSG00000235358.1	RP11-399E6.1	4.22	4.25e-05	0.0368	0.77	0.33	Intelligence (multi-trait analysis);	chr1:41283225	chr1:41242373~41284861:+
UCEC	cis	rs12478296	1	rs66612947	ENSG00000261186.2	RP11-341N2.1	-4.22	4.26e-05	0.0368	-0.45	-0.33	Obesity-related traits;	chr2:242093811	chr2:242087351~242088457:-
UCEC	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	4.22	4.26e-05	0.0369	0.31	0.33	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
UCEC	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-4.22	4.27e-05	0.0369	-0.41	-0.33	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
UCEC	cis	rs617219	0.698	rs72764988	ENSG00000245556.2	SCAMP1-AS1	4.22	4.27e-05	0.0369	0.31	0.33	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79237761	chr5:78342365~78360507:-
UCEC	cis	rs7914558	0.966	rs3977751	ENSG00000272912.1	RP11-724N1.1	-4.22	4.27e-05	0.037	-0.31	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103160475	chr10:102914585~102915404:+
UCEC	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	4.22	4.28e-05	0.037	0.39	0.33	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
UCEC	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-4.22	4.28e-05	0.037	-0.36	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
UCEC	cis	rs12478296	1	rs67535150	ENSG00000261186.2	RP11-341N2.1	-4.22	4.28e-05	0.037	-0.44	-0.33	Obesity-related traits;	chr2:242103948	chr2:242087351~242088457:-
UCEC	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	4.22	4.28e-05	0.0371	0.43	0.33	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
UCEC	cis	rs73607972	0.593	rs4784321	ENSG00000275191.1	RP11-36I17.2	-4.22	4.28e-05	0.0371	-0.36	-0.33	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602497	chr16:53628256~53628816:-
UCEC	cis	rs9545047	0.604	rs9318641	ENSG00000227354.5	RBM26-AS1	-4.22	4.29e-05	0.0371	-0.32	-0.33	Schizophrenia;	chr13:79426545	chr13:79406309~79424328:+
UCEC	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-4.22	4.29e-05	0.0371	-0.37	-0.33	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-4.22	4.29e-05	0.0371	-0.37	-0.33	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-4.22	4.29e-05	0.0371	-0.37	-0.33	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
UCEC	cis	rs858267	1	rs858309	ENSG00000230658.1	KLHL7-AS1	-4.22	4.29e-05	0.0371	-0.85	-0.33	Blood protein levels;	chr7:23166854	chr7:23101228~23105703:-
UCEC	cis	rs858267	1	rs858308	ENSG00000230658.1	KLHL7-AS1	-4.22	4.29e-05	0.0371	-0.85	-0.33	Blood protein levels;	chr7:23168727	chr7:23101228~23105703:-
UCEC	cis	rs858267	1	rs858267	ENSG00000230658.1	KLHL7-AS1	-4.22	4.29e-05	0.0371	-0.85	-0.33	Blood protein levels;	chr7:23170510	chr7:23101228~23105703:-
UCEC	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	4.22	4.29e-05	0.0371	0.36	0.33	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
UCEC	cis	rs9309473	0.5	rs11688718	ENSG00000163016.8	ALMS1P	4.22	4.3e-05	0.0372	0.34	0.33	Metabolite levels;	chr2:73533812	chr2:73644919~73685576:+
UCEC	cis	rs12986413	0.763	rs35049177	ENSG00000267283.1	AC005306.3	4.22	4.3e-05	0.0372	0.3	0.33	Height;	chr19:2162129	chr19:1989401~1990370:+
UCEC	cis	rs12986413	0.817	rs12985346	ENSG00000267283.1	AC005306.3	4.22	4.3e-05	0.0372	0.3	0.33	Height;	chr19:2164352	chr19:1989401~1990370:+
UCEC	cis	rs875971	1	rs1981798	ENSG00000236529.1	RP13-254B10.1	4.22	4.31e-05	0.0372	0.39	0.33	Aortic root size;	chr7:66489916	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs6945019	ENSG00000236529.1	RP13-254B10.1	4.22	4.31e-05	0.0372	0.38	0.33	Aortic root size;	chr7:66457471	chr7:65840212~65840596:+
UCEC	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	4.22	4.31e-05	0.0372	0.37	0.33	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
UCEC	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	4.22	4.31e-05	0.0372	0.41	0.33	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
UCEC	cis	rs1790761	0.505	rs6591256	ENSG00000184224.3	C11orf72	-4.22	4.31e-05	0.0372	-0.35	-0.33	Mean corpuscular volume;	chr11:67582428	chr11:67602880~67606706:-
UCEC	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-4.21	4.32e-05	0.0373	-0.42	-0.33	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
UCEC	cis	rs875971	1	rs778726	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66363744	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.767	rs1695815	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66366357	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs778685	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66371189	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.929	rs778682	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66372947	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs1643388	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66379575	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs778722	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66379841	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs778721	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66380410	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.895	rs778700	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66401463	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs778699	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66403303	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.929	rs778692	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66407462	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs4718343	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66409301	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs1968225	ENSG00000236529.1	RP13-254B10.1	4.21	4.33e-05	0.0373	0.36	0.33	Aortic root size;	chr7:66409786	chr7:65840212~65840596:+
UCEC	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-4.21	4.33e-05	0.0374	-0.38	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
UCEC	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-4.21	4.33e-05	0.0374	-0.43	-0.33	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
UCEC	cis	rs7914558	1	rs7071373	ENSG00000272912.1	RP11-724N1.1	-4.21	4.33e-05	0.0374	-0.31	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103012165	chr10:102914585~102915404:+
UCEC	cis	rs7914558	1	rs4917380	ENSG00000272912.1	RP11-724N1.1	-4.21	4.33e-05	0.0374	-0.31	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103015578	chr10:102914585~102915404:+
UCEC	cis	rs7914558	1	rs7914558	ENSG00000272912.1	RP11-724N1.1	-4.21	4.33e-05	0.0374	-0.31	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103016151	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs11191518	ENSG00000272912.1	RP11-724N1.1	-4.21	4.33e-05	0.0374	-0.31	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103023096	chr10:102914585~102915404:+
UCEC	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-4.21	4.33e-05	0.0374	-0.31	-0.33	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
UCEC	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	4.21	4.33e-05	0.0374	0.39	0.33	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
UCEC	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-4.21	4.34e-05	0.0374	-0.42	-0.33	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
UCEC	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-4.21	4.34e-05	0.0374	-0.42	-0.33	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
UCEC	cis	rs950169	0.84	rs35522895	ENSG00000259295.5	CSPG4P12	4.21	4.34e-05	0.0374	0.51	0.33	Schizophrenia;	chr15:84259297	chr15:85191438~85213905:+
UCEC	cis	rs597583	0.715	rs11216436	ENSG00000254528.6	RP11-728F11.4	4.21	4.34e-05	0.0374	0.64	0.33	Putamen volume;	chr11:117520659	chr11:117833719~117838942:+
UCEC	cis	rs73219805	0.838	rs7840859	ENSG00000228451.3	SDAD1P1	-4.21	4.34e-05	0.0374	-0.42	-0.33	Schizophrenia;	chr8:26377501	chr8:26379259~26382953:-
UCEC	cis	rs2739330	0.731	rs5751792	ENSG00000272787.1	KB-226F1.2	-4.21	4.34e-05	0.0374	-0.4	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23969211~23969873:+
UCEC	cis	rs2976388	0.647	rs2585154	ENSG00000253931.1	RP11-909N17.2	4.21	4.36e-05	0.0375	0.34	0.33	Urinary tract infection frequency;	chr8:142702067	chr8:143412749~143417054:+
UCEC	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-4.21	4.36e-05	0.0376	-0.43	-0.33	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
UCEC	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	4.21	4.36e-05	0.0376	0.4	0.33	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
UCEC	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-4.21	4.36e-05	0.0376	-0.29	-0.33	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
UCEC	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	4.21	4.36e-05	0.0376	0.38	0.33	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
UCEC	cis	rs17106184	1	rs2095864	ENSG00000213478.2	CFL1P2	-4.21	4.37e-05	0.0376	-0.65	-0.33	Type 2 diabetes;	chr1:50833925	chr1:51157788~51158471:-
UCEC	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-4.21	4.37e-05	0.0376	-0.32	-0.33	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
UCEC	cis	rs1185460	0.967	rs1784460	ENSG00000278376.1	RP11-158I9.8	4.21	4.37e-05	0.0376	0.3	0.33	Coronary artery disease;	chr11:119067660	chr11:118791254~118793137:+
UCEC	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-4.21	4.37e-05	0.0376	-0.29	-0.33	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-4.21	4.37e-05	0.0376	-0.29	-0.33	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
UCEC	cis	rs6137726	0.652	rs6075933	ENSG00000277901.1	RP5-851M4.1	-4.21	4.37e-05	0.0376	-0.41	-0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22673421	chr20:23320958~23325352:-
UCEC	cis	rs6137726	0.652	rs73304706	ENSG00000277901.1	RP5-851M4.1	-4.21	4.37e-05	0.0376	-0.41	-0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22673756	chr20:23320958~23325352:-
UCEC	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-4.21	4.37e-05	0.0377	-0.46	-0.33	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
UCEC	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-4.21	4.38e-05	0.0377	-0.3	-0.33	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
UCEC	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	4.21	4.38e-05	0.0377	0.36	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
UCEC	cis	rs62103177	0.568	rs2365388	ENSG00000261126.6	RP11-795F19.1	4.21	4.38e-05	0.0377	0.37	0.33	Opioid sensitivity;	chr18:80215819	chr18:80046900~80095482:+
UCEC	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	4.21	4.38e-05	0.0377	0.41	0.33	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	4.21	4.38e-05	0.0377	0.41	0.33	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
UCEC	cis	rs9525927	0.817	rs6561169	ENSG00000227258.4	SMIM2-AS1	-4.21	4.39e-05	0.0377	-0.38	-0.33	Dupuytren's disease;	chr13:44270102	chr13:44110451~44240517:+
UCEC	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-4.21	4.39e-05	0.0377	-0.36	-0.33	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
UCEC	cis	rs7688540	0.8	rs6837796	ENSG00000211553.1	AC253576.2	-4.21	4.39e-05	0.0378	-0.4	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:136461~136568:+
UCEC	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	4.21	4.39e-05	0.0378	0.35	0.33	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
UCEC	cis	rs2976388	0.647	rs2244163	ENSG00000253931.1	RP11-909N17.2	4.21	4.39e-05	0.0378	0.33	0.33	Urinary tract infection frequency;	chr8:142703082	chr8:143412749~143417054:+
UCEC	cis	rs1293970	1	rs1293987	ENSG00000273129.1	PACERR	4.21	4.39e-05	0.0378	0.35	0.33	Clozapine-induced cytotoxicity;	chr1:186296816	chr1:186680622~186681446:+
UCEC	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-4.21	4.39e-05	0.0378	-0.36	-0.33	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
UCEC	cis	rs6840360	0.642	rs2709838	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2724580	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.693	rs28622593	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2709834	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs6845648	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2724571	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2709833	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.667	rs2709832	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2709831	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2709816	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2709817	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2709818	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs7682770	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.667	rs9994482	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs11729923	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs7676059	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs7657747	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs4696089	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs11932398	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs4263379	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs12647555	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs1899550	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs7680013	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs7680236	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs4696092	ENSG00000251611.1	RP11-610P16.1	-4.21	4.4e-05	0.0378	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2724574	ENSG00000251611.1	RP11-610P16.1	4.21	4.4e-05	0.0378	0.27	0.33	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151407551~151408835:-
UCEC	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.34	0.33	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs10950025	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66158946	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.52	rs12666485	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66160135	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs67688847	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66161064	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs7787063	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66164012	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs12673308	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66166374	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs67397473	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66168318	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs10950027	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66169164	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs73376401	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66174841	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs6460276	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66182290	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs67775320	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66193792	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs6460281	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66216128	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs17138149	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66228193	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs17138156	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66249708	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs1547529	ENSG00000236529.1	RP13-254B10.1	4.21	4.4e-05	0.0378	0.48	0.33	Aortic root size;	chr7:66258859	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs316324	ENSG00000236529.1	RP13-254B10.1	-4.21	4.4e-05	0.0378	-0.48	-0.33	Aortic root size;	chr7:66145627	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs316323	ENSG00000236529.1	RP13-254B10.1	-4.21	4.4e-05	0.0378	-0.48	-0.33	Aortic root size;	chr7:66146002	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs316305	ENSG00000236529.1	RP13-254B10.1	-4.21	4.4e-05	0.0378	-0.48	-0.33	Aortic root size;	chr7:66152984	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs316306	ENSG00000236529.1	RP13-254B10.1	-4.21	4.4e-05	0.0378	-0.48	-0.33	Aortic root size;	chr7:66153687	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs2460427	ENSG00000236529.1	RP13-254B10.1	-4.21	4.4e-05	0.0378	-0.48	-0.33	Aortic root size;	chr7:66154218	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	4.21	4.41e-05	0.0378	0.37	0.33	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	4.21	4.41e-05	0.0378	0.37	0.33	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	4.21	4.41e-05	0.0378	0.37	0.33	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	4.21	4.41e-05	0.0378	0.37	0.33	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	4.21	4.41e-05	0.0378	0.37	0.33	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
UCEC	cis	rs9545047	0.967	rs9593396	ENSG00000227354.5	RBM26-AS1	4.21	4.41e-05	0.0378	0.36	0.33	Schizophrenia;	chr13:79396164	chr13:79406309~79424328:+
UCEC	cis	rs9545047	1	rs9545101	ENSG00000227354.5	RBM26-AS1	4.21	4.41e-05	0.0378	0.36	0.33	Schizophrenia;	chr13:79399806	chr13:79406309~79424328:+
UCEC	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-4.21	4.42e-05	0.0379	-0.37	-0.33	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
UCEC	cis	rs875971	0.862	rs2909688	ENSG00000236529.1	RP13-254B10.1	4.21	4.42e-05	0.0379	0.39	0.33	Aortic root size;	chr7:66376625	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.83	rs778711	ENSG00000236529.1	RP13-254B10.1	4.21	4.42e-05	0.0379	0.39	0.33	Aortic root size;	chr7:66386670	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs1083554	ENSG00000236529.1	RP13-254B10.1	4.21	4.42e-05	0.0379	0.39	0.33	Aortic root size;	chr7:66387354	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs778707	ENSG00000236529.1	RP13-254B10.1	4.21	4.42e-05	0.0379	0.39	0.33	Aortic root size;	chr7:66392040	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs778705	ENSG00000236529.1	RP13-254B10.1	4.21	4.42e-05	0.0379	0.39	0.33	Aortic root size;	chr7:66396128	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs778697	ENSG00000236529.1	RP13-254B10.1	4.21	4.42e-05	0.0379	0.39	0.33	Aortic root size;	chr7:66405439	chr7:65840212~65840596:+
UCEC	cis	rs13053175	0.967	rs35435644	ENSG00000278420.1	MIR6819	4.21	4.44e-05	0.038	0.35	0.33	Longevity;	chr22:37217119	chr22:36286847~36286907:-
UCEC	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-4.21	4.44e-05	0.0381	-0.38	-0.33	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
UCEC	cis	rs1031391	0.716	rs10772416	ENSG00000247157.5	LINC01252	-4.21	4.44e-05	0.0381	-0.43	-0.33	Bitter taste perception;	chr12:11017488	chr12:11548030~11590369:+
UCEC	cis	rs6540731	0.54	rs7548606	ENSG00000237980.1	RP11-338C15.3	-4.21	4.45e-05	0.0381	-0.47	-0.33	Intelligence (childhood);	chr1:212215265	chr1:212653999~212665434:-
UCEC	cis	rs2445284	0.874	rs2034839	ENSG00000229534.1	HNRNPA1P53	4.21	4.45e-05	0.0381	0.4	0.33	Sickle cell anemia (haemolysis);	chr11:5039711	chr11:5571247~5572192:-
UCEC	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-4.21	4.45e-05	0.0382	-0.39	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
UCEC	cis	rs6840360	0.642	rs7677131	ENSG00000251611.1	RP11-610P16.1	-4.21	4.46e-05	0.0382	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151407551~151408835:-
UCEC	cis	rs875971	1	rs12698523	ENSG00000236529.1	RP13-254B10.1	4.21	4.46e-05	0.0382	0.36	0.33	Aortic root size;	chr7:66503126	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs6970030	ENSG00000236529.1	RP13-254B10.1	4.21	4.46e-05	0.0382	0.36	0.33	Aortic root size;	chr7:66503692	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.928	rs6970357	ENSG00000236529.1	RP13-254B10.1	4.21	4.46e-05	0.0382	0.36	0.33	Aortic root size;	chr7:66503891	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs3735148	ENSG00000236529.1	RP13-254B10.1	4.21	4.46e-05	0.0382	0.36	0.33	Aortic root size;	chr7:66506022	chr7:65840212~65840596:+
UCEC	cis	rs7914558	1	rs7094843	ENSG00000272912.1	RP11-724N1.1	-4.21	4.46e-05	0.0382	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103046897	chr10:102914585~102915404:+
UCEC	cis	rs7914558	1	rs4917994	ENSG00000272912.1	RP11-724N1.1	-4.21	4.46e-05	0.0382	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:102914585~102915404:+
UCEC	cis	rs7914558	1	rs2275271	ENSG00000272912.1	RP11-724N1.1	-4.21	4.46e-05	0.0382	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:102914585~102915404:+
UCEC	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	4.21	4.46e-05	0.0382	0.33	0.33	Height;	chr6:109424305	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	4.21	4.46e-05	0.0382	0.33	0.33	Height;	chr6:109425054	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	4.21	4.46e-05	0.0382	0.33	0.33	Height;	chr6:109427644	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	4.21	4.46e-05	0.0382	0.33	0.33	Height;	chr6:109430292	chr6:109382795~109383666:+
UCEC	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-4.21	4.46e-05	0.0382	-0.3	-0.33	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-4.21	4.46e-05	0.0382	-0.3	-0.33	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-4.21	4.46e-05	0.0382	-0.3	-0.33	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
UCEC	cis	rs9545047	0.604	rs1853830	ENSG00000227354.5	RBM26-AS1	-4.21	4.46e-05	0.0382	-0.32	-0.33	Schizophrenia;	chr13:79406877	chr13:79406309~79424328:+
UCEC	cis	rs2991971	0.901	rs11211122	ENSG00000280836.1	AL355480.1	4.21	4.46e-05	0.0382	0.37	0.33	High light scatter reticulocyte count;	chr1:45488978	chr1:45581219~45581321:-
UCEC	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-4.21	4.47e-05	0.0382	-0.4	-0.33	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
UCEC	cis	rs62025270	0.688	rs55738258	ENSG00000202081.1	RNU6-1280P	-4.21	4.47e-05	0.0382	-0.44	-0.33	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85651522~85651628:-
UCEC	cis	rs62025270	0.688	rs55957626	ENSG00000202081.1	RNU6-1280P	-4.21	4.47e-05	0.0382	-0.44	-0.33	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85651522~85651628:-
UCEC	cis	rs853679	0.542	rs6934769	ENSG00000216901.1	AL022393.7	4.21	4.47e-05	0.0382	0.39	0.33	Depression;	chr6:28123153	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs17711801	ENSG00000216901.1	AL022393.7	4.21	4.47e-05	0.0382	0.39	0.33	Depression;	chr6:28124529	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.527	rs9461433	ENSG00000216901.1	AL022393.7	4.21	4.47e-05	0.0382	0.39	0.33	Parkinson's disease;	chr6:28127394	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs9468292	ENSG00000216901.1	AL022393.7	4.21	4.47e-05	0.0382	0.39	0.33	Depression;	chr6:28127577	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs1947863	ENSG00000216901.1	AL022393.7	4.21	4.47e-05	0.0382	0.39	0.33	Depression;	chr6:28131566	chr6:28176188~28176674:+
UCEC	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	4.21	4.47e-05	0.0383	0.38	0.33	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
UCEC	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	4.21	4.47e-05	0.0383	0.38	0.33	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
UCEC	cis	rs7240205	0.657	rs1111208	ENSG00000275805.1	RP11-349H17.2	-4.21	4.48e-05	0.0383	-0.38	-0.33	Breast cancer;	chr18:26545901	chr18:26565723~26575626:-
UCEC	cis	rs617219	0.698	rs12189248	ENSG00000245556.2	SCAMP1-AS1	-4.2	4.49e-05	0.0384	-0.31	-0.33	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79221320	chr5:78342365~78360507:-
UCEC	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	4.2	4.49e-05	0.0384	0.39	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
UCEC	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-4.2	4.49e-05	0.0384	-0.35	-0.33	Height;	chr11:118749988	chr11:118704607~118750263:+
UCEC	cis	rs7246967	0.611	rs8102927	ENSG00000198153.8	ZNF849P	-4.2	4.49e-05	0.0384	-0.53	-0.33	Bronchopulmonary dysplasia;	chr19:22696554	chr19:22685167~22686732:+
UCEC	cis	rs875971	0.862	rs4236208	ENSG00000236529.1	RP13-254B10.1	-4.2	4.5e-05	0.0384	-0.37	-0.33	Aortic root size;	chr7:66284091	chr7:65840212~65840596:+
UCEC	cis	rs10895275	0.884	rs8504	ENSG00000277459.1	RP11-732A21.3	-4.2	4.5e-05	0.0385	-0.31	-0.33	Migraine;	chr11:102232869	chr11:102109827~102110457:-
UCEC	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-4.2	4.5e-05	0.0385	-0.37	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
UCEC	cis	rs6740462	0.537	rs116408193	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65445601	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs35824125	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65449925	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs34191258	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65451673	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs13032509	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65454885	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs35476092	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65454918	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs35490361	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65454955	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs35339087	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65455220	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs71424185	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65456461	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs35518316	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65456538	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs34479540	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65460661	chr2:65623272~65628424:+
UCEC	cis	rs6740462	0.568	rs62141139	ENSG00000281920.1	RP11-418H16.1	-4.2	4.51e-05	0.0385	-0.58	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:65463230	chr2:65623272~65628424:+
UCEC	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-4.2	4.51e-05	0.0385	-0.41	-0.33	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
UCEC	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-4.2	4.51e-05	0.0385	-0.39	-0.33	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
UCEC	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-4.2	4.51e-05	0.0385	-0.39	-0.33	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
UCEC	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-4.2	4.51e-05	0.0385	-0.41	-0.33	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
UCEC	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	4.2	4.52e-05	0.0386	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	4.2	4.52e-05	0.0386	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	4.2	4.52e-05	0.0386	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	4.2	4.52e-05	0.0386	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	4.2	4.52e-05	0.0386	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	4.2	4.52e-05	0.0386	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	4.2	4.52e-05	0.0386	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	4.2	4.52e-05	0.0386	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
UCEC	cis	rs763121	0.853	rs5750671	ENSG00000273076.1	RP3-508I15.22	4.2	4.53e-05	0.0386	0.35	0.33	Menopause (age at onset);	chr22:38698614	chr22:38743495~38743910:+
UCEC	cis	rs763121	0.853	rs926299	ENSG00000273076.1	RP3-508I15.22	4.2	4.53e-05	0.0386	0.35	0.33	Menopause (age at onset);	chr22:38699693	chr22:38743495~38743910:+
UCEC	cis	rs763121	0.785	rs6001203	ENSG00000273076.1	RP3-508I15.22	4.2	4.53e-05	0.0386	0.35	0.33	Menopause (age at onset);	chr22:38703597	chr22:38743495~38743910:+
UCEC	cis	rs763121	0.853	rs6001204	ENSG00000273076.1	RP3-508I15.22	4.2	4.53e-05	0.0386	0.35	0.33	Menopause (age at onset);	chr22:38704234	chr22:38743495~38743910:+
UCEC	cis	rs763121	0.853	rs5757253	ENSG00000273076.1	RP3-508I15.22	4.2	4.53e-05	0.0386	0.35	0.33	Menopause (age at onset);	chr22:38708315	chr22:38743495~38743910:+
UCEC	cis	rs11651753	0.636	rs4794332	ENSG00000266601.1	RP11-6N17.3	4.2	4.53e-05	0.0386	0.37	0.33	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47929682~47933106:-
UCEC	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-4.2	4.53e-05	0.0386	-0.42	-0.33	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
UCEC	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	4.2	4.53e-05	0.0386	0.37	0.33	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
UCEC	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	4.2	4.53e-05	0.0386	0.34	0.33	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
UCEC	cis	rs12289961	0.634	rs11229378	ENSG00000280010.1	AP001350.4	4.2	4.53e-05	0.0386	0.63	0.33	Lymphoma;	chr11:58364344	chr11:58627435~58628528:+
UCEC	cis	rs12289961	0.634	rs77183714	ENSG00000280010.1	AP001350.4	4.2	4.53e-05	0.0386	0.63	0.33	Lymphoma;	chr11:58364460	chr11:58627435~58628528:+
UCEC	cis	rs12289961	0.634	rs11229433	ENSG00000280010.1	AP001350.4	4.2	4.53e-05	0.0386	0.63	0.33	Lymphoma;	chr11:58417863	chr11:58627435~58628528:+
UCEC	cis	rs6137726	0.524	rs1203953	ENSG00000277901.1	RP5-851M4.1	4.2	4.53e-05	0.0386	0.41	0.33	Amyotrophic lateral sclerosis (sporadic);	chr20:22635505	chr20:23320958~23325352:-
UCEC	cis	rs6048205	0.881	rs73902879	ENSG00000277901.1	RP5-851M4.1	-4.2	4.54e-05	0.0387	-0.58	-0.33	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr20:22540048	chr20:23320958~23325352:-
UCEC	cis	rs922692	0.744	rs12903203	ENSG00000261143.1	ADAMTS7P3	4.2	4.54e-05	0.0387	0.46	0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78792591	chr15:77976042~77993057:+
UCEC	cis	rs6687821	0.515	rs11161914	ENSG00000267734.1	RP4-604K5.3	-4.2	4.55e-05	0.0387	-0.34	-0.33	Yeast infection;	chr1:86977846	chr1:86932199~86934891:-
UCEC	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	4.2	4.55e-05	0.0388	0.41	0.33	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
UCEC	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	4.2	4.55e-05	0.0388	0.36	0.33	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	4.2	4.55e-05	0.0388	0.36	0.33	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	4.2	4.55e-05	0.0388	0.36	0.33	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	4.2	4.55e-05	0.0388	0.36	0.33	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
UCEC	cis	rs10232172	0.673	rs5006078	ENSG00000234707.2	RP11-745C15.2	-4.2	4.56e-05	0.0388	-0.49	-0.33	Periodontal disease-related phenotypes;	chr7:54098975	chr7:54759425~54804928:+
UCEC	cis	rs10232172	0.778	rs1524387	ENSG00000234707.2	RP11-745C15.2	-4.2	4.56e-05	0.0388	-0.49	-0.33	Periodontal disease-related phenotypes;	chr7:54098980	chr7:54759425~54804928:+
UCEC	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	4.2	4.56e-05	0.0388	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	4.2	4.56e-05	0.0388	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	4.2	4.56e-05	0.0388	0.37	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-4.2	4.57e-05	0.0389	-0.36	-0.33	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-4.2	4.57e-05	0.0389	-0.36	-0.33	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-4.2	4.57e-05	0.0389	-0.36	-0.33	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-4.2	4.57e-05	0.0389	-0.36	-0.33	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
UCEC	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-4.2	4.58e-05	0.0389	-0.35	-0.33	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
UCEC	cis	rs9907295	1	rs11653282	ENSG00000270871.1	AC015849.19	4.2	4.58e-05	0.0389	0.37	0.33	Fibroblast growth factor basic levels;	chr17:35909742	chr17:35816717~35830293:-
UCEC	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	4.2	4.58e-05	0.039	0.41	0.33	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
UCEC	cis	rs1185460	0.967	rs2509121	ENSG00000278376.1	RP11-158I9.8	-4.2	4.58e-05	0.039	-0.34	-0.33	Coronary artery disease;	chr11:119057542	chr11:118791254~118793137:+
UCEC	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	4.2	4.59e-05	0.039	0.34	0.33	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
UCEC	cis	rs7914558	0.966	rs10786745	ENSG00000272912.1	RP11-724N1.1	-4.2	4.59e-05	0.039	-0.32	-0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103197070	chr10:102914585~102915404:+
UCEC	cis	rs6840360	0.607	rs2724565	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2724568	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs7657670	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.606	rs2709813	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.606	rs2724550	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2709815	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2709825	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.607	rs2724547	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2724578	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.574	rs2709844	ENSG00000251611.1	RP11-610P16.1	-4.2	4.59e-05	0.039	-0.27	-0.33	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151407551~151408835:-
UCEC	cis	rs507080	0.922	rs625513	ENSG00000278376.1	RP11-158I9.8	-4.2	4.59e-05	0.039	-0.32	-0.33	Serum metabolite levels;	chr11:118685010	chr11:118791254~118793137:+
UCEC	cis	rs2445284	0.817	rs2500040	ENSG00000229534.1	HNRNPA1P53	-4.2	4.59e-05	0.039	-0.39	-0.33	Sickle cell anemia (haemolysis);	chr11:5053803	chr11:5571247~5572192:-
UCEC	cis	rs7267979	0.744	rs6050464	ENSG00000276952.1	RP5-965G21.6	4.2	4.6e-05	0.0391	0.42	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25284915~25285588:-
UCEC	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-4.2	4.6e-05	0.0391	-0.34	-0.33	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-4.2	4.6e-05	0.0391	-0.34	-0.33	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-4.2	4.6e-05	0.0391	-0.34	-0.33	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-4.2	4.6e-05	0.0391	-0.34	-0.33	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-4.2	4.6e-05	0.0391	-0.34	-0.33	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-4.2	4.6e-05	0.0391	-0.34	-0.33	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-4.2	4.6e-05	0.0391	-0.34	-0.33	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
UCEC	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-4.2	4.6e-05	0.0391	-0.35	-0.33	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
UCEC	cis	rs28386778	0.863	rs6504178	ENSG00000240280.5	TCAM1P	4.2	4.6e-05	0.0391	0.38	0.33	Prudent dietary pattern;	chr17:63735373	chr17:63849292~63864379:+
UCEC	cis	rs507080	0.922	rs546890	ENSG00000278376.1	RP11-158I9.8	-4.2	4.6e-05	0.0391	-0.31	-0.33	Serum metabolite levels;	chr11:118686489	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.922	rs555356	ENSG00000278376.1	RP11-158I9.8	-4.2	4.6e-05	0.0391	-0.31	-0.33	Serum metabolite levels;	chr11:118687369	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.883	rs693306	ENSG00000278376.1	RP11-158I9.8	-4.2	4.6e-05	0.0391	-0.31	-0.33	Serum metabolite levels;	chr11:118687624	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.922	rs561845	ENSG00000278376.1	RP11-158I9.8	-4.2	4.6e-05	0.0391	-0.31	-0.33	Serum metabolite levels;	chr11:118688118	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.922	rs638805	ENSG00000278376.1	RP11-158I9.8	-4.2	4.6e-05	0.0391	-0.31	-0.33	Serum metabolite levels;	chr11:118688180	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.845	rs510408	ENSG00000278376.1	RP11-158I9.8	-4.2	4.6e-05	0.0391	-0.31	-0.33	Serum metabolite levels;	chr11:118688192	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.845	rs509641	ENSG00000278376.1	RP11-158I9.8	-4.2	4.6e-05	0.0391	-0.31	-0.33	Serum metabolite levels;	chr11:118688243	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.883	rs563549	ENSG00000278376.1	RP11-158I9.8	-4.2	4.6e-05	0.0391	-0.31	-0.33	Serum metabolite levels;	chr11:118688244	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.885	rs533144	ENSG00000278376.1	RP11-158I9.8	-4.2	4.6e-05	0.0391	-0.31	-0.33	Serum metabolite levels;	chr11:118688538	chr11:118791254~118793137:+
UCEC	cis	rs28386778	0.897	rs9912557	ENSG00000240280.5	TCAM1P	-4.2	4.6e-05	0.0391	-0.38	-0.33	Prudent dietary pattern;	chr17:63707603	chr17:63849292~63864379:+
UCEC	cis	rs28386778	0.897	rs7210443	ENSG00000240280.5	TCAM1P	-4.2	4.6e-05	0.0391	-0.38	-0.33	Prudent dietary pattern;	chr17:63708014	chr17:63849292~63864379:+
UCEC	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-4.2	4.6e-05	0.0391	-0.38	-0.33	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
UCEC	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-4.2	4.6e-05	0.0391	-0.38	-0.33	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
UCEC	cis	rs950169	0.649	rs12905952	ENSG00000225151.9	GOLGA2P7	-4.2	4.61e-05	0.0391	-0.55	-0.33	Schizophrenia;	chr15:84022509	chr15:84199311~84230136:-
UCEC	cis	rs950169	0.61	rs34529571	ENSG00000225151.9	GOLGA2P7	-4.2	4.61e-05	0.0391	-0.55	-0.33	Schizophrenia;	chr15:84023055	chr15:84199311~84230136:-
UCEC	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	4.2	4.61e-05	0.0391	0.43	0.33	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
UCEC	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	4.2	4.61e-05	0.0392	0.38	0.33	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
UCEC	cis	rs34792	0.637	rs2450356	ENSG00000275910.1	RP11-680G24.6	4.2	4.62e-05	0.0392	0.36	0.33	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:15015828~15016390:-
UCEC	cis	rs7760535	0.826	rs3777905	ENSG00000271789.1	RP5-1112D6.7	-4.2	4.63e-05	0.0392	-0.39	-0.33	Metabolic traits;	chr6:111549385	chr6:111297126~111298510:+
UCEC	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	4.2	4.63e-05	0.0393	0.36	0.33	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
UCEC	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-4.2	4.63e-05	0.0393	-0.43	-0.33	Height;	chr3:53070344	chr3:53064283~53065091:-
UCEC	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-4.2	4.64e-05	0.0394	-0.38	-0.33	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-4.2	4.64e-05	0.0394	-0.38	-0.33	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-4.2	4.64e-05	0.0394	-0.38	-0.33	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-4.2	4.64e-05	0.0394	-0.38	-0.33	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-4.2	4.64e-05	0.0394	-0.38	-0.33	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
UCEC	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	4.2	4.64e-05	0.0394	0.56	0.33	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
UCEC	cis	rs6840360	0.642	rs10454251	ENSG00000270265.1	RP11-731D1.4	-4.2	4.64e-05	0.0394	-0.31	-0.33	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151333775~151353224:-
UCEC	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-4.2	4.64e-05	0.0394	-0.41	-0.33	Height;	chr3:53069965	chr3:53064283~53065091:-
UCEC	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-4.2	4.65e-05	0.0394	-0.39	-0.33	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
UCEC	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	4.2	4.65e-05	0.0394	0.4	0.33	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-4.2	4.65e-05	0.0394	-0.35	-0.33	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-4.2	4.65e-05	0.0394	-0.35	-0.33	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
UCEC	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-4.2	4.66e-05	0.0394	-0.35	-0.33	Height;	chr11:118761813	chr11:118704607~118750263:+
UCEC	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-4.2	4.66e-05	0.0394	-0.42	-0.33	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
UCEC	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	4.2	4.66e-05	0.0394	0.4	0.33	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	4.2	4.66e-05	0.0394	0.4	0.33	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	4.2	4.66e-05	0.0394	0.4	0.33	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
UCEC	cis	rs67478160	0.572	rs8015603	ENSG00000270108.1	RP11-73M18.6	-4.2	4.66e-05	0.0395	-0.35	-0.33	Schizophrenia;	chr14:103827341	chr14:103687576~103688127:+
UCEC	cis	rs4073582	0.595	rs3016319	ENSG00000255320.1	RP11-755F10.1	-4.2	4.66e-05	0.0395	-0.44	-0.33	Gout;	chr11:66214375	chr11:66244840~66246239:-
UCEC	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	4.19	4.67e-05	0.0395	0.36	0.32	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
UCEC	cis	rs7170668	0.93	rs4984581	ENSG00000260521.2	CTD-2576F9.1	-4.19	4.67e-05	0.0395	-0.35	-0.32	Motion sickness;	chr15:95472992	chr15:94855474~94856914:+
UCEC	cis	rs7170668	0.93	rs12910890	ENSG00000260521.2	CTD-2576F9.1	-4.19	4.67e-05	0.0395	-0.35	-0.32	Motion sickness;	chr15:95473444	chr15:94855474~94856914:+
UCEC	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-4.19	4.68e-05	0.0396	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
UCEC	cis	rs9545047	0.935	rs1475797	ENSG00000227354.5	RBM26-AS1	-4.19	4.68e-05	0.0396	-0.36	-0.32	Schizophrenia;	chr13:79519690	chr13:79406309~79424328:+
UCEC	cis	rs677325	0.604	rs6676832	ENSG00000232498.1	RP5-1011O1.2	4.19	4.68e-05	0.0396	0.51	0.32	Subjective well-being (multi-trait analysis);	chr1:191608539	chr1:192517639~192567217:-
UCEC	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-4.19	4.68e-05	0.0396	-0.3	-0.32	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-4.19	4.68e-05	0.0396	-0.3	-0.32	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
UCEC	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	4.19	4.68e-05	0.0396	0.39	0.32	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	4.19	4.68e-05	0.0396	0.39	0.32	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	4.19	4.68e-05	0.0396	0.39	0.32	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
UCEC	cis	rs10740039	0.734	rs10821831	ENSG00000254271.1	RP11-131N11.4	4.19	4.68e-05	0.0396	0.38	0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60720717	chr10:60734342~60741828:+
UCEC	cis	rs853679	0.55	rs6901017	ENSG00000216901.1	AL022393.7	4.19	4.69e-05	0.0396	0.4	0.32	Depression;	chr6:28184805	chr6:28176188~28176674:+
UCEC	cis	rs35824328	0.666	rs10932534	ENSG00000230076.1	AC016708.2	-4.19	4.69e-05	0.0396	-0.35	-0.32	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214335263	chr2:214847128~214847445:+
UCEC	cis	rs35824328	0.571	rs6744356	ENSG00000230076.1	AC016708.2	-4.19	4.69e-05	0.0396	-0.35	-0.32	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214335644	chr2:214847128~214847445:+
UCEC	cis	rs35824328	0.666	rs4673819	ENSG00000230076.1	AC016708.2	-4.19	4.69e-05	0.0396	-0.35	-0.32	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214336048	chr2:214847128~214847445:+
UCEC	cis	rs35824328	0.666	rs1995842	ENSG00000230076.1	AC016708.2	-4.19	4.69e-05	0.0396	-0.35	-0.32	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214336782	chr2:214847128~214847445:+
UCEC	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-4.19	4.69e-05	0.0396	-0.42	-0.32	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
UCEC	cis	rs2276314	0.857	rs28396546	ENSG00000267627.4	RP11-905K4.1	-4.19	4.69e-05	0.0397	-0.4	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35951803~35966118:-
UCEC	cis	rs11603023	0.874	rs613243	ENSG00000278376.1	RP11-158I9.8	-4.19	4.69e-05	0.0397	-0.29	-0.32	Cholesterol, total;	chr11:118643304	chr11:118791254~118793137:+
UCEC	cis	rs4776970	0.632	rs8030996	ENSG00000260657.2	RP11-315D16.4	4.19	4.7e-05	0.0397	0.38	0.32	Body mass index;Waist circumference;	chr15:67739068	chr15:68267792~68277994:-
UCEC	cis	rs2445284	0.845	rs2500027	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5048183	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2445281	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5048563	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500030	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5048693	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500032	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5049199	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500033	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5049467	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500034	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5049526	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs3002639	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5050723	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2445316	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051037	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500036	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051268	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500037	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051327	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs35069595	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051391	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs11035337	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051408	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2959183	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051477	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs3002641	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051540	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs3002642	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051592	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2445317	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051712	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.79	rs3002643	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051903	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.79	rs2445318	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5051910	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.79	rs2500038	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5052290	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.764	rs2445320	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5052304	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs1378748	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5053071	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500039	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5053300	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2445323	ENSG00000229534.1	HNRNPA1P53	-4.19	4.7e-05	0.0397	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5053715	chr11:5571247~5572192:-
UCEC	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-4.19	4.7e-05	0.0397	-0.45	-0.32	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
UCEC	cis	rs709400	1	rs58133129	ENSG00000259775.1	RP11-45P15.4	4.19	4.7e-05	0.0397	0.4	0.32	Body mass index;	chr14:103638422	chr14:103331674~103332367:-
UCEC	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	4.19	4.7e-05	0.0397	0.36	0.32	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
UCEC	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	4.19	4.71e-05	0.0397	0.4	0.32	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
UCEC	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-4.19	4.71e-05	0.0397	-0.3	-0.32	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-4.19	4.71e-05	0.0397	-0.3	-0.32	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	4.19	4.71e-05	0.0397	0.3	0.32	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	4.19	4.71e-05	0.0397	0.3	0.32	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	4.19	4.71e-05	0.0397	0.3	0.32	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	4.19	4.71e-05	0.0397	0.3	0.32	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	4.19	4.71e-05	0.0397	0.3	0.32	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	4.19	4.71e-05	0.0397	0.3	0.32	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	4.19	4.71e-05	0.0397	0.3	0.32	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.935	rs11772264	ENSG00000224316.1	RP11-479O9.2	4.19	4.71e-05	0.0397	0.3	0.32	Aortic root size;	chr7:66711400	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	4.19	4.71e-05	0.0397	0.3	0.32	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
UCEC	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	4.19	4.71e-05	0.0397	0.49	0.32	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
UCEC	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	4.19	4.71e-05	0.0398	0.39	0.32	Depression;	chr6:28109824	chr6:28115628~28116551:+
UCEC	cis	rs62025270	0.631	rs55968154	ENSG00000202081.1	RNU6-1280P	-4.19	4.72e-05	0.0398	-0.47	-0.32	Idiopathic pulmonary fibrosis;	chr15:85725399	chr15:85651522~85651628:-
UCEC	cis	rs62025270	0.688	rs55851385	ENSG00000202081.1	RNU6-1280P	-4.19	4.72e-05	0.0398	-0.47	-0.32	Idiopathic pulmonary fibrosis;	chr15:85725400	chr15:85651522~85651628:-
UCEC	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	4.19	4.72e-05	0.0398	0.35	0.32	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
UCEC	cis	rs948562	0.744	rs12362087	ENSG00000280010.1	AP001350.4	4.19	4.73e-05	0.0399	0.5	0.32	Lymphoma;	chr11:58456447	chr11:58627435~58628528:+
UCEC	cis	rs9907295	0.581	rs4251751	ENSG00000270871.1	AC015849.19	4.19	4.73e-05	0.0399	0.52	0.32	Fibroblast growth factor basic levels;	chr17:35823733	chr17:35816717~35830293:-
UCEC	cis	rs9907295	0.748	rs4251752	ENSG00000270871.1	AC015849.19	4.19	4.73e-05	0.0399	0.52	0.32	Fibroblast growth factor basic levels;	chr17:35823900	chr17:35816717~35830293:-
UCEC	cis	rs35914442	0.708	rs6994642	ENSG00000254432.1	RP11-33I11.2	-4.19	4.73e-05	0.0399	-0.43	-0.32	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;	chr8:60811218	chr8:60808735~60809606:-
UCEC	cis	rs17826219	0.706	rs2322197	ENSG00000266490.1	CTD-2349P21.9	4.19	4.74e-05	0.0399	0.43	0.32	Body mass index;	chr17:30778787	chr17:30792372~30792833:+
UCEC	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-4.19	4.74e-05	0.0399	-0.4	-0.32	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
UCEC	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-4.19	4.74e-05	0.0399	-0.3	-0.32	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-4.19	4.74e-05	0.0399	-0.3	-0.32	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-4.19	4.74e-05	0.0399	-0.3	-0.32	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-4.19	4.74e-05	0.0399	-0.3	-0.32	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-4.19	4.74e-05	0.0399	-0.3	-0.32	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
UCEC	cis	rs2732480	0.538	rs2468943	ENSG00000273765.1	RP11-370I10.11	-4.19	4.74e-05	0.0399	-0.41	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48360920~48361377:+
UCEC	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	4.19	4.75e-05	0.04	0.38	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
UCEC	cis	rs7160336	0.641	rs10136002	ENSG00000259065.1	RP5-1021I20.1	-4.19	4.75e-05	0.04	-0.39	-0.32	Blood protein levels;	chr14:74215072	chr14:73787360~73803270:+
UCEC	cis	rs7160336	0.604	rs10149539	ENSG00000259065.1	RP5-1021I20.1	-4.19	4.75e-05	0.04	-0.39	-0.32	Blood protein levels;	chr14:74215524	chr14:73787360~73803270:+
UCEC	cis	rs875971	1	rs778706	ENSG00000236529.1	RP13-254B10.1	4.19	4.75e-05	0.04	0.36	0.32	Aortic root size;	chr7:66395437	chr7:65840212~65840596:+
UCEC	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-4.19	4.75e-05	0.04	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
UCEC	cis	rs686320	1	rs679643	ENSG00000245532.5	NEAT1	4.19	4.75e-05	0.04	0.44	0.32	Hip circumference adjusted for BMI;	chr11:65483119	chr11:65422774~65445540:+
UCEC	cis	rs6901004	0.803	rs9320360	ENSG00000271789.1	RP5-1112D6.7	-4.19	4.76e-05	0.04	-0.38	-0.32	Blood metabolite levels;	chr6:111141069	chr6:111297126~111298510:+
UCEC	cis	rs6901004	0.835	rs1150079	ENSG00000271789.1	RP5-1112D6.7	-4.19	4.76e-05	0.04	-0.38	-0.32	Blood metabolite levels;	chr6:111150222	chr6:111297126~111298510:+
UCEC	cis	rs7760535	0.757	rs10456875	ENSG00000271789.1	RP5-1112D6.7	-4.19	4.76e-05	0.04	-0.4	-0.32	Metabolic traits;	chr6:111428522	chr6:111297126~111298510:+
UCEC	cis	rs9400467	0.528	rs4276544	ENSG00000271789.1	RP5-1112D6.7	-4.19	4.76e-05	0.04	-0.4	-0.32	Amino acid levels;Blood metabolite levels;	chr6:111438496	chr6:111297126~111298510:+
UCEC	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
UCEC	cis	rs12478296	1	rs6743297	ENSG00000261186.2	RP11-341N2.1	-4.19	4.76e-05	0.0401	-0.42	-0.32	Obesity-related traits;	chr2:242071663	chr2:242087351~242088457:-
UCEC	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-4.19	4.76e-05	0.0401	-0.3	-0.32	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-4.19	4.76e-05	0.0401	-0.3	-0.32	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs7782320	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66712111	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	4.19	4.76e-05	0.0401	0.3	0.32	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
UCEC	cis	rs28386778	0.863	rs1376110	ENSG00000240280.5	TCAM1P	-4.19	4.77e-05	0.0401	-0.38	-0.32	Prudent dietary pattern;	chr17:63702567	chr17:63849292~63864379:+
UCEC	cis	rs28386778	0.863	rs9897229	ENSG00000240280.5	TCAM1P	-4.19	4.77e-05	0.0401	-0.38	-0.32	Prudent dietary pattern;	chr17:63704965	chr17:63849292~63864379:+
UCEC	cis	rs677325	0.866	rs6428061	ENSG00000232498.1	RP5-1011O1.2	-4.19	4.77e-05	0.0401	-0.48	-0.32	Subjective well-being (multi-trait analysis);	chr1:191569900	chr1:192517639~192567217:-
UCEC	cis	rs2276314	0.857	rs56230698	ENSG00000267627.4	RP11-905K4.1	-4.19	4.77e-05	0.0401	-0.38	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35951803~35966118:-
UCEC	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-4.19	4.77e-05	0.0401	-0.4	-0.32	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
UCEC	cis	rs6547705	1	rs6547705	ENSG00000231351.2	AC111200.7	4.19	4.77e-05	0.0401	0.56	0.32	Progressive supranuclear palsy;	chr2:86817193	chr2:86930250~86930754:-
UCEC	cis	rs36032232	1	rs67706488	ENSG00000240163.1	RP11-745A24.1	4.19	4.77e-05	0.0401	0.55	0.32	Blood protein levels;	chr15:60438964	chr15:60390371~60390682:+
UCEC	cis	rs2817782	0.527	rs9374182	ENSG00000272356.1	RP5-1112D6.8	4.19	4.77e-05	0.0401	0.41	0.32	Electroencephalogram traits;	chr6:110557228	chr6:111309203~111313517:+
UCEC	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	4.19	4.77e-05	0.0401	0.35	0.32	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
UCEC	cis	rs11818084	0.564	rs10794182	ENSG00000278831.1	RP11-12J10.4	4.19	4.77e-05	0.0401	0.31	0.32	Clozapine-induced cytotoxicity;	chr10:124291739	chr10:124623353~124624079:+
UCEC	cis	rs10740039	0.766	rs2119917	ENSG00000254271.1	RP11-131N11.4	4.19	4.78e-05	0.0402	0.38	0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677626	chr10:60734342~60741828:+
UCEC	cis	rs948562	0.69	rs734777	ENSG00000280010.1	AP001350.4	4.19	4.79e-05	0.0402	0.66	0.32	Lymphoma;	chr11:58343636	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.69	rs17473544	ENSG00000280010.1	AP001350.4	4.19	4.79e-05	0.0402	0.66	0.32	Lymphoma;	chr11:58388994	chr11:58627435~58628528:+
UCEC	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-4.19	4.79e-05	0.0403	-0.3	-0.32	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
UCEC	cis	rs9309473	0.528	rs11126395	ENSG00000163016.8	ALMS1P	4.19	4.79e-05	0.0403	0.35	0.32	Metabolite levels;	chr2:73337836	chr2:73644919~73685576:+
UCEC	cis	rs9309473	0.528	rs11898362	ENSG00000163016.8	ALMS1P	4.19	4.79e-05	0.0403	0.35	0.32	Metabolite levels;	chr2:73338165	chr2:73644919~73685576:+
UCEC	cis	rs7188861	0.768	rs423674	ENSG00000262420.3	RP11-490O6.2	4.19	4.8e-05	0.0403	0.44	0.32	HDL cholesterol;	chr16:11279548	chr16:11741910~11744506:+
UCEC	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-4.19	4.8e-05	0.0403	-0.42	-0.32	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
UCEC	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	4.19	4.8e-05	0.0403	0.35	0.32	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
UCEC	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	4.19	4.8e-05	0.0403	0.41	0.32	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
UCEC	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-4.19	4.8e-05	0.0403	-0.41	-0.32	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
UCEC	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-4.19	4.8e-05	0.0403	-0.41	-0.32	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
UCEC	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	4.19	4.81e-05	0.0404	0.37	0.32	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
UCEC	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	4.19	4.82e-05	0.0404	0.5	0.32	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
UCEC	cis	rs1185460	1	rs1614264	ENSG00000278376.1	RP11-158I9.8	-4.19	4.82e-05	0.0405	-0.29	-0.32	Coronary artery disease;	chr11:119071928	chr11:118791254~118793137:+
UCEC	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-4.19	4.83e-05	0.0405	-0.42	-0.32	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
UCEC	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	4.19	4.83e-05	0.0405	0.42	0.32	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	4.19	4.83e-05	0.0405	0.42	0.32	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	4.19	4.83e-05	0.0405	0.42	0.32	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
UCEC	cis	rs9545047	0.604	rs7331867	ENSG00000227354.5	RBM26-AS1	-4.19	4.84e-05	0.0406	-0.32	-0.32	Schizophrenia;	chr13:79418791	chr13:79406309~79424328:+
UCEC	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-4.19	4.84e-05	0.0406	-0.35	-0.32	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
UCEC	cis	rs853679	0.55	rs1233707	ENSG00000216901.1	AL022393.7	4.19	4.84e-05	0.0406	0.39	0.32	Depression;	chr6:28205175	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-4.19	4.85e-05	0.0406	-0.39	-0.32	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
UCEC	cis	rs28386778	0.897	rs2044125	ENSG00000240280.5	TCAM1P	4.19	4.85e-05	0.0406	0.37	0.32	Prudent dietary pattern;	chr17:63785824	chr17:63849292~63864379:+
UCEC	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	4.19	4.85e-05	0.0407	0.42	0.32	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
UCEC	cis	rs853679	0.55	rs1150689	ENSG00000216901.1	AL022393.7	4.18	4.86e-05	0.0407	0.39	0.32	Depression;	chr6:28197321	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.55	rs1225599	ENSG00000216901.1	AL022393.7	4.18	4.86e-05	0.0407	0.39	0.32	Depression;	chr6:28197412	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.574	rs1233705	ENSG00000216901.1	AL022393.7	4.18	4.86e-05	0.0407	0.39	0.32	Depression;	chr6:28198669	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.55	rs1233704	ENSG00000216901.1	AL022393.7	-4.18	4.86e-05	0.0407	-0.39	-0.32	Depression;	chr6:28199145	chr6:28176188~28176674:+
UCEC	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-4.18	4.86e-05	0.0407	-0.3	-0.32	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-4.18	4.86e-05	0.0407	-0.3	-0.32	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
UCEC	cis	rs2445284	1	rs2445284	ENSG00000229534.1	HNRNPA1P53	-4.18	4.86e-05	0.0407	-0.4	-0.32	Sickle cell anemia (haemolysis);	chr11:5008473	chr11:5571247~5572192:-
UCEC	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	4.18	4.87e-05	0.0407	0.41	0.32	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	4.18	4.87e-05	0.0407	0.41	0.32	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	4.18	4.87e-05	0.0407	0.41	0.32	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
UCEC	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	4.18	4.87e-05	0.0407	0.41	0.32	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
UCEC	cis	rs875971	1	rs12532998	ENSG00000236529.1	RP13-254B10.1	4.18	4.87e-05	0.0407	0.36	0.32	Aortic root size;	chr7:66502472	chr7:65840212~65840596:+
UCEC	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	4.18	4.87e-05	0.0407	0.35	0.32	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
UCEC	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	4.18	4.87e-05	0.0408	0.78	0.32	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
UCEC	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	4.18	4.87e-05	0.0408	0.78	0.32	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
UCEC	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	4.18	4.87e-05	0.0408	0.78	0.32	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
UCEC	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	4.18	4.87e-05	0.0408	0.78	0.32	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
UCEC	cis	rs2239633	0.647	rs7157021	ENSG00000279656.1	RP11-298I3.6	4.18	4.87e-05	0.0408	0.38	0.32	Eosinophil percentage of white cells;Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Eosinophil percentage of granulocytes;Eosinophil counts;	chr14:23129743	chr14:23023083~23024217:-
UCEC	cis	rs11959928	0.673	rs700220	ENSG00000249740.1	OSMR-AS1	4.18	4.87e-05	0.0408	0.42	0.32	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr5:39356489	chr5:38736055~38845829:-
UCEC	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	4.18	4.87e-05	0.0408	0.34	0.32	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
UCEC	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-4.18	4.88e-05	0.0408	-0.37	-0.32	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
UCEC	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	4.18	4.88e-05	0.0408	0.39	0.32	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
UCEC	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-4.18	4.88e-05	0.0408	-0.31	-0.32	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.545	rs12670811	ENSG00000236529.1	RP13-254B10.1	4.18	4.89e-05	0.0409	0.48	0.32	Aortic root size;	chr7:66358032	chr7:65840212~65840596:+
UCEC	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-4.18	4.89e-05	0.0409	-0.41	-0.32	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
UCEC	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	4.18	4.9e-05	0.0409	0.5	0.32	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
UCEC	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	4.18	4.9e-05	0.0409	0.37	0.32	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
UCEC	cis	rs875971	0.83	rs6976714	ENSG00000236529.1	RP13-254B10.1	4.18	4.9e-05	0.041	0.39	0.32	Aortic root size;	chr7:66426474	chr7:65840212~65840596:+
UCEC	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-4.18	4.91e-05	0.041	-0.38	-0.32	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
UCEC	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	4.18	4.92e-05	0.041	0.26	0.32	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
UCEC	cis	rs17094222	0.577	rs72838576	ENSG00000233690.1	EBAG9P1	-4.18	4.92e-05	0.041	-0.45	-0.32	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);Body mass index;	chr10:100637946	chr10:99697407~99697949:-
UCEC	cis	rs6840360	0.642	rs10454251	ENSG00000251611.1	RP11-610P16.1	-4.18	4.92e-05	0.041	-0.28	-0.32	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151407551~151408835:-
UCEC	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	4.18	4.92e-05	0.041	0.42	0.32	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
UCEC	cis	rs2915495	0.618	rs2915501	ENSG00000253475.1	RP11-110G21.2	-4.18	4.93e-05	0.0411	-0.39	-0.32	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr8:51376530	chr8:51895957~51896374:-
UCEC	cis	rs6687821	0.515	rs10782587	ENSG00000267734.1	RP4-604K5.3	-4.18	4.93e-05	0.0411	-0.34	-0.32	Yeast infection;	chr1:86962204	chr1:86932199~86934891:-
UCEC	cis	rs6687821	0.515	rs12734749	ENSG00000267734.1	RP4-604K5.3	-4.18	4.93e-05	0.0411	-0.34	-0.32	Yeast infection;	chr1:86971063	chr1:86932199~86934891:-
UCEC	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-4.18	4.94e-05	0.0412	-0.39	-0.32	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
UCEC	cis	rs6137726	0.652	rs6036172	ENSG00000277901.1	RP5-851M4.1	-4.18	4.95e-05	0.0412	-0.39	-0.32	Amyotrophic lateral sclerosis (sporadic);	chr20:22670551	chr20:23320958~23325352:-
UCEC	cis	rs6137726	0.652	rs6048241	ENSG00000277901.1	RP5-851M4.1	4.18	4.95e-05	0.0412	0.39	0.32	Amyotrophic lateral sclerosis (sporadic);	chr20:22669505	chr20:23320958~23325352:-
UCEC	cis	rs492146	0.765	rs316133	ENSG00000243236.5	GSTA9P	-4.18	4.96e-05	0.0413	-0.41	-0.32	Epilepsy (remission after treatment);	chr6:52982753	chr6:52939726~52957521:-
UCEC	cis	rs6071166	0.683	rs6071101	ENSG00000224635.1	RP4-564F22.5	-4.18	4.96e-05	0.0413	-0.37	-0.32	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689335	chr20:38406011~38416797:-
UCEC	cis	rs6071166	0.683	rs6015637	ENSG00000224635.1	RP4-564F22.5	-4.18	4.96e-05	0.0413	-0.37	-0.32	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689862	chr20:38406011~38416797:-
UCEC	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	4.18	4.96e-05	0.0413	0.33	0.32	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
UCEC	cis	rs9309473	0.528	rs11126396	ENSG00000163016.8	ALMS1P	4.18	4.96e-05	0.0413	0.35	0.32	Metabolite levels;	chr2:73338015	chr2:73644919~73685576:+
UCEC	cis	rs8089364	0.917	rs12955983	ENSG00000267742.1	FAM60CP	-4.18	4.97e-05	0.0413	-0.31	-0.32	Body mass index;Type 2 diabetes;	chr18:60205756	chr18:60016778~60017441:-
UCEC	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	4.18	4.97e-05	0.0414	0.39	0.32	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
UCEC	cis	rs56114371	0.53	rs9357045	ENSG00000216901.1	AL022393.7	4.18	4.97e-05	0.0414	0.38	0.32	Breast cancer;	chr6:27721148	chr6:28176188~28176674:+
UCEC	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	4.18	4.98e-05	0.0414	0.4	0.32	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
UCEC	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	4.18	4.98e-05	0.0414	0.4	0.32	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
UCEC	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	4.18	4.98e-05	0.0414	0.41	0.32	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
UCEC	cis	rs7611238	0.967	rs55672262	ENSG00000237418.1	AC069257.6	-4.18	4.98e-05	0.0414	-0.28	-0.32	Body mass index;	chr3:195327127	chr3:196298061~196298215:-
UCEC	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	4.18	4.99e-05	0.0415	0.4	0.32	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	4.18	4.99e-05	0.0415	0.4	0.32	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	4.18	4.99e-05	0.0415	0.4	0.32	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
UCEC	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-4.18	4.99e-05	0.0415	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
UCEC	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-4.18	4.99e-05	0.0415	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
UCEC	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-4.18	4.99e-05	0.0415	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
UCEC	cis	rs6437061	0.614	rs3116152	ENSG00000172799.5	ZBTB8OSP2	-4.18	4.99e-05	0.0415	-0.38	-0.32	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr2:232085437	chr2:231433923~231434426:-
UCEC	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-4.18	5e-05	0.0415	-0.41	-0.32	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
UCEC	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-4.18	5e-05	0.0416	-0.31	-0.32	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-4.18	5e-05	0.0416	-0.31	-0.32	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
UCEC	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	4.18	5.01e-05	0.0416	0.41	0.32	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	4.18	5.01e-05	0.0416	0.41	0.32	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	4.18	5.01e-05	0.0416	0.41	0.32	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
UCEC	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	4.18	5.01e-05	0.0416	0.35	0.32	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
UCEC	cis	rs6948404	0.748	rs12112147	ENSG00000225739.1	NPM1P18	4.18	5.01e-05	0.0416	0.63	0.32	HIV-1 viral setpoint;	chr7:36537976	chr7:36818959~36819690:+
UCEC	cis	rs617219	0.597	rs10474581	ENSG00000245556.2	SCAMP1-AS1	-4.18	5.02e-05	0.0417	-0.31	-0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79283061	chr5:78342365~78360507:-
UCEC	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-4.18	5.02e-05	0.0417	-0.37	-0.32	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
UCEC	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	4.18	5.02e-05	0.0417	0.37	0.32	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	4.18	5.02e-05	0.0417	0.37	0.32	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	4.18	5.02e-05	0.0417	0.37	0.32	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	4.18	5.02e-05	0.0417	0.37	0.32	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
UCEC	cis	rs7914558	1	rs7920251	ENSG00000272912.1	RP11-724N1.1	-4.18	5.02e-05	0.0417	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103190440	chr10:102914585~102915404:+
UCEC	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-4.18	5.03e-05	0.0417	-0.45	-0.32	Height;	chr3:53097932	chr3:53064283~53065091:-
UCEC	cis	rs6901004	0.803	rs354531	ENSG00000271789.1	RP5-1112D6.7	-4.18	5.03e-05	0.0418	-0.39	-0.32	Blood metabolite levels;	chr6:111227730	chr6:111297126~111298510:+
UCEC	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	4.18	5.03e-05	0.0418	0.39	0.32	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
UCEC	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	4.18	5.03e-05	0.0418	0.39	0.32	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
UCEC	cis	rs9545047	0.935	rs4885634	ENSG00000227354.5	RBM26-AS1	-4.18	5.04e-05	0.0418	-0.36	-0.32	Schizophrenia;	chr13:79482772	chr13:79406309~79424328:+
UCEC	cis	rs7674212	0.57	rs2126470	ENSG00000246560.2	RP11-10L12.4	4.18	5.05e-05	0.0418	0.39	0.32	Type 2 diabetes;	chr4:103140605	chr4:102828055~102844075:+
UCEC	cis	rs875971	0.965	rs6971509	ENSG00000236529.1	RP13-254B10.1	-4.18	5.05e-05	0.0418	-0.37	-0.32	Aortic root size;	chr7:66249983	chr7:65840212~65840596:+
UCEC	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-4.18	5.05e-05	0.0418	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-4.18	5.05e-05	0.0418	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-4.18	5.05e-05	0.0418	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-4.18	5.05e-05	0.0418	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-4.18	5.05e-05	0.0418	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-4.18	5.05e-05	0.0418	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-4.18	5.05e-05	0.0418	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	4.18	5.05e-05	0.0418	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
UCEC	cis	rs495337	0.76	rs4810995	ENSG00000229222.1	KRT18P4	-4.17	5.05e-05	0.0419	-0.43	-0.32	Psoriasis;	chr20:49955265	chr20:49956745~49958032:+
UCEC	cis	rs875971	0.798	rs7789615	ENSG00000236529.1	RP13-254B10.1	4.17	5.06e-05	0.0419	0.39	0.32	Aortic root size;	chr7:66413674	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6978028	ENSG00000236529.1	RP13-254B10.1	4.17	5.06e-05	0.0419	0.39	0.32	Aortic root size;	chr7:66421313	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6947339	ENSG00000236529.1	RP13-254B10.1	4.17	5.06e-05	0.0419	0.39	0.32	Aortic root size;	chr7:66423483	chr7:65840212~65840596:+
UCEC	cis	rs763121	0.853	rs4821810	ENSG00000273076.1	RP3-508I15.22	4.17	5.07e-05	0.042	0.34	0.32	Menopause (age at onset);	chr22:38676093	chr22:38743495~38743910:+
UCEC	cis	rs763121	0.853	rs5757234	ENSG00000273076.1	RP3-508I15.22	4.17	5.07e-05	0.042	0.34	0.32	Menopause (age at onset);	chr22:38676681	chr22:38743495~38743910:+
UCEC	cis	rs10740039	0.804	rs894384	ENSG00000254271.1	RP11-131N11.4	4.17	5.07e-05	0.042	0.39	0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60692535	chr10:60734342~60741828:+
UCEC	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	4.17	5.08e-05	0.042	0.48	0.32	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
UCEC	cis	rs8089364	0.633	rs9955666	ENSG00000267742.1	FAM60CP	4.17	5.08e-05	0.042	0.29	0.32	Body mass index;Type 2 diabetes;	chr18:60245552	chr18:60016778~60017441:-
UCEC	cis	rs11811982	0.793	rs11803919	ENSG00000270598.1	RP11-396C23.3	4.17	5.08e-05	0.0421	0.52	0.32	Optic disc area;	chr1:227041254	chr1:226127178~226127346:+
UCEC	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-4.17	5.09e-05	0.0421	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
UCEC	cis	rs7246967	0.736	rs2546463	ENSG00000198153.8	ZNF849P	-4.17	5.09e-05	0.0421	-0.4	-0.32	Bronchopulmonary dysplasia;	chr19:22811804	chr19:22685167~22686732:+
UCEC	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	4.17	5.09e-05	0.0421	0.43	0.32	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
UCEC	cis	rs2839619	0.504	rs2839617	ENSG00000225731.1	AP001627.1	-4.17	5.1e-05	0.0422	-0.36	-0.32	Biochemical measures;	chr21:43011613	chr21:42733594~42741758:-
UCEC	cis	rs758747	0.514	rs735830	ENSG00000276754.1	RP11-461A8.5	4.17	5.1e-05	0.0422	0.39	0.32	Body mass index;	chr16:3645353	chr16:3686998~3687380:+
UCEC	cis	rs7267979	0.565	rs6107060	ENSG00000276952.1	RP5-965G21.6	4.17	5.1e-05	0.0422	0.41	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:25284915~25285588:-
UCEC	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-4.17	5.1e-05	0.0422	-0.3	-0.32	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
UCEC	cis	rs11971779	0.616	rs10269683	ENSG00000273391.1	RP11-634H22.1	4.17	5.11e-05	0.0422	0.35	0.32	Diisocyanate-induced asthma;	chr7:139416122	chr7:139359032~139359566:-
UCEC	cis	rs763121	0.853	rs2284073	ENSG00000273076.1	RP3-508I15.22	4.17	5.11e-05	0.0423	0.34	0.32	Menopause (age at onset);	chr22:38709943	chr22:38743495~38743910:+
UCEC	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-4.17	5.11e-05	0.0423	-0.29	-0.32	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
UCEC	cis	rs12928939	0.815	rs11648483	ENSG00000260886.1	TAT-AS1	4.17	5.11e-05	0.0423	0.36	0.32	Post bronchodilator FEV1;	chr16:71673495	chr16:71565789~71578187:+
UCEC	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-4.17	5.11e-05	0.0423	-0.3	-0.32	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
UCEC	cis	rs11959928	0.733	rs700226	ENSG00000249740.1	OSMR-AS1	4.17	5.11e-05	0.0423	0.42	0.32	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr5:39361454	chr5:38736055~38845829:-
UCEC	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	4.17	5.12e-05	0.0423	0.33	0.32	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
UCEC	cis	rs62103177	0.673	rs7242867	ENSG00000261126.6	RP11-795F19.1	4.17	5.12e-05	0.0423	0.38	0.32	Opioid sensitivity;	chr18:79843270	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.714	rs7227962	ENSG00000261126.6	RP11-795F19.1	4.17	5.12e-05	0.0423	0.38	0.32	Opioid sensitivity;	chr18:79843283	chr18:80046900~80095482:+
UCEC	cis	rs62103177	0.714	rs12607447	ENSG00000261126.6	RP11-795F19.1	4.17	5.12e-05	0.0423	0.38	0.32	Opioid sensitivity;	chr18:79845212	chr18:80046900~80095482:+
UCEC	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-4.17	5.13e-05	0.0424	-0.31	-0.32	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
UCEC	cis	rs7760535	0.763	rs10457240	ENSG00000271789.1	RP5-1112D6.7	-4.17	5.13e-05	0.0424	-0.39	-0.32	Metabolic traits;	chr6:111527671	chr6:111297126~111298510:+
UCEC	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-4.17	5.13e-05	0.0424	-0.3	-0.32	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.798	rs12698522	ENSG00000236529.1	RP13-254B10.1	4.17	5.13e-05	0.0424	0.39	0.32	Aortic root size;	chr7:66502354	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.83	rs28714531	ENSG00000236529.1	RP13-254B10.1	4.17	5.13e-05	0.0424	0.39	0.32	Aortic root size;	chr7:66503250	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs12698526	ENSG00000236529.1	RP13-254B10.1	4.17	5.13e-05	0.0424	0.39	0.32	Aortic root size;	chr7:66504118	chr7:65840212~65840596:+
UCEC	cis	rs2445284	0.874	rs2499985	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5040537	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499986	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5040623	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499987	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5040766	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2445275	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5040792	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499988	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5040969	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2445276	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5040980	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499989	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5041003	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499991	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5041158	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2499992	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5041400	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.874	rs2499993	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5041629	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2499994	ENSG00000229534.1	HNRNPA1P53	-4.17	5.14e-05	0.0424	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5041659	chr11:5571247~5572192:-
UCEC	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	4.17	5.15e-05	0.0424	0.39	0.32	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
UCEC	cis	rs12478296	0.892	rs60545379	ENSG00000261186.2	RP11-341N2.1	-4.17	5.15e-05	0.0424	-0.45	-0.32	Obesity-related traits;	chr2:242092239	chr2:242087351~242088457:-
UCEC	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	4.17	5.15e-05	0.0424	0.38	0.32	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
UCEC	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-4.17	5.15e-05	0.0424	-0.45	-0.32	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
UCEC	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	4.17	5.15e-05	0.0424	0.4	0.32	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
UCEC	cis	rs875971	0.964	rs778723	ENSG00000236529.1	RP13-254B10.1	4.17	5.15e-05	0.0424	0.36	0.32	Aortic root size;	chr7:66364510	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.929	rs778712	ENSG00000236529.1	RP13-254B10.1	4.17	5.15e-05	0.0424	0.36	0.32	Aortic root size;	chr7:66384991	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs778710	ENSG00000236529.1	RP13-254B10.1	4.17	5.15e-05	0.0424	0.36	0.32	Aortic root size;	chr7:66389847	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs778708	ENSG00000236529.1	RP13-254B10.1	4.17	5.15e-05	0.0424	0.36	0.32	Aortic root size;	chr7:66391332	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs778696	ENSG00000236529.1	RP13-254B10.1	4.17	5.15e-05	0.0424	0.36	0.32	Aortic root size;	chr7:66405826	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs778694	ENSG00000236529.1	RP13-254B10.1	4.17	5.15e-05	0.0424	0.36	0.32	Aortic root size;	chr7:66406571	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs4718344	ENSG00000236529.1	RP13-254B10.1	4.17	5.15e-05	0.0424	0.36	0.32	Aortic root size;	chr7:66409394	chr7:65840212~65840596:+
UCEC	cis	rs11959928	0.733	rs835220	ENSG00000249740.1	OSMR-AS1	4.17	5.16e-05	0.0424	0.42	0.32	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr5:39359671	chr5:38736055~38845829:-
UCEC	cis	rs948562	0.947	rs7481388	ENSG00000280010.1	AP001350.4	4.17	5.16e-05	0.0424	0.56	0.32	Lymphoma;	chr11:58592143	chr11:58627435~58628528:+
UCEC	cis	rs573521	1	rs617819	ENSG00000243777.1	RP11-864G5.1	-4.17	5.16e-05	0.0424	-0.35	-0.32	Cerebrospinal fluid levels of Alzheimer's disease-related proteins;	chr11:102843985	chr11:102295060~102295806:+
UCEC	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	4.17	5.16e-05	0.0424	0.4	0.32	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
UCEC	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs10271297	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139367564	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs10274480	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139367682	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-4.17	5.16e-05	0.0424	-0.35	-0.32	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs7783619	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139376691	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.59	rs6467839	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139378044	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-4.17	5.16e-05	0.0424	-0.35	-0.32	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
UCEC	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	4.17	5.16e-05	0.0424	0.35	0.32	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
UCEC	cis	rs853679	0.55	rs1237875	ENSG00000216901.1	AL022393.7	-4.17	5.16e-05	0.0424	-0.38	-0.32	Depression;	chr6:28205232	chr6:28176188~28176674:+
UCEC	cis	rs28386778	0.965	rs2854154	ENSG00000240280.5	TCAM1P	4.17	5.17e-05	0.0425	0.37	0.32	Prudent dietary pattern;	chr17:63904336	chr17:63849292~63864379:+
UCEC	cis	rs6137726	0.524	rs1203924	ENSG00000277901.1	RP5-851M4.1	4.17	5.17e-05	0.0425	0.43	0.32	Amyotrophic lateral sclerosis (sporadic);	chr20:22605670	chr20:23320958~23325352:-
UCEC	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-4.17	5.17e-05	0.0425	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
UCEC	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-4.17	5.17e-05	0.0425	-0.4	-0.32	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
UCEC	cis	rs591166	0.622	rs494111	ENSG00000267742.1	FAM60CP	-4.17	5.18e-05	0.0425	-0.26	-0.32	Body mass index;	chr18:60241513	chr18:60016778~60017441:-
UCEC	cis	rs591166	0.592	rs1788041	ENSG00000267742.1	FAM60CP	-4.17	5.18e-05	0.0425	-0.26	-0.32	Body mass index;	chr18:60242152	chr18:60016778~60017441:-
UCEC	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-4.17	5.18e-05	0.0425	-0.31	-0.32	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
UCEC	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	4.17	5.18e-05	0.0425	0.38	0.32	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
UCEC	cis	rs12357812	0.691	rs11252715	ENSG00000226647.2	RP11-336A10.2	4.17	5.18e-05	0.0425	0.35	0.32	Major depressive disorder;	chr10:4757862	chr10:5712174~5744067:-
UCEC	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-4.17	5.21e-05	0.0427	-0.39	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
UCEC	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-4.17	5.21e-05	0.0427	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
UCEC	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	4.17	5.21e-05	0.0427	0.35	0.32	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
UCEC	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	4.17	5.21e-05	0.0427	0.37	0.32	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
UCEC	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-4.17	5.21e-05	0.0428	-0.46	-0.32	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
UCEC	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-4.17	5.22e-05	0.0428	-0.36	-0.32	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
UCEC	cis	rs11971779	0.616	rs1862878	ENSG00000273391.1	RP11-634H22.1	4.17	5.22e-05	0.0428	0.35	0.32	Diisocyanate-induced asthma;	chr7:139335168	chr7:139359032~139359566:-
UCEC	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	4.17	5.22e-05	0.0428	0.32	0.32	Height;	chr11:118703185	chr11:118688039~118690600:-
UCEC	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	4.17	5.22e-05	0.0428	0.32	0.32	Height;	chr11:118703207	chr11:118688039~118690600:-
UCEC	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	4.17	5.22e-05	0.0428	0.32	0.32	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
UCEC	cis	rs853679	0.542	rs9393892	ENSG00000216901.1	AL022393.7	4.17	5.22e-05	0.0428	0.39	0.32	Depression;	chr6:28113616	chr6:28176188~28176674:+
UCEC	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	4.17	5.23e-05	0.0429	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
UCEC	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	4.17	5.23e-05	0.0429	0.46	0.32	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
UCEC	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-4.17	5.23e-05	0.0429	-0.37	-0.32	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
UCEC	cis	rs2839619	0.525	rs11702511	ENSG00000225731.1	AP001627.1	-4.17	5.24e-05	0.0429	-0.36	-0.32	Biochemical measures;	chr21:43024169	chr21:42733594~42741758:-
UCEC	cis	rs853679	0.517	rs6922063	ENSG00000216901.1	AL022393.7	4.17	5.25e-05	0.043	0.39	0.32	Depression;	chr6:28126588	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs2275508	ENSG00000216901.1	AL022393.7	4.17	5.25e-05	0.043	0.39	0.32	Depression;	chr6:28126953	chr6:28176188~28176674:+
UCEC	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	4.17	5.25e-05	0.043	0.3	0.32	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
UCEC	cis	rs6687821	0.515	rs1407132	ENSG00000267734.1	RP4-604K5.3	4.16	5.25e-05	0.043	0.33	0.32	Yeast infection;	chr1:86928231	chr1:86932199~86934891:-
UCEC	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-4.16	5.26e-05	0.043	-0.3	-0.32	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-4.16	5.26e-05	0.043	-0.3	-0.32	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-4.16	5.26e-05	0.043	-0.3	-0.32	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-4.16	5.26e-05	0.043	-0.3	-0.32	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-4.16	5.26e-05	0.043	-0.3	-0.32	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
UCEC	cis	rs10946940	1	rs10946940	ENSG00000216901.1	AL022393.7	-4.16	5.27e-05	0.0431	-0.34	-0.32	Systemic lupus erythematosus;	chr6:27592808	chr6:28176188~28176674:+
UCEC	cis	rs9319321	0.715	rs9553910	ENSG00000277368.1	RP11-380N8.7	-4.16	5.27e-05	0.0431	-0.36	-0.32	Asthma (toluene diisocyanate-induced);	chr13:26843330	chr13:26222191~26222654:+
UCEC	cis	rs950169	0.649	rs12911612	ENSG00000225151.9	GOLGA2P7	-4.16	5.28e-05	0.0432	-0.55	-0.32	Schizophrenia;	chr15:84022262	chr15:84199311~84230136:-
UCEC	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-4.16	5.28e-05	0.0432	-0.36	-0.32	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
UCEC	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	4.16	5.28e-05	0.0432	0.49	0.32	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
UCEC	cis	rs7208859	0.524	rs11653098	ENSG00000266490.1	CTD-2349P21.9	4.16	5.28e-05	0.0432	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30792372~30792833:+
UCEC	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	4.16	5.28e-05	0.0432	0.38	0.32	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
UCEC	cis	rs9611565	0.921	rs2143695	ENSG00000233903.2	Z83851.4	-4.16	5.28e-05	0.0432	-0.41	-0.32	Vitiligo;	chr22:41332616	chr22:42276355~42277052:+
UCEC	cis	rs875971	0.928	rs2036263	ENSG00000236529.1	RP13-254B10.1	-4.16	5.28e-05	0.0432	-0.36	-0.32	Aortic root size;	chr7:66335210	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs10240949	ENSG00000236529.1	RP13-254B10.1	-4.16	5.28e-05	0.0432	-0.36	-0.32	Aortic root size;	chr7:66339430	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs7782704	ENSG00000236529.1	RP13-254B10.1	-4.16	5.28e-05	0.0432	-0.36	-0.32	Aortic root size;	chr7:66340379	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs6959268	ENSG00000236529.1	RP13-254B10.1	-4.16	5.28e-05	0.0432	-0.36	-0.32	Aortic root size;	chr7:66347979	chr7:65840212~65840596:+
UCEC	cis	rs948562	0.947	rs7482383	ENSG00000280010.1	AP001350.4	4.16	5.28e-05	0.0432	0.66	0.32	Lymphoma;	chr11:58602225	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.947	rs76985515	ENSG00000280010.1	AP001350.4	4.16	5.28e-05	0.0432	0.66	0.32	Lymphoma;	chr11:58604321	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.947	rs78176302	ENSG00000280010.1	AP001350.4	4.16	5.28e-05	0.0432	0.66	0.32	Lymphoma;	chr11:58615176	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.947	rs11541682	ENSG00000280010.1	AP001350.4	4.16	5.28e-05	0.0432	0.66	0.32	Lymphoma;	chr11:58618279	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.793	rs11229552	ENSG00000280010.1	AP001350.4	4.16	5.28e-05	0.0432	0.66	0.32	Lymphoma;	chr11:58633441	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.947	rs75708979	ENSG00000280010.1	AP001350.4	4.16	5.28e-05	0.0432	0.66	0.32	Lymphoma;	chr11:58662312	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.947	rs78629620	ENSG00000280010.1	AP001350.4	4.16	5.28e-05	0.0432	0.66	0.32	Lymphoma;	chr11:58662329	chr11:58627435~58628528:+
UCEC	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	4.16	5.29e-05	0.0432	0.37	0.32	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	4.16	5.29e-05	0.0432	0.37	0.32	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	4.16	5.29e-05	0.0432	0.37	0.32	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	4.16	5.29e-05	0.0432	0.37	0.32	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	4.16	5.29e-05	0.0432	0.37	0.32	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	4.16	5.29e-05	0.0432	0.37	0.32	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
UCEC	cis	rs617219	0.71	rs10474578	ENSG00000245556.2	SCAMP1-AS1	4.16	5.29e-05	0.0432	0.3	0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79246467	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.671	rs13165414	ENSG00000245556.2	SCAMP1-AS1	4.16	5.29e-05	0.0432	0.3	0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79253050	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.71	rs2166344	ENSG00000245556.2	SCAMP1-AS1	4.16	5.29e-05	0.0432	0.3	0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79238311	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.71	rs10805925	ENSG00000245556.2	SCAMP1-AS1	4.16	5.29e-05	0.0432	0.3	0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79243576	chr5:78342365~78360507:-
UCEC	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-4.16	5.29e-05	0.0432	-0.45	-0.32	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
UCEC	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-4.16	5.29e-05	0.0432	-0.45	-0.32	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
UCEC	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	4.16	5.3e-05	0.0433	0.34	0.32	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
UCEC	cis	rs763121	0.853	rs1043441	ENSG00000273076.1	RP3-508I15.22	4.16	5.3e-05	0.0433	0.42	0.32	Menopause (age at onset);	chr22:38734959	chr22:38743495~38743910:+
UCEC	cis	rs6840360	0.642	rs7676493	ENSG00000251611.1	RP11-610P16.1	-4.16	5.31e-05	0.0433	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs11735957	ENSG00000251611.1	RP11-610P16.1	-4.16	5.31e-05	0.0433	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs11099819	ENSG00000251611.1	RP11-610P16.1	-4.16	5.31e-05	0.0433	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs11726254	ENSG00000251611.1	RP11-610P16.1	-4.16	5.31e-05	0.0433	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs2053566	ENSG00000251611.1	RP11-610P16.1	-4.16	5.31e-05	0.0433	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.607	rs1561918	ENSG00000251611.1	RP11-610P16.1	-4.16	5.31e-05	0.0433	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151407551~151408835:-
UCEC	cis	rs6840360	0.642	rs1443089	ENSG00000251611.1	RP11-610P16.1	-4.16	5.31e-05	0.0433	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151407551~151408835:-
UCEC	cis	rs9291683	0.588	rs17246745	ENSG00000250413.1	RP11-448G15.1	-4.16	5.31e-05	0.0433	-0.36	-0.32	Bone mineral density;	chr4:9992959	chr4:10006482~10009725:+
UCEC	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-4.16	5.31e-05	0.0434	-0.28	-0.32	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
UCEC	cis	rs4073582	0.595	rs801741	ENSG00000255320.1	RP11-755F10.1	-4.16	5.32e-05	0.0434	-0.41	-0.32	Gout;	chr11:66149613	chr11:66244840~66246239:-
UCEC	cis	rs875971	0.651	rs2420596	ENSG00000236529.1	RP13-254B10.1	4.16	5.33e-05	0.0434	0.39	0.32	Aortic root size;	chr7:66450996	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.52	rs2420597	ENSG00000236529.1	RP13-254B10.1	4.16	5.33e-05	0.0434	0.39	0.32	Aortic root size;	chr7:66450999	chr7:65840212~65840596:+
UCEC	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-4.16	5.33e-05	0.0435	-0.29	-0.32	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
UCEC	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	4.16	5.33e-05	0.0435	0.5	0.32	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
UCEC	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	4.16	5.34e-05	0.0435	0.35	0.32	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	4.16	5.34e-05	0.0435	0.35	0.32	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	4.16	5.34e-05	0.0435	0.35	0.32	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	4.16	5.34e-05	0.0435	0.35	0.32	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	4.16	5.34e-05	0.0435	0.35	0.32	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
UCEC	cis	rs10254284	0.765	rs10281935	ENSG00000254369.5	HOXA-AS3	-4.16	5.34e-05	0.0435	-0.45	-0.32	Systemic lupus erythematosus;Lymphocyte percentage of white cells;	chr7:28109414	chr7:27129977~27155928:+
UCEC	cis	rs10254284	0.765	rs6963719	ENSG00000254369.5	HOXA-AS3	-4.16	5.34e-05	0.0435	-0.45	-0.32	Systemic lupus erythematosus;Lymphocyte percentage of white cells;	chr7:28109424	chr7:27129977~27155928:+
UCEC	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-4.16	5.34e-05	0.0435	-0.3	-0.32	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-4.16	5.34e-05	0.0435	-0.3	-0.32	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-4.16	5.34e-05	0.0435	-0.3	-0.32	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-4.16	5.34e-05	0.0435	-0.3	-0.32	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-4.16	5.34e-05	0.0435	-0.3	-0.32	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-4.16	5.34e-05	0.0435	-0.3	-0.32	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-4.16	5.34e-05	0.0435	-0.3	-0.32	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
UCEC	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-4.16	5.34e-05	0.0435	-0.45	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
UCEC	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	4.16	5.34e-05	0.0435	0.34	0.32	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
UCEC	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	4.16	5.35e-05	0.0436	0.35	0.32	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
UCEC	cis	rs948562	0.69	rs17152616	ENSG00000280010.1	AP001350.4	4.16	5.35e-05	0.0436	0.61	0.32	Lymphoma;	chr11:58300849	chr11:58627435~58628528:+
UCEC	cis	rs11959928	0.674	rs1421095	ENSG00000249740.1	OSMR-AS1	4.16	5.35e-05	0.0436	0.42	0.32	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr5:39355546	chr5:38736055~38845829:-
UCEC	cis	rs6137726	0.524	rs2208168	ENSG00000277901.1	RP5-851M4.1	4.16	5.35e-05	0.0436	0.41	0.32	Amyotrophic lateral sclerosis (sporadic);	chr20:22642628	chr20:23320958~23325352:-
UCEC	cis	rs6137726	0.568	rs2424442	ENSG00000277901.1	RP5-851M4.1	4.16	5.35e-05	0.0436	0.41	0.32	Amyotrophic lateral sclerosis (sporadic);	chr20:22644151	chr20:23320958~23325352:-
UCEC	cis	rs7267979	0.565	rs6076364	ENSG00000276952.1	RP5-965G21.6	-4.16	5.35e-05	0.0436	-0.41	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:25284915~25285588:-
UCEC	cis	rs9876781	1	rs2045554	ENSG00000229759.1	MRPS18AP1	-4.16	5.36e-05	0.0436	-0.33	-0.32	Longevity;	chr3:48453142	chr3:48256350~48256938:-
UCEC	cis	rs875971	1	rs12533997	ENSG00000236529.1	RP13-254B10.1	4.16	5.36e-05	0.0436	0.36	0.32	Aortic root size;	chr7:66500390	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs1860469	ENSG00000236529.1	RP13-254B10.1	-4.16	5.36e-05	0.0436	-0.41	-0.32	Aortic root size;	chr7:66641888	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs4718383	ENSG00000236529.1	RP13-254B10.1	-4.16	5.36e-05	0.0436	-0.41	-0.32	Aortic root size;	chr7:66643422	chr7:65840212~65840596:+
UCEC	cis	rs6137726	0.524	rs1203952	ENSG00000277901.1	RP5-851M4.1	4.16	5.36e-05	0.0436	0.42	0.32	Amyotrophic lateral sclerosis (sporadic);	chr20:22633494	chr20:23320958~23325352:-
UCEC	cis	rs875971	0.838	rs2173570	ENSG00000236529.1	RP13-254B10.1	-4.16	5.36e-05	0.0436	-0.37	-0.32	Aortic root size;	chr7:66297976	chr7:65840212~65840596:+
UCEC	cis	rs2445284	0.817	rs2499981	ENSG00000229534.1	HNRNPA1P53	-4.16	5.36e-05	0.0437	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5039762	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2499982	ENSG00000229534.1	HNRNPA1P53	-4.16	5.36e-05	0.0437	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5039767	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2445273	ENSG00000229534.1	HNRNPA1P53	-4.16	5.36e-05	0.0437	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5040045	chr11:5571247~5572192:-
UCEC	cis	rs11175834	0.655	rs11175839	ENSG00000225422.4	RBMS1P1	-4.16	5.37e-05	0.0437	-0.37	-0.32	Differentiated thyroid cancer;Papillary thyroid cancer;	chr12:65613113	chr12:66234079~66235234:-
UCEC	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-4.16	5.37e-05	0.0437	-0.45	-0.32	Height;	chr3:53094335	chr3:53064283~53065091:-
UCEC	cis	rs617219	0.71	rs2255913	ENSG00000245556.2	SCAMP1-AS1	4.16	5.37e-05	0.0437	0.3	0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79266576	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.659	rs13182512	ENSG00000245556.2	SCAMP1-AS1	-4.16	5.37e-05	0.0437	-0.3	-0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79277967	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.71	rs16876598	ENSG00000245556.2	SCAMP1-AS1	-4.16	5.37e-05	0.0437	-0.3	-0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79278147	chr5:78342365~78360507:-
UCEC	cis	rs617219	0.71	rs6874525	ENSG00000245556.2	SCAMP1-AS1	-4.16	5.37e-05	0.0437	-0.3	-0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79278414	chr5:78342365~78360507:-
UCEC	cis	rs875971	1	rs6460295	ENSG00000236529.1	RP13-254B10.1	4.16	5.37e-05	0.0437	0.35	0.32	Aortic root size;	chr7:66417741	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs6978721	ENSG00000236529.1	RP13-254B10.1	4.16	5.37e-05	0.0437	0.35	0.32	Aortic root size;	chr7:66418217	chr7:65840212~65840596:+
UCEC	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-4.16	5.37e-05	0.0437	-0.31	-0.32	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
UCEC	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-4.16	5.38e-05	0.0437	-0.4	-0.32	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
UCEC	cis	rs6840360	0.642	rs7682837	ENSG00000270265.1	RP11-731D1.4	-4.16	5.38e-05	0.0437	-0.3	-0.32	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151333775~151353224:-
UCEC	cis	rs4713118	0.516	rs7739216	ENSG00000216901.1	AL022393.7	4.16	5.38e-05	0.0437	0.39	0.32	Parkinson's disease;	chr6:28112168	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs35512245	ENSG00000216901.1	AL022393.7	4.16	5.38e-05	0.0437	0.39	0.32	Depression;	chr6:28112175	chr6:28176188~28176674:+
UCEC	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-4.16	5.38e-05	0.0437	-0.42	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
UCEC	cis	rs9648716	1	rs2109742	ENSG00000240889.1	NDUFB2-AS1	4.16	5.39e-05	0.0438	0.43	0.32	Type 2 diabetes;	chr7:140821719	chr7:140695336~140697077:-
UCEC	cis	rs9648716	1	rs2109743	ENSG00000240889.1	NDUFB2-AS1	4.16	5.39e-05	0.0438	0.43	0.32	Type 2 diabetes;	chr7:140821741	chr7:140695336~140697077:-
UCEC	cis	rs570399	0.623	rs4653224	ENSG00000201448.1	SNORA63	4.16	5.39e-05	0.0438	0.32	0.32	Neuroticism;	chr1:36750327	chr1:36418450~36418578:-
UCEC	cis	rs7760535	0.831	rs62420437	ENSG00000271789.1	RP5-1112D6.7	-4.16	5.39e-05	0.0439	-0.4	-0.32	Metabolic traits;	chr6:111427577	chr6:111297126~111298510:+
UCEC	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	4.16	5.4e-05	0.0439	0.34	0.32	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
UCEC	cis	rs7914558	0.966	rs56946876	ENSG00000272912.1	RP11-724N1.1	-4.16	5.4e-05	0.0439	-0.32	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893788	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.933	rs12763665	ENSG00000272912.1	RP11-724N1.1	-4.16	5.4e-05	0.0439	-0.32	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893960	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs10786721	ENSG00000272912.1	RP11-724N1.1	-4.16	5.4e-05	0.0439	-0.32	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894626	chr10:102914585~102915404:+
UCEC	cis	rs875971	0.964	rs11765965	ENSG00000236529.1	RP13-254B10.1	4.16	5.4e-05	0.0439	0.36	0.32	Aortic root size;	chr7:66377234	chr7:65840212~65840596:+
UCEC	cis	rs11168351	0.926	rs10875719	ENSG00000226413.2	OR8T1P	4.16	5.4e-05	0.0439	0.43	0.32	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48442030~48442947:-
UCEC	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	4.16	5.41e-05	0.044	0.36	0.32	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	4.16	5.41e-05	0.044	0.36	0.32	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
UCEC	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	4.16	5.42e-05	0.044	0.34	0.32	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	4.16	5.42e-05	0.044	0.34	0.32	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	4.16	5.42e-05	0.044	0.34	0.32	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
UCEC	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	4.16	5.42e-05	0.044	0.42	0.32	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
UCEC	cis	rs948562	0.744	rs4313600	ENSG00000280010.1	AP001350.4	4.16	5.42e-05	0.044	0.53	0.32	Lymphoma;	chr11:58463748	chr11:58627435~58628528:+
UCEC	cis	rs948562	0.69	rs11229480	ENSG00000280010.1	AP001350.4	4.16	5.42e-05	0.044	0.53	0.32	Lymphoma;	chr11:58464209	chr11:58627435~58628528:+
UCEC	cis	rs4713118	0.911	rs2394000	ENSG00000216901.1	AL022393.7	4.16	5.43e-05	0.0441	0.37	0.32	Parkinson's disease;	chr6:27719212	chr6:28176188~28176674:+
UCEC	cis	rs4713118	0.955	rs9393847	ENSG00000216901.1	AL022393.7	4.16	5.43e-05	0.0441	0.37	0.32	Parkinson's disease;	chr6:27720194	chr6:28176188~28176674:+
UCEC	cis	rs2276314	0.857	rs28379448	ENSG00000267627.4	RP11-905K4.1	-4.16	5.43e-05	0.0441	-0.4	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35951803~35966118:-
UCEC	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-4.16	5.43e-05	0.0441	-0.3	-0.32	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
UCEC	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-4.16	5.43e-05	0.0441	-0.41	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
UCEC	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-4.16	5.44e-05	0.0441	-0.34	-0.32	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
UCEC	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-4.16	5.44e-05	0.0441	-0.34	-0.32	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
UCEC	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-4.16	5.44e-05	0.0441	-0.37	-0.32	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
UCEC	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	4.16	5.44e-05	0.0442	0.35	0.32	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
UCEC	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-4.16	5.44e-05	0.0442	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
UCEC	cis	rs7592578	0.771	rs4258824	ENSG00000272979.1	RP11-647K16.1	-4.16	5.44e-05	0.0442	-0.53	-0.32	Diastolic blood pressure;	chr2:190530301	chr2:190454092~190454521:-
UCEC	cis	rs13160562	0.623	rs26509	ENSG00000272109.1	CTD-2260A17.3	4.16	5.45e-05	0.0442	0.39	0.32	Alcohol dependence;	chr5:96746976	chr5:96804353~96806105:+
UCEC	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-4.16	5.45e-05	0.0442	-0.41	-0.32	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
UCEC	cis	rs875971	0.571	rs160641	ENSG00000236529.1	RP13-254B10.1	-4.16	5.45e-05	0.0442	-0.47	-0.32	Aortic root size;	chr7:66112359	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-4.16	5.45e-05	0.0442	-0.3	-0.32	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
UCEC	cis	rs6948404	0.748	rs59564654	ENSG00000225739.1	NPM1P18	4.16	5.45e-05	0.0442	0.63	0.32	HIV-1 viral setpoint;	chr7:36542329	chr7:36818959~36819690:+
UCEC	cis	rs2501276	1	rs2501276	ENSG00000218510.5	LINC00339	4.16	5.45e-05	0.0442	0.55	0.32	Immune response to smallpox vaccine (IL-6);	chr1:22047131	chr1:22025188~22031223:+
UCEC	cis	rs617219	0.671	rs1316753	ENSG00000245556.2	SCAMP1-AS1	4.16	5.46e-05	0.0442	0.3	0.32	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79235514	chr5:78342365~78360507:-
UCEC	cis	rs1598856	0.932	rs230530	ENSG00000246560.2	RP11-10L12.4	-4.16	5.46e-05	0.0443	-0.42	-0.32	Primary biliary cholangitis;	chr4:102532823	chr4:102828055~102844075:+
UCEC	cis	rs3002142	0.658	rs3008634	ENSG00000272750.1	RP11-378J18.8	4.16	5.46e-05	0.0443	0.4	0.32	LDL peak particle diameter (total fat intake interaction);	chr1:222672069	chr1:222658867~222661512:-
UCEC	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-4.16	5.46e-05	0.0443	-0.34	-0.32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
UCEC	cis	rs922692	0.744	rs4886592	ENSG00000261143.1	ADAMTS7P3	4.15	5.46e-05	0.0443	0.45	0.32	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78790205	chr15:77976042~77993057:+
UCEC	cis	rs922692	0.715	rs2277546	ENSG00000261143.1	ADAMTS7P3	4.15	5.46e-05	0.0443	0.45	0.32	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78791034	chr15:77976042~77993057:+
UCEC	cis	rs922692	0.744	rs2277545	ENSG00000261143.1	ADAMTS7P3	4.15	5.46e-05	0.0443	0.45	0.32	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78791249	chr15:77976042~77993057:+
UCEC	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-4.15	5.47e-05	0.0443	-0.33	-0.32	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
UCEC	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-4.15	5.47e-05	0.0443	-0.33	-0.32	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	4.15	5.47e-05	0.0443	0.33	0.32	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
UCEC	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	4.15	5.47e-05	0.0443	0.33	0.32	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
UCEC	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	4.15	5.47e-05	0.0443	0.33	0.32	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
UCEC	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	4.15	5.47e-05	0.0443	0.33	0.32	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
UCEC	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	4.15	5.47e-05	0.0443	0.33	0.32	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
UCEC	cis	rs2445284	0.845	rs2500021	ENSG00000229534.1	HNRNPA1P53	-4.15	5.47e-05	0.0443	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5047748	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500022	ENSG00000229534.1	HNRNPA1P53	-4.15	5.47e-05	0.0443	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5047786	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500023	ENSG00000229534.1	HNRNPA1P53	-4.15	5.47e-05	0.0443	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5047801	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2500025	ENSG00000229534.1	HNRNPA1P53	-4.15	5.47e-05	0.0443	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5048014	chr11:5571247~5572192:-
UCEC	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-4.15	5.47e-05	0.0443	-0.34	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
UCEC	cis	rs7267979	0.565	rs4815437	ENSG00000276952.1	RP5-965G21.6	-4.15	5.47e-05	0.0443	-0.41	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:25284915~25285588:-
UCEC	cis	rs7267979	0.565	rs6107059	ENSG00000276952.1	RP5-965G21.6	-4.15	5.47e-05	0.0443	-0.41	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:25284915~25285588:-
UCEC	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-4.15	5.47e-05	0.0443	-0.3	-0.32	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
UCEC	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-4.15	5.47e-05	0.0443	-0.3	-0.32	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
UCEC	cis	rs710913	0.717	rs2243761	ENSG00000237624.1	OXCT2P1	-4.15	5.47e-05	0.0443	-0.38	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39514956~39516490:+
UCEC	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	4.15	5.48e-05	0.0444	0.34	0.32	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	4.15	5.48e-05	0.0444	0.34	0.32	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	4.15	5.48e-05	0.0444	0.34	0.32	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
UCEC	cis	rs875971	0.862	rs778686	ENSG00000236529.1	RP13-254B10.1	4.15	5.48e-05	0.0444	0.37	0.32	Aortic root size;	chr7:66370923	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.767	rs1643394	ENSG00000236529.1	RP13-254B10.1	4.15	5.48e-05	0.0444	0.37	0.32	Aortic root size;	chr7:66371107	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs778684	ENSG00000236529.1	RP13-254B10.1	4.15	5.48e-05	0.0444	0.37	0.32	Aortic root size;	chr7:66371416	chr7:65840212~65840596:+
UCEC	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-4.15	5.49e-05	0.0444	-0.36	-0.32	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
UCEC	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-4.15	5.49e-05	0.0444	-0.34	-0.32	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
UCEC	cis	rs9545047	0.716	rs7333904	ENSG00000227354.5	RBM26-AS1	4.15	5.49e-05	0.0444	0.32	0.32	Schizophrenia;	chr13:79281413	chr13:79406309~79424328:+
UCEC	cis	rs8089364	0.917	rs11664883	ENSG00000267742.1	FAM60CP	-4.15	5.49e-05	0.0444	-0.3	-0.32	Body mass index;Type 2 diabetes;	chr18:60210567	chr18:60016778~60017441:-
UCEC	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-4.15	5.49e-05	0.0444	-0.65	-0.32	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
UCEC	cis	rs6740462	0.568	rs34288960	ENSG00000281920.1	RP11-418H16.1	-4.15	5.5e-05	0.0445	-0.58	-0.32	Inflammatory bowel disease;Crohn's disease;	chr2:65423831	chr2:65623272~65628424:+
UCEC	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-4.15	5.5e-05	0.0445	-0.34	-0.32	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
UCEC	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	4.15	5.5e-05	0.0445	0.56	0.32	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
UCEC	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-4.15	5.5e-05	0.0445	-0.39	-0.32	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
UCEC	cis	rs4787951	0.517	rs3024585	ENSG00000261736.1	AC002551.1	4.15	5.52e-05	0.0446	0.29	0.32	Eosinophil percentage of white cells;	chr16:27348523	chr16:27643199~27644663:+
UCEC	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	4.15	5.52e-05	0.0446	0.34	0.32	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	4.15	5.52e-05	0.0446	0.34	0.32	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	4.15	5.52e-05	0.0446	0.34	0.32	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	4.15	5.52e-05	0.0446	0.34	0.32	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	4.15	5.52e-05	0.0446	0.34	0.32	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
UCEC	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-4.15	5.52e-05	0.0446	-0.3	-0.32	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
UCEC	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-4.15	5.52e-05	0.0446	-0.39	-0.32	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
UCEC	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	4.15	5.53e-05	0.0446	0.3	0.32	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
UCEC	cis	rs6907340	0.517	rs6939160	ENSG00000237404.1	RP3-471C18.2	-4.15	5.53e-05	0.0446	-0.31	-0.32	Endometriosis;	chr6:19802086	chr6:19689825~19753113:-
UCEC	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-4.15	5.53e-05	0.0446	-0.34	-0.32	Height;	chr11:118764443	chr11:118704607~118750263:+
UCEC	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	4.15	5.53e-05	0.0447	0.39	0.32	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
UCEC	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	4.15	5.53e-05	0.0447	0.38	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
UCEC	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	4.15	5.53e-05	0.0447	0.38	0.32	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
UCEC	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	4.15	5.53e-05	0.0447	0.34	0.32	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
UCEC	cis	rs7267979	0.527	rs6083891	ENSG00000276952.1	RP5-965G21.6	-4.15	5.54e-05	0.0447	-0.41	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:25284915~25285588:-
UCEC	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	4.15	5.54e-05	0.0447	0.33	0.32	Height;	chr6:109390116	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	4.15	5.54e-05	0.0447	0.33	0.32	Height;	chr6:109390638	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	4.15	5.54e-05	0.0447	0.33	0.32	Height;	chr6:109391534	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	4.15	5.54e-05	0.0447	0.33	0.32	Height;	chr6:109393881	chr6:109382795~109383666:+
UCEC	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	4.15	5.54e-05	0.0447	0.33	0.32	Height;	chr6:109397362	chr6:109382795~109383666:+
UCEC	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	4.15	5.54e-05	0.0447	0.33	0.32	Height;	chr6:109402736	chr6:109382795~109383666:+
UCEC	cis	rs875971	1	rs2036264	ENSG00000236529.1	RP13-254B10.1	-4.15	5.54e-05	0.0447	-0.36	-0.32	Aortic root size;	chr7:66334917	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs7783613	ENSG00000236529.1	RP13-254B10.1	-4.15	5.54e-05	0.0447	-0.36	-0.32	Aortic root size;	chr7:66340274	chr7:65840212~65840596:+
UCEC	cis	rs4792901	0.765	rs2127224	ENSG00000267595.1	RP11-242D8.2	4.15	5.54e-05	0.0447	0.32	0.32	Dupuytren's disease;	chr17:43491657	chr17:43168170~43168249:-
UCEC	cis	rs6783573	0.894	rs939408	ENSG00000268324.2	LRRC2-AS1	4.15	5.54e-05	0.0447	0.45	0.32	Cerebrospinal fluid biomarker levels;	chr3:46557589	chr3:46557398~46559694:+
UCEC	cis	rs710913	0.717	rs11206377	ENSG00000237624.1	OXCT2P1	4.15	5.54e-05	0.0447	0.38	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39514956~39516490:+
UCEC	cis	rs9545047	0.604	rs12875039	ENSG00000227354.5	RBM26-AS1	-4.15	5.54e-05	0.0447	-0.31	-0.32	Schizophrenia;	chr13:79327449	chr13:79406309~79424328:+
UCEC	cis	rs9545047	0.604	rs7988784	ENSG00000227354.5	RBM26-AS1	-4.15	5.55e-05	0.0447	-0.31	-0.32	Schizophrenia;	chr13:79335337	chr13:79406309~79424328:+
UCEC	cis	rs62025270	0.848	rs2554	ENSG00000202081.1	RNU6-1280P	-4.15	5.55e-05	0.0448	-0.4	-0.32	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85651522~85651628:-
UCEC	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-4.15	5.55e-05	0.0448	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-4.15	5.56e-05	0.0448	-0.3	-0.32	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
UCEC	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-4.15	5.57e-05	0.0449	-0.45	-0.32	QT interval;	chr16:28857143	chr16:28700294~28701540:-
UCEC	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	4.15	5.57e-05	0.0449	0.38	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
UCEC	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-4.15	5.57e-05	0.0449	-0.41	-0.32	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
UCEC	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-4.15	5.57e-05	0.0449	-0.41	-0.32	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
UCEC	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	4.15	5.57e-05	0.0449	0.3	0.32	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
UCEC	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	4.15	5.58e-05	0.0449	0.41	0.32	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
UCEC	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	4.15	5.58e-05	0.0449	0.41	0.32	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
UCEC	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	4.15	5.58e-05	0.0449	0.48	0.32	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
UCEC	cis	rs4789693	0.544	rs4789770	ENSG00000265458.1	RP13-20L14.6	4.15	5.58e-05	0.0449	0.37	0.32	Glucocorticoid-induced osteonecrosis;	chr17:82418779	chr17:82454273~82458521:-
UCEC	cis	rs56949836	0.901	rs73649403	ENSG00000235641.4	LINC00484	4.15	5.58e-05	0.0449	0.61	0.32	Luteinizing hormone levels in polycystic ovary syndrome;	chr9:90168153	chr9:91159573~91165658:+
UCEC	cis	rs12744310	0.895	rs1892417	ENSG00000235358.1	RP11-399E6.1	4.15	5.58e-05	0.0449	0.53	0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41314001	chr1:41242373~41284861:+
UCEC	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	4.15	5.59e-05	0.0449	0.39	0.32	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	4.15	5.59e-05	0.0449	0.39	0.32	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	4.15	5.59e-05	0.0449	0.39	0.32	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	4.15	5.59e-05	0.0449	0.39	0.32	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	4.15	5.59e-05	0.0449	0.39	0.32	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	4.15	5.59e-05	0.0449	0.39	0.32	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	4.15	5.59e-05	0.0449	0.39	0.32	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
UCEC	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	4.15	5.59e-05	0.0449	0.39	0.32	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
UCEC	cis	rs7914558	0.966	rs7908280	ENSG00000272912.1	RP11-724N1.1	-4.15	5.59e-05	0.0449	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103057190	chr10:102914585~102915404:+
UCEC	cis	rs6901004	0.712	rs367734	ENSG00000271789.1	RP5-1112D6.7	-4.15	5.59e-05	0.0449	-0.38	-0.32	Blood metabolite levels;	chr6:111191175	chr6:111297126~111298510:+
UCEC	cis	rs2276314	1	rs9304153	ENSG00000267627.4	RP11-905K4.1	-4.15	5.6e-05	0.045	-0.37	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35951803~35966118:-
UCEC	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	4.15	5.61e-05	0.0451	0.34	0.32	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
UCEC	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	4.15	5.61e-05	0.0451	0.3	0.32	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
UCEC	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	4.15	5.61e-05	0.0451	0.33	0.32	Height;	chr6:109403734	chr6:109382795~109383666:+
UCEC	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	4.15	5.61e-05	0.0451	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	4.15	5.61e-05	0.0451	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
UCEC	cis	rs28386778	0.897	rs11079510	ENSG00000240280.5	TCAM1P	-4.15	5.63e-05	0.0452	-0.37	-0.32	Prudent dietary pattern;	chr17:63743542	chr17:63849292~63864379:+
UCEC	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-4.15	5.63e-05	0.0452	-0.3	-0.32	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
UCEC	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-4.15	5.63e-05	0.0452	-0.4	-0.32	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
UCEC	cis	rs6968355	0.799	rs6961188	ENSG00000237513.1	RP11-325F22.2	4.15	5.63e-05	0.0452	0.62	0.32	Myopia (pathological);	chr7:104956308	chr7:104941063~104962334:+
UCEC	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-4.15	5.64e-05	0.0453	-0.3	-0.32	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
UCEC	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	4.15	5.64e-05	0.0453	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
UCEC	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-4.15	5.64e-05	0.0453	-0.3	-0.32	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
UCEC	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-4.15	5.64e-05	0.0453	-0.3	-0.32	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
UCEC	cis	rs35160687	0.644	rs4832271	ENSG00000273080.1	RP11-301O19.1	-4.15	5.64e-05	0.0453	-0.37	-0.32	Night sleep phenotypes;	chr2:86278204	chr2:86195590~86196049:+
UCEC	cis	rs35160687	0.644	rs28488524	ENSG00000273080.1	RP11-301O19.1	-4.15	5.64e-05	0.0453	-0.37	-0.32	Night sleep phenotypes;	chr2:86284021	chr2:86195590~86196049:+
UCEC	cis	rs4845570	1	rs7416415	ENSG00000203288.3	RP11-98D18.9	4.15	5.65e-05	0.0453	0.48	0.32	Coronary artery disease;	chr1:151785322	chr1:151790804~151794402:+
UCEC	cis	rs4845570	0.92	rs10788809	ENSG00000203288.3	RP11-98D18.9	4.15	5.65e-05	0.0453	0.48	0.32	Coronary artery disease;	chr1:151788316	chr1:151790804~151794402:+
UCEC	cis	rs35914442	0.71	rs67670110	ENSG00000254432.1	RP11-33I11.2	-4.15	5.68e-05	0.0455	-0.48	-0.32	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;	chr8:60837102	chr8:60808735~60809606:-
UCEC	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	4.15	5.68e-05	0.0455	0.4	0.32	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
UCEC	cis	rs11971779	0.68	rs10273527	ENSG00000273391.1	RP11-634H22.1	-4.14	5.68e-05	0.0455	-0.35	-0.32	Diisocyanate-induced asthma;	chr7:139351852	chr7:139359032~139359566:-
UCEC	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-4.14	5.68e-05	0.0455	-0.3	-0.32	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
UCEC	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	4.14	5.68e-05	0.0455	0.35	0.32	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
UCEC	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-4.14	5.68e-05	0.0455	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
UCEC	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-4.14	5.68e-05	0.0455	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
UCEC	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	4.14	5.69e-05	0.0455	0.41	0.32	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
UCEC	cis	rs7914558	1	rs10883826	ENSG00000272912.1	RP11-724N1.1	-4.14	5.69e-05	0.0455	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103071062	chr10:102914585~102915404:+
UCEC	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	4.14	5.69e-05	0.0455	0.35	0.32	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
UCEC	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	4.14	5.69e-05	0.0455	0.35	0.32	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
UCEC	cis	rs9545047	0.935	rs1577416	ENSG00000227354.5	RBM26-AS1	-4.14	5.69e-05	0.0455	-0.35	-0.32	Schizophrenia;	chr13:79500646	chr13:79406309~79424328:+
UCEC	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-4.14	5.69e-05	0.0455	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
UCEC	cis	rs853679	0.517	rs9393890	ENSG00000216901.1	AL022393.7	4.14	5.7e-05	0.0455	0.38	0.32	Depression;	chr6:28096077	chr6:28176188~28176674:+
UCEC	cis	rs853679	0.517	rs9366715	ENSG00000216901.1	AL022393.7	4.14	5.7e-05	0.0455	0.38	0.32	Depression;	chr6:28096855	chr6:28176188~28176674:+
UCEC	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-4.14	5.7e-05	0.0455	-0.32	-0.32	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
UCEC	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-4.14	5.7e-05	0.0455	-0.41	-0.32	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
UCEC	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-4.14	5.7e-05	0.0455	-0.38	-0.32	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
UCEC	cis	rs7914558	0.966	rs10748839	ENSG00000272912.1	RP11-724N1.1	-4.14	5.7e-05	0.0456	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103193790	chr10:102914585~102915404:+
UCEC	cis	rs62025270	0.632	rs62022919	ENSG00000202081.1	RNU6-1280P	-4.14	5.71e-05	0.0456	-0.43	-0.32	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85651522~85651628:-
UCEC	cis	rs62025270	0.632	rs17636096	ENSG00000202081.1	RNU6-1280P	-4.14	5.71e-05	0.0456	-0.43	-0.32	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85651522~85651628:-
UCEC	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	4.14	5.71e-05	0.0456	0.38	0.32	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
UCEC	cis	rs1876905	0.539	rs240969	ENSG00000271789.1	RP5-1112D6.7	4.14	5.71e-05	0.0456	0.5	0.32	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111297126~111298510:+
UCEC	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	4.14	5.72e-05	0.0456	0.4	0.32	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
UCEC	cis	rs2281636	0.66	rs61871318	ENSG00000233690.1	EBAG9P1	4.14	5.72e-05	0.0457	0.32	0.32	Obesity-related traits;	chr10:99606784	chr10:99697407~99697949:-
UCEC	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-4.14	5.72e-05	0.0457	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-4.14	5.72e-05	0.0457	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-4.14	5.72e-05	0.0457	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	4.14	5.72e-05	0.0457	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	4.14	5.72e-05	0.0457	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	4.14	5.72e-05	0.0457	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	4.14	5.72e-05	0.0457	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
UCEC	cis	rs507080	0.769	rs7389	ENSG00000278376.1	RP11-158I9.8	4.14	5.73e-05	0.0457	0.32	0.32	Serum metabolite levels;	chr11:118657756	chr11:118791254~118793137:+
UCEC	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-4.14	5.73e-05	0.0457	-0.45	-0.32	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
UCEC	cis	rs7914558	0.966	rs10748836	ENSG00000272912.1	RP11-724N1.1	-4.14	5.73e-05	0.0457	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102934160	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs10786727	ENSG00000272912.1	RP11-724N1.1	-4.14	5.73e-05	0.0457	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102938766	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs10883805	ENSG00000272912.1	RP11-724N1.1	-4.14	5.73e-05	0.0457	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102948494	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.933	rs10786729	ENSG00000272912.1	RP11-724N1.1	-4.14	5.73e-05	0.0457	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102959621	chr10:102914585~102915404:+
UCEC	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-4.14	5.74e-05	0.0458	-0.41	-0.32	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
UCEC	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-4.14	5.74e-05	0.0458	-0.42	-0.32	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
UCEC	cis	rs875971	0.545	rs6460298	ENSG00000236529.1	RP13-254B10.1	4.14	5.75e-05	0.0458	0.48	0.32	Aortic root size;	chr7:66442783	chr7:65840212~65840596:+
UCEC	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	4.14	5.76e-05	0.0459	0.34	0.32	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
UCEC	cis	rs4699052	0.625	rs6828829	ENSG00000248740.4	RP11-328K4.1	4.14	5.76e-05	0.0459	0.33	0.32	Testicular germ cell tumor;	chr4:103414510	chr4:103256159~103453658:+
UCEC	cis	rs7665090	0.528	rs4235405	ENSG00000246560.2	RP11-10L12.4	4.14	5.77e-05	0.0459	0.42	0.32	Primary biliary cholangitis;	chr4:102595654	chr4:102828055~102844075:+
UCEC	cis	rs875971	1	rs4717300	ENSG00000236529.1	RP13-254B10.1	4.14	5.79e-05	0.046	0.37	0.32	Aortic root size;	chr7:66482393	chr7:65840212~65840596:+
UCEC	cis	rs9545047	0.604	rs9318640	ENSG00000227354.5	RBM26-AS1	-4.14	5.79e-05	0.046	-0.31	-0.32	Schizophrenia;	chr13:79426527	chr13:79406309~79424328:+
UCEC	cis	rs7674212	0.541	rs2251322	ENSG00000246560.2	RP11-10L12.4	4.14	5.79e-05	0.046	0.38	0.32	Type 2 diabetes;	chr4:103158267	chr4:102828055~102844075:+
UCEC	cis	rs7674212	0.57	rs2251634	ENSG00000246560.2	RP11-10L12.4	4.14	5.79e-05	0.046	0.38	0.32	Type 2 diabetes;	chr4:103161192	chr4:102828055~102844075:+
UCEC	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-4.14	5.79e-05	0.046	-0.41	-0.32	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
UCEC	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-4.14	5.79e-05	0.046	-0.41	-0.32	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
UCEC	cis	rs948562	0.744	rs11229481	ENSG00000280010.1	AP001350.4	4.14	5.79e-05	0.046	0.53	0.32	Lymphoma;	chr11:58464426	chr11:58627435~58628528:+
UCEC	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-4.14	5.79e-05	0.046	-0.41	-0.32	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
UCEC	cis	rs7208859	0.623	rs8075163	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.706	rs8075107	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Body mass index;	chr17:30779631	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs7223209	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs7223404	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9916725	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9916727	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs73269945	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9897728	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs1054400	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs1054397	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9890558	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9912283	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs3752020	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9890855	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9893422	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9891166	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs73269974	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs34756112	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.573	rs60724269	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs76633166	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs1061346	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs1061343	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs73269988	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.673	rs9899525	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9911784	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9911997	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9890862	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs78071511	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs2035494	ENSG00000266490.1	CTD-2349P21.9	4.14	5.79e-05	0.046	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30792372~30792833:+
UCEC	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-4.14	5.82e-05	0.0462	-0.41	-0.32	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
UCEC	cis	rs9926296	0.568	rs4420527	ENSG00000260259.1	RP11-368I7.4	4.14	5.82e-05	0.0462	0.29	0.32	Vitiligo;	chr16:89747780	chr16:89682620~89686569:-
UCEC	cis	rs1555322	0.53	rs8122819	ENSG00000269202.1	RP4-614O4.12	-4.14	5.82e-05	0.0462	-0.34	-0.32	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35201747~35203288:-
UCEC	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	4.14	5.83e-05	0.0463	0.38	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
UCEC	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	4.14	5.84e-05	0.0463	0.39	0.32	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
UCEC	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	4.14	5.84e-05	0.0463	0.43	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
UCEC	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	4.14	5.84e-05	0.0463	0.36	0.32	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	4.14	5.84e-05	0.0463	0.36	0.32	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	4.14	5.84e-05	0.0463	0.36	0.32	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	4.14	5.84e-05	0.0463	0.36	0.32	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
UCEC	cis	rs17133935	1	rs2331140	ENSG00000228903.5	RASA4CP	4.14	5.84e-05	0.0464	0.46	0.32	Systolic blood pressure change trajectories;	chr7:44710628	chr7:44026951~44041892:-
UCEC	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-4.14	5.86e-05	0.0464	-0.38	-0.32	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
UCEC	cis	rs2445284	0.845	rs2500052	ENSG00000229534.1	HNRNPA1P53	-4.14	5.86e-05	0.0464	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5058838	chr11:5571247~5572192:-
UCEC	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-4.14	5.86e-05	0.0464	-0.33	-0.32	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
UCEC	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	4.14	5.86e-05	0.0464	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
UCEC	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	4.14	5.86e-05	0.0464	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
UCEC	cis	rs465969	1	rs17510733	ENSG00000271789.1	RP5-1112D6.7	4.14	5.86e-05	0.0465	0.84	0.32	Psoriasis;	chr6:111389715	chr6:111297126~111298510:+
UCEC	cis	rs2276314	0.857	rs7237599	ENSG00000267627.4	RP11-905K4.1	-4.14	5.86e-05	0.0465	-0.34	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35951803~35966118:-
UCEC	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
UCEC	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	4.14	5.86e-05	0.0465	0.4	0.32	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
UCEC	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	4.14	5.88e-05	0.0465	0.34	0.32	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
UCEC	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	4.14	5.88e-05	0.0465	0.35	0.32	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
UCEC	cis	rs9322193	0.923	rs958953	ENSG00000216906.2	RP11-350J20.9	4.14	5.88e-05	0.0466	0.34	0.32	Lung cancer;	chr6:149840735	chr6:149904243~149906418:+
UCEC	cis	rs12780046	0.505	rs7893990	ENSG00000229278.1	RP11-483F11.7	4.14	5.89e-05	0.0466	0.38	0.32	Non-glioblastoma glioma;	chr10:98905019	chr10:99651989~99653905:-
UCEC	cis	rs10895275	0.649	rs1895916	ENSG00000277459.1	RP11-732A21.3	4.14	5.89e-05	0.0466	0.32	0.32	Migraine;	chr11:102221938	chr11:102109827~102110457:-
UCEC	cis	rs6840360	0.642	rs7658169	ENSG00000251611.1	RP11-610P16.1	-4.14	5.9e-05	0.0467	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151407551~151408835:-
UCEC	cis	rs2445284	0.756	rs2442418	ENSG00000229534.1	HNRNPA1P53	-4.14	5.9e-05	0.0467	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5009356	chr11:5571247~5572192:-
UCEC	cis	rs875971	0.964	rs778735	ENSG00000236529.1	RP13-254B10.1	4.14	5.9e-05	0.0467	0.37	0.32	Aortic root size;	chr7:66349822	chr7:65840212~65840596:+
UCEC	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	4.14	5.9e-05	0.0467	0.4	0.32	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
UCEC	cis	rs4776970	0.632	rs12592101	ENSG00000260657.2	RP11-315D16.4	4.14	5.9e-05	0.0467	0.37	0.32	Body mass index;Waist circumference;	chr15:67737232	chr15:68267792~68277994:-
UCEC	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-4.13	5.91e-05	0.0467	-0.36	-0.32	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-4.13	5.91e-05	0.0467	-0.36	-0.32	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
UCEC	cis	rs6071166	0.683	rs6064884	ENSG00000224635.1	RP4-564F22.5	-4.13	5.91e-05	0.0467	-0.36	-0.32	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38691352	chr20:38406011~38416797:-
UCEC	cis	rs4699052	0.597	rs951598	ENSG00000248740.4	RP11-328K4.1	4.13	5.92e-05	0.0468	0.34	0.32	Testicular germ cell tumor;	chr4:103431408	chr4:103256159~103453658:+
UCEC	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-4.13	5.92e-05	0.0468	-0.3	-0.32	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
UCEC	cis	rs4073582	0.595	rs10896104	ENSG00000255320.1	RP11-755F10.1	-4.13	5.92e-05	0.0468	-0.43	-0.32	Gout;	chr11:66234398	chr11:66244840~66246239:-
UCEC	cis	rs11697848	1	rs76939398	ENSG00000234693.1	RP4-530I15.6	4.13	5.92e-05	0.0468	0.75	0.32	Systemic lupus erythematosus;	chr20:49974050	chr20:50645471~50662275:+
UCEC	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-4.13	5.92e-05	0.0468	-0.37	-0.32	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
UCEC	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	4.13	5.92e-05	0.0468	0.33	0.32	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	4.13	5.92e-05	0.0468	0.33	0.32	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	4.13	5.92e-05	0.0468	0.33	0.32	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
UCEC	cis	rs875971	0.862	rs778734	ENSG00000236529.1	RP13-254B10.1	4.13	5.93e-05	0.0468	0.37	0.32	Aortic root size;	chr7:66349862	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	4.13	5.93e-05	0.0469	0.36	0.32	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
UCEC	cis	rs10740039	0.883	rs10994468	ENSG00000254271.1	RP11-131N11.4	4.13	5.93e-05	0.0469	0.38	0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60666533	chr10:60734342~60741828:+
UCEC	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	4.13	5.94e-05	0.0469	0.33	0.32	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	4.13	5.94e-05	0.0469	0.33	0.32	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	4.13	5.94e-05	0.0469	0.33	0.32	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	4.13	5.94e-05	0.0469	0.33	0.32	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	4.13	5.94e-05	0.0469	0.33	0.32	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	4.13	5.94e-05	0.0469	0.33	0.32	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
UCEC	cis	rs62103177	0.714	rs28691615	ENSG00000261126.6	RP11-795F19.1	4.13	5.94e-05	0.0469	0.39	0.32	Opioid sensitivity;	chr18:79852254	chr18:80046900~80095482:+
UCEC	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-4.13	5.95e-05	0.047	-0.34	-0.32	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
UCEC	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-4.13	5.95e-05	0.047	-0.34	-0.32	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
UCEC	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-4.13	5.95e-05	0.047	-0.34	-0.32	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
UCEC	cis	rs7246967	0.608	rs437859	ENSG00000198153.8	ZNF849P	4.13	5.95e-05	0.047	0.37	0.32	Bronchopulmonary dysplasia;	chr19:22824547	chr19:22685167~22686732:+
UCEC	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	4.13	5.95e-05	0.047	0.37	0.32	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
UCEC	cis	rs2445284	0.845	rs2445330	ENSG00000229534.1	HNRNPA1P53	-4.13	5.96e-05	0.047	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5058411	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs2445331	ENSG00000229534.1	HNRNPA1P53	-4.13	5.96e-05	0.047	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5058418	chr11:5571247~5572192:-
UCEC	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-4.13	5.96e-05	0.047	-0.38	-0.32	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
UCEC	cis	rs7760535	0.763	rs10457241	ENSG00000271789.1	RP5-1112D6.7	-4.13	5.96e-05	0.047	-0.39	-0.32	Metabolic traits;	chr6:111527831	chr6:111297126~111298510:+
UCEC	cis	rs875971	1	rs7781698	ENSG00000224316.1	RP11-479O9.2	4.13	5.96e-05	0.047	0.33	0.32	Aortic root size;	chr7:66431325	chr7:65773620~65802067:+
UCEC	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	4.13	5.97e-05	0.0471	0.33	0.32	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
UCEC	cis	rs12304921	0.639	rs7722	ENSG00000277201.1	AC087884.1	4.13	5.97e-05	0.0471	0.29	0.32	Type 2 diabetes;	chr12:51061621	chr12:51049921~51050025:+
UCEC	cis	rs12304921	0.639	rs2306732	ENSG00000277201.1	AC087884.1	4.13	5.97e-05	0.0471	0.29	0.32	Type 2 diabetes;	chr12:51061956	chr12:51049921~51050025:+
UCEC	cis	rs875971	0.867	rs1002053	ENSG00000236529.1	RP13-254B10.1	-4.13	5.98e-05	0.0471	-0.35	-0.32	Aortic root size;	chr7:66333558	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs6460292	ENSG00000236529.1	RP13-254B10.1	-4.13	5.98e-05	0.0471	-0.35	-0.32	Aortic root size;	chr7:66345088	chr7:65840212~65840596:+
UCEC	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	4.13	5.99e-05	0.0471	0.4	0.32	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
UCEC	cis	rs7520050	0.751	rs2230657	ENSG00000280836.1	AL355480.1	4.13	5.99e-05	0.0472	0.34	0.32	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45581219~45581321:-
UCEC	cis	rs875971	0.862	rs908915	ENSG00000236529.1	RP13-254B10.1	-4.13	5.99e-05	0.0472	-0.37	-0.32	Aortic root size;	chr7:66149664	chr7:65840212~65840596:+
UCEC	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-4.13	5.99e-05	0.0472	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
UCEC	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-4.13	5.99e-05	0.0472	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
UCEC	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	4.13	6e-05	0.0472	0.42	0.32	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
UCEC	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	4.13	6e-05	0.0472	0.5	0.32	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
UCEC	cis	rs2991971	0.81	rs998199	ENSG00000280836.1	AL355480.1	-4.13	6e-05	0.0473	-0.36	-0.32	High light scatter reticulocyte count;	chr1:45447226	chr1:45581219~45581321:-
UCEC	cis	rs2991971	0.81	rs2356413	ENSG00000280836.1	AL355480.1	-4.13	6e-05	0.0473	-0.36	-0.32	High light scatter reticulocyte count;	chr1:45448376	chr1:45581219~45581321:-
UCEC	cis	rs2991971	0.716	rs7532573	ENSG00000280836.1	AL355480.1	-4.13	6e-05	0.0473	-0.36	-0.32	High light scatter reticulocyte count;	chr1:45450220	chr1:45581219~45581321:-
UCEC	cis	rs229541	0.931	rs2858484	ENSG00000237862.1	RP1-63G5.7	4.13	6.01e-05	0.0473	0.39	0.32	Type 1 diabetes;	chr22:37190636	chr22:37352190~37354839:-
UCEC	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-4.13	6.01e-05	0.0473	-0.39	-0.32	Height;	chr3:52994045	chr3:53064283~53065091:-
UCEC	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-4.13	6.01e-05	0.0473	-0.39	-0.32	Height;	chr3:52994990	chr3:53064283~53065091:-
UCEC	cis	rs6840360	0.642	rs1470281	ENSG00000251611.1	RP11-610P16.1	-4.13	6.01e-05	0.0473	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151407551~151408835:-
UCEC	cis	rs4266144	0.558	rs4680339	ENSG00000241770.1	RP11-555M1.3	4.13	6.02e-05	0.0473	0.36	0.32	Coronary artery disease;	chr3:157117630	chr3:157163452~157169133:+
UCEC	cis	rs1577917	0.559	rs7763210	ENSG00000234155.1	RP11-30P6.6	-4.13	6.02e-05	0.0473	-0.33	-0.32	Response to antipsychotic treatment;	chr6:86098900	chr6:85387219~85390186:-
UCEC	cis	rs1002107	0.628	rs73133296	ENSG00000257526.2	RP11-20E24.1	-4.13	6.02e-05	0.0474	-0.62	-0.32	Methadone dose in opioid dependence;	chr12:77076050	chr12:76562294~76615567:+
UCEC	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	4.13	6.03e-05	0.0474	0.48	0.32	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
UCEC	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	4.13	6.03e-05	0.0474	0.48	0.32	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
UCEC	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	4.13	6.03e-05	0.0474	0.48	0.32	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
UCEC	cis	rs542925	0.737	rs6569548	ENSG00000227945.1	RP11-103C16.2	-4.13	6.03e-05	0.0474	-0.39	-0.32	Caudate activity during reward;	chr6:128707759	chr6:128027886~128085248:+
UCEC	cis	rs7674212	0.57	rs1031804	ENSG00000246560.2	RP11-10L12.4	4.13	6.03e-05	0.0474	0.38	0.32	Type 2 diabetes;	chr4:103144892	chr4:102828055~102844075:+
UCEC	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	4.13	6.05e-05	0.0475	0.4	0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
UCEC	cis	rs7674212	0.54	rs2720469	ENSG00000246560.2	RP11-10L12.4	4.13	6.05e-05	0.0476	0.38	0.32	Type 2 diabetes;	chr4:103165327	chr4:102828055~102844075:+
UCEC	cis	rs7674212	0.57	rs12501621	ENSG00000246560.2	RP11-10L12.4	4.13	6.05e-05	0.0476	0.38	0.32	Type 2 diabetes;	chr4:103174348	chr4:102828055~102844075:+
UCEC	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-4.13	6.06e-05	0.0476	-0.35	-0.32	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
UCEC	cis	rs7246967	0.611	rs62118770	ENSG00000198153.8	ZNF849P	-4.13	6.06e-05	0.0476	-0.51	-0.32	Bronchopulmonary dysplasia;	chr19:22641227	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs62118771	ENSG00000198153.8	ZNF849P	-4.13	6.06e-05	0.0476	-0.51	-0.32	Bronchopulmonary dysplasia;	chr19:22641496	chr19:22685167~22686732:+
UCEC	cis	rs7246967	0.611	rs62118780	ENSG00000198153.8	ZNF849P	-4.13	6.06e-05	0.0476	-0.51	-0.32	Bronchopulmonary dysplasia;	chr19:22648312	chr19:22685167~22686732:+
UCEC	cis	rs4845570	0.92	rs6694952	ENSG00000203288.3	RP11-98D18.9	4.13	6.06e-05	0.0476	0.48	0.32	Coronary artery disease;	chr1:151787655	chr1:151790804~151794402:+
UCEC	cis	rs573521	1	rs679620	ENSG00000243777.1	RP11-864G5.1	-4.13	6.07e-05	0.0477	-0.34	-0.32	Cerebrospinal fluid levels of Alzheimer's disease-related proteins;	chr11:102842889	chr11:102295060~102295806:+
UCEC	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	4.13	6.07e-05	0.0477	0.3	0.32	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
UCEC	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	4.13	6.07e-05	0.0477	0.3	0.32	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	4.13	6.07e-05	0.0477	0.3	0.32	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
UCEC	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	4.13	6.07e-05	0.0477	0.3	0.32	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
UCEC	cis	rs34286592	1	rs3815824	ENSG00000238045.8	AC009133.12	4.13	6.07e-05	0.0477	0.52	0.32	Multiple sclerosis;	chr16:29841539	chr16:29808636~29821252:-
UCEC	cis	rs34286592	0.929	rs9939514	ENSG00000238045.8	AC009133.12	4.13	6.07e-05	0.0477	0.52	0.32	Multiple sclerosis;	chr16:29844410	chr16:29808636~29821252:-
UCEC	cis	rs34286592	1	rs4787480	ENSG00000238045.8	AC009133.12	4.13	6.07e-05	0.0477	0.52	0.32	Multiple sclerosis;	chr16:29845995	chr16:29808636~29821252:-
UCEC	cis	rs34286592	1	rs7201519	ENSG00000238045.8	AC009133.12	4.13	6.07e-05	0.0477	0.52	0.32	Multiple sclerosis;	chr16:29848656	chr16:29808636~29821252:-
UCEC	cis	rs34286592	1	rs28599680	ENSG00000238045.8	AC009133.12	4.13	6.07e-05	0.0477	0.52	0.32	Multiple sclerosis;	chr16:29849364	chr16:29808636~29821252:-
UCEC	cis	rs7914558	1	rs3740387	ENSG00000272912.1	RP11-724N1.1	-4.13	6.07e-05	0.0477	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103089711	chr10:102914585~102915404:+
UCEC	cis	rs12478296	1	rs7603984	ENSG00000261186.2	RP11-341N2.1	-4.13	6.08e-05	0.0477	-0.44	-0.32	Obesity-related traits;	chr2:242105143	chr2:242087351~242088457:-
UCEC	cis	rs7208859	0.524	rs11653605	ENSG00000266490.1	CTD-2349P21.9	4.13	6.08e-05	0.0477	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30792372~30792833:+
UCEC	cis	rs507080	0.922	rs478296	ENSG00000278376.1	RP11-158I9.8	-4.13	6.08e-05	0.0477	-0.31	-0.32	Serum metabolite levels;	chr11:118696666	chr11:118791254~118793137:+
UCEC	cis	rs507080	0.922	rs493834	ENSG00000278376.1	RP11-158I9.8	-4.13	6.08e-05	0.0477	-0.31	-0.32	Serum metabolite levels;	chr11:118696735	chr11:118791254~118793137:+
UCEC	cis	rs7914558	0.966	rs11191471	ENSG00000272912.1	RP11-724N1.1	-4.13	6.08e-05	0.0477	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102942293	chr10:102914585~102915404:+
UCEC	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	4.13	6.09e-05	0.0478	0.45	0.32	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
UCEC	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	4.13	6.09e-05	0.0478	0.3	0.32	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
UCEC	cis	rs2732480	0.538	rs1387259	ENSG00000226413.2	OR8T1P	-4.13	6.09e-05	0.0478	-0.48	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48442030~48442947:-
UCEC	cis	rs11971779	0.68	rs4398844	ENSG00000273391.1	RP11-634H22.1	4.13	6.09e-05	0.0478	0.34	0.32	Diisocyanate-induced asthma;	chr7:139358393	chr7:139359032~139359566:-
UCEC	cis	rs12468226	0.938	rs7585867	ENSG00000273456.1	RP11-686O6.2	4.13	6.09e-05	0.0478	0.39	0.32	Urate levels;	chr2:202287040	chr2:202374932~202375604:-
UCEC	cis	rs12468226	0.938	rs55681656	ENSG00000273456.1	RP11-686O6.2	4.13	6.09e-05	0.0478	0.39	0.32	Urate levels;	chr2:202319041	chr2:202374932~202375604:-
UCEC	cis	rs875971	0.893	rs62465470	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66136231	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs4368860	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66143495	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.825	rs4587224	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66271195	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.792	rs6971752	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66272999	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs10950033	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66274686	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs11760844	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66274896	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs4149461	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66279745	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs10261398	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66285177	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs10224872	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66294786	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs949930	ENSG00000236529.1	RP13-254B10.1	-4.13	6.09e-05	0.0478	-0.37	-0.32	Aortic root size;	chr7:66301835	chr7:65840212~65840596:+
UCEC	cis	rs17772222	0.582	rs12050316	ENSG00000258983.2	RP11-507K2.2	4.13	6.09e-05	0.0478	0.3	0.32	Coronary artery calcification;	chr14:88522097	chr14:88499334~88515502:+
UCEC	cis	rs7208859	0.524	rs8069400	ENSG00000266490.1	CTD-2349P21.9	4.13	6.09e-05	0.0478	0.49	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30792372~30792833:+
UCEC	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-4.13	6.1e-05	0.0478	-0.36	-0.32	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
UCEC	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-4.13	6.1e-05	0.0478	-0.39	-0.32	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
UCEC	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-4.13	6.1e-05	0.0478	-0.39	-0.32	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
UCEC	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-4.13	6.1e-05	0.0478	-0.39	-0.32	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
UCEC	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-4.13	6.1e-05	0.0478	-0.4	-0.32	Depression;	chr6:28193021	chr6:28115628~28116551:+
UCEC	cis	rs7208859	0.562	rs8078897	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9914499	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs12006	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs3752021	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs1061342	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs55938328	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs55961983	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.573	rs7222803	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.568	rs7213925	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Body mass index;	chr17:30794616	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs11658945	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs11657990	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs11650982	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs9915546	ENSG00000266490.1	CTD-2349P21.9	4.13	6.1e-05	0.0478	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30792372~30792833:+
UCEC	cis	rs7914558	0.966	rs943035	ENSG00000272912.1	RP11-724N1.1	-4.13	6.11e-05	0.0478	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103079395	chr10:102914585~102915404:+
UCEC	cis	rs7914558	0.966	rs7921574	ENSG00000272912.1	RP11-724N1.1	-4.13	6.11e-05	0.0478	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103081213	chr10:102914585~102915404:+
UCEC	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-4.13	6.11e-05	0.0479	-0.43	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
UCEC	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-4.13	6.11e-05	0.0479	-0.42	-0.32	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
UCEC	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	4.13	6.11e-05	0.0479	0.33	0.32	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
UCEC	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	4.13	6.11e-05	0.0479	0.33	0.32	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
UCEC	cis	rs875971	0.862	rs17747530	ENSG00000236529.1	RP13-254B10.1	4.13	6.12e-05	0.0479	0.39	0.32	Aortic root size;	chr7:66529742	chr7:65840212~65840596:+
UCEC	cis	rs6430585	0.591	rs309118	ENSG00000231890.6	DARS-AS1	-4.13	6.12e-05	0.0479	-0.43	-0.32	Corneal structure;	chr2:135988654	chr2:135985176~136022593:+
UCEC	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-4.13	6.12e-05	0.0479	-0.31	-0.32	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
UCEC	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	4.13	6.12e-05	0.0479	0.37	0.32	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
UCEC	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	4.13	6.12e-05	0.0479	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
UCEC	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-4.13	6.12e-05	0.0479	-0.38	-0.32	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
UCEC	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	4.13	6.12e-05	0.0479	0.34	0.32	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	4.13	6.12e-05	0.0479	0.34	0.32	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	4.13	6.12e-05	0.0479	0.34	0.32	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
UCEC	cis	rs9322193	0.962	rs2275045	ENSG00000216906.2	RP11-350J20.9	4.13	6.12e-05	0.0479	0.34	0.32	Lung cancer;	chr6:149842775	chr6:149904243~149906418:+
UCEC	cis	rs17826219	0.5	rs28452421	ENSG00000266490.1	CTD-2349P21.9	4.13	6.13e-05	0.0479	0.45	0.32	Body mass index;	chr17:30756962	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.573	rs28779471	ENSG00000266490.1	CTD-2349P21.9	4.13	6.13e-05	0.0479	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30792372~30792833:+
UCEC	cis	rs17826219	0.5	rs61685770	ENSG00000266490.1	CTD-2349P21.9	4.13	6.13e-05	0.0479	0.45	0.32	Body mass index;	chr17:30758695	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs57486336	ENSG00000266490.1	CTD-2349P21.9	4.13	6.13e-05	0.0479	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs12103440	ENSG00000266490.1	CTD-2349P21.9	4.13	6.13e-05	0.0479	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30792372~30792833:+
UCEC	cis	rs7208859	0.623	rs11657777	ENSG00000266490.1	CTD-2349P21.9	4.13	6.13e-05	0.0479	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30792372~30792833:+
UCEC	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-4.13	6.13e-05	0.0479	-0.43	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
UCEC	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-4.13	6.13e-05	0.0479	-0.33	-0.32	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-4.13	6.13e-05	0.0479	-0.33	-0.32	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-4.13	6.13e-05	0.0479	-0.33	-0.32	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-4.13	6.13e-05	0.0479	-0.33	-0.32	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
UCEC	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-4.13	6.13e-05	0.0479	-0.33	-0.32	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
UCEC	cis	rs4073582	0.595	rs801736	ENSG00000255320.1	RP11-755F10.1	-4.13	6.13e-05	0.048	-0.42	-0.32	Gout;	chr11:66160959	chr11:66244840~66246239:-
UCEC	cis	rs4073582	0.595	rs801734	ENSG00000255320.1	RP11-755F10.1	-4.13	6.13e-05	0.048	-0.42	-0.32	Gout;	chr11:66163745	chr11:66244840~66246239:-
UCEC	cis	rs875971	0.895	rs4145009	ENSG00000236529.1	RP13-254B10.1	-4.13	6.14e-05	0.048	-0.37	-0.32	Aortic root size;	chr7:66261628	chr7:65840212~65840596:+
UCEC	cis	rs75422866	0.867	rs73111258	ENSG00000274902.1	RP1-197B17.4	4.13	6.14e-05	0.048	0.81	0.32	Pneumonia;	chr12:47597313	chr12:47731908~47732351:+
UCEC	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-4.13	6.14e-05	0.048	-0.42	-0.32	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
UCEC	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	4.12	6.14e-05	0.048	0.37	0.32	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
UCEC	cis	rs12744310	0.83	rs12045184	ENSG00000235358.1	RP11-399E6.1	4.12	6.15e-05	0.048	0.55	0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333939	chr1:41242373~41284861:+
UCEC	cis	rs28386778	0.863	rs4968661	ENSG00000240280.5	TCAM1P	-4.12	6.15e-05	0.048	-0.36	-0.32	Prudent dietary pattern;	chr17:63718946	chr17:63849292~63864379:+
UCEC	cis	rs5770917	0.522	rs8142477	ENSG00000272821.1	CTA-384D8.36	-4.12	6.15e-05	0.0481	-0.38	-0.32	Narcolepsy;	chr22:50572947	chr22:50523926~50524780:+
UCEC	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-4.12	6.16e-05	0.0481	-0.4	-0.32	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
UCEC	cis	rs642858	0.83	rs9376507	ENSG00000234147.1	RP3-460G2.2	-4.12	6.16e-05	0.0481	-0.53	-0.32	Type 2 diabetes;	chr6:140256961	chr6:140845958~140852924:-
UCEC	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	4.12	6.16e-05	0.0481	0.35	0.32	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
UCEC	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-4.12	6.16e-05	0.0481	-0.36	-0.32	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
UCEC	cis	rs17064136	0.778	rs2872892	ENSG00000278291.1	RP11-172H24.4	-4.12	6.16e-05	0.0482	-0.41	-0.32	Obesity-related traits;	chr13:21234958	chr13:20699307~20703718:-
UCEC	cis	rs17772222	0.606	rs449338	ENSG00000258983.2	RP11-507K2.2	-4.12	6.17e-05	0.0482	-0.31	-0.32	Coronary artery calcification;	chr14:88411690	chr14:88499334~88515502:+
UCEC	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-4.12	6.17e-05	0.0482	-0.35	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
UCEC	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-4.12	6.17e-05	0.0482	-0.41	-0.32	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
UCEC	cis	rs7611238	1	rs13059843	ENSG00000237418.1	AC069257.6	-4.12	6.17e-05	0.0482	-0.28	-0.32	Body mass index;	chr3:195307454	chr3:196298061~196298215:-
UCEC	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	4.12	6.17e-05	0.0482	0.33	0.32	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
UCEC	cis	rs7173743	0.518	rs12899452	ENSG00000261143.1	ADAMTS7P3	-4.12	6.17e-05	0.0482	-0.41	-0.32	Coronary artery disease;	chr15:78820208	chr15:77976042~77993057:+
UCEC	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-4.12	6.18e-05	0.0482	-0.43	-0.32	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-4.12	6.18e-05	0.0482	-0.43	-0.32	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-4.12	6.18e-05	0.0482	-0.43	-0.32	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
UCEC	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-4.12	6.18e-05	0.0482	-0.43	-0.32	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
UCEC	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-4.12	6.18e-05	0.0482	-0.44	-0.32	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
UCEC	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-4.12	6.18e-05	0.0483	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-4.12	6.18e-05	0.0483	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
UCEC	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	4.12	6.19e-05	0.0483	0.48	0.32	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
UCEC	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	4.12	6.19e-05	0.0483	0.36	0.32	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
UCEC	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-4.12	6.19e-05	0.0483	-0.43	-0.32	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
UCEC	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	4.12	6.19e-05	0.0483	0.34	0.32	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
UCEC	cis	rs34286592	1	rs13332078	ENSG00000260853.1	RP11-264B17.2	4.12	6.19e-05	0.0483	0.26	0.32	Multiple sclerosis;	chr16:29839384	chr16:28956687~28966883:-
UCEC	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	4.12	6.2e-05	0.0483	0.26	0.32	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
UCEC	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	4.12	6.2e-05	0.0483	0.38	0.32	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
UCEC	cis	rs749052	0.561	rs3103268	ENSG00000224376.1	AC017104.6	4.12	6.2e-05	0.0483	0.63	0.32	Height;	chr2:232120259	chr2:231388976~231394991:+
UCEC	cis	rs6806528	0.908	rs6772387	ENSG00000244513.5	CTD-2013N24.2	4.12	6.2e-05	0.0483	0.53	0.32	Celiac disease;	chr3:69203110	chr3:69013941~69056622:+
UCEC	cis	rs6806528	1	rs6781505	ENSG00000244513.5	CTD-2013N24.2	4.12	6.2e-05	0.0483	0.53	0.32	Celiac disease;	chr3:69203673	chr3:69013941~69056622:+
UCEC	cis	rs4789693	0.873	rs8069111	ENSG00000265458.1	RP13-20L14.6	4.12	6.2e-05	0.0483	0.38	0.32	Glucocorticoid-induced osteonecrosis;	chr17:82437581	chr17:82454273~82458521:-
UCEC	cis	rs2445284	0.845	rs2445334	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5060258	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2959185	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5060343	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2445337	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5060498	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.79	rs1840639	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5060794	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs1840640	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5060925	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.764	rs1455971	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5061037	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.817	rs1455972	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5061047	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2257785	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5061938	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.845	rs2445339	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5061977	chr11:5571247~5572192:-
UCEC	cis	rs2445284	0.78	rs2445344	ENSG00000229534.1	HNRNPA1P53	-4.12	6.21e-05	0.0484	-0.38	-0.32	Sickle cell anemia (haemolysis);	chr11:5062402	chr11:5571247~5572192:-
UCEC	cis	rs7188861	0.813	rs1794021	ENSG00000262420.3	RP11-490O6.2	4.12	6.21e-05	0.0484	0.43	0.32	HDL cholesterol;	chr16:11283377	chr16:11741910~11744506:+
UCEC	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	4.12	6.21e-05	0.0484	0.44	0.32	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
UCEC	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	4.12	6.22e-05	0.0485	0.34	0.32	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
UCEC	cis	rs7592578	0.771	rs12052514	ENSG00000272979.1	RP11-647K16.1	-4.12	6.23e-05	0.0485	-0.54	-0.32	Diastolic blood pressure;	chr2:190513444	chr2:190454092~190454521:-
UCEC	cis	rs875971	0.545	rs2420456	ENSG00000236529.1	RP13-254B10.1	4.12	6.23e-05	0.0485	0.48	0.32	Aortic root size;	chr7:66280619	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.545	rs7783889	ENSG00000236529.1	RP13-254B10.1	4.12	6.23e-05	0.0485	0.48	0.32	Aortic root size;	chr7:66283366	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs6945019	ENSG00000224316.1	RP11-479O9.2	4.12	6.23e-05	0.0485	0.33	0.32	Aortic root size;	chr7:66457471	chr7:65773620~65802067:+
UCEC	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	4.12	6.24e-05	0.0486	0.45	0.32	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
UCEC	cis	rs875971	0.965	rs10267430	ENSG00000236529.1	RP13-254B10.1	-4.12	6.25e-05	0.0486	-0.35	-0.32	Aortic root size;	chr7:66278036	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs10257427	ENSG00000236529.1	RP13-254B10.1	-4.12	6.25e-05	0.0486	-0.35	-0.32	Aortic root size;	chr7:66278221	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs10215948	ENSG00000236529.1	RP13-254B10.1	-4.12	6.25e-05	0.0486	-0.35	-0.32	Aortic root size;	chr7:66282799	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.964	rs55748098	ENSG00000236529.1	RP13-254B10.1	-4.12	6.25e-05	0.0486	-0.35	-0.32	Aortic root size;	chr7:66298631	chr7:65840212~65840596:+
UCEC	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-4.12	6.25e-05	0.0486	-0.3	-0.32	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
UCEC	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-4.12	6.26e-05	0.0487	-0.42	-0.32	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
UCEC	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-4.12	6.26e-05	0.0487	-0.42	-0.32	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
UCEC	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-4.12	6.26e-05	0.0487	-0.42	-0.32	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
UCEC	cis	rs875971	0.545	rs35459055	ENSG00000236529.1	RP13-254B10.1	4.12	6.26e-05	0.0487	0.48	0.32	Aortic root size;	chr7:66479399	chr7:65840212~65840596:+
UCEC	cis	rs9400467	0.528	rs462432	ENSG00000271789.1	RP5-1112D6.7	-4.12	6.26e-05	0.0487	-0.39	-0.32	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111297126~111298510:+
UCEC	cis	rs7760535	0.931	rs466923	ENSG00000271789.1	RP5-1112D6.7	-4.12	6.26e-05	0.0487	-0.39	-0.32	Metabolic traits;	chr6:111341774	chr6:111297126~111298510:+
UCEC	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-4.12	6.27e-05	0.0487	-0.31	-0.32	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
UCEC	cis	rs9863	0.827	rs6488913	ENSG00000269938.1	RP11-214K3.20	4.12	6.29e-05	0.0489	0.36	0.32	White blood cell count;	chr12:123961022	chr12:123968023~123968579:-
UCEC	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	4.12	6.29e-05	0.0489	0.31	0.32	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
UCEC	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-4.12	6.29e-05	0.0489	-0.38	-0.32	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
UCEC	cis	rs3002142	0.57	rs3008633	ENSG00000272750.1	RP11-378J18.8	-4.12	6.29e-05	0.0489	-0.4	-0.32	LDL peak particle diameter (total fat intake interaction);	chr1:222671498	chr1:222658867~222661512:-
UCEC	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	4.12	6.29e-05	0.0489	0.45	0.32	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
UCEC	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	4.12	6.3e-05	0.0489	0.38	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
UCEC	cis	rs7760535	0.764	rs2343614	ENSG00000271789.1	RP5-1112D6.7	-4.12	6.3e-05	0.0489	-0.38	-0.32	Metabolic traits;	chr6:111383955	chr6:111297126~111298510:+
UCEC	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	4.12	6.3e-05	0.0489	0.35	0.32	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
UCEC	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-4.12	6.3e-05	0.0489	-0.43	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
UCEC	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-4.12	6.3e-05	0.0489	-0.3	-0.32	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
UCEC	cis	rs7914558	1	rs8139	ENSG00000272912.1	RP11-724N1.1	-4.12	6.3e-05	0.049	-0.31	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103088366	chr10:102914585~102915404:+
UCEC	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-4.12	6.31e-05	0.049	-0.45	-0.32	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
UCEC	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	4.12	6.32e-05	0.049	0.36	0.32	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
UCEC	cis	rs1185460	0.967	rs1786685	ENSG00000278376.1	RP11-158I9.8	-4.12	6.32e-05	0.049	-0.29	-0.32	Coronary artery disease;	chr11:119068246	chr11:118791254~118793137:+
UCEC	cis	rs1185460	0.967	rs1784302	ENSG00000278376.1	RP11-158I9.8	-4.12	6.32e-05	0.049	-0.29	-0.32	Coronary artery disease;	chr11:119070247	chr11:118791254~118793137:+
UCEC	cis	rs6840360	0.642	rs1372977	ENSG00000251611.1	RP11-610P16.1	-4.12	6.32e-05	0.049	-0.27	-0.32	Intelligence (multi-trait analysis);	chr4:151531246	chr4:151407551~151408835:-
UCEC	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-4.12	6.32e-05	0.0491	-0.46	-0.32	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
UCEC	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	4.12	6.33e-05	0.0491	0.36	0.32	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
UCEC	cis	rs686320	1	rs1787666	ENSG00000245532.5	NEAT1	4.12	6.34e-05	0.0492	0.43	0.32	Hip circumference adjusted for BMI;	chr11:65481618	chr11:65422774~65445540:+
UCEC	cis	rs6048205	0.616	rs4815117	ENSG00000277901.1	RP5-851M4.1	4.12	6.34e-05	0.0492	0.56	0.32	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr20:22526517	chr20:23320958~23325352:-
UCEC	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-4.12	6.35e-05	0.0492	-0.36	-0.32	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-4.12	6.35e-05	0.0492	-0.36	-0.32	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
UCEC	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-4.12	6.35e-05	0.0492	-0.36	-0.32	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
UCEC	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	4.12	6.35e-05	0.0492	0.36	0.32	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
UCEC	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-4.12	6.35e-05	0.0492	-0.35	-0.32	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
UCEC	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-4.12	6.35e-05	0.0492	-0.36	-0.32	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
UCEC	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	4.12	6.36e-05	0.0493	0.39	0.32	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
UCEC	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	4.12	6.36e-05	0.0493	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
UCEC	cis	rs875971	0.737	rs7803424	ENSG00000236529.1	RP13-254B10.1	4.12	6.36e-05	0.0493	0.35	0.32	Aortic root size;	chr7:66415618	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.83	rs7799834	ENSG00000236529.1	RP13-254B10.1	4.12	6.36e-05	0.0493	0.35	0.32	Aortic root size;	chr7:66415707	chr7:65840212~65840596:+
UCEC	cis	rs5742933	0.512	rs80277863	ENSG00000253559.1	OSGEPL1-AS1	-4.12	6.36e-05	0.0493	-0.37	-0.32	Ferritin levels;	chr2:189766733	chr2:189762704~189765556:+
UCEC	cis	rs6137726	0.687	rs6048247	ENSG00000277901.1	RP5-851M4.1	-4.12	6.37e-05	0.0493	-0.39	-0.32	Amyotrophic lateral sclerosis (sporadic);	chr20:22677335	chr20:23320958~23325352:-
UCEC	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-4.12	6.37e-05	0.0493	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
UCEC	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-4.12	6.37e-05	0.0493	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
UCEC	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	4.12	6.37e-05	0.0493	0.35	0.32	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
UCEC	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	4.12	6.37e-05	0.0493	0.42	0.32	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
UCEC	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	4.11	6.39e-05	0.0494	0.42	0.32	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
UCEC	cis	rs4740829	0.735	rs7048559	ENSG00000224083.1	RP11-39K24.4	4.11	6.39e-05	0.0495	0.38	0.32	Gut microbiome composition (winter);	chr9:5892859	chr9:5096666~5098193:+
UCEC	cis	rs709400	1	rs8018979	ENSG00000259775.1	RP11-45P15.4	4.11	6.39e-05	0.0495	0.39	0.32	Body mass index;	chr14:103642750	chr14:103331674~103332367:-
UCEC	cis	rs17772222	0.675	rs1099698	ENSG00000258983.2	RP11-507K2.2	-4.11	6.39e-05	0.0495	-0.31	-0.32	Coronary artery calcification;	chr14:88414904	chr14:88499334~88515502:+
UCEC	cis	rs2445284	0.845	rs2500003	ENSG00000229534.1	HNRNPA1P53	-4.11	6.4e-05	0.0495	-0.39	-0.32	Sickle cell anemia (haemolysis);	chr11:5043844	chr11:5571247~5572192:-
UCEC	cis	rs6471393	0.929	rs7016930	ENSG00000253848.1	RP11-10N23.5	4.11	6.4e-05	0.0495	0.41	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743185	chr8:93741193~93744534:+
UCEC	cis	rs6471393	0.929	rs7017036	ENSG00000253848.1	RP11-10N23.5	4.11	6.4e-05	0.0495	0.41	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743216	chr8:93741193~93744534:+
UCEC	cis	rs10740039	0.729	rs7091383	ENSG00000254271.1	RP11-131N11.4	4.11	6.4e-05	0.0495	0.38	0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60676419	chr10:60734342~60741828:+
UCEC	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	4.11	6.4e-05	0.0495	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	4.11	6.4e-05	0.0495	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	4.11	6.4e-05	0.0495	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	4.11	6.4e-05	0.0495	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
UCEC	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	4.11	6.41e-05	0.0496	0.42	0.32	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
UCEC	cis	rs7160336	0.641	rs4899503	ENSG00000259065.1	RP5-1021I20.1	4.11	6.41e-05	0.0496	0.38	0.32	Blood protein levels;	chr14:74217234	chr14:73787360~73803270:+
UCEC	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-4.11	6.41e-05	0.0496	-0.42	-0.32	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
UCEC	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-4.11	6.42e-05	0.0496	-0.3	-0.32	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
UCEC	cis	rs875971	1	rs937495	ENSG00000236529.1	RP13-254B10.1	-4.11	6.42e-05	0.0496	-0.36	-0.32	Aortic root size;	chr7:66314811	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	4.11	6.42e-05	0.0497	0.31	0.32	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
UCEC	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	4.11	6.43e-05	0.0497	0.42	0.32	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
UCEC	cis	rs28386778	0.863	rs6919	ENSG00000240280.5	TCAM1P	4.11	6.43e-05	0.0497	0.37	0.32	Prudent dietary pattern;	chr17:63832125	chr17:63849292~63864379:+
UCEC	cis	rs6802315	0.604	rs9863103	ENSG00000272247.1	RP11-379F4.9	4.11	6.43e-05	0.0497	0.35	0.32	Periodontitis (CDC/AAP);	chr3:158746014	chr3:158801257~158801935:-
UCEC	cis	rs34286592	1	rs62056375	ENSG00000260853.1	RP11-264B17.2	4.11	6.43e-05	0.0497	0.29	0.32	Multiple sclerosis;	chr16:29846580	chr16:28956687~28966883:-
UCEC	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-4.11	6.43e-05	0.0497	-0.4	-0.32	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
UCEC	cis	rs10232172	0.63	rs9649837	ENSG00000234707.2	RP11-745C15.2	-4.11	6.43e-05	0.0497	-0.49	-0.32	Periodontal disease-related phenotypes;	chr7:54098735	chr7:54759425~54804928:+
UCEC	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	4.11	6.44e-05	0.0497	0.31	0.32	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
UCEC	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-4.11	6.44e-05	0.0497	-0.39	-0.32	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
UCEC	cis	rs875971	1	rs709595	ENSG00000236529.1	RP13-254B10.1	4.11	6.44e-05	0.0498	0.35	0.32	Aortic root size;	chr7:66352346	chr7:65840212~65840596:+
UCEC	cis	rs875971	1	rs811880	ENSG00000236529.1	RP13-254B10.1	4.11	6.44e-05	0.0498	0.35	0.32	Aortic root size;	chr7:66353659	chr7:65840212~65840596:+
UCEC	cis	rs454422	0.556	rs6053817	ENSG00000275632.1	RP5-967N21.11	4.11	6.44e-05	0.0498	0.34	0.32	HIV-1 viral setpoint;	chr20:6000052	chr20:6000418~6000941:+
UCEC	cis	rs875971	1	rs875971	ENSG00000236529.1	RP13-254B10.1	-4.11	6.44e-05	0.0498	-0.35	-0.32	Aortic root size;	chr7:66152608	chr7:65840212~65840596:+
UCEC	cis	rs875971	0.862	rs10276077	ENSG00000236529.1	RP13-254B10.1	-4.11	6.45e-05	0.0498	-0.37	-0.32	Aortic root size;	chr7:66263424	chr7:65840212~65840596:+
UCEC	cis	rs1150668	0.805	rs2859348	ENSG00000204709.4	LINC01556	4.11	6.45e-05	0.0498	0.41	0.32	Pubertal anthropometrics;	chr6:28391393	chr6:28943877~28944537:+
UCEC	cis	rs9545047	0.967	rs9318627	ENSG00000227354.5	RBM26-AS1	4.11	6.45e-05	0.0498	0.35	0.32	Schizophrenia;	chr13:79355944	chr13:79406309~79424328:+
UCEC	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	4.11	6.46e-05	0.0499	0.36	0.32	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
UCEC	cis	rs1974653	0.781	rs175163	ENSG00000236540.6	AC006547.13	-4.11	6.46e-05	0.0499	-0.38	-0.32	Schizophrenia;	chr22:20126254	chr22:20058030~20070569:-
UCEC	cis	rs6840360	0.582	rs2709812	ENSG00000270265.1	RP11-731D1.4	4.11	6.46e-05	0.0499	0.3	0.32	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151333775~151353224:-
UCEC	cis	rs12744310	0.887	rs12043581	ENSG00000235358.1	RP11-399E6.1	4.11	6.46e-05	0.0499	0.52	0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41322593	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12047161	ENSG00000235358.1	RP11-399E6.1	4.11	6.46e-05	0.0499	0.52	0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41341856	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12028244	ENSG00000235358.1	RP11-399E6.1	4.11	6.46e-05	0.0499	0.52	0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343490	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12046670	ENSG00000235358.1	RP11-399E6.1	4.11	6.46e-05	0.0499	0.52	0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343640	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12045979	ENSG00000235358.1	RP11-399E6.1	4.11	6.46e-05	0.0499	0.52	0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343805	chr1:41242373~41284861:+
UCEC	cis	rs12744310	0.887	rs12047439	ENSG00000235358.1	RP11-399E6.1	4.11	6.46e-05	0.0499	0.52	0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343968	chr1:41242373~41284861:+
UCEC	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-4.11	6.47e-05	0.0499	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-4.11	6.47e-05	0.0499	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-4.11	6.47e-05	0.0499	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-4.11	6.47e-05	0.0499	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-4.11	6.47e-05	0.0499	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-4.11	6.47e-05	0.0499	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-4.11	6.47e-05	0.0499	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
UCEC	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-4.11	6.47e-05	0.0499	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
UCEC	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-4.11	6.47e-05	0.0499	-0.36	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
UCEC	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-4.11	6.47e-05	0.0499	-0.38	-0.32	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
UCEC	cis	rs7246967	0.608	rs428613	ENSG00000198153.8	ZNF849P	-4.11	6.47e-05	0.0499	-0.38	-0.32	Bronchopulmonary dysplasia;	chr19:22827117	chr19:22685167~22686732:+
UCEC	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	4.11	6.47e-05	0.0499	0.29	0.32	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
UCEC	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-4.11	6.47e-05	0.0499	-0.36	-0.32	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-4.11	6.47e-05	0.0499	-0.36	-0.32	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
UCEC	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-4.11	6.47e-05	0.0499	-0.36	-0.32	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
UCEC	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	4.11	6.47e-05	0.0499	0.33	0.32	Height;	chr6:109409679	chr6:109382795~109383666:+
UCEC	cis	rs6840360	0.582	rs11733820	ENSG00000278978.1	RP11-164P12.5	-4.11	6.48e-05	0.05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.582	rs4473638	ENSG00000278978.1	RP11-164P12.5	-4.11	6.48e-05	0.05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151669786~151670503:+
UCEC	cis	rs6840360	0.548	rs4254751	ENSG00000278978.1	RP11-164P12.5	-4.11	6.48e-05	0.05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151669786~151670503:+
UCEC	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	19.61	4.05e-43	3.8e-34	1.14	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
UCEC	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	19.51	7.19e-43	5.14e-34	1.1	0.85	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-18.89	2.15e-41	1.06e-32	-1.1	-0.84	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	18.89	2.16e-41	1.06e-32	1.1	0.84	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	18.73	5.36e-41	2.46e-32	1.1	0.84	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	18.73	5.36e-41	2.46e-32	1.1	0.84	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	18.73	5.36e-41	2.46e-32	1.1	0.84	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-18	3.29e-39	9.59e-31	-1.07	-0.83	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-18	3.29e-39	9.59e-31	-1.07	-0.83	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-18	3.29e-39	9.59e-31	-1.07	-0.83	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
UCEC	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	17.95	4.36e-39	1.26e-30	1.11	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
UCEC	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	17.81	9.71e-39	2.68e-30	1.19	0.82	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	17.81	9.71e-39	2.68e-30	1.19	0.82	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	17.81	9.71e-39	2.68e-30	1.19	0.82	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	17.81	9.71e-39	2.68e-30	1.19	0.82	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	17.81	9.71e-39	2.68e-30	1.19	0.82	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
UCEC	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	17.67	2.17e-38	5.93e-30	0.9	0.82	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
UCEC	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	17.66	2.32e-38	6.33e-30	1.11	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
UCEC	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-17.58	3.72e-38	1e-29	-1.07	-0.82	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
UCEC	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	17.52	5.15e-38	1.37e-29	1.09	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
UCEC	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	17.35	1.41e-37	3.51e-29	1.07	0.82	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-17.35	1.41e-37	3.51e-29	-1.07	-0.82	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-17.35	1.41e-37	3.51e-29	-1.07	-0.82	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-17.35	1.41e-37	3.51e-29	-1.07	-0.82	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
UCEC	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	17.28	2.03e-37	5.04e-29	1.19	0.82	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	17.23	2.71e-37	6.71e-29	1.17	0.82	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	17.19	3.55e-37	8.75e-29	1.18	0.82	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	17.16	4.19e-37	1.03e-28	1.19	0.81	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
UCEC	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-17.15	4.32e-37	1.06e-28	-1.06	-0.81	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
UCEC	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	17.15	4.35e-37	1.06e-28	1.19	0.81	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	16.92	1.7e-36	4.03e-28	1.21	0.81	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	16.89	1.91e-36	4.51e-28	1.18	0.81	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
UCEC	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	16.87	2.18e-36	5.1e-28	1.1	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
UCEC	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	16.87	2.18e-36	5.1e-28	1.1	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
UCEC	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	16.85	2.48e-36	5.75e-28	1.18	0.81	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	16.85	2.48e-36	5.75e-28	1.18	0.81	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
UCEC	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	16.84	2.6e-36	5.99e-28	0.98	0.81	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
UCEC	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	16.83	2.8e-36	6.28e-28	1.1	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
UCEC	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	16.83	2.8e-36	6.28e-28	1.1	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
UCEC	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	16.61	9.95e-36	2.2e-27	1.12	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
UCEC	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	16.61	9.95e-36	2.2e-27	1.12	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
UCEC	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	16.49	2.08e-35	4.49e-27	1.13	0.8	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
UCEC	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	16.46	2.36e-35	5.07e-27	1.08	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
UCEC	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	16.43	2.85e-35	6.04e-27	0.9	0.8	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	16.43	2.85e-35	6.04e-27	0.9	0.8	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	16.43	2.85e-35	6.04e-27	0.9	0.8	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
UCEC	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	16.4	3.4e-35	7.18e-27	1.11	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
UCEC	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	16.39	3.72e-35	7.76e-27	0.9	0.8	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	16.39	3.72e-35	7.76e-27	0.9	0.8	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	16.39	3.72e-35	7.76e-27	0.9	0.8	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
UCEC	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	16.21	1.04e-34	2.16e-26	1.07	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
UCEC	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	16.12	1.76e-34	3.49e-26	0.89	0.8	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	16.12	1.76e-34	3.49e-26	0.89	0.8	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	16.12	1.76e-34	3.49e-26	0.89	0.8	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	16.12	1.76e-34	3.49e-26	0.89	0.8	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	16.12	1.76e-34	3.49e-26	0.89	0.8	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	16.12	1.76e-34	3.49e-26	0.89	0.8	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
UCEC	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	16.1	2e-34	3.94e-26	1.12	0.8	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
UCEC	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	16.09	2.14e-34	4.2e-26	0.89	0.8	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	16.09	2.14e-34	4.2e-26	0.89	0.8	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	16.08	2.28e-34	4.43e-26	0.89	0.8	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	16.08	2.28e-34	4.43e-26	0.89	0.8	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	16.08	2.28e-34	4.43e-26	0.89	0.8	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	16.06	2.61e-34	4.99e-26	0.89	0.8	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	16.02	3.29e-34	6.24e-26	0.89	0.8	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	16.01	3.41e-34	6.45e-26	0.89	0.8	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
UCEC	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	16	3.63e-34	6.83e-26	1.13	0.8	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
UCEC	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	16	3.67e-34	6.87e-26	0.9	0.8	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	16	3.67e-34	6.87e-26	0.9	0.8	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	15.99	3.77e-34	6.94e-26	0.88	0.79	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	15.99	3.77e-34	6.94e-26	0.88	0.79	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	15.99	3.77e-34	6.94e-26	0.88	0.79	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	15.99	3.77e-34	6.94e-26	0.88	0.79	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	15.97	4.34e-34	7.96e-26	0.89	0.79	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
UCEC	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	15.94	5.16e-34	9.41e-26	1.14	0.79	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
UCEC	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	15.89	7.07e-34	1.28e-25	0.89	0.79	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
UCEC	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-15.87	7.95e-34	1.44e-25	-1.11	-0.79	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
UCEC	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-15.86	8.25e-34	1.48e-25	-0.89	-0.79	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
UCEC	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	15.82	1.03e-33	1.84e-25	0.97	0.79	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
UCEC	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	15.8	1.21e-33	2.15e-25	1.11	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
UCEC	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	15.8	1.21e-33	2.15e-25	1.11	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
UCEC	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-15.63	3.2e-33	5.66e-25	-1.04	-0.79	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-15.63	3.2e-33	5.66e-25	-1.04	-0.79	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
UCEC	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	15.6	4e-33	6.94e-25	0.89	0.79	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	15.6	4e-33	6.94e-25	0.89	0.79	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	15.6	4e-33	6.94e-25	0.89	0.79	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	15.6	4e-33	6.94e-25	0.89	0.79	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	15.6	4e-33	6.94e-25	0.89	0.79	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	15.51	6.68e-33	1.15e-24	0.88	0.79	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
UCEC	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	15.43	1.06e-32	1.81e-24	0.89	0.78	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
UCEC	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	15.34	1.83e-32	3.12e-24	1.05	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
UCEC	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	15.3	2.35e-32	4e-24	1.12	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
UCEC	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	15.24	3.41e-32	5.77e-24	0.89	0.78	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
UCEC	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-15.23	3.62e-32	6.07e-24	-1.03	-0.78	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-15.23	3.62e-32	6.07e-24	-1.03	-0.78	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-15.23	3.62e-32	6.07e-24	-1.03	-0.78	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
UCEC	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	15.2	4.28e-32	7.17e-24	0.88	0.78	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
UCEC	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-15.16	5.27e-32	8.72e-24	-1.03	-0.78	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
UCEC	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-15.08	8.71e-32	1.34e-23	-1.02	-0.78	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-15.05	1.04e-31	1.59e-23	-1.03	-0.78	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
UCEC	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	15.04	1.13e-31	1.71e-23	0.88	0.78	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
UCEC	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	15.03	1.19e-31	1.78e-23	1	0.78	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-14.97	1.69e-31	2.5e-23	-1.03	-0.77	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-14.97	1.69e-31	2.5e-23	-1.03	-0.77	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
UCEC	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	14.94	2.06e-31	3.04e-23	1.1	0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
UCEC	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	14.85	3.36e-31	4.93e-23	0.88	0.77	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
UCEC	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	14.84	3.68e-31	5.39e-23	0.88	0.77	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
UCEC	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	14.79	5e-31	7.25e-23	0.88	0.77	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
UCEC	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	14.67	1e-30	1.43e-22	1.04	0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
UCEC	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	14.63	1.27e-30	1.8e-22	0.98	0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
UCEC	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-14.62	1.36e-30	1.9e-22	-1.01	-0.77	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-14.62	1.36e-30	1.9e-22	-1.01	-0.77	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-14.62	1.36e-30	1.9e-22	-1.01	-0.77	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-14.61	1.48e-30	2.07e-22	-1	-0.77	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-14.56	1.95e-30	2.65e-22	-1.01	-0.77	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-14.56	1.95e-30	2.65e-22	-1.01	-0.77	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
UCEC	trans	rs9899728	0.764	rs7219493	ENSG00000234925.2	ATP5HP4	14.38	5.8e-30	7.81e-22	0.89	0.76	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr12:68642519~68642993:-
UCEC	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	14.38	5.93e-30	7.96e-22	0.88	0.76	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
UCEC	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	14.33	7.91e-30	1.03e-21	0.93	0.76	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
UCEC	trans	rs7121616	0.562	rs2061602	ENSG00000234176.1	HSPA8P1	14.29	9.98e-30	1.3e-21	0.87	0.76	Breast cancer;	chr11:123065079	chrX:121203182~121205014:-
UCEC	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	14.27	1.17e-29	1.52e-21	1.05	0.76	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
UCEC	trans	rs9899728	0.665	rs2307008	ENSG00000234925.2	ATP5HP4	14.26	1.25e-29	1.61e-21	0.91	0.76	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr12:68642519~68642993:-
UCEC	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-14.18	2.01e-29	2.59e-21	-1.02	-0.76	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
UCEC	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	14.17	2.1e-29	2.7e-21	0.96	0.76	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
UCEC	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	14.09	3.47e-29	4.41e-21	0.84	0.76	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
UCEC	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	14.08	3.69e-29	4.68e-21	0.91	0.76	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
UCEC	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	13.83	1.64e-28	1.89e-20	1.08	0.75	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
UCEC	trans	rs13253073	0.525	rs35509895	ENSG00000260318.1	COX6CP1	13.83	1.65e-28	1.9e-20	1.21	0.75	Glucose homeostasis traits;	chr8:99872093	chr16:11903923~11904137:-
UCEC	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	13.77	2.33e-28	2.65e-20	0.87	0.75	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
UCEC	trans	rs6708331	0.752	rs6721306	ENSG00000232654.1	FAM136BP	13.71	3.35e-28	3.79e-20	1.03	0.75	Obesity-related traits;	chr2:70190013	chr6:3045384~3045800:+
UCEC	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	13.71	3.39e-28	3.83e-20	1.1	0.75	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
UCEC	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	13.71	3.48e-28	3.93e-20	0.83	0.75	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	13.6	6.59e-28	7.3e-20	0.82	0.74	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	13.59	7.26e-28	8.03e-20	0.79	0.74	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
UCEC	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	13.52	1.13e-27	1.24e-19	0.98	0.74	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
UCEC	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	13.48	1.36e-27	1.49e-19	0.89	0.74	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	13.48	1.41e-27	1.55e-19	0.8	0.74	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	13.4	2.31e-27	2.51e-19	0.8	0.74	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	13.4	2.31e-27	2.51e-19	0.8	0.74	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
UCEC	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	13.39	2.4e-27	2.58e-19	0.95	0.74	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
UCEC	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	13.39	2.4e-27	2.58e-19	0.95	0.74	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
UCEC	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	13.39	2.4e-27	2.58e-19	0.95	0.74	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
UCEC	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	13.37	2.73e-27	2.93e-19	0.8	0.74	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	13.28	4.89e-27	5.17e-19	0.79	0.74	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	13.28	4.89e-27	5.17e-19	0.79	0.74	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	13.28	4.89e-27	5.17e-19	0.79	0.74	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	13.28	4.89e-27	5.17e-19	0.79	0.74	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	13.27	4.96e-27	5.22e-19	0.8	0.74	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	13.26	5.41e-27	5.66e-19	0.8	0.74	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	13.26	5.41e-27	5.66e-19	0.8	0.74	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	13.25	5.68e-27	5.95e-19	0.8	0.74	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
UCEC	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	13.25	5.75e-27	6e-19	0.88	0.74	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	13.24	5.9e-27	6.13e-19	0.81	0.74	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	13.23	6.47e-27	6.68e-19	0.89	0.73	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
UCEC	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	13.23	6.47e-27	6.68e-19	0.89	0.73	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
UCEC	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	13.21	7.49e-27	7.71e-19	0.93	0.73	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
UCEC	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	13.19	8.28e-27	8.45e-19	0.8	0.73	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
UCEC	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	13.18	8.78e-27	8.88e-19	0.94	0.73	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
UCEC	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	13.18	8.78e-27	8.88e-19	0.94	0.73	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
UCEC	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	13.18	8.78e-27	8.88e-19	0.94	0.73	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
UCEC	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	13.1	1.39e-26	1.39e-18	0.9	0.73	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
UCEC	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-13.06	1.86e-26	1.84e-18	-0.82	-0.73	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
UCEC	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	13.06	1.88e-26	1.86e-18	1.13	0.73	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	13.05	1.9e-26	1.86e-18	1.19	0.73	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	13.05	1.9e-26	1.86e-18	1.19	0.73	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	13.05	1.9e-26	1.86e-18	1.19	0.73	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	13	2.61e-26	2.53e-18	0.78	0.73	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
UCEC	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	12.98	3.03e-26	2.92e-18	0.93	0.73	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
UCEC	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	12.98	3.03e-26	2.92e-18	0.93	0.73	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
UCEC	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-12.97	3.07e-26	2.96e-18	-1.18	-0.73	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	12.94	3.71e-26	3.55e-18	0.78	0.73	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-12.94	3.74e-26	3.57e-18	-1.19	-0.73	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-12.94	3.74e-26	3.57e-18	-1.19	-0.73	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-12.94	3.74e-26	3.57e-18	-1.19	-0.73	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-12.94	3.79e-26	3.61e-18	-1.14	-0.73	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
UCEC	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	12.93	4.1e-26	3.9e-18	0.89	0.73	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	12.91	4.51e-26	4.26e-18	0.9	0.73	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
UCEC	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	12.91	4.57e-26	4.31e-18	1.18	0.73	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-12.9	4.81e-26	4.54e-18	-1.19	-0.73	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-12.86	6.36e-26	5.96e-18	-1.13	-0.73	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
UCEC	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-12.84	6.82e-26	6.38e-18	-0.89	-0.72	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	12.82	7.92e-26	7.13e-18	1.15	0.72	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	12.82	7.92e-26	7.13e-18	1.15	0.72	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	12.82	7.92e-26	7.13e-18	1.15	0.72	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	12.81	8.46e-26	7.58e-18	1.15	0.72	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-12.8	8.89e-26	7.94e-18	-1.13	-0.72	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
UCEC	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	12.8	9.01e-26	8.03e-18	0.86	0.72	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	12.8	9.14e-26	8.13e-18	1.16	0.72	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	12.78	1.02e-25	9.03e-18	1.17	0.72	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	12.77	1.05e-25	9.28e-18	0.78	0.72	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	12.76	1.16e-25	1.01e-17	1.16	0.72	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	12.76	1.16e-25	1.01e-17	1.16	0.72	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	12.76	1.16e-25	1.01e-17	1.16	0.72	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	12.76	1.16e-25	1.01e-17	1.16	0.72	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	12.76	1.16e-25	1.01e-17	1.16	0.72	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	12.76	1.16e-25	1.01e-17	1.16	0.72	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	12.7	1.64e-25	1.41e-17	0.79	0.72	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
UCEC	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	12.69	1.72e-25	1.48e-17	0.89	0.72	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
UCEC	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-12.69	1.78e-25	1.52e-17	-1.17	-0.72	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	12.65	2.2e-25	1.87e-17	0.78	0.72	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
UCEC	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-12.61	2.96e-25	2.5e-17	-0.89	-0.72	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
UCEC	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	12.58	3.4e-25	2.86e-17	0.83	0.72	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
UCEC	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	12.58	3.4e-25	2.86e-17	0.83	0.72	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
UCEC	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	12.57	3.62e-25	3.04e-17	0.87	0.72	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
UCEC	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-12.55	4.24e-25	3.54e-17	-1.13	-0.72	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	12.55	4.29e-25	3.56e-17	1.15	0.72	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	12.55	4.29e-25	3.56e-17	1.15	0.72	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
UCEC	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	12.52	5.09e-25	4.19e-17	0.93	0.72	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
UCEC	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	12.5	5.75e-25	4.71e-17	0.87	0.72	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
UCEC	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	12.46	7.23e-25	5.87e-17	0.93	0.71	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
UCEC	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-12.34	1.49e-24	1.2e-16	-0.9	-0.71	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
UCEC	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-12.33	1.59e-24	1.28e-16	-1.16	-0.71	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-12.32	1.76e-24	1.41e-16	-1.11	-0.71	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	12.3	1.88e-24	1.5e-16	0.82	0.71	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-12.3	1.88e-24	1.5e-16	-1.15	-0.71	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-12.3	1.88e-24	1.5e-16	-1.15	-0.71	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
UCEC	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-12.24	2.85e-24	2.22e-16	-0.89	-0.71	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	12.24	2.86e-24	2.22e-16	0.89	0.71	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
UCEC	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	12.21	3.32e-24	2.57e-16	0.82	0.71	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
UCEC	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-12.21	3.34e-24	2.58e-16	-0.8	-0.71	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
UCEC	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-12.2	3.48e-24	2.63e-16	-0.89	-0.71	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-12.2	3.48e-24	2.63e-16	-0.89	-0.71	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	12.2	3.48e-24	2.63e-16	0.89	0.71	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	12.2	3.48e-24	2.63e-16	0.89	0.71	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	12.2	3.48e-24	2.63e-16	0.89	0.71	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	12.2	3.48e-24	2.63e-16	0.89	0.71	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	12.2	3.48e-24	2.63e-16	0.89	0.71	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
UCEC	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-12.19	3.83e-24	2.89e-16	-1.06	-0.71	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
UCEC	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	12.15	4.8e-24	3.61e-16	0.94	0.71	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
UCEC	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	12.13	5.38e-24	4.03e-16	0.77	0.7	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	12.09	6.92e-24	4.95e-16	1.14	0.7	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
UCEC	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	12.09	7.14e-24	5.08e-16	1.14	0.7	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	12.09	7.14e-24	5.08e-16	1.14	0.7	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
UCEC	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	12.08	7.44e-24	5.28e-16	0.88	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
UCEC	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	12.05	8.92e-24	6.26e-16	0.87	0.7	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
UCEC	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	12.04	9.47e-24	6.63e-16	1.06	0.7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
UCEC	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	12.04	9.77e-24	6.84e-16	1.05	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
UCEC	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	12.02	1.07e-23	7.42e-16	0.92	0.7	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
UCEC	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	11.94	1.81e-23	1.23e-15	0.75	0.7	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	11.92	2.02e-23	1.35e-15	0.75	0.7	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	11.9	2.26e-23	1.49e-15	0.74	0.7	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	11.9	2.26e-23	1.49e-15	0.74	0.7	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	11.9	2.26e-23	1.49e-15	0.74	0.7	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	11.9	2.26e-23	1.49e-15	0.74	0.7	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
UCEC	trans	rs7554547	0.667	rs7525521	ENSG00000261819.1	RP11-680G24.4	11.9	2.29e-23	1.5e-15	0.88	0.7	Nonsyndromic cleft lip with cleft palate;	chr1:11915109	chr16:14988259~14990160:-
UCEC	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	11.89	2.46e-23	1.61e-15	0.75	0.7	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	11.89	2.47e-23	1.61e-15	1.09	0.7	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	11.89	2.47e-23	1.61e-15	1.09	0.7	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	11.89	2.47e-23	1.61e-15	1.09	0.7	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	11.88	2.55e-23	1.66e-15	0.75	0.7	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	11.88	2.59e-23	1.68e-15	0.75	0.7	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	11.88	2.59e-23	1.68e-15	0.75	0.7	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	11.84	3.2e-23	2.06e-15	0.75	0.7	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
UCEC	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	11.84	3.24e-23	2.08e-15	1.1	0.7	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
UCEC	trans	rs7554547	0.667	rs4846072	ENSG00000261819.1	RP11-680G24.4	11.84	3.33e-23	2.13e-15	0.88	0.7	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr16:14988259~14990160:-
UCEC	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	11.81	3.81e-23	2.42e-15	0.76	0.7	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
UCEC	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	11.8	4.1e-23	2.58e-15	1.09	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
UCEC	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	11.8	4.1e-23	2.58e-15	1.09	0.7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
UCEC	trans	rs7554547	0.63	rs4845889	ENSG00000261819.1	RP11-680G24.4	11.8	4.14e-23	2.6e-15	0.88	0.7	Nonsyndromic cleft lip with cleft palate;	chr1:11911288	chr16:14988259~14990160:-
UCEC	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	11.74	6.08e-23	3.77e-15	0.76	0.69	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
UCEC	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-11.73	6.55e-23	4.03e-15	-0.85	-0.69	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
UCEC	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-11.72	6.98e-23	4.28e-15	-1.03	-0.69	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	11.69	8.32e-23	5e-15	0.74	0.69	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	11.69	8.32e-23	5e-15	0.74	0.69	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	11.65	1.06e-22	6.17e-15	0.73	0.69	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	11.65	1.07e-22	6.2e-15	0.73	0.69	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	11.65	1.07e-22	6.2e-15	0.73	0.69	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	11.65	1.07e-22	6.2e-15	0.73	0.69	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
UCEC	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	11.63	1.15e-22	6.66e-15	0.79	0.69	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
UCEC	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	11.63	1.22e-22	6.99e-15	0.91	0.69	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	11.63	1.22e-22	6.99e-15	0.91	0.69	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	11.63	1.22e-22	6.99e-15	0.91	0.69	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	11.63	1.22e-22	6.99e-15	0.91	0.69	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	11.63	1.22e-22	6.99e-15	0.91	0.69	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	11.63	1.22e-22	6.99e-15	0.91	0.69	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
UCEC	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-11.62	1.27e-22	7.26e-15	-1.04	-0.69	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-11.54	2.12e-22	1.19e-14	-1.2	-0.69	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
UCEC	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	11.52	2.3e-22	1.29e-14	0.91	0.69	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
UCEC	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	11.52	2.39e-22	1.34e-14	0.88	0.69	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
UCEC	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-11.49	2.79e-22	1.56e-14	-1.07	-0.69	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	11.48	2.99e-22	1.67e-14	1.13	0.69	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-11.46	3.43e-22	1.9e-14	-1.1	-0.68	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-11.46	3.43e-22	1.9e-14	-1.1	-0.68	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-11.46	3.43e-22	1.9e-14	-1.1	-0.68	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	11.45	3.5e-22	1.94e-14	1.07	0.68	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-11.42	4.4e-22	2.41e-14	-1.11	-0.68	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
UCEC	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	11.42	4.41e-22	2.41e-14	1.16	0.68	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	11.42	4.41e-22	2.41e-14	1.16	0.68	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	11.42	4.41e-22	2.41e-14	1.16	0.68	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	11.42	4.41e-22	2.41e-14	1.16	0.68	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	11.42	4.41e-22	2.41e-14	1.16	0.68	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	11.42	4.41e-22	2.41e-14	1.16	0.68	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
UCEC	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	11.38	5.6e-22	3e-14	0.83	0.68	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
UCEC	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-11.37	5.83e-22	3.12e-14	-0.88	-0.68	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
UCEC	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	11.34	6.93e-22	3.7e-14	0.72	0.68	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
UCEC	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-11.34	6.94e-22	3.7e-14	-0.82	-0.68	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
UCEC	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	11.33	7.25e-22	3.85e-14	0.72	0.68	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	11.33	7.25e-22	3.85e-14	0.72	0.68	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	11.33	7.25e-22	3.85e-14	0.72	0.68	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
UCEC	trans	rs7554547	0.721	rs12092734	ENSG00000261819.1	RP11-680G24.4	11.33	7.37e-22	3.91e-14	0.84	0.68	Nonsyndromic cleft lip with cleft palate;	chr1:11908349	chr16:14988259~14990160:-
UCEC	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-11.32	7.88e-22	4.16e-14	-1.15	-0.68	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
UCEC	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-11.32	8.04e-22	4.23e-14	-1.15	-0.68	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
UCEC	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	11.31	8.31e-22	4.35e-14	0.72	0.68	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	11.31	8.31e-22	4.35e-14	0.72	0.68	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	11.31	8.35e-22	4.36e-14	0.73	0.68	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	11.31	8.35e-22	4.36e-14	0.73	0.68	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
UCEC	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	11.3	8.73e-22	4.55e-14	0.9	0.68	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	11.3	8.73e-22	4.55e-14	0.9	0.68	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	11.3	8.73e-22	4.55e-14	0.9	0.68	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	11.3	8.73e-22	4.55e-14	0.9	0.68	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-11.3	9.24e-22	4.79e-14	-0.9	-0.68	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	11.28	9.95e-22	5.15e-14	0.9	0.68	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	11.28	9.95e-22	5.15e-14	0.9	0.68	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
UCEC	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	11.28	1.05e-21	5.38e-14	0.72	0.68	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	11.28	1.05e-21	5.38e-14	0.72	0.68	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	11.28	1.05e-21	5.38e-14	0.72	0.68	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-11.27	1.06e-21	5.43e-14	-1.04	-0.68	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-11.25	1.21e-21	6.18e-14	-0.97	-0.68	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	11.24	1.27e-21	6.46e-14	0.92	0.68	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-11.23	1.35e-21	6.89e-14	-1.01	-0.68	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-11.23	1.35e-21	6.89e-14	-1.01	-0.68	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	11.22	1.49e-21	7.48e-14	1.06	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	11.22	1.49e-21	7.48e-14	1.06	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	11.22	1.49e-21	7.48e-14	1.06	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	11.22	1.49e-21	7.48e-14	1.06	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	11.22	1.49e-21	7.48e-14	1.06	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	11.22	1.49e-21	7.48e-14	1.06	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	11.22	1.49e-21	7.48e-14	1.06	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
UCEC	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-11.21	1.52e-21	7.63e-14	-1.1	-0.68	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
UCEC	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-11.21	1.53e-21	7.67e-14	-0.9	-0.68	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
UCEC	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	11.2	1.62e-21	8.08e-14	0.99	0.68	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-11.2	1.7e-21	8.49e-14	-1.03	-0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
UCEC	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	11.19	1.79e-21	8.91e-14	0.9	0.68	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
UCEC	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	11.18	1.91e-21	9.43e-14	1.14	0.68	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	11.18	1.91e-21	9.43e-14	1.14	0.68	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	11.18	1.91e-21	9.43e-14	1.14	0.68	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	11.18	1.91e-21	9.43e-14	1.14	0.68	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
UCEC	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	11.17	1.94e-21	9.51e-14	0.9	0.68	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	11.17	1.94e-21	9.51e-14	0.9	0.68	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
UCEC	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-11.17	2.01e-21	9.86e-14	-1.01	-0.68	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
UCEC	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-11.16	2.18e-21	1.07e-13	-0.86	-0.67	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
UCEC	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-11.15	2.22e-21	1.08e-13	-1.09	-0.67	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-11.13	2.49e-21	1.21e-13	-1.03	-0.67	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
UCEC	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-11.1	3.07e-21	1.46e-13	-1.13	-0.67	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-11.1	3.07e-21	1.46e-13	-1.13	-0.67	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-11.1	3.07e-21	1.46e-13	-1.13	-0.67	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
UCEC	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	11.1	3.11e-21	1.47e-13	0.81	0.67	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
UCEC	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	11.09	3.22e-21	1.52e-13	1.15	0.67	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
UCEC	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	11.09	3.28e-21	1.55e-13	0.9	0.67	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	11.09	3.28e-21	1.55e-13	0.9	0.67	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
UCEC	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	11.08	3.38e-21	1.59e-13	0.86	0.67	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
UCEC	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-11.08	3.49e-21	1.64e-13	-1	-0.67	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	11.04	4.35e-21	2.03e-13	1.03	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	11.04	4.35e-21	2.03e-13	1.03	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
UCEC	trans	rs7949030	0.596	rs11231137	ENSG00000186676.3	EEF1GP1	11.04	4.36e-21	2.03e-13	0.99	0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548227	chr7:125033453~125035301:+
UCEC	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-11.03	4.61e-21	2.15e-13	-1.01	-0.67	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	11.03	4.66e-21	2.16e-13	1.05	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	11.03	4.71e-21	2.17e-13	1.05	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	11.03	4.71e-21	2.17e-13	1.05	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	11.03	4.71e-21	2.17e-13	1.05	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
UCEC	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	11.02	5.14e-21	2.37e-13	1.13	0.67	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-11	5.63e-21	2.59e-13	-1.15	-0.67	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	10.99	5.85e-21	2.68e-13	1.14	0.67	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
UCEC	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	10.98	6.21e-21	2.84e-13	1.06	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	10.98	6.28e-21	2.87e-13	1.05	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
UCEC	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-10.97	6.63e-21	3.02e-13	-1.03	-0.67	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-10.97	6.85e-21	3.12e-13	-0.96	-0.67	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	10.96	7.08e-21	3.21e-13	1.05	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
UCEC	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-10.96	7.37e-21	3.33e-13	-1.14	-0.67	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
UCEC	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-10.95	7.89e-21	3.56e-13	-1.08	-0.67	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-10.94	8.19e-21	3.67e-13	-0.99	-0.67	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
UCEC	trans	rs2885056	0.783	rs73007347	ENSG00000227534.1	RP3-323B6.1	10.93	8.89e-21	3.95e-13	0.85	0.67	Red cell distribution width;	chr19:10539973	chrX:65469087~65470380:+
UCEC	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-10.92	9.33e-21	4.14e-13	-1.13	-0.67	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-10.92	9.33e-21	4.14e-13	-1.13	-0.67	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
UCEC	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-10.92	9.35e-21	4.14e-13	-0.95	-0.67	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-10.92	9.35e-21	4.14e-13	-0.95	-0.67	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-10.91	9.5e-21	4.2e-13	-0.99	-0.67	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-10.91	9.5e-21	4.2e-13	-0.99	-0.67	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	10.9	1.02e-20	4.47e-13	1.05	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
UCEC	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	10.89	1.11e-20	4.83e-13	1.06	0.67	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
UCEC	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	10.89	1.11e-20	4.83e-13	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-10.88	1.17e-20	5.1e-13	-1.13	-0.67	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	10.87	1.23e-20	5.32e-13	1.14	0.67	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
UCEC	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	10.87	1.28e-20	5.5e-13	0.87	0.66	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	10.87	1.28e-20	5.5e-13	0.87	0.66	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	10.85	1.38e-20	5.93e-13	0.88	0.66	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	10.85	1.38e-20	5.93e-13	0.88	0.66	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-10.84	1.47e-20	6.28e-13	-0.95	-0.66	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-10.84	1.47e-20	6.28e-13	-0.95	-0.66	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-10.84	1.47e-20	6.28e-13	-0.95	-0.66	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
UCEC	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	10.84	1.48e-20	6.28e-13	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	10.84	1.48e-20	6.28e-13	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	10.84	1.48e-20	6.28e-13	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	10.84	1.48e-20	6.28e-13	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	10.84	1.48e-20	6.28e-13	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	10.84	1.48e-20	6.28e-13	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
UCEC	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-10.84	1.53e-20	6.51e-13	-0.99	-0.66	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	10.83	1.56e-20	6.62e-13	1.1	0.66	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
UCEC	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	10.82	1.68e-20	7.13e-13	1.08	0.66	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
UCEC	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	10.81	1.82e-20	7.62e-13	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	10.81	1.82e-20	7.62e-13	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	10.81	1.82e-20	7.62e-13	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	10.81	1.82e-20	7.62e-13	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	10.81	1.82e-20	7.62e-13	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	10.81	1.82e-20	7.62e-13	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	10.81	1.82e-20	7.62e-13	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
UCEC	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-10.81	1.82e-20	7.62e-13	-0.99	-0.66	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-10.81	1.82e-20	7.62e-13	-0.99	-0.66	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	10.8	1.91e-20	7.99e-13	1.1	0.66	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
UCEC	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	10.79	2e-20	8.38e-13	1.1	0.66	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-10.79	2.03e-20	8.46e-13	-0.82	-0.66	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
UCEC	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	10.77	2.27e-20	9.43e-13	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	10.77	2.27e-20	9.43e-13	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	10.76	2.42e-20	1e-12	0.89	0.66	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
UCEC	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	10.74	2.71e-20	1.12e-12	1.05	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	10.74	2.71e-20	1.12e-12	1.05	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	10.74	2.71e-20	1.12e-12	1.05	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
UCEC	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-10.73	2.99e-20	1.23e-12	-0.78	-0.66	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
UCEC	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	10.72	3.07e-20	1.26e-12	0.88	0.66	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	10.72	3.07e-20	1.26e-12	0.88	0.66	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
UCEC	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	10.69	3.7e-20	1.5e-12	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	10.69	3.7e-20	1.5e-12	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	10.69	3.7e-20	1.5e-12	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	10.69	3.7e-20	1.5e-12	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	10.69	3.7e-20	1.5e-12	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	10.69	3.7e-20	1.5e-12	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	10.69	3.7e-20	1.5e-12	1.06	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	10.67	4.25e-20	1.7e-12	1.05	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
UCEC	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-10.66	4.47e-20	1.79e-12	-0.97	-0.66	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	10.66	4.61e-20	1.84e-12	0.87	0.66	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	10.66	4.61e-20	1.84e-12	0.87	0.66	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	10.65	4.84e-20	1.93e-12	1.14	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	10.65	4.84e-20	1.93e-12	1.14	0.66	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	10.64	5.11e-20	2.02e-12	0.87	0.66	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	10.64	5.11e-20	2.02e-12	0.87	0.66	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	10.63	5.47e-20	2.15e-12	1.02	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	10.63	5.47e-20	2.15e-12	1.02	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	10.63	5.48e-20	2.15e-12	1.05	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	10.62	5.81e-20	2.27e-12	1.05	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
UCEC	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-10.6	6.36e-20	2.47e-12	-1.1	-0.66	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
UCEC	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	10.6	6.67e-20	2.57e-12	0.88	0.66	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	10.6	6.67e-20	2.57e-12	0.88	0.66	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	10.6	6.67e-20	2.57e-12	0.88	0.66	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	10.6	6.67e-20	2.57e-12	0.88	0.66	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	10.56	8.29e-20	3.01e-12	1.14	0.65	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	10.55	8.99e-20	3.24e-12	1.13	0.65	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	10.52	1.07e-19	3.8e-12	1.05	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
UCEC	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	10.51	1.14e-19	4.03e-12	1.08	0.65	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-10.51	1.15e-19	4.06e-12	-1.02	-0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
UCEC	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	10.48	1.36e-19	4.79e-12	0.85	0.65	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
UCEC	trans	rs6708331	0.504	rs2169837	ENSG00000232654.1	FAM136BP	10.46	1.48e-19	5.19e-12	0.78	0.65	Obesity-related traits;	chr2:70324775	chr6:3045384~3045800:+
UCEC	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	10.46	1.51e-19	5.27e-12	1.08	0.65	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	10.46	1.51e-19	5.27e-12	1.08	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	10.46	1.51e-19	5.27e-12	1.08	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	10.46	1.51e-19	5.27e-12	1.08	0.65	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	10.46	1.51e-19	5.27e-12	1.08	0.65	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	10.46	1.51e-19	5.27e-12	1.08	0.65	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	10.46	1.51e-19	5.27e-12	1.08	0.65	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	10.46	1.51e-19	5.27e-12	1.08	0.65	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	10.46	1.51e-19	5.27e-12	1.08	0.65	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	10.46	1.53e-19	5.33e-12	1.02	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	10.46	1.53e-19	5.33e-12	1.02	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
UCEC	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	10.45	1.57e-19	5.47e-12	1.08	0.65	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	10.45	1.62e-19	5.63e-12	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	10.45	1.64e-19	5.69e-12	1.05	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
UCEC	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	10.44	1.73e-19	5.99e-12	0.85	0.65	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	10.44	1.73e-19	5.99e-12	0.85	0.65	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
UCEC	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-10.44	1.75e-19	6.04e-12	-1	-0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
UCEC	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-10.43	1.81e-19	6.23e-12	-1.09	-0.65	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
UCEC	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	10.42	1.89e-19	6.47e-12	1.08	0.65	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
UCEC	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	10.42	1.89e-19	6.47e-12	1.08	0.65	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	10.42	1.89e-19	6.47e-12	1.08	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	10.42	1.89e-19	6.47e-12	1.08	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	10.42	1.92e-19	6.59e-12	1.08	0.65	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
UCEC	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	10.42	1.93e-19	6.59e-12	0.85	0.65	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	10.42	1.93e-19	6.59e-12	0.85	0.65	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	10.42	1.93e-19	6.59e-12	0.85	0.65	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	10.42	1.93e-19	6.59e-12	0.85	0.65	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	10.42	1.93e-19	6.59e-12	0.85	0.65	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
UCEC	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	10.41	2.05e-19	6.97e-12	1.08	0.65	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	10.41	2.1e-19	7.15e-12	1.07	0.65	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	10.41	2.1e-19	7.15e-12	1.07	0.65	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	10.41	2.1e-19	7.15e-12	1.07	0.65	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	10.4	2.16e-19	7.28e-12	1.08	0.65	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	10.4	2.16e-19	7.28e-12	1.08	0.65	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	10.4	2.16e-19	7.28e-12	1.08	0.65	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	10.4	2.16e-19	7.28e-12	1.08	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	10.4	2.16e-19	7.28e-12	1.08	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	10.4	2.16e-19	7.28e-12	1.08	0.65	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	10.4	2.23e-19	7.5e-12	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	10.4	2.23e-19	7.5e-12	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	10.4	2.23e-19	7.5e-12	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
UCEC	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	10.39	2.29e-19	7.69e-12	0.86	0.65	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	10.39	2.31e-19	7.75e-12	1.08	0.65	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
UCEC	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	10.39	2.34e-19	7.85e-12	0.86	0.65	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
UCEC	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	10.38	2.51e-19	8.4e-12	0.78	0.65	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
UCEC	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	10.38	2.53e-19	8.46e-12	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
UCEC	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	10.38	2.55e-19	8.54e-12	1.06	0.65	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	10.37	2.58e-19	8.63e-12	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
UCEC	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-10.37	2.63e-19	8.72e-12	-1.11	-0.65	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-10.37	2.63e-19	8.72e-12	-1.11	-0.65	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-10.37	2.63e-19	8.72e-12	-1.11	-0.65	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-10.37	2.63e-19	8.72e-12	-1.11	-0.65	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-10.37	2.63e-19	8.72e-12	-1.11	-0.65	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	10.37	2.63e-19	8.72e-12	1.11	0.65	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	10.37	2.69e-19	8.9e-12	1	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	10.37	2.69e-19	8.9e-12	1	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	10.37	2.69e-19	8.9e-12	1	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
UCEC	trans	rs7121616	0.576	rs1461495	ENSG00000234176.1	HSPA8P1	-10.36	2.8e-19	9.24e-12	-0.76	-0.65	Breast cancer;	chr11:123056136	chrX:121203182~121205014:-
UCEC	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	10.36	2.87e-19	9.41e-12	1.06	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	10.36	2.87e-19	9.41e-12	1.06	0.65	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	10.36	2.87e-19	9.41e-12	1.06	0.65	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	10.36	2.87e-19	9.41e-12	1.06	0.65	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	10.35	3.03e-19	9.91e-12	1.15	0.65	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-10.35	3.05e-19	9.96e-12	-1.04	-0.65	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	10.34	3.06e-19	1e-11	1.06	0.65	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	10.33	3.26e-19	1.06e-11	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
UCEC	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-10.32	3.47e-19	1.13e-11	-1.11	-0.65	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.626	rs12186649	ENSG00000224114.1	RP11-343H5.4	10.32	3.51e-19	1.14e-11	1.05	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:206695837~206696269:-
UCEC	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-10.32	3.53e-19	1.14e-11	-0.98	-0.65	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-10.32	3.53e-19	1.14e-11	-0.98	-0.65	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	10.32	3.54e-19	1.14e-11	1.07	0.65	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	10.32	3.54e-19	1.14e-11	1.07	0.65	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	10.32	3.54e-19	1.14e-11	1.07	0.65	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
UCEC	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	10.32	3.59e-19	1.16e-11	0.87	0.65	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
UCEC	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	10.31	3.68e-19	1.19e-11	1.06	0.65	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
UCEC	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	10.3	4e-19	1.29e-11	0.83	0.64	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	10.3	4e-19	1.29e-11	0.83	0.64	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
UCEC	trans	rs2885056	0.783	rs12459941	ENSG00000227534.1	RP3-323B6.1	-10.29	4.15e-19	1.33e-11	-0.79	-0.64	Red cell distribution width;	chr19:10555436	chrX:65469087~65470380:+
UCEC	trans	rs2885056	0.699	rs34275421	ENSG00000227534.1	RP3-323B6.1	10.28	4.62e-19	1.47e-11	0.82	0.64	Red cell distribution width;	chr19:10534136	chrX:65469087~65470380:+
UCEC	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	10.27	4.84e-19	1.53e-11	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	10.27	4.84e-19	1.53e-11	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	10.27	4.84e-19	1.53e-11	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	10.27	4.84e-19	1.53e-11	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	10.27	4.84e-19	1.53e-11	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	10.27	4.84e-19	1.53e-11	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
UCEC	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-10.27	4.93e-19	1.56e-11	-1.04	-0.64	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	10.27	4.98e-19	1.57e-11	1.11	0.64	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	10.27	4.98e-19	1.57e-11	1.11	0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
UCEC	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	10.27	4.98e-19	1.57e-11	1.11	0.64	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	10.26	5.04e-19	1.58e-11	0.92	0.64	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-10.26	5.09e-19	1.6e-11	-0.69	-0.64	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
UCEC	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	10.24	5.91e-19	1.85e-11	0.94	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	10.24	5.91e-19	1.85e-11	0.94	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
UCEC	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-10.23	6.02e-19	1.88e-11	-0.96	-0.64	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-10.23	6.02e-19	1.88e-11	-0.96	-0.64	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	10.23	6.09e-19	1.9e-11	0.98	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
UCEC	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	10.22	6.49e-19	2.02e-11	1.13	0.64	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
UCEC	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	10.21	6.77e-19	2.1e-11	0.83	0.64	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	10.21	6.77e-19	2.1e-11	0.83	0.64	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	10.21	6.77e-19	2.1e-11	0.83	0.64	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	10.21	6.77e-19	2.1e-11	0.83	0.64	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	10.21	6.77e-19	2.1e-11	0.83	0.64	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	10.21	6.77e-19	2.1e-11	0.83	0.64	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
UCEC	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-10.21	6.81e-19	2.1e-11	-1.1	-0.64	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-10.21	6.81e-19	2.1e-11	-1.1	-0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-10.21	6.81e-19	2.1e-11	-1.1	-0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-10.21	6.81e-19	2.1e-11	-1.1	-0.64	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-10.21	6.81e-19	2.1e-11	-1.1	-0.64	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
UCEC	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	10.19	7.77e-19	2.39e-11	0.83	0.64	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	10.19	7.96e-19	2.45e-11	0.84	0.64	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
UCEC	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-10.17	8.95e-19	2.72e-11	-0.87	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
UCEC	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-10.16	9.27e-19	2.81e-11	-0.87	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
UCEC	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-10.13	1.11e-18	3.34e-11	-1.1	-0.64	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-10.13	1.13e-18	3.42e-11	-0.96	-0.64	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-10.13	1.14e-18	3.45e-11	-0.95	-0.64	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
UCEC	trans	rs4822044	0.568	rs1883370	ENSG00000268568.1	AC007228.9	10.11	1.25e-18	3.76e-11	1.06	0.64	Cannabis dependence symptom count;	chr22:41747736	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-10.11	1.29e-18	3.87e-11	-0.88	-0.64	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
UCEC	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-10.11	1.31e-18	3.92e-11	-0.75	-0.64	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
UCEC	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	10.1	1.33e-18	3.99e-11	0.93	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
UCEC	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	10.1	1.36e-18	4.05e-11	0.83	0.64	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
UCEC	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-10.1	1.38e-18	4.13e-11	-1.1	-0.64	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
UCEC	trans	rs7554547	0.595	rs12092731	ENSG00000261819.1	RP11-680G24.4	10.09	1.44e-18	4.28e-11	0.78	0.64	Nonsyndromic cleft lip with cleft palate;	chr1:11908338	chr16:14988259~14990160:-
UCEC	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	10.08	1.52e-18	4.51e-11	1.09	0.64	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	10.08	1.52e-18	4.51e-11	1.09	0.64	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-10.08	1.52e-18	4.52e-11	-0.97	-0.64	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-10.08	1.52e-18	4.52e-11	-0.97	-0.64	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-10.08	1.55e-18	4.61e-11	-1	-0.64	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
UCEC	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	10.07	1.66e-18	4.91e-11	0.84	0.64	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
UCEC	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	10.06	1.68e-18	4.97e-11	0.78	0.64	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
UCEC	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	10.06	1.68e-18	4.97e-11	0.78	0.64	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
UCEC	trans	rs7949030	0.523	rs67308910	ENSG00000186676.3	EEF1GP1	10.05	1.83e-18	5.39e-11	1.06	0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62609887	chr7:125033453~125035301:+
UCEC	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-10.05	1.88e-18	5.53e-11	-0.76	-0.64	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
UCEC	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-10.04	2e-18	5.85e-11	-1.1	-0.64	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	10.03	2.02e-18	5.87e-11	1.09	0.64	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	10.03	2.02e-18	5.87e-11	1.09	0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	10.03	2.02e-18	5.87e-11	1.09	0.64	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	10.03	2.02e-18	5.87e-11	1.09	0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	10.03	2.02e-18	5.87e-11	1.09	0.64	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	10.03	2.02e-18	5.87e-11	1.09	0.64	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-10.03	2.04e-18	5.91e-11	-1.13	-0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
UCEC	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-10.03	2.04e-18	5.91e-11	-1.13	-0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
UCEC	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	10.02	2.15e-18	6.24e-11	0.86	0.63	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
UCEC	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-10.01	2.34e-18	6.78e-11	-0.95	-0.63	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	10	2.49e-18	7.21e-11	1.07	0.63	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-9.99	2.66e-18	7.64e-11	-1	-0.63	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-9.99	2.68e-18	7.7e-11	-1.09	-0.63	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-9.99	2.68e-18	7.7e-11	-1.09	-0.63	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
UCEC	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	9.98	2.72e-18	7.8e-11	0.83	0.63	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
UCEC	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-9.98	2.77e-18	7.96e-11	-1.13	-0.63	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	9.98	2.86e-18	8.19e-11	1.09	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
UCEC	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	9.98	2.86e-18	8.19e-11	1.09	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	9.97	2.98e-18	8.53e-11	1.12	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
UCEC	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	9.97	2.98e-18	8.53e-11	1.12	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
UCEC	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	9.97	3.03e-18	8.64e-11	0.83	0.63	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	9.97	3.03e-18	8.64e-11	0.83	0.63	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
UCEC	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	9.95	3.35e-18	9.53e-11	0.74	0.63	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
UCEC	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-9.87	5.5e-18	1.54e-10	-0.81	-0.63	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
UCEC	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	9.86	5.7e-18	1.59e-10	1.03	0.63	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
UCEC	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	9.84	6.59e-18	1.83e-10	0.73	0.63	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	9.84	6.59e-18	1.83e-10	0.73	0.63	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
UCEC	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-9.81	7.81e-18	2.15e-10	-1.02	-0.63	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
UCEC	trans	rs2731664	0.792	rs652242	ENSG00000215571.5	GRK6P1	9.81	7.81e-18	2.15e-10	0.77	0.63	Intelligence (multi-trait analysis);	chr5:177446009	chr13:21319156~21320866:+
UCEC	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	9.81	7.99e-18	2.2e-10	1.12	0.63	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
UCEC	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-9.81	8.01e-18	2.21e-10	-1.03	-0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
UCEC	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	9.78	9.5e-18	2.6e-10	0.81	0.63	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	9.78	9.5e-18	2.6e-10	0.81	0.63	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
UCEC	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-9.77	9.65e-18	2.64e-10	-1.09	-0.63	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
UCEC	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	9.76	1.05e-17	2.84e-10	0.84	0.62	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
UCEC	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	9.75	1.09e-17	2.95e-10	0.8	0.62	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
UCEC	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	9.75	1.11e-17	2.99e-10	0.98	0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
UCEC	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	9.74	1.18e-17	3.18e-10	0.77	0.62	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
UCEC	trans	rs2885056	0.83	rs2018810	ENSG00000227534.1	RP3-323B6.1	9.74	1.21e-17	3.26e-10	0.81	0.62	Red cell distribution width;	chr19:10558496	chrX:65469087~65470380:+
UCEC	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	9.74	1.22e-17	3.29e-10	0.97	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
UCEC	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-9.73	1.27e-17	3.41e-10	-0.96	-0.62	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
UCEC	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	9.69	1.58e-17	4.24e-10	0.75	0.62	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
UCEC	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	9.69	1.6e-17	4.29e-10	0.74	0.62	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
UCEC	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	9.68	1.73e-17	4.61e-10	0.98	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
UCEC	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-9.67	1.82e-17	4.85e-10	-0.8	-0.62	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-9.66	1.94e-17	5.15e-10	-1.09	-0.62	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
UCEC	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	9.66	1.94e-17	5.15e-10	1.04	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
UCEC	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	9.66	1.94e-17	5.15e-10	1.04	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	9.65	2.04e-17	5.42e-10	0.88	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	9.65	2.04e-17	5.42e-10	0.88	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
UCEC	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	9.64	2.13e-17	5.61e-10	1.01	0.62	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	9.64	2.13e-17	5.61e-10	1.01	0.62	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
UCEC	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	9.64	2.16e-17	5.67e-10	0.72	0.62	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	9.64	2.16e-17	5.67e-10	0.72	0.62	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	9.64	2.16e-17	5.67e-10	0.72	0.62	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
UCEC	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	9.63	2.3e-17	6.01e-10	1	0.62	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-9.61	2.54e-17	6.64e-10	-1.09	-0.62	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
UCEC	trans	rs10242455	0.702	rs3528	ENSG00000228834.1	RP11-249L21.4	9.6	2.67e-17	6.95e-10	1.32	0.62	Blood metabolite levels;	chr7:99458317	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs55927283	ENSG00000228834.1	RP11-249L21.4	9.6	2.67e-17	6.95e-10	1.32	0.62	Blood metabolite levels;	chr7:99459568	chr6:108907615~108907873:-
UCEC	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	9.6	2.69e-17	6.99e-10	1.01	0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	9.6	2.7e-17	7e-10	0.82	0.62	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
UCEC	trans	rs10242455	0.702	rs112475236	ENSG00000228834.1	RP11-249L21.4	9.6	2.72e-17	7.05e-10	1.31	0.62	Blood metabolite levels;	chr7:99447056	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.557	rs45529541	ENSG00000228834.1	RP11-249L21.4	9.6	2.72e-17	7.05e-10	1.31	0.62	Blood metabolite levels;	chr7:99450520	chr6:108907615~108907873:-
UCEC	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	9.6	2.83e-17	7.33e-10	0.76	0.62	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
UCEC	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	9.59	2.86e-17	7.38e-10	1.08	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
UCEC	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	9.59	2.86e-17	7.38e-10	1.08	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
UCEC	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-9.58	3.05e-17	7.81e-10	-0.72	-0.62	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
UCEC	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	9.58	3.07e-17	7.87e-10	0.89	0.62	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	9.58	3.08e-17	7.88e-10	0.83	0.62	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
UCEC	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	9.58	3.1e-17	7.92e-10	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
UCEC	trans	rs7121616	0.576	rs7111598	ENSG00000234176.1	HSPA8P1	9.57	3.31e-17	8.44e-10	0.78	0.62	Breast cancer;	chr11:123055438	chrX:121203182~121205014:-
UCEC	trans	rs10242455	0.557	rs2404487	ENSG00000228834.1	RP11-249L21.4	9.56	3.49e-17	8.87e-10	1.48	0.62	Blood metabolite levels;	chr7:99440434	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs73711280	ENSG00000228834.1	RP11-249L21.4	9.56	3.49e-17	8.87e-10	1.48	0.62	Blood metabolite levels;	chr7:99441981	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs45448997	ENSG00000228834.1	RP11-249L21.4	9.56	3.49e-17	8.87e-10	1.48	0.62	Blood metabolite levels;	chr7:99443975	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.557	rs45492501	ENSG00000228834.1	RP11-249L21.4	9.56	3.49e-17	8.87e-10	1.48	0.62	Blood metabolite levels;	chr7:99449407	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs17854665	ENSG00000228834.1	RP11-249L21.4	9.56	3.49e-17	8.87e-10	1.48	0.62	Blood metabolite levels;	chr7:99452416	chr6:108907615~108907873:-
UCEC	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-9.53	4.17e-17	1.05e-09	-0.72	-0.62	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
UCEC	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	9.52	4.41e-17	1.11e-09	0.98	0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
UCEC	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	9.52	4.41e-17	1.11e-09	0.98	0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
UCEC	trans	rs13177918	0.871	rs11745194	ENSG00000213058.3	RP4-765C7.2	9.51	4.63e-17	1.16e-09	1.05	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	9.51	4.64e-17	1.16e-09	0.87	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
UCEC	trans	rs3749237	0.595	rs17650792	ENSG00000197582.5	GPX1P1	9.5	5e-17	1.25e-09	0.8	0.61	Resting heart rate;	chr3:49352817	chrX:13378735~13379340:-
UCEC	trans	rs2731664	0.792	rs163199	ENSG00000215571.5	GRK6P1	9.5	5.04e-17	1.26e-09	0.77	0.61	Intelligence (multi-trait analysis);	chr5:177463066	chr13:21319156~21320866:+
UCEC	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-9.49	5.21e-17	1.3e-09	-1.11	-0.61	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
UCEC	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	9.49	5.23e-17	1.3e-09	1.05	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
UCEC	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	9.49	5.23e-17	1.3e-09	1.05	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
UCEC	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	9.49	5.26e-17	1.31e-09	0.76	0.61	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	9.49	5.43e-17	1.35e-09	0.75	0.61	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
UCEC	trans	rs13177918	0.871	rs11745194	ENSG00000224114.1	RP11-343H5.4	9.47	5.9e-17	1.46e-09	1.07	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr1:206695837~206696269:-
UCEC	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	9.47	5.9e-17	1.46e-09	0.99	0.61	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	9.44	7.23e-17	1.77e-09	0.72	0.61	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-9.43	7.63e-17	1.86e-09	-0.83	-0.61	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
UCEC	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-9.42	8.1e-17	1.97e-09	-0.97	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
UCEC	trans	rs13177918	0.871	rs11745133	ENSG00000213058.3	RP4-765C7.2	9.41	8.57e-17	2.08e-09	1.04	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	9.41	8.62e-17	2.09e-09	0.96	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	9.41	8.62e-17	2.09e-09	0.96	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	9.41	8.62e-17	2.09e-09	0.96	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
UCEC	trans	rs2731664	0.792	rs335467	ENSG00000215571.5	GRK6P1	9.41	8.64e-17	2.09e-09	0.76	0.61	Intelligence (multi-trait analysis);	chr5:177463641	chr13:21319156~21320866:+
UCEC	trans	rs1816752	0.704	rs7995968	ENSG00000237917.1	PARP4P1	-9.4	9.11e-17	2.19e-09	-0.67	-0.61	Obesity-related traits;	chr13:24392754	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	9.4	9.17e-17	2.21e-09	1	0.61	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-9.35	1.2e-16	2.87e-09	-0.82	-0.61	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
UCEC	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	9.34	1.31e-16	3.12e-09	1.03	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
UCEC	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	9.34	1.31e-16	3.12e-09	1.03	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
UCEC	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-9.32	1.49e-16	3.52e-09	-0.97	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
UCEC	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-9.32	1.5e-16	3.56e-09	-0.64	-0.61	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
UCEC	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	9.3	1.64e-16	3.89e-09	0.67	0.61	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
UCEC	trans	rs13177918	0.834	rs13163277	ENSG00000213058.3	RP4-765C7.2	9.29	1.73e-16	4.09e-09	1.05	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr1:178411616~178411972:+
UCEC	trans	rs13177918	0.798	rs12516161	ENSG00000213058.3	RP4-765C7.2	9.29	1.73e-16	4.09e-09	1.05	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:178411616~178411972:+
UCEC	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-9.28	1.91e-16	4.49e-09	-0.65	-0.61	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
UCEC	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	9.27	1.94e-16	4.55e-09	0.79	0.6	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
UCEC	trans	rs13177918	0.871	rs11745133	ENSG00000224114.1	RP11-343H5.4	9.27	2.03e-16	4.74e-09	1.06	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr1:206695837~206696269:-
UCEC	trans	rs13190036	1	rs351864	ENSG00000217325.2	PRELID1P1	-9.24	2.32e-16	5.41e-09	-0.96	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr6:126643488~126644390:+
UCEC	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-9.24	2.37e-16	5.53e-09	-0.8	-0.6	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
UCEC	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	9.24	2.4e-16	5.58e-09	0.7	0.6	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	9.24	2.4e-16	5.58e-09	0.7	0.6	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	9.24	2.41e-16	5.6e-09	0.69	0.6	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-9.24	2.42e-16	5.62e-09	-0.73	-0.6	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
UCEC	trans	rs10242455	0.702	rs73401510	ENSG00000228834.1	RP11-249L21.4	9.19	3.17e-16	7.29e-09	1.44	0.6	Blood metabolite levels;	chr7:99468189	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.557	rs73401516	ENSG00000228834.1	RP11-249L21.4	9.19	3.17e-16	7.29e-09	1.44	0.6	Blood metabolite levels;	chr7:99470728	chr6:108907615~108907873:-
UCEC	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-9.19	3.27e-16	7.5e-09	-0.95	-0.6	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
UCEC	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-9.17	3.53e-16	8.09e-09	-0.71	-0.6	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
UCEC	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	9.17	3.64e-16	8.32e-09	0.87	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	9.17	3.64e-16	8.32e-09	0.87	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
UCEC	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	9.16	3.8e-16	8.68e-09	0.79	0.6	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
UCEC	trans	rs941207	0.507	rs2958124	ENSG00000121089.4	NACA3P	-9.16	3.87e-16	8.83e-09	-0.72	-0.6	Platelet count;	chr12:56633837	chr4:164943290~164943937:+
UCEC	trans	rs13177918	0.834	rs13163277	ENSG00000224114.1	RP11-343H5.4	9.16	3.9e-16	8.9e-09	1.06	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr1:206695837~206696269:-
UCEC	trans	rs13177918	0.798	rs12516161	ENSG00000224114.1	RP11-343H5.4	9.16	3.9e-16	8.9e-09	1.06	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:206695837~206696269:-
UCEC	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	9.15	4.12e-16	9.39e-09	0.72	0.6	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	9.15	4.12e-16	9.39e-09	0.72	0.6	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	9.14	4.29e-16	9.74e-09	0.72	0.6	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	9.14	4.29e-16	9.74e-09	0.72	0.6	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
UCEC	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	9.14	4.31e-16	9.78e-09	0.79	0.6	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
UCEC	trans	rs2731664	0.792	rs335452	ENSG00000215571.5	GRK6P1	9.13	4.47e-16	1.01e-08	0.74	0.6	Intelligence (multi-trait analysis);	chr5:177452670	chr13:21319156~21320866:+
UCEC	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	9.13	4.52e-16	1.01e-08	0.79	0.6	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
UCEC	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	9.13	4.57e-16	1.02e-08	0.93	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	9.13	4.57e-16	1.02e-08	0.93	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	9.13	4.57e-16	1.02e-08	0.93	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
UCEC	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	9.12	4.69e-16	1.04e-08	0.71	0.6	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
UCEC	trans	rs2731664	0.792	rs385981	ENSG00000215571.5	GRK6P1	9.12	4.76e-16	1.06e-08	0.74	0.6	Intelligence (multi-trait analysis);	chr5:177459538	chr13:21319156~21320866:+
UCEC	trans	rs6477998	1	rs6477998	ENSG00000238072.1	RP11-305M3.2	-9.12	4.78e-16	1.06e-08	-0.72	-0.6	Hematology traits;	chr9:113234969	chr7:129410113~129410370:-
UCEC	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	9.12	4.9e-16	1.09e-08	0.72	0.6	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
UCEC	trans	rs2731664	0.792	rs465670	ENSG00000215571.5	GRK6P1	9.12	4.94e-16	1.1e-08	0.74	0.6	Intelligence (multi-trait analysis);	chr5:177450623	chr13:21319156~21320866:+
UCEC	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	9.11	5e-16	1.11e-08	0.91	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
UCEC	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-9.08	6.04e-16	1.33e-08	-0.97	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
UCEC	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-9.08	6.04e-16	1.33e-08	-0.97	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
UCEC	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-9.08	6.04e-16	1.33e-08	-0.97	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
UCEC	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-9.08	6.04e-16	1.33e-08	-0.97	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
UCEC	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-9.08	6.04e-16	1.33e-08	-0.97	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
UCEC	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-9.08	6.04e-16	1.33e-08	-0.97	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
UCEC	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	9.07	6.55e-16	1.44e-08	0.95	0.6	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
UCEC	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-9.07	6.56e-16	1.44e-08	-0.8	-0.6	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
UCEC	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	9.05	7.23e-16	1.58e-08	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
UCEC	trans	rs10242455	0.557	rs59672032	ENSG00000228834.1	RP11-249L21.4	9.05	7.3e-16	1.59e-08	1.21	0.6	Blood metabolite levels;	chr7:99461074	chr6:108907615~108907873:-
UCEC	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	9.05	7.31e-16	1.59e-08	1.38	0.6	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
UCEC	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	9.04	7.84e-16	1.71e-08	0.92	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
UCEC	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	9.04	7.89e-16	1.72e-08	0.72	0.59	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
UCEC	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	9	9.51e-16	2.06e-08	0.78	0.59	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	9	9.51e-16	2.06e-08	0.78	0.59	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
UCEC	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	8.98	1.12e-15	2.39e-08	0.78	0.59	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	8.98	1.12e-15	2.39e-08	0.78	0.59	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	8.98	1.12e-15	2.39e-08	0.78	0.59	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	8.98	1.12e-15	2.39e-08	0.78	0.59	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	8.98	1.12e-15	2.39e-08	0.78	0.59	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	8.98	1.12e-15	2.39e-08	0.78	0.59	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	8.98	1.12e-15	2.39e-08	0.78	0.59	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
UCEC	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	8.98	1.12e-15	2.39e-08	0.78	0.59	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
UCEC	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-8.98	1.13e-15	2.41e-08	-0.73	-0.59	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
UCEC	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	8.97	1.13e-15	2.41e-08	0.94	0.59	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	8.97	1.13e-15	2.41e-08	0.94	0.59	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	8.97	1.13e-15	2.41e-08	0.94	0.59	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
UCEC	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	8.97	1.19e-15	2.52e-08	0.72	0.59	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	8.97	1.2e-15	2.54e-08	0.72	0.59	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	8.97	1.2e-15	2.54e-08	0.72	0.59	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	8.97	1.2e-15	2.54e-08	0.72	0.59	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	8.97	1.2e-15	2.54e-08	0.72	0.59	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	8.97	1.2e-15	2.54e-08	0.72	0.59	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
UCEC	trans	rs13190036	1	rs351862	ENSG00000217325.2	PRELID1P1	-8.96	1.23e-15	2.61e-08	-0.94	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr6:126643488~126644390:+
UCEC	trans	rs2731664	0.819	rs449351	ENSG00000215571.5	GRK6P1	8.96	1.24e-15	2.62e-08	0.75	0.59	Intelligence (multi-trait analysis);	chr5:177445590	chr13:21319156~21320866:+
UCEC	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	8.95	1.32e-15	2.78e-08	0.92	0.59	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
UCEC	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	8.92	1.58e-15	3.32e-08	0.74	0.59	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
UCEC	trans	rs7554547	1	rs7554547	ENSG00000261819.1	RP11-680G24.4	8.92	1.58e-15	3.33e-08	0.73	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11913831	chr16:14988259~14990160:-
UCEC	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	8.92	1.6e-15	3.37e-08	0.74	0.59	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
UCEC	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	8.92	1.6e-15	3.37e-08	0.74	0.59	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
UCEC	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	8.92	1.6e-15	3.37e-08	0.74	0.59	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
UCEC	trans	rs7554547	1	rs926270	ENSG00000261819.1	RP11-680G24.4	8.91	1.65e-15	3.46e-08	0.73	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11909729	chr16:14988259~14990160:-
UCEC	trans	rs7554547	1	rs926271	ENSG00000261819.1	RP11-680G24.4	8.91	1.65e-15	3.46e-08	0.73	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11909860	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.967	rs4845888	ENSG00000261819.1	RP11-680G24.4	8.91	1.65e-15	3.46e-08	0.73	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11910946	chr16:14988259~14990160:-
UCEC	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	8.9	1.72e-15	3.59e-08	0.76	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
UCEC	trans	rs2731664	0.756	rs2545796	ENSG00000215571.5	GRK6P1	8.9	1.81e-15	3.77e-08	0.76	0.59	Intelligence (multi-trait analysis);	chr5:177437268	chr13:21319156~21320866:+
UCEC	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	8.89	1.87e-15	3.9e-08	0.74	0.59	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
UCEC	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	8.89	1.9e-15	3.96e-08	0.94	0.59	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
UCEC	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	8.89	1.91e-15	3.98e-08	0.69	0.59	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
UCEC	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-8.87	2.1e-15	4.35e-08	-0.7	-0.59	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
UCEC	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	8.87	2.14e-15	4.45e-08	0.89	0.59	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
UCEC	trans	rs4240897	0.561	rs12043045	ENSG00000261819.1	RP11-680G24.4	8.86	2.19e-15	4.53e-08	0.72	0.59	Tuberculosis;	chr1:11900294	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.508	rs7520898	ENSG00000261819.1	RP11-680G24.4	8.86	2.19e-15	4.53e-08	0.72	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11901078	chr16:14988259~14990160:-
UCEC	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-8.85	2.43e-15	5e-08	-0.86	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
UCEC	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	8.83	2.66e-15	5.46e-08	0.72	0.59	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
UCEC	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	8.82	2.75e-15	5.61e-08	0.74	0.59	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
UCEC	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	8.8	3.13e-15	6.38e-08	0.84	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
UCEC	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-8.8	3.25e-15	6.61e-08	-0.67	-0.58	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	8.79	3.41e-15	6.9e-08	0.64	0.58	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	8.79	3.41e-15	6.9e-08	0.64	0.58	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	8.77	3.69e-15	7.45e-08	0.64	0.58	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
UCEC	trans	rs3749237	0.576	rs62259939	ENSG00000197582.5	GPX1P1	8.74	4.38e-15	8.79e-08	0.77	0.58	Resting heart rate;	chr3:49348614	chrX:13378735~13379340:-
UCEC	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-8.73	4.71e-15	9.4e-08	-0.72	-0.58	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
UCEC	trans	rs941207	0.526	rs2950387	ENSG00000121089.4	NACA3P	-8.73	4.8e-15	9.56e-08	-0.72	-0.58	Platelet count;	chr12:56627222	chr4:164943290~164943937:+
UCEC	trans	rs6688567	1	rs6688567	ENSG00000213331.4	RP11-713C19.2	8.72	4.97e-15	9.88e-08	0.67	0.58	Mosquito bite size;	chr1:173614275	chr4:187970273~187971284:+
UCEC	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-8.72	5.14e-15	1.02e-07	-1.21	-0.58	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
UCEC	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	8.71	5.23e-15	1.04e-07	0.73	0.58	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
UCEC	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-8.71	5.38e-15	1.07e-07	-0.94	-0.58	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
UCEC	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-8.7	5.68e-15	1.12e-07	-0.92	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
UCEC	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-8.7	5.68e-15	1.12e-07	-0.92	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
UCEC	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	8.69	5.95e-15	1.17e-07	0.83	0.58	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
UCEC	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	8.69	6.01e-15	1.18e-07	1.37	0.58	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
UCEC	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-8.69	6.06e-15	1.19e-07	-0.68	-0.58	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
UCEC	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	8.67	6.83e-15	1.33e-07	0.66	0.58	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
UCEC	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-8.67	6.86e-15	1.34e-07	-0.92	-0.58	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
UCEC	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	8.66	7.33e-15	1.42e-07	0.83	0.58	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	8.66	7.33e-15	1.42e-07	0.83	0.58	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	8.66	7.33e-15	1.42e-07	0.83	0.58	Platelet count;	chr7:100385512	chr7:102337316~102339115:+
UCEC	trans	rs2731664	0.792	rs335468	ENSG00000215571.5	GRK6P1	-8.64	8.28e-15	1.61e-07	-0.75	-0.58	Intelligence (multi-trait analysis);	chr5:177465348	chr13:21319156~21320866:+
UCEC	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	8.63	8.61e-15	1.66e-07	0.98	0.58	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
UCEC	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	8.63	8.61e-15	1.66e-07	0.98	0.58	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
UCEC	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-8.62	8.83e-15	1.7e-07	-0.91	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
UCEC	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-8.62	8.83e-15	1.7e-07	-0.91	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
UCEC	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-8.62	8.83e-15	1.7e-07	-0.91	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
UCEC	trans	rs2731664	0.792	rs335434	ENSG00000215571.5	GRK6P1	8.62	9.1e-15	1.75e-07	0.76	0.58	Intelligence (multi-trait analysis);	chr5:177440275	chr13:21319156~21320866:+
UCEC	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	8.62	9.17e-15	1.76e-07	0.63	0.58	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	8.62	9.17e-15	1.76e-07	0.63	0.58	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	8.62	9.17e-15	1.76e-07	0.63	0.58	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	8.62	9.17e-15	1.76e-07	0.63	0.58	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
UCEC	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	8.61	9.79e-15	1.87e-07	0.83	0.58	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	8.61	9.79e-15	1.87e-07	0.83	0.58	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs6955367	ENSG00000228546.2	CTA-313A17.3	8.61	9.8e-15	1.87e-07	0.83	0.58	Platelet count;	chr7:100363571	chr7:102337316~102339115:+
UCEC	trans	rs12709013	0.591	rs30841	ENSG00000230849.2	GOT2P2	8.6	1.05e-14	1.99e-07	0.66	0.58	Blood metabolite ratios;	chr16:58709819	chr1:173141100~173142350:-
UCEC	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	8.59	1.05e-14	2e-07	0.83	0.58	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	8.59	1.05e-14	2e-07	0.83	0.58	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
UCEC	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	8.59	1.07e-14	2.04e-07	0.91	0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
UCEC	trans	rs7503168	0.558	rs12945102	ENSG00000234130.2	RP13-88F20.1	8.59	1.08e-14	2.05e-07	1.37	0.58	Plateletcrit;	chr17:35601894	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs12945980	ENSG00000234130.2	RP13-88F20.1	8.59	1.08e-14	2.05e-07	1.37	0.58	Plateletcrit;	chr17:35603002	chrX:93222220~93225015:-
UCEC	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	8.59	1.09e-14	2.07e-07	0.6	0.58	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	8.59	1.09e-14	2.07e-07	0.6	0.58	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	8.58	1.11e-14	2.11e-07	0.61	0.58	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	8.58	1.11e-14	2.11e-07	0.61	0.58	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	8.57	1.21e-14	2.28e-07	0.6	0.57	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
UCEC	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	8.56	1.26e-14	2.36e-07	0.98	0.57	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
UCEC	trans	rs13177918	0.871	rs11745133	ENSG00000239528.1	RPS14P8	8.56	1.28e-14	2.4e-07	0.99	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr5:116562562~116562930:+
UCEC	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	8.56	1.31e-14	2.46e-07	1.36	0.57	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	8.56	1.31e-14	2.46e-07	1.36	0.57	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	8.56	1.31e-14	2.46e-07	1.36	0.57	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	8.56	1.31e-14	2.46e-07	1.36	0.57	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
UCEC	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	8.56	1.31e-14	2.46e-07	1.36	0.57	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
UCEC	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	8.56	1.31e-14	2.46e-07	1.36	0.57	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
UCEC	trans	rs7811142	0.666	rs28401739	ENSG00000228546.2	CTA-313A17.3	8.55	1.34e-14	2.5e-07	0.82	0.57	Platelet count;	chr7:100308061	chr7:102337316~102339115:+
UCEC	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	8.55	1.35e-14	2.5e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	8.55	1.35e-14	2.5e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	8.55	1.35e-14	2.5e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	8.55	1.35e-14	2.5e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
UCEC	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-8.55	1.35e-14	2.5e-07	-0.68	-0.57	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
UCEC	trans	rs7121616	0.576	rs9665920	ENSG00000234176.1	HSPA8P1	8.55	1.37e-14	2.54e-07	0.66	0.57	Breast cancer;	chr11:123041700	chrX:121203182~121205014:-
UCEC	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	8.55	1.37e-14	2.55e-07	0.86	0.57	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
UCEC	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	8.54	1.4e-14	2.6e-07	1.02	0.57	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
UCEC	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	8.54	1.42e-14	2.63e-07	1.36	0.57	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
UCEC	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	8.54	1.44e-14	2.66e-07	0.83	0.57	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	8.54	1.44e-14	2.66e-07	0.83	0.57	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	8.54	1.44e-14	2.66e-07	0.83	0.57	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
UCEC	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-8.54	1.45e-14	2.68e-07	-0.91	-0.57	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
UCEC	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	8.53	1.49e-14	2.74e-07	1.01	0.57	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	8.53	1.49e-14	2.74e-07	1.01	0.57	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
UCEC	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	8.53	1.51e-14	2.78e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
UCEC	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-8.53	1.53e-14	2.81e-07	-0.73	-0.57	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
UCEC	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	8.53	1.54e-14	2.83e-07	0.67	0.57	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
UCEC	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	8.53	1.55e-14	2.84e-07	0.71	0.57	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
UCEC	trans	rs13177918	0.871	rs11745194	ENSG00000239528.1	RPS14P8	8.53	1.56e-14	2.85e-07	0.99	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr5:116562562~116562930:+
UCEC	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	8.52	1.61e-14	2.95e-07	0.97	0.57	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
UCEC	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	8.49	1.94e-14	3.51e-07	1.01	0.57	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
UCEC	trans	rs12709013	0.591	rs30840	ENSG00000230849.2	GOT2P2	8.49	1.94e-14	3.51e-07	0.66	0.57	Blood metabolite ratios;	chr16:58710165	chr1:173141100~173142350:-
UCEC	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	8.48	2.08e-14	3.75e-07	0.67	0.57	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	8.47	2.19e-14	3.94e-07	0.68	0.57	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
UCEC	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-8.47	2.22e-14	3.99e-07	-0.86	-0.57	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
UCEC	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	8.46	2.26e-14	4.06e-07	0.64	0.57	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	8.46	2.26e-14	4.06e-07	0.64	0.57	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
UCEC	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-8.46	2.35e-14	4.19e-07	-0.91	-0.57	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-8.46	2.35e-14	4.19e-07	-0.91	-0.57	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	8.46	2.35e-14	4.19e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	8.46	2.35e-14	4.19e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	8.46	2.35e-14	4.19e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	8.46	2.35e-14	4.19e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
UCEC	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-8.45	2.43e-14	4.34e-07	-0.7	-0.57	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
UCEC	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	8.45	2.44e-14	4.35e-07	0.97	0.57	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
UCEC	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-8.45	2.5e-14	4.45e-07	-0.89	-0.57	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
UCEC	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	8.44	2.54e-14	4.53e-07	0.6	0.57	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
UCEC	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	8.44	2.59e-14	4.61e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	8.44	2.59e-14	4.61e-07	0.91	0.57	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
UCEC	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	8.41	3e-14	5.28e-07	0.68	0.57	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
UCEC	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-8.41	3.01e-14	5.28e-07	-0.9	-0.57	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-8.41	3.01e-14	5.28e-07	-0.9	-0.57	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-8.41	3.01e-14	5.28e-07	-0.9	-0.57	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-8.41	3.01e-14	5.28e-07	-0.9	-0.57	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
UCEC	trans	rs10242455	0.702	rs73397499	ENSG00000228834.1	RP11-249L21.4	8.41	3.05e-14	5.35e-07	1.38	0.57	Blood metabolite levels;	chr7:99442004	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs45461000	ENSG00000228834.1	RP11-249L21.4	8.41	3.05e-14	5.35e-07	1.38	0.57	Blood metabolite levels;	chr7:99455087	chr6:108907615~108907873:-
UCEC	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	8.41	3.12e-14	5.47e-07	0.83	0.57	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
UCEC	trans	rs12709013	0.569	rs30837	ENSG00000230849.2	GOT2P2	8.4	3.3e-14	5.78e-07	0.65	0.57	Blood metabolite ratios;	chr16:58711942	chr1:173141100~173142350:-
UCEC	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	8.39	3.37e-14	5.9e-07	1.09	0.57	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
UCEC	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	8.39	3.37e-14	5.9e-07	1.09	0.57	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
UCEC	trans	rs941207	0.526	rs2242497	ENSG00000121089.4	NACA3P	-8.38	3.72e-14	6.49e-07	-0.68	-0.57	Platelet count;	chr12:56598846	chr4:164943290~164943937:+
UCEC	trans	rs13177918	0.834	rs13163277	ENSG00000239528.1	RPS14P8	8.38	3.75e-14	6.54e-07	0.99	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr5:116562562~116562930:+
UCEC	trans	rs13177918	0.798	rs12516161	ENSG00000239528.1	RPS14P8	8.38	3.75e-14	6.54e-07	0.99	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr5:116562562~116562930:+
UCEC	trans	rs7949030	0.964	rs2957122	ENSG00000186676.3	EEF1GP1	-8.37	3.82e-14	6.64e-07	-0.72	-0.57	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62624628	chr7:125033453~125035301:+
UCEC	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	8.37	3.94e-14	6.85e-07	0.7	0.57	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
UCEC	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-8.35	4.44e-14	7.67e-07	-1.03	-0.56	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
UCEC	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	8.34	4.5e-14	7.76e-07	0.7	0.56	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
UCEC	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	8.34	4.53e-14	7.81e-07	0.69	0.56	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
UCEC	trans	rs7554547	0.778	rs2008113	ENSG00000261819.1	RP11-680G24.4	-8.34	4.64e-14	8e-07	-0.69	-0.56	Nonsyndromic cleft lip with cleft palate;	chr1:11878809	chr16:14988259~14990160:-
UCEC	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	8.33	4.76e-14	8.19e-07	0.69	0.56	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
UCEC	trans	rs2885056	0.8	rs8105074	ENSG00000227534.1	RP3-323B6.1	8.33	4.93e-14	8.46e-07	0.73	0.56	Red cell distribution width;	chr19:10598016	chrX:65469087~65470380:+
UCEC	trans	rs6708331	0.941	rs6749886	ENSG00000232654.1	FAM136BP	8.33	5e-14	8.58e-07	0.98	0.56	Obesity-related traits;	chr2:70062968	chr6:3045384~3045800:+
UCEC	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	8.32	5.19e-14	8.87e-07	0.69	0.56	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
UCEC	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	8.32	5.19e-14	8.87e-07	0.69	0.56	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
UCEC	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-8.3	5.85e-14	9.95e-07	-0.64	-0.56	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
UCEC	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	8.29	5.96e-14	1.01e-06	0.7	0.56	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	8.29	5.96e-14	1.01e-06	0.7	0.56	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	8.29	5.96e-14	1.01e-06	0.7	0.56	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
UCEC	trans	rs2731664	0.792	rs2630765	ENSG00000215571.5	GRK6P1	8.29	6.03e-14	1.02e-06	0.71	0.56	Intelligence (multi-trait analysis);	chr5:177449824	chr13:21319156~21320866:+
UCEC	trans	rs7811142	1	rs68116612	ENSG00000228546.2	CTA-313A17.3	8.28	6.5e-14	1.09e-06	0.83	0.56	Platelet count;	chr7:100408870	chr7:102337316~102339115:+
UCEC	trans	rs13190036	0.551	rs28932178	ENSG00000217325.2	PRELID1P1	-8.27	6.86e-14	1.15e-06	-0.85	-0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr6:126643488~126644390:+
UCEC	trans	rs2731664	0.756	rs335433	ENSG00000215571.5	GRK6P1	8.26	7.43e-14	1.23e-06	0.73	0.56	Intelligence (multi-trait analysis);	chr5:177440206	chr13:21319156~21320866:+
UCEC	trans	rs2731664	0.792	rs2731662	ENSG00000215571.5	GRK6P1	-8.26	7.46e-14	1.24e-06	-0.69	-0.56	Intelligence (multi-trait analysis);	chr5:177445493	chr13:21319156~21320866:+
UCEC	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	8.25	7.89e-14	1.3e-06	0.68	0.56	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
UCEC	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	8.24	8.01e-14	1.32e-06	1	0.56	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
UCEC	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	8.23	8.73e-14	1.42e-06	0.82	0.56	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	8.23	8.73e-14	1.42e-06	0.82	0.56	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467791	ENSG00000242375.1	RP11-498P14.3	-8.22	8.92e-14	1.45e-06	-0.71	-0.56	Intelligence (multi-trait analysis);	chr6:26562258	chr9:97195351~97197687:-
UCEC	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	8.22	9.1e-14	1.48e-06	0.52	0.56	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
UCEC	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	8.22	9.11e-14	1.48e-06	0.8	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
UCEC	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	8.22	9.37e-14	1.52e-06	0.67	0.56	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
UCEC	trans	rs7811142	1	rs1000215	ENSG00000228546.2	CTA-313A17.3	8.21	9.78e-14	1.58e-06	0.8	0.56	Platelet count;	chr7:100406920	chr7:102337316~102339115:+
UCEC	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	8.18	1.16e-13	1.86e-06	0.69	0.56	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
UCEC	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	8.18	1.16e-13	1.86e-06	0.6	0.56	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	8.18	1.16e-13	1.86e-06	0.6	0.56	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
UCEC	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	8.18	1.18e-13	1.88e-06	0.66	0.56	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
UCEC	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	8.17	1.2e-13	1.91e-06	0.68	0.56	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
UCEC	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	8.16	1.32e-13	2.1e-06	1.03	0.56	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
UCEC	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	8.12	1.6e-13	2.46e-06	0.88	0.55	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
UCEC	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	8.12	1.67e-13	2.56e-06	0.79	0.55	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
UCEC	trans	rs13253073	0.883	rs2305290	ENSG00000260318.1	COX6CP1	8.11	1.71e-13	2.63e-06	1.05	0.55	Glucose homeostasis traits;	chr8:99819066	chr16:11903923~11904137:-
UCEC	trans	rs7554547	0.871	rs6661289	ENSG00000261819.1	RP11-680G24.4	8.11	1.72e-13	2.64e-06	0.69	0.55	Nonsyndromic cleft lip with cleft palate;	chr1:11882724	chr16:14988259~14990160:-
UCEC	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	8.11	1.76e-13	2.69e-06	0.65	0.55	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
UCEC	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	8.1	1.86e-13	2.84e-06	0.67	0.55	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	8.1	1.86e-13	2.84e-06	0.67	0.55	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
UCEC	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	8.08	2.03e-13	3.08e-06	0.61	0.55	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
UCEC	trans	rs10242455	0.557	rs77997620	ENSG00000228834.1	RP11-249L21.4	8.08	2.04e-13	3.09e-06	1.33	0.55	Blood metabolite levels;	chr7:99472792	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs59240302	ENSG00000228834.1	RP11-249L21.4	8.08	2.04e-13	3.09e-06	1.33	0.55	Blood metabolite levels;	chr7:99475368	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs73403247	ENSG00000228834.1	RP11-249L21.4	8.08	2.04e-13	3.09e-06	1.33	0.55	Blood metabolite levels;	chr7:99491107	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs6974831	ENSG00000228834.1	RP11-249L21.4	8.08	2.04e-13	3.09e-06	1.33	0.55	Blood metabolite levels;	chr7:99533982	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.557	rs73403272	ENSG00000228834.1	RP11-249L21.4	8.08	2.04e-13	3.09e-06	1.33	0.55	Blood metabolite levels;	chr7:99536585	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs7794068	ENSG00000228834.1	RP11-249L21.4	8.08	2.04e-13	3.09e-06	1.33	0.55	Blood metabolite levels;	chr7:99549250	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs73403290	ENSG00000228834.1	RP11-249L21.4	8.08	2.04e-13	3.09e-06	1.33	0.55	Blood metabolite levels;	chr7:99560205	chr6:108907615~108907873:-
UCEC	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	8.08	2.06e-13	3.12e-06	0.67	0.55	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	8.08	2.06e-13	3.12e-06	0.67	0.55	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
UCEC	trans	rs7554547	0.818	rs4993566	ENSG00000261819.1	RP11-680G24.4	8.07	2.11e-13	3.2e-06	0.68	0.55	Nonsyndromic cleft lip with cleft palate;	chr1:11909937	chr16:14988259~14990160:-
UCEC	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-8.07	2.13e-13	3.22e-06	-0.69	-0.55	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
UCEC	trans	rs7554547	0.791	rs2064614	ENSG00000261819.1	RP11-680G24.4	8.07	2.16e-13	3.27e-06	0.71	0.55	Nonsyndromic cleft lip with cleft palate;	chr1:11893883	chr16:14988259~14990160:-
UCEC	trans	rs7811142	1	rs28490152	ENSG00000228546.2	CTA-313A17.3	8.05	2.38e-13	3.6e-06	0.8	0.55	Platelet count;	chr7:100423359	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.943	rs28660238	ENSG00000228546.2	CTA-313A17.3	8.05	2.38e-13	3.6e-06	0.8	0.55	Platelet count;	chr7:100425685	chr7:102337316~102339115:+
UCEC	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-8.05	2.4e-13	3.61e-06	-0.94	-0.55	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
UCEC	trans	rs2731664	0.792	rs335420	ENSG00000215571.5	GRK6P1	-8.05	2.49e-13	3.74e-06	-0.7	-0.55	Intelligence (multi-trait analysis);	chr5:177471618	chr13:21319156~21320866:+
UCEC	trans	rs7811142	0.943	rs111493473	ENSG00000228546.2	CTA-313A17.3	8.04	2.52e-13	3.78e-06	0.79	0.55	Platelet count;	chr7:100452119	chr7:102337316~102339115:+
UCEC	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-8.03	2.78e-13	4.16e-06	-0.67	-0.55	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
UCEC	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-8.03	2.78e-13	4.17e-06	-0.61	-0.55	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
UCEC	trans	rs13190036	1	rs7714695	ENSG00000217325.2	PRELID1P1	-8.02	2.93e-13	4.38e-06	-0.92	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr6:126643488~126644390:+
UCEC	trans	rs72615157	0.613	rs56089143	ENSG00000228546.2	CTA-313A17.3	8	3.19e-13	4.74e-06	0.8	0.55	Lung function (FEV1/FVC);	chr7:100222221	chr7:102337316~102339115:+
UCEC	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	8	3.2e-13	4.76e-06	0.65	0.55	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
UCEC	trans	rs7949030	1	rs2956993	ENSG00000186676.3	EEF1GP1	-7.99	3.43e-13	5.08e-06	-0.69	-0.55	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62638690	chr7:125033453~125035301:+
UCEC	trans	rs7554547	0.791	rs1321073	ENSG00000261819.1	RP11-680G24.4	7.98	3.63e-13	5.36e-06	0.71	0.55	Nonsyndromic cleft lip with cleft palate;	chr1:11891569	chr16:14988259~14990160:-
UCEC	trans	rs7811142	1	rs112317829	ENSG00000228546.2	CTA-313A17.3	7.98	3.65e-13	5.38e-06	0.8	0.55	Platelet count;	chr7:100445550	chr7:102337316~102339115:+
UCEC	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	7.97	3.79e-13	5.58e-06	1.04	0.55	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
UCEC	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	7.97	3.8e-13	5.6e-06	0.68	0.55	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
UCEC	trans	rs13190036	0.551	rs1052432	ENSG00000217325.2	PRELID1P1	-7.96	4.1e-13	6e-06	-0.79	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr6:126643488~126644390:+
UCEC	trans	rs72615157	0.612	rs7786505	ENSG00000228546.2	CTA-313A17.3	7.95	4.38e-13	6.39e-06	0.8	0.55	Lung function (FEV1/FVC);	chr7:100219962	chr7:102337316~102339115:+
UCEC	trans	rs72615157	0.664	rs6953580	ENSG00000228546.2	CTA-313A17.3	7.95	4.38e-13	6.39e-06	0.8	0.55	Lung function (FEV1/FVC);	chr7:100227652	chr7:102337316~102339115:+
UCEC	trans	rs2731664	0.792	rs337374	ENSG00000215571.5	GRK6P1	-7.94	4.46e-13	6.5e-06	-0.68	-0.55	Intelligence (multi-trait analysis);	chr5:177463415	chr13:21319156~21320866:+
UCEC	trans	rs7811142	0.943	rs67483801	ENSG00000228546.2	CTA-313A17.3	7.94	4.6e-13	6.69e-06	0.79	0.55	Platelet count;	chr7:100434135	chr7:102337316~102339115:+
UCEC	trans	rs7811142	1	rs11761784	ENSG00000228546.2	CTA-313A17.3	7.94	4.6e-13	6.69e-06	0.79	0.55	Platelet count;	chr7:100442347	chr7:102337316~102339115:+
UCEC	trans	rs2731664	0.721	rs2450333	ENSG00000215571.5	GRK6P1	7.93	4.73e-13	6.88e-06	0.7	0.54	Intelligence (multi-trait analysis);	chr5:177472545	chr13:21319156~21320866:+
UCEC	trans	rs2731664	0.765	rs2630766	ENSG00000215571.5	GRK6P1	7.93	4.81e-13	6.98e-06	0.68	0.54	Intelligence (multi-trait analysis);	chr5:177447940	chr13:21319156~21320866:+
UCEC	trans	rs10242455	0.702	rs73397481	ENSG00000228834.1	RP11-249L21.4	7.93	4.87e-13	7.05e-06	1.45	0.54	Blood metabolite levels;	chr7:99432485	chr6:108907615~108907873:-
UCEC	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-7.92	5.02e-13	7.27e-06	-0.7	-0.54	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
UCEC	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	7.92	5.04e-13	7.28e-06	0.67	0.54	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
UCEC	trans	rs7811142	0.943	rs111757992	ENSG00000228546.2	CTA-313A17.3	7.91	5.23e-13	7.53e-06	0.78	0.54	Platelet count;	chr7:100418731	chr7:102337316~102339115:+
UCEC	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-7.9	5.54e-13	7.96e-06	-0.59	-0.54	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
UCEC	trans	rs9425766	0.639	rs10798295	ENSG00000213331.4	RP11-713C19.2	7.9	5.71e-13	8.18e-06	0.59	0.54	Life satisfaction;	chr1:173714815	chr4:187970273~187971284:+
UCEC	trans	rs10242455	0.702	rs73403286	ENSG00000228834.1	RP11-249L21.4	7.9	5.71e-13	8.18e-06	1.33	0.54	Blood metabolite levels;	chr7:99557242	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.571	rs56167514	ENSG00000228834.1	RP11-249L21.4	7.9	5.71e-13	8.18e-06	1.33	0.54	Blood metabolite levels;	chr7:99563724	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.571	rs7805661	ENSG00000228834.1	RP11-249L21.4	7.9	5.71e-13	8.18e-06	1.33	0.54	Blood metabolite levels;	chr7:99573899	chr6:108907615~108907873:-
UCEC	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	7.9	5.73e-13	8.21e-06	0.74	0.54	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
UCEC	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	7.88	6.19e-13	8.85e-06	0.66	0.54	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
UCEC	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	7.87	6.81e-13	9.6e-06	0.58	0.54	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
UCEC	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	7.86	7.01e-13	9.86e-06	0.62	0.54	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
UCEC	trans	rs7811142	1	rs4472444	ENSG00000228546.2	CTA-313A17.3	7.86	7.03e-13	9.89e-06	0.78	0.54	Platelet count;	chr7:100473135	chr7:102337316~102339115:+
UCEC	trans	rs7811142	1	rs7809801	ENSG00000228546.2	CTA-313A17.3	7.86	7.03e-13	9.89e-06	0.78	0.54	Platelet count;	chr7:100474408	chr7:102337316~102339115:+
UCEC	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	7.86	7.21e-13	1.01e-05	0.68	0.54	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
UCEC	trans	rs7811142	0.943	rs67196635	ENSG00000228546.2	CTA-313A17.3	7.85	7.53e-13	1.06e-05	0.78	0.54	Platelet count;	chr7:100427941	chr7:102337316~102339115:+
UCEC	trans	rs7811142	1	rs6962151	ENSG00000228546.2	CTA-313A17.3	7.85	7.53e-13	1.06e-05	0.78	0.54	Platelet count;	chr7:100430861	chr7:102337316~102339115:+
UCEC	trans	rs7811142	1	rs67239991	ENSG00000228546.2	CTA-313A17.3	7.84	7.89e-13	1.1e-05	0.78	0.54	Platelet count;	chr7:100448881	chr7:102337316~102339115:+
UCEC	trans	rs7811142	1	rs11766752	ENSG00000228546.2	CTA-313A17.3	7.84	8.06e-13	1.12e-05	0.78	0.54	Platelet count;	chr7:100475669	chr7:102337316~102339115:+
UCEC	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	7.83	8.56e-13	1.19e-05	0.62	0.54	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	7.83	8.56e-13	1.19e-05	0.62	0.54	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
UCEC	trans	rs10242455	0.702	rs73405247	ENSG00000228834.1	RP11-249L21.4	7.79	1.04e-12	1.41e-05	1.37	0.54	Blood metabolite levels;	chr7:99561551	chr6:108907615~108907873:-
UCEC	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-7.79	1.08e-12	1.47e-05	-0.73	-0.54	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	7.78	1.11e-12	1.51e-05	0.67	0.54	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
UCEC	trans	rs7811142	0.943	rs28578163	ENSG00000228546.2	CTA-313A17.3	7.77	1.16e-12	1.58e-05	0.77	0.54	Platelet count;	chr7:100447131	chr7:102337316~102339115:+
UCEC	trans	rs9425766	0.679	rs7552939	ENSG00000213331.4	RP11-713C19.2	7.76	1.24e-12	1.69e-05	0.59	0.54	Life satisfaction;	chr1:173798305	chr4:187970273~187971284:+
UCEC	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	7.76	1.25e-12	1.69e-05	0.59	0.54	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
UCEC	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	7.76	1.25e-12	1.7e-05	0.7	0.54	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
UCEC	trans	rs7554547	0.714	rs4846071	ENSG00000261819.1	RP11-680G24.4	7.76	1.25e-12	1.7e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11889612	chr16:14988259~14990160:-
UCEC	trans	rs10242455	0.702	rs3823813	ENSG00000228834.1	RP11-249L21.4	7.76	1.26e-12	1.7e-05	1.36	0.54	Blood metabolite levels;	chr7:99451766	chr6:108907615~108907873:-
UCEC	trans	rs7554547	0.765	rs4845886	ENSG00000261819.1	RP11-680G24.4	7.76	1.26e-12	1.7e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11888603	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs4846069	ENSG00000261819.1	RP11-680G24.4	7.76	1.26e-12	1.7e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11888974	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs11121837	ENSG00000261819.1	RP11-680G24.4	7.76	1.26e-12	1.7e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11889414	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.765	rs4846070	ENSG00000261819.1	RP11-680G24.4	7.76	1.26e-12	1.7e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11889464	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.69	rs7516708	ENSG00000261819.1	RP11-680G24.4	7.76	1.26e-12	1.7e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11890148	chr16:14988259~14990160:-
UCEC	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	7.76	1.26e-12	1.71e-05	0.68	0.54	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
UCEC	trans	rs9467773	1	rs1001687	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26572990	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1570059	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26573097	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1570060	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26573334	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1977201	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26573446	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6456735	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26573921	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs1321482	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26574926	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467798	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26575469	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1570061	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26575758	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs12665431	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26577080	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs12663883	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26577098	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs12663894	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26577142	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs6913877	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26577260	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6913462	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26577302	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6918506	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26577629	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6918360	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26577639	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6918854	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26577696	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467799	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26578136	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467800	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26578297	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.901	rs10223789	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26579381	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs10223792	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26579388	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs9461272	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26579420	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467802	ENSG00000242375.1	RP11-498P14.3	7.75	1.29e-12	1.74e-05	0.71	0.54	Intelligence (multi-trait analysis);	chr6:26580940	chr9:97195351~97197687:-
UCEC	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-7.75	1.3e-12	1.75e-05	-0.74	-0.54	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
UCEC	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	7.75	1.31e-12	1.76e-05	0.57	0.54	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
UCEC	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	7.75	1.32e-12	1.77e-05	0.6	0.54	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	7.75	1.32e-12	1.77e-05	0.6	0.54	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	7.75	1.32e-12	1.77e-05	0.6	0.54	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
UCEC	trans	rs7554547	0.791	rs6665662	ENSG00000261819.1	RP11-680G24.4	7.75	1.34e-12	1.78e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11891804	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs34117126	ENSG00000261819.1	RP11-680G24.4	7.75	1.34e-12	1.78e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11892138	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs12749498	ENSG00000261819.1	RP11-680G24.4	7.75	1.34e-12	1.78e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11892570	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs12036266	ENSG00000261819.1	RP11-680G24.4	7.75	1.34e-12	1.78e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11893257	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs2065611	ENSG00000261819.1	RP11-680G24.4	7.75	1.34e-12	1.78e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11893469	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs4492637	ENSG00000261819.1	RP11-680G24.4	7.75	1.34e-12	1.78e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11895787	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs4846074	ENSG00000261819.1	RP11-680G24.4	7.75	1.34e-12	1.78e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11896172	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs4846076	ENSG00000261819.1	RP11-680G24.4	7.75	1.34e-12	1.78e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11896708	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.739	rs4846073	ENSG00000261819.1	RP11-680G24.4	7.74	1.39e-12	1.85e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11890521	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.791	rs57678332	ENSG00000261819.1	RP11-680G24.4	7.74	1.39e-12	1.85e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11890834	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.765	rs57176983	ENSG00000261819.1	RP11-680G24.4	7.74	1.39e-12	1.85e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11891041	chr16:14988259~14990160:-
UCEC	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	7.74	1.39e-12	1.85e-05	0.61	0.54	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
UCEC	trans	rs7554547	0.791	rs1321072	ENSG00000261819.1	RP11-680G24.4	7.73	1.44e-12	1.92e-05	0.69	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11891261	chr16:14988259~14990160:-
UCEC	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-7.72	1.6e-12	2.1e-05	-0.81	-0.53	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	7.72	1.6e-12	2.1e-05	0.81	0.53	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	7.72	1.6e-12	2.1e-05	0.81	0.53	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	7.72	1.6e-12	2.1e-05	0.81	0.53	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	7.72	1.6e-12	2.1e-05	0.81	0.53	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	7.72	1.6e-12	2.1e-05	0.81	0.53	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
UCEC	trans	rs7113874	0.625	rs16938253	ENSG00000266891.1	RP11-692N5.2	7.71	1.65e-12	2.17e-05	0.71	0.53	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8478833	chr18:9734882~9735602:-
UCEC	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-7.71	1.68e-12	2.2e-05	-0.92	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
UCEC	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-7.71	1.7e-12	2.23e-05	-0.58	-0.53	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
UCEC	trans	rs7554547	0.838	rs885770	ENSG00000261819.1	RP11-680G24.4	7.7	1.71e-12	2.24e-05	0.67	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11878699	chr16:14988259~14990160:-
UCEC	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	7.67	2.04e-12	2.66e-05	0.66	0.53	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
UCEC	trans	rs12709013	0.601	rs2432621	ENSG00000230849.2	GOT2P2	7.67	2.11e-12	2.74e-05	0.58	0.53	Blood metabolite ratios;	chr16:58749676	chr1:173141100~173142350:-
UCEC	trans	rs10242455	0.85	rs57367781	ENSG00000228834.1	RP11-249L21.4	7.66	2.2e-12	2.84e-05	1.33	0.53	Blood metabolite levels;	chr7:99519196	chr6:108907615~108907873:-
UCEC	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	7.66	2.2e-12	2.84e-05	0.71	0.53	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
UCEC	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	7.66	2.2e-12	2.84e-05	0.71	0.53	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
UCEC	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	7.66	2.21e-12	2.86e-05	0.75	0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
UCEC	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	7.65	2.3e-12	2.96e-05	0.6	0.53	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
UCEC	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-7.65	2.32e-12	2.98e-05	-0.72	-0.53	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
UCEC	trans	rs12709013	0.636	rs1646268	ENSG00000230849.2	GOT2P2	7.63	2.64e-12	3.38e-05	0.57	0.53	Blood metabolite ratios;	chr16:58743292	chr1:173141100~173142350:-
UCEC	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-7.62	2.69e-12	3.45e-05	-0.79	-0.53	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
UCEC	trans	rs2731664	0.792	rs335432	ENSG00000215571.5	GRK6P1	7.62	2.76e-12	3.54e-05	0.7	0.53	Intelligence (multi-trait analysis);	chr5:177439257	chr13:21319156~21320866:+
UCEC	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	7.6	2.97e-12	3.79e-05	0.7	0.53	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
UCEC	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	7.59	3.2e-12	4.06e-05	0.61	0.53	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
UCEC	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	7.58	3.48e-12	4.4e-05	0.59	0.53	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	7.57	3.58e-12	4.52e-05	0.59	0.53	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
UCEC	trans	rs7554547	0.739	rs61527718	ENSG00000261819.1	RP11-680G24.4	7.56	3.74e-12	4.7e-05	0.68	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11889583	chr16:14988259~14990160:-
UCEC	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	7.56	3.82e-12	4.81e-05	0.59	0.53	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
UCEC	trans	rs7554547	0.791	rs17037520	ENSG00000261819.1	RP11-680G24.4	7.55	3.95e-12	4.96e-05	0.68	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11892349	chr16:14988259~14990160:-
UCEC	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-7.55	3.96e-12	4.98e-05	-0.65	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
UCEC	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	7.54	4.2e-12	5.26e-05	0.58	0.53	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
UCEC	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	7.54	4.28e-12	5.35e-05	0.76	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
UCEC	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	7.53	4.52e-12	5.63e-05	0.78	0.52	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
UCEC	trans	rs9425766	0.85	rs9425755	ENSG00000213331.4	RP11-713C19.2	7.53	4.53e-12	5.63e-05	0.59	0.52	Life satisfaction;	chr1:173843501	chr4:187970273~187971284:+
UCEC	trans	rs72615157	0.628	rs7801070	ENSG00000228546.2	CTA-313A17.3	7.53	4.53e-12	5.63e-05	0.73	0.52	Lung function (FEV1/FVC);	chr7:100249524	chr7:102337316~102339115:+
UCEC	trans	rs72615157	0.645	rs11771660	ENSG00000228546.2	CTA-313A17.3	7.53	4.53e-12	5.63e-05	0.73	0.52	Lung function (FEV1/FVC);	chr7:100253646	chr7:102337316~102339115:+
UCEC	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.597	rs1657171	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58752083	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1646285	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58752102	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	7.53	4.55e-12	5.63e-05	0.57	0.52	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	7.52	4.73e-12	5.85e-05	0.57	0.52	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	7.52	4.73e-12	5.85e-05	0.57	0.52	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
UCEC	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-7.52	4.79e-12	5.91e-05	-0.68	-0.52	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
UCEC	trans	rs4606360	1	rs4606360	ENSG00000213331.4	RP11-713C19.2	7.51	4.96e-12	6.11e-05	0.56	0.52	Subjective well-being;	chr1:173729868	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.511	rs10912676	ENSG00000213331.4	RP11-713C19.2	7.51	4.96e-12	6.11e-05	0.56	0.52	Life satisfaction;	chr1:173740477	chr4:187970273~187971284:+
UCEC	trans	rs3779195	0.86	rs12704986	ENSG00000225169.1	BRI3P1	7.51	5.07e-12	6.23e-05	0.74	0.52	Sex hormone-binding globulin levels;	chr7:98357118	chr1:100213293~100213670:+
UCEC	trans	rs3779195	0.858	rs3779196	ENSG00000225169.1	BRI3P1	7.51	5.07e-12	6.23e-05	0.74	0.52	Sex hormone-binding globulin levels;	chr7:98360794	chr1:100213293~100213670:+
UCEC	trans	rs3779195	0.789	rs6965424	ENSG00000225169.1	BRI3P1	7.51	5.07e-12	6.23e-05	0.74	0.52	Sex hormone-binding globulin levels;	chr7:98361813	chr1:100213293~100213670:+
UCEC	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	7.5	5.26e-12	6.45e-05	0.58	0.52	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	7.5	5.26e-12	6.45e-05	0.58	0.52	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	7.49	5.63e-12	6.9e-05	0.57	0.52	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
UCEC	trans	rs3779195	0.697	rs1688606	ENSG00000225169.1	BRI3P1	7.49	5.66e-12	6.93e-05	0.74	0.52	Sex hormone-binding globulin levels;	chr7:98345539	chr1:100213293~100213670:+
UCEC	trans	rs7121616	1	rs7121616	ENSG00000234176.1	HSPA8P1	7.49	5.7e-12	6.97e-05	0.61	0.52	Breast cancer;	chr11:123095918	chrX:121203182~121205014:-
UCEC	trans	rs7121616	0.96	rs7122306	ENSG00000234176.1	HSPA8P1	7.49	5.7e-12	6.97e-05	0.61	0.52	Breast cancer;	chr11:123096254	chrX:121203182~121205014:-
UCEC	trans	rs3779195	0.697	rs13232861	ENSG00000225169.1	BRI3P1	7.48	5.88e-12	7.17e-05	0.77	0.52	Sex hormone-binding globulin levels;	chr7:98299769	chr1:100213293~100213670:+
UCEC	trans	rs2727020	0.688	rs2734002	ENSG00000134612.10	FOLH1B	7.47	6.36e-12	7.72e-05	0.61	0.52	Coronary artery disease;	chr11:49212610	chr11:89639227~89698718:+
UCEC	trans	rs13253073	0.825	rs6984511	ENSG00000260318.1	COX6CP1	7.45	6.84e-12	8.3e-05	0.93	0.52	Glucose homeostasis traits;	chr8:99869513	chr16:11903923~11904137:-
UCEC	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	7.45	6.89e-12	8.36e-05	0.62	0.52	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
UCEC	trans	rs7121616	0.961	rs11218976	ENSG00000234176.1	HSPA8P1	7.44	7.35e-12	8.89e-05	0.6	0.52	Breast cancer;	chr11:123090950	chrX:121203182~121205014:-
UCEC	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-7.44	7.42e-12	8.97e-05	-0.48	-0.52	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
UCEC	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-7.44	7.42e-12	8.97e-05	-0.48	-0.52	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
UCEC	trans	rs7554547	0.871	rs11588551	ENSG00000261819.1	RP11-680G24.4	-7.44	7.42e-12	8.97e-05	-0.65	-0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr16:14988259~14990160:-
UCEC	trans	rs6477998	0.651	rs10121845	ENSG00000238072.1	RP11-305M3.2	7.44	7.59e-12	9.17e-05	0.64	0.52	Hematology traits;	chr9:113227443	chr7:129410113~129410370:-
UCEC	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	7.43	7.8e-12	9.41e-05	0.65	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
UCEC	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-7.42	8.3e-12	9.97e-05	-0.66	-0.52	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
UCEC	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	7.4	9.01e-12	0.000108	0.56	0.52	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
UCEC	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	7.4	9.2e-12	0.00011	0.72	0.52	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
UCEC	trans	rs10242455	0.702	rs73711294	ENSG00000228834.1	RP11-249L21.4	7.39	9.53e-12	0.000113	1.41	0.52	Blood metabolite levels;	chr7:99491091	chr6:108907615~108907873:-
UCEC	trans	rs2209875	0.549	rs3211707	ENSG00000234819.1	RP11-336N8.4	7.39	9.64e-12	0.000115	0.62	0.52	Pelvic organ prolapse (moderate/severe);	chr9:89318219	chr9:78219120~78219357:+
UCEC	trans	rs2209875	0.573	rs74703137	ENSG00000234819.1	RP11-336N8.4	7.39	9.64e-12	0.000115	0.62	0.52	Pelvic organ prolapse (moderate/severe);	chr9:89336429	chr9:78219120~78219357:+
UCEC	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	7.39	9.86e-12	0.000117	0.57	0.52	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
UCEC	trans	rs12709013	0.613	rs1657178	ENSG00000230849.2	GOT2P2	7.38	1.01e-11	0.000119	0.57	0.52	Blood metabolite ratios;	chr16:58735300	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.585	rs7188608	ENSG00000230849.2	GOT2P2	7.38	1.01e-11	0.000119	0.57	0.52	Blood metabolite ratios;	chr16:58736236	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1657176	ENSG00000230849.2	GOT2P2	7.38	1.01e-11	0.000119	0.57	0.52	Blood metabolite ratios;	chr16:58736833	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1646282	ENSG00000230849.2	GOT2P2	7.38	1.01e-11	0.000119	0.57	0.52	Blood metabolite ratios;	chr16:58741296	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs4784977	ENSG00000230849.2	GOT2P2	7.38	1.01e-11	0.000119	0.57	0.52	Blood metabolite ratios;	chr16:58742120	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1657161	ENSG00000230849.2	GOT2P2	7.38	1.01e-11	0.000119	0.57	0.52	Blood metabolite ratios;	chr16:58743234	chr1:173141100~173142350:-
UCEC	trans	rs12709013	0.636	rs1646269	ENSG00000230849.2	GOT2P2	7.38	1.01e-11	0.000119	0.57	0.52	Blood metabolite ratios;	chr16:58743412	chr1:173141100~173142350:-
UCEC	trans	rs959695	1	rs2442756	ENSG00000260318.1	COX6CP1	7.38	1.01e-11	0.000119	0.66	0.52	Hippocampal atrophy;	chr8:99816910	chr16:11903923~11904137:-
UCEC	trans	rs10242455	0.702	rs73711293	ENSG00000228834.1	RP11-249L21.4	7.38	1.03e-11	0.000122	1.29	0.52	Blood metabolite levels;	chr7:99483972	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs73713507	ENSG00000228834.1	RP11-249L21.4	7.38	1.03e-11	0.000122	1.29	0.52	Blood metabolite levels;	chr7:99540980	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs78218664	ENSG00000228834.1	RP11-249L21.4	7.38	1.03e-11	0.000122	1.29	0.52	Blood metabolite levels;	chr7:99556758	chr6:108907615~108907873:-
UCEC	trans	rs61990749	0.511	rs2052444	ENSG00000235400.1	RP4-641G12.4	7.38	1.03e-11	0.000122	0.97	0.52	Fibroblast growth factor basic levels;	chr14:77846575	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.511	rs724263	ENSG00000235400.1	RP4-641G12.4	7.38	1.03e-11	0.000122	0.97	0.52	Fibroblast growth factor basic levels;	chr14:77855531	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.511	rs10130790	ENSG00000235400.1	RP4-641G12.4	7.38	1.03e-11	0.000122	0.97	0.52	Fibroblast growth factor basic levels;	chr14:77857849	chr1:78749073~78750659:+
UCEC	trans	rs61990749	0.511	rs10146144	ENSG00000235400.1	RP4-641G12.4	7.38	1.03e-11	0.000122	0.97	0.52	Fibroblast growth factor basic levels;	chr14:77858957	chr1:78749073~78750659:+
UCEC	trans	rs2727020	0.612	rs603672	ENSG00000134612.10	FOLH1B	7.37	1.1e-11	0.000129	0.61	0.52	Coronary artery disease;	chr11:49213014	chr11:89639227~89698718:+
UCEC	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	7.36	1.14e-11	0.000134	0.56	0.52	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
UCEC	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	7.35	1.19e-11	0.000139	0.55	0.52	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
UCEC	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	7.35	1.23e-11	0.000144	0.62	0.52	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
UCEC	trans	rs5022636	0.525	rs6681163	ENSG00000180764.13	PIPSL	7.34	1.31e-11	0.000152	0.62	0.52	Gut microbiota (functional units);	chr1:151259161	chr10:93958191~93961540:-
UCEC	trans	rs13177918	0.603	rs2343806	ENSG00000213058.3	RP4-765C7.2	7.34	1.31e-11	0.000152	0.65	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:178411616~178411972:+
UCEC	trans	rs7554547	0.905	rs4993564	ENSG00000261819.1	RP11-680G24.4	7.33	1.37e-11	0.000158	0.66	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11909934	chr16:14988259~14990160:-
UCEC	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	7.33	1.37e-11	0.000159	0.62	0.51	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
UCEC	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	7.33	1.38e-11	0.000159	0.99	0.51	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
UCEC	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	7.33	1.38e-11	0.000159	0.65	0.51	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
UCEC	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	7.33	1.39e-11	0.00016	0.62	0.51	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
UCEC	trans	rs1814175	0.538	rs1684260	ENSG00000134612.10	FOLH1B	7.32	1.44e-11	0.000166	0.6	0.51	Height;	chr11:49202679	chr11:89639227~89698718:+
UCEC	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	7.31	1.49e-11	0.000171	0.69	0.51	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
UCEC	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-7.31	1.53e-11	0.000175	-0.61	-0.51	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
UCEC	trans	rs2727020	0.729	rs685789	ENSG00000134612.10	FOLH1B	7.3	1.58e-11	0.00018	0.6	0.51	Coronary artery disease;	chr11:49219676	chr11:89639227~89698718:+
UCEC	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	7.28	1.78e-11	0.000201	0.97	0.51	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
UCEC	trans	rs12709013	0.755	rs1424245	ENSG00000233719.3	GOT2P3	7.27	1.84e-11	0.000208	0.53	0.51	Blood metabolite ratios;	chr16:58729926	chr12:9641802~9643007:+
UCEC	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	7.27	1.89e-11	0.000213	0.56	0.51	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
UCEC	trans	rs959695	1	rs35845479	ENSG00000260318.1	COX6CP1	7.26	2.03e-11	0.000229	0.67	0.51	Hippocampal atrophy;	chr8:99834273	chr16:11903923~11904137:-
UCEC	trans	rs3779195	0.929	rs10953259	ENSG00000225169.1	BRI3P1	-7.25	2.08e-11	0.000234	-0.76	-0.51	Sex hormone-binding globulin levels;	chr7:98383795	chr1:100213293~100213670:+
UCEC	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-7.25	2.1e-11	0.000235	-0.7	-0.51	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
UCEC	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	7.25	2.15e-11	0.000241	0.65	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
UCEC	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-7.24	2.27e-11	0.000253	-0.54	-0.51	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-7.24	2.27e-11	0.000253	-0.54	-0.51	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-7.24	2.27e-11	0.000253	-0.54	-0.51	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-7.24	2.27e-11	0.000253	-0.54	-0.51	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-7.24	2.27e-11	0.000253	-0.54	-0.51	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
UCEC	trans	rs3779195	0.627	rs6950023	ENSG00000225169.1	BRI3P1	7.24	2.28e-11	0.000254	0.78	0.51	Sex hormone-binding globulin levels;	chr7:98286323	chr1:100213293~100213670:+
UCEC	trans	rs3779195	0.627	rs6967728	ENSG00000225169.1	BRI3P1	7.24	2.28e-11	0.000254	0.78	0.51	Sex hormone-binding globulin levels;	chr7:98286325	chr1:100213293~100213670:+
UCEC	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	7.23	2.35e-11	0.000261	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
UCEC	trans	rs2727020	0.664	rs4929893	ENSG00000134612.10	FOLH1B	-7.21	2.55e-11	0.000282	-0.6	-0.51	Coronary artery disease;	chr11:49174780	chr11:89639227~89698718:+
UCEC	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-7.2	2.71e-11	0.000299	-0.53	-0.51	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
UCEC	trans	rs7811142	1	rs11763511	ENSG00000228546.2	CTA-313A17.3	7.2	2.77e-11	0.000304	0.77	0.51	Platelet count;	chr7:100484321	chr7:102337316~102339115:+
UCEC	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	7.2	2.79e-11	0.000306	0.64	0.51	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
UCEC	trans	rs2727020	0.729	rs10742932	ENSG00000134612.10	FOLH1B	-7.19	2.89e-11	0.000316	-0.6	-0.51	Coronary artery disease;	chr11:49151682	chr11:89639227~89698718:+
UCEC	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	7.18	3.03e-11	0.00033	0.56	0.51	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
UCEC	trans	rs959695	1	rs60891426	ENSG00000260318.1	COX6CP1	7.18	3.06e-11	0.000333	0.67	0.51	Hippocampal atrophy;	chr8:99831798	chr16:11903923~11904137:-
UCEC	trans	rs10242455	0.702	rs74416635	ENSG00000228834.1	RP11-249L21.4	7.17	3.17e-11	0.000345	1.27	0.51	Blood metabolite levels;	chr7:99582946	chr6:108907615~108907873:-
UCEC	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-7.17	3.24e-11	0.000351	-0.57	-0.51	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
UCEC	trans	rs9467773	1	rs12526680	ENSG00000242375.1	RP11-498P14.3	7.17	3.31e-11	0.000359	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26550726	chr9:97195351~97197687:-
UCEC	trans	rs10242455	0.702	rs2293256	ENSG00000228834.1	RP11-249L21.4	-7.17	3.33e-11	0.000361	-1.13	-0.51	Blood metabolite levels;	chr7:99460078	chr6:108907615~108907873:-
UCEC	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	7.15	3.58e-11	0.000386	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	7.15	3.58e-11	0.000386	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	7.15	3.58e-11	0.000386	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
UCEC	trans	rs10242455	0.702	rs73397447	ENSG00000228834.1	RP11-249L21.4	7.15	3.63e-11	0.000392	1.31	0.51	Blood metabolite levels;	chr7:99413326	chr6:108907615~108907873:-
UCEC	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-7.15	3.66e-11	0.000395	-0.55	-0.51	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
UCEC	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-7.15	3.66e-11	0.000395	-0.55	-0.51	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
UCEC	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	7.15	3.7e-11	0.000399	0.75	0.51	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
UCEC	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	7.15	3.72e-11	4e-04	0.56	0.51	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
UCEC	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	7.14	3.72e-11	4e-04	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	7.14	3.72e-11	4e-04	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	7.14	3.72e-11	4e-04	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	7.14	3.72e-11	4e-04	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	7.14	3.72e-11	4e-04	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	7.14	3.72e-11	4e-04	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	7.14	3.72e-11	4e-04	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
UCEC	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	7.14	3.76e-11	0.000404	0.63	0.51	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
UCEC	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-7.14	3.78e-11	0.000405	-0.69	-0.51	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
UCEC	trans	rs12709013	0.636	rs1646279	ENSG00000230849.2	GOT2P2	7.14	3.81e-11	0.000409	0.56	0.5	Blood metabolite ratios;	chr16:58750235	chr1:173141100~173142350:-
UCEC	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	7.14	3.86e-11	0.000413	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
UCEC	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	7.13	4.09e-11	0.000437	0.54	0.5	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
UCEC	trans	rs7121616	1	rs7113273	ENSG00000234176.1	HSPA8P1	-7.13	4.11e-11	0.000439	-0.58	-0.5	Breast cancer;	chr11:123092192	chrX:121203182~121205014:-
UCEC	trans	rs7811142	1	rs60844404	ENSG00000228546.2	CTA-313A17.3	7.12	4.27e-11	0.00045	0.76	0.5	Platelet count;	chr7:100482851	chr7:102337316~102339115:+
UCEC	trans	rs7811142	1	rs113738841	ENSG00000228546.2	CTA-313A17.3	7.12	4.27e-11	0.00045	0.76	0.5	Platelet count;	chr7:100483683	chr7:102337316~102339115:+
UCEC	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	7.12	4.3e-11	0.000453	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
UCEC	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	7.11	4.39e-11	0.000461	0.54	0.5	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
UCEC	trans	rs916888	0.61	rs199529	ENSG00000214425.5	LRRC37A4P	-7.1	4.74e-11	0.000496	-0.6	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45506741~45550335:-
UCEC	trans	rs9899728	0.539	rs56267297	ENSG00000234925.2	ATP5HP4	7.09	5.03e-11	0.000522	0.65	0.5	Alzheimer's disease or small vessel stroke;	chr17:75050901	chr12:68642519~68642993:-
UCEC	trans	rs9899728	0.539	rs113775187	ENSG00000234925.2	ATP5HP4	7.09	5.08e-11	0.000527	0.65	0.5	Alzheimer's disease or small vessel stroke;	chr17:75051195	chr12:68642519~68642993:-
UCEC	trans	rs7113874	0.802	rs10128597	ENSG00000266891.1	RP11-692N5.2	7.08	5.18e-11	0.000535	0.64	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8673283	chr18:9734882~9735602:-
UCEC	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	7.08	5.43e-11	0.00056	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
UCEC	trans	rs2727020	0.729	rs6485965	ENSG00000134612.10	FOLH1B	7.07	5.65e-11	0.000581	0.59	0.5	Coronary artery disease;	chr11:49145178	chr11:89639227~89698718:+
UCEC	trans	rs7113874	0.802	rs10840102	ENSG00000266891.1	RP11-692N5.2	7.07	5.71e-11	0.000588	0.59	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8654691	chr18:9734882~9735602:-
UCEC	trans	rs9425766	1	rs9425766	ENSG00000213331.4	RP11-713C19.2	7.06	5.79e-11	0.000596	0.52	0.5	Life satisfaction;	chr1:173883989	chr4:187970273~187971284:+
UCEC	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-7.06	5.85e-11	0.000602	-0.53	-0.5	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
UCEC	trans	rs2731664	0.792	rs2630764	ENSG00000215571.5	GRK6P1	7.05	6.25e-11	0.000641	0.64	0.5	Intelligence (multi-trait analysis);	chr5:177453084	chr13:21319156~21320866:+
UCEC	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	7.04	6.68e-11	0.000682	0.65	0.5	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
UCEC	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-7.03	6.92e-11	0.000706	-0.63	-0.5	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
UCEC	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	7.03	6.94e-11	0.000708	0.5	0.5	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
UCEC	trans	rs6477998	0.627	rs10114381	ENSG00000238072.1	RP11-305M3.2	7.02	7.17e-11	0.00073	0.63	0.5	Hematology traits;	chr9:113213692	chr7:129410113~129410370:-
UCEC	trans	rs7121616	1	rs7123187	ENSG00000234176.1	HSPA8P1	7.02	7.3e-11	0.000743	0.58	0.5	Breast cancer;	chr11:123090915	chrX:121203182~121205014:-
UCEC	trans	rs7121616	0.774	rs74693612	ENSG00000234176.1	HSPA8P1	7.02	7.3e-11	0.000743	0.58	0.5	Breast cancer;	chr11:123092310	chrX:121203182~121205014:-
UCEC	trans	rs7113874	0.802	rs7941510	ENSG00000266891.1	RP11-692N5.2	7.01	7.73e-11	0.000786	0.59	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8655516	chr18:9734882~9735602:-
UCEC	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	7.01	7.74e-11	0.000786	0.49	0.5	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
UCEC	trans	rs10242455	0.702	rs17161726	ENSG00000228834.1	RP11-249L21.4	7.01	7.83e-11	0.000795	1.14	0.5	Blood metabolite levels;	chr7:99410772	chr6:108907615~108907873:-
UCEC	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	7	7.99e-11	0.00081	0.55	0.5	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
UCEC	trans	rs9467773	1	rs9467782	ENSG00000242375.1	RP11-498P14.3	7	8.18e-11	0.000827	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26542545	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.935	rs9461270	ENSG00000242375.1	RP11-498P14.3	7	8.18e-11	0.000827	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26543882	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs4871	ENSG00000242375.1	RP11-498P14.3	7	8.18e-11	0.000827	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26545404	chr9:97195351~97197687:-
UCEC	trans	rs9425766	0.85	rs7349095	ENSG00000213331.4	RP11-713C19.2	6.99	8.37e-11	0.000846	0.55	0.5	Life satisfaction;	chr1:173887899	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.962	rs1322777	ENSG00000213331.4	RP11-713C19.2	6.99	8.39e-11	0.000847	0.55	0.5	Life satisfaction;	chr1:173889962	chr4:187970273~187971284:+
UCEC	trans	rs6477998	0.651	rs10114423	ENSG00000238072.1	RP11-305M3.2	6.99	8.51e-11	0.000849	0.62	0.5	Hematology traits;	chr9:113213751	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.676	rs10817460	ENSG00000238072.1	RP11-305M3.2	6.99	8.51e-11	0.000849	0.62	0.5	Hematology traits;	chr9:113214118	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.603	rs7859189	ENSG00000238072.1	RP11-305M3.2	6.99	8.51e-11	0.000849	0.62	0.5	Hematology traits;	chr9:113217389	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.676	rs6477997	ENSG00000238072.1	RP11-305M3.2	6.99	8.51e-11	0.000849	0.62	0.5	Hematology traits;	chr9:113218833	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.627	rs3810914	ENSG00000238072.1	RP11-305M3.2	6.99	8.51e-11	0.000849	0.62	0.5	Hematology traits;	chr9:113219441	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.676	rs4978536	ENSG00000238072.1	RP11-305M3.2	6.99	8.51e-11	0.000849	0.62	0.5	Hematology traits;	chr9:113220123	chr7:129410113~129410370:-
UCEC	trans	rs9425766	0.962	rs9425430	ENSG00000213331.4	RP11-713C19.2	6.99	8.53e-11	0.000849	0.55	0.5	Life satisfaction;	chr1:173888145	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.886	rs1322775	ENSG00000213331.4	RP11-713C19.2	6.99	8.59e-11	0.000855	0.54	0.5	Life satisfaction;	chr1:173886160	chr4:187970273~187971284:+
UCEC	trans	rs2727020	0.731	rs10450572	ENSG00000134612.10	FOLH1B	6.99	8.75e-11	0.000869	0.58	0.5	Coronary artery disease;	chr11:49259521	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.729	rs2866328	ENSG00000134612.10	FOLH1B	6.99	8.75e-11	0.000869	0.58	0.5	Coronary artery disease;	chr11:49260869	chr11:89639227~89698718:+
UCEC	trans	rs9611565	0.765	rs132906	ENSG00000268568.1	AC007228.9	6.98	8.99e-11	0.000892	0.57	0.5	Vitiligo;	chr22:41403763	chr19:56672574~56673901:-
UCEC	trans	rs6477998	0.676	rs10817470	ENSG00000238072.1	RP11-305M3.2	6.98	9e-11	0.000892	0.61	0.5	Hematology traits;	chr9:113252129	chr7:129410113~129410370:-
UCEC	trans	rs9425766	0.962	rs6663875	ENSG00000213331.4	RP11-713C19.2	6.96	9.89e-11	0.000976	0.53	0.5	Life satisfaction;	chr1:173894071	chr4:187970273~187971284:+
UCEC	trans	rs9467773	0.967	rs6924865	ENSG00000242375.1	RP11-498P14.3	6.96	1.01e-10	0.000995	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26521125	chr9:97195351~97197687:-
UCEC	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	6.95	1.05e-10	0.00103	0.63	0.49	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
UCEC	trans	rs6477998	0.676	rs10981698	ENSG00000238072.1	RP11-305M3.2	6.94	1.1e-10	0.00108	0.62	0.49	Hematology traits;	chr9:113233500	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.676	rs10759631	ENSG00000238072.1	RP11-305M3.2	6.94	1.1e-10	0.00108	0.62	0.49	Hematology traits;	chr9:113233764	chr7:129410113~129410370:-
UCEC	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	6.94	1.1e-10	0.00108	0.6	0.49	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
UCEC	trans	rs928391	0.541	rs1888863	ENSG00000227183.3	HDGFP1	-6.94	1.11e-10	0.00109	-0.68	-0.49	Platelet count;	chr1:156828046	chrX:131646639~131646890:+
UCEC	trans	rs9467773	1	rs9295695	ENSG00000242375.1	RP11-498P14.3	-6.94	1.14e-10	0.00112	-0.64	-0.49	Intelligence (multi-trait analysis);	chr6:26528022	chr9:97195351~97197687:-
UCEC	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	6.93	1.17e-10	0.00114	0.52	0.49	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.899	rs2777898	ENSG00000187870.7	RNFT1P3	-6.93	1.18e-10	0.00115	-0.53	-0.49	White blood cell count;	chr17:59738247	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.899	rs8070345	ENSG00000187870.7	RNFT1P3	-6.93	1.18e-10	0.00115	-0.53	-0.49	White blood cell count;	chr17:59739396	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.834	rs2665397	ENSG00000187870.7	RNFT1P3	-6.93	1.18e-10	0.00115	-0.53	-0.49	White blood cell count;	chr17:59749370	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.804	rs2777884	ENSG00000187870.7	RNFT1P3	-6.93	1.18e-10	0.00115	-0.53	-0.49	White blood cell count;	chr17:59753065	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.932	rs2777885	ENSG00000187870.7	RNFT1P3	-6.93	1.18e-10	0.00115	-0.53	-0.49	White blood cell count;	chr17:59753112	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.866	rs2777899	ENSG00000187870.7	RNFT1P3	-6.93	1.18e-10	0.00115	-0.53	-0.49	White blood cell count;	chr17:59755030	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.899	rs2645477	ENSG00000187870.7	RNFT1P3	-6.93	1.18e-10	0.00115	-0.53	-0.49	White blood cell count;	chr17:59768263	chr17:20743333~20754501:-
UCEC	trans	rs8081395	0.834	rs11650106	ENSG00000187870.7	RNFT1P3	-6.93	1.18e-10	0.00115	-0.53	-0.49	White blood cell count;	chr17:59772890	chr17:20743333~20754501:-
UCEC	trans	rs61990749	0.571	rs4903655	ENSG00000235400.1	RP4-641G12.4	6.93	1.21e-10	0.00117	0.94	0.49	Fibroblast growth factor basic levels;	chr14:77839983	chr1:78749073~78750659:+
UCEC	trans	rs7554547	0.69	rs6667637	ENSG00000261819.1	RP11-680G24.4	6.92	1.23e-10	0.0012	0.63	0.49	Nonsyndromic cleft lip with cleft palate;	chr1:11887900	chr16:14988259~14990160:-
UCEC	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	6.92	1.25e-10	0.00122	0.58	0.49	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
UCEC	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	6.91	1.32e-10	0.00127	0.61	0.49	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
UCEC	trans	rs9611565	0.729	rs137831	ENSG00000268568.1	AC007228.9	-6.91	1.32e-10	0.00128	-0.62	-0.49	Vitiligo;	chr22:41507809	chr19:56672574~56673901:-
UCEC	trans	rs6477998	0.676	rs4979224	ENSG00000238072.1	RP11-305M3.2	6.91	1.32e-10	0.00128	0.61	0.49	Hematology traits;	chr9:113219998	chr7:129410113~129410370:-
UCEC	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	6.9	1.39e-10	0.00134	0.63	0.49	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
UCEC	trans	rs2727020	0.755	rs652655	ENSG00000134612.10	FOLH1B	6.9	1.42e-10	0.00136	0.58	0.49	Coronary artery disease;	chr11:49229741	chr11:89639227~89698718:+
UCEC	trans	rs9425766	0.962	rs1322780	ENSG00000213331.4	RP11-713C19.2	6.89	1.47e-10	0.0014	0.54	0.49	Life satisfaction;	chr1:173896448	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.962	rs9425435	ENSG00000213331.4	RP11-713C19.2	6.89	1.47e-10	0.0014	0.54	0.49	Life satisfaction;	chr1:173896936	chr4:187970273~187971284:+
UCEC	trans	rs7554547	0.69	rs6669571	ENSG00000261819.1	RP11-680G24.4	6.89	1.49e-10	0.00142	0.63	0.49	Nonsyndromic cleft lip with cleft palate;	chr1:11887253	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.69	rs1474576	ENSG00000261819.1	RP11-680G24.4	6.88	1.56e-10	0.00148	0.62	0.49	Nonsyndromic cleft lip with cleft palate;	chr1:11887572	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.69	rs1474577	ENSG00000261819.1	RP11-680G24.4	6.88	1.56e-10	0.00148	0.62	0.49	Nonsyndromic cleft lip with cleft palate;	chr1:11887712	chr16:14988259~14990160:-
UCEC	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	6.88	1.57e-10	0.00149	0.54	0.49	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
UCEC	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-6.87	1.65e-10	0.00156	-0.64	-0.49	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
UCEC	trans	rs2727020	0.729	rs2204366	ENSG00000134612.10	FOLH1B	6.86	1.72e-10	0.00161	0.58	0.49	Coronary artery disease;	chr11:49327815	chr11:89639227~89698718:+
UCEC	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-6.85	1.79e-10	0.00167	-0.44	-0.49	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
UCEC	trans	rs11077773	1	rs11077773	ENSG00000234925.2	ATP5HP4	-6.84	1.94e-10	0.0018	-0.56	-0.49	Information processing speed;	chr17:75063978	chr12:68642519~68642993:-
UCEC	trans	rs6477998	0.676	rs4979225	ENSG00000238072.1	RP11-305M3.2	6.83	1.99e-10	0.00185	0.61	0.49	Hematology traits;	chr9:113225130	chr7:129410113~129410370:-
UCEC	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	6.83	2e-10	0.00186	0.66	0.49	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
UCEC	trans	rs6477998	0.676	rs10081797	ENSG00000238072.1	RP11-305M3.2	6.83	2.02e-10	0.00188	0.61	0.49	Hematology traits;	chr9:113237973	chr7:129410113~129410370:-
UCEC	trans	rs6477998	0.676	rs10759632	ENSG00000238072.1	RP11-305M3.2	6.83	2.02e-10	0.00188	0.61	0.49	Hematology traits;	chr9:113238703	chr7:129410113~129410370:-
UCEC	trans	rs9425766	0.927	rs9425757	ENSG00000213331.4	RP11-713C19.2	6.82	2.18e-10	0.00202	0.54	0.49	Life satisfaction;	chr1:173855675	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.85	rs1322770	ENSG00000213331.4	RP11-713C19.2	6.82	2.18e-10	0.00202	0.54	0.49	Life satisfaction;	chr1:173863198	chr4:187970273~187971284:+
UCEC	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	6.81	2.3e-10	0.00212	0.6	0.49	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
UCEC	trans	rs13190036	0.748	rs28395268	ENSG00000217325.2	PRELID1P1	6.8	2.31e-10	0.00213	0.75	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr6:126643488~126644390:+
UCEC	trans	rs3849046	0.846	rs256002	ENSG00000226666.1	HSPA9P1	6.8	2.33e-10	0.00215	0.41	0.49	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138559529	chr2:221961737~221963765:+
UCEC	trans	rs1816752	0.603	rs9551099	ENSG00000237917.1	PARP4P1	-6.8	2.36e-10	0.00217	-0.58	-0.49	Obesity-related traits;	chr13:24410978	chrY:26594851~26634652:-
UCEC	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	6.8	2.36e-10	0.00218	0.72	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
UCEC	trans	rs7395662	1	rs11039819	ENSG00000134612.10	FOLH1B	-6.79	2.5e-10	0.0023	-0.55	-0.49	HDL cholesterol;	chr11:48540629	chr11:89639227~89698718:+
UCEC	trans	rs7113874	0.802	rs35319120	ENSG00000266891.1	RP11-692N5.2	6.79	2.51e-10	0.00231	0.57	0.49	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8648147	chr18:9734882~9735602:-
UCEC	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	6.79	2.51e-10	0.00231	0.6	0.49	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
UCEC	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	6.79	2.51e-10	0.00231	0.6	0.49	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
UCEC	trans	rs7113874	0.559	rs34378489	ENSG00000266891.1	RP11-692N5.2	6.79	2.51e-10	0.00231	0.63	0.49	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8407803	chr18:9734882~9735602:-
UCEC	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-6.78	2.59e-10	0.00237	-0.51	-0.49	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
UCEC	trans	rs10242455	0.702	rs58348977	ENSG00000228834.1	RP11-249L21.4	6.78	2.59e-10	0.00237	1.19	0.49	Blood metabolite levels;	chr7:99590391	chr6:108907615~108907873:-
UCEC	trans	rs9467773	0.967	rs9295694	ENSG00000242375.1	RP11-498P14.3	6.78	2.68e-10	0.00245	0.64	0.49	Intelligence (multi-trait analysis);	chr6:26512766	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs9467775	ENSG00000242375.1	RP11-498P14.3	6.78	2.68e-10	0.00245	0.64	0.49	Intelligence (multi-trait analysis);	chr6:26513207	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9393729	ENSG00000242375.1	RP11-498P14.3	6.78	2.68e-10	0.00245	0.64	0.49	Intelligence (multi-trait analysis);	chr6:26513938	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs6456732	ENSG00000242375.1	RP11-498P14.3	6.78	2.68e-10	0.00245	0.64	0.49	Intelligence (multi-trait analysis);	chr6:26514217	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs4713006	ENSG00000242375.1	RP11-498P14.3	6.78	2.68e-10	0.00245	0.64	0.49	Intelligence (multi-trait analysis);	chr6:26519644	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs1535276	ENSG00000242375.1	RP11-498P14.3	6.78	2.68e-10	0.00245	0.64	0.49	Intelligence (multi-trait analysis);	chr6:26520713	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6925703	ENSG00000242375.1	RP11-498P14.3	6.78	2.68e-10	0.00245	0.64	0.49	Intelligence (multi-trait analysis);	chr6:26521361	chr9:97195351~97197687:-
UCEC	trans	rs3740713	0.669	rs2896526	ENSG00000235847.2	LDHAP7	6.77	2.73e-10	0.0025	0.69	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:84777259~84778223:-
UCEC	trans	rs9467773	1	rs6910899	ENSG00000242375.1	RP11-498P14.3	6.77	2.78e-10	0.00253	0.64	0.48	Intelligence (multi-trait analysis);	chr6:26524111	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs9461267	ENSG00000242375.1	RP11-498P14.3	6.77	2.8e-10	0.00255	0.64	0.48	Intelligence (multi-trait analysis);	chr6:26525227	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs1056347	ENSG00000242375.1	RP11-498P14.3	6.77	2.8e-10	0.00255	0.64	0.48	Intelligence (multi-trait analysis);	chr6:26527296	chr9:97195351~97197687:-
UCEC	trans	rs7554547	0.765	rs34175640	ENSG00000261819.1	RP11-680G24.4	-6.76	2.93e-10	0.00266	-0.64	-0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11892155	chr16:14988259~14990160:-
UCEC	trans	rs14057	0.827	rs6682920	ENSG00000215869.3	RP11-364B6.1	6.75	3.05e-10	0.00277	0.67	0.48	Systolic blood pressure;	chr1:6585807	chr1:104073023~104077087:+
UCEC	trans	rs2727020	0.729	rs588458	ENSG00000134612.10	FOLH1B	6.75	3.08e-10	0.00279	0.57	0.48	Coronary artery disease;	chr11:49192496	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.729	rs4315497	ENSG00000134612.10	FOLH1B	6.75	3.08e-10	0.00279	0.57	0.48	Coronary artery disease;	chr11:49192947	chr11:89639227~89698718:+
UCEC	trans	rs9467773	1	rs9467773	ENSG00000242375.1	RP11-498P14.3	6.75	3.13e-10	0.00284	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26498198	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6926629	ENSG00000242375.1	RP11-498P14.3	6.75	3.13e-10	0.00284	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26499675	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6903973	ENSG00000242375.1	RP11-498P14.3	6.75	3.13e-10	0.00284	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26499714	chr9:97195351~97197687:-
UCEC	trans	rs3740713	0.592	rs73434674	ENSG00000235847.2	LDHAP7	6.74	3.21e-10	0.0029	0.69	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr2:84777259~84778223:-
UCEC	trans	rs9611565	0.525	rs9611548	ENSG00000268568.1	AC007228.9	-6.74	3.29e-10	0.00297	-0.71	-0.48	Vitiligo;	chr22:41308139	chr19:56672574~56673901:-
UCEC	trans	rs2209875	0.574	rs2274576	ENSG00000234819.1	RP11-336N8.4	6.73	3.47e-10	0.00312	0.55	0.48	Pelvic organ prolapse (moderate/severe);	chr9:89311531	chr9:78219120~78219357:+
UCEC	trans	rs2727020	0.702	rs609054	ENSG00000134612.10	FOLH1B	6.73	3.47e-10	0.00312	0.57	0.48	Coronary artery disease;	chr11:49198173	chr11:89639227~89698718:+
UCEC	trans	rs8081395	1	rs8081395	ENSG00000187870.7	RNFT1P3	-6.73	3.49e-10	0.00314	-0.52	-0.48	White blood cell count;	chr17:59724400	chr17:20743333~20754501:-
UCEC	trans	rs7113874	0.802	rs11042030	ENSG00000266891.1	RP11-692N5.2	6.72	3.69e-10	0.00329	0.6	0.48	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8669171	chr18:9734882~9735602:-
UCEC	trans	rs9425766	0.924	rs5877	ENSG00000213331.4	RP11-713C19.2	6.71	3.78e-10	0.00337	0.53	0.48	Life satisfaction;	chr1:173909724	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.924	rs9286895	ENSG00000213331.4	RP11-713C19.2	6.7	3.9e-10	0.00347	0.52	0.48	Life satisfaction;	chr1:173873329	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.886	rs9661233	ENSG00000213331.4	RP11-713C19.2	6.7	3.9e-10	0.00347	0.52	0.48	Life satisfaction;	chr1:173874913	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.962	rs2065171	ENSG00000213331.4	RP11-713C19.2	6.7	3.9e-10	0.00347	0.52	0.48	Life satisfaction;	chr1:173876972	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.962	rs4652229	ENSG00000213331.4	RP11-713C19.2	6.7	3.9e-10	0.00347	0.52	0.48	Life satisfaction;	chr1:173877452	chr4:187970273~187971284:+
UCEC	trans	rs9425766	0.927	rs9425765	ENSG00000213331.4	RP11-713C19.2	6.7	3.9e-10	0.00347	0.52	0.48	Life satisfaction;	chr1:173878871	chr4:187970273~187971284:+
UCEC	trans	rs7395662	1	rs11039871	ENSG00000134612.10	FOLH1B	6.7	3.92e-10	0.00348	0.53	0.48	HDL cholesterol;	chr11:48605068	chr11:89639227~89698718:+
UCEC	trans	rs10242455	0.702	rs76840929	ENSG00000228834.1	RP11-249L21.4	6.7	4.03e-10	0.00357	1.21	0.48	Blood metabolite levels;	chr7:99348235	chr6:108907615~108907873:-
UCEC	trans	rs7554547	0.69	rs12087996	ENSG00000261819.1	RP11-680G24.4	6.7	4.09e-10	0.00363	0.65	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11897152	chr16:14988259~14990160:-
UCEC	trans	rs7113874	0.802	rs7118611	ENSG00000266891.1	RP11-692N5.2	6.69	4.18e-10	0.00369	0.6	0.48	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8664138	chr18:9734882~9735602:-
UCEC	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	6.68	4.38e-10	0.00385	0.48	0.48	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
UCEC	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	6.68	4.46e-10	0.00392	0.46	0.48	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
UCEC	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	6.68	4.55e-10	0.004	0.54	0.48	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
UCEC	trans	rs10242455	0.702	rs73713521	ENSG00000228834.1	RP11-249L21.4	6.67	4.58e-10	0.00402	1.23	0.48	Blood metabolite levels;	chr7:99591026	chr6:108907615~108907873:-
UCEC	trans	rs3849046	0.846	rs154076	ENSG00000226666.1	HSPA9P1	-6.67	4.6e-10	0.00404	-0.4	-0.48	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138527445	chr2:221961737~221963765:+
UCEC	trans	rs9467773	1	rs9393731	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26529146	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs11756120	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26529580	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9393732	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26530670	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.967	rs9358954	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26530950	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs28558133	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26531205	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1321480	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26532514	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs10946834	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26533436	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs10946835	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26533529	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467778	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26534515	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs2393670	ENSG00000242375.1	RP11-498P14.3	6.67	4.65e-10	0.00406	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26535313	chr9:97195351~97197687:-
UCEC	trans	rs7554547	0.667	rs12065911	ENSG00000261819.1	RP11-680G24.4	6.67	4.72e-10	0.00413	0.62	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11908323	chr16:14988259~14990160:-
UCEC	trans	rs7554547	0.714	rs4845890	ENSG00000261819.1	RP11-680G24.4	6.67	4.72e-10	0.00413	0.62	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11912612	chr16:14988259~14990160:-
UCEC	trans	rs14057	0.896	rs2235566	ENSG00000215869.3	RP11-364B6.1	6.67	4.78e-10	0.00417	0.68	0.48	Systolic blood pressure;	chr1:6594993	chr1:104073023~104077087:+
UCEC	trans	rs9467773	0.967	rs6932865	ENSG00000242375.1	RP11-498P14.3	6.67	4.79e-10	0.00418	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26539938	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs6933176	ENSG00000242375.1	RP11-498P14.3	6.67	4.79e-10	0.00418	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26539950	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1321481	ENSG00000242375.1	RP11-498P14.3	6.67	4.81e-10	0.0042	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26537982	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs4713008	ENSG00000242375.1	RP11-498P14.3	6.67	4.81e-10	0.0042	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26538040	chr9:97195351~97197687:-
UCEC	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	6.66	4.86e-10	0.00423	0.78	0.48	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	6.66	4.86e-10	0.00423	0.78	0.48	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	6.65	5.1e-10	0.00442	0.78	0.48	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
UCEC	trans	rs9467773	1	rs1884946	ENSG00000242375.1	RP11-498P14.3	6.65	5.12e-10	0.00443	0.63	0.48	Intelligence (multi-trait analysis);	chr6:26545080	chr9:97195351~97197687:-
UCEC	trans	rs7395662	0.963	rs12365014	ENSG00000134612.10	FOLH1B	-6.65	5.2e-10	0.0045	-0.54	-0.48	HDL cholesterol;	chr11:48607882	chr11:89639227~89698718:+
UCEC	trans	rs9467773	1	rs9357010	ENSG00000242375.1	RP11-498P14.3	6.64	5.39e-10	0.00463	0.62	0.48	Intelligence (multi-trait analysis);	chr6:26527717	chr9:97195351~97197687:-
UCEC	trans	rs2727020	0.688	rs4929894	ENSG00000134612.10	FOLH1B	-6.64	5.43e-10	0.00467	-0.56	-0.48	Coronary artery disease;	chr11:49174781	chr11:89639227~89698718:+
UCEC	trans	rs13190036	0.681	rs28461408	ENSG00000217325.2	PRELID1P1	6.64	5.55e-10	0.00476	0.9	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr6:126643488~126644390:+
UCEC	trans	rs16920624	0.85	rs12247444	ENSG00000204894.4	RP11-208G20.2	6.64	5.55e-10	0.00476	0.69	0.48	Response to antidepressants;	chr10:20575563	chr7:152367171~152367260:+
UCEC	trans	rs16920624	0.85	rs12254179	ENSG00000204894.4	RP11-208G20.2	6.64	5.55e-10	0.00476	0.69	0.48	Response to antidepressants;	chr10:20575581	chr7:152367171~152367260:+
UCEC	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-6.64	5.57e-10	0.00478	-0.5	-0.48	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
UCEC	trans	rs6132905	0.52	rs2422823	ENSG00000235559.1	NOP56P1	-6.63	5.65e-10	0.00483	-0.58	-0.48	Mumps;	chr20:2665687	chr6:28783633~28784004:-
UCEC	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-6.63	5.87e-10	0.00501	-0.52	-0.48	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
UCEC	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	6.62	5.95e-10	0.00508	0.65	0.48	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
UCEC	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-6.62	6.18e-10	0.00526	-0.59	-0.48	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
UCEC	trans	rs2727020	0.729	rs2299650	ENSG00000134612.10	FOLH1B	-6.62	6.25e-10	0.00532	-0.56	-0.48	Coronary artery disease;	chr11:49152455	chr11:89639227~89698718:+
UCEC	trans	rs1707322	0.682	rs3014241	ENSG00000255397.1	AC022182.2	6.61	6.46e-10	0.00548	0.54	0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr8:60937705~60939871:-
UCEC	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	6.61	6.49e-10	0.00551	0.65	0.48	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	6.61	6.49e-10	0.00551	0.65	0.48	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	6.61	6.49e-10	0.00551	0.65	0.48	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
UCEC	trans	rs7258465	1	rs4808136	ENSG00000267533.1	RP11-815J4.7	-6.6	6.73e-10	0.00568	-0.58	-0.48	Breast cancer;	chr19:18508057	chr18:12067173~12068417:-
UCEC	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	6.6	6.81e-10	0.00573	0.65	0.48	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	6.6	6.81e-10	0.00573	0.65	0.48	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	6.6	6.91e-10	0.0058	0.67	0.48	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
UCEC	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-6.59	6.97e-10	0.00585	-0.7	-0.48	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
UCEC	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	6.59	7.3e-10	0.00611	0.58	0.47	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
UCEC	trans	rs7976838	0.731	rs7971641	ENSG00000224682.1	SOCS5P2	6.58	7.35e-10	0.00614	0.86	0.47	Response to zileuton treatment in asthma (FEV1 change interaction);	chr12:59835215	chr9:135447446~135450154:+
UCEC	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	6.58	7.59e-10	0.00632	0.64	0.47	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	6.58	7.59e-10	0.00632	0.64	0.47	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	6.58	7.59e-10	0.00632	0.64	0.47	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	6.58	7.59e-10	0.00632	0.64	0.47	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	6.58	7.59e-10	0.00632	0.64	0.47	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
UCEC	trans	rs13190036	1	rs351862	ENSG00000228305.2	AC016734.2	-6.57	7.84e-10	0.0065	-0.62	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr2:63622178~63622831:-
UCEC	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	6.57	7.9e-10	0.00654	0.63	0.47	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
UCEC	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-6.57	7.96e-10	0.00657	-0.51	-0.47	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-6.57	7.96e-10	0.00657	-0.51	-0.47	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-6.57	7.96e-10	0.00657	-0.51	-0.47	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-6.57	7.96e-10	0.00657	-0.51	-0.47	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-6.57	7.96e-10	0.00657	-0.51	-0.47	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-6.57	7.96e-10	0.00657	-0.51	-0.47	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
UCEC	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	6.57	8e-10	0.0066	0.65	0.47	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
UCEC	trans	rs13190036	1	rs625882	ENSG00000217325.2	PRELID1P1	-6.57	8.03e-10	0.00662	-0.68	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr6:126643488~126644390:+
UCEC	trans	rs9425766	0.962	rs941989	ENSG00000213331.4	RP11-713C19.2	-6.57	8.05e-10	0.00664	-0.51	-0.47	Life satisfaction;	chr1:173912733	chr4:187970273~187971284:+
UCEC	trans	rs4648045	0.565	rs62327181	ENSG00000243099.1	AC020983.5	6.57	8.06e-10	0.00664	0.55	0.47	Lymphocyte percentage of white cells;	chr4:102624981	chr7:138688980~138689522:+
UCEC	trans	rs6437061	0.614	rs3116240	ENSG00000211937.3	IGHV2-5	-6.56	8.31e-10	0.00682	-0.36	-0.47	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr2:232055720	chr14:106037902~106038365:-
UCEC	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-6.56	8.44e-10	0.00691	-0.51	-0.47	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-6.56	8.44e-10	0.00691	-0.51	-0.47	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-6.56	8.44e-10	0.00691	-0.51	-0.47	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-6.56	8.44e-10	0.00691	-0.51	-0.47	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-6.56	8.46e-10	0.00693	-0.51	-0.47	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-6.56	8.46e-10	0.00693	-0.51	-0.47	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-6.56	8.46e-10	0.00693	-0.51	-0.47	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-6.56	8.52e-10	0.00696	-0.51	-0.47	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-6.55	8.65e-10	0.00702	-0.51	-0.47	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
UCEC	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	6.55	8.65e-10	0.00702	0.65	0.47	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
UCEC	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-6.55	8.66e-10	0.00703	-0.57	-0.47	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-6.55	8.73e-10	0.00708	-0.51	-0.47	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-6.55	8.73e-10	0.00708	-0.51	-0.47	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-6.55	8.73e-10	0.00708	-0.51	-0.47	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-6.55	8.73e-10	0.00708	-0.51	-0.47	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-6.55	8.73e-10	0.00708	-0.51	-0.47	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-6.55	8.73e-10	0.00708	-0.51	-0.47	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-6.55	8.73e-10	0.00708	-0.51	-0.47	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
UCEC	trans	rs1707322	0.686	rs2991977	ENSG00000255397.1	AC022182.2	6.55	8.77e-10	0.0071	0.54	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.656	rs2991981	ENSG00000255397.1	AC022182.2	6.55	8.77e-10	0.0071	0.54	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr8:60937705~60939871:-
UCEC	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	6.55	8.87e-10	0.00717	0.61	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
UCEC	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	6.55	8.91e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	6.55	8.92e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	6.55	8.92e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	6.55	8.92e-10	0.00717	0.64	0.47	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
UCEC	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	6.55	8.94e-10	0.00718	0.58	0.47	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
UCEC	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	6.54	9.12e-10	0.00731	1	0.47	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
UCEC	trans	rs7976838	0.708	rs71463241	ENSG00000224682.1	SOCS5P2	6.54	9.16e-10	0.00734	0.83	0.47	Response to zileuton treatment in asthma (FEV1 change interaction);	chr12:59833605	chr9:135447446~135450154:+
UCEC	trans	rs13190036	1	rs351864	ENSG00000228305.2	AC016734.2	-6.54	9.34e-10	0.00748	-0.62	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr2:63622178~63622831:-
UCEC	trans	rs3779195	1	rs3779195	ENSG00000225169.1	BRI3P1	-6.54	9.38e-10	0.00751	-0.76	-0.47	Sex hormone-binding globulin levels;	chr7:98364050	chr1:100213293~100213670:+
UCEC	trans	rs3849046	0.79	rs188731	ENSG00000226666.1	HSPA9P1	6.54	9.4e-10	0.00752	0.4	0.47	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138545415	chr2:221961737~221963765:+
UCEC	trans	rs3849046	0.619	rs181919	ENSG00000226666.1	HSPA9P1	6.54	9.4e-10	0.00752	0.4	0.47	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138546923	chr2:221961737~221963765:+
UCEC	trans	rs3849046	0.875	rs255999	ENSG00000226666.1	HSPA9P1	6.54	9.4e-10	0.00752	0.4	0.47	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138554110	chr2:221961737~221963765:+
UCEC	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	6.54	9.45e-10	0.00754	0.65	0.47	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	6.54	9.45e-10	0.00754	0.65	0.47	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	6.54	9.45e-10	0.00754	0.65	0.47	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	6.54	9.45e-10	0.00754	0.65	0.47	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	6.53	9.54e-10	0.0076	0.65	0.47	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
UCEC	trans	rs11141597	0.677	rs10868508	ENSG00000280206.1	CTB-193M12.5	-6.53	9.62e-10	0.00766	-0.95	-0.47	Asthma (childhood onset);	chr9:86955816	chr16:15701237~15702118:+
UCEC	trans	rs4648045	0.565	rs11733293	ENSG00000243099.1	AC020983.5	-6.53	9.9e-10	0.00785	-0.52	-0.47	Lymphocyte percentage of white cells;	chr4:102624096	chr7:138688980~138689522:+
UCEC	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	6.53	9.94e-10	0.00788	0.58	0.47	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
UCEC	trans	rs6844153	1	rs74642474	ENSG00000250903.7	GMDS-AS1	6.52	1.02e-09	0.00803	0.67	0.47	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26854979	chr6:2245748~2482022:+
UCEC	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	6.52	1.02e-09	0.00803	0.63	0.47	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
UCEC	trans	rs2727020	0.587	rs1164658	ENSG00000134612.10	FOLH1B	6.52	1.02e-09	0.00806	0.55	0.47	Coronary artery disease;	chr11:49276999	chr11:89639227~89698718:+
UCEC	trans	rs3849046	0.817	rs154069	ENSG00000226666.1	HSPA9P1	6.52	1.03e-09	0.00813	0.4	0.47	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138541231	chr2:221961737~221963765:+
UCEC	trans	rs3740713	0.669	rs113003553	ENSG00000235847.2	LDHAP7	6.52	1.03e-09	0.00815	0.68	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr2:84777259~84778223:-
UCEC	trans	rs7976838	0.731	rs35661132	ENSG00000224682.1	SOCS5P2	6.52	1.04e-09	0.00816	0.83	0.47	Response to zileuton treatment in asthma (FEV1 change interaction);	chr12:59834998	chr9:135447446~135450154:+
UCEC	trans	rs7976838	0.831	rs7956657	ENSG00000224682.1	SOCS5P2	6.52	1.04e-09	0.00816	0.83	0.47	Response to zileuton treatment in asthma (FEV1 change interaction);	chr12:59835076	chr9:135447446~135450154:+
UCEC	trans	rs3849046	0.846	rs10117	ENSG00000226666.1	HSPA9P1	6.52	1.05e-09	0.00826	0.4	0.47	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138556481	chr2:221961737~221963765:+
UCEC	trans	rs4648045	0.565	rs4698860	ENSG00000243099.1	AC020983.5	6.51	1.06e-09	0.00832	0.53	0.47	Lymphocyte percentage of white cells;	chr4:102624170	chr7:138688980~138689522:+
UCEC	trans	rs9611565	0.694	rs5758389	ENSG00000268568.1	AC007228.9	-6.51	1.07e-09	0.00844	-0.58	-0.47	Vitiligo;	chr22:41545745	chr19:56672574~56673901:-
UCEC	trans	rs7395662	0.864	rs7483617	ENSG00000134612.10	FOLH1B	-6.51	1.09e-09	0.00856	-0.53	-0.47	HDL cholesterol;	chr11:48530107	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs12365220	ENSG00000134612.10	FOLH1B	-6.51	1.09e-09	0.00856	-0.53	-0.47	HDL cholesterol;	chr11:48534405	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.929	rs12363679	ENSG00000134612.10	FOLH1B	-6.51	1.09e-09	0.00856	-0.53	-0.47	HDL cholesterol;	chr11:48534471	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs10838943	ENSG00000134612.10	FOLH1B	-6.51	1.09e-09	0.00856	-0.53	-0.47	HDL cholesterol;	chr11:48535890	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs4882109	ENSG00000134612.10	FOLH1B	-6.51	1.09e-09	0.00856	-0.53	-0.47	HDL cholesterol;	chr11:48536133	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882111	ENSG00000134612.10	FOLH1B	-6.51	1.09e-09	0.00856	-0.53	-0.47	HDL cholesterol;	chr11:48536895	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882010	ENSG00000134612.10	FOLH1B	-6.51	1.09e-09	0.00856	-0.53	-0.47	HDL cholesterol;	chr11:48537621	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs10838944	ENSG00000134612.10	FOLH1B	-6.51	1.09e-09	0.00856	-0.53	-0.47	HDL cholesterol;	chr11:48538019	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs4882112	ENSG00000134612.10	FOLH1B	-6.51	1.09e-09	0.00856	-0.53	-0.47	HDL cholesterol;	chr11:48539531	chr11:89639227~89698718:+
UCEC	trans	rs941898	0.541	rs1951486	ENSG00000249485.1	RBBP4P1	-6.51	1.1e-09	0.00858	-0.37	-0.47	White matter hyperintensity burden;	chr14:100141023	chr5:14797125~14798400:-
UCEC	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	6.51	1.1e-09	0.00862	0.49	0.47	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
UCEC	trans	rs7395662	1	rs11039817	ENSG00000134612.10	FOLH1B	-6.5	1.11e-09	0.00869	-0.52	-0.47	HDL cholesterol;	chr11:48539928	chr11:89639227~89698718:+
UCEC	trans	rs7662987	0.793	rs12697	ENSG00000233859.2	ADH5P4	-6.5	1.14e-09	0.00891	-0.64	-0.47	Smoking initiation;	chr4:99072225	chr6:65836930~65838039:-
UCEC	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	6.5	1.15e-09	0.00897	0.64	0.47	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
UCEC	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-6.49	1.21e-09	0.00939	-0.43	-0.47	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
UCEC	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-6.49	1.21e-09	0.00944	-0.51	-0.47	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
UCEC	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	6.48	1.23e-09	0.0095	0.64	0.47	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	6.48	1.23e-09	0.0095	0.64	0.47	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	6.48	1.23e-09	0.0095	0.64	0.47	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	6.48	1.23e-09	0.0095	0.64	0.47	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	6.48	1.23e-09	0.0095	0.64	0.47	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	6.48	1.23e-09	0.0095	0.64	0.47	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	6.48	1.23e-09	0.0095	0.64	0.47	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	6.48	1.23e-09	0.0095	0.64	0.47	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	6.48	1.23e-09	0.0095	0.64	0.47	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	6.48	1.26e-09	0.00972	0.63	0.47	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
UCEC	trans	rs14057	0.929	rs1556034	ENSG00000215869.3	RP11-364B6.1	6.48	1.29e-09	0.00989	0.66	0.47	Systolic blood pressure;	chr1:6629259	chr1:104073023~104077087:+
UCEC	trans	rs61990749	0.571	rs4448861	ENSG00000235400.1	RP4-641G12.4	6.47	1.3e-09	0.00992	0.86	0.47	Fibroblast growth factor basic levels;	chr14:77841392	chr1:78749073~78750659:+
UCEC	trans	rs10040989	0.585	rs6892609	ENSG00000215493.3	XXbac-B562F10.11	6.47	1.32e-09	0.0101	0.53	0.47	QT interval;	chr5:138479533	chr22:20450122~20451824:+
UCEC	trans	rs12709013	0.536	rs1646260	ENSG00000233719.3	GOT2P3	6.47	1.33e-09	0.0102	0.56	0.47	Blood metabolite ratios;	chr16:58734951	chr12:9641802~9643007:+
UCEC	trans	rs3779195	0.929	rs1635612	ENSG00000225169.1	BRI3P1	6.47	1.36e-09	0.0104	0.66	0.47	Sex hormone-binding globulin levels;	chr7:98385737	chr1:100213293~100213670:+
UCEC	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	6.47	1.36e-09	0.0104	0.64	0.47	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	6.47	1.36e-09	0.0104	0.64	0.47	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	6.47	1.36e-09	0.0104	0.64	0.47	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	6.47	1.36e-09	0.0104	0.64	0.47	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	6.47	1.36e-09	0.0104	0.64	0.47	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	6.47	1.36e-09	0.0104	0.64	0.47	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	6.47	1.36e-09	0.0104	0.64	0.47	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
UCEC	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	6.46	1.39e-09	0.0105	0.46	0.47	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
UCEC	trans	rs7395662	0.929	rs7108559	ENSG00000134612.10	FOLH1B	-6.46	1.39e-09	0.0106	-0.52	-0.47	HDL cholesterol;	chr11:48597599	chr11:89639227~89698718:+
UCEC	trans	rs4648045	0.565	rs11733749	ENSG00000243099.1	AC020983.5	6.45	1.44e-09	0.0109	0.53	0.47	Lymphocyte percentage of white cells;	chr4:102625985	chr7:138688980~138689522:+
UCEC	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-6.45	1.44e-09	0.0109	-0.51	-0.47	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
UCEC	trans	rs10242455	0.85	rs3779354	ENSG00000228834.1	RP11-249L21.4	6.45	1.45e-09	0.011	0.82	0.47	Blood metabolite levels;	chr7:99454805	chr6:108907615~108907873:-
UCEC	trans	rs7395662	0.929	rs7952580	ENSG00000134612.10	FOLH1B	-6.45	1.45e-09	0.011	-0.52	-0.47	HDL cholesterol;	chr11:48573654	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882019	ENSG00000134612.10	FOLH1B	-6.45	1.45e-09	0.011	-0.52	-0.47	HDL cholesterol;	chr11:48577196	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882134	ENSG00000134612.10	FOLH1B	-6.45	1.45e-09	0.011	-0.52	-0.47	HDL cholesterol;	chr11:48577243	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7483920	ENSG00000134612.10	FOLH1B	-6.45	1.45e-09	0.011	-0.52	-0.47	HDL cholesterol;	chr11:48578417	chr11:89639227~89698718:+
UCEC	trans	rs9611519	0.78	rs9611546	ENSG00000268568.1	AC007228.9	-6.45	1.46e-09	0.011	-0.68	-0.47	Neuroticism;	chr22:41302538	chr19:56672574~56673901:-
UCEC	trans	rs7554547	0.667	rs11121839	ENSG00000261819.1	RP11-680G24.4	6.45	1.48e-09	0.0112	0.61	0.47	Nonsyndromic cleft lip with cleft palate;	chr1:11908280	chr16:14988259~14990160:-
UCEC	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-6.44	1.53e-09	0.0115	-0.51	-0.47	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
UCEC	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	6.44	1.56e-09	0.0117	0.55	0.47	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
UCEC	trans	rs9467773	0.844	rs2393669	ENSG00000242375.1	RP11-498P14.3	6.43	1.59e-09	0.0119	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26503645	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9461259	ENSG00000242375.1	RP11-498P14.3	6.43	1.59e-09	0.0119	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26504607	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9467774	ENSG00000242375.1	RP11-498P14.3	6.43	1.59e-09	0.0119	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26504808	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs3736781	ENSG00000242375.1	RP11-498P14.3	6.43	1.59e-09	0.0119	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26505134	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs3736782	ENSG00000242375.1	RP11-498P14.3	6.43	1.59e-09	0.0119	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26505175	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs2208331	ENSG00000242375.1	RP11-498P14.3	6.43	1.59e-09	0.0119	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26507091	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	6.43	1.6e-09	0.012	0.64	0.47	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs2255070	ENSG00000242375.1	RP11-498P14.3	6.43	1.62e-09	0.0121	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26501549	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs9393728	ENSG00000242375.1	RP11-498P14.3	6.43	1.63e-09	0.0121	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26509102	chr9:97195351~97197687:-
UCEC	trans	rs9467773	1	rs1056667	ENSG00000242375.1	RP11-498P14.3	6.43	1.63e-09	0.0121	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26510336	chr9:97195351~97197687:-
UCEC	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	6.43	1.65e-09	0.0122	0.55	0.47	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
UCEC	trans	rs7395662	1	rs12366208	ENSG00000134612.10	FOLH1B	-6.42	1.69e-09	0.0125	-0.51	-0.47	HDL cholesterol;	chr11:48541576	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.864	rs12366262	ENSG00000134612.10	FOLH1B	-6.42	1.69e-09	0.0125	-0.51	-0.47	HDL cholesterol;	chr11:48541920	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882117	ENSG00000134612.10	FOLH1B	-6.42	1.69e-09	0.0125	-0.51	-0.47	HDL cholesterol;	chr11:48543916	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882015	ENSG00000134612.10	FOLH1B	-6.42	1.69e-09	0.0125	-0.51	-0.47	HDL cholesterol;	chr11:48544021	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs11039826	ENSG00000134612.10	FOLH1B	-6.42	1.69e-09	0.0125	-0.51	-0.47	HDL cholesterol;	chr11:48550846	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs6485865	ENSG00000134612.10	FOLH1B	-6.42	1.69e-09	0.0125	-0.51	-0.47	HDL cholesterol;	chr11:48554437	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7107184	ENSG00000134612.10	FOLH1B	-6.42	1.69e-09	0.0125	-0.51	-0.47	HDL cholesterol;	chr11:48555517	chr11:89639227~89698718:+
UCEC	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-6.42	1.7e-09	0.0126	-0.51	-0.47	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
UCEC	trans	rs7395662	1	rs10838954	ENSG00000134612.10	FOLH1B	-6.42	1.71e-09	0.0126	-0.52	-0.47	HDL cholesterol;	chr11:48557771	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs11039862	ENSG00000134612.10	FOLH1B	-6.42	1.71e-09	0.0126	-0.51	-0.47	HDL cholesterol;	chr11:48596754	chr11:89639227~89698718:+
UCEC	trans	rs4648045	0.565	rs17033014	ENSG00000243099.1	AC020983.5	6.42	1.73e-09	0.0128	0.52	0.47	Lymphocyte percentage of white cells;	chr4:102625029	chr7:138688980~138689522:+
UCEC	trans	rs2727020	0.729	rs4980439	ENSG00000134612.10	FOLH1B	-6.42	1.75e-09	0.0129	-0.54	-0.47	Coronary artery disease;	chr11:49320694	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.638	rs1164668	ENSG00000134612.10	FOLH1B	6.42	1.75e-09	0.0129	0.54	0.47	Coronary artery disease;	chr11:49309075	chr11:89639227~89698718:+
UCEC	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	6.42	1.76e-09	0.013	0.66	0.47	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	6.41	1.77e-09	0.013	0.64	0.47	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
UCEC	trans	rs9899728	0.539	rs12940199	ENSG00000234925.2	ATP5HP4	6.41	1.79e-09	0.0132	0.62	0.47	Alzheimer's disease or small vessel stroke;	chr17:75058664	chr12:68642519~68642993:-
UCEC	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	6.41	1.83e-09	0.0134	0.51	0.46	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
UCEC	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	6.41	1.84e-09	0.0135	0.9	0.46	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	6.41	1.84e-09	0.0135	0.9	0.46	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
UCEC	trans	rs7395662	1	rs12419576	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48560092	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs61930968	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48560097	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.929	rs10838956	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48560213	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7949554	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48560440	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.895	rs7924481	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48560905	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.929	rs10838959	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48563180	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882129	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48567222	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882130	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48567402	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs10838966	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48568171	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs34636547	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48568551	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs10769382	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48568863	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs7951432	ENSG00000134612.10	FOLH1B	-6.4	1.89e-09	0.0137	-0.52	-0.46	HDL cholesterol;	chr11:48569728	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7121992	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48571030	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.89	rs4882133	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48571898	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs10838967	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48573455	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7481308	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48578515	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs11039851	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48579287	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs11039854	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48586136	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.777	rs7114291	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48586699	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs6485889	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48587233	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7481880	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48587795	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.929	rs7946248	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48591964	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882136	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48593759	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs10769389	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48596459	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs10769390	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48596670	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs11039868	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48600594	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.895	rs11039869	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48600760	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs12421159	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48603289	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7479134	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48603857	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs11039870	ENSG00000134612.10	FOLH1B	-6.4	1.91e-09	0.0138	-0.52	-0.46	HDL cholesterol;	chr11:48604926	chr11:89639227~89698718:+
UCEC	trans	rs12709013	0.636	rs1646268	ENSG00000233719.3	GOT2P3	6.4	1.91e-09	0.0138	0.53	0.46	Blood metabolite ratios;	chr16:58743292	chr12:9641802~9643007:+
UCEC	trans	rs2727020	0.658	rs4980431	ENSG00000134612.10	FOLH1B	-6.4	1.92e-09	0.0139	-0.54	-0.46	Coronary artery disease;	chr11:49328519	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs6485888	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48583787	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs10838971	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48585072	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7944356	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48588602	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs11039857	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48589301	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs11039859	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48590436	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7928083	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48591596	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882021	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48594414	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7129386	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48595142	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs10838975	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48596063	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs12418721	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48596899	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.864	rs7482764	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48604306	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.929	rs34584314	ENSG00000134612.10	FOLH1B	-6.39	1.96e-09	0.0141	-0.52	-0.46	HDL cholesterol;	chr11:48606134	chr11:89639227~89698718:+
UCEC	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	6.39	1.97e-09	0.0142	0.59	0.46	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
UCEC	trans	rs7395662	0.963	rs12800770	ENSG00000134612.10	FOLH1B	-6.39	1.98e-09	0.0143	-0.51	-0.46	HDL cholesterol;	chr11:48583375	chr11:89639227~89698718:+
UCEC	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	6.39	2.02e-09	0.0145	0.9	0.46	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	6.39	2.02e-09	0.0145	0.9	0.46	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	6.39	2.02e-09	0.0145	0.9	0.46	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
UCEC	trans	rs7395662	1	rs7121460	ENSG00000134612.10	FOLH1B	-6.39	2.04e-09	0.0146	-0.52	-0.46	HDL cholesterol;	chr11:48523680	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.929	rs10838934	ENSG00000134612.10	FOLH1B	-6.39	2.04e-09	0.0146	-0.52	-0.46	HDL cholesterol;	chr11:48525520	chr11:89639227~89698718:+
UCEC	trans	rs9425766	0.888	rs1799876	ENSG00000213331.4	RP11-713C19.2	6.39	2.04e-09	0.0146	0.52	0.46	Life satisfaction;	chr1:173909333	chr4:187970273~187971284:+
UCEC	trans	rs7395662	1	rs10838931	ENSG00000134612.10	FOLH1B	-6.39	2.05e-09	0.0147	-0.52	-0.46	HDL cholesterol;	chr11:48519421	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.929	rs12366252	ENSG00000134612.10	FOLH1B	-6.39	2.05e-09	0.0147	-0.52	-0.46	HDL cholesterol;	chr11:48520766	chr11:89639227~89698718:+
UCEC	trans	rs10242455	0.702	rs1045012	ENSG00000228834.1	RP11-249L21.4	6.38	2.07e-09	0.0148	1.12	0.46	Blood metabolite levels;	chr7:99386731	chr6:108907615~108907873:-
UCEC	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	6.38	2.09e-09	0.0149	0.65	0.46	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	6.38	2.09e-09	0.0149	0.65	0.46	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
UCEC	trans	rs7395662	1	rs55834832	ENSG00000134612.10	FOLH1B	-6.38	2.1e-09	0.0149	-0.51	-0.46	HDL cholesterol;	chr11:48541031	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs11039821	ENSG00000134612.10	FOLH1B	-6.38	2.1e-09	0.0149	-0.51	-0.46	HDL cholesterol;	chr11:48541323	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs12361812	ENSG00000134612.10	FOLH1B	-6.38	2.1e-09	0.0149	-0.51	-0.46	HDL cholesterol;	chr11:48541552	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882016	ENSG00000134612.10	FOLH1B	-6.38	2.1e-09	0.0149	-0.51	-0.46	HDL cholesterol;	chr11:48548573	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.864	rs10838951	ENSG00000134612.10	FOLH1B	-6.38	2.1e-09	0.0149	-0.51	-0.46	HDL cholesterol;	chr11:48549536	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882120	ENSG00000134612.10	FOLH1B	-6.38	2.1e-09	0.0149	-0.51	-0.46	HDL cholesterol;	chr11:48551977	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882123	ENSG00000134612.10	FOLH1B	-6.38	2.1e-09	0.0149	-0.51	-0.46	HDL cholesterol;	chr11:48554187	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7931984	ENSG00000134612.10	FOLH1B	-6.38	2.1e-09	0.0149	-0.51	-0.46	HDL cholesterol;	chr11:48559283	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs6485875	ENSG00000134612.10	FOLH1B	-6.38	2.1e-09	0.0149	-0.51	-0.46	HDL cholesterol;	chr11:48559482	chr11:89639227~89698718:+
UCEC	trans	rs7258465	0.931	rs1560119	ENSG00000267533.1	RP11-815J4.7	6.38	2.11e-09	0.015	0.57	0.46	Breast cancer;	chr19:18462865	chr18:12067173~12068417:-
UCEC	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-6.38	2.12e-09	0.015	-0.5	-0.46	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
UCEC	trans	rs6759518	0.655	rs7081	ENSG00000248884.1	CTC-537E7.3	6.38	2.12e-09	0.015	0.58	0.46	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr2:27199737	chr5:68430427~68434481:-
UCEC	trans	rs6759518	0.655	rs1275525	ENSG00000248884.1	CTC-537E7.3	6.38	2.12e-09	0.015	0.58	0.46	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr2:27205834	chr5:68430427~68434481:-
UCEC	trans	rs7258465	1	rs10425982	ENSG00000267533.1	RP11-815J4.7	6.38	2.13e-09	0.0151	0.57	0.46	Breast cancer;	chr19:18475709	chr18:12067173~12068417:-
UCEC	trans	rs7258465	0.965	rs7256534	ENSG00000267533.1	RP11-815J4.7	6.38	2.13e-09	0.0151	0.57	0.46	Breast cancer;	chr19:18475981	chr18:12067173~12068417:-
UCEC	trans	rs7258465	1	rs2278238	ENSG00000267533.1	RP11-815J4.7	6.38	2.14e-09	0.0151	0.57	0.46	Breast cancer;	chr19:18465674	chr18:12067173~12068417:-
UCEC	trans	rs7258465	1	rs8109573	ENSG00000267533.1	RP11-815J4.7	6.38	2.16e-09	0.0153	0.56	0.46	Breast cancer;	chr19:18506341	chr18:12067173~12068417:-
UCEC	trans	rs7258465	0.931	rs271629	ENSG00000267533.1	RP11-815J4.7	6.38	2.16e-09	0.0153	0.56	0.46	Breast cancer;	chr19:18512388	chr18:12067173~12068417:-
UCEC	trans	rs7258465	0.965	rs271628	ENSG00000267533.1	RP11-815J4.7	6.38	2.16e-09	0.0153	0.56	0.46	Breast cancer;	chr19:18513523	chr18:12067173~12068417:-
UCEC	trans	rs6759518	0.655	rs1290029	ENSG00000248884.1	CTC-537E7.3	6.37	2.18e-09	0.0154	0.58	0.46	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr2:27195348	chr5:68430427~68434481:-
UCEC	trans	rs9899728	0.52	rs12936866	ENSG00000234925.2	ATP5HP4	6.37	2.2e-09	0.0154	0.62	0.46	Alzheimer's disease or small vessel stroke;	chr17:75055955	chr12:68642519~68642993:-
UCEC	trans	rs9899728	0.539	rs57813751	ENSG00000234925.2	ATP5HP4	6.37	2.2e-09	0.0154	0.62	0.46	Alzheimer's disease or small vessel stroke;	chr17:75057417	chr12:68642519~68642993:-
UCEC	trans	rs13190036	0.748	rs28395268	ENSG00000228305.2	AC016734.2	6.37	2.21e-09	0.0155	0.59	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr2:63622178~63622831:-
UCEC	trans	rs2727020	0.553	rs11040400	ENSG00000134612.10	FOLH1B	-6.37	2.21e-09	0.0155	-0.53	-0.46	Coronary artery disease;	chr11:49496744	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4881994	ENSG00000134612.10	FOLH1B	-6.37	2.22e-09	0.0155	-0.51	-0.46	HDL cholesterol;	chr11:48476587	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.895	rs1945183	ENSG00000134612.10	FOLH1B	-6.37	2.22e-09	0.0155	-0.51	-0.46	HDL cholesterol;	chr11:48480875	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs10838917	ENSG00000134612.10	FOLH1B	-6.37	2.22e-09	0.0155	-0.51	-0.46	HDL cholesterol;	chr11:48481575	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs11039774	ENSG00000134612.10	FOLH1B	-6.37	2.22e-09	0.0155	-0.51	-0.46	HDL cholesterol;	chr11:48492407	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs12420372	ENSG00000134612.10	FOLH1B	6.37	2.22e-09	0.0155	0.51	0.46	HDL cholesterol;	chr11:48476051	chr11:89639227~89698718:+
UCEC	trans	rs9611565	0.921	rs5758297	ENSG00000268568.1	AC007228.9	-6.37	2.22e-09	0.0155	-0.56	-0.46	Vitiligo;	chr22:41324693	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.921	rs5751077	ENSG00000268568.1	AC007228.9	-6.37	2.22e-09	0.0155	-0.56	-0.46	Vitiligo;	chr22:41324724	chr19:56672574~56673901:-
UCEC	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-6.37	2.23e-09	0.0155	-0.5	-0.46	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
UCEC	trans	rs10242455	0.702	rs57832867	ENSG00000228834.1	RP11-249L21.4	6.37	2.24e-09	0.0156	1.11	0.46	Blood metabolite levels;	chr7:99368773	chr6:108907615~108907873:-
UCEC	trans	rs4648045	0.565	rs4698862	ENSG00000243099.1	AC020983.5	6.37	2.25e-09	0.0157	0.51	0.46	Lymphocyte percentage of white cells;	chr4:102624640	chr7:138688980~138689522:+
UCEC	trans	rs4648045	0.565	rs4698863	ENSG00000243099.1	AC020983.5	6.37	2.25e-09	0.0157	0.51	0.46	Lymphocyte percentage of white cells;	chr4:102624691	chr7:138688980~138689522:+
UCEC	trans	rs9611565	0.921	rs5751080	ENSG00000268568.1	AC007228.9	-6.37	2.25e-09	0.0157	-0.53	-0.46	Vitiligo;	chr22:41340263	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-6.37	2.25e-09	0.0157	-0.53	-0.46	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
UCEC	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-6.37	2.25e-09	0.0157	-0.53	-0.46	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
UCEC	trans	rs10242455	0.702	rs28753399	ENSG00000228834.1	RP11-249L21.4	6.36	2.28e-09	0.0159	1.13	0.46	Blood metabolite levels;	chr7:99399636	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs28668326	ENSG00000228834.1	RP11-249L21.4	6.36	2.28e-09	0.0159	1.13	0.46	Blood metabolite levels;	chr7:99400530	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs917152	ENSG00000228834.1	RP11-249L21.4	6.36	2.28e-09	0.0159	1.13	0.46	Blood metabolite levels;	chr7:99406874	chr6:108907615~108907873:-
UCEC	trans	rs7395662	1	rs7949348	ENSG00000134612.10	FOLH1B	-6.36	2.29e-09	0.016	-0.51	-0.46	HDL cholesterol;	chr11:48472249	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs10838912	ENSG00000134612.10	FOLH1B	-6.36	2.29e-09	0.016	-0.51	-0.46	HDL cholesterol;	chr11:48474925	chr11:89639227~89698718:+
UCEC	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	6.36	2.29e-09	0.016	0.66	0.46	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
UCEC	trans	rs3779195	0.584	rs1688605	ENSG00000225169.1	BRI3P1	-6.36	2.3e-09	0.016	-0.71	-0.46	Sex hormone-binding globulin levels;	chr7:98410534	chr1:100213293~100213670:+
UCEC	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	6.36	2.3e-09	0.016	0.47	0.46	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
UCEC	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	6.36	2.32e-09	0.0161	0.62	0.46	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
UCEC	trans	rs7395662	1	rs11039820	ENSG00000134612.10	FOLH1B	-6.36	2.32e-09	0.0161	-0.51	-0.46	HDL cholesterol;	chr11:48540700	chr11:89639227~89698718:+
UCEC	trans	rs7662987	0.793	rs7684735	ENSG00000233859.2	ADH5P4	6.36	2.33e-09	0.0162	0.6	0.46	Smoking initiation;	chr4:99070355	chr6:65836930~65838039:-
UCEC	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	6.36	2.37e-09	0.0164	0.48	0.46	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
UCEC	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	6.36	2.39e-09	0.0165	0.63	0.46	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
UCEC	trans	rs7395662	0.963	rs7125110	ENSG00000134612.10	FOLH1B	-6.36	2.4e-09	0.0166	-0.52	-0.46	HDL cholesterol;	chr11:48523955	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs4882002	ENSG00000134612.10	FOLH1B	-6.36	2.4e-09	0.0166	-0.52	-0.46	HDL cholesterol;	chr11:48525179	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.89	rs11039806	ENSG00000134612.10	FOLH1B	-6.36	2.4e-09	0.0166	-0.52	-0.46	HDL cholesterol;	chr11:48526164	chr11:89639227~89698718:+
UCEC	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-6.35	2.42e-09	0.0167	-0.5	-0.46	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
UCEC	trans	rs2727020	0.729	rs34647977	ENSG00000134612.10	FOLH1B	-6.35	2.43e-09	0.0168	-0.55	-0.46	Coronary artery disease;	chr11:49173991	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs7478900	ENSG00000134612.10	FOLH1B	-6.35	2.44e-09	0.0168	-0.52	-0.46	HDL cholesterol;	chr11:48522451	chr11:89639227~89698718:+
UCEC	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	6.35	2.44e-09	0.0168	0.53	0.46	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
UCEC	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	6.35	2.46e-09	0.0169	0.63	0.46	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
UCEC	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	6.35	2.46e-09	0.0169	0.63	0.46	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
UCEC	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-6.35	2.48e-09	0.017	-0.61	-0.46	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
UCEC	trans	rs1814175	0.654	rs1164676	ENSG00000134612.10	FOLH1B	6.35	2.5e-09	0.0171	0.51	0.46	Height;	chr11:49303316	chr11:89639227~89698718:+
UCEC	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	6.35	2.51e-09	0.0171	0.9	0.46	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
UCEC	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-6.35	2.52e-09	0.0172	-0.58	-0.46	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
UCEC	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	6.34	2.53e-09	0.0173	0.63	0.46	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
UCEC	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-6.34	2.55e-09	0.0174	-0.5	-0.46	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
UCEC	trans	rs7395662	0.963	rs4882137	ENSG00000134612.10	FOLH1B	-6.34	2.57e-09	0.0175	-0.51	-0.46	HDL cholesterol;	chr11:48594119	chr11:89639227~89698718:+
UCEC	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	6.34	2.57e-09	0.0175	0.64	0.46	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
UCEC	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-6.34	2.58e-09	0.0175	-0.64	-0.46	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
UCEC	trans	rs1814175	0.935	rs11040465	ENSG00000134612.10	FOLH1B	-6.34	2.58e-09	0.0176	-0.52	-0.46	Height;	chr11:49667771	chr11:89639227~89698718:+
UCEC	trans	rs7258465	1	rs7252848	ENSG00000267533.1	RP11-815J4.7	6.34	2.61e-09	0.0177	0.55	0.46	Breast cancer;	chr19:18501541	chr18:12067173~12068417:-
UCEC	trans	rs1863918	0.917	rs1106858	ENSG00000239528.1	RPS14P8	6.34	2.62e-09	0.0177	0.63	0.46	Depression in response to interferon-based therapy in chronic hepatitis C;	chr5:179069049	chr5:116562562~116562930:+
UCEC	trans	rs7258465	0.931	rs8107347	ENSG00000267533.1	RP11-815J4.7	6.34	2.62e-09	0.0178	0.55	0.46	Breast cancer;	chr19:18501938	chr18:12067173~12068417:-
UCEC	trans	rs7258465	0.931	rs8107351	ENSG00000267533.1	RP11-815J4.7	6.34	2.62e-09	0.0178	0.55	0.46	Breast cancer;	chr19:18501948	chr18:12067173~12068417:-
UCEC	trans	rs12709013	0.613	rs4238801	ENSG00000233719.3	GOT2P3	6.33	2.66e-09	0.018	0.55	0.46	Blood metabolite ratios;	chr16:58738275	chr12:9641802~9643007:+
UCEC	trans	rs12709013	0.636	rs4575523	ENSG00000233719.3	GOT2P3	6.33	2.66e-09	0.018	0.55	0.46	Blood metabolite ratios;	chr16:58738559	chr12:9641802~9643007:+
UCEC	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	6.33	2.67e-09	0.018	0.42	0.46	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
UCEC	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-6.33	2.71e-09	0.0183	-0.5	-0.46	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
UCEC	trans	rs3740713	0.748	rs35292478	ENSG00000235847.2	LDHAP7	6.33	2.72e-09	0.0183	0.67	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr2:84777259~84778223:-
UCEC	trans	rs7976838	0.831	rs12827221	ENSG00000224682.1	SOCS5P2	6.33	2.73e-09	0.0184	0.92	0.46	Response to zileuton treatment in asthma (FEV1 change interaction);	chr12:59824871	chr9:135447446~135450154:+
UCEC	trans	rs7976838	0.831	rs10431558	ENSG00000224682.1	SOCS5P2	6.33	2.73e-09	0.0184	0.92	0.46	Response to zileuton treatment in asthma (FEV1 change interaction);	chr12:59829696	chr9:135447446~135450154:+
UCEC	trans	rs9611565	0.625	rs2076199	ENSG00000268568.1	AC007228.9	-6.33	2.79e-09	0.0187	-0.54	-0.46	Vitiligo;	chr22:41507739	chr19:56672574~56673901:-
UCEC	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	6.33	2.79e-09	0.0187	0.64	0.46	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	6.33	2.79e-09	0.0187	0.64	0.46	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	6.32	2.81e-09	0.0188	0.64	0.46	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
UCEC	trans	rs2727020	0.688	rs11040338	ENSG00000134612.10	FOLH1B	6.32	2.82e-09	0.0189	0.53	0.46	Coronary artery disease;	chr11:49339049	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.566	rs10839234	ENSG00000134612.10	FOLH1B	-6.32	2.82e-09	0.0189	-0.55	-0.46	Coronary artery disease;	chr11:49163972	chr11:89639227~89698718:+
UCEC	trans	rs10242455	0.702	rs10251282	ENSG00000228834.1	RP11-249L21.4	6.32	2.85e-09	0.019	1.14	0.46	Blood metabolite levels;	chr7:99392613	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs28460612	ENSG00000228834.1	RP11-249L21.4	6.32	2.85e-09	0.019	1.14	0.46	Blood metabolite levels;	chr7:99395582	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs76702117	ENSG00000228834.1	RP11-249L21.4	6.32	2.86e-09	0.0191	1.17	0.46	Blood metabolite levels;	chr7:99319156	chr6:108907615~108907873:-
UCEC	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	6.32	2.89e-09	0.0193	0.65	0.46	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
UCEC	trans	rs1707322	0.717	rs3014237	ENSG00000255397.1	AC022182.2	6.32	2.91e-09	0.0194	0.54	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr8:60937705~60939871:-
UCEC	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	6.32	2.93e-09	0.0195	0.63	0.46	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	6.32	2.93e-09	0.0195	0.63	0.46	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	6.32	2.93e-09	0.0195	0.63	0.46	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
UCEC	trans	rs9611519	0.78	rs9611542	ENSG00000268568.1	AC007228.9	-6.32	2.93e-09	0.0195	-0.63	-0.46	Neuroticism;	chr22:41281313	chr19:56672574~56673901:-
UCEC	trans	rs7395662	0.963	rs11039772	ENSG00000134612.10	FOLH1B	-6.32	2.93e-09	0.0195	-0.51	-0.46	HDL cholesterol;	chr11:48492340	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs11039773	ENSG00000134612.10	FOLH1B	-6.32	2.93e-09	0.0195	-0.51	-0.46	HDL cholesterol;	chr11:48492379	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs11039777	ENSG00000134612.10	FOLH1B	-6.32	2.93e-09	0.0195	-0.51	-0.46	HDL cholesterol;	chr11:48495497	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs11039779	ENSG00000134612.10	FOLH1B	-6.32	2.93e-09	0.0195	-0.51	-0.46	HDL cholesterol;	chr11:48496343	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.864	rs11039872	ENSG00000134612.10	FOLH1B	-6.32	2.93e-09	0.0195	-0.51	-0.46	HDL cholesterol;	chr11:48607981	chr11:89639227~89698718:+
UCEC	trans	rs6732160	0.596	rs7605923	ENSG00000236165.1	PRADC1P1	6.32	2.94e-09	0.0195	0.58	0.46	Intelligence (multi-trait analysis);	chr2:73175205	chr3:36976316~36976840:+
UCEC	trans	rs2727020	0.563	rs10769582	ENSG00000134612.10	FOLH1B	-6.31	2.99e-09	0.0198	-0.53	-0.46	Coronary artery disease;	chr11:49452488	chr11:89639227~89698718:+
UCEC	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	6.31	3e-09	0.0199	0.62	0.46	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	6.31	3e-09	0.0199	0.62	0.46	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
UCEC	trans	rs2727020	0.553	rs3862350	ENSG00000134612.10	FOLH1B	-6.31	3.01e-09	0.02	-0.53	-0.46	Coronary artery disease;	chr11:49574360	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.681	rs1976901	ENSG00000134612.10	FOLH1B	-6.31	3.05e-09	0.0202	-0.54	-0.46	Coronary artery disease;	chr11:49357145	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.681	rs2866362	ENSG00000134612.10	FOLH1B	-6.31	3.05e-09	0.0202	-0.54	-0.46	Coronary artery disease;	chr11:49357764	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.729	rs10839268	ENSG00000134612.10	FOLH1B	-6.31	3.05e-09	0.0202	-0.54	-0.46	Coronary artery disease;	chr11:49358776	chr11:89639227~89698718:+
UCEC	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	6.31	3.09e-09	0.0205	0.61	0.46	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
UCEC	trans	rs2731664	0.74	rs2731670	ENSG00000215571.5	GRK6P1	-6.3	3.13e-09	0.0207	-0.59	-0.46	Intelligence (multi-trait analysis);	chr5:177421018	chr13:21319156~21320866:+
UCEC	trans	rs2591576	1	rs2591576	ENSG00000179859.7	AC025335.1	6.3	3.14e-09	0.0207	0.53	0.46	Intelligence (multi-trait analysis);	chr5:165981054	chr17:7913324~7915953:-
UCEC	trans	rs7395662	1	rs6485872	ENSG00000134612.10	FOLH1B	-6.3	3.15e-09	0.0208	-0.5	-0.46	HDL cholesterol;	chr11:48558158	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs7483713	ENSG00000134612.10	FOLH1B	-6.3	3.18e-09	0.0209	-0.51	-0.46	HDL cholesterol;	chr11:48607662	chr11:89639227~89698718:+
UCEC	trans	rs1707322	0.656	rs9429172	ENSG00000255397.1	AC022182.2	6.3	3.18e-09	0.021	0.53	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr8:60937705~60939871:-
UCEC	trans	rs2727020	0.729	rs1917325	ENSG00000134612.10	FOLH1B	-6.3	3.21e-09	0.0211	-0.54	-0.46	Coronary artery disease;	chr11:49348452	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.704	rs4144700	ENSG00000134612.10	FOLH1B	-6.3	3.21e-09	0.0211	-0.54	-0.46	Coronary artery disease;	chr11:49349282	chr11:89639227~89698718:+
UCEC	trans	rs12709013	0.636	rs4538000	ENSG00000233719.3	GOT2P3	6.3	3.23e-09	0.0213	0.53	0.46	Blood metabolite ratios;	chr16:58744506	chr12:9641802~9643007:+
UCEC	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	6.3	3.25e-09	0.0213	0.63	0.46	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
UCEC	trans	rs11971779	0.68	rs6947215	ENSG00000233223.2	AC113189.5	-6.29	3.26e-09	0.0214	-0.61	-0.46	Diisocyanate-induced asthma;	chr7:139341892	chr17:7581964~7584072:-
UCEC	trans	rs9467773	0.838	rs3734540	ENSG00000242375.1	RP11-498P14.3	6.29	3.38e-09	0.0221	0.67	0.46	Intelligence (multi-trait analysis);	chr6:26463093	chr9:97195351~97197687:-
UCEC	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-6.29	3.38e-09	0.0221	-0.64	-0.46	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
UCEC	trans	rs13190036	1	rs351864	ENSG00000226986.4	RP11-543B16.2	-6.28	3.43e-09	0.0224	-0.68	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr1:211207239~211207897:+
UCEC	trans	rs2727020	0.658	rs10839278	ENSG00000134612.10	FOLH1B	-6.28	3.45e-09	0.0225	-0.53	-0.46	Coronary artery disease;	chr11:49429295	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.636	rs11040368	ENSG00000134612.10	FOLH1B	-6.28	3.45e-09	0.0225	-0.53	-0.46	Coronary artery disease;	chr11:49432050	chr11:89639227~89698718:+
UCEC	trans	rs14057	0.792	rs78728410	ENSG00000215869.3	RP11-364B6.1	6.28	3.45e-09	0.0225	0.65	0.46	Systolic blood pressure;	chr1:6602971	chr1:104073023~104077087:+
UCEC	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	6.28	3.54e-09	0.0231	0.53	0.46	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
UCEC	trans	rs10429371	0.573	rs79230440	ENSG00000228168.1	HNRNPA1P21	6.28	3.58e-09	0.0233	0.99	0.46	Smooth-surface caries;	chr8:88971785	chr3:39334979~39335939:+
UCEC	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	6.27	3.61e-09	0.0235	0.67	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
UCEC	trans	rs10242455	0.571	rs117370443	ENSG00000228834.1	RP11-249L21.4	6.27	3.62e-09	0.0235	1.09	0.46	Blood metabolite levels;	chr7:99377635	chr6:108907615~108907873:-
UCEC	trans	rs708547	0.874	rs1315006	ENSG00000267920.1	SNX6P1	6.27	3.66e-09	0.0238	0.66	0.46	Response to bleomycin (chromatid breaks);	chr4:56992027	chr19:23126569~23127792:-
UCEC	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-6.27	3.67e-09	0.0239	-0.45	-0.46	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
UCEC	trans	rs13190036	0.901	rs4631	ENSG00000228305.2	AC016734.2	6.27	3.67e-09	0.0239	0.6	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr2:63622178~63622831:-
UCEC	trans	rs1814175	0.935	rs28586931	ENSG00000134612.10	FOLH1B	-6.27	3.69e-09	0.024	-0.52	-0.46	Height;	chr11:49672320	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.658	rs1851992	ENSG00000134612.10	FOLH1B	-6.26	3.82e-09	0.0247	-0.53	-0.46	Coronary artery disease;	chr11:49416558	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.636	rs10839275	ENSG00000134612.10	FOLH1B	-6.26	3.82e-09	0.0247	-0.53	-0.46	Coronary artery disease;	chr11:49417410	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.658	rs4980442	ENSG00000134612.10	FOLH1B	-6.26	3.82e-09	0.0247	-0.53	-0.46	Coronary artery disease;	chr11:49423464	chr11:89639227~89698718:+
UCEC	trans	rs1979679	0.879	rs1002863	ENSG00000278616.1	BEND3P3	6.26	3.83e-09	0.0248	0.37	0.46	Ossification of the posterior longitudinal ligament of the spine;	chr12:28500768	chr10:79682997~79685436:+
UCEC	trans	rs3806843	0.568	rs2530232	ENSG00000231043.3	AC007238.1	6.26	3.84e-09	0.0249	0.46	0.46	Depressive symptoms (multi-trait analysis);	chr5:140703293	chr2:58460292~58462032:-
UCEC	trans	rs4648045	0.536	rs12648696	ENSG00000243099.1	AC020983.5	6.26	3.85e-09	0.0249	0.51	0.46	Lymphocyte percentage of white cells;	chr4:102625739	chr7:138688980~138689522:+
UCEC	trans	rs928391	0.592	rs1888862	ENSG00000227183.3	HDGFP1	-6.26	3.94e-09	0.0255	-0.63	-0.46	Platelet count;	chr1:156828113	chrX:131646639~131646890:+
UCEC	trans	rs2727020	0.553	rs7479975	ENSG00000134612.10	FOLH1B	-6.26	3.94e-09	0.0255	-0.53	-0.46	Coronary artery disease;	chr11:49560412	chr11:89639227~89698718:+
UCEC	trans	rs345013	0.514	rs9883003	ENSG00000231858.4	AC067945.4	6.26	3.96e-09	0.0256	0.57	0.46	Prostate cancer;	chr3:145307826	chr2:191021526~191032314:+
UCEC	trans	rs13190036	1	rs351862	ENSG00000226986.4	RP11-543B16.2	-6.26	3.96e-09	0.0256	-0.68	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr1:211207239~211207897:+
UCEC	trans	rs1707322	0.686	rs1250	ENSG00000255397.1	AC022182.2	-6.26	3.97e-09	0.0257	-0.52	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr8:60937705~60939871:-
UCEC	trans	rs7395662	1	rs10769371	ENSG00000134612.10	FOLH1B	-6.25	4e-09	0.0258	-0.52	-0.46	HDL cholesterol;	chr11:48509632	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.963	rs4882094	ENSG00000134612.10	FOLH1B	-6.25	4e-09	0.0258	-0.52	-0.46	HDL cholesterol;	chr11:48510908	chr11:89639227~89698718:+
UCEC	trans	rs7395662	1	rs4882096	ENSG00000134612.10	FOLH1B	-6.25	4e-09	0.0258	-0.52	-0.46	HDL cholesterol;	chr11:48512550	chr11:89639227~89698718:+
UCEC	trans	rs13190036	1	rs4976682	ENSG00000228305.2	AC016734.2	6.25	4e-09	0.0258	0.58	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr2:63622178~63622831:-
UCEC	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	6.25	4e-09	0.0259	0.63	0.46	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
UCEC	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-6.25	4.04e-09	0.026	-0.5	-0.46	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
UCEC	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-6.25	4.04e-09	0.026	-0.48	-0.46	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
UCEC	trans	rs955423	0.727	rs1540718	ENSG00000234515.1	PPP1R2P1	-6.25	4.1e-09	0.0264	-0.62	-0.46	Body mass index;	chr5:166320200	chr6:32879171~32879848:-
UCEC	trans	rs2591576	0.809	rs152271	ENSG00000179859.7	AC025335.1	-6.25	4.15e-09	0.0266	-0.55	-0.46	Intelligence (multi-trait analysis);	chr5:165985342	chr17:7913324~7915953:-
UCEC	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	6.24	4.23e-09	0.0271	0.6	0.46	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	6.24	4.23e-09	0.0271	0.6	0.46	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
UCEC	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	6.24	4.29e-09	0.0275	0.45	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
UCEC	trans	rs1707322	0.685	rs56177313	ENSG00000255397.1	AC022182.2	-6.24	4.31e-09	0.0276	-0.52	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs11211178	ENSG00000255397.1	AC022182.2	-6.24	4.31e-09	0.0276	-0.52	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr8:60937705~60939871:-
UCEC	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-6.24	4.39e-09	0.028	-0.5	-0.45	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
UCEC	trans	rs13190036	1	rs628506	ENSG00000226986.4	RP11-543B16.2	-6.24	4.4e-09	0.0281	-0.53	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr1:211207239~211207897:+
UCEC	trans	rs1355223	0.545	rs7106831	ENSG00000225531.1	RP11-196I18.3	6.23	4.43e-09	0.0283	0.59	0.45	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34857995	chr9:107116829~107117557:+
UCEC	trans	rs13190036	0.901	rs28563911	ENSG00000228305.2	AC016734.2	6.23	4.48e-09	0.0285	0.6	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr2:63622178~63622831:-
UCEC	trans	rs13190036	1	rs28580074	ENSG00000228305.2	AC016734.2	6.23	4.48e-09	0.0285	0.6	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr2:63622178~63622831:-
UCEC	trans	rs6759518	0.655	rs1275519	ENSG00000248884.1	CTC-537E7.3	6.23	4.52e-09	0.0287	0.56	0.45	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr2:27200778	chr5:68430427~68434481:-
UCEC	trans	rs6759518	0.655	rs1006898	ENSG00000248884.1	CTC-537E7.3	6.23	4.52e-09	0.0287	0.56	0.45	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr2:27201628	chr5:68430427~68434481:-
UCEC	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	6.23	4.54e-09	0.0289	0.62	0.45	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
UCEC	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	6.23	4.57e-09	0.029	0.58	0.45	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
UCEC	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	6.23	4.57e-09	0.029	0.58	0.45	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
UCEC	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	6.23	4.57e-09	0.029	0.58	0.45	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
UCEC	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	6.23	4.6e-09	0.0292	0.62	0.45	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
UCEC	trans	rs1814175	0.935	rs10839329	ENSG00000134612.10	FOLH1B	-6.23	4.61e-09	0.0292	-0.52	-0.45	Height;	chr11:49672654	chr11:89639227~89698718:+
UCEC	trans	rs2591576	1	rs2591577	ENSG00000179859.7	AC025335.1	-6.23	4.64e-09	0.0294	-0.53	-0.45	Intelligence (multi-trait analysis);	chr5:165980852	chr17:7913324~7915953:-
UCEC	trans	rs13190036	0.901	rs28715668	ENSG00000228305.2	AC016734.2	6.23	4.64e-09	0.0294	0.59	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr2:63622178~63622831:-
UCEC	trans	rs1707322	0.656	rs3014210	ENSG00000255397.1	AC022182.2	6.23	4.65e-09	0.0294	0.53	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.686	rs2991986	ENSG00000255397.1	AC022182.2	6.22	4.69e-09	0.0297	0.53	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr8:60937705~60939871:-
UCEC	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	6.22	4.78e-09	0.0302	0.57	0.45	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
UCEC	trans	rs7395662	1	rs7482176	ENSG00000134612.10	FOLH1B	-6.22	4.78e-09	0.0302	-0.5	-0.45	HDL cholesterol;	chr11:48583068	chr11:89639227~89698718:+
UCEC	trans	rs2591576	0.935	rs153286	ENSG00000179859.7	AC025335.1	-6.22	4.79e-09	0.0302	-0.54	-0.45	Intelligence (multi-trait analysis);	chr5:165982172	chr17:7913324~7915953:-
UCEC	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	6.21	4.96e-09	0.0312	0.57	0.45	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
UCEC	trans	rs7662987	0.793	rs28730632	ENSG00000233859.2	ADH5P4	6.21	5e-09	0.0314	0.61	0.45	Smoking initiation;	chr4:99074552	chr6:65836930~65838039:-
UCEC	trans	rs7662987	0.793	rs4699700	ENSG00000233859.2	ADH5P4	6.21	5e-09	0.0314	0.61	0.45	Smoking initiation;	chr4:99077184	chr6:65836930~65838039:-
UCEC	trans	rs7662987	0.793	rs78790289	ENSG00000233859.2	ADH5P4	6.21	5.03e-09	0.0316	0.6	0.45	Smoking initiation;	chr4:99066736	chr6:65836930~65838039:-
UCEC	trans	rs10242455	0.702	rs17161700	ENSG00000228834.1	RP11-249L21.4	6.21	5.05e-09	0.0317	1.09	0.45	Blood metabolite levels;	chr7:99379444	chr6:108907615~108907873:-
UCEC	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-6.21	5.07e-09	0.0318	-0.49	-0.45	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
UCEC	trans	rs116095464	0.558	rs10055354	ENSG00000185986.11	SDHAP3	6.21	5.08e-09	0.0318	0.61	0.45	Breast cancer;	chr5:243679	chr5:1572222~1594620:-
UCEC	trans	rs7662987	0.793	rs12106	ENSG00000233859.2	ADH5P4	6.21	5.09e-09	0.0319	0.6	0.45	Smoking initiation;	chr4:99072199	chr6:65836930~65838039:-
UCEC	trans	rs58680346	1	rs58628761	ENSG00000255220.1	DDX18P5	6.21	5.11e-09	0.032	0.85	0.45	Hair color;	chr9:7586572	chr11:130295641~130296946:+
UCEC	trans	rs2727020	0.615	rs10128582	ENSG00000134612.10	FOLH1B	-6.21	5.13e-09	0.0321	-0.52	-0.45	Coronary artery disease;	chr11:49425872	chr11:89639227~89698718:+
UCEC	trans	rs448720	0.508	rs17247210	ENSG00000264269.1	RP11-15F12.1	-6.2	5.15e-09	0.0322	-0.51	-0.45	Cognitive performance;	chr15:67927734	chr18:49023703~49048474:+
UCEC	trans	rs7395662	1	rs6485882	ENSG00000134612.10	FOLH1B	6.2	5.15e-09	0.0322	0.5	0.45	HDL cholesterol;	chr11:48570883	chr11:89639227~89698718:+
UCEC	trans	rs13300284	0.558	rs7035858	ENSG00000227205.4	PFN1P9	-6.2	5.18e-09	0.0324	-0.71	-0.45	RR interval (heart rate);	chr9:25440874	chr1:119853316~119853748:+
UCEC	trans	rs11161851	0.935	rs277367	ENSG00000223715.1	LINC01208	6.2	5.19e-09	0.0324	0.48	0.45	Visceral fat;	chr1:74834634	chr3:176604143~176635532:-
UCEC	trans	rs9611519	0.754	rs4820435	ENSG00000268568.1	AC007228.9	-6.2	5.28e-09	0.0328	-0.63	-0.45	Neuroticism;	chr22:41256842	chr19:56672574~56673901:-
UCEC	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	6.2	5.32e-09	0.0331	0.57	0.45	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
UCEC	trans	rs9425766	0.927	rs5878	ENSG00000213331.4	RP11-713C19.2	6.2	5.32e-09	0.0331	0.48	0.45	Life satisfaction;	chr1:173909694	chr4:187970273~187971284:+
UCEC	trans	rs1707322	0.717	rs3014245	ENSG00000255397.1	AC022182.2	6.2	5.4e-09	0.0335	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr8:60937705~60939871:-
UCEC	trans	rs9315702	0.528	rs17060207	ENSG00000234160.1	RP11-613M10.6	-6.2	5.4e-09	0.0335	-0.51	-0.45	Hippocampal atrophy;	chr13:39544277	chr9:37509150~37510299:+
UCEC	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-6.19	5.42e-09	0.0336	-0.5	-0.45	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
UCEC	trans	rs2727020	0.558	rs1164675	ENSG00000134612.10	FOLH1B	6.19	5.46e-09	0.0338	0.5	0.45	Coronary artery disease;	chr11:49304420	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.904	rs7924371	ENSG00000134612.10	FOLH1B	-6.19	5.5e-09	0.034	-0.51	-0.45	Height;	chr11:49599043	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.935	rs11040438	ENSG00000134612.10	FOLH1B	-6.19	5.5e-09	0.034	-0.51	-0.45	Height;	chr11:49600969	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.935	rs1827017	ENSG00000134612.10	FOLH1B	-6.19	5.5e-09	0.034	-0.51	-0.45	Height;	chr11:49611040	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.717	rs11040450	ENSG00000134612.10	FOLH1B	-6.19	5.5e-09	0.034	-0.51	-0.45	Height;	chr11:49629086	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.803	rs11040451	ENSG00000134612.10	FOLH1B	-6.19	5.5e-09	0.034	-0.51	-0.45	Height;	chr11:49629087	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.935	rs10839317	ENSG00000134612.10	FOLH1B	-6.19	5.5e-09	0.034	-0.51	-0.45	Height;	chr11:49635676	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.935	rs6485999	ENSG00000134612.10	FOLH1B	-6.19	5.5e-09	0.034	-0.51	-0.45	Height;	chr11:49637434	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.935	rs7479914	ENSG00000134612.10	FOLH1B	-6.19	5.5e-09	0.034	-0.51	-0.45	Height;	chr11:49639799	chr11:89639227~89698718:+
UCEC	trans	rs1707322	0.721	rs10890346	ENSG00000255397.1	AC022182.2	6.19	5.55e-09	0.0343	0.51	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr8:60937705~60939871:-
UCEC	trans	rs2727020	0.553	rs61904166	ENSG00000134612.10	FOLH1B	-6.19	5.55e-09	0.0343	-0.52	-0.45	Coronary artery disease;	chr11:49559909	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.935	rs7482690	ENSG00000134612.10	FOLH1B	-6.19	5.59e-09	0.0344	-0.51	-0.45	Height;	chr11:49627262	chr11:89639227~89698718:+
UCEC	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-6.19	5.69e-09	0.035	-0.54	-0.45	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-
UCEC	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	6.18	5.69e-09	0.035	0.64	0.45	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
UCEC	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-6.18	5.71e-09	0.0352	-0.5	-0.45	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
UCEC	trans	rs6708331	1	rs35734267	ENSG00000232654.1	FAM136BP	6.18	5.82e-09	0.0357	0.71	0.45	Obesity-related traits;	chr2:70054058	chr6:3045384~3045800:+
UCEC	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	6.18	5.87e-09	0.036	0.6	0.45	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
UCEC	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-6.18	5.92e-09	0.0362	-0.42	-0.45	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
UCEC	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	6.18	5.94e-09	0.0363	0.58	0.45	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
UCEC	trans	rs2727020	0.553	rs3907576	ENSG00000134612.10	FOLH1B	-6.18	5.95e-09	0.0363	-0.53	-0.45	Coronary artery disease;	chr11:49515087	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.575	rs10769587	ENSG00000134612.10	FOLH1B	-6.18	5.95e-09	0.0363	-0.53	-0.45	Coronary artery disease;	chr11:49528297	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.514	rs4980444	ENSG00000134612.10	FOLH1B	-6.18	5.95e-09	0.0363	-0.53	-0.45	Coronary artery disease;	chr11:49529212	chr11:89639227~89698718:+
UCEC	trans	rs6759518	0.655	rs13399758	ENSG00000248884.1	CTC-537E7.3	-6.17	6.03e-09	0.0368	-0.58	-0.45	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr2:27232858	chr5:68430427~68434481:-
UCEC	trans	rs3849046	0.846	rs256006	ENSG00000226666.1	HSPA9P1	6.17	6.05e-09	0.0369	0.38	0.45	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138561405	chr2:221961737~221963765:+
UCEC	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	6.17	6.11e-09	0.0372	0.63	0.45	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
UCEC	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-6.17	6.22e-09	0.0378	-0.5	-0.45	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
UCEC	trans	rs1707322	0.721	rs4559551	ENSG00000255397.1	AC022182.2	-6.17	6.24e-09	0.0379	-0.52	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs11488313	ENSG00000255397.1	AC022182.2	-6.17	6.25e-09	0.038	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr8:60937705~60939871:-
UCEC	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	6.16	6.31e-09	0.0383	0.61	0.45	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
UCEC	trans	rs1707322	0.506	rs2991983	ENSG00000255397.1	AC022182.2	6.16	6.35e-09	0.0384	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.717	rs3014249	ENSG00000255397.1	AC022182.2	6.16	6.35e-09	0.0384	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.686	rs3014242	ENSG00000255397.1	AC022182.2	6.16	6.35e-09	0.0384	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.655	rs3014240	ENSG00000255397.1	AC022182.2	6.16	6.35e-09	0.0384	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.686	rs3014239	ENSG00000255397.1	AC022182.2	6.16	6.35e-09	0.0384	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.686	rs3014236	ENSG00000255397.1	AC022182.2	6.16	6.35e-09	0.0384	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.686	rs3014235	ENSG00000255397.1	AC022182.2	6.16	6.35e-09	0.0384	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.717	rs1135850	ENSG00000255397.1	AC022182.2	-6.16	6.35e-09	0.0384	-0.52	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr8:60937705~60939871:-
UCEC	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-6.16	6.37e-09	0.0385	-0.45	-0.45	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
UCEC	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-6.16	6.37e-09	0.0385	-0.45	-0.45	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
UCEC	trans	rs2209875	0.588	rs7469084	ENSG00000234819.1	RP11-336N8.4	6.16	6.38e-09	0.0386	0.53	0.45	Pelvic organ prolapse (moderate/severe);	chr9:89366248	chr9:78219120~78219357:+
UCEC	trans	rs1814175	0.904	rs1846289	ENSG00000134612.10	FOLH1B	-6.16	6.42e-09	0.0388	-0.51	-0.45	Height;	chr11:49598701	chr11:89639227~89698718:+
UCEC	trans	rs7918232	0.882	rs788211	ENSG00000241668.2	RPL19P11	6.16	6.47e-09	0.039	0.72	0.45	Breast cancer;	chr10:27190141	chr5:31053565~31054153:+
UCEC	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	6.16	6.49e-09	0.0391	0.63	0.45	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	6.16	6.49e-09	0.0391	0.63	0.45	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
UCEC	trans	rs9899728	0.614	rs12949451	ENSG00000234925.2	ATP5HP4	-6.16	6.51e-09	0.0392	-0.66	-0.45	Alzheimer's disease or small vessel stroke;	chr17:75036224	chr12:68642519~68642993:-
UCEC	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-6.16	6.52e-09	0.0392	-0.53	-0.45	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
UCEC	trans	rs1814175	0.869	rs10769600	ENSG00000134612.10	FOLH1B	-6.16	6.53e-09	0.0393	-0.51	-0.45	Height;	chr11:49660280	chr11:89639227~89698718:+
UCEC	trans	rs3740713	0.669	rs34740438	ENSG00000235847.2	LDHAP7	6.16	6.56e-09	0.0395	0.67	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr2:84777259~84778223:-
UCEC	trans	rs3806843	0.735	rs2530240	ENSG00000231043.3	AC007238.1	6.16	6.59e-09	0.0396	0.44	0.45	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr2:58460292~58462032:-
UCEC	trans	rs6759518	0.655	rs1659700	ENSG00000248884.1	CTC-537E7.3	6.15	6.62e-09	0.0398	0.57	0.45	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr2:27191266	chr5:68430427~68434481:-
UCEC	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-6.15	6.66e-09	0.0399	-0.48	-0.45	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
UCEC	trans	rs12483205	0.502	rs2211838	ENSG00000224476.3	RPL36P16	6.15	6.66e-09	0.0399	0.63	0.45	HIV-1 replication;	chr21:37369672	chr19:41169861~41170166:+
UCEC	trans	rs10763170	0.669	rs17599730	ENSG00000228857.2	AC104653.1	6.15	6.7e-09	0.0401	0.54	0.45	Sporadic pituitary adenoma;	chr10:55039107	chr2:113831049~113843356:-
UCEC	trans	rs6813517	0.557	rs113440344	ENSG00000201321.1	RNA5S9	6.15	6.71e-09	0.0401	0.4	0.45	Verbal declarative memory;	chr4:167611982	chr1:228628148~228628266:-
UCEC	trans	rs6813517	0.557	rs115957874	ENSG00000201321.1	RNA5S9	6.15	6.71e-09	0.0401	0.4	0.45	Verbal declarative memory;	chr4:167613416	chr1:228628148~228628266:-
UCEC	trans	rs6813517	0.557	rs116392631	ENSG00000201321.1	RNA5S9	6.15	6.71e-09	0.0401	0.4	0.45	Verbal declarative memory;	chr4:167613440	chr1:228628148~228628266:-
UCEC	trans	rs6813517	0.557	rs7675041	ENSG00000201321.1	RNA5S9	6.15	6.71e-09	0.0401	0.4	0.45	Verbal declarative memory;	chr4:167615005	chr1:228628148~228628266:-
UCEC	trans	rs6813517	0.557	rs115914084	ENSG00000201321.1	RNA5S9	6.15	6.71e-09	0.0401	0.4	0.45	Verbal declarative memory;	chr4:167620297	chr1:228628148~228628266:-
UCEC	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	6.15	6.75e-09	0.0403	0.56	0.45	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
UCEC	trans	rs28485846	1	rs28523755	ENSG00000255062.1	RP11-712L6.5	6.15	6.76e-09	0.0404	0.8	0.45	Foot ulcer and neuropathy in diabetes;	chr8:35389909	chr11:126294298~126304318:-
UCEC	trans	rs13190036	1	rs655623	ENSG00000228305.2	AC016734.2	6.15	6.79e-09	0.0405	0.53	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr2:63622178~63622831:-
UCEC	trans	rs7258465	1	rs10403249	ENSG00000267533.1	RP11-815J4.7	6.15	6.81e-09	0.0406	0.54	0.45	Breast cancer;	chr19:18494132	chr18:12067173~12068417:-
UCEC	trans	rs12709013	0.613	rs1657178	ENSG00000233719.3	GOT2P3	6.15	6.84e-09	0.0407	0.52	0.45	Blood metabolite ratios;	chr16:58735300	chr12:9641802~9643007:+
UCEC	trans	rs12709013	0.585	rs7188608	ENSG00000233719.3	GOT2P3	6.15	6.84e-09	0.0407	0.52	0.45	Blood metabolite ratios;	chr16:58736236	chr12:9641802~9643007:+
UCEC	trans	rs12709013	0.636	rs1657176	ENSG00000233719.3	GOT2P3	6.15	6.84e-09	0.0407	0.52	0.45	Blood metabolite ratios;	chr16:58736833	chr12:9641802~9643007:+
UCEC	trans	rs12709013	0.636	rs1646282	ENSG00000233719.3	GOT2P3	6.15	6.84e-09	0.0407	0.52	0.45	Blood metabolite ratios;	chr16:58741296	chr12:9641802~9643007:+
UCEC	trans	rs12709013	0.636	rs4784977	ENSG00000233719.3	GOT2P3	6.15	6.84e-09	0.0407	0.52	0.45	Blood metabolite ratios;	chr16:58742120	chr12:9641802~9643007:+
UCEC	trans	rs12709013	0.636	rs1657161	ENSG00000233719.3	GOT2P3	6.15	6.84e-09	0.0407	0.52	0.45	Blood metabolite ratios;	chr16:58743234	chr12:9641802~9643007:+
UCEC	trans	rs12709013	0.636	rs1646269	ENSG00000233719.3	GOT2P3	6.15	6.84e-09	0.0407	0.52	0.45	Blood metabolite ratios;	chr16:58743412	chr12:9641802~9643007:+
UCEC	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	6.15	6.85e-09	0.0408	0.49	0.45	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
UCEC	trans	rs2727020	0.553	rs10839295	ENSG00000134612.10	FOLH1B	-6.15	6.91e-09	0.0411	-0.52	-0.45	Coronary artery disease;	chr11:49505793	chr11:89639227~89698718:+
UCEC	trans	rs1707322	0.752	rs11211168	ENSG00000255397.1	AC022182.2	-6.15	6.93e-09	0.0411	-0.52	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.682	rs12037459	ENSG00000255397.1	AC022182.2	-6.14	6.97e-09	0.0413	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr8:60937705~60939871:-
UCEC	trans	rs7258465	1	rs4808801	ENSG00000267533.1	RP11-815J4.7	6.14	6.99e-09	0.0414	0.54	0.45	Breast cancer;	chr19:18460331	chr18:12067173~12068417:-
UCEC	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	6.14	6.99e-09	0.0414	0.63	0.45	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
UCEC	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-6.14	7e-09	0.0414	-0.48	-0.45	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-6.14	7e-09	0.0414	-0.48	-0.45	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
UCEC	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-6.14	7e-09	0.0414	-0.48	-0.45	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
UCEC	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-6.14	7e-09	0.0414	-0.64	-0.45	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
UCEC	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-6.14	7.02e-09	0.0415	-0.48	-0.45	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
UCEC	trans	rs1814175	0.715	rs7479622	ENSG00000134612.10	FOLH1B	-6.14	7.03e-09	0.0416	-0.51	-0.45	Height;	chr11:49651788	chr11:89639227~89698718:+
UCEC	trans	rs9831278	0.681	rs57629026	ENSG00000233836.6	RP11-255H23.2	-6.14	7.04e-09	0.0416	-1.09	-0.45	Gut microbiota (bacterial taxa);	chr3:99169867	chr19:23762944~23833314:+
UCEC	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-6.14	7.04e-09	0.0416	-0.48	-0.45	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
UCEC	trans	rs7258465	1	rs4808133	ENSG00000267533.1	RP11-815J4.7	6.14	7.1e-09	0.0419	0.54	0.45	Breast cancer;	chr19:18497708	chr18:12067173~12068417:-
UCEC	trans	rs7258465	1	rs4808134	ENSG00000267533.1	RP11-815J4.7	6.14	7.1e-09	0.0419	0.54	0.45	Breast cancer;	chr19:18497769	chr18:12067173~12068417:-
UCEC	trans	rs116095464	0.558	rs9654452	ENSG00000185986.11	SDHAP3	6.14	7.12e-09	0.042	0.6	0.45	Breast cancer;	chr5:299446	chr5:1572222~1594620:-
UCEC	trans	rs7995618	0.57	rs7320177	ENSG00000237701.1	ATP5JP1	-6.14	7.15e-09	0.0422	-0.44	-0.45	Plasma clusterin levels;	chr13:89205508	chrY:6900753~6901372:+
UCEC	trans	rs3806843	0.735	rs2563314	ENSG00000231043.3	AC007238.1	6.14	7.17e-09	0.0423	0.44	0.45	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.735	rs801189	ENSG00000231043.3	AC007238.1	6.14	7.17e-09	0.0423	0.44	0.45	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.706	rs1089305	ENSG00000231043.3	AC007238.1	6.14	7.17e-09	0.0423	0.44	0.45	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.735	rs801185	ENSG00000231043.3	AC007238.1	6.14	7.17e-09	0.0423	0.44	0.45	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.735	rs2563306	ENSG00000231043.3	AC007238.1	6.14	7.17e-09	0.0423	0.44	0.45	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.735	rs813897	ENSG00000231043.3	AC007238.1	6.14	7.17e-09	0.0423	0.44	0.45	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.676	rs2563304	ENSG00000231043.3	AC007238.1	6.14	7.17e-09	0.0423	0.44	0.45	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.735	rs3776129	ENSG00000231043.3	AC007238.1	6.14	7.17e-09	0.0423	0.44	0.45	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr2:58460292~58462032:-
UCEC	trans	rs1995082	0.762	rs17768230	ENSG00000235830.1	SRGAP3-AS4	6.14	7.19e-09	0.0424	0.87	0.45	Educational attainment;	chr16:76996494	chr3:9256759~9257507:+
UCEC	trans	rs10242455	0.702	rs74347626	ENSG00000228834.1	RP11-249L21.4	6.14	7.26e-09	0.0427	1.07	0.45	Blood metabolite levels;	chr7:99608398	chr6:108907615~108907873:-
UCEC	trans	rs9858542	0.953	rs9827708	ENSG00000279583.1	RP11-368N21.5	-6.14	7.26e-09	0.0427	-0.55	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49612556	chr16:29595130~29596137:-
UCEC	trans	rs7395662	1	rs11039800	ENSG00000134612.10	FOLH1B	6.14	7.26e-09	0.0427	0.51	0.45	HDL cholesterol;	chr11:48521027	chr11:89639227~89698718:+
UCEC	trans	rs1707322	0.721	rs11211163	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.647	rs6686944	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs12037803	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.716	rs10890342	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs11211165	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs11211166	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs10789470	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs6658700	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs12047629	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs61784796	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs10749856	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs10890344	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs11211169	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs4564187	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs11211171	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs28438704	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs28623463	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs28442079	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.716	rs28370457	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs28817701	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs28890893	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.691	rs28495425	ENSG00000255397.1	AC022182.2	-6.13	7.32e-09	0.0428	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.691	rs61784803	ENSG00000255397.1	AC022182.2	6.13	7.32e-09	0.0428	0.51	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.663	rs3935296	ENSG00000255397.1	AC022182.2	6.13	7.32e-09	0.0428	0.51	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr8:60937705~60939871:-
UCEC	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	6.13	7.34e-09	0.0429	0.62	0.45	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	6.13	7.34e-09	0.0429	0.62	0.45	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
UCEC	trans	rs9467773	1	rs1321479	ENSG00000242375.1	RP11-498P14.3	-6.13	7.48e-09	0.0435	-0.57	-0.45	Intelligence (multi-trait analysis);	chr6:26501669	chr9:97195351~97197687:-
UCEC	trans	rs1707322	0.752	rs28568986	ENSG00000255397.1	AC022182.2	-6.13	7.48e-09	0.0435	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr8:60937705~60939871:-
UCEC	trans	rs7258465	1	rs10164323	ENSG00000267533.1	RP11-815J4.7	6.13	7.51e-09	0.0437	0.55	0.45	Breast cancer;	chr19:18458682	chr18:12067173~12068417:-
UCEC	trans	rs1814175	0.647	rs61306292	ENSG00000134612.10	FOLH1B	-6.13	7.56e-09	0.0439	-0.54	-0.45	Height;	chr11:49834488	chr11:89639227~89698718:+
UCEC	trans	rs1814175	0.935	rs11040463	ENSG00000134612.10	FOLH1B	-6.13	7.6e-09	0.044	-0.51	-0.45	Height;	chr11:49664022	chr11:89639227~89698718:+
UCEC	trans	rs941408	0.515	rs1005556	ENSG00000234665.7	RP11-262H14.3	6.13	7.63e-09	0.0442	0.59	0.45	Total cholesterol levels;	chr19:2778545	chr9:62856999~62898087:-
UCEC	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	6.13	7.69e-09	0.0445	0.75	0.45	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	6.13	7.69e-09	0.0445	0.75	0.45	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	6.13	7.69e-09	0.0445	0.75	0.45	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	6.12	7.74e-09	0.0447	0.75	0.45	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	6.12	7.74e-09	0.0447	0.75	0.45	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	6.12	7.74e-09	0.0447	0.75	0.45	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	6.12	7.74e-09	0.0447	0.75	0.45	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
UCEC	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	6.12	7.74e-09	0.0447	0.75	0.45	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
UCEC	trans	rs3740713	0.669	rs78098319	ENSG00000235847.2	LDHAP7	6.12	7.79e-09	0.045	0.67	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr2:84777259~84778223:-
UCEC	trans	rs6477998	0.647	rs10981704	ENSG00000238072.1	RP11-305M3.2	-6.12	7.8e-09	0.045	-0.58	-0.45	Hematology traits;	chr9:113253989	chr7:129410113~129410370:-
UCEC	trans	rs6708331	0.941	rs62151166	ENSG00000232654.1	FAM136BP	6.12	7.84e-09	0.0452	0.98	0.45	Obesity-related traits;	chr2:70085174	chr6:3045384~3045800:+
UCEC	trans	rs7395662	1	rs4882017	ENSG00000134612.10	FOLH1B	6.12	7.87e-09	0.0453	0.5	0.45	HDL cholesterol;	chr11:48548630	chr11:89639227~89698718:+
UCEC	trans	rs7395662	0.624	rs11040162	ENSG00000134612.10	FOLH1B	6.12	7.87e-09	0.0453	0.51	0.45	HDL cholesterol;	chr11:48938439	chr11:89639227~89698718:+
UCEC	trans	rs2727020	0.658	rs7111215	ENSG00000134612.10	FOLH1B	-6.12	7.88e-09	0.0453	-0.52	-0.45	Coronary artery disease;	chr11:49409000	chr11:89639227~89698718:+
UCEC	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	6.12	7.91e-09	0.0453	0.46	0.45	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
UCEC	trans	rs10242455	0.571	rs13438288	ENSG00000228834.1	RP11-249L21.4	6.12	7.98e-09	0.0456	1.1	0.45	Blood metabolite levels;	chr7:99318791	chr6:108907615~108907873:-
UCEC	trans	rs1707322	0.685	rs28617418	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.716	rs28375469	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.682	rs28490344	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs28501477	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs28545085	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs28719889	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs28812624	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs28507722	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs28641748	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.717	rs28396194	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.717	rs28752166	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.717	rs10890345	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs10789471	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs4330955	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.752	rs11211173	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.691	rs11211174	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.691	rs12031182	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr8:60937705~60939871:-
UCEC	trans	rs1707322	0.721	rs10430123	ENSG00000255397.1	AC022182.2	-6.12	8.02e-09	0.0457	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr8:60937705~60939871:-
UCEC	trans	rs3779635	0.742	rs1045511	ENSG00000227230.1	RP11-261C10.5	6.12	8.03e-09	0.0457	0.41	0.45	Neuroticism;	chr8:27397629	chr1:243135898~243140588:+
UCEC	trans	rs13190036	1	rs17078781	ENSG00000228305.2	AC016734.2	-6.12	8.06e-09	0.0458	-0.59	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr2:63622178~63622831:-
UCEC	trans	rs1979679	0.918	rs2348234	ENSG00000278616.1	BEND3P3	-6.12	8.08e-09	0.0459	-0.37	-0.45	Ossification of the posterior longitudinal ligament of the spine;	chr12:28354126	chr10:79682997~79685436:+
UCEC	trans	rs1979679	0.918	rs78500430	ENSG00000278616.1	BEND3P3	-6.12	8.08e-09	0.0459	-0.37	-0.45	Ossification of the posterior longitudinal ligament of the spine;	chr12:28369828	chr10:79682997~79685436:+
UCEC	trans	rs3806843	0.735	rs801183	ENSG00000231043.3	AC007238.1	-6.11	8.13e-09	0.0461	-0.43	-0.45	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.705	rs35614340	ENSG00000231043.3	AC007238.1	6.11	8.13e-09	0.0461	0.43	0.45	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.706	rs2563302	ENSG00000231043.3	AC007238.1	6.11	8.13e-09	0.0461	0.43	0.45	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.735	rs809635	ENSG00000231043.3	AC007238.1	6.11	8.13e-09	0.0461	0.43	0.45	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.648	rs2530233	ENSG00000231043.3	AC007238.1	6.11	8.13e-09	0.0461	0.43	0.45	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.735	rs6849	ENSG00000231043.3	AC007238.1	6.11	8.13e-09	0.0461	0.43	0.45	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.735	rs702394	ENSG00000231043.3	AC007238.1	6.11	8.13e-09	0.0461	0.43	0.45	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr2:58460292~58462032:-
UCEC	trans	rs3806843	0.735	rs801180	ENSG00000231043.3	AC007238.1	6.11	8.13e-09	0.0461	0.43	0.45	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr2:58460292~58462032:-
UCEC	trans	rs7811142	1	rs7811142	ENSG00000228546.2	CTA-313A17.3	6.11	8.14e-09	0.0461	0.72	0.45	Platelet count;	chr7:100467820	chr7:102337316~102339115:+
UCEC	trans	rs7554511	0.858	rs11583328	ENSG00000231826.4	AC016735.2	6.11	8.14e-09	0.0461	0.64	0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201033045	chr2:43027853~43039547:-
UCEC	trans	rs1707322	0.691	rs61784799	ENSG00000255397.1	AC022182.2	6.11	8.21e-09	0.0465	0.51	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr8:60937705~60939871:-
UCEC	trans	rs7258465	0.931	rs7249020	ENSG00000267533.1	RP11-815J4.7	6.11	8.31e-09	0.047	0.53	0.45	Breast cancer;	chr19:18497337	chr18:12067173~12068417:-
UCEC	trans	rs13190036	0.901	rs28684504	ENSG00000228305.2	AC016734.2	6.11	8.35e-09	0.0472	0.58	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr2:63622178~63622831:-
UCEC	trans	rs7662987	0.793	rs7669660	ENSG00000233859.2	ADH5P4	6.11	8.37e-09	0.0473	0.59	0.45	Smoking initiation;	chr4:99071451	chr6:65836930~65838039:-
UCEC	trans	rs1707322	0.721	rs6697821	ENSG00000255397.1	AC022182.2	-6.11	8.43e-09	0.0476	-0.51	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr8:60937705~60939871:-
UCEC	trans	rs13063635	0.915	rs71325092	ENSG00000228960.5	OR2A9P	-6.11	8.47e-09	0.0478	-1.1	-0.45	Eosinophil percentage of granulocytes;	chr3:45905526	chr7:144294480~144300934:+
UCEC	trans	rs9611565	0.592	rs4822040	ENSG00000268568.1	AC007228.9	-6.11	8.48e-09	0.0478	-0.58	-0.45	Vitiligo;	chr22:41567549	chr19:56672574~56673901:-
UCEC	trans	rs1707322	0.717	rs3014246	ENSG00000255397.1	AC022182.2	6.11	8.5e-09	0.0479	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr8:60937705~60939871:-
UCEC	trans	rs7976838	0.614	rs34688627	ENSG00000224682.1	SOCS5P2	6.1	8.54e-09	0.0481	0.92	0.45	Response to zileuton treatment in asthma (FEV1 change interaction);	chr12:59811177	chr9:135447446~135450154:+
UCEC	trans	rs10242455	0.702	rs116671616	ENSG00000228834.1	RP11-249L21.4	6.1	8.57e-09	0.0482	1.14	0.45	Blood metabolite levels;	chr7:99356935	chr6:108907615~108907873:-
UCEC	trans	rs10242455	0.702	rs75156180	ENSG00000228834.1	RP11-249L21.4	6.1	8.57e-09	0.0482	1.14	0.45	Blood metabolite levels;	chr7:99366477	chr6:108907615~108907873:-
UCEC	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-6.1	8.68e-09	0.0488	-0.56	-0.45	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
UCEC	trans	rs1399645	0.85	rs73960709	ENSG00000240898.1	RP11-48B14.1	-6.1	8.74e-09	0.0491	-0.79	-0.45	Male infertility;	chr2:139670596	chr17:3665220~3665702:+
UCEC	trans	rs7258465	0.931	rs875396	ENSG00000267533.1	RP11-815J4.7	6.1	8.76e-09	0.0492	0.53	0.45	Breast cancer;	chr19:18500337	chr18:12067173~12068417:-
UCEC	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	6.1	8.81e-09	0.0494	0.6	0.45	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
UCEC	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	6.1	8.81e-09	0.0494	0.6	0.45	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
UCEC	trans	rs7258465	1	rs7251653	ENSG00000267533.1	RP11-815J4.7	6.1	8.87e-09	0.0498	0.54	0.45	Breast cancer;	chr19:18497473	chr18:12067173~12068417:-